oseltamivir has been researched along with Grippe in 2220 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 19 (0.86) | 18.2507 |
| 2000's | 615 (27.70) | 29.6817 |
| 2010's | 1342 (60.45) | 24.3611 |
| 2020's | 244 (10.99) | 2.80 |
| Authors | Studies |
|---|---|
| Bailey, KW; Barnard, DL; Day, CW; Furuta, Y; Morrey, JD; Sidwell, RW; Smee, DF; Wong, MH | 1 |
| Kakuta, M; Kubo, S; Nasu, H; Tokumitsu, A; Tomozawa, T; Yamashita, M | 1 |
| Demmler-Harrison, GJ; Deyde, VM; Gubareva, LV; Klimov, AI; Okomo-Adhiambo, M; Sheu, TG; Xu, X | 1 |
| Gubareva, LV; Klimov, AI; Mishin, VP; Nguyen, HT; Sheu, TG | 1 |
| Dao, TT; Kim, EH; Kim, SK; Nguyen, PH; Oh, WK; Thuong, PT; Tung, BT; Yoo, SS | 1 |
| Cheng, YS; Fang, JM; Lee, PS; Liu, KC; Wang, SY; Wong, CH | 1 |
| Braun, H; Grienke, U; Kirchmair, J; Krumbholz, A; Liedl, KR; Richter, M; Rollinger, JM; Schmidtke, M; Seidel, N; von Grafenstein, S | 1 |
| Boechat, Fda C; Brozeguini, L; Cunha, AC; de Souza, MC; Faro, LV; Ferreira, VF; Fintelman-Rodrigues, N; Forezi, Lda S; Marques, IP; Nogueira, CM; Riscado, CS; Sacramento, CQ; Sagrillo, FS; Santos-Filho, O; Souza, TM | 1 |
| Botta, M; de Esch, I; Deodato, D; Edink, E; Fallacara, AL; Gospodova, T; Loregian, A; Mercorelli, B; Nannetti, G; Palù, G; Tintori, C; Trist, IM; Verheij, M; Viteva, L; Wijtmans, M | 1 |
| Albiñana, CB; Konvalinka, J; Kožíšek, M; Machara, A; Pachl, P; Řezáčová, P | 1 |
| Dechoux, L; Si, L; Sollogoub, M; Sun, W; Thorimbert, S; Wang, Q; Wu, S; Xiao, S; Yang, L; Zhang, Y; Zhou, D | 1 |
| Hao, C; Jiang, T; Wang, W; Yin, R; Yu, R; Zhang, L; Zhang, M | 1 |
| Alessi, MC; Bertrand, HC; Chebbo, M; Companys, S; Dilly, S; Fotso Fotso, A; Lejal, N; Noiray, M; Quideau, S; Rahman, F; Riteau, B; Slama-Schwok, A; Tarus, B; Vidic, J; Zedda, G | 1 |
| Cao, R; Jiang, S; Li, Y; Liang, G; Liu, K; Meng, G; Shi, W; Wang, C; Wang, W; Xia, S; Zhang, T; Zhao, L; Zhong, W | 1 |
| Aisa, HA; Li, G; Liu, GY; Lu, W; Obul, M; Zhao, JY | 1 |
| Alonzi, DS; Barnard, D; Biggins, J; Caputo, AT; Duchars, M; Dwek, RA; Hill, JC; Kiappes, JL; Roversi, P; Sheets, N; Shresta, S; Treston, AM; Warfield, KL; Zitzmann, N | 1 |
| Alqarni, S; Bott, R; Brown, A; Cooper, L; Gaisina, IN; Galvan Achi, J; Krunic, A; Manicassamy, B; Moore, TW; Peet, NP; Rong, L; Sali, VK; Santarsiero, BD; Thatcher, GRJ; Zhang, P | 1 |
| Chikumi, H; Igari, H; Ishiguro, N; Ito, YM; Iwasaki, S; Kanai, S; Kawamura, H; Koike, R; Miyara, T; Murakami, N; Nagao, M; Nukui, Y; Sano, C; Tokuda, K; Yagi, T; Yamada, K | 1 |
| Bai, H; Ingber, DE; Jin, L; Oh, CY; Prantil-Baun, R; Si, L | 1 |
| Liu, G; Mao, G; Qian, L; Qiao, Y; Shang, J; Wang, H | 1 |
| Brock, M; Fremau, A; Humblet-Baron, S; Jacobs, C; Laeveren, B; Lagrou, K; Naesens, L; Ostyn, T; Reséndiz-Sharpe, A; Seldeslachts, L; Van De Veerdonk, FL; Vande Velde, G; Vanderbeke, L; Verbeken, E; Wauters, J | 1 |
| Chen, RH; Chen, SC; Li, J; Mao, LF; Wang, HQ; Yang, XH; Yang, Z; Yu, XF; Zhang, GZ; Zhao, G | 1 |
| Azzam, O; Buet, E; Cazzorla, F; Gallouche, M; Giner, C; Landelle, C; Larrat, S; Mallaret, MR; Morand, P | 1 |
| Choi, GJ; Choi, JS; Choi, SR; Kim, D; Kim, YJ; Lee, J; Lee, JH; Park, JY; Woo, YJ | 1 |
| Aldhahri, FA; Alghanem, AF; Althemery, AU | 1 |
| Funk, GC; Karolyi, M; Kelani, H; Lindner, B; Omid, S; Pawelka, E; Porpaczy, C; Publig, S; Seitz, T; Traugott, M; Turner, M; Wenisch, C; Zoufaly, A | 1 |
| Carrico, RM; Fry, AM; Furmanek, SP; Hoft, D; Peyrani, P; Ramirez, JA; Wiemken, TL | 1 |
| Azimi, PH; Boom, JA; Campbell, AP; Englund, JA; Haddadin, Z; Halasa, NB; Hamdan, L; Harrison, CJ; Klein, EJ; McNeal, M; Munoz, F; Patel, M; Probst, V; Rahman, H; Sahni, LC; Selvarangan, R; Singer, MN; Spieker, AJ; Staat, MA; Stewart, LS; Szilagyi, PG; Vandekar, S; Weinberg, GA; Williams, JV | 1 |
| Kato, Y; Miyazaki, C; Ohkusa, Y; Okabe, N; Sugawara, T; Taniguchi, K | 1 |
| Jo, T; Michihata, N; Ono, S; Yamana, H; Yasunaga, H | 1 |
| Feng, IJ; Hua, YM; Shih, MF; Su, HC; Tang, HJ | 1 |
| Bando, T; Chong, Y; Ikematsu, H; Iwaki, N; Kashiwagi, S; Kawai, N; Tani, N | 1 |
| Fujiwara, M; Hara, A; Hara, K; Kobayashi, C; Komeda, T; Miyazawa, S; Ogura, E; Urushihara, H; Yoshida, M | 1 |
| Charernmak, B; Chusri, S; Hortiwakul, T; Kanchanasuwan, S; Kositpantawong, N; Nwabor, OF; Siripaitoon, P; Surasombatpattana, S | 1 |
| Bandera, A; Castelli, V; Gori, A; Lombardi, A; Palomba, E; Renisi, G | 1 |
| Blyth, CC; Cheng, AC; Macartney, KK; McRae, JE; Quinn, HE; Wood, NJ | 1 |
| Jayabalan, T; Joshi, A; Miller, I; Oliver, A; Peppercorn, A; Wang-Jairaj, J; Zammit-Tabona, P | 1 |
| Arita, T; Fujisaki, S; Hasegawa, H; Iwanaka, M; Kageyama, T; Kishida, N; Mine, J; Miura, H; Morita, H; Nagata, S; Nakamura, K; Sakuma, S; Shibata, A; Shirakura, M; Suzuki, Y; Takashita, E; Takayama, I; Tanikawa, T; Tsunekuni, R; Uchida, Y; Watanabe, S; Yamaoka, M | 1 |
| Bykov, VV; Garshinina, AV; Khazanov, VA; Leonov, KA; Motov, VS; Salakhutdinov, NF; Slita, AV; Volobueva, AS; Yarovaya, OI; Zarubaev, VV | 1 |
| Bolon, DNA; Finberg, RW; Jensen, JD; Jiang, L; Kowalik, TF; Liu, P; Marasco, WA; Samant, N; Schiffer, CA; Somasundaran, M; Wang, JP | 1 |
| Ding, P; Guo, Y; Li, Y; Ping, J; Suzuki, Y; Yu, M; Zhang, H; Zhang, Y; Zheng, Y | 1 |
| Havlíčková, M; Nováková, L | 1 |
| Beutels, P; Bilcke, J; Bruyndonckx, R; Butler, CC; Coenen, S; Hens, N; Li, X; van der Velden, AW | 1 |
| Fujita, S; Fujiwara, M; Hosogaya, N; Miyazawa, S; Mukae, H; Takazono, T; Watanabe, H; Yamamoto, K | 1 |
| Friedman, JN; Ostrow, O; Richardson, SE; Savlov, D | 1 |
| Bohn, J; Carruth, A; Cocoros, NM; Cosgrove, A; Dutcher, SK; Francis, H; Htoo, PT; Measer, G; Orr, R; Sorbello, A; Toh, S | 1 |
| Cicek, C; Keskin, G; Saz, EU; Turan, C; Yurtseven, A | 1 |
| Deshpande, A; Haessler, S; Higgins, T; Imrey, PB; Klompas, M; Lindenauer, PK; Pallotta, AM; Rothberg, MB; Yu, PC; Zilberberg, MD | 1 |
| Siemieniak, S; Yoo, MJ | 1 |
| Brown, SK; Daniels, RS; Fujisaki, S; Govorkova, EA; Gubareva, LV; Huang, W; Lackenby, A; Meijer, A; Nguyen, HT; Patel, MC; Pereyaslov, D; Presser, LD; Rattigan, A; Samaan, M; Subbarao, K; Takashita, E; Wang, D; Webby, RJ; Wong, S; Yen, HL; Zhang, W | 1 |
| Chan, KA; Fang, CT; Huang, CT; Su, CP | 1 |
| Aziz, A; Barr, IG; Baz, M; Brown, SK; Tseng, YY | 1 |
| Chon, I; Fujio, K; Hamabata, H; Jiaming, L; Kawashima, T; Kitano, A; Kodo, N; Masaki, H; Minato, M; Ono, Y; Phyu, WW; Saito, R; Saito, T; Sato, I; Shirahige, Y; Suzuki, E; Wagatsuma, K; Watanabe, H; Yuyang, S | 1 |
| Castro, RC; Chawla, D; Neuberger, E; Wallick, C | 1 |
| Caceres, CJ; Cardenas-Garcia, S; Cargnin Faccin, F; Perez, DR; Rajao, DS; Seibert, B | 1 |
| Lampejo, T | 1 |
| Lai, CC; Wei, JCC | 1 |
| Duan, N; Li, L; Li, X; Liu, B; Lu, C; Xiong, Y; Zhang, C; Zhang, Y | 1 |
| Iacobucci, G | 1 |
| Chidichimo, L; Greco, F; Greco, S; Mastroianni, A; Mauro, MV; Urso, F; Vangeli, V | 1 |
| Schmitz, U; Swaminathan, S | 1 |
| Baz, M; Koszalka, P; Subbarao, K | 1 |
| Dong, G; Guan, S; Wang, C; Xu, H; Zhang, W | 1 |
| Ayun, RQ; Hoang, PT; Kim, D; Kim, T; Kim, WK; Lee, S; Lee, Y; Luong, QXT; Na, K; Oh, Y | 1 |
| Chang, YH; Chen, ZY; Chern, JH; Ho, JY; Horng, JT; Hsieh, CF; Huang, LY; Jheng, JR; Lin, TJ; Liu, CJ; Tang, WF | 1 |
| Chen, D; Jiang, Y; Lin, YF; Shi, S; Shu, Y | 1 |
| Fujiyasu, H; Kakuya, F; Kinebuchi, T; Kurisawa, MJ; Okubo, H | 1 |
| Chang, R; Chen, HY; Hung, YM; Sun, CK | 1 |
| Bao, YB; Li, S; Liu, WB; Qin, HJ; Tang, Q; Yang, Y; Zhao, Y; Zhong, M; Zhu, YB | 1 |
| Farrukee, R; Gunalan, V; Hurt, AC; Maurer-Stroh, S; Reading, PC | 1 |
| Abubakar, BH; Appiah-Kubi, P; Kumalo, HM; Mtambo, SE; Mushebenge, AG; Ntuli, ML; Ugbaja, SC | 1 |
| Chen, M; Feng, S; Guo, W; He, Z; Li, G; Li, X; Liang, X; Liu, J; Liu, X; Mi, N; Ouyang, J; Tao, J; Wang, H; Wang, W; Wang, X; Wen, Q; Zhang, W; Zhao, H; Zhao, Z | 1 |
| Cinar, G; Dirauf, M; Hauptstein, N; Lühmann, T; Meinel, L; Nischang, I; Pfaller, CK; Raschig, M; Sawatsky, B; Scherf-Clavel, O; Schubert, US; Siering, O; Wittwer, K | 1 |
| Helve, O; Juutinen, A; Kaila, M; Mukka, M; Mustonen, P; Pesälä, S; Virtanen, MJ | 1 |
| Briestenská, K; Mikušová, M; Tomčíková, K; Varečková, E | 1 |
| Ding, YL; Hu, CC; Li, WF; Yuan, B | 1 |
| Guo, YH; Li, B; Li, ZY; Liu, QQ; Yan, YM; Yang, XJ; Zhao, CX; Zhao, GZ | 1 |
| Boonma, T; Nunthaboot, N; Nutho, B; Rungrotmongkol, T; Soikudrua, N | 1 |
| Tian, Y; Wang, K; Zhang, H | 1 |
| Chen, X; Cheng, Y; Jiang, N; Li, H; Li, R; Liu, D; Quan, L; Zhou, Y | 1 |
| Ramgopal, S; Schnadower, D; Shah, SS; Walsh, PS; Wilson, PM; Zhang, Y | 2 |
| Aabenhus, R; Beutels, P; Bilcke, J; Bongard, E; Bruyndonckx, R; Bucher, HC; Butler, CC; Chlabicz, S; Coenen, S; Colliers, A; de Paor, M; De Sutter, A; Francis, N; Garcia-Sangenis, A; Glinz, D; Godycki-Cwirko, M; Goossens, H; Harbin, NJ; Kosiek, K; Li, X; Lindbæk, M; Lionis, C; Llor, C; Mikó-Pauer, R; Radzeviciene Jurgute, R; Seifert, B; Sundvall, PD; Touboul Lundgren, P; Tsakountakis, N; van der Velden, AW; Verheij, TJ | 1 |
| Dandekar, T; Sarukhanyan, E; Shanmugam, TA | 1 |
| Aziz, A; Barr, IG; Baz, M; Brown, SK; Deng, YM; Kuba, M; Lau, H; O'Neill, G; Peck, H; Soppe, S; Subbarao, K | 1 |
| Brown, D; Cavalcanti, AC; de Almeida, WAF; Debur, MDC; Fernandes, SB; Ferreira, JA; Garcia, CC; Gregianini, TS; Iani, FCM; Martins, JSCC; Matos, ADR; Miranda, MD; Motta, F; Pereira, FM; Resende, PC; Rodrigues, RR; Santos, CA; Santos, KCO; Siqueira, MM; Sousa, TDC | 1 |
| Haesendonckx, S; Leopold, L; Van Dromme, I; van Duijnhoven, W; Witek, J | 1 |
| Akca Çağlar, A; Bodur, İ; Göktuğ, A; Güneylioğlu, MM; Güngör, A; Karacan, CD; Öztürk, B; Tekeli, A; Tuygun, N; Yaradılmış, RM | 1 |
| Chesnokov, A; Elal, AA; Feng, C; Flanigan, D; Gubareva, LV; Kondor, RJ; Mishin, VP; Nguyen, HT; Patel, MC; Steel, J; Wentworth, DE | 1 |
| Balan, V; Blumberg, L; Cai, E; Cheng, V; Dagens, A; Dahmash, D; Groves, H; Harriss, E; Hart, P; Horby, PW; Jacob, S; Joseph, R; Lipworth, S; Michelen, M; Oti, A; Rigby, I; Sigfrid, L | 1 |
| Berenger, BM; Bibby, HL; Church, DL; de Koning, L; Seiden-Long, I; Zelyas, N | 1 |
| Oriola, AO; Oyedeji, AO | 1 |
| Aliyu, B; Chee, HY; Raji, YE; Sekawi, ZB; Wong, MY | 1 |
| Abelyan, N; Arakelov, G; Arakelov, V; Gabrielyan, Y; Gevorgyan, S; Harutyunyan, V; Khachatryan, H; Matevosyan, M; Sahakyan, V; Tirosyan, I; Zakaryan, H | 1 |
| Adams, P; Armstrong, K; Govorkova, EA; Jones, JC; Yen, HL | 1 |
| Arguello, CJ; Asher, J; Charoin, JE; Clay, M; Clinch, B; Durham, DP; Jolivet, S; Kuhlbusch, K; Lemenuel-Diot, A; Mier-Y-Teran-Romero, L; Wong, DY | 1 |
| Cai, T; De Clercq, E; Huang, J; Ji, C; Li, G; Li, Z; Liu, Q; Luo, L; Luo, R; Tan, X; Wang, Y; Whitley, R; Xu, M; Yin, Q; Yue, T; Zhang, P; Zheng, Y | 1 |
| Casto, AM; Chu, HY; Englund, JA; Han, PD; Hughes, JP; Link, AC; Martinez, MA; Nackviseth, C; Nwanne, G; Pfau, B; Rogers, JH; Shendure, J; Sugg, N; Uyeki, TM; Wolf, CR | 1 |
| Mehta, N; Peppercorn, AF; Watson, HA; Yates, PJ | 1 |
| Carpenter, R; Choudhry, S; Christou, S; Everden, A; Jalal, H; Jarman, E; Jones, NK; Khalid, A; Lam, K; Myers, C; Popay, A; Ranellou, K; Reacher, M; Reeve, L; Ren, S; Rolfe, KJ; Sander, C; Sithole, N; Sutton, T; Verlander, NQ; Warne, B; Wright, C; Zambon, M; Zhang, H | 1 |
| Kayani, MD | 1 |
| Chen, YW; Li, SG; Liang, H; Pang, YS | 1 |
| Adlhoch, C; Bossuyt, N; Brytting, M; Carnahan, A; Delgado-Sanz, C; Domegan, L; Gomes Dias, J; Guiomar, R; Kynčl, J; Larrauri, A; Maistre Melillo, J; Marbus, SD; Melillo, T; O'Donnell, J; Olsen, SJ; Popovici, O; Redlberger-Fritz, M; Slezak, P; Thomas, I; van Gageldonk-Lafeber, AB | 1 |
| Bai, H; Chen, R; Cui, X; Hong, J; Liu, Q; Liu, X; Lou, K; Wang, F; Yang, Y | 1 |
| Chan, KKP; Hui, DSC | 1 |
| Al Rumaih, Z; Chaudhri, G; Karupiah, G; Kc, R; Kels, MJT; Malley, R; Ng, E; Pandey, P | 1 |
| Barlow, S; Checovich, M; Hamrick, I; Mundt, M; Reisdorf, E; Temte, J | 1 |
| Aoki, S; Chon, I; Kakuya, F; Kawashima, T; Kitano, A; Kodo, N; Li, J; Minato, M; Nagata, N; Ono, Y; Phyu, WW; Saito, R; Saito, T; Sato, I; Shimada, Y; Sun, Y; Suzuki, E; Tanaka, T; Wagatsuma, K; Watanabe, H | 1 |
| Agarwal, V; Bröjer, C; Ellström, P; Järhult, JD; Lundkvist, Å; Naguib, MM; Nykvist, M; Skog, E; Westman, G; Wille, M | 1 |
| Fujisaki, S; Hashimoto, K; Hosoya, M; Katayose, M; Nemoto, K; Sakai, N; Sato, M; Takashita, E | 2 |
| Chen, K; Chen, Y; Fang, Z; Gong, L; Li, Z; Lou, X; Mao, H; Su, L; Sun, Y; Wang, X; Yan, H; Zhang, Y | 1 |
| Kumar, R; Sagar, R; Tyagi, R; Yadav, Y | 1 |
| Kawaoka, Y; Kiso, M; Yamayoshi, S | 1 |
| Jagadesh, A; Jayaram, A; Krishna, S; Mukhopadhyay, C; Shetty, U; Varamballi, P | 1 |
| Anderson, D; De Meyer, S; Leopold, L; Van Dromme, I; van Duijnhoven, W; Vingerhoets, J | 1 |
| Ando, Y; Baba, K; Fukao, K; Kuroda, T; Noshi, T; Oka, R; Shishido, T; Taniguchi, K; Yoshida, S | 1 |
| Miyairi, I; Okubo, Y; Uda, K | 1 |
| Caulfield, W; Estrada, LD; Freeman, B; Govorkova, E; Honce, R; Jones, J; Livingston, B; Meliopoulos, VA; Schultz-Cherry, S; Sharp, B; Wang, L | 1 |
| Balligand, T; Carpenet, C; Liu, X; Ploegh, HL | 1 |
| Cao, B; Cui, D; Deng, X; Liu, S; Mu, S; Wang, Y; Zou, X | 1 |
| Alám, LC; David, ML; Elaheh, M; Jazmin, GM; José, CB; Manuel Jonathan, FV; Martiniano, B | 1 |
| Barlow, S; Checovich, MM; Hamrick, I; Haupt, TE; Mundt, MP; Reisdorf, E; Shult, PA; Temte, JL | 1 |
| Wang, LX; Xie, YM; Yang, S | 1 |
| Desvergez, A; Gazaille, V; Lilienthal, F; Paganin, F; Verdier, V; Winer, A | 1 |
| Bodí, M; Canadell, L; Carbonell, R; Correig, E; Díaz, E; Guardiola, J; Marín-Corral, J; Martín-Loeches, I; Moreno, G; Papiol, E; Restrepo, MI; Reyes, LF; Rodríguez, A; Socias, L; Solé-Violán, J; Trefler, S; Vidaur, L | 1 |
| Govorkova, EA; Ivachtchenko, AV; Ivanenkov, YA; Ivashchenko, AA; Jones, JC; Karapetian, RN; Pascua, PNQ; Penaflor, MK; Shkil, DO | 1 |
| Bai, X; Chen, G; Fan, X; Li, Y; Tian, Y; Wang, K; Wang, W; Xi, S; Zhao, Y | 1 |
| Hayashida, S; Morioka, I; Nagano, N; Nezu, K; Udagawa, S | 1 |
| Ding, LM; Jiang, QR; Li, WG; Ma, WZ; Ma, X; Wu, DX; Yan, ZG; Yang, DW; Zhang, HC; Zhang, ST | 1 |
| Ferreira da Silva-Júnior, E; Huang, B; Jia, H; Ju, H; Kar, P; Li, P; Liu, C; Liu, X; Samanta, S; Zhan, P; Zhang, J; Zhang, Y | 1 |
| Barr, IG; Bobbitt, ME; Brown, SK; Chanthalavanh, P; Dapat, C; Deng, YM; Diefenbach-Elstob, TR; Peck, H; Rynehart, C; Spirason, N; Subbarao, K | 1 |
| Abdelaziz, A; Antoon, JW; Grijalva, CG; Lee, TA; Lien, PW; Sarker, J; Williams, DJ | 1 |
| Baba, K; Fukao, K; Kitade, N; Kusakabe, S; Noshi, T; Sakuramoto, M; Sato, K; Shano, S; Shishido, T; Tanioka, H | 1 |
| Chambers, CD; Johnson, D; Jones, KL; Luo, Y; Xu, R | 1 |
| Kerr, SM; Mitchell, AA; Van Bennekom, CM | 1 |
| Chi, Y; Cui, L; Ge, Y; Min, X; Shi, Z; Wu, B; Wu, T; Zhao, K; Zhu, F; Zhu, X | 1 |
| Branch-Elliman, W; Wright, SB; Yassa, DS | 1 |
| Balmaseda, A; Foxman, B; Gordon, A; Kuan, G; Lee, KH; López, R; Ng, S; Shedden, K | 1 |
| Chang, CS; Chen, TA; Chen, TC; Dutta, A; He, YC; Hseih, YC; Huang, CT; Huang, YL; Hung, CY; Lin, CY; Lin, YC; Shih, SR; Velu, AB | 1 |
| Arunkumar, G; Borkakoty, B; Chadha, M; Gupta, N; Hinge, D; Kaur, H; Malhotra, B; Potdar, V; Rabha, D; Vijay, N | 1 |
| L'Ecuyer, TJ; McCulloch, MD; Shirley, DA; Smith, CJ | 1 |
| Arias, G; Buitrago, R; Estupiñán, MC; Montenegro, JS; Osorio, JP; Poveda, CM; Silva, E | 1 |
| Monto, AS; Whitley, RJ | 2 |
| Behillil, S; Chicheportiche, T; de Prost, N; Dessap, AM; Enouf, V; Ferré, A; Fourati, S; Georger, JF; Guérin, L; Luyt, CE; Maury, E; May, F; Mayaux, J; Roux, D; Sonneville, R; Tandjaoui-Lambiotte, Y; van der Werf, S; Voiriot, G | 1 |
| Avihingsanon, A; Bao, Y; Beasley, RL; Beeler, J; Beigel, JH; Davey, RT; Holley, HP; Hoopes, J; Hoppers, M; Hughes, MD; Ison, M; Lane, HC; Langlois, N; Losso, MH; Manosuthi, W; Myers, CA; Ruxrungtham, K | 1 |
| Hashizume, H; Konishi, T; Matsubara, H; Naito, A; Nakayama, S; Saito, K; Sugisawa, J; Takebayashi, K | 1 |
| Azrad, M; Ben-Amram, H; Glikman, D; Kalish, T; Miron, D; Peretz, A; Rechnitzer, H | 1 |
| Ramanathan, K; Rohini, K; Shanthi, V | 1 |
| Boucher, CA; Clinch, B; Fouchier, RAM; Fraaij, PLA; Kenwright, A; Kumar, D; Monto, A; Nguyen-Van-Tam, JS; Osterhaus, ADME; Reed, V; Roosenhoff, R; Schutten, M; Whitley, R | 1 |
| Babiker, AG; Beigel, JH; Davey, RT; Engen, N; Fernández-Cruz, E; Gordin, F; Jain, MK; Kan, V; Khurana, S; Lane, HC; Lundgren, J; Markowitz, N; Neaton, JD; Pett, S; Polizzotto, MN; Riska, P; Ruxrungtham, K; Temesgen, Z; Wentworth, D | 1 |
| Collins, O; Kelly, E; McGrath, E; O’ Sullivan, S; Waqas, S | 1 |
| Choudhry, S; Christou, S; Jalal, H; Jones, NK; Ranellou, K; Reacher, M; Reeve, L; Sander, C; Verlander, NQ; Warne, B; Wright, C; Zambon, M; Zhang, H | 1 |
| Castañeda-Prado, A; Castillo-Flores, GDD; Kuri-Morales, PA; Pacheco-Montes, SR | 1 |
| Hibino, A; Kondo, H; Mawatari, M; Odagiri, T; Saito, R; Shobugawa, Y; Tanabe, I; Yagami, R | 1 |
| Ellis, J; Kennedy, M; Lackenby, A; Lam, T; Tang, JW | 1 |
| Bai, Q; Fei, GH; Ji, S; Shen, JL; Wang, S; Wu, X; Zhang, DW | 1 |
| Benken, LA; Kaplan, JM; Krallman, KA; Mizuno, T; Stoneman, EM; Tang Girdwood, SC; Vinks, AA; Wong, HR; Yunger, TM | 1 |
| Reacher, M; Verlander, NQ; Zambon, M | 1 |
| Bonovas, S; Lytras, T; Nikolopoulos, GK; Tsiodras, S | 1 |
| Hanpaibool, C; Leelawiwat, M; Rungrotmongkol, T; Takahashi, K | 1 |
| Cao, B; Chen, C; Fan, G; Guo, L; Hayden, FG; Horby, P; Lu, B; Pan, J; Salam, A; Wang, C; Wang, Y; Zheng, J | 1 |
| Voß, S | 1 |
| Ison, M; Lee, N | 1 |
| Aabenhus, R; Bjerrum, L; Bongard, E; Bucher, HC; Butler, CC; Chlabicz, S; Coenen, S; Colliers, A; Connor, JT; Cook, J; de Jong, MD; De Sutter, A; Francis, NA; Glinz, D; Godycki-Cwirko, M; Goossens, H; Holmes, J; Ieven, M; Jonassen Harbin, N; Kovács, B; Lewis, RJ; Lindbæk, M; Lionis, C; Little, P; Llor, C; Matheeussen, V; Murphy, AW; Openshaw, P; Radzeviciene Jurgute, R; Saville, BR; Seifert, B; Sundvall, PD; Touboul Lundgren, P; van der Velden, AW; Verheij, TJ | 1 |
| Eltorki, M; Sharif, S | 1 |
| Kampouri, E; Manuel, O; Mombelli, M | 1 |
| Ison, MG; Linder, JA | 1 |
| Bao, J; Chen, R; Chen, Y; Li, Y; Liu, S; Ma, J; Shen, B; Shen, W; Vijaykrishna, D; Wang, W; Wang, X; Wang, Y; Wu, W; Wu, X; Xie, F; Yu, F; Zhao, Z; Zheng, S; Zhou, T; Zou, Q | 1 |
| Hong, J; Huh, K; Jung, J; Kang, M; Shin, DH | 1 |
| Ahmad, S; Davies, E; Farooq, HZ; Guiver, M; Hesketh, L; Machin, N; Turner, AJ | 1 |
| Aguado-Barrera, M; Alcocer-González, JM; Alvarado-Díaz, A; Álvarez-Galván, E; Bermúdez de León, M; Castorena-Torres, F; Currás-Tuala, MJ; Elizondo, G; Escobedo-Guajardo, B; González-González, E; González-Ríos, RN; León-Cachón, RBR; Leyva-Parra, R; Mata-Tijerina, V; Puente-Lugo, L; Salinas-Martínez, AM; Silva-Ramírez, B; Tovar-Cisneros, B; Vázquez-Monsiváis, O | 1 |
| Abed, Y; Boivin, G; Carbonneau, J; Checkmahomed, L; Fage, C; Giannotti, F; Goncalves, AR; Kaiser, L; Schibler, M; Venable, MC | 1 |
| Chen, JY; Lai, CC; Wang, HH; Wei, SK; Weng, TS | 1 |
| Arabi, YM; Fowler, R; Hayden, FG | 1 |
| Rech, MA | 1 |
| Alsultan, MT; Ishaqui, AA; Khan, AH; Khan, I; Naqvi, AA; Sulaiman, SAS | 1 |
| Martin-Loeches, I; O'Sullivan, S; Rodriguez, A; Torres, A | 1 |
| Han, N; Kim, IW; Oh, JM | 1 |
| Miyazaki, C; Momoi, MY; Ohkusa, Y; Okabe, N; Sugawara, T; Taniguchi, K | 2 |
| Chon, I; Dapat, C; Hirokawa, C; Kamata, K; Kyaw Win, SM; Kyaw, LL; Kyaw, Y; Lasham, DJ; Lin, N; Odagiri, T; Osada, H; Saito, R; Saito, T; Saitoh, A; Tamura, T; Thein, KN; Thein, W; Tin, HH; Tin, OS; Uchida, Y; Watanabe, H; Watanabe, S; Win, NC | 1 |
| Banerjee, A; Biswas, M; Chawla-Sarkar, M; Dutta, S; Gupta, R; Majumdar, A; Mitra, S; Mukherjee, A; Saha, P | 1 |
| Bass, L; Cohen, A; Dowdell-Smith, CP; Foradori, D; Iacobas, I; Laufman, J; Owolabi, FS | 1 |
| Gubareva, L; Mohan, T | 1 |
| Kuentzmann-Klein, P; Martinot, M | 1 |
| Cheng, YH; Fang, QQ; Huang, WJ; Li, XY; Liu, J; Meng, Y; Tan, MJ; Wang, DY; Wei, HJ | 1 |
| Barr, IG; Brown, SK; Chow, MK; Patel, M; Peck, H; Price, OH; Rynehart, C; Soppe, S; Spirason, N; Todd, A | 1 |
| Lobo, RD; Luders, C; Roque, FL; Sousa, IQ; Ventura, CG | 1 |
| Astray, J; Castilla, J; Domínguez, À; Egurrola, M; Fernández, MA; Martín, V; Morales Suárez-Varela, M; Ortiz de Lejarazu, R; Soldevila, N; Tamames, S; Toledo, D | 1 |
| Abe, Y; Izumita, Y; Tsukano, S; Yamanaka, T | 1 |
| Sacks, HS | 1 |
| Cao, R; Dai, Q; Guo, X; Li, W; Li, X; Li, Y; Xia, Q; Xu, K; Yan, Y; Yang, J; Yang, K; Zhao, L; Zhong, W; Zou, G | 1 |
| Alexandrova, A; Dimitrova, A; Galabov, A; Georgieva, A; Krastev, D; Mileva, M; Tsvetanova, E | 1 |
| Campbell, AP; Uyeki, TM | 1 |
| Aiyer, H; Bhagwati, G; Chakrabarti, S; Jaiswal, SR; Soni, M; Thatai, A | 1 |
| Assy, N; Castro, A; Chu, T; Deng, R; Galanter, J; Horn, P; Kulkarni, P; Li, C; Lim, JJ; Maia, M; McBride, JM; Newton, EM; Nguyen, A; Nilsson, AC; Peck, MC; Silverman, M; Tavel, JA; Yang, X | 1 |
| Fukui, K; Ito, F; Kato, Y; Mimaki, M; Suzuki, K; Suzuki, S; Takahashi, K | 1 |
| Laplante, JM; Orfali, N; Plate, M; Salvatore, M; Soave, R; St George, K; van Besien, K | 1 |
| Kenjale, P; Pokharkar, V; Sahastrabudhe, H | 1 |
| Du, Z; Galvani, AP; Krug, RM; Meyers, LA; Nugent, C | 1 |
| Li, L; Liu, J; Qin, K | 1 |
| Hayden, FG; Ison, MG; Mitchener, M; Portsmouth, S; Shishido, T; Tsuchiya, K; Uehara, T; Yoshida, Y | 1 |
| Bankhead, C; Butler, CC; Kousoulis, AA; Lee, JJ; Perera Salazar, R; Smith, M; Wang, K | 1 |
| Baba, K; Kamimori, H; Kitano, M; Kiyota, K; Matsuzaki, T; Mizutare, T; Naito, A; Noda, T; Oka, R; Sato, A; Sato, K; Shishido, T; Yoshida, R; Yoshida, Y | 1 |
| Alexander, K; Boonwaat, L; Dronavalli, M; Fletcher-Lartey, SM; Lord, H; Pal, N | 1 |
| Guan, Y; Han, Y; Song, C; Yang, J; Zhang, X; Zheng, L | 1 |
| Bongard, E; Butler, CC; Cianci, D; Coenen, S; de Paor, M; Gobat, N; Goossens, H; Ieven, M; Saville, BR; van der Velden, AW; Verheij, TJ | 1 |
| Bulgakova, VA; Gorodin, VN; Kareva, EN; Pshenichnaya, NY; Selkova, EP; Volchkova, EV | 1 |
| Anderson, D; Deleu, S; Hallouin-Bernard, MC; Ison, MG; Kosoglou, T; Leopold, L; Nilsson, AC; O'Neil, B; Rossenu, S; Torres, A; Van Dromme, I; van Duijnhoven, W; Vingerhoets, J; Wilburn, JM | 1 |
| Fujita, J; Fujita, M; Inafuku, Y; Matsumoto, H; Toyama, J | 1 |
| Goretzko, J; Ludwig, S; Pleschka, S; Rescher, U; Schloer, S | 1 |
| Castro, A; Deng, R; Hanley, WD; Horn, P; Kulkarni, P; Lim, JJ; Maia, M; McBride, JM; Newton, E; Peck, MC; She, G; Tavel, JA | 1 |
| Fujisaki, S; Harada, N; Hino, M; Kakeya, H; Koh, H; Nakamae, H; Nanno, S; Okamura, H; Shibata, W; Takashita, E; Yamada, K | 1 |
| Chung, YS; Kang, C; Kim, HM; Kim, MS; Lee, N | 1 |
| Bando, T; Kato, M; Saisho, Y; Tanaka, H | 2 |
| Bejou, N; Gritsenko, D; Lemieux, SM; McManus, D; Rouse, GE; Shah, S; Tirmizi, S; Topal, JE | 1 |
| Erdil, E; Koytak, PK; Tuncer, EN; Vural, E | 1 |
| Bhardwaj, R; Dang, S; Gibiansky, L; Lemenuel-Diot, A; Nasmyth-Miller, C; Patel, K; Ravva, P; Smith, PF; Sturm, S; Zwanziger, E | 1 |
| Isoda, T; Kanegane, H; Miyaoka, F; Moiro, T; Toyofuku, E | 1 |
| Bo, H; Dong, J; Huang, WJ; Li, XY; Liu, J; Tang, J; Wang, DY; Xin, L; Yang, L; Zhang, J; Zhang, SX; Zhou, JF; Zou, SM | 1 |
| Alsultan, M; Ishaqui, AA; Khan, AH; Khan, I; Sulaiman, SA | 1 |
| de Boer, MGJ; de Vries, JJC; Groeneveld, GH; Ismail, N; Marbus, SD; Oosterheert, JJ; Schneeberger, P; van Dissel, JT | 1 |
| Arlett, P; Cocoros, NM; Dreyer, NA; Ishiguro, C; Iyasu, S; Sturkenboom, M; Toh, S; Zhou, W | 1 |
| Chow, K; Hooshmand, SI; Obeidat, AZ | 1 |
| Jones, TE | 1 |
| Dimopoulou, D; Douros, K; Papaevangelou, V; Pournaras, S; Vourli, S | 1 |
| Chi, H; Chiu, NC; Huang, CY; Huang, DT; Huang, FY; Huang, LM; Lee, CW; Tai, YL; Tu, YH; Wang, JY | 1 |
| Andreeva, IS; Filippova, EI; Mazurkova, NA; Puchkova, LI; Safatov, AS; Zakabunin, AI | 1 |
| Chon, I; Kawashima, T; Kodo, N; Ono, Y; Osada, H; Phyu, W; Saito, R; Saito, T; Sato, I; Shimada, Y; Shobugawa, Y; Wagatsuma, K | 1 |
| Dugas, AF; Hsieh, YH; LoVecchio, F; McBryde, B; Ricketts, EP; Rothman, RE; Saliba-Shaw, K | 1 |
| Slain, D | 1 |
| Bennett, C; Brehony, C; De Gascun, CF; Domegan, L; Dunford, L; McNamara, E; O'Donnell, J | 1 |
| Ernst, K; Obata, R | 1 |
| Al Moamen, A; Margolesky, J; Yen, J | 1 |
| Laurich, VM; Patel, P; Smith, S; Sturm, J | 1 |
| Ajisawa, Y; Fujiwara, M; Hara, K; Honda, K; Hosogaya, N; Iwata, S; Kitanishi, Y; Komeda, T; Miyauchi, H; Mukae, H; Ogura, E; Takazono, T; Watanabe, H | 1 |
| Drabko, K; Lejman, M; Zaucha-Prażmo, A; Zawitkowska, J | 1 |
| Aytekin, S; Aytekin, V; Çelik, HG; Ergönül, Ö; Kapmaz, M; Keske, Ş; Özyıldırım, A; Şahin, ŞT; Şener, Ü; Tekbaş, M | 1 |
| Chang, GT; Choi, M; Lee, SH | 1 |
| Jang, SC; Kang, HR; Shin, JY | 1 |
| Martins, J; Monteiro, A; Ribeiro, L | 1 |
| Chen, Y; Chi, YM; Du, JF; Du, WX; Han, GC; Li, M; Liu, F | 1 |
| Aaron, JG; DiMango, EA; Laplante, JM; Macesic, N; Miko, BA; Pereira, MR; Reshef, R; St George, K | 1 |
| Chiba, S | 1 |
| Ajisawa, Y; Fujiwara, M; Hara, K; Honda, K; Hosogaya, N; Iwata, S; Kitanishi, Y; Komeda, T; Miyauchi, H; Miyazaki, T; Mukae, H; Ogura, E; Takazono, T; Watanabe, H | 1 |
| Jansson, M; Rello, J; Solé-Lleonart, C; Tejada, S | 1 |
| Fang, J; Han, LM; Jiang, SJ; Li, FH; Li, GF; Li, L; Lin, JT; Liu, XP; Lu, GB; Lu, XL; Luo, SK; Ma, X; Meng, L; Nong, Y; Pang, GF; Peng, LP; Shen, DP; Sun, XW; Wang, H; Wang, HQ; Wang, J; Wang, WP; Wei, BL; Yuan, YD; Zha, RT; Zhang, W; Zhao, Q; Zhao, ZY; Zhen, H; Zhou, W | 1 |
| Botelho-Nevers, E; Cantais, A; Cizeron, A; Gagneux-Brunon, A; Pillet, S; Saunier, F | 1 |
| Amaya Dimas, LDC; Aoki, Y; Kitazawa, K; Mizushiro, N | 1 |
| Hakendorf, P; Horwood, C; Sharma, Y; Thompson, C | 1 |
| Achanta, M; Ashar, HK; Chow, VTK; Malayer, JR; Maram, P; Pulavendran, S; Rudd, JM; Snider, TA; Teluguakula, N | 1 |
| Hayat Khan, A; Ishaqui, A; Khan, I; Sulaiman, SAS; Taher Alsultan, M | 1 |
| Alsultan, M; Ishaqui, AA; Khan, AH; Khan, I; Syed Sulaiman, SA | 1 |
| Brady, J; Fetters, M; Francisco, J; Kim, C; MacLaren, R; Welker, C | 1 |
| Chou, SC; Fang, YH; Hsu, TH; Lin, TY; Liu, CH; Perng, PC; Wu, JY | 1 |
| Milano, G | 1 |
| Bhat, P; Kalra, A; Kaur, IP | 1 |
| Clinch, B; Fouchier, RAM; Fraaij, PLA; Reed, V; Roosenhoff, R; Schutten, M; van der Linden, A | 1 |
| Laghdir, Z; Quach, C; Tadount, F | 1 |
| Au Yeung, V; Georgiou, A; Overton, K; Post, JJ; Rawlinson, W; Thapa, K | 1 |
| Andresen Vásquez, M; Ávila-Smirnow, D; Barriga Gonzaga, J; Muñoz-Osores, E; Sánchez Ortiz, N; Valle Muñoz, P | 1 |
| Bai, Y; Jones, JC; Wong, SS; Zanin, M | 1 |
| Antikainen, P; Heikkinen, T; Mattila, JM; Vuorinen, T; Waris, M | 1 |
| Chen, CH; Kuo, YC; Lai, CC; Wang, CY; Wang, YH | 1 |
| Bando, T; Chong, Y; Ikematsu, H; Kawai, N; Shindo, S; Takasaki, Y; Tani, N | 1 |
| Aizawa, F; Azuma, M; Chuma, M; Fujiwara, N; Goda, M; Hamano, H; Hashimoto, I; Ishizawa, K; Kirino, Y; Nakamura, T; Okada, N; Tsujinaka, K; Yagi, K; Zamami, Y | 1 |
| Blevins, P; Chesnokov, A; De La Cruz, JA; Gubareva, LV; Kniss, K; Kondor, R; Laplante, J; Merced-Morales, AA; Mishin, VP; Mohan, T; Nguyen, HT; St George, K; Wentworth, DE | 1 |
| Asher, J; Cowling, BJ; Du, Z; Hayden, FG; Hurt, AC; Ikematsu, H; Kuhlbusch, K; Lemenuel-Diot, A; Meyers, LA; Monto, AS; Piedra, PA; Takazono, T; Yen, HL | 1 |
| Aabenhus, R; Beutels, P; Bilcke, J; Bongard, E; Bruno, P; Bruyndonckx, R; Butler, CC; Coenen, S; Francis, N; Garcia-Sangenis, A; Glinz, D; Harbin, NJ; Kosiek, K; Li, X; Mikó-Pauer, R; Radzeviciene Jurgute, R; Seifert, B; Sundvall, PD; Tsakountakis, N; van der Velden, AW | 1 |
| Govorkova, EA; Gubareva, LV; Hay, AJ; Hayden, FG; Ison, MG; McKimm-Breschkin, JL; Takashita, E | 1 |
| Furukawa, M; Ishiguro, N; Kinoshita, M; Manabe, A; Morioka, I; Nakano, T; Tanaka, S | 1 |
| Fang, Q; Feng, Z; Gao, R; Huang, W; Li, X; Liu, J; Liu, L; Tang, J; Wang, D; Xu, C; Zhang, S | 1 |
| Bhardwaj, R; Gibiansky, L; Hernández-Sánchez, J; Jolivet, S; Jordie, EB; Knab, T; Lemenuel-Diot, A; Nasmyth-Miller, C; Ravva, P; Sturm, S; Zwanziger, E | 1 |
| Brydak, LB; Gołębiak, I; Kanecki, K; Kuchar, E; Nitsch-Osuch, A; Tarka, P | 1 |
| Kondrich, J; Rosenthal, M | 1 |
| Aarthy, R; Bhushan, A; Chadha, MS; Deoshatwar, AR; Gurav, YK; Pawar, SD; Potdar, VA; Shil, P; Tandale, BV | 1 |
| Klinfueng, S; Korkong, S; Poovorawan, Y; Suntronwong, N; Tewawong, N; Theamboonlers, A; Thongmee, T; Vichiwattana, P; Vongpunsawad, S | 1 |
| Cho, JY; Jang, IJ; Lee, H; Lee, S; Lim, KS; Oh, J; Yoon, SH; Yu, KS | 1 |
| Gambhir, HS; Patel, KM; Shah, SP; Subedi, R | 1 |
| Atreya, A; Gupta, J; Malhotra, B; Meena, BR; Meena, D; Sharma, P; Singh, R | 1 |
| Alessi, MC; Courtin, N; Fautrad, P; Fotso, AF; Mas, F; Riteau, B | 1 |
| Chu, CY; de Silva, UC; Guo, JP; Huang, LY; Lee, VJ; Li, SL; Wang, Y; Wen, L | 1 |
| Barnes, J; Brooks, A; Fallows, E; Fry, AM; Gubareva, LV; Hodges, E; Jacobson, R; Kramp, W; Mishin, VP; Shively, R; Weidemaier, K; Wentworth, DE | 1 |
| Del Mar, C; Doshi, P; Jones, M | 1 |
| Chan, MCW; Chan, PKS; Cheung, CSK; Choi, KW; Hui, DSC; Kwok, A; Lee, N; Leung, WS; Lui, GCY; Tam, WWS; Tsang, OTY; Wong, CK; Wong, RYK; Yeung, ESL; Yung, IMH | 1 |
| Jwa, H; Kim, YH; Lee, J; Park, JH | 1 |
| Angioletti-Uberti, S; Bardua, M; Bhatia, S; Böttcher, C; Budt, M; Haag, R; Hamann, A; Herrmann, A; Hoffmann, U; Lauster, D; Ludwig, K; Paulus, F; Popp, N; Stadtmüller, M; Wolff, T | 1 |
| Luis, BAL; Navarro, AO; Palacios, GMR | 1 |
| Asis, E; Azarbal, A; Chahal, K; Hassoun, A; Huff, MD; Lu, S | 1 |
| Chen, T; Feng, Z; Greene, CM; Havers, F; Iuliano, AD; Kang, M; Li, C; Li, D; Li, Q; Liu, F; Ni, D; Ren, R; Tan, Y; Uyeki, TM; Wang, D; Wang, Y; Wu, J; Yang, Y; Zhang, H; Zhou, L; Zhou, S | 1 |
| Chen, RS; Chen, YM; Deng, L; He, CH; Liao, JY; Lin, CX; Lin, GY; Lin, JH; Liu, CY; Peng, Q; Wang, SJ; Zhang, T; Zheng, XF | 1 |
| Kmietowicz, Z | 7 |
| Ahmed, JJ; Constable, JD; De, M; Kamani, T | 1 |
| Bin, Y; Huachong, X; Jia, C; Jiao, N; Ke, Z; Li, D; Peng, P; Xianlin, W; Xiaoyin, C | 1 |
| Cai, J; Chen, T; Fang, XB; Fu, XY; Li, J; Li, Z; Pan, ZQ; Qiu, LM; Wang, WL; Zhang, Y; Zhou, JL | 1 |
| Han, H; Lin, H; Lu, G; Pang, Y; Qi, J; Qiu, H; Wang, X; Yang, R; Yang, Y; Yu, L; Zhang, Y; Zhu, W | 1 |
| Blanchon, T; Charlois-Ou, C; Chevret, S; Duval, X; Flicoteaux, R; Leport, C; Lina, B; Mosnier, A; Protopopescu, C; Tibi, A; Werf, SV | 1 |
| Ebell, MH | 4 |
| Escuret, V; Gaymard, A; Josset, L; Lina, B; Millat, G; Pichon, M; Valette, M | 1 |
| Dechering, DG; Eckardt, L; Ellermann, C; Frommeyer, G; Kochhäuser, S; Leitz, P; Mittelstedt, A; Wolfes, J | 1 |
| Asai, N; Furui, T; Hagihara, M; Kato, H; Kato, Y; Koizumi, Y; Kurumiya, A; Mikamo, H; Nishiyama, N; Sakata, M; Takahashi, T; Yamagishi, Y | 1 |
| Abed, Y; Boivin, G; Fage, C; Pizzorno, A; Rhéaume, C | 1 |
| Dong, X; Feng, Y; Gao, L; Miao, J; Min, H; Wang, X; Xia, X; Zhang, C; Zhang, M; Zhao, J; Zhao, Y | 1 |
| Besselaar, TG; Daniels, RS; Fry, A; Gregory, V; Gubareva, LV; Huang, W; Hurt, AC; Jorquera, PA; Lackenby, A; Leang, SK; Lo, J; Meijer, A; Odagiri, T; Pereyaslov, D; Rebelo-de-Andrade, H; Siqueira, MM; Takashita, E; Wang, D; Zhang, W | 1 |
| Jiang, LZ; Jiao, XY; Ke, CW; Liu, SS; Su, WZ; Wang, S; Xiong, P; Zhang, X | 1 |
| Fukushima, W; Hatayama, H; Hirota, Y; Hosoya, M; Ito, K; Kondo, K; Mori, M; Nakamura, Y; Nakano, T; Ochiai, H; Ohfuji, S; Okumura, A; Ozasa, K; Suzuki, H; Tanabe, T; Yamaguchi, N | 1 |
| Kumar, A; Pooniya, V; Verma, N | 1 |
| Chang, YS; Cho, SH; Cho, YJ; Kang, HR; Kim, MH; Kim, SH; Kim, YY; Kwon, JW; Lee, SH; Min, KU; Park, HW; Song, WJ; Yang, MS | 1 |
| Buettner, I; Chow, MK; Lau, H; Leang, SK; Leung, VK; Spirason, N | 1 |
| Baranovich, T; Davis, CT; Gubareva, LV; Guo, Z; Hodges, E; Sleeman, K; Stevens, J; Yang, H | 1 |
| Ison, MG | 3 |
| Bao, Y; Beasley, RL; Beeler, J; Beigel, JH; Bozzolo, DR; Dar, SM; Davey, RT; Holley, HP; Hoopes, J; Hughes, MD; Lane, HC; Losso, MH; Manosuthi, W; McClure, N; Myers, C; Panuto, J; Perez-Patrigeon, S; Slandzicki, A; Suwanpimolkul, G | 1 |
| Boikos, C; Doll, MK; Gore, G; Kraicer-Melamed, H; Quach, C; Winters, N | 1 |
| Mulinari, S; Vilhelmsson, A | 1 |
| Allou, N; Allyn, J; Antok, E; Brottet, E; Coolen-Allou, N; Dangers, L; Persichini, R; Roquebert, B; Vandroux, D | 1 |
| Argaud, L; Casalegno, JS; Chroboczek, T; Cour, M; Hernu, R; Lina, B; Madelaine, T | 1 |
| Ahn, SJ; Baek, YH; Chae, HB; Choi, WS; Choi, YK; Govorkova, EA; Hwang, J; Jeong, JH; Kim, CJ; Kim, MH; Kwon, HI; Kwon, JJ; Lloren, KKS; Song, MS; Webby, RJ | 1 |
| Andreatos, N; Mylonakis, E | 1 |
| Barde, PV; Potdar, VA; Sahare, LK; Sahu, M; Sharma, RK; Shukla, MK; Singh, N; Ukey, MJ | 1 |
| Behzadian, F; Fotouhi, F; Moasser, E; Moattari, A; Zaraket, H | 1 |
| Geladari, E; Lu, D; Moore, H; Papademetriou, V | 1 |
| Guo, L; He, J; Huang, G; Kang, M; Song, T; Tan, X; Yang, Y; Zhong, H | 1 |
| Azzam, ZS; Braun, E; Khoury, J; Kra-Oz, Z; Neuberger, A; Paul, M; Saffuri, M; Seh, K; Szwarcwort, M; Yahalomi, T | 1 |
| Ishii, H; Ishimoto, H; Kadota, JI; Mukae, H; Nishida, C; Noguchi, S; Sakamoto, N; Umeki, K; Yamasaki, K; Yatera, K | 1 |
| Cleghorn, S | 1 |
| Favié, LM; Meijer, A; Murk, JL; Nijstad, AL; Sikma, MA; van Maarseveen, EM | 1 |
| Brooks, WA; Heikkinen, T; Malosh, RE; Martin, ET; Monto, AS; Whitley, RJ | 1 |
| Kannan, S; Kolandaivel, P | 1 |
| Bae, MA; Go, YY; Jang, Y; Kim, M; Kim, SS; Ku, KB; Kwon, OS; Shin, D; Shin, JS; Yoon, YS | 1 |
| Boucher, C; Lina, B; Monto, AS; Nguyen-Van-Tam, JS; Osterhaus, A; Schutten, M; Whitley, RJ | 1 |
| Behzadian, F; Kananizadeh, P; Moeini, S; Mozhgani, SH; Pakzad, R; Zarei Ghobadi, M | 1 |
| Hasegawa, T; Hirotsu, N; Saisho, Y; Shishido, T | 1 |
| Dash, PK; Parida, M; Sharma, S; Tandel, K | 1 |
| Uyeki, TM | 3 |
| Ait-Aissa, A; Bouslama, Z; Derrar, F; Gradi, EA; Hannoun, D; Scaravelli, D | 1 |
| Ahmad, K; Ammar, W; El Bazzal, B; Farah, ZE; Ghosn, N; Hamadeh, S; Khatib, O; Zalloua, P | 1 |
| Cooper, MJ; Darling, N; Doepking, M; Harris, S; Hawksworth, AW; Kremer, P; Myers, CA; Sanchez, JL; Steiner, SC; Swanson, KC | 1 |
| Liang, CY; Lin, JN; Yang, CH | 1 |
| Liese, JG; Prifert, C; Sauerbrei, A; Schmidt-Ott, R; Streng, A; Weissbrich, B | 1 |
| Chillarige, Y; Ferdinands, JM; Forshee, R; Fry, A; Izurieta, HS; Kelman, JA; Lu, M; Lu, Y; Pratt, D; Qiang, Y; Shay, DK; Wei, Y; Wernecke, M; Xu, W | 1 |
| Hagihara, M; Hirai, J; Kato, H; Kato, Y; Koizumi, Y; Kurumiya, A; Mikamo, H; Nishiyama, N; Sakanashi, D; Sakata, M; Suematsu, H; Takahashi, T; Yamada, A; Yamagishi, Y | 1 |
| Chaiyakunapruk, N; Chong, HY; Dall, G; Kamal, MA; Kamauu, A; Kirkpatrick, CM; Kong, DCM; Lee, KKC; Nelson, RE; Nieforth, K; Pratoomsoot, C; Rayner, CR; Smith, PF; Toovey, S; Wu, DBC | 2 |
| Christiansen, CB; Fischer, TK; Trebbien, R | 1 |
| Bamba, D; Galarneau, JR; Growcott, EJ; Leonard, VHJ; Osborne, CS; Schul, W; Stein, D | 1 |
| Cárdenas, AM; Chang, YC; Feemster, K; Mitchell, SL | 1 |
| Akutsu, Y; Aoyagi, H; Ariga, T; Arioka, H; Azuma, K; Furuyama, H; Hatae, Y; Hazama, K; Inagawa, A; Ishiguro, N; Ishizaka, A; Kaiho, M; Kawamura, N; Kikuta, H; Koike, A; Konno, M; Koseki, N; Kumita, Y; Matsuzono, Y; Morita, K; Murashita, M; Nagano, N; Oba, K; Odagawa, Y; Okamura, A; Sawada, Y; Shibata, M; Shida, S; Tabata, Y; Takada, K; Tobise, C; Togashi, T; Tsubakihara, K; Tsuchida, A; Tsuchiyama, A; Uetsuji, K; Watanabe, T; Yamanaka, T; Yamazaki, S; Yasoshima, K; Yasuda, K; Yoshioka, M | 1 |
| Harris, M; Paul Duprex, W; Stertz, S | 1 |
| Chillarige, Y; Dahlgren, FS; Forshee, RA; Izurieta, HS; Kelman, JA; Lu, Y; Reed, C; Shay, DK; Wernecke, M | 2 |
| Adimadhyam, S; Antoon, JW; Harrington, R; Lee, TA; Schumock, GT | 1 |
| Liu, J; Long, X; Luo, H; Pan, X; Shen, F; Wang, S; Wu, J; Yao, L; Yuan, T | 1 |
| Chen, Y; Dou, J; Guo, M; Jin, J; Ma, L; Wang, D; Zhou, C | 1 |
| Allen, JD; Ross, TM | 1 |
| Cai, LH; Cao, B; Chen, P; Chen, S; Chi, R; Deng, X; Deng, Y; Fu, L; Gu, L; Guo, B; Guo, Q; He, Z; Hong, L; Hong, Y; Huang, X; Ing Zhou, Y; Jiang, M; Li, H; Li, YP; Lu, W; Luo, H; Mao, W; Min, H; Shang, J; Shen, X; Shu, H; Song, K; Uyeki, TM; Wang, C; Wang, Y; Wei, T; Weng, H; Wu, M; Wu, W; Wu, YF; Yan, Z; Yang, Y; Yao, L; Yu, L; Yuan, J; Zhang, L; Zhang, W; Zhang, Z; Zhao, B; Zhao, H; Zhou, D; Zhou, S | 1 |
| Chaves, SS; Fry, AM; Peyrani, P; Ramirez, J; Wiemken, T | 1 |
| Burdiles, P; Herrera, P; Kraemer, P; Mendoza, C; Muñoz, C; Neumann, I; Núñez, E; Sepúlveda, D | 1 |
| Bahirwani, J; Gonakoti, S; Maddala, RNM; Vidyasagar, S | 1 |
| Fushimi, K; Matsui, H; Michihata, N; Miyairi, I; Morisaki, N; Okubo, Y; Shoji, K; Uda, K; Yasunaga, H | 1 |
| Rohini, K; Shanthi, V | 1 |
| Bai, W; Cao, B; Chen, H; Fan, Y; Guo, Q; Liu, C; Lu, B; Wang, Y; Zhang, W; Zhou, F; Zou, X | 1 |
| Bradbury, N; Lim, WS; Nguyen-Van-Tam, J | 1 |
| Basnet, A; Dy, P; Shah, S; Shaikh, N | 1 |
| Bakulina, AY; Durymanov, AG; Goncharova, NI; Ilyicheva, TN; Kolosova, NP; Maksyutov, RA; Marchenko, VY; Pyankova, OG; Ryzhikov, AB; Sobolev, IA; Susloparov, IM; Svyatchenko, SV | 1 |
| Chang, H; Chung, KH; Huang, YJ; Lin, SY | 1 |
| Alghsoon, S; Hassankrishnamurthy, S; Kota, VK; Puttagunta, H; Regula, P | 1 |
| Jiang, D; Loeppky, C; Singh, D; Van Caeseele, P | 1 |
| Tong, XC; Weng, SS; Wu, X; Xu, TM; Xue, F; Zhang, WH | 1 |
| Fukushima, A; Okamura, M; Ono, H | 1 |
| Hejdánek, J; Hudlický, J; Karlukova, E; Konvalinka, J; Kožíšek, M; Machara, A; Pachl, P; Pokorná, J; Řezáčová, P | 1 |
| Hasegawa, T; Hirotsu, N; Saisho, Y | 1 |
| Ahmed, A; Kapadia, S; Millership, S; Yip, JLY | 1 |
| Ikeda, K; Kato, D; Kurebayashi, Y; Minami, A; Otake, H; Otsubo, T; Suzuki, T; Takahashi, T; Tamoto, C; Yamazaki, M | 1 |
| Beutels, P; Bongard, E; Brugman, C; Butler, CC; Chlabicz, S; Coenen, S; Colliers, A; Cook, J; Davies, M; de Jong, M; De Paor, M; De Sutter, A; Francis, NA; Glinz, D; Godycki-Ćwirko, M; Goossens, H; Holmes, J; Ieven, M; Lindbaek, M; Little, P; Martinón-Torres, F; Moragas, A; Munck Aabenhus, R; Pauer, J; Pfeiferová, M; Radzeviciene-Jurgute, R; Saville, B; Sundvall, PD; Torres, A; Touboul, P; van der Velden, AW; Varthalis, D; Verheij, T | 1 |
| Boianelli, A; Hernandez-Vargas, EA; Meyer-Hermann, M; Montaseri, G | 1 |
| Albati, F; Chilundo, J; Daniels, R; Gudo, E; Machalele, L; Mateonane, E; Mavale, S; McCauley, J; Mussá, T; Muteto, D; Nacoto, A; Nguenha, N; Pale, M; Salência, J; Tivane, A | 1 |
| Cocoros, NM; Haug, N; Maher, C; Panucci, G; Reichman, M; Toh, S | 1 |
| Bi, Y; Gao, GF; Li, H; Li, S; Lin, J; Liu, W; Liu, Y; Ma, S; Wong, G; Xu, W; Xu, Z; Yang, Y; Zhao, Q; Zhao, X; Zheng, H | 1 |
| Chen, C; Chen, L; Guo, L; Guo, Q; Huang, JA; Mu, C; Wang, J; Xu, H | 1 |
| Hernandez-Mejia, G; Hernandez-Vargas, EA; Nguyen, VK; Parra-Rojas, C | 1 |
| Ali, SO; Chiong, R; Dubovsky, F; Kallewaard, NL; Mallory, RM; Nyborg, A; Shoemaker, K; Takas, T | 1 |
| Eom, G; Guk, K; Ha, K; Hwang, SG; Jung, J; Kang, T; Lee, DK; Lim, EK; Park, H; Song, S | 1 |
| Arai, M; de Jong, MD; Hayden, FG; Hirotsu, N; Hurt, AC; Ishida, T; Kawaguchi, K; Lee, N; Portsmouth, S; Sekino, H; Shishido, T; Sugaya, N; Tsuchiya, K; Uehara, T; Watanabe, A; Yamada, K | 1 |
| Scott, LJ | 1 |
| Dai, H; Lu, Y; Ma, L; Mu, X; Wang, Y; Yao, J; Yu, P; Zhang, H | 1 |
| Del Mar, C; Jones, M; Tett, SE | 1 |
| Araki, K; Atsuta, N; Ito, M; Kagawashira, Y; Katsuno, M; Senda, J; Sobue, G; Tachi, Y; Watanabe, H | 1 |
| Abed, Y; Boivin, G; Carbonneau, J; Checkmahomed, L; Dufresne, SF; Fage, C; Kobinger, G; Tu, V; Venable, MC | 1 |
| Mazzetti, A; Neary, JD | 1 |
| Hung, IFN; Yuen, KY | 1 |
| Akand, EH; Downard, KM | 1 |
| de Jong, MD | 2 |
| Houk, JL; Ison, MG; Katzen, J; Kohn, R | 1 |
| Escuret, V; Gaymard, A; Javouhey, E; Josset, L; Lina, B; Malcus, C; Massenavette, B; Millat, G; Monneret, G; Morfin-Sherpa, F; Picard, C; Pichon, M; Renard, C; Simon, B; Valette, M | 1 |
| Beard, KR; Brendish, NJ; Clark, TW | 1 |
| Clinch, B; Ehrenstein, V; Kenwright, A; Kristensen, NR; Monz, BU; Sørensen, HT | 1 |
| Sandoval-Gutiérrez, JL | 1 |
| Abdalla, MI; Aliberti, S; Blasi, F; Di Pasquale, MF; Gramegna, A; Jankovic, M; Mahesh, PA; Marcos, PJ; Radovanovic, D; Restrepo, MI; Reyes, LF; Santus, P; Sotgiu, G; Terraneo, S | 1 |
| Berenguer Albiñana, C; Císařová, I; Hudlický, J; Konvalinka, J; Kožíšek, M; Machara, A; Navrátil, V; Pachl, P; Pokorná, J; Řezáčová, P; Rojíková, K; Šácha, P; Zemanová, J | 1 |
| Kang, HR; Kim, WJ; Lee, EK; Shin, JY | 1 |
| Anderson, D; Finberg, RW; Fleischhackl, R; Kauffman, RS; Kosoglou, T; Lanno, R; Leopold, L; van Duijnhoven, W; Vingerhoets, J | 1 |
| Ison, MG; Lee, N | 1 |
| Belucci, TR; Dos Santos, OFP; Edmond, MB; Mafra, ACCN; Marra, AR; Pinho, JRR; Yokota, PKO | 1 |
| De Briel, D; Gerber, V; Greigert, V; Gronnwald, A; Martinot, M; Mohseni Zadeh, M; Rosolen, B; Thibaud, E | 1 |
| Beekmann, SE; Butler, K; Coffin, SE; Cunney, R; Drew, RJ; Kitt, E; Polgreen, P; Zaoutis, T | 1 |
| Hassan, F; Jackson, MA; Lee, BR; Selvarangan, R | 1 |
| Ben-Hamouda, N; Jahns, FP; Kirsch, M; Liaudet, L; Roumy, A | 1 |
| Brendish, NJ; Clark, TW | 1 |
| Asai, K; Fujioka, M; Hirata, K; Kimura, T; Kureya, Y; Shinataku, H; Tocino, Y; Yoshi, N | 1 |
| Ishibashi, T; Koshimichi, H; Tsuda, Y; Wajima, T | 1 |
| Aoi, S; Golfeyz, S; Harrington, M; Kobayashi, T | 1 |
| Cheng, TJ; Cheng, YE; Fang, JM; Hong, BT | 1 |
| Angeletti, S; Anguissola, GB; Ciccozzi, M; Costantino, S; Locorriere, L; Pantano, AL; Riva, E; Spoto, S; Terracciani, F; Valeriani, E | 1 |
| Bromley, C; Reynard, C | 1 |
| Ban, C; Chung, J; Chung, WJ; Heo, P; Hwang, BJ; Jung, Y; Kim, P; Kim, Y; Kim, YH; Kong, B; Kweon, DH; Moon, S; Seong, BL; Shin, YK; Yu, SH | 1 |
| Cheng, Y; Huang, W; Li, X; Shu, Y; Tan, M; Wang, D; Wei, H; Xiao, N; Yang, L; Zhao, X | 1 |
| Miyazaki, C; Momoi, M; Ohkusa, Y; Okabe, N; Sugawara, T; Taniguchi, K | 1 |
| Andreopoulou, A; Bonovas, S; Lytras, T; Mouratidou, E; Tsiodras, S | 1 |
| Demesmaecker, M; Grootaert, V; Reynders, M; Steyaert, S; Van Praet, JT | 1 |
| Alfayate, S; Couceiro, JA; Cruz-Cañete, M; Launes, C; Otheo, E; Pérez, C; Tagarro, A | 1 |
| Chen, R; Fang, Z; Huang, Y | 1 |
| Sato, D; Takeuchi, S; Tetsuhashi, M | 1 |
| Bragstad, K; Dorenberg, DH; Hauge, SH; Hungnes, O; Litleskare, I; Nyrerød, HC | 1 |
| Bakota, E; Becker, L; Beckham, D; Haynie, A; Hornstein, BD; Jin, S; Kiger, J; Liu, L; McClendon, M; Perez, E; Reed, BC; Schaffer, M; Shah, UA; Zangeneh, A | 1 |
| Helve, O; Kaila, M; Mukka, M; Mustonen, P; Pesälä, S; Virtanen, MJ; Ylilammi, K | 1 |
| Böttiger, B; Brytting, M; Carnahan, A; Enkirch, T; Fält, R; Hagey, TS; Hagstam, P; Wiman, Å | 1 |
| Guan, W; He, J; Huang, W; Li, Z; Ma, H; Wang, X; Yang, ZF | 1 |
| Kang, HR; Kim, JH; Lee, EK; Shin, JY | 1 |
| Hoepelman, AIM; Kaasjager, KHAH; Oosterheert, JJ; Riezebos-Brilman, A; Vos, LM; Weehuizen, JM | 1 |
| Gabriel, G; Klingen, TR; Loers, J; McHardy, AC; Stanelle-Bertram, S | 1 |
| Calistri, A; Del Vecchio, C; Franchin, E; Marini, G; Nicolè, S; Palù, G; Parolin, C; Salata, C; Sgarabotto, D; Solimbergo, E | 1 |
| Barisione, G; Bruzzone, B; Butera, F; Grammatico, F; Guarona, G; Murdaca, G; Orsi, A; Schenone, S; Setti, M; Tisa, V | 1 |
| Leung, CH; Liu, JB; Ma, DL; Wu, C; Wu, KJ; Zhou, XM | 1 |
| Bando, T; Chong, Y; Ikematsu, H; Iwaki, N; Kashiwagi, S; Kawai, N | 1 |
| Covello, LHS; Da Silva Teixeira, RER; de Godoy, LG; de Oliveira, NE; Dutra, KR; Frini, ICM; Furlan, NP; Gandolfi, JV; Lobo, SM; Nogueira, ML; Queiroz, F; Sacillotto, GH; Salomão, MLM; Simões, ES; Watanabe, ASA | 1 |
| Monto, AS | 4 |
| Ando, Y; Fukao, K; Kawai, M; Kitano, M; Naito, A; Noda, T; Noshi, T; Sato, A; Shishido, T; Yoshida, R | 1 |
| Bassetti, M; Carnelutti, A; Castaldo, N | 1 |
| Benden, C; Jungo, C; Russmann, S; Schuurmans, MM | 1 |
| Buettner, I; Chow, MK; Iannello, P; Kaye, M; Lau, H; Leung, VK; Roe, M; Tolosa, MX; Zakis, T | 1 |
| Doganis, D; Giannouli, G; Goussetis, E; Kattamis, A; Kosmidis, H; Kottaridi, C; Kourlamba, G; Paisiou, A; Papadakis, V; Papaevangelou, V; Polychronopoulou, S; Priftis, K; Syridou, G; Tourkantoni, N; Vliora, C; Zaoutis, T | 1 |
| Chen, PC; Ho, TH; Lee, JT; Wang, CW; Yang, FC; Yuan, HT | 1 |
| Cheng, Y; Huang, W; Li, X; Tang, J; Wang, D; Wei, H; Xin, L; Yang, L; Zhang, J; Zhou, J; Zhu, W; Zou, S | 1 |
| Ai, B; Chen, MX; He, DM; Li, XF; Liu, HS; Tan, LM; Xu, Y; Yang, FX; Yang, HM; Ye, JW; Zeng, FS | 1 |
| Cao, L; Chen, R; Huo, Z; Xie, G; Yang, X; Yu, F; Zheng, S; Zou, Q | 1 |
| Al Nami, H; Alsultan, MT; Ishaqui, AA; Khan, AH; Khan, I; Syed Sulaiman, SA | 1 |
| A, K; A, S; C, T; Dv, S; V, K | 1 |
| Baba, K; De Jong, MD; Hayden, FG; Hirotsu, N; Hurt, AC; Kawaguchi, K; Kida, H; Lee, N; Omoto, S; Portsmouth, S; Shishido, T; Sugaya, N; Tsuchiya, K; Uehara, T | 1 |
| de Jong, MD; Eggink, D; Isfandari, S; Pawestri, HA; Rogier van Doorn, H; Setiawaty, V; Thanh, TT | 1 |
| Biggs, M; Bradley, CW; Carmalt, S; Garvey, MI; Holden, E; Osman, H; Reddy-Kolanu, V; Wilkinson, MAC | 1 |
| Chen, Y; Ding, C; Fu, X; Huang, C; Li, L; Liu, X; Vijaykrishna, D; Wu, J; Yang, S; Zheng, S; Zhou, Y | 1 |
| Chen, G; Fan, HW; Han, Y; Huang, J; Li, GW; Li, HL; Li, LZ; Li, TS; Li, XW; Liu, SM; Liu, W; Lu, QF; Lu, WZ; Su, ZQ; Wang, SY; Wang, Y; Wu, H; Yao, HY; Ye, WX; Zhang, WH; Zhu, GF | 1 |
| Aktas, AR; Altas, AB; Bakkaloglu, Z; Bayraktar, F; Coskun-Ari, FF; Durmaz, R; Guldemir, D; Korukluoglu, G; Unaldi, O | 1 |
| Ala-Kokko, T; Herwald, H; Kaukonen, KM; Lindbom, L; Linko, R; Pettilä, V; Ruokonen, E | 1 |
| Adachi-Akahane, S; Ikeda, T; Kitahara, K; Nakamura, Y; Sugiyama, A; Takahara, A; Tanaka, H; Tsuneoka, Y; Yamazaki, H; Yamazaki, J | 1 |
| Dahdouh, Z; Grollier, G; Lognone, T; Massetti, M; Roule, V; Sabatier, R | 1 |
| Bâ, M; Dia, N; Diadhiou, SA; Diop, OM; Faye, A; Goudiaby, DG; Kiori, D; Michel, R; Niang, MN | 1 |
| Beijnen, JH; de Lange, DW; Huitema, AD; Kromdijk, W; Sikma, MA; van den Broek, MP | 1 |
| Edwards, AS | 1 |
| Chen, S; Liu, Q; Wang, D; Wang, S; Zhang, Y | 1 |
| Garnacho-Montero, J; Granada, R; Gutiérrez-Pizarraya, A; Màrquez, JA; Rello, J; Rodríguez, A; Ruiz-Santana, S; Zaragoza, R | 1 |
| Bonfanti, C; Cattaneo, C; Corbellini, S; Perandin, F; Piccinelli, G; Pollara, CP; Rossi, G; Tomasi, DD | 1 |
| Haasbach, E; Hartmayer, C; Planz, O | 1 |
| Abed, Y; Boivin, G; Pizzorno, A; Samson, M | 1 |
| Cabral, E; Carratalá, J; Cordero, E; Cruzado, JM; Delgado, JF; Gavaldá, J; Gómez-Bravo, MÁ; López-Medrano, F; Marcos, MÁ; Pérez-Romero, P; Sabé, N | 2 |
| Fujisaki, S; Imai, M; Kishida, N; Odagiri, T; Sato, H; Takashita, E; Taniwaki, T; Tashiro, M; Xu, H; Yokoyama, M | 1 |
| Barr, IG; Butler, J; Downie, P; Hurt, AC; Kelso, A; Leang, SK; Mechinaud, F; Tiedemann, K | 1 |
| Rawat, G; Saxena, RK; Tripathi, P | 2 |
| Cohen, D | 6 |
| Coenen, S; Michiels, B; Van Puyenbroeck, K; Verhoeven, V; Vermeire, E | 1 |
| Gubareva, LV; Klimov, AI; Li, Y; Lysén, C; Nguyen, HT; Okomo-Adhiambo, M; Sleeman, K; Xu, X | 1 |
| Kubo, T; Minakami, H; Nakai, A; Saito, S; Unno, N; Yoshimura, Y | 1 |
| Ávila-Arcos, MC; Bragstad, K; Bruhn, CA; Daniels, R; Fordyce, SL; Gahrn-Hansen, B; Gilbert, MT; Hay, A; Jensen, TG; Kampmann, ML; Moreno-Mayar, JV; Nielsen, LP; Pedersen, SS | 1 |
| Bielefeld-Buss, AJ; Boucher, CA; Faber, HJ; Lutisan, JG; Maaskant, J; Ott, A; van Kampen, JJ | 1 |
| Amendola, A; Baldanti, F; Campanini, G; Fiorina, L; Pariani, E; Piralla, A; Ranghiero, A; Rovida, F; Zanetti, A | 1 |
| Jiang, T; Lu, Y | 1 |
| Chen, HS; Hsueh, CW; Wu, CP; Yu, HM | 1 |
| Anber, J; Boucher, C; Maaskant, J; Osterhaus, A; Rimmelzwaan, G; Schutten, M; Stadhouders, R; van Beek, R; van der Linden, A; van der Vries, E; Wu, Y | 1 |
| Felices, V; García, J; Gómez, E; Gómez, J; Laguna-Torres, VA | 1 |
| Bowes, MJ; Fedorova, G; Fick, J; Grabic, R; Järhult, JD; Khan, GA; Lindberg, RH; Olsen, B; Singer, AC; Söderström, H | 1 |
| Adu, DA; Asiedu-Bekoe, F; Offei, A | 1 |
| Ambrose, PG; Bhavnani, SM; Bulik, CC; Forrest, A; Hammel, JP; Kamal, MA; Rayner, CR; Reynolds, DK; Smith, PF; Toovey, S; Van Wart, SA | 1 |
| Heron, L; Rashid, H | 1 |
| Kamal, MA | 1 |
| Lutsar, I; Standing, JF; Tsolia, M | 1 |
| Ceyhan, M; Karadag-Oncel, E | 1 |
| Adamou, E; Chen, X; Conrad, T; Hoppe, C; Karsch, K; Muehlhans, S; Obermeier, P; Peiser, C; Rath, B; Schweiger, B; Seeber, L; Tief, F; von Kleist, M | 1 |
| Booy, R; Dixit, R; Ilgoutz, S; Khandaker, G; Rashid, H | 1 |
| Booy, R; Haworth, E; Heron, L; Memish, ZA; Rashid, H; Ridda, I; Tashani, M | 1 |
| Booy, R; Heron, L; Rashid, H; Salkeld, G; Yin, JK | 1 |
| Chen, YH; Lai, HJ | 1 |
| Cho, HG; Choi, JH; Jho, EH; Kang, C; Lee, HK; Lee, JB; Lim, YH; Mun, SK | 1 |
| de Waal, L; Fraaij, PL; Koch, B; Luider, TM; Meesters, RJ; Osterhaus, AD; Schutten, M; Stittelaar, KJ; van Amerongen, G; van der Nagel, B; van der Vries, E; Veldhuis Kroeze, EJ; Vulto, AG | 1 |
| Blazquez, D; Bueno, M; Calvo, C; Carrasco, J; Cilleruelo, MJ; de Blas, A; de José, MI; Escosa, L; García-García, ML; Guillén, S; Llorente, M; Mazagatos, D; Méndez-Echevarría, A; Otheo, E; Santos, M; Tarrago, A; Tomatis, C; Tovizi, M | 1 |
| Barr, IG; Hurt, AC | 1 |
| Chen, H; Guan, W; Hao, P; He, J; Hu, Y; Huang, K; Kang, B; Li, J; Li, T; Li, X; Li, Y; Liu, Y; Lu, S; Peiris, M; Ping, J; Shi, B; Song, Z; Tian, D; Wang, S; Wang, W; Xi, X; Xu, L; Yen, HL; Yuan, Z; Zha, L; Zhang, X; Zhang, Z; Zheng, L; Zhu, Z | 1 |
| Fujisaki, S; Imai, M; Kishida, N; Odagiri, T; Takashita, E; Tashiro, M; Xu, H | 1 |
| Ihashi, M; Inoue, Y; Kaneno, H; Kase, T; Mizoguchi, Y; Okabe, N; Shimotsuji, T; Yamamoto, K; Yamamoto, T | 1 |
| Andrews, N; Bermingham, A; Durnall, H; Elliot, AJ; Ellis, J; Fleming, D; Galiano, M; Lackenby, A; Large, S; Powers, C; Smith, G; Thompson, C; Zambon, M | 1 |
| Bagdadi, F; Khan, UH; Koul, PA; Shah, TH | 1 |
| Hui, Y; Jin, J; Li, T; Lu, S; Mei, Z; Shao, L; Wang, J; Wang, X; Wu, X; Yang, F; Zhang, H; Zhang, W; Zhang, Y | 1 |
| Chong, CY; Fu, S; Menon, A; Tan, NW; Tee, NW; Thoon, KC | 1 |
| Bellei, NC; Burattini, MN; Cabeça, TK; Carraro, E; Cuba, GT; Goto, JM; Hidalgo, SR | 1 |
| Hashimoto, K; Hosoya, M; Ishii, K; Kawasaki, Y; Sakai, N; Sato, M; Suyama, K; Suzuki, Y | 1 |
| Jurek, T; Kuchar, E; Rorat, M; Szenborn, L | 1 |
| Alessandrino, PE; Baldanti, F; Colombo, AA; Fiorina, L; Gozalo-Margüello, M; Muzzi, A; Piralla, A; Rovida, F | 1 |
| Enserink, M | 7 |
| Gu, Q; Wang, H; Wang, Y; Wu, C; Zhang, Y; Zhou, Z; Zhu, B | 1 |
| Chen, HW; Cheng, JX; King, K; Liu, MT; Liu, YT; Peng, JY; Schooley, RT; Shresta, S; Wang, CH; Zhang, XQ | 1 |
| Carrat, F; Chidiac, C; Cohen, B; Desenclos, JC; Javouhey, E; Leport, C; Lina, B; Mayaud, C; Ploin, D | 1 |
| Bhadelia, N; Furuya, EY; Jia, H; McCarthy, JW; Saiman, L; Sonti, R; Vorenkamp, J | 1 |
| Carrillo-Valenzo, E; Cruz-Hervert, P; García-García, L; Gómez-Barreto, RE; Hidalgo, AC; Luna, RS; Martínez-Barnetche, J; Ramos, C; Rodríguez, MH; Téllez-Sosa, J; Valdovinos-Torres, H | 1 |
| Chang, CH; Chuang, JH; Lai, MS; Liu, CH; Su, CP; Wang, JL | 1 |
| Cheung, PP; Choy, KT; Guan, Y; McKimm-Breschkin, JL; Ng, IH; Peiris, JS; Webby, RJ; Webster, RG; Wong, DD; Yen, HL; Zhou, J; Zhu, H | 1 |
| Azuma, T; Nakada, N; Tanaka, H; Yamashita, N | 2 |
| Delvin, ME; Fiddler, A; Fisman, DN; Patel, Z; Xiao, Y; Yuan, L | 1 |
| Hernán, MA; Lipsitch, M | 2 |
| Groves, T | 1 |
| Gao, GF; Wu, Y | 1 |
| Adams, W; Gregg, K; Humar, A; Huprikar, S; Kumar, D; Levi, M; Mossad, S; Patel, G; Razonable, RR; Reid, G; Shoham, S | 1 |
| Chahin, A; Chapin, K; Hagau, D; Pop-Vicas, A | 1 |
| Gubareva, LV; Guo, L; Marjuki, H; Mishin, VP; Okomo-Adhiambo, M; Sheu, TG; Sleeman, K; Xu, X | 1 |
| Choi, YK; Decano, AG; Hee Baek, Y; Kim, EH; Kim, S; Kim, YI; Kwon, HI; Lee, BJ; Lim, GJ; Park, SJ; Pascua, PN; Song, MS; Webby, RJ | 1 |
| Hargraves, J; Patel, DM; Pitts, SR | 1 |
| Cai, JH; Ge, YL; Wang, XS; Yao, WL; Zeng, M; Zhu, QR | 1 |
| Hackett, I; O'Sullivan, R; Rea, D; Walsh, S; Zaid, AA | 1 |
| Bumpenkiatigul, N; Sritipsukho, P; Tangsathapornpong, A | 1 |
| Bae, JY; Han, SZ; Heo, J; Hwang, MW; Kim, D; Kim, JI; Lee, I; Lee, S; Park, MS; Park, S | 1 |
| Baranovich, T; Burnham, AJ; Govorkova, EA | 1 |
| Akl, EA; Alonso-Coello, P; Brozek, J; Chen, YL; Cheung, A; Flottorp, SA; Hopkins, JP; Hovhannisyan, G; Hsu, J; Ivanova, L; Mustafa, R; Saeterdal, I; Santesso, N; Schünemann, HJ; Smaill, F; Tian, J; Uyeki, TM; Wong, AD | 2 |
| Hubbard, RJ; Li, J; Meyer, AE; Miller, PE; Mounts, AW; Penn, CR; Rambachan, A; Rolfes, MA; Stephens, P | 2 |
| Chan, MC; Chan, PK; Choi, KW; Hayden, FG; Hui, DS; Lee, EL; Lee, N; Lui, GC; Ngai, KL; Sin, WW; Tam, WW; Tomlinson, B; Wo, SK; Wong, BC; Wong, RY; Zuo, Z | 1 |
| Jang, HC; Jung, SI; Kang, SJ; Kee, SJ; Kwon, YS; Park, KH; Shin, JH | 1 |
| Bai, T; Cheng, YH; Guo, JF; Han, GY; Huang, WJ; Lan, Y; Li, XY; Liu, YF; Qi, SX; Shu, YL; Tan, MJ; Wang, DY; Wang, Z; Wei, HJ; Xiao, N; Yang, L; Zhao, X | 1 |
| Chang, CK; Chang, SC; Chang, SY; Chao, TL; Chen, HH; Chen, YC; Ho, SY; Huang, MS; Hung, CC; Kuo, SW; Lai, HS; Lin, HC; Lin, PH; Wang, JT; Yang, PC; Yang, ZY | 1 |
| Bao, L; Chen, H; Deng, W; Li, F; Lv, Q; Qin, C; Xu, L; Xu, Y; Yao, Y; Yu, P; Yuan, J; Yuen, KY | 1 |
| Hagiwara, M; Nozaki, S; Sugiyama, A; Suzuki, S; Takahara, A | 1 |
| Abed, Y; Boivin, G; Bouhy, X; Roussy, JF | 1 |
| Farrukee, R; Hurt, AC; Mosse, J | 1 |
| Baird, M; Balogun, E; Eshaghi, A; Farrell, DJ; Gubbay, JB; Higgins, RR; Kristjanson, E; Li, A; Memari, N; Peci, A; Winter, AL | 1 |
| Dutkowski, R; Smith, JR; Smith, P; Toovey, S | 1 |
| Chen, L; Chen, Z; Cheng, J; Deng, Y; Huang, L; Jiang, R; Jiao, Y; Li, C; Li, X; Liu, J; Lu, L; Ma, J; Pang, X; Peng, X; Shu, Y; Song, R; Wang, Q; Yang, P; Zeng, H; Zhang, Y; Zheng, Y | 1 |
| Avni-Shemer, Y; Ben-Harush, M; Ben-Shimol, S; Dotan, A; Fruchtman, Y; Givon-Lavi, N; Greenberg, D; Kapelushnik, J; Leibovitz, E | 1 |
| Qiu, X; Ruan, J; Shao, Y; Sheng, Y; Zhang, C; Zheng, W | 1 |
| Hooiveld, M; Tacken, MA; van de Groep, T; van der Sande, MA; van Essen, GA; Verheij, RA; Verheij, TJ | 1 |
| Cao, B; Hayden, FG | 1 |
| Chen, Y; Cui, L; Fan, H; Ge, Y; Guo, X; Li, Y; Qi, X; Qi, Y; Shan, Y; Shi, Z; Wang, H; Wu, T; Zhao, K; Zhou, M; Zhu, Z | 1 |
| Aris-Brosou, S; Garcia, V | 1 |
| Yang, G; Yang, Z; Zhou, L | 1 |
| Jurek, T; Rorat, M | 1 |
| Cury, AL; Fernandes, SB; Fintelman-Rodrigues, N; Gregianini, TS; Ikuta, N; Resende, PC; Rosa, Mdo C; Siqueira, MM; Souza, TM | 1 |
| Abed, Y; Boivin, G; Bouhy, X; Pizzorno, A; Rhéaume, C | 1 |
| Azim, T; Bresee, J; Brooks, WA; Fry, AM; Goswami, D; Gubareva, L; Luby, SP; Nahar, K; Rahman, M; Sharmin, AT | 1 |
| Louie, JK; Samuel, MC; Schechter, R; Uyeki, TM; Yang, S | 1 |
| Kelman, JA; MaCurdy, TE; Mosholder, AD; Racoosin, JA; Shoaibi, A; Wernecke, M; Worrall, C; Young, S | 1 |
| Choudhary, C; Moghekar, A; Narula, T; Raman, D; Reddy, AJ; Wiesen, J | 1 |
| Barnard, DL; Furuta, Y; Hurst, BL; Smee, DF; Tarbet, EB; Vollmer, AH | 1 |
| Bouvier, NM; García-Sastre, A; Hai, R; Jaffe, EL; Krammer, F; Leyva-Grado, VH; Margine, I; Palese, P; Schmolke, M; Solórzano, A; Thangavel, RR | 1 |
| Ge, YL; Pu, DB; Wang, XH; Xia, AM; Yu, H; Zeng, M; Zhu, QR; Zhu, YF | 1 |
| Bao, M; Chen, L; Dong, Y; Hu, Y; Huang, Y; Lau, EH; Leung, CY; Liu, X; Peiris, JS; Song, Z; Sun, J; Tian, D; Wan, Y; Wu, JT; Xu, J; Yuan, S; Zhang, A; Zhang, J; Zhang, X; Zhang, Z; Zhou, M; Zhu, Z | 1 |
| Chong, M; Henry, B; Kendall, P; Marra, F; Patrick, DM | 1 |
| Carter, WA; Liu, Q; Ma, J; Ma, W; Mitchell, WM; Richt, JA; Strayer, DR | 1 |
| Cao, Y; Chen, Z; Guan, W; Hu, Y; Li, X; Shen, Z; Xu, L; Zhang, J | 1 |
| Long, B; Malaisree, M; McIntosh-Smith, S; Mulholland, AJ; Woods, CJ | 1 |
| Basson, E; Boibieux, A; Haÿs, S; Leick-Courtois, C; Mory-Thomas, N; Picaud, JC | 1 |
| Lu, H; Shen, Y; Sun, Y | 1 |
| Chang, FY; Chang, SC; Chen, GW; Chen, SJ; Lin, TY; Liu, MT; Lo, YL; Mok, CK; Shih, SR; Wu, HS | 1 |
| Ning, J | 1 |
| Ejima, M; Itoh, R; Miura, M; Nishimura, H; Odagiri, T; Ohnishi, A; Takashita, E; Tashiro, M | 1 |
| Hashimoto, K; Honzumi, K; Hosoya, M; Kawasaki, Y; Miyazaki, K; Sato, M; Sato, T; Watanabe, M | 2 |
| Bao, C; Cui, L; Qi, X; Tang, F; Wang, H; Wu, B; Xu, K; Zhou, MH; Zhu, Y | 1 |
| Bal, CK; Bhatia, V; Choudhury, A; Daman, R; Gupta, E; Khillan, V; Kumar, N; Kumar, S; Rathor, N; Saini, D; Sarin, SK | 1 |
| Beau, AB; Damase-Michel, C; Hurault-Delarue, C; Lacroix, I; Montastruc, JL; Vial, T | 1 |
| Adisasmito, W; Bamgboye, EL; Chan, PK; Coker, R; Dogan, N; Dreyer, NA; Gasimov, V; Hanshaoworakul, W; Lee, N; Oner, AF; Phommasack, B; Swenson, A; Toovey, S; Touch, S; Tsang, O; Zaman, M | 1 |
| Chan, KW; Chua, C; Inoue, M; Lim, EA; Tambyah, PA; Tan, BH; Virk, RK | 1 |
| Cai, J; Wang, X; Yao, W; Zeng, M; Zhao, B; Zhu, Q | 1 |
| Herxheimer, A; McGettigan, P; Pollock, A | 1 |
| Bank, C; Bolon, DN; Caffrey, DR; Ewing, G; Ferrer-Admetlla, A; Finberg, RW; Foll, M; Jensen, JD; Kowalik, TF; Liu, P; Malaspinas, AS; Poh, YP; Renzette, N; Schiffer, CA; Shim, H; Wang, JP; Wegmann, D; Zeldovich, KB | 1 |
| Koay, ES; Kong, DH; Lau, YW; Lee, HK; Loh, TP; Tang, JW; Yap, HK | 1 |
| Dunstan, HJ; Mill, AC; Stephens, S; Thomas, SH; Yates, LM | 1 |
| Wiwanitkit, V | 3 |
| de Briel, D; Heller, R; Martin, A; Martinot, M; Mohseni-Zadeh, M; Mothes, A; Sagot, E; Souply, L | 1 |
| Kitazawa, T; Koga, I; Ota, Y; Seo, K; Yoshino, Y | 2 |
| Imamura, Y; Izumikawa, K; Kakeya, H; Kohno, S; Kosai, K; Kurihara, S; Miyazaki, T; Morinaga, Y; Nakamura, S; Seki, M; Tashiro, T; Tsukamoto, M; Yanagihara, K | 1 |
| 't Hart, P; de Haan, CA; Johnson, SA; Martin, NI; Mooney, CA; Moret, EE; Quarles van Ufford, L | 1 |
| Kang, C; Kim, SJ; Kwon, D; Lee, JY; Shin, K | 1 |
| Joob, B; Wiwanitkit, V | 1 |
| Chen, R; Guan, W; Lee, SM; Li, X; Luo, Y; Oshitani, H; Suzuki, A; Tsui, SK; Wang, Y; Wu, S; Yang, Z; Zhong, N | 1 |
| Baas, C; Barr, IG; Bloom, JD; Butler, J; Guarnaccia, T; Hooper, KA; Hurt, AC; Kelso, A; Leang, SK; Lee, R; Maurer-Stroh, S; McCaw, JM; McVernon, J; Petrie, S; Reh, L; Vitesnik, S; Xue, L | 1 |
| Feng, F; Geng, D; Hua, Y; Jiang, Y; Shen, J; Shi, J; Shi, Y; Xu, J; Yin, H; Yuan, M; Zhang, Z | 1 |
| Del Mar, CB; Doshi, P; Hama, R; Heneghan, CJ; Howick, J; Jefferson, T; Jones, MA; Mahtani, KR; Nunan, D; Onakpoya, I; Spencer, EA; Thompson, MJ | 2 |
| Torjesen, I | 2 |
| Doshi, P; Jefferson, T | 3 |
| Canini, L; Carrat, F; Conway, JM; Perelson, AS | 1 |
| Bandyopadhyay, A; Chaves, SS; D'Mello, T; Farley, MM; Fowler, B; Fry, AM; Hancock, EB; Harris, M; Hollick, GE; Horan, V; Kirley, PD; Lindegren, ML; Lynfield, R; McDonald-Hamm, C; Morin, C; Perez, A; Price, A; Schaffner, W; Sharangpani, R; Su, S; Thomas, A; Yousey-Hindes, K; Zansky, S | 1 |
| Guan, W; Hu, Y; Li, J; Liu, Y; Song, Z; Wang, W; Xu, L; Yuan, Z; Zhang, X | 1 |
| Aiello, AE; Choi, BM; Kilgore, PE; Kim, TH; Kim, YK; Lee, KC; Lim, JK; Song, YH; Yoo, KH | 1 |
| Butler, D | 4 |
| Bratasena, A; Kosasih, H; Laras, K; Pangesti, K; Samaan, G | 1 |
| Godlee, F | 1 |
| Nguyen-Van-Tam, JS | 2 |
| Middleton, J; Saunders, PJ | 1 |
| Biondi, E | 1 |
| Leonardi-Bee, J; Myles, PR | 2 |
| Jones, M | 1 |
| Lutsevich, KA; Reshet'ko, OV; Sanina, II | 1 |
| Benden, C; Boeni, J; Isenring, BD; Jungo, C; Kohler, M; Mueller, NJ; Schuurmans, MM | 1 |
| Belluz, J | 1 |
| Calvert, MJ; Freemantle, N; Kyte, D; Rader, T; Shallcross, LJ | 1 |
| Jack, A | 3 |
| Doshi, P; Heneghan, CJ; Jefferson, T; Jones, M; Onakpoya, I; Spencer, EA | 1 |
| Krumholz, HM | 1 |
| Godlee, F; Loder, E; Tovey, D | 1 |
| Fry, AM | 1 |
| Al Khuwaitir, TS; Al Mamun, A; Amine, IL; Anovadiya, AP; Azziz-Baumgartner, E; Báez, C; Bassetti, M; Beovic, B; Bertisch, B; Bonmarin, I; Booy, R; Borja-Aburto, VH; Burgmann, H; Cao, B; Carratala, J; Denholm, JT; Dominguez, SR; Duarte, PA; Dubnov-Raz, G; Echavarria, M; Fanella, S; Gao, Z; Gérardin, P; Giannella, M; Gubbels, S; Herberg, J; Hoger, PH; Hu, X; Iglesias, AL; Islam, QT; Jiménez, MF; Kandeel, A; Keijzers, G; Khalili, H; Knight, M; Kudo, K; Kusznierz, G; Kuzman, I; Kwan, AM; Langenegger, E; Lankarani, KB; Leo, YS; Leonardi-Bee, J; Linko, R; Liu, P; Madanat, F; Mayo-Montero, E; McGeer, A; Memish, Z; Metan, G; Mickiene, A; Mikić, D; Mohn, KG; Moradi, A; Muthuri, SG; Myles, PR; Nguyen-Van-Tam, JS; Nymadawa, P; Oliva, ME; Ozkan, M; Parekh, D; Paul, M; Polack, FP; Rath, BA; Rodríguez, AH; Sarrouf, EB; Seale, AC; Sertogullarindan, B; Siqueira, MM; Skręt-Magierło, J; Stephan, F; Talarek, E; Tang, JW; To, KK; Torres, A; Törün, SH; Tran, D; Uyeki, TM; Van Zwol, A; Vaudry, W; Venkatesan, S; Vidmar, T; Yokota, RT; Zarogoulidis, P | 1 |
| Asai, T; Ichikawa, M; Ikezoe, I; Matsumoto, J; Miyagawa, S; Takemoto, Y; Yano, T | 1 |
| Avorn, J; Brennan, TA; Brill, G; Choudhry, NK; Fischer, MA; Franklin, JM; Matlin, OS; Schneeweiss, S; Shrank, WH; Uscher-Pines, L | 1 |
| Bamba, M; Ichikawa, M; Ide, Y; Kawakami, C; Kawaoka, Y; Mitamura, K; Sakai-Tagawa, Y; Sugaya, N; Yamaguchi, Y; Yamazaki, M; Yasuhara, R | 1 |
| Nguyen-Van-Tam, JS; Nicholson, KG; Openshaw, PJ | 1 |
| Arkinstall, R; Barr, IG; Haining, J; Hurt, AC; Kelso, A; Leang, SK; Lowther, S; McCaw, JM; Mcvernon, J; Middleton, D; Oh, DY; Sullivan, SG | 1 |
| Acosta, EP; Ampofo, K; Clinch, B; Gibiansky, L; Jester, P; Kamal, MA; Kimberlin, DW; Niranjan, V; Rath, B; Rayner, CR; Sánchez, PJ; Whitley, R | 1 |
| Hurt, AC | 1 |
| Choi, HW; Chow, VT; Moorthy, AN; Narasaraju, T; Phoon, MC; Samy, RP; Tan, KS; van Rooijen, N; Yang, E | 1 |
| Booy, R; Dixit, R; Dwyer, D; Hay, P; Heron, L; Khandaker, G; McPhie, K; Rashid, H; Taylor, J | 1 |
| Ak, Ö; Alan, S; Aslan, T; Badur, S; Balkan, II; Benzonana, N; Ceylan, B; Ciblak, M; Dokucu, AI; Engin, D; Eraksoy, H; Ergönül, Ö; Fincancı, M; Gencer, S; Göktaş, P; Gulhan, E; Gündüz, A; Inan, A; Kantürk, A; Midilli, K; Nazlıcan, O; Öncül, O; Özer, S; Özgüneş, N; Ozyurt, M; Saltoğlu, N; Sargın, F; Şimşek, F; Uzun, N; Yazıcı, S; Yıldırmak, T | 1 |
| Alcalá Minagorre, PJ; Mira-Perceval Juan, G; Sánchez Bautista, A; Segura Sánchez, S | 1 |
| Adams, O; Gkioule, C; Grund, S; Kobbe, G; Pfeifer, N; Termos, T; Verheyen, J | 1 |
| Antes, G; Meerpohl, JJ | 1 |
| Del Mar, C; Hama, R; Jones, M | 2 |
| Leonardi-Bee, J; Muthuri, SG; Myles, PR; Nguyen-Van-Tam, JS; Venkatesan, S | 1 |
| Schumacher, M; Wolkewitz, M | 2 |
| Manosuthi, W; Moolasart, V | 1 |
| Norris, A; Sandrock, CE | 1 |
| Chandrasekaran, A; Tomianovic, D; Wollenhaupt, M | 1 |
| Carruthers, S; Herman, M; Loeb, M; Smieja, M | 1 |
| Dhawane, A; Dinh, H; He, Y; Iyer, SS; Sweeney, J; Yang, Y; Zhang, X | 1 |
| Blechová, Z; Džupová, O; Havlíčková, M; Herrmannová, K; Jiřincová, H; Kynčl, J; Marešová, V; Nagy, A; Trojánek, M | 1 |
| Calderon, A; Cañizares, A; Casas, I; Cuesta, I; Gonzalez, M; Gonzalez-Velasco, C; Lackenby, A; Lopez-Miragaya, I; Molinero, M; Monzon, S; Perez-Sautu, U; Pozo, F; Rey, S; Rodriguez, G | 1 |
| Almeida-Santos, MM; Correia, V; Gíria, M; Rebelo-de-Andrade, H; Santos, LA | 1 |
| Besselaar, T; Correia, V; Daniels, RS; Drager-Dayal, R; Fry, A; Gregory, V; Gubareva, L; Hurt, AC; Kageyama, T; Lackenby, A; Lo, J; Meijer, A; Odagiri, T; Pereyaslov, D; Rebelo-de-Andrade, H; Siqueira, MM; Takashita, E; Tashiro, M; Wang, D; Wong, S; Zhang, W | 1 |
| Toniolo Neto, J | 1 |
| Almirall, J; Blanquer, J; Canadell, L; Díaz, E; Grau, S; Martín-Loeches, I; Olona, M; Rodriguez, A; Sureda, F; Trefler, S; Yebenes, JC | 1 |
| Chang, FY; Chesnokov, AP; Cox, NJ; Davis, CT; De La Cruz, JA; Fry, AM; Gubareva, LV; Jones, J; Liu, MT; Marjuki, H; Mishin, VP; Nguyen, HT; Sleeman, K; Tamura, D; Villanueva, JM; Wu, HS | 1 |
| Chi, HC; Hsiao, NW; Lin, CY; Shih, KC; Tang, CY; Zhou, J | 1 |
| Król, E; Rychłowska, M; Szewczyk, B | 1 |
| Brydak, LB; Nitsch-Osuch, A | 2 |
| Bartoszcze, M; Joniec, J; Kocik, J; Kołodziej, M; Kwiatek, M | 1 |
| Haredy, AM; Mizuguchi, K; Mori, Y; Nagao, C; Okamoto, S; Yamada, H; Yamanishi, K | 1 |
| Kitahori, Y; Okayama, A; Yoneda, M | 1 |
| Azhar, M; Dharmayanti, NL; Pawestri, HA; Samaan, G; Schoonman, L; Setiawaty, V; Tallis, G | 1 |
| Donnelly, RP; Ilyushina, NA | 1 |
| Bastien, N; Eshaghi, A; Gubbay, JB; Higgins, RR; Li, A; Li, Y; Rosenfeld, P; Rotstein, C; Savchenko, A; Shalhoub, S; Stogios, PJ | 1 |
| Ding, C; Gao, Z; Horby, P; Jiang, G; Jiang, R; Li, R; Liu, X; Nie, C; Qian, K; Sun, J; Wan, J; Wang, Q; Xiao, Z; Zeng, Z; Zhang, J; Zhang, W | 1 |
| Chen, Q; Guo, Y; Wei, YN; Zhang, C | 1 |
| Ikematsu, H; Iwaki, N; Kashiwagi, S; Kawai, N | 2 |
| Beigi, RH; Caritis, SN; Venkataramanan, R | 1 |
| Fry, AM; Gubareva, LV; Zhong, W | 1 |
| Balaratnam, G; Bonavia, A; Fredlund, P; Koller, TD; Mitcham, JL; Ramos, EL; Swiderek, KM; Usner, DW | 1 |
| Miyazaki, C; Momoi, M; Nakamura, Y; Ohkusa, Y; Okabe, N; Sugawara, T; Taniguchi, K | 1 |
| Ali, Z; Dapat, C; Dapat, IC; Dbaibo, G; Ghanem, S; Kayali, G; Kondo, H; Lteif, M; Saito, K; Saito, R; Suzuki, H; Zaraket, H | 1 |
| Millard, PS | 1 |
| Aiello, AE; Chung, E; Foxman, B; Jang, GY; Kilgore, PE; Kim, YK; Letson, GW; Lim, JK; Song, YH | 1 |
| Blumentals, WA; Miller, MK; Rath, BA; Starzyk, K; Tetiurka, B; Wollenhaupt, M | 1 |
| Zambon, M | 1 |
| O'Dowd, A | 3 |
| Danchin, M; Kornberg, A; McSwiney, P; Purnama, J | 1 |
| Shaughnessy, AF | 1 |
| Bachelet, VC | 1 |
| Gorišek Miksić, N; Lobnik Rojko, P; Lusa, L; Petrovec, M; Simonović, Z; Strle, F; Uršič, T | 1 |
| Chen, HC; Kuo, RL; Lee, CK; Leu, CM; Lin, CN; Lin, MY; Lin, SJ; Lo, M; Lu, J; Ojcius, DM; Shih, SR; Tsai, CH | 1 |
| Born, Pda S; Carney, S; Magalhães, V; Mello, WA; Mesquita, M; Motta, Fdo C; Oliveira, Mde L; Oliveira, MJ; Resende, PC; Siqueira, MM; Souza, TM | 1 |
| Chang, CH; Chuang, JH; Hsu, YF; Huang, WT | 1 |
| Chintakrindi, AS; Chowdhary, AS; Deshmukh, RA; Gohil, DJ; Kanyalkar, MA; Kothari, ST; Meharunkar, R; Shinde, PS; Warke, RV | 1 |
| Chen, HL; Gao, HN; Guo, J; Li, LJ; Liang, WF; Su, KK; Wu, HB; Wu, NP; Wu, XX; Yang, SG; Yao, HP; Yuen, KY; Zhang, Q; Zheng, SF; Zhu, YX | 1 |
| He, JY; Li, C; Wu, G | 1 |
| McCarthy, M | 1 |
| Abed, Y; Boivin, G; Bouhy, X; Pizzorno, A | 2 |
| Arastoo, M; Khorshid, HR | 1 |
| Barnes, J; Elal, AA; Fry, AM; Garten, RJ; Gubareva, LV; Hand, J; Negron, E; Nguyen, HT; Okomo-Adhiambo, M; Su, S; Villanueva, JM; Xiyan, X | 1 |
| Blair, M; McQuade, B | 1 |
| Cao, B; Chan, PK; Cheung, CS; Gu, L; Hui, DS; Kyaw, WM; Lee, N; Leo, YS; Li, H; Liu, Y; Liu, Z; Qu, J; Tam, WW; Uyeki, TM; Yung, IM | 1 |
| Babady, NE; Laplante, JM; St George, K; Tang, YW | 1 |
| McCartney, M | 1 |
| Hou, M; Jansen, AJ; Ni, H; Peng, J; Zhao, HG | 1 |
| Chan, JF; Chan, KH; Chan, WM; Chen, JH; Cheng, VC; Ho, PL; Lee, WM; Poon, RW; Tai, JW; To, KK; Wong, SC; Yuen, KY | 1 |
| Kang, X; Zhang, J | 1 |
| Dobson, J; Monto, AS; Pocock, S; Whitley, RJ | 3 |
| Cowling, BJ; Kelly, H | 1 |
| Chan, KH; Cheung, DH; Cowling, BJ; Fang, VJ; Ip, DK; Leung, GM; Peiris, JS; Tsang, TK; Xu, J | 1 |
| Birnkrant, DB; Chan-Tack, KM; Kim, C; Moruf, A | 1 |
| Burleigh, L; Chappey, C; Giraudon, M; Várkonyi, I | 1 |
| Clinch, B; Smith, J | 1 |
| Pulla, P | 1 |
| Fairbanks, AJ; Fee, CJ; Fredericks, R; Hall, RJ; Somasundaram, B; Watson, AJ | 1 |
| Chesnokov, AP; Davis, CT; De La Cruz, JA; Fry, AM; Gubareva, LV; Marjuki, H; Mishin, VP; Villanueva, JM | 1 |
| Bozza, FA; Cury, AL; Fernandes, SB; Fintelman-Rodrigues, N; Gregianini, TS; Lopes e Souza, TM; Mesquita, M; Pecego, AC; Resende, PC; Riediger, IN; Siqueira, MM | 1 |
| Cao, H; Fang, X; Gu, Y; He, J; Lu, H; Lu, S; Qi, T; Qu, H; Shen, Y; Wu, X; Xiang, M; Ye, J; Zhang, W; Zhang, Z | 1 |
| Barr, IG; Kelly, HA | 1 |
| Azim, T; Barnes, J; Bresee, J; Brooks, WA; Fry, AM; Goswami, D; Gubareva, L; Luby, SP; Nahar, K; Rahman, M; Sharmin, AT; Trujillo, A | 1 |
| Langley, K; Ogletree, RL | 1 |
| Chen, YS; Lan, CC; Liu, CC | 1 |
| Boucher, CA; Burleigh, L; Fraaij, PL; Javouhey, E; Kumar, D; Outlaw, R; Schutten, M | 1 |
| Chen, TT; Li, CY; Li, L; Li, ZT; Wang, DQ; Yang, ZF; Zhong, NS | 1 |
| Garrison, S; Kolber, MR; Korownyk, C | 1 |
| Cauchemez, S; Chan, KH; Cowling, BJ; Fang, VJ; Ip, DK; Leung, GM; Peiris, JS; Tsang, TK | 1 |
| Lindh, M; Norberg, P; Olofsson, S | 1 |
| Nau, JY | 11 |
| Blaser, MJ; Buffa, R; Cabras, S; Contreras, M; Dominguez-Bello, MG; Hidalgo, G; Magris, M; Marini, E; Ortiz, V; Sanchez, W; Urbaez, M | 1 |
| Abdel-Rahman, SM; Wagner, J | 1 |
| Fumeaux, T; Hsieh, A | 1 |
| Campbell, AP; DeBiasi, RL; Fry, AM; Gubareva, LV; Loechelt, B; Mishin, VP; Okomo-Adhiambo, M; Tamura, D; Wiedermann, BL | 1 |
| Choi, SH; Hong, SB; Huh, JW; Koh, Y; Lim, CM; Yoo, JW | 1 |
| Bass, SN; Bauer, SR; Lam, SW; Neuner, EA; Welch, SC | 1 |
| Abed, Y; Beauchemin, CA; Boivin, G; Holder, BP; Paradis, EG; Pinilla, LT | 1 |
| Brzostek, J; Chappey, C; Clinch, B; Guillén, S; Niranjan, V; Rath, BA; Rayner, CR | 1 |
| Chan, JD; Chu, HY; Dellit, TH; Englund, JA; Huang, D; Jain, R; Jerome, KR; Kuypers, J; Lynch, JB; Pottinger, PS; Scott, E | 1 |
| Dapaah-Afriyie, K; Finn, A; Stewart, E; Wang, J | 1 |
| Anderson, EJ; Clinch, B; Deville, JG; Kamal, MA; Muñoz, FM | 1 |
| Cheng, VC; Ho, PL; Lee, WM; Sridhar, S; Yuen, KY | 1 |
| Chao, WC; Liu, PY; Wu, CL | 1 |
| Doi, M; Igarashi, M; Ishida, H; Ishigaki, H; Ishii, A; Itoh, Y; Kida, H; Kitagawa, N; Nakamura, S; Nakayama, M; Ogasawara, K; Okamatsu, M; Sakoda, Y; Sasamura, T; Shichinohe, S; Shiohara, M; Tsuchiya, H | 1 |
| Cummins, A; Millership, S | 1 |
| Bird, NL; Chua, BY; Handel, A; Hurt, AC; Jackson, DC; Kedzierska, K; Oh, DY; Olson, MR; Oshansky, CM; Reading, PC; Sun, Y; Tang, L; Thomas, PG; Turner, SJ | 1 |
| Chen, J; Hu, J; King, CC; Mao, S; Pan, H; Pan, Q; Teng, Z; Wu, F; Zhang, H; Zhang, X; Zheng, Y | 1 |
| Cheng, Y; Guo, J; Huang, W; Lan, Y; Li, X; Shu, Y; Tan, M; Wang, D; Wang, Z; Wei, H; Xiao, N; Zhao, X | 1 |
| Beigi, RH; Caritis, SN; Pillai, VC; Venkataramanan, R | 1 |
| Biçer, S; Ercan Sariçoban, H; Ergenekon Ulutaş, P; Gürol, Y; Özelgün, B; Özen, AO; Saf, C; Vitrinel, A; Yilmaz, G | 1 |
| Ferda, K; Guven, O; Halis, A; Ilker, C; Meltem, OT; Nermin, KG; Remzi, I; Zeynep, A | 1 |
| Chen, HL; Guan, Y | 1 |
| Boucher, CA; Cowling, BJ; Ip, DK; Schutten, M; Tong, X; van der Vries, E; Wojtowicz, K; Zhang, JD | 1 |
| Chang, YJ; Chen, CY; Chiu, ML; Liang, WM; Lin, PC; Sung, FC; Wang, CB; Wang, JH; Wu, TN | 1 |
| Pan, H; Qiu, S; Shen, Y; Wang, J; Zhang, Q | 1 |
| Osterhaus, AD; Vanlangendonck, C | 1 |
| Rabenau, HF; Wicker, S | 1 |
| Chuang, SK; Lam, TS; Leung, OS; Leung, YH; To, MK; Yau, SW | 1 |
| Azziz-Baumgartner, E; Blanco, N; Bonilla, L; Chacon, R; Clara, WA; Guzman, G; Jara, J; Minaya, P; Mirza, S; Moreno, L; Palekar, R; Paredes, A; Rodriguez, D; Then, CJ | 1 |
| Hosokawa, M; Kashii, H; Kubota, M; Morimoto, K; Nagai, A; Nagaoka, K; Ogihara, T; Takahashi, Y | 1 |
| Cheong, HJ; Choi, WS; Kim, WJ; Noh, JY; Song, JY | 1 |
| Ampornareekul, S; Chittaganpitch, M; Likanonsakul, S; Srisophaa, S; Wongsawat, J | 1 |
| Cheng, Y; Guo, J; Huang, W; Li, X; Shu, Y; Tan, M; Wang, D; Wang, Z; Wei, H; Xiao, N; Zhao, X | 1 |
| Boivin, G; Carbonneau, J; Shelton, DN; Taylor, SC | 1 |
| Almirante, B; Escolà-Vergé, L; Len, O; Magnifico, B; Mora, C; Papiol, E; Revilla, E; Sousa, A | 1 |
| Abe, J; Kato, Y; Kato, Z; Kinosada, Y; Nakamura, M; Nakayama, Y; Ueda, N; Umetsu, R | 1 |
| Hawkes, N | 3 |
| Doshi, P; Heneghan, C; Jefferson, T | 2 |
| Radecki, RP | 1 |
| Komiya, N; Kubo, K; Otsu, S | 1 |
| Gao, HN; Li, LJ; Ou, HL; Peng, XM; Wu, HB; Wu, XX | 1 |
| Kwong, JC | 1 |
| Fung, CP; Huang, SF; Perng, DW; Wang, FD | 1 |
| Agarwal, A; Agarwal, S; Bhandari, S; Mehta, S; Nawal, CL; Rathore, M; Sharma, R | 1 |
| Buckeridge, DL; Charland, KM; DE Serres, G; Papenburg, J | 1 |
| Esposito, S; Principi, N | 1 |
| Bank, C; Bolon, DNA; Caffrey, DR; Finberg, RW; Jensen, JD; Jiang, L; Kowalik, TF; Liu, P; Prachanronarong, K; Renzette, N; Schiffer, CA; Wang, JP; Yilmaz, LS; Zeldovich, KB | 1 |
| Bushell, CA; Cowen, S; Foy, CA; Garson, JA; Grant, PR; Gutierrez-Aguirre, I; Huggett, JF; Milavec, M; Nastouli, E; O'Sullivan, DM; Whale, AS; Žel, J | 1 |
| Kossyvakis, A; Lytras, T; Mentis, A | 1 |
| Phillips, AM; Shoulders, MD | 1 |
| James, EJ; Sudhakar, SV; Thomas, MM; Yoganathan, S | 1 |
| Bischoff, A | 1 |
| Burtseva, EI; Fedyakina, IT; Kirillova, ES; Leneva, IA; Maleev, VV; Osipova, E; Selkova, EP; Yatsyshina, SB | 1 |
| Barr, IG; Chow, MK; Kelso, A; Sullivan, SG | 1 |
| Dou, J; Jin, J; Li, M; Wang, D; Wang, H; Xu, J; Yu, J; Zhou, C | 1 |
| Agarwal, S; Agrawal, A; Chejara, R; Kumar, V; Mital, P; Nawal, CL | 1 |
| Bassinet, L; Boelle, PY; Boussaud, V; Bremont, F; Bucher, J; Corvol, H; Delaisi, B; Deneuville, E; Durieu, I; Grenet, D; Hubert, D; Launay, O; Lebourgeois, M; Leruez-Ville, M; Remus, N; Sermet-Gaudelus, I; Stremler, N; Treluyer, JM; Troussier, F; Vodoff, MV | 1 |
| Alame, MM; Ghulmiyyah, LM; Mirza, FG; Nassar, AH; Zaraket, H | 1 |
| Chen, P; Gao, H; Li, L; Liang, W; Ou, H; Tang, L; Wu, X; Yang, Y; Yu, L; Zhang, Y; Zheng, S | 1 |
| Fry, AM; McKimm-Breschkin, JL | 1 |
| Agarwal, A; Dash, PK; Joshi, G; Karothia, D; Kumar, JS; Malviya, V; Parida, M; Saha, A; Saraswat, S; Sharma, S; Srivastava, A; Tandel, K | 1 |
| Andrews, WW; Tita, AT | 1 |
| Cunningham, MA; Rao, S; Williams, JT; Wilson, KM | 1 |
| Assawabhumi, J; Auewarakul, P; Bhattarakosol, P; Boonarkart, C; Chakritbudsabong, W; Jongkaewwattana, A; Maneechotesuwan, K; Puthavathana, P; Ruangrung, K; Suptawiwat, O; Uiprasertkul, M; Wiriyarat, W | 1 |
| Dor, D; Handel, A; Pawelek, KA; Salmeron, C | 1 |
| La Combe, B; Lepere, V; Messika, J; Ricard, JD | 1 |
| Calvo, C; Casas, I; García-García, ML; Pozo, F | 1 |
| Bastin, MLT; Flannery, AH; Montgomery, AA; Noel, ZR | 1 |
| Amann, V; Berger, F; Chen, X; de Zwart, M; Duwe, S; Fraaij, P; Francis, RC; Heider, A; Karsch, K; Miera, O; Obermeier, P; Osterhaus, A; Peters, B; Rath, B; Schweiger, B | 1 |
| Haraki, M; Hishiki, H; Inoue, N; Ishiwada, N; Kameoka, Y; Kurosaki, T; Nagasawa, K; Naito, S; Someya, T; Suzuki, K | 1 |
| Han, J; Lichtveld, M; Liu, J; Liu, S; Shi, L; Spagnuolo, PJ; Xu, Y; Zhang, M | 1 |
| Shen, K; Tan, SC; Wu, J; Xiong, T | 1 |
| Asai, Y; Hsin, KY; Kamiyoshi, K; Kawaoka, Y; Kitano, H; Matsuoka, Y; Watanabe, T | 1 |
| Brennan, BJ; Frey, N; Kamal, MA; Lien, YT; Morcos, PN; Rayner, CR; Subramoney, V | 1 |
| Aguero-Sánchez, M; Falcón-Neyra, L; Molinos-Quintana, A; Neth, O; Olbrich, P | 1 |
| Ando, K; Cao, X; Hamaguchi, S; Izumi-Nakaseko, H; Nakamura, Y; Sasaki, R; Sugiyama, A; Takahara, A; Tanaka, H; Wada, T | 1 |
| Heikkinen, T | 1 |
| Hurt, AC; Kelly, H | 1 |
| Anderson, RM; Cauët, E; de Wolf, F; Hadjichrysanthou, C; Lawrence, E; Vegvari, C | 1 |
| Fujisaki, S; Kishida, N; Kuwahara, T; Nakamura, K; Odagiri, T; Shimazu, Y; Shimomura, T; Shirakura, M; Takashita, E; Watanabe, S | 1 |
| Auffret, M; Bigot, P; Coupé, P; Ettahar, NK; Gautier, S; Weinborn, M | 1 |
| Akizawa, K; Fukumoto, T; Iijima, H; Imai, S; Ishiguro, N; Iwasaki, S; Miyamoto, T; Nasuhara, Y; Ono, K; Oyamada, R; Yamada, T | 1 |
| Falagas, ME; Rafailidis, P; Tansarli, GS; Theocharis, G; Vardakas, KZ | 1 |
| Bach, TT; Chinh, VT; Choi, S; Eum, S; Ha, TK; Lee, CH; Nguyen, NH; Oh, WK | 1 |
| Furuta, K; Hirabayashi, Y; Isobe, R; Ito, T; Kaneko, N; Kawakami, F; Kawakami, T; Kitano, K; Mimura, Y; Nakazawa, H; Shimazaki, M | 1 |
| Boianelli, A; Bruder, D; Hernandez-Vargas, EA; Sharma-Chawla, N | 1 |
| Doroshenko, A; Jacobs, A; Jaipaul, J; Johnson, M; Khan, MN; Oda, J; Ye, M | 1 |
| Amaranond, P; Athipanyasilp, N; Horthongkham, N; Kaewnapan, B; Kantakamalakul, W; Pattama, A; Sornprasert, S; Srisurapanont, S; Sutthent, R | 1 |
| Chen, G; Chen, Z; Di, B; Li, G; Li, K; Li, T; Li, W; Lin, C; Liu, H; Lu, J; Luo, L; Mei, X; Su, W; Tang, X; Wang, M; Xiao, X; Yang, L; Yang, Z; Zhao, P; Zheng, B | 1 |
| Duan, J; Huang, H; Li, Q; Tian, Y; Wang, J; Wu, D; Yao, Q; Zhang, J; Zheng, Q; Zhou, Q | 1 |
| Ashcroft, JW; Barclay, WS; Bradley, K; Donnelly, CA; Elderfield, RA; Fernandez-Alonso, M; Frise, R; Galiano, M; Lackenby, A; Miah, S; Roberts, KL; Stilwell, P; van Doremalen, N | 1 |
| Bastien, N; Chaudhry, A; Drews, SJ; Li, Y; Pabbaraju, K; Scott, A; Stewart, D; Wong, S | 1 |
| Azziz-Baumgartner, E; Barahona, A; Castillo, JM; Castillo, M; Cazares, RA; Clara, W; Dawood, FS; De León, T; de Viana, D; Estripeaut, D; Franco, D; Fry, AM; Gargiullo, P; Gonzalez, R; Gubareva, L; Hughes, M; Jara, J; Lawson, AM; Luciani, K; Rodriguez, M; Sujey Brizuela, Y; Tamura, D; Widdowson, MA | 1 |
| Pan, Q; Tang, Z; Xi, M; Yu, Y; Zang, G | 1 |
| Aden, JK; Bebarta, VS; Schauer, SG; Varney, SM | 1 |
| Fowler, R; Jones, M | 1 |
| Abed, Y; Boivin, G; Carbonneau, J; Kaiser, L; L'Huillier, AG | 1 |
| Andrianova, E; Averyanov, A; Bart, B; Epstein, O; Minina, E; Putilovskiy, M; Rafalsky, V | 1 |
| Campbell, SM; Green, DA; Hitoaliaj, L; Kotansky, B; Peaper, DR | 1 |
| Broadhurst, R; Mounsey, A | 1 |
| Berger, A; Christopeit, M; Hauf, E; Hentrich, M; Heussel, CP; Kalkreuth, J; Klein, M; Kochanek, M; Lehners, N; Mayer, K; Penack, O; Rieger, C; Schalk, E; Silling, G; Vehreschild, M; von Lilienfeld-Toal, M; Weber, T; Wolf, HH | 1 |
| El Zeenni, N; Forestier, E; Rogeaux, O; Tardy, N; Vercueil, L | 1 |
| Hannongbua, S; Kungwan, N; Phanich, J; Rungrotmongkol, T | 1 |
| Hibino, A; Kondo, H; Masaki, H; Saito, R; Saito, T; Sato, I; Takemae, N; Tanabe, Y; Zaraket, H | 1 |
| Chen, Z; Li, K; Liu, H; Lu, J; Luo, L; Wang, H; Wang, M; Xiao, X; Yang, Z | 1 |
| Chuang, YC; Ku, YH; Yu, WL | 1 |
| Collins, JT; Kennedy, GA; Subramoniapillai, E; Yue, MC | 1 |
| Martin-Loeches, I; Mc Mahon, A | 1 |
| Cinti, S; Gallagher, BA; Li, S; Luo, R; Patel, TS; Stevenson, JG; Sun, D; Wen, B | 1 |
| Bello, S; de Pablo, F; Fandos, S; Figueredo, AL; Minchole, E; Omeñaca, M; Panadero, C; Royo, L; Vengoechea, JJ | 1 |
| Boden, K; Brodhun, M; Hermann, B; Hochhaus, A; Kochanek, M; Lehners, N; Mayer, K; Meckel, K; Rachow, T; Rieger, C; Schalk, E; Schlattmann, P; Schmeier-Jürchott, A; Teschner, D; von Lilienfeld-Toal, M; Weber, T | 1 |
| Antalis, E; Kalliaropoulos, A; Karakitsos, P; Kossyvakis, A; Lytras, T; Meijer, A; Mentis, AA; Mentis, AF; Pogka, V; Tryfinopoulou, K; Tsiodras, S | 1 |
| Avaro, M; Baumeister, E; Benedetti, E; Campos, A; Czech, A; Periolo, N; Pontoriero, A; Russo, M; Zamora, A | 1 |
| Franquiz, MJ; Gonzales, JP; Saleeb, PG; Shanholtz, CB | 1 |
| Chan, JFW; Chan, KH; Chan, TC; Chen, H; Cheng, VCC; Cheung, MKS; Fok, M; Hung, IFN; Lau, JYN; Leung, W; Li, P; Liu, KSH; Tam, A; To, KKW; Wong, TL; Yuen, KY; Zhang, AJ; Zhang, R | 1 |
| Işikay, S | 1 |
| Leung, K; Lipsitch, M; Wu, JT; Yuen, KY | 1 |
| Chowell, G; Viboud, C | 1 |
| Beerens, N; Bestebroer, TM; Cotten, M; de Jonge, HC; de Kleer, I; Fouchier, RA; Fraaij, PL; Hoebe, CJ; Houmes, RJ; Koopmans, MP; Oude Munnink, BB; Pas, SD; Phan, MV; Roosenhoff, RS; Swaan, CM; Timen, A; Tolsma, P; van den Kerkhof, JH; van Kampen, JJ; Wildschut, ED | 1 |
| Busson, L; De Foor, M; Hallin, M; Mahadeb, B; Vandenberg, O | 1 |
| Bernstein, HH; Munoz, FM | 1 |
| Bolon, DN; Finberg, RW; Jensen, JD; Kowalik, TF; Kurt-Yilmaz, N; Özen, A; Prachanronarong, KL; Schiffer, CA; Thayer, KM; Wang, JP; Yilmaz, LS; Zeldovich, KB | 1 |
| Fu, LC; Lai, YN; Li, Y; Liu, N; Xu, PP; Zhang, FX; Zhao, F | 1 |
| Arthur Chen, YM; Chen, HY; Chen, KH; Huang, JC; Lee, YM; Li, MC; Liu, FT; Loh, EW; Tsai, WC; Tseng, SP; Wang, SF; Wang, WH | 1 |
| Chawla-Sarkar, M; Dutta, S; Mukherjee, A; Nayak, MK; Panda, S; Satpathi, BR | 1 |
| Martin, ET | 1 |
| Anderson, E; Appiah, GD; Bargsten, M; Bennett, N; Brady, D; Campbell, AP; Chaves, SS; Eckel, S; Fry, AM; Garg, S; Hill, M; Kirley, PD; Lindegren, ML; Lung, K; Lynfield, R; McDonald-Hamm, C; Meek, J; Miller, L; Oni, O; Ryan, P; Schaffner, W; Thomas, A; Zansky, SM | 1 |
| Ariza-Heredia, EJ; Chemaly, RF; Shahani, L | 1 |
| Beauchemin, CA; Dobrovolny, HM; Palmer, J | 1 |
| Chapman, MJ; Clark, C; Garot, D; Gupta, SK; Husa, P; Jacobs, F; Marty, FM; Merino, E; Peppercorn, AF; Rodriguez-Noriega, E; Shortino, D; Vidal-Puigserver, J; Watson, HA; Yates, PJ | 1 |
| Fischer, TK; Franck, KT; Pedersen, SS; Trebbien, R; Vorborg, K | 1 |
| Aguilar-Faisal, L; Barrón, BL; Correa-Basurto, J; Fragoso-Vázquez, MJ; García-Machorro, J; Martínez-Ramos, F; Méndez-Luna, D; Neri-Bazán, RM; Padilla-Martínez, II; Soriano-Ursúa, MA; Tolentino-López, LE; Trujillo-Ferrara, JG | 1 |
| Boikos, C; Caya, C; Delisle, G; Doll, MK; Dolph, M; Gore, G; Kraicer-Melamed, H; Quach, C; Winters, N | 1 |
| Chen, X; Duwe, SC; Karsch, K; Milde, J; Muehlhans, S; Obermeier, P; Rath, B; Schweiger, B; Seeber, L; Skopnik, H; Spies, V; Tief, F | 1 |
| Kolber, MR; Korownyk, C | 1 |
| Koyfman, A; Long, B; Simon, E | 1 |
| Arunkumar, G; Jagadesh, A; Krishnan, A; Salam, AAA; Zadeh, VR | 1 |
| Das, S; Mandal, RS; Panda, S | 1 |
| Brennan, M; Clooney, L; Coughlan, S; Drew, RJ; Eogan, M; Griffin, J; LeBlanc, D; Linehan, E; O'Rourke, S | 1 |
| Chidiac, C | 1 |
| Del Piero, L; Lehmann, P; Ruf, BR; Sandow, P; Skopnik, H | 1 |
| Cunningham, F; Davey, RT; Deyton, LR; Goetz, MB; Holodniy, M; Lee, KK; Lin, ET; Olivo, N; Penzak, SR; Raisch, DW; Straight, TM | 1 |
| Ruef, C | 1 |
| Nüesch, R | 1 |
| Ichikawa, M; Kawakami, C; Kawaoka, Y; Mitamura, K; Sugaya, N; Tamura, D; Yamazaki, M | 1 |
| Albertini, M; Berlioz, M; Haas, H; Ollier, L; Pierron, S | 1 |
| Reina, J | 3 |
| Maltezou, HC | 1 |
| Fang, JM; Shie, JJ; Wong, CH | 1 |
| Sugrue, RJ; Sutejo, R; Tan, BH; Yeo, DS | 1 |
| Bright, RA; Butler, EN; Deyde, VM; Garten, RJ; Gubareva, LV; Klimov, AI; Okomo-Adhiambo, M; Sheu, TG; Wallis, TR; Xu, X | 1 |
| Anderson, PD; Johnson, AC; Singer, AC; Snyder, SA | 1 |
| English, BK; McCullers, JA | 1 |
| Glezen, WP | 2 |
| Boak, L; Ereshefsky, L; Hoffmann, G; Jhee, SS; Kaeser, B; Leibowitz, M; Patel, A; Prinssen, EP; Rayner, CR; Schulte, M; Yen, M | 1 |
| Barr, CE; Moscona, A; Peters, PH; Schulman, KL | 1 |
| Ades, AE; Cooper, NJ; Lu, G; Sutton, AJ; Welton, NJ | 1 |
| Aubert, RE; Bresee, JS; Epstein, RS; Kamimoto, L; Ortiz, JR; Shay, DK; Yao, J | 1 |
| Bouvier, NM; Lowen, AC; Palese, P | 1 |
| Bresee, JS; Broder, K; Cox, NS; Fiore, AE; Iskander, JK; Mootrey, G; Shay, DK; Uyeki, TM | 1 |
| Jongwutiwes, U; Leelarasamee, A; Puthavathana, P; Siritantikorn, S; Tantipong, H | 1 |
| Bird, SM; Farrar, J | 1 |
| Kimura, F; Kobayashi, A; Kobayashi, S; Motoyoshi, K; Sato, K | 1 |
| Carr, MJ; Connell, J; Duffy, M; Hall, WW; Sayre, N | 1 |
| Honda, A; Ishii, T; Yamazaki, Y | 1 |
| Schutten, M; van den Berg, B; van der Vries, E | 1 |
| Kawano, R; Kouzaki, Y; Tokunaga, M; Uchino, M; Yamashita, S | 1 |
| Blanc, MC; Dennetière, G; Gaillat, J; Raffin-Bru, E; Valette, M | 1 |
| Bui, TN; Crusat, M; de Jong, MD; Do, HQ; Farrar, J; Fox, A; Hoang, PV; Horby, P; Le, MT; Luong, ST; Ngoc, BT; Nguyen, BG; Nguyen, CV; Nguyen, HD; Nguyen, HH; Nguyen, HL; Nguyen, HT; Nguyen, LT; Nguyen, T; Nguyen, TQ; Nguyen, TV; Pham, HV; Phan, PH; Taylor, W; Van, TD; Vuong, CD; Wertheim, HF | 1 |
| Brydak, LB; Nitsch-Osuch, A; Wardyn, AK | 1 |
| de Jong, JC; Donker, GA; Fouchier, RA; Meijer, A; Osterhaus, AD; Rimmelzwaan, GF | 1 |
| Belmaker, I; Bilenko, N; Bitran, E; Dukhan, L; Grotto, I; Lyandres, M; Mandelboim, M; Mendelson, E; Shahar-Rotberg, L; Yossef, Y | 1 |
| Anh, GT; Bien, NM; Binh, NG; Chau, NQ; Crusat, M; Day, N; de Jong, MD; Farrar, JJ; Fox, A; Ha, NH; Hanh, TT; Hien, ND; Horby, P; Lien, TT; Lindegardh, N; Ngoc, NM; Stepniewska, K; Taylor, WR; Thinh, BN; Trung, NV; Wertheim, H; White, NJ | 1 |
| McAndrew, JM; Muder, RR; Risa, KJ | 1 |
| Besselaar, TG; Blumberg, L; Buys, A; Gregory, V; Manamela, JM; McAnerney, J; Naidoo, D; Schoub, BD | 1 |
| Altindağ, H; Boga, I; Dogan, N; Kizilkaya, M; Ozkan, B | 1 |
| Blumentals, WA; Curkendall, S; Madjid, M | 1 |
| Guralnick, RP; Habib, F; Hill, AW; Janies, D; Wilson, MJ | 1 |
| Boak, L; Breidenbach, A; Carey, E; Chu, T; Donner, B; Dutkowski, R; Gieschke, R; Hoffmann, G; Lindemann, L; Prinssen, E; Rayner, C; Reddy, D; Sacks, S; Small, I; Solsky, J; Thakrar, B; Toovey, S | 1 |
| Abed, Y; Baz, M; Boivin, G | 1 |
| Traynor, K | 2 |
| Accinelli, C; Bernard, I; Bird, S; Boucard, T; Boxall, A; Brian, JV; Caracciolo, AB; Cartmell, E; Chubb, C; Churchley, J; Costigan, S; Crane, M; Dempsey, MJ; Dorrington, B; Ellor, B; Fick, J; Holmes, J; Howard, BM; Hutchinson, T; Jackman, S; Johnson, AC; Karcher, F; Kelleher, SL; Knowles, CJ; Marsden, P; Noone, G; Nunn, MA; Oxford, J; Rachwal, T; Roberts, M; Roberts, N; Saccà, ML; Sanders, M; Singer, AC; Straub, JO; Terry, A; Thomas, D; Toovey, S; Townsend, R; Voulvoulis, N; Watts, C | 1 |
| Gong, J; Xu, W | 1 |
| Shiro, H; Tomono, N | 1 |
| Blair, J; Burton, L; Choi, K; De Lima, C; Drews, SJ; Eshaghi, A; Lombos, E | 1 |
| Davies, G; Day, NP; Fukuda, C; Hanpithakpong, W; Lindegårdh, N; Piyaphanee, W; Pongtavornpinyo, W; Pukrittayakamee, S; Silachamroon, U; Singhasivanon, P; Singtoroj, T; Stepniewska, K; Tarning, J; Wattanagoon, Y; White, NJ | 1 |
| Akita, S; Ha, NH; Ha, NT; Hien, ND; Kato, Y; Kawana, A; Kudo, K; Lien, TT; Shimbo, T; Takahashi, Y; Thai, NQ; Trang, VD; Van, NT | 1 |
| Kuhne, M; McDougal, M; Morgan, O; Nair, P; Preece, R; Reacher, M; Verlander, NQ; Zambon, M | 1 |
| Hayashi, Y; Ishikawa, H; Suzuki, T | 1 |
| Balish, A; Bright, RA; Deyde, VM; Gubareva, LV; Klimov, AI; Lindstrom, S; Nguyen, T; Shu, B | 1 |
| Bermingham, A; Democratis, J; Ellis, J; Lackenby, A; McNally, T; Nicholson, K; Pareek, M; Smith, J; Stephenson, I; Zambon, M | 1 |
| Farrar, J | 1 |
| Falahee, ML; Vallerand, AH; Vantine, M | 1 |
| Cohen-Daniel, L; Dorozhko, M; Greenbaum, E; Mador, N; Resnick, IB; Shapira, MY; Wolf, DG; Zakay-Rones, Z | 1 |
| Iwata, M; Kawakami, C; Noguchi, Y; Obuchi, M; Odagiri, T; Saikusa, M; Tashiro, M; Toyozawa, T; Ujike, M | 1 |
| Bejaoui, M; Dhouib, N; Hajkacem, MA; Mellouli, F; Ouederni, M; Slim, A | 1 |
| Flückiger, U; Gratwohl, A; Halter, J; Hirsch, HH; Khanna, N; Lehmann, T; Schreiber, A; Steffen, I; Studt, JD; Weisser, M | 1 |
| Mehling, P | 1 |
| Borgen, K; Dudman, S; Hauge, SH; Hungnes, O; Lackenby, A | 1 |
| Hara, K; Nakajima, M; Shimakawa, S; Tamai, H; Tanabe, T | 1 |
| Halloran, ME; Longini, IM; Yang, Y | 1 |
| Cooper, K; Jackson, R; Nicholson, K; Read, R; Rees, A; Simpson, E; Tappenden, P | 1 |
| Ciancio, B; Kramarz, P; Monnet, D; Nicoll, A; Yilmaz, C | 1 |
| Elliot, AJ; Fleming, DM; Meijer, A; Paget, WJ | 1 |
| Baek, YH; Choi, YK; Hahn, YS; Han, HS; Kang, C; Kim, KS; Lee, OJ; Park, JH; Pascua, PN; Song, MS; Song, YJ | 1 |
| Brogan, AJ; Sander, B; Talbird, SE; Winiarski, AP | 1 |
| Kamigaki, T; Oshitani, H; Tamaki, R | 1 |
| Bilker, WB; Fishman, NO; Gasink, LB; Lautenbach, E; Linkin, DR; Weiner, MG | 1 |
| Brammer, L; Bresee, JS; Dharan, NJ; Epperson, S; Fry, AM; Gubareva, LV; Klimov, AI; Marshall, SA; McClinton, RC; Meyer, JJ; Okomo-Adhiambo, M; St George, K | 1 |
| Claas, EC; Gooskens, J; Jonges, M; Kroes, AM; Meijer, A; van den Broek, PJ | 1 |
| Moscona, A | 3 |
| Hirotsu, N; Ikematsu, H; Iwaki, N; Kashiwagi, S; Kawai, N; Kawashima, T; Maeda, T | 1 |
| Fujino, M; Hata, M; Hiroi, S; Horimoto, T; Kaneda, S; Kawakami, C; Kawaoka, Y; Kimura, K; Kimura, Y; Kiso, M; Minagawa, H; Mitamura, K; Nirasawa, M; Shimizu, H; Sugaya, N; Sugita, S; Takahashi, K; Tamura, D; Yamazaki, M | 1 |
| Layne, SP; Monto, AS; Taubenberger, JK | 1 |
| Coffin, SE; Desai, B; Hodinka, RL; Keren, R; Leckerman, KH; Metjian, TA; Wilkes, JJ; Zaoutis, TE | 1 |
| Wang, NX; Zheng, JJ | 1 |
| Jacobson, RM; Ovsyannikova, IG; Poland, GA | 1 |
| Hay, A; Hungnes, O; Lackenby, A; Lina, B; Meijer, A; Opp, M; Paget, J; Schweiger, B; van-de-Kassteele, J; van-der-Werf, S; Zambon, M | 1 |
| Sacks, S; Smith, JR | 1 |
| Holodniy, M; Schirmer, P | 1 |
| Maeda, M; Tanioka, E; Yamamoto, A | 1 |
| Suzuki, E; Tsuda, T; Yorifuji, T | 1 |
| Jhamandas, JH; McCombe, JA; Narayansingh, MJ | 1 |
| Lugnér, AK; Mylius, SD; Wallinga, J | 1 |
| Claas, EC; Gooskens, J; Jonges, M; Kroes, AC; Meijer, A | 1 |
| Beesley, A; Frickers, PE; Hutchinson, TH; Readman, JW; Shaw, JP; Straub, JO | 1 |
| Coombes, R | 2 |
| Couzin-Frankel, J | 1 |
| McConnell, J | 2 |
| Bauer, K; Richter, M; Schmidtke, M; Wutzler, P | 1 |
| Foust, AS; Garten, RJ; Gubareva, LV; Guo, L; Klimov, AI; Okomo-Adhiambo, M; Sessions, WM; Xu, X | 1 |
| Chau, NQ; Farrar, J; Hien, ND; Hien, NT; Hien, TT; Horby, P; Khang, DD; Liem, NT; Long, HT; Mai, le Q; Taylor, WR; Tung, CV; Wertheim, H | 1 |
| Aavitsland, P; Blix, HS; Borgen, K; Dudman, SG; Hauge, SH; Hungnes, O | 1 |
| Jefferson, T | 1 |
| Beardsworth, P; Postma, MJ; Wilschut, JC | 1 |
| Bolotin, S; Burton, L; Drews, SJ; Eshaghi, A; Low, DE; Mazzulli, T | 1 |
| Allchin, L; Booy, R; Dwyer, DE; MacIntyre, CR; Seale, H; Weston, KM; Zhu, M | 1 |
| Oxford, JS | 1 |
| Cilla, G; Mendiola, J; Montes, M; Pérez-Trallero, E; Vicente, D | 1 |
| Hannongbua, S; Intharathep, P; Kaiyawet, N; Malaisree, M; Nunthaboot, N; Payungporn, S; Poovorawan, Y; Rungrotmongkol, T; Sompornpisut, P | 1 |
| Ewig, S; Torres, A; Woodhead, MA | 1 |
| Chiu, CH; Huang, CG; Huang, YC; Li, WC; Lin, TY; Tsao, KC | 1 |
| Agudo, R; Barrantes, M; Comach, G; de Rivera, I; Douce, R; García, J; Gomez, J; Jimenez, M; Kochel, T; Sanchez, F; Sovero, M; Torres, AL | 1 |
| Barr, IG; Besselaar, TG; Birch, C; Buchy, P; Chittaganpitch, M; Chiu, SC; D'Souza, H; Deng, YM; Dwyer, D; Ernest, J; Guigon, A; Harrower, B; Hurt, AC; Iannello, P; Kei, IP; Kelso, A; Kok, T; Komadina, N; Lin, C; McPhie, K; Mohd, A; Olveda, R; Panayotou, T; Rawlinson, W; Scott, L; Shaw, R; Smith, D | 1 |
| Temte, JL | 2 |
| Cheng, PK; Ho, EC; Lai, MY; Leung, PC; Leung, TW; Lim, WW; Ng, AY | 1 |
| Chou, KC; Du, QS; Huang, RB; Wang, SQ; Zhang, DW | 1 |
| Garcia-Bournissen, F; Ito, S; Koren, G; Murashima, A; Nakajima, K; Tanaka, T | 1 |
| Hayashi, Y; Ishii, F; Iwaki, K; Kobari, T; Nagashima, T; Yajima, T | 1 |
| Magano, J | 1 |
| Farrar, J; Hayden, FG; Ruiz-Palacios, GM; Tran, TH | 1 |
| Govorkova, EA; Uyeki, TM; Webster, RG; White, NJ | 1 |
| Areechokechai, D; Hanshaoworakul, W; Kaewchana, S; Levy, J; Narueponjirakul, U; Sanasuttipun, W; Shinde, V; Simmerman, JM; Ungchusak, K | 1 |
| Fick, J; Järhult, JD; Lindberg, RH; Olsen, B; Söderström, H; Tanaka, H | 1 |
| Straub, JO | 1 |
| Agarwal, N; Arya, SC | 1 |
| Blumentals, WA; Piedra, PA; Schulman, KL | 1 |
| Bautista, E; Cordova-Villalobos, JA; Corrales, A; de la Rosa-Zamboni, D; Hernandez, M; Higuera, A; Mondragon, E; Ormsby, CE; Perez-Padilla, R; Ponce de Leon, S; Quiñones-Falconi, F; Ramirez-Venegas, A; Rojas-Serrano, J | 1 |
| Deyde, VM; Gubareva, LV | 1 |
| Ellis, C; McEwen, R | 1 |
| Ali, M; Haidari, M; Madjid, M; Ward Casscells, S | 1 |
| Sepkowitz, KA | 1 |
| Durand, C; Grout, L; Guinard, A; Schwoebel, V | 1 |
| Coles, S; Ihekweazu, C; Johnson, S; O'Moore, E; Saldana, L; Smith, A | 1 |
| Coutinho, R; Donker, T; Hahné, S; Koopmans, M; Meijer, A; Osterhaus, A; Timen, A; van der Sande, M; van Steenbergen, J; Wallinga, J | 1 |
| Chan, PK; Choi, KW; Chu, IM; Cockram, CS; Hui, DS; Lai, RW; Lam, WY; Lee, N; Lui, GC; Rainer, TH; Sung, JJ; Wong, BC; Wong, E; Wong, RY | 1 |
| Agarwal, SK; Gupta, A; Ignatius, A; Khaira, A | 1 |
| Doniwa, K; Hirotsu, N; Ikematsu, H; Iwaki, N; Kashiwagi, S; Kawai, N; Kawashima, T; Kondou, K; Maeda, T; Tanaka, O | 1 |
| Badur, S; Bozkaya, E; Ciblak, MA; Escuret, V; Gul, F; Hasoksuz, M; Turan, N; Valette, M; Yilmaz, H | 1 |
| Clarke, M; Edwards, R; Herxheimer, A; Jefferson, T; Loke, Y | 1 |
| Barr, IG; Holien, JK; Hurt, AC; Kelso, A; Parker, M | 1 |
| Gu, Y; Kamiya, H; Komiya, N; Matsui, T; Okabe, N; Yahata, Y; Yasui, Y | 1 |
| Harrison, S; Lewis, D; Oliver, I; Wallensten, A | 1 |
| Bocacao, J; Gunn, W; Hall, RJ; Huang, QS; Peacey, MP; Quirk, A; Ralston, JC; Ziki, M | 1 |
| Balasegaram, S; Heathcock, R; Kitching, A; Maguire, H; Roche, A | 1 |
| Buttery, JP; Cheng, AC; Dwyer, DE; Jenkins, CR; Johnson, PD; Korman, TM; Kotsimbos, AT; Krause, VL; Starr, M | 1 |
| Fitzgerald, DA | 1 |
| Bravata, DM; Gould, MK; Holty, JE; Khazeni, N; Stave, CD; Uyeki, TM | 1 |
| Bots, J; Faidherbe, MT; Gerard, C; Gutiérrez, I; Hammadi, S; Litzroth, A; Robesyn, E; Van Oyen, H; Wuillaume, F | 1 |
| Even, J; Gerloff, N; Gregory, V; Hau, P; Huberty-Krau, P; Kremer, J; Lackenby, A; Mossong, J; Muller, CP; Opp, M; Schneider, F | 1 |
| Burch, J; Corbett, M; Duffy, S; Elliot, AJ; Nicholson, K; Palmer, S; Stewart, L; Stock, C; Westwood, M | 1 |
| Harnden, A; Heneghan, C; Mant, D; Perera, R; Shun-Shin, M; Thompson, M | 1 |
| Hirst, TM | 1 |
| Burrows, J; Redgrave, P; Strong, M | 1 |
| Amazzough, K; Blanche, S; Charlier, C; Enouf, V; Grandadam, M; Lanternier, F; Lecuit, M; Lortholary, O; van der Werf, S | 1 |
| Lugnér, AK; Postma, MJ | 1 |
| Braun, C; Buchholz, U; Duwe, S; Heider, A; Schweiger, B | 1 |
| Cheng, PK; Kong, MS; Leung, TW; Lim, W; Tai, AL | 1 |
| Albert, P; Alvarez-Lerma, F; Avellanas, M; Cebrian, J; Del Nogal-Saez, F; Ferrer, M; Galván, B; Granada, R; Guerrero, J; Ibañez, P; León-Gil, C; Maraví-Poma, E; Marques, A; Marquez, E; Martínez, S; Ortiz, P; Prieto del Portillo, I; Rello, J; Rodríguez, A; Ruiz-Santana, S; Sierra, R; Socias, L; Vidaur, L | 1 |
| Rashford, M | 1 |
| Adalja, A | 1 |
| Bennett, S; Brown, I; Hoschler, K; Oliver, I; Salter, M; Wallensten, A | 1 |
| Brown, LE; Doherty, PC; Kelso, A; Turner, SJ | 1 |
| Kondro, W | 1 |
| Jiang, H; Li, N; Liu, H; Luo, C; Ma, J; Qin, G; Shen, X; Wang, Q; Xu, Z; Yang, C; Yu, K; Zhu, W | 1 |
| Rolls, S; Thompson, C | 1 |
| Gerloff, NA; Kremer, JR; Mossong, J; Muller, CP; Opp, M | 1 |
| Gordon, SM | 1 |
| Gu, QH; Hai, ZH; Hu, CP; Li, M; Li, XM; Tan, DM; Xiao, GL; Zhao, SP | 1 |
| Cunningham, AL; Dwyer, DE; Hurt, AC; Kol, C; Saksena, NK; Steain, MC; Wang, B | 1 |
| Crawford, SM | 1 |
| Burrel, S; Fleury, H; Lafon, ME; Roncin, L | 1 |
| Bueti, J; Komenda, P; Reslerova, M; Rigatto, C; Sood, MM; Wiebe, C | 1 |
| Barrière, J; Coindard, G; Cua, E; Otto, J; Peyrade, F | 1 |
| Hacker, J | 1 |
| Brogan, AJ; Talbird, SE; Winiarski, AP | 1 |
| Auwanit, W; Bai, GR; Chittaganpitch, M; Ikuta, K; Kanai, Y; Li, YG; Sawanpanyalert, P | 1 |
| Burioni, R; Canducci, F; Clementi, M | 1 |
| Biswas, A; Chan, J; Chong, YS; Choolani, M; Su, LL; Yong, EL | 1 |
| Daunis, JV; López, Cde H; Roca, RF | 1 |
| Koopmans, MP; van den Wijngaard, CC; van der Sande, MA; van Steenbergen, JE | 1 |
| Bonneux, L | 2 |
| Aron, GI; Bestebroer, TM; Boucher, CA; Fouchier, RA; Guldemeester, J; Herfst, S; Jonges, M; Koopmans, M; Maaskant, J; Meijer, A; Osterhaus, AD; Schutten, M; Van der Linden, A; van der Vries, E | 1 |
| de Almeida, M; Jurawan, R; Smith, A; Weilert, F | 1 |
| Bonten, MJ; Hak, E; van den Dool, C; Wallinga, J | 1 |
| Farndon, P; Palmer, N; Wan Po, AL | 1 |
| Ami, O; Donnadieu, AC; Dupont-Bernabé, C; Fernandez, H; Frydman, R; Guillet, M; Martinez, V; Picone, O; Senat, MV; Trichot, C; Vauloup-Fellous, C | 1 |
| Bi, S; Li, Z; Lin, X; Shu, Y; Wang, Y; Wu, J; Zhang, F; Zhang, Y; Zhou, J | 1 |
| Bryant, A; Chapman, J; Morse, J; Saleeby, E | 1 |
| Belser, JA; Chan, MC; Chan, RW; Chen, LM; Fang, F; Gubareva, LV; Hedlund, M; Katz, JM; Larson, JL; Mishin, VP; Moss, RB; Nicholls, JM; Pearce, MB; Triana-Baltzer, GB; Tumpey, TM | 1 |
| Belshe, RB; Fang, F; Gubareva, LV; Hedlund, M; Klimov, AI; Larson, JL; Moss, RB; Triana-Baltzer, GB; Wurtman, DF | 1 |
| Abed, Y; Baz, M; Boivin, G; Bouhy, X; Hamelin, ME; Papenburg, J | 1 |
| Chida, J; Ito, C; Iwase, K; Kido, H; Mizuno, D; Sawabuchi, T; Suzuki, S; Talukder, SR; Togari, H; Watanabe, I | 1 |
| Hirotsu, N; Ikematsu, H; Iwaki, N; Kashiwagi, S; Kawai, N; Kawamura, K; Kawashima, T; Maeda, T; Matsuura, S; Nishimura, M; Tanaka, O; Yamauchi, S | 1 |
| Baum, SG | 2 |
| Deyde, VM; Garten, RJ; Gubareva, LV; Klimov, AI; Nguyen, HT; Okomo-Adhiambo, M; Shaw, MW; Sheu, TG; Sleeman, K; Xu, X | 1 |
| Bingisser, R; Blume, K; Dangel, M; Dumoulin, A; Gehrisch, R; Hirsch, HH; Keller, DI; Nickel, CH; Stephan, FP; Tschudin, S; Widmer, AF | 1 |
| Burgaleta, C; Callejas, M; Galán, JC; García-Suárez, J; Martín, Y; Rodriguez-Dominguez, M | 1 |
| Barberio, PA; Bracco, JD; Campagne, CG; Meduri, GU; Quispe-Laime, AM; Rolfo, VE; Umberger, R | 1 |
| Bermingham, A; Brock, A; Calatayud, L; Catchpole, M; Ellis, J; Heathcock, R; Kurkela, S; Maguire, H; Neave, PE; Pebody, R; Perkins, S; Sudhanva, M; Zuckerman, M | 1 |
| Chang, SC; Chen, YC; Kao, TM; Ko, WJ; Wang, CH | 1 |
| Gulland, A | 1 |
| Ariano, RE; Smith, JR; Toovey, S | 1 |
| Bonmarin, I; Borgen, K; Boucher, CA; Buchholz, U; Buda, S; Ciancio, BC; Dijkstra, F; Dudman, S; Duwe, S; Hauge, SH; Hungnes, O; Kramarz, P; Meerhoff, TJ; Meijer, A; Mossong, J; Nicoll, A; Paget, WJ; Phin, N; Schweiger, B; van der Sande, M | 1 |
| Barr, IG; Holien, JK; Hurt, AC; Parker, MW | 1 |
| Daneman, N; Kuper, A; Rosenberg, M; Tram, C | 1 |
| Abughali, N; Abzug, MJ; Bradley, JS; Cloud, GA; Englund, J; Griffin, J; Guzman-Cottrill, J; Jacobs, RF; Jester, P; Kimberlin, DW; Lang, D; Leach, C; Ramilo, O; Robinson, J; Romero, JR; Shalabi, M; Shelton, M; Storch, G; Wade, KC; Whitley, RJ | 1 |
| Dill, CE; Favata, MA | 1 |
| Chen, H; He, SH; Liu, YL; Wang, GF; Zeng, YL | 1 |
| Bowman, CS; Fisman, DN; Moghadas, SM; Röst, G; Wu, J | 1 |
| Bresee, JS; Deyde, V; Dharan, NJ; Fry, AM; Gubareva, LV; Klimov, AI; Morita, J; Patton, M; Ramirez, E; Siston, AM; Wallis, TR | 1 |
| Baranovich, T; Caperig-Dapat, I; Dapat, C; Oguma, T; Saito, R; Saito, T; Shabana, II; Suzuki, H; Suzuki, Y; Zaraket, H | 1 |
| Doshi, P | 1 |
| Del Mar, C; Doshi, P; Jefferson, T; Jones, M | 1 |
| Calvert, M; Freemantle, N | 1 |
| Clarke, M; Godlee, F | 1 |
| Nayak, JL; Treanor, JJ | 1 |
| Akalin, E; Chapochnick-Friedmann, J; Lu, A; Marfo, K | 1 |
| Horby, P; Le, QM; Nguyen, TH; Tran, ND; van Doorn, HR; Wertheim, HF | 1 |
| Cao, B; Chen, YS; Gu, L; Li, XW; Liang, L; Liang, ZA; Lu, HZ; Lu, LH; Mao, Y; Wang, C; Wang, DY; Wang, J; Zhang, B; Zhang, SJ | 1 |
| Carleton, B; Goldman, RD; Jain, R; Jamieson, B | 1 |
| Cerdan, M; Kimbrough, R; Nugent, K; Raj, R; Yepeshurtado, A | 1 |
| Field, T; Greene, JN; Kharfan-Dabaja, MA; Richards, K; Sandin, R; Velez, A | 1 |
| Forrester, MB | 1 |
| Burke, JD; Fish, EN | 1 |
| Clardy, BH; Payne, EM; Spradlin, TL; Vinson, J | 1 |
| Deyde, VM; Garten, R; Gubareva, LV; Klimov, AI; Okomo-Adhiambo, M; Sheu, TG; Trujillo, AA | 1 |
| Cheng, PK; Lee, CW; Leung, PC; Leung, TW; Lim, WW; To, AP | 1 |
| Casscells, SW; Cottrell, L; Granger, E; Kress, AM; Linton, A; Madjid, M | 1 |
| Bagga, B; Barman, S; Bhojwani, D; Flynn, PM; Gaur, AH; Hayden, R; Hoffman, JM; Lamptey, A; Tuomanen, E; Webby, R | 1 |
| Siedler, K; Skopnik, H | 1 |
| Boyle, G; Carl, J; Danziger-Isakov, L; Davis, S; Flagg, A; Foster, C; Kwon, C; Nasman, C; Smedira, N | 1 |
| Chan, CH; Chen, CL; Su, ZY; Wang, YT | 1 |
| Eggertson, L | 1 |
| Coutinho, RA; van der Sande, MA; van Dissel, JT | 1 |
| Du, GH; Liu, AL; Wang, HD; Yang, F | 1 |
| Ghosh, GC; Nakada, N; Tanaka, H; Yamashita, N | 1 |
| Albaya-Moreno, A; Algora-Weber, A; Balasini, C; Barahona, D; Figueira, JC; González, N; Guerrero, JE; León-Gil, C; Lisboa, T; Lorente, L; Maraví-Poma, E; Martín, M; Pérez-Padilla, R; Rello, J; Rodríguez, A; Socías, L; Vallés, J; Villabón, M | 1 |
| Chan, JF; Chan, KH; Cheng, VC; Hung, IF; Lai, ST; Lau, YL; Li, IW; To, KK; Tsang, OT; Wong, SS; Yuen, KY | 1 |
| Caram, LB; Cunningham, CK; Cunningham, HM; Hendershot, EF; Lopez-Marti, MG; Purdy, WK; Sangvai, DG; Tsalik, EL; Woods, CW | 1 |
| Bridges, CB; Ciancio, BC; Nicoll, A; Weber, JT | 1 |
| Eagel, BA | 1 |
| Maryon-Davis, AR | 1 |
| Nakamura-Uchiyama, F; Ohnishi, K | 1 |
| Furuta, Y; Kawaoka, Y; Kiso, M; Le, QM; Ozawa, M; Sakabe, S; Sakai-Tagawa, Y; Shinya, K; Takahashi, K | 1 |
| Correia, V; de Andrade, HR; Lackenby, A; Santos, LA; Zambon, M | 1 |
| Calfee, D; Daefler, S; Goldberg, M; Halverstam, C; Kapelusznik, L; Phelps, RG; Vidal, C | 1 |
| Bozzo, P; Djokanovic, N; Koren, G | 1 |
| Barak, S; Chulski, E; Kushnir, A; Miron, D | 1 |
| Hasegawa, H; Katano, H; Kawagishi, N; Kimura, T; Kunieda, Y; Nakajima, N; Nishihara, H; Sata, T; Takagi, T; Takiyama, A; Tanaka, S; Tanino, M; Wang, L | 1 |
| Brown, CM | 1 |
| Bresee, JS; Dharan, NJ; Fiore, AE; Fry, AM; Gubareva, LV; Klimov, AI | 1 |
| Vergara Serrano, JC | 1 |
| Chantratitaya, W; Mavichak, V; Mossad, SB; Suwatanapongched, T; Wacharawanichkul, P; Watcharananan, SP | 1 |
| Cheng, X; Huang, Q; Lu, Y; Ou, Q | 1 |
| Changpinyo, M; Dulyachai, W; Kitikoon, P; Makkoch, J; Payungporn, S; Poovorawan, Y; Prayangprecha, S; Rianthavorn, P; Tantilertcharoen, R | 1 |
| Agut, H; Boutolleau, D; Brun-Vezinet, F; Deback, C; Houhou, N | 1 |
| Bergstrom, KG | 1 |
| Okamoto, E | 1 |
| Hayward, A | 1 |
| Chan, KH; Cheng, CK; Cowling, BJ; Fang, VJ; Houck, PM; Ip, DK; Leung, GM; Malik Peiris, JS; Ng, S; Uyeki, TM | 1 |
| Hurt, AC; Moody, HR; Pinder, M; Smith, DW; Speers, DJ; Williams, SH | 1 |
| Chapman, W; Dronet, M; Escude, J; Gantner, J; Hammond, R; Jester, P; Kimberlin, DW; Ott, J; Redden, DT; Stewart, TA | 1 |
| Schei, E; Simonsen, GS; Swensen, E; Ulvestad, E | 1 |
| Baranovich, T; Caperig-Dapat, I; Dapat, C; Saito, R; Suzuki, H; Suzuki, Y; Zaraket, H | 1 |
| Fadnis, VP | 1 |
| Chee, JJ; Chong, CY; Lim, ML; Lim, WY; Tee, WS | 1 |
| Levy, MH; Turner, KB | 1 |
| Mukhopadhyay, S; Philip, AT; Stoppacher, R | 1 |
| an der Heiden, M; Brockmann, S; Buchholz, U; Buda, S; Duwe, S; Reinhardt, B; Schweiger, B | 1 |
| Ahern, S; Ariano, RE; Kanji, S; Kumar, A; Pisipati, A; Rello, J; Sitar, DS; Zarychanski, R; Zelenitsky, SA | 1 |
| Del Mar, C; Dooley, L; Doshi, P; Foxlee, R; Jefferson, T; Jones, M | 1 |
| Boibieux, A | 1 |
| Biemond, BJ; Nur, E; van Beers, EJ; van Tuijn, CF; Zaaijer, HL | 1 |
| Diaz-Diaz, J; German-Diaz, M; Giangaspro-Corradi, E; Negreira-Cepeda, S; Pavo-Garcia, R | 1 |
| Chan, M; Chow, AL; Cui, L; Krishnan, P; Lee, CC; Leo, YS; Lim, PL; Ling, LM; Lye, DC; Tan, AS; Win, NN | 1 |
| Alexandrov, BB; Hardman, J; Janies, DA; Studer, J; Treseder, TW; Valson, C; Voronkin, IO | 1 |
| Ellis, JB | 1 |
| Baskouta, E; Falagas, ME; Polyzos, K; Rafailidis, PI; Rello, J; Vouloumanou, EK | 1 |
| Kobayashi, N; Koizumi, T; Kubo, K; Tsushima, K; Urushihata, K; Ushiki, A; Yokoyama, T | 1 |
| Guglielmo, BJ; Keh, C; Lindegårdh, N; Nakamura, K; Schwartz, BS | 1 |
| Chen, YY; Huang, SP; Lu, SH; Ou, Q; Xiao, H | 1 |
| Choy, KL; Chung, JP; Ho, LN | 1 |
| Dubey, NK; Gupta, VK; Jha, N; Kalaivani, M; Saha, A | 1 |
| Abiko, C; Aoki, Y; Itagaki, T; Katsushima, Y; Matsuzaki, Y; Mizuta, K; Obuchi, M; Odagiri, T; Sanjoh, K; Sugawara, K; Suto, A; Takashita, E; Tashiro, M; Ujike, M | 1 |
| Ichiyama, T | 1 |
| Azevedo, VF; Gonçalves, BP; Machado, DM; Sabatoski, V; Serrato, VA | 1 |
| Andrade, A; Gomez, F; Leal, JL; Martínez, W; Uribe, M; Zapata, R | 1 |
| Cappy, P; Collins, P; Gregory, V; Hay, A; Mba, SA; Njouom, R; Noah, DN; Rousset, D | 1 |
| Dutkowski, R | 1 |
| Smith, JR | 1 |
| Reddy, D | 1 |
| Davies, BE | 1 |
| Chen, P; Liu, XW; Ma, J; Ng, S; Than, A; Zeng, J; Zhang, J; Zhao, Y | 1 |
| Chan, PA; Chapin, K; Connell, NT; Gabonay, AM; Larkin, JM; LaRosa, SP; Mermel, L; Westley, B | 1 |
| Azar, R; Grossman, Z; Hindiyeh, M; Hirsh, S; Levy, V; Mandelboim, M; Mendelson, E; Meningher, T; Orzitzer, S; Ram, D; Robinov, J | 1 |
| Fujiwara, N; Hata, M; Kobayashi, S; Minagawa, H; Tanaka, S; Yasui, Y | 1 |
| Afif, M; Arnott, S; Gadong, N; Heath, P; Inusa, B; Marais, G; Payne, H; Rees, DC; Robertson, P; Wilkey, O; Zuckerman, M | 1 |
| Bouscambert-Duchamp, M; Escuret, V; Ferraris, O; Lina, B; Morfin, F | 1 |
| Greer, LG; McIntire, DD; Roberts, SW; Rogers, VL; Sheffield, JS; Wendel, GD | 1 |
| Haas, W | 1 |
| Colombo, C; Daccò, V; Daleno, C; Esposito, S; Lackenby, A; Molteni, CG; Principi, N | 1 |
| Eichelberger, MC; Hassantoufighi, A; Hrabal, RJ; Memoli, MJ; Taubenberger, JK | 1 |
| Berrueco, R; Camós, M; Català, A; Estella, J; García-García, JJ; Launes, C; Muñoz-Almagro, C; Rives, S; Toll, T | 1 |
| Alsip, B; Blevins, PA; Cohen, AL; Dawood, F; Duffy, MR; Emery, S; Fonseca, VP; Fry, AM; Guerra, F; Guerra, S; Lindstrom, S; Loustalot, F; Lucas, PM; Menon, M; Mills, G; Morgan, OW; Olsen, SJ; Parks, S; Sanchez, R; Shim, MJ; Shim, T; Shu, B; Verani, J; Walea, N | 1 |
| Chen, YS; Lee, SS; Liu, MT; Sy, CL; Tsai, HC | 1 |
| Engelhard, D; Glikman, D; Hindiyeh, M; Hindyieh, M; Mandelboim, M; Mendelson, E; Ram, D; Zonis, Z | 1 |
| Avaro, M; Baumeister, E; Campos, A; Cané, A; Carabajal, E; Casanueva, E; Diez, MA; Iolster, T; Pontoriero, A; Richards, L; Rivarola, MR; Rojas, M; Sosa, P; Sticco, N; Zcech, A | 1 |
| Hernández-Garay, M; Namendys-Silva, SA | 1 |
| Block, SL; Dutkowski, R; Reisinger, K; Winther, B | 1 |
| Ohashi, Y; Sugaya, N | 1 |
| Sethi, SK | 1 |
| Freebairn, RC; More, R; Scott, A | 1 |
| Davey, RT; Fang, F; Moss, RB; Steigbigel, RT | 1 |
| Combes, A; Farinotti, R; Fernandez, C; Lemaitre, F; Luyt, CE; Nieszkowska, A; Roullet-Renoleau, F; Zahr, N | 1 |
| Blyth, CC; Cunningham, AL; Dwyer, DE; Kesson, A; McPhie, K; Ratnamohan, M; Saksena, NK; Shi, H; Soedjono, M; Wang, B | 1 |
| Aitken, C; Bennett, S; Bremner, J; Clark, A; Gunson, R; Hardie, A; Harvala, H; McKnight, J; Roddie, H; Rowney, D; Scott, F; Simmonds, P; Templeton, K; Walsh, T | 1 |
| Eissler, M; Mosshammer, D | 1 |
| Deindl, P; Varnholt, V | 1 |
| Brüggemann, RJ; Knops, NB; Koster-Kamphuis, L; Schreuder, MF; van der Flier, M | 1 |
| Hindiyeh, M; Mandelboim, M; Mendelson, E; Meningher, T | 1 |
| Cattle, N; Collins, P; Daniels, R; Gregory, V; Hay, A; Kloess, J; Lackenby, A; Lin, YP; Wharton, S | 1 |
| Dembinski, J | 1 |
| Chappell, JD; Creech, CB; Denison, MR; Domm, J; Dulek, DE; Frangoul, HA; Schulert, AK; Williams, JV | 1 |
| Lecumberri, J; Montané, E; Pedro-Botet, ML | 1 |
| Han, J; Liu, H; Wang, C; Yao, X | 1 |
| DU, HB; Li, XW; Ni, L; Wang, RB; Wang, YG; Zhang, W | 1 |
| Kessler, HH; Linkesch, W; Neumeister, P; Rohn, A; Valentin, T | 1 |
| Baranovich, T; Dapat, C; Dapat, IC; Ishitani, N; Matsuda, R; Oguma, T; Saito, R; Sato, I; Suzuki, H; Suzuki, Y; Zaraket, H | 1 |
| Bautista, E; Chotpitayasunondh, T; Gao, Z; Harper, SA; Hayden, FG; Hui, DS; Kettner, JD; Kumar, A; Lim, M; Nicholson, KG; Penn, C; Shaw, M; Shindo, N; Uyeki, TM; Zaki, SR | 1 |
| Baldanti, F; Campanini, G; Donatelli, I; Facchini, M; Locatelli, F; Minoli, L; Percivalle, E; Piralla, A; Puzelli, S; Rovida, F | 1 |
| Al-Bahlooli, SH; Al-Kohlani, A; Shoja'a, A; Thabet, AA | 1 |
| Chee, JJ; Lim, ML; Lim, SH; Lim, WY; Tee, NW | 1 |
| Aardema, H; Boucher, CA; de Jager, CM; Riezebos-Brilman, A; Tulleken, JE; van den Biggelaar, RJ; Wolters, BA | 1 |
| Hirsch, HH; Ison, MG | 1 |
| Guidot, DM | 1 |
| Coleman, RA; Cook, RT; Langlois, RA; Legge, KL; Meyerholz, DK; Waldschmidt, TJ | 1 |
| Hibberd, M; Lai, FY; Lin, R; Low, CL; Ooi, PL; Tambyah, PA; Wong, C | 1 |
| Cholewińska, G; Higersberger, J; Horban, A; Lipowski, D; Olszyńska-Krowicka, M; Podlasin, R; Przyjałkowski, W; Wiercińska-Drapało, A | 1 |
| Avery, L; Kumar, A; Lapinsky, S; Menticoglou, S; Oluyomi-Obi, T; Schneider, C; Zarychanski, R | 1 |
| Boni, MF; Bryant, JE; Chau, NV; Chinh, NT; Dung, NT; Farrar, J; Ha, do Q; Hien, TT; Hien, VM; Ngan, TT; Nguyen, TD; Nhien, PT; Nhu, le NT; Thanh, TT; Truong, NT; Uyen, le TT; van Doorn, HR; Wolbers, M | 1 |
| Shaw, DM | 1 |
| Fujita, N; Horikawa, H; Kageyama, T; Kato, Y; Kishida, N; Mochizuki, K; Obuchi, M; Odagiri, T; Shimabukuro, K; Shirakura, M; Tashiro, M; Ujike, M; Yamashita, K | 1 |
| Lu, H; Shen, Y | 1 |
| Engelhard, D; Glikman, D; Hindiyeh, M; Mandelboim, M; Mendelson, E; Ram, D; Zonis, Z | 1 |
| Aditama, TY; Baird, JK; Benamore, R; Burhan, E; Ikhsan, M; Isbaniah, F; Malik, S; Mangunnegoro, H; Nawas, A; Partakusuma, L; Soepandi, PZ; Sutiyoso, A; Swidarmoko, B; Taylor, WR | 1 |
| Griffiths, SM; Kim, JH; Lau, JT; Wong, AH; Yung, TK | 1 |
| Baranovich, T; Caperig-Dapat, I; Dapat, C; Dbaibo, GS; Medlej, F; Reda, M; Saito, R; Suzuki, H; Suzuki, Y; Tabet, C; Wakim, R; Zaraket, H | 1 |
| Prosenc, K; Socan, M; Tevz-Cizej, N | 1 |
| Cunha, BA; Davis, M; Syed, U; Thekkel, V | 1 |
| Holmes, EC | 1 |
| Baltimore, D; Bloom, JD; Gong, LI | 1 |
| Barr, I; Chen, MI; Gao, Q; Ho, HJ; Kelly, PM; Kelso, A; Lee, VJ; Tambyah, PA; Tan, BH; Tay, JK; Yap, J | 1 |
| Al Aklabi, MM; Ghorpade, N; Humar, A; Weinkauf, JG | 1 |
| Farrar, J; Fox, A; Ha, NH; Hoa, le NM; Horby, P; Lam, NT; Simmons, C; Van Kinh, N; Wertheim, H | 1 |
| Perret P, C | 1 |
| Canneti, E; Croci, L; Di Tomassi, M; Mariotta, S; Migliorini, MG; Ricci, A; Sposato, B; Toti, M | 1 |
| Castrodeza Sanz, J; Eiros Bouza, JM; Pérez Rubio, A | 1 |
| Bakal, I; Fox, BD; Kramer, MR; Raviv, Y; Rozengarten, D; Rusanov, V | 1 |
| Chen, MI; Chew, SW; Cook, AR; Cui, L; Hibberd, ML; Kang, WL; Koh, WH; Lee, CW; Lee, VJ; Lin, R; Loh, JP; Seet, B; Sung, WK; Tambyah, PA; Tan, BH; Tay, JK; Wong, CW; Yap, J | 1 |
| Cho, BK; Kim, JE; Kwon, NH; Park, HJ | 1 |
| Chuang, SK; Leung, YH; Li, MP | 1 |
| Booy, R; Doyle, B; Dwyer, DE; Khandaker, G | 1 |
| Boltz, DA; Castillo, R; Holland, LE | 1 |
| Chan, PK; Hui, DS; Lam, WY; Lee, N; Leung, TF; Ngai, KL | 1 |
| Bilgin, H; Odabas, D; Sert, A; Yazar, A | 1 |
| Haura, L; Makkoch, J; Poovorawan, Y; Warachit, B | 1 |
| Buising, KL; Cheng, AC; Denholm, JT; Doyle, JS; Dwyer, DE; Ferguson, PE; George, B; Harper, JM; Harrison, SJ; Hurt, AC; Johnson, PD; Langan, K; Morrissey, CO; Reid, AB; Seymour, JF; Slavin, M; Thursky, K; Tramontana, AR; Wang, B; Worth, LJ | 1 |
| Abd el Kareem, E; de Mattos, CC; Earhart, KC; El-Refaie, S; El-Sayed, N; Essmat, H; Kandeel, A; Manoncourt, S; Marfin, AA; Mohamed Ahmed, AN; Tjaden, J | 1 |
| Dervisevic, S; Hill-Cawthorne, GA; Lawes, M; Schelenz, S | 1 |
| Akyüz, S; Bülbül, M; Demircin, G; Erdogan, O; Renda, R; Yilmaz, A | 1 |
| Abdelrahman, M; AlOyouni, W; Jasim, MR; Karkar, A | 1 |
| Acosta, EP; Gal, P; Jester, P; Kimberlin, DW; Wade, J; Whitley, RJ; Wimmer, J | 1 |
| Bracebridge, S; Campbell, C; Chamberland, M; Dallman, T; Ellis, J; Green, J; Harris, R; Hawkins, C; Ihekweazu, C; Kafatos, G; Maguire, H; McLean, E; McMenamin, J; Myers, R; Nguyen-Van-Tam, JS; Oliver, I; Pebody, RG; Phin, N; Smith, GE; Smyth, B; Underwood, A; Watson, JM; White, PJ; Wreghitt, T; Wynne-Evans, E; Zambon, M | 1 |
| Chishti, T; Oakeshott, P | 1 |
| Chidlow, GR; Deng, YM; Harnett, GB; Hurt, AC; Smith, DW; Speers, DJ; Tempone, SS; Williams, SH | 1 |
| Berkovitch, M; Karplus, R; Sanset, S; Schneider, D; Zaidenstein, R | 1 |
| Dolley-Hitze, T; Le Tulzo, Y; Marqué, S; Tribut, O; Verdier, MC | 1 |
| Dalhuijsen, A; Donker, T; Hahné, S; Koopmans, M; Meijer, A; Swaan, C; te Beest, DE; Teunis, P; Timen, A; van Boven, M; van den Hoek, A; van der Lubben, M; van der Sande, MA; van Gageldonk-Lafeber, RB; Wallinga, J | 1 |
| Battegay, M; Daneschwar, F; Tschudin Sutter, S; Widmer, AF | 1 |
| Brocklehurst, P; Knight, M; Kurinczuk, JJ; Mill, AC; Pierce, M; Spark, P; Stephens, S; Thomas, SH; Valappil, M; Yates, L | 1 |
| Barr, IG; Fryer, HR; Hurt, AC; McCaw, JM; McLean, AR; Mosse, J; Nor'e, SS | 1 |
| Campello, C; Confalonieri, M; D'Agaro, P | 1 |
| Donner, B; Hoffmann, G; Niranjan, V | 1 |
| Cao, WC; Jiang, T; Li, XF; Liu, LJ; Liu, W; Qin, CF; Tang, F; Wei, MT; Yu, M; Yu, XD; Zhao, H | 1 |
| Ferguson, P; George, B; Gilroy, N; Gottlieb, D; Hertzberg, M; Kerridge, I | 1 |
| Biolo, M; Cifaldi, R; Confalonieri, M; Dreas, L; Gabrielli, M; Viviani, M | 1 |
| Bertisch, B; Boggian, K; Vernazza, P | 1 |
| Biedrzycki, P; Cowling, BJ; Danon, L; Fang, VJ; Goldstein, E; Hagy, A; Lipsitch, M; Miller, JC; O'Hagan, JJ; Reshef, D; Robins, J | 1 |
| Asilioğlu, N; Dinler, G; Kalayci, AG; Sensoy, G; Sungur, M; Taşdemir, HA | 1 |
| Barrientos, A; Ridao-Cano, N; Rodriguez-Moreno, A; Sanchez-Fructuoso, AI | 1 |
| Moura, FE | 1 |
| Kiefer, B | 2 |
| Basse, G; Daudé, M; Esposito, L; Guitard, J; Izopet, J; Kamar, N; Mansuy, JM; Rostaing, L | 1 |
| Calitri, C; Cuozzo, M; Gabiano, C; Garazzino, S; Pinon, M; Scolfaro, C; Tovo, PA; Zoppo, M | 1 |
| Helbig, G; Kyrcz-Krzemien, S; Pająk, J; Wieczorkiewicz, A; Woźniczka, K | 1 |
| Darbar, D; Hardin, B; Raj, SR; Wells, Q | 1 |
| DeLiberto, T; DuBois, RM; Govorkova, EA; Gramer, MR; Krauss, S; Negovetich, NJ; Senne, DA; Stallknecht, DE; Stoner, TD; Swafford, S; Webster, RG | 1 |
| Koranyi, K; Leber, A; Ramilo, O; Rohrer, Z; Yontz, D | 1 |
| Bouscambert-Duchamp, M; Caro, V; Casalegno, JS; Escuret, V; Ferraris, O; Lina, B; Sabatier, M; Schuffenecker, I; Traversier, A; Valette, M | 1 |
| Moser, MJ; Operario, DJ; St George, K | 1 |
| Cayley, WE | 2 |
| Corey, L; Kuypers, J; Renaud, C | 1 |
| Costas, E; Hernández, JM; López-Rodas, V | 1 |
| Buettner, PG; Burgher, B; Dixit, R; Egan, A; Francis, F; Grewal, A; Harris, PN; Jayalath, R; Leahy, C; Norton, RE; Proud, M | 1 |
| Chang, LS; Eng, HL; Huang, EY; Kuo, HC; Lee, IK; Li, CC; Lin, YJ; Liu, JW; Tang, KS; Wang, L; Yang, KD; You, HL | 1 |
| Amitai, Z; Grotto, I; Hindiyeh, M; Kaliner, E; Kopel, E; Mandelboim, M; Mendelson, E; Volovik, I | 1 |
| Agrawal, AS; Chadha, MS; Chakrabarti, S; Chawla-Sarkar, M; Ghosh, S; Lal, R; Mishra, AC; Roy, T; Sarkar, M | 1 |
| Boltz, DA; Bragstad, K; Duan, S; Govorkova, EA; Li, J; Nielsen, LP; Seiler, P; Webby, RJ; Webster, RG | 1 |
| Chan, KH; Hung, IF; Li, IW; To, KK; Tse, H; Wong, SS; Woo, PC; Yuen, KY | 1 |
| Lundgren, J; Madsen, L; Nielsen, A | 1 |
| Abdelghani, AS; Abdelsattar, A; Boynton, BR; Deyde, VM; Earhart, KC; Elsayed, NM; Essmat, HM; Gubareva, LV; Klimov, A; Mansour, MM; Monteville, MR; Nayel, A; Saad, MD; Shuck-Lee, D; Tjaden, JA | 1 |
| Sinha, M | 1 |
| Finn, A; Fraser, JI; Seale, AC; Toussaint, FS | 1 |
| Chappell, JD; Cronin, RM; O'Leary, MF; Stratton, CW; Tang, YW; Taylor, MB | 1 |
| Boyko, Y; Jensen, R; Nielsen, LP; Severinsen, IK; Storgaard, M; Terp, K | 1 |
| Bruzzese, E; Cecinati, V; Da Dalt, L; Daleno, C; Esposito, S; Fossali, E; Galeone, C; Giacchino, R; Giaquinto, C; Lackenby, A; Molteni, CG; Principi, N; Valzano, A | 1 |
| Beekmann, SE; Dharan, NJ; Finelli, L; Fiore, A; Fry, AM; Polgreen, PM; Uyeki, TM | 1 |
| Albrecht, RA; García-Sastre, A; Kaminski, M; Kochs, G; Medina, RA; Palese, P; Philipp, J; Rubbenstroth, D; Schwalm, F; Seibert, CW; Staeheli, P; Stertz, S | 1 |
| Chang, HR; Chen, CC; Chen, SC; Lee, MC; Lee, YT; Liu, KS | 1 |
| Dutta, AK; Khare, S; Kumar, A; Kumar, V; Parakh, A | 1 |
| Chan, KP; Kee, T; Low, CY; Oon, LL; Tan, BH; Tan, CK; Tee, NW | 1 |
| Heikkinen, T; Heinonen, S; Ikonen, N; Lehtinen, P; Puhakka, T; Silvennoinen, H; Vahlberg, T; Vainionpää, R; Ziegler, T | 1 |
| Barbas, SG; Falagas, ME; Rafailidis, PI; Spiropoulos, T; Theocharis, G; Vouloumanou, EK | 1 |
| Campins, A; Carratalà, J; Fariñas, MC; Gudiol, F; López-Medrano, F; Martínez-Montauti, J; Moreno, A; Oteo, JA; Pachón, J; Paño-Pardo, JR; Rodríguez-Baño, J; Segura, F; Torre-Cisneros, J; Viasus, D; Villoslada, A | 1 |
| Booy, R; Dibben, C; Elliott, EJ; Khandaker, GM; Zurynski, Y | 1 |
| Adisasmito, W; Aghayev, F; Bamgboye, E; Chan, PK; Coker, R; Dogan, N; Dreyer, NA; Gasimov, V; Lee, N; Oner, AF; Starzyk, K; Toovey, S; Zaman, M | 1 |
| Couch, RB; Davis, BR | 1 |
| Fu, Y; Nie, Y; Yang, G; Yang, Z; Zhou, L; Zu, Y | 1 |
| Furuse, Y; Khandaker, I; Nukiwa, N; Odagiri, T; Oshitani, H; Shimabukuro, K; Suzuki, A | 1 |
| Barrero, PR; Diez, RA; Farías, JA; López, EL; Mistchenko, AS; Valinotto, LE | 1 |
| Saito, R | 1 |
| Bender, JM; Couturier, BA; Hanson, KE; Pavia, AT; Schwarz, MA; She, RC | 1 |
| Adalja, AA | 1 |
| Agrawal, R; Kalra, A; Kokil, GR; Rewatkar, PV; Verma, A | 1 |
| Abdel-Haq, N; Alangaden, GJ; Ang, JY; Bheemreddy, S; Chandrasekar, P; Lum, L; McGrath, E; Mehta, T; Salimnia, H | 1 |
| Mitamura, K | 3 |
| Tsukahara, Y | 1 |
| Arakawa, S; Matsuo, M; Morioka, I | 1 |
| Hatakeyama, S | 1 |
| Watanabe, A | 2 |
| Ishii, H; Kadota, J; Tokimatsu, I; Yoshioka, D | 1 |
| Adachi, M; Nishiyama, A; Oyazato, Y | 1 |
| Chong, S; Luinstra, K; Mahony, JB; Petrich, A; Smieja, M | 1 |
| Allenet, B; Bussières, JF; Ferreira, E; Skalli, S | 1 |
| Alcalá, W; Barberis, F; Bonvehí, P; Carballal, G; Chavez, N; Echavarría, M; Figueras, L; Herrera, F; Martínez, A; Querci, M; Stryjewski, ME; Temporiti, E; Videla, C | 1 |
| Altas, AB; Aydin, M; Dursun, A; Hakan, N; Ipek, MS; Karadag, NN; Karagol, BS; Korukluoglu, G; Kundak, AA; Okumus, N; Zenciroglu, A | 1 |
| Ana Pasquali, M; Belaus, A; Beltramo, DM; Del Carmen Montes, C; Galván, C; Velez, P; Walter Soria, N | 1 |
| Fry, AM; Gubareva, LV; Klimov, AI; Loveless, PA; Nguyen, HT | 1 |
| Reece, PA | 2 |
| Hsu, LC; Huang, YP; Kuo, CY; Lin, YC; Liu, MT; Su, CH; Wu, HS; Yang, JR | 1 |
| Chang, TP; Chen, YC; Lo, CP | 1 |
| Bos, ME; Koopmans, MP; Stegeman, A; te Beest, DE; van Boven, M | 1 |
| Bandaranayake, D; Ducatez, M; Hall, RJ; Hope, V; Huang, S; Nicol, M; Paine, S; Peacey, M; Ralston, JC; Sonnberg, S; Webby, RJ | 1 |
| Barkham, T; Chan, KP; Chow, A; Inoue, M; Leo, YS; Lin, C; Lin, R; Maurer-Stroh, S; Tze Chuen Lee, R; Wong, CW | 1 |
| Farrar, J; Feng, Z; Gao, Z; Guo, X; Huai, Y; Liao, Q; van Doorn, HR; Wang, Y; Xiang, N; Yang, W; Yu, H; Yuan, Y; Zheng, Y; Zhou, L | 1 |
| Boucher, CA; Stelma, FF; van der Vries, E | 1 |
| Bhat, VB; Kumar, M; Mondal, N; Renitha, R; Sriram, P | 1 |
| Aouri, M; Buclin, T; Decosterd, LA; Ivanyuk, A; Meylan, P; Widmer, N | 1 |
| Li, H; Wang, SX | 1 |
| Chang, SC; Chu, DW; Kim, MJ; Ohashi, Y; Watanabe, A | 1 |
| Chappuy, H; Duchêne, P; Ducrocq, S; Giraud, C; Hubert, P; Manceau, S; Mogenet, A; Oualha, M; Treluyer, JM | 1 |
| Ando, K; Asai, N; Iwasaki, T; Kaneko, N; Komatsu, A; Matsunuma, R; Misawa, M; Nakashima, K; Ohkuni, Y; Otsuka, Y; Yasui, D | 1 |
| Dubielzig, RR; Hatta, M; Hatta, Y; Hershberger, K; Katze, MG; Kawaoka, Y; Proll, SC; Shinya, K; Suresh, M | 1 |
| Cooper, KL; Jackson, RJ; Nicholson, KG; Read, RC; Rees, A; Simpson, EL; Tappenden, P | 1 |
| Bennett, S; Carman, WF; Gunson, RN; MacLean, A; Miller, R | 1 |
| Abrisqueta, P; Antón, A; Bosch, F; de Anta, MT; Llopart, L; López-Iglesias, AA; Marcos, MÁ; Martínez, MJ; Pahissa, A; Pumarola, T; Ruiz-Camps, I; Tórtola, T; Tudó, G | 1 |
| Dilmen, U; Erdeve, O; Kanmaz, G; Oguz, SS; Uras, N | 1 |
| Chang, SC; Chen, YC; Hsieh, SM; Liu, MT; Wang, JT; Wu, UI | 1 |
| Beauchemin, CA; Davies, BE; Dobrovolny, HM; Gieschke, R; Jumbe, NL | 1 |
| Kinikar, A; Kulkarni, R; Valvi, C | 1 |
| Adams-Huet, B; Ardura, MI; Brock, E; Cost, C; Siegel, JD | 1 |
| Guo, AM; Kong, XC; Peng, WH; Song, HJ; Wang, P; Xiao, Q; Xing, SL; Zhu, ML | 1 |
| Heikkinen, T; Heinonen, S; Lehtinen, P; Silvennoinen, H; Vainionpää, R | 1 |
| Chen, L; Greenwald, I; Wolfe, C | 1 |
| Calistri, A; Chillemi, C; Cusinato, R; Da Dalt, L; Franchin, E; Gambino, A; Palù, G; Salata, C; Sgarabotto, D; Toscano, G | 1 |
| Donaldson, LJ; Sachedina, N | 1 |
| Fan, YM; Li, TM; Liu, XQ; Zhou, BT | 1 |
| Bergmann, F; Edelmann, A; Feiterna-Sperling, C; Hofmann, J; Krüger, DH; Magdorf, K; Nickel, R; Rautenberg, P; Schweiger, B; Wahn, V | 1 |
| Casas, I; González-Vincent, M; Pérez-Breña, P; Pozo, F; Ruiz-Carrascoso, G | 1 |
| Dashti-Khavidaki, S; Fathi, M; Gholamalipour, F; Hajabdolbaghi, M; Khalili, H; Mokhtari Azad, T; Nasiripour, S; Rasoolinejad, M; Soudbakhsh, A; Talasaz, AH; Talebian, MT | 1 |
| Barrero, PR; Mistchenko, AS; Valinotto, LE; Viegas, M | 1 |
| Kinikar, A; Kulkarni, R | 1 |
| Adderson, EE; Caniza, M; Carr, S; Franks, J; Govorkova, EA; Ilyushina, NA; Webster, RG | 1 |
| Li, X; Liang, L; Liu, Y; Nie, G; Tan, X; Tian, Y; Xia, Z; Zhang, G; Zhou, B | 1 |
| Krishna, V; Lohiya, GS; Tan-Figueroa, L | 1 |
| Boeckh, MJ; Corey, L; Englund, JA; Jain, R; Kuypers, J; Pergam, SA; Polyak, C; Renaud, C | 1 |
| Alioglu, B; Dallar, Y; Ozen, C; Selver, B; Tasar, A | 1 |
| Birkner, P; Duwe, SC; Schweiger, B; Wedde, M | 1 |
| Andreoletti, L; Blanchon, T; Bouscambert-Duchamp, M; Charlois-Ou, C; Duval, X; Enouf, V; Leport, C; Lina, B; Mentré, F; Mosnier, A; Tibi, A; Tubach, F; van der Werf, S; Vincent, C | 1 |
| Alonso, M; Bouza, E; Catalán, P; García de Viedma, D; Gayoso, J; Giannella, M; López Bernaldo de Quirós, JC; Rodríguez-Sánchez, B | 1 |
| Hirata, K; Kadowaki, T; Komagamine, T; Suzuki, K | 1 |
| Baranovich, T; Caperig-Dapat, I; Dapat, C; Nishikawa, M; Saito, R; Sato, I; Suzuki, H; Suzuki, T; Suzuki, Y; Tamura, T; Zaraket, H | 1 |
| Anraku, M; Husain, S; Mazulli, T; Pierre, AF | 1 |
| Eisenhaber, F; Hibberd, ML; Kelly, PM; Koay, ES; Lee, RT; Lee, VJ; Loh, JP; Maurer-Stroh, S; Tan, BH; Tay, JK; Ting, PJ; Wong, CW; Yap, J | 1 |
| Abed, Y; Beauchemin, CA; Boivin, G; Bouhy, X; Holder, BP; Simon, P | 1 |
| Yamashita, M | 1 |
| Krause, M; Kruker, AT | 1 |
| Amayiri, N; Madanat, F | 1 |
| Feng, YQ; Guo, TS; Li, B; Li, BA; Li, YL; Liu, LM; Liu, ZG; Mao, YL; Sun, ZQ; Zhao, M | 1 |
| Nguyen-Van-Tam, JS; Nicholson, KG | 1 |
| Hirotsu, N; Ikematsu, H; Iwaki, N; Kashiwagi, S; Kawai, N; Maeda, T; Matsuura, S; Nishimura, M; Tanaka, O; Yamauchi, S | 1 |
| Isaacs, D | 1 |
| Choi, JH; Choi, WY; Hong, EH; Kang, C; Kim, KS; Kim, MS; Kwon, D; Lee, JK; Lee, JY; Oh, HB; Yi, H | 1 |
| He, JJ; Wang, WL; Yan, S; Zhang, M; Zheng, SS | 1 |
| Bondarev, VP; Borisevich, SV; Loginova, SIa; Maksimov, VA; Nebol'sin, VE; Shkliaeva, OM | 1 |
| Danisman, N; Dilmen, U; Erdeve, O; Kanmaz, HG; Mollamahmutoglu, L; Oguz, SS; Unlu, S; Uras, N | 1 |
| Cansiz, M; Kaynar, K; Kazaz, N; Ozkan, G; Oztuna, F; Ulusoy, S | 1 |
| de Jong, MD; Hayden, FG | 1 |
| Bullion, L; Deyde, VM; Fry, AM; Garten, RJ; Gubareva, LV; Klimov, AI; Li, Y; Peebles, PJ; Sheu, TG; Shwe, T | 1 |
| Abdelrahman, T; Barnes, R; Davies, E; Evans, MR; Fegan, C; Froude, S; Galiano, M; Hastings, M; Knapper, S; Lackenby, A; Litt, E; Moore, C; Price, N; Salmon, R; Temple, M | 1 |
| Deyde, VM; Fry, AM; Garten, RJ; Gubareva, LV; Klimov, AI; Mishin, VP; Nguyen, HT; Okomo-Adhiambo, M; Shaw, MW; Sheu, TG; Sleeman, K; Trujillo, AA | 1 |
| Bozza, FA; de Lourdes Oliveira, M; Gonçalves, VM; Gubareva, LV; Marques, VP; Mesquita, M; Mishin, VP; Motta, FC; Pitrowsky, MT; Rocco, SA; Salluh, JI; Siqueira, MM; Soares, M; Souza, TM; Velasco, E; Whitney, A | 1 |
| Albedwawi, S; Alfaresi, M; Hag-Ali, M | 1 |
| Abdel-Rahman, SM; Kearns, GL; Newland, JG | 1 |
| Fasanello, J; Hereth, J; Sharp, JK | 1 |
| Barclay, WS; Brookes, DW; Hartgroves, L; Lackenby, A; Miah, S | 1 |
| Beer, M; Fazekas, T; Frank-Gehrke, B; Graf, P; Grassauer, A; Kalthoff, D; König-Schuster, M; Leibbrandt, A; Meier, C; Pflugfelder, B; Prieschl-Grassauer, E; Unger, H; Weinmüllner, R | 1 |
| Godara, SM; Goplani, KR; Gumber, MR; Kute, VB; Shah, PR; Shah, VR; Trivedi, HL; Vanikar, AV | 1 |
| Watanabe, N | 1 |
| García-García, JJ; Jordán, I; Launes, C; Martínez-Planas, A; Muñoz-Almagro, C; Selva, L | 1 |
| Koay, ES; Lee, HK; Lin, C; Quak, SH; Suhaila, M; Tambyah, PA; Tang, JW; Yap, HK | 1 |
| Das, RR | 1 |
| Gao, J; Lin, X; Lu, J; Song, J; Tan, W; Wang, M; Wang, Y; Wu, J; Wu, X; Xu, C; Zhang, F; Zhang, Y; Zhao, H; Zhao, P; Zhou, J | 1 |
| Aki, Z; Altindal, S; Güzel, Ö; Senol, E; Sucak, G; Suyani, E | 1 |
| Cho, B; Kang, YA; Kim, HS; Kim, JH; Kim, JS; Lee, HG; Lee, JK; Shin, SY | 1 |
| Feng, L; Feng, Y; Feng, Z; Gao, Z; Gargiullo, P; Huai, Y; Jiang, H; Liao, Q; Peng, Z; Shu, Y; Uyeki, TM; Wang, Y; Xiang, N; Xu, C; Yang, W; Ye, M; Yu, H; Yuan, Y; Zhang, Y; Zheng, J; Zheng, Y; Zhou, L | 1 |
| Doshi, P; Heneghan, C; Jefferson, T; Thompson, M | 1 |
| Ishiguro, T; Miyahara, Y; Samejima, T; Sugita, Y; Takayanagi, N; Yanagisawa, T | 1 |
| Akan, D; Pannaraj, PS; Tam, B | 1 |
| Abdel-Rahman, F; Al-Zaben, A; Ghatasheh, L; Hayajneh, W; Hussein, A; Hussein, N; Rihani, R; Saad, M; Sarhan, M; Sultan, I | 1 |
| Bornhäuser, M; Duwe, S; Ehninger, G; Pöhlmann, C; Schetelig, J; Schweiger, B; Shayegi, N | 1 |
| Cipriano, SL; Faintuch, J; Marin, ML; Oliveira, BB; Suslik, CA | 1 |
| Dolin, R | 1 |
| Ichikawa, M; Kawakami, C; Kawakami, E; Kawaoka, Y; Kiso, M; Mitamura, K; Ozawa, M; Shimizu, H; Sugaya, N; Takano, R; Tamura, D; Uehara, R; Yamazaki, M | 1 |
| Alexander, D; Bastien, N; Boivin, G; Doyle, J; Eshaghi, A; Gubbay, J; Higgins, R; Lee, C; Li, Y; Lombos, E; Longtin, J; Low, D; Olsha, R; Patel, S; Sarabia, A; Tran, D | 1 |
| Al-Ateeqi, W; Al-Baghli, F | 1 |
| Jamieson, DJ; Louie, JK; Norman, A; Wadford, DA | 1 |
| Holton, AE; Love, B; Mackert, M | 1 |
| Khadse, S; Kinikar, A; Kulkarni, R; Valvi, C | 1 |
| Beskardes, AE; Hatipoglu, S; Kural, B; Sevketoglu, E | 1 |
| Barr, IG; Caldwell, N; Deng, YM; Dwyer, DE; Ernest, J; Freeman, K; Hurt, AC; Iannello, P; Kelso, A; Komadina, N; Leang, L; Lin, RT; Shaw, R; Smith, D; Tramontana, AR | 1 |
| Aldunate, S; Almirall, J; Arenzana, A; Arnau, E; Bermejo-Martin, JF; Cambra, K; Gonzalez, N; Guerrero, JE; Laplaza, C; Lorente, L; Loza-Vazquez, A; Magret, M; Maraví-Poma, E; Marquez, E; Martin-Loeches, I; Regidor, E; Reig Valero, R; Rello, J | 1 |
| Borrego, A; Campins, M; Casquero, A; Cebrián, R; Fàbregas, A; Figueras, C; Lera, E; Melendo, S; Miserachs, M; Moraga, F; Sancosmed, M; Tórtola, T; Wörner, NT | 1 |
| Balick Weber, C; Bessede, E; Fleury, HJ; Llavador, V; Malato, L; Marmier, E; Rozé, H; Youssef, J | 1 |
| Aihara, T; Hayakawa, T; Kashii, Y; Maeda, K; Momoi, MY; Morimoto, A; Nozaki, Y | 1 |
| Çiftçi, E; Doğru, U; Ertem, M; Ince, E; Ince, EU; Ozdemir, H | 1 |
| DePasse, J; Fitch, A; Ghedin, E; Griesemer, S; Halpin, RA; Holmes, EC; Laplante, J; Lepow, ML; Lin, X; Operario, D; Porter, J; Santos, RP; Spiro, DJ; St George, K; Stellrecht, K; Stockwell, TB; Wentworth, DE | 1 |
| Doshi, S; Fry, AM; Graitcer, SB; Gubareva, L; Kamimoto, L; Klimov, A; LaPlante, JM; Louie, J; Marshall, SA; Moore, Z; Okomo-Adhiambo, M; Pan, CY; Sleeman, K; St George, K; Vandermeer, M; Waters, C | 1 |
| Alcantara-Perez, P; Alpuche-Aranda, C; Barrera-Badillo, G; Cordova Villalobos, JA; Cortez-Ortiz, I; Díaz-Quiñonez, JA; Gatell-Ramírez, HL; Gonzalez-Duran, E; Gubareva, L; Hernández-Avila, M; Lezana-Fernández, MA; Lopez-Martinez, I; Nguyen, H; Olivera-Diaz, H; Ramirez-Gonzalez, JE; Wong-Arambula, C | 1 |
| Ellermann-Eriksen, S; Gubbels, S; Ilkjær, S; Jensen-Fangel, S; Keld, DB; Lindskov, C; Petersen, E | 1 |
| Bermingham, A; Bolotin, S; Calatayud, L; Ellis, J; Galiano, M; Guiver, M; Gunson, R; Lackenby, A; McMenamin, J; Miah, S; Moore, C; Moran Gilad, J; Muir, P; Pebody, R; Reynolds, A; Thompson, C; Vipond, I; Zambon, M | 1 |
| Kasim, FM; Murad, S; Othman, KA; Saat, Z; Saraswathy, TS; Suppiah, J; Thayan, R; Yusof, MA | 1 |
| Bastien, N; Garceau, R; Hatchette, TF; Li, Y; Webster, D | 1 |
| Born, M; Eis-Hübinger, AM; Fleischhack, G; Köster, B; Lentze, M; Linden, K; Moser, O; Rosenbaum, T; Simon, A; Tschampa, H | 1 |
| Chambers, CD; Jones, KL; Louik, C; Mitchell, AA; Schatz, M | 1 |
| Anderson, DJ; Chen, LF; Dailey, NJ; Deyde, VM; Duffy, J; Fleischauer, AT; Fry, AM; Greenwald, I; Gubareva, LV; Moore, ZS; Rao, AK; Sexton, DJ; Srinivasan, A; Wolfe, CR | 1 |
| Goldfarb, I; Panda, B; Riley, L; Wylie, B | 1 |
| Cheuh, H; Jang, JH; Jung, CW; Kim, DH; Kim, K; Kim, SJ; Kim, YJ; Koo, HH; Lee, SH; Sung, KW; Yoo, KH | 1 |
| Drews, SJ; Fonseca, K; Pabbaraju, K; Wong, A; Wong, S | 1 |
| Li, JF; Shen, JS; Xiong, RS; Zhang, Q; Zhao, QJ | 1 |
| Al-Hegelan, MS; Cheifetz, IM; Noble, PW; Ozment, CP; Peters, MA; Peterson-Carmichael, SL; Rehder, KJ; Turner, DA; Williford, WL | 1 |
| Casas, I; Cuevas, MT; Fernández, M; Galán, JC; García Costa, J; Ledesma, J; Montes, M; Navarro, JM; Pérez Breña, P; Pérez Castro, S; Pérez Ruiz, M; Piñeiro, L; Pozo, F; Suárez Fernández, J | 1 |
| Baracat, EC; Fraga, AM; Miranda, ML; Omae, CC; Pereira, RM; Reis, MC; Romaneli, MT; Tresoldi, AT | 1 |
| Hankins, RW; Hattori, H; Iida, H; Miyachi, K; Takano, T; Ukai, H; Watanabe, A | 1 |
| Benton, J; George, A; Joiner, CH; Kalfa, TA; Kalinyak, KA; Kim, MO; Pratt, J | 1 |
| Bailey, AL; Bennink, JR; Das, SR; Gibbs, JS; Hensley, SE; Schmidt, LM; Yewdell, JW | 1 |
| Trost, BM; Zhang, T | 1 |
| Benachi, A; Bernabe-Dupont, C; Boileau, P; Castel, C; Cordier, AG; Frydman, R; Grangeot-Keros, L; Guillet, M; Picone, O; Vauloup-Fellous, C | 1 |
| Alvarez-Lerma, F; Baladín, B; Blanquer, J; Bonastre, J; Canadell, L; Díaz, E; Díaz, JJ; Figueira, JC; García-López, F; Marques, A; Martín-Loeches, I; Rello, J; Rodríguez, A; Sandiumenge, A; Suberviola, B; Trefler, S; Vallés, J; Zaragoza, R | 1 |
| Ohkusa, Y; Okabe, N; Sugawara, T; Taniguchi, K | 1 |
| Abdo, A; Alfonso, C; Diaz, G; Rocha, M; Verdecia, N; Wilford, M | 1 |
| Anraku, A; Ejima, M; Fujisaki, S; Fujita, N; Hong, X; Horikawa, H; Kato, Y; Kishida, N; Obuchi, M; Odagiri, T; Oguchi, A; Shimabukuro, K; Takashita, E; Tashiro, M; Ujike, M; Yamashita, K | 1 |
| Chowers, M; Hiba, V; Leibovici, L; Levi-Vinograd, I; Paul, M; Rubinovitch, B | 1 |
| Davies, BE; Prinssen, EP; Shi, D; Yan, B; Yang, D | 1 |
| Kumar, A | 1 |
| Alimena, G; Breccia, M; Brunetti, GA; De Vellis, A; Delogu, G; Federico, V; Foà, R; Gentile, G; Girmenia, C; Latagliata, R; Mercanti, C; Micozzi, A; Morano, SG; Rea, M; Sali, M; Valle, V | 1 |
| Carratalà, J; Fariñas, MC; López-Medrano, F; Moreno, A; Ortega, L; Oteo, JA; Pachón, J; Paño-Pardo, JR; Payeras, A; Riera, M; Rodríguez-Baño, J; Segura, F; Torre-Cisneros, J; Viasus, D | 1 |
| Chang, WC; Hsieh, YC; Huang, JL; Liao, YC; Ting, CT; Wu, TJ | 1 |
| Bernimoulin, M; Chalandon, Y; Kaiser, L; Levrat, E; Mohty, B; Nagy, M; Passweg, J; Roosnek, E; Thomas, Y; Vukicevic, M | 1 |
| Koide, H; Nakamura, T; Sato, E | 1 |
| Ferraro, MJ; Hancock, K; Hyle, EP; Klimov, A; Lindstrom, S; Michelow, IC; Shu, B; Traum, AZ | 1 |
| Bance, N; Mario Pinto, B; Mohan, S; Niikura, M | 1 |
| Heraud, JM; Rajatonirina, S; Ramandimbisoa, T; Randrianasolo, L; Ratsitorahina, M; Razanajatovo, N; Richard, V | 1 |
| McCullers, JA | 1 |
| Bader-Weder, S; Donner, B; Niranjan, V; Peng, MM; Schwarz, R; Smith, JR | 1 |
| D'Andréa, C; Michault, A; Rakotoson, R; Souab, A; Staikowsky, F; Vanhecke, C | 1 |
| Altuntaş, F; Arda, K; Arıbaş, B; Arslan, H; Demiriz, I; Erbay, C; Koçubaba, S; Özdilekcan, C; Tekgündüz, E; Tetik, A; Yüksel, MK | 1 |
| Kang, JH; Kil, HR; Lee, JH; Lee, KY; Rhim, JW; Youn, YS | 1 |
| Chéron, G; Claudet, I; Desmoulins, C; Michard-Lenoir, AP; Naud, J; Nouyrigat, V | 1 |
| Gwack, J; Kang, C; Kang, YA; Kim, HS; Kim, JH; Kim, JS; Kim, SH; Lee, HG; Lee, JK; Shin, SY | 1 |
| Bellissima, G; Bellissima, P | 1 |
| Dembiński, Ł; Jackowska, T; Marczyńska, M; Radzikowski, A; Smalisz-Skrzypczyk, K; Talarek, E | 1 |
| Cornejo-Juárez, P; Ñamendys-Silva, SA; Pérez-Jiménez, C; Vilar-Compte, D; Volkow, P | 1 |
| Ho, YL; Hsu, LC; Huang, YP; Lin, YC; Liu, MT; Lo, J; Su, CH; Wu, HS; Yang, JR; Yao, CY | 1 |
| Alp, E; Bekci, TT; Coskun, R; Doganay, M; Erayman, I; Guven, M; Maden, E; Sungur, M; Teke, T; Uzun, K | 1 |
| Greer, LG; Leff, RD; McCracken, GH; Roberts, SW; Rogers, VL; Sheffield, JS; Wendel, GD | 1 |
| Beigi, RH; Caritis, SN; Clark, S; Easterling, T; Han, K; Hankins, GD; Hebert, MF; Mattison, DR; Ren, Z; Venkataramanan, R; Zajicek, A | 1 |
| Anderson, DJ; Brown, M; Cunningham, CK; Cunningham, HM; Hendershot, EF; Jaggers, LB; Lopez-Marti, MG; Purdy, WK; Sangvai, DG; Thompson, JR; Tsalik, EL; Woods, CW | 1 |
| Anderson, BL; Fitzsimmons, C; Rouse, DJ | 1 |
| Bridger, NA; Bullard, JM; Coombs, JM; Crockett, ME; Embree, JE; Fanella, ST; Olekson, KL; Pinto, MA; Poliquin, PG; Van Caeseele, PG | 1 |
| Chen, N; Lee, BP; Lin, M; Pinsky, BA; Schrijver, I | 1 |
| Burgmann, H; Egle, A; Fritsche, G; Gattringer, R; Hell, M; Herkner, H; Jones, N; Maass, M; Poeppl, G; Poeppl, W; Schurz-Bamieh, N; Stoiser, B | 1 |
| Abecasis, M; Cannata-Ortiz, MJ; Cordonnier, C; de la Camara, R; Einsele, H; Engelhard, D; Espigado, I; Gonzalez-Vicent, M; Halter, J; Ljungman, P; Martino, R; Mohty, B; Nieto Campuzano, JB; Perez-Bercoff, L; Sucak, G; Ullmann, AJ; Vázquez, L; Ward, KN | 1 |
| Geyer, H; McKimm-Breschkin, JL; Mohr, PG | 1 |
| Dbaibo, GS; Hanna-Wakim, R; Kondo, H; Saito, R; Suzuki, H; Suzuki, Y; Tabet, C; Zaraket, H | 1 |
| Ejima, M; Kageyama, T; Konomi, N; Nakauchi, M; Oba, K; Obuchi, M; Odagiri, T; Takashita, E; Takayama, I; Tashiro, M; Ujike, M | 1 |
| Chen, LL; Zha, RS; Zhang, J; Zhang, LJ; Zhu, BP | 1 |
| Aoki, S; Ban, T; Fukunaga, M; Hanami, M; Hata, T; Hayashi, E; Hayashizaki, Y; Himeno, Y; Hirai, A; Inoue, K; Ishikawa, T; Iwatsuki-Horimoto, K; Izumi, S; Jalloh, A; Kawai, Y; Kawaoka, Y; Kijima, Y; Kishima, M; Koretsune, Y; Kudo, K; Mano, M; Morlighem, JÉ; Ogawa, C; Saga, S; Sakai-Tagawa, Y; Shiomi, M; Takahashi, K; Takahashi, Y; Wada, A | 1 |
| Breña, PP; Casas, I; Castro, SP; Cilla, G; Cuevas, MT; Fernández, JS; Fernández, M; Galán, JC; Larrauri, A; Ledesma, J; Navarro, JM; Pozo, F; Reina, J; Ruiz, MP; Vicente, D | 1 |
| Hou, N; Jonges, M; Ke, C; Koopmans, M; Li, H; Liao, J; Meijer, A; Ni, H; Wang, Y; Wu, J; Zhang, X; Zhou, J; Zou, L | 1 |
| Aspesberro, F; Englund, JA; Kuypers, J; Renaud, C; Rosenfeld, M | 1 |
| Antillon-Klussmann, F; Asturias, EJ; Caniza, MA; De-Leon, RE; Gerónimo, M; Guimera, D; Melgar, M; Ramírez, M | 1 |
| Yoo, ES | 1 |
| Jankovic, B; Martic, J; Minic, P; Nedeljkovic, J; Pasic, S; Savic, N | 1 |
| Chantratita, W; Malathum, K; Pasomsub, E; Sankuntaw, N; Sirinavin, S; Srichantaratsamee, C; Sukasem, C | 1 |
| Holzgrabe, U | 1 |
| Clarke, D; Mirochnick, M | 1 |
| Yingying, C | 1 |
| Bekker, A; Cotton, MF; Holgate, SL; Rabie, H | 1 |
| Boggild, AK; Coleman, BL; Drews, SJ; Li, Y; Low, DE; McGeer, AJ | 1 |
| Devroey, D; Semaille, P; Van De Vijver, E; Vandevoorde, J; Vansintejan, J | 1 |
| Anderson, GP; Gualano, RC; Jones, JE; Wong, ZX | 1 |
| Ahmed, S; Hutchinson, S; McMenamin, J; Penrice, G; van Velzen, E | 1 |
| Corbett, S; Harden, S; Khambekar, SK | 1 |
| Bijl, D | 1 |
| Bijl, D; Schellekens, H | 1 |
| Barazzone, C; Crisinel, PA; Delcò, C; Kaiser, L; L'Huillier, AG; Posfay-Barbe, KM; Siegrist, CA; Taguebue, J; Wagner, N | 1 |
| Barr, IG; Caldwell, N; Cui, L; Deng, YM; Freeman, K; Hurt, AC; Kelso, A; Komadina, N; Leang, SK; Lee, RT; Lin, RT; Maurer-Stroh, S; Phuah, SP; Smith, D; Speers, D | 1 |
| Englund, JA; Kuypers, J; Renaud, C | 1 |
| Agou, F; Cuvelier, F; Enouf, V; Le Gal, S; Munier, S; Naffakh, N; Rameix-Welti, MA; van der Werf, S | 1 |
| Staff, M; Torres, MI | 1 |
| Constantinidis, TC; Courcoutsakis, N; Kerenidi, T; Kouliatsis, G; Kouroumichakis, I; Mabroudi, M; Maltezos, E; Matthaios, D; Papanas, N; Spyratos, D; Steiropoulos, P; Zarogoulidis, K; Zarogoulidis, P | 1 |
| Chen, Y; Qiao, H; Shang, S; Tong, M; Zhang, CM | 1 |
| Birge, M; Carbain, B; Martin, SR; Stanley, M; Streicher, H | 1 |
| Mitamura, K; Shinjoh, M; Sugaya, N; Takahashi, T | 1 |
| Babu, YS; Bantia, S; Upshaw, R | 1 |
| Chang, CM; Chang, YS; Huang, FC; Lai, CC; Li, ML; Tseng, SH | 1 |
| Bowkalow, S; Brauer, M; Gross, W; Schleussner, E | 1 |
| Hujikawa, Y; Kase, T; Morikawa, S; Nakaya, H; Shimotsuji, T; Takano, M; Yamamoto, K; Yamamoto, T | 1 |
| Godara, SM; Goplani, KR; Kute, V; Shah, PR; Trivedii, HL; Vanikar, AV | 1 |
| Dabscheck, G; Johnston, H; McMullan, B; Rawlinson, W; Robertson, P; Walls, T | 1 |
| Dwyer, DE | 1 |
| Hobson, MJ; Morgan, CI; Rice, MA; Seger, B; Staat, MA; Wheeler, DS | 1 |
| Alfaro Ramos, L; Bautista, E; Corcho Berdugo, AE; Corrales Baeza, A; Guevara Gutiérrez, R; Higuera Iglesias, AL; Izumi, S; Kudo, K; Manabe, T; Manjarrez Zavala, ME; Perez Padilla, JR; Takasaki, J | 1 |
| Dabanch, J; Fasce, R; Gonzalez, C; Guerrero, A; Morales, C; Najera, M; Olea, A; Perret, C | 1 |
| Bongers, KM; Brandjes, DP; Kuiper, RJ; Smit, PM; Smits, PH; von Rosenstiel, IA | 1 |
| Abbink, F; Ang, W; Beersma, M; Bloembergen, P; Boucher, C; Claas, E; de Jong, A; Donker, G; Isken, L; Jonges, M; Koopmans, M; Kroes, A; Leenders, S; Mascini, E; Meijer, A; Niesters, B; Oosterheert, JJ; Osterhaus, A; Riesmeijer, R; Riezebos-Brilman, A; Schutten, M; Sebens, F; Stelma, F; Swaan, C; te Wierik, M; Timen, A; van 't Veen, A; van Beek, J; van der Lubben, M; van der Vries, E; van Gageldonk-Lafeber, R | 1 |
| Abid, S; Cuffari, C; Liu, D; Montecalvo, M; Nadelman, RB; Sandoval, C; Seiter, K; Shah, D; Shi, Q; Sinaki, B | 1 |
| Adiga, RB; Alsup, R; Clay, PG; Gerk, PM; McRae, M; Taylor, TAH | 1 |
| Granath, F; Kieler, H; Stephansson, O; Svensson, T | 1 |
| Buchbinder, N; Dumesnil, C; Filhon, B; Merle, V; Pinquier, D; Schneider, P; Vannier, JP | 1 |
| Aguiar-Oliveira, Mde L; de Azeredo-Lima, CH; Fernandes, SB; Gregianini, TS; Machado, V; Marinelli, R; Mesquita, M; Motta, FC; Oliveira, IC; Resende, P; Rosa, Mdo C; Siqueira, MM; Souza, TM | 1 |
| Al'khovskiĭ, SV; Aristova, VA; Bazarova, MV; Burtseva, EI; Chuchalin, AG; Fediakina, IT; Kolobukhina, LV; Malyshev, NA; Maslov, AM; Merkulova, LN; Morozova, TN; Ponomarenko, RA; Prilipov, AG; Proshina, ES; Samokhvalov, EI; Shchelkanov, MIu; Sutochnikova, OA | 1 |
| Angeles-Garay, U; Arias-Flores, R; Gayosso Rivera, JA; Rechy-Luna, M; Terrazas Estrada, JJ; Zacate-Palacios, Y | 1 |
| Baltimore, D; Bloom, JD; Nayak, JS | 1 |
| Chuang, SK; Leung, YH; Lim, WL; Wong, MH | 1 |
| Alexander, DC; Bastien, N; Eshaghi, A; Gubbay, JB; Higgins, RR; Li, Y; Low, DE; Patel, SN; Sarabia, A; Savchenko, A; Stojios, PJ | 1 |
| Au, V; Fock, KM; Oh, HM; Raghuram, J; Siau, C; Tee, A; Teo, EK | 1 |
| Chan, K; Chua, YY; Cui, L; Tan, BH; Wijaya, L | 1 |
| Makkoch, J; Payungporn, S; Poomipak, W; Poovorawan, Y; Rianthavorn, P; Theamboonlers, A | 1 |
| Chiang, VW; Chung, EY | 1 |
| Cheong, HJ; Hirotsu, N; Ishida, T; Kadota, J; Kida, H; Kohno, S; Mizuguchi, M; Shimada, J; Yen, MY | 1 |
| Ahn, JH; Choi, HJ; Kwak, IS; Lee, SB; Lee, YJ; Rhee, H; Seong, EY; Song, SH | 1 |
| Fujioka, T; Hisamatsu, A; Kai, S; Murakami, K; Nagai, T; Nakagawa, Y; Nakashima, H; Okawara, H; Shuto, M; Yamauchi, M; Yokoyama, S | 1 |
| Chuntrakul, C; Kanchana, S; Malathum, K; Poovorawan, Y; Prachayangprecha, S | 1 |
| Beersma, MF; Boucher, CA; de Jong, MD; Fouchier, RA; Fraaij, PL; Horrevorts, AM; Houmes, RJ; Koopmans, MP; Kroes, AC; Niesters, HG; Osterhaus, AD; Reis Miranda, D; Ridwan, BU; Riezebos-Brilman, A; van der Eijk, AA; van der Vries, E; van Dissel, JT; Wolfhagen, MJ | 1 |
| An, Y; Cao, B; Cao, ZX; Dong, JP; Gu, L; Guo, YM; He, XS; Hu, K; Jiang, LD; Li, XW; Liang, LR; Liang, ZA; Liu, QQ; Liu, YL; Sun, YH; Wang, C; Wang, YG; Wen, XM; Yang, T; Zou, ZQ | 1 |
| Beauloye, C; Courouble, P; Geukens, P; Jacquet, LM; Laarbaui, F; Van Caenegem, O | 1 |
| Ohuchi, M; Ushirogawa, H | 1 |
| Arisoy, A; Baran, A; Bilgin, HM; Duran, M; Ekin, S; Gunini, H; Mermit Cilingir, B; Ozbay, B; Sertogullarindan, B; Sunnetcioglu, A; Yildiz, H | 1 |
| Antia, R; Bloom, JD; Chao, DL; Kochin, BF; Longini, IM | 1 |
| Koay, ES; Lee, CK; Lee, HK; Loh, TP; Tambyah, PA; Tang, JW | 2 |
| Atkins, CY; Biggerstaff, M; Borse, RH; Dulin, SM; Erickson, BA; Hunkler, R; Meltzer, MI; Merlin, TL; Patel, A; Taylor, TH | 1 |
| Itabashi, K; Kitajima, H; Kusuda, S; Morioka, I; Takahashi, N | 1 |
| Eropkin, MIu; Grudinin, MP; Karpova, LS; Kiselev, OI; Komissarov, AB; Tsybalova, LM | 1 |
| Barbe, RP; Crisinel, PA; Dayer, P; Desmeules, JA; Fluss, J; Ing Lorenzini, K; Korff, CM; L'Huillier, AG; Posfay-Barbe, KM; Rebsamen, MC; Siegrist, CA | 1 |
| Felderhoff-Müser, U; Göpel, W; Härtel, C; Heitmann, F; Hoehn, T; Keller, M; Roggendorf, M; Ross, S; Stein, A | 1 |
| Deriabin, PG; Fediakina, IT; Gudova, NV; Kondrat'eva, TV; L'vov, DK; Leneva, IA; Shchelkanov, MIu | 1 |
| Lavelle, TA; Prosser, LA; Uyeki, TM | 1 |
| Al Shareef, T; Allen, UD; Frieling, ML; Hebert, D; Kala, G; Langlois, V; Robinson, LA; Teh, JC; Williams, A | 1 |
| Basson, E; Boibieux, A; Haÿs, S; Leick-Courtois, C; Lina, B; Perpoint, T; Picaud, JC; Valette, M | 1 |
| Basar, C; Erden, EC; Erden, I; Ozhan, H | 1 |
| Ahmad, N; Cockbain, AJ; Ecuyer, C; Hostert, L; Jacob, M | 1 |
| Bentley, R; Fielding, J; Kavanagh, A; LaMontagne, AD; Mason, K; McVernon, J; Nathan, P; Petrony, S; Studdert, DM | 1 |
| Razonable, RR | 1 |
| Calvo Aguilar, O; Canalizo Mendoza, YR; Hernández Cuevas, MJ | 1 |
| Choi, SH; Chon, GR; Han, MS; Hong, SB; Huh, JW; Kim, HR; Kim, MJ; Kim, SH; Kim, WY; Kim, YS; Ko, YG; Lee, KH; Ryu, YJ; Young Suh, G | 1 |
| Ikematsu, H; Kawai, N | 1 |
| Brenkle, K; Commandini, M; Just, B; Mateu, P; Passouant, O | 1 |
| Imai, Y | 1 |
| Andrews, TC; Athauda, D; Holmes, PA; Howard, RS | 1 |
| Coffin, SE; Hall, M; Keren, R; Leckerman, K; Localio, R; Zaoutis, TE | 1 |
| Gutierrez, C; Nazar, GA; Torres, JP | 1 |
| Aleemi, VE; Bao, JR; Clark, RB; Coon, SL; Huard, TK; Lewinski, MA; Master, RN; Piscitelli, AE; Tummala, PR | 1 |
| Calatayud, L; Lackenby, A; McMenamin, J; Pebody, R; Phin, NF; Reynolds, A; Zambon, M | 1 |
| Cheng, A; Kuo, KH; Yang, CJ | 1 |
| Choi, SH; Hong, SB; Kim, MN; Kim, SH; Kim, YS; Koh, Y; Lee, SO; Lim, CM; Woo, JH | 1 |
| Ginting, TE; Kaneda, S; Kawaoka, Y; Kyan, Y; Makino, A; Matsumoto, N; Shinya, K | 1 |
| Arnold, K; Baumbach, J; Bennett, NM; Doshi, S; Finelli, L; Fry, AM; Gershman, K; Hancock, EB; Kamimoto, L; Lynfield, R; Morin, C; Perez, A; Reingold, A; Ryan, P; Schaffner, W; Thomas, A; Yousey-Hindes, K; Zansky, S | 1 |
| Booy, R; Dwyer, DE; Elliott, EJ; Heron, L; Kesson, A; Khandaker, G; Lester-Smith, D; Zurynski, Y | 1 |
| Aziz, M; Aziz, Z; Eltoukhy, N; Patel, S; Singh, K; Vasoo, S | 1 |
| Cho, HJ; Cho, YK; Kim, YN; Ma, JS | 1 |
| Donner, B; Dutkowski, R; Klumpp, K; Rayner, CR; Smith, JR; Wollenhaupt, M | 1 |
| Armano, R; Blumental, S; Cornet, MC; De Schutter, I; Ferreiro, C; Fonteyne, C; Hermans, D; Huisman, E; Kabamba-Mukadi, B; Lepage, P; Levy, J; Mahadeb, B; Malfroot, A; Moulin, D; Nassogne, MC; Reynders, M; Van Berlaer, G; Vergison, A; Wybo, I | 1 |
| Ala-Kokko, T; Karlsson, S; Linko, R; Parviainen, I; Perttilä, J; Pettilä, V; Reinikainen, M; Ruokonen, E; Saarinen, K; Tenhunen, J; Varpula, T | 1 |
| Chang, CL; Hwang, SH; Kim, HH; Koh, YR; Lee, EY; Son, HC | 1 |
| Fry, AM; Garg, S; Gubareva, LV; Kilpatrick, S; Moore, Z; Sheu, TG; Sleeman, K | 1 |
| Aoki, FY; Jeffery, J; Lam, H; Sitar, DS | 1 |
| Gøtzsche, PC | 1 |
| Kim, IY; Kim, SR; Kwak, IS; Lee, DW; Lee, SB; Rhee, H; Seong, EY; Song, SH | 1 |
| Ghossein, C; Griffith, MM; Hollister, AS; Ison, MG; Scheetz, MH | 1 |
| Belongia, EA; Coleman, L; Dharan, NJ; Fry, AM; Gubareva, LV; Kieke, BA; Klimov, AI; Meece, J; Vandermause, M | 1 |
| Dye, C; Leknes, H; Sturtzel, IE | 1 |
| Al-Khabaz, A; Al-Qattan, HY; Al-Shammari, N; Husain, EH; Owayed, AF | 1 |
| Haruyama, T; Mori, K; Nagata, K | 1 |
| Al'khovskiĭ, SV; Ambrosi, OE; Arseneva, TV; Avdeev, SN; Bazarova, MV; Blank, IA; Burtseva, EI; Chuchalin, AG; Kelli, EI; Kolivashko, ON; Kolobukhina, LV; L'vov, DK; Lavrishcheva, VV; Malyshev, NA; Merkulova, LN; Popov, AF; Prilipov, AG; Proshina, ES; Samokhvalov, EI; Shchelkanov, MIu; Shestakova, OM; Shul'diakov, AA; Simakova, AI; Sutochnikova, OA; Tserukalova, ND | 1 |
| Cho, SH; Hong, KS; Jung, JW; Kang, HR; Kwon, JW; Lee, SH; Yu, KS | 1 |
| Belser, JA; Gubareva, LV; Katz, JM; Pearce, MB; Sleeman, K; Tumpey, TM | 1 |
| Hama, R; Hayashi, K; Jones, M; Kitao, M; Noda, N; Okushima, H; Sakaguchi, K | 1 |
| Palmer, R | 1 |
| Arai, M; Doi, Y; Fujii, Y; Iino, N; Kawakami, K; Kawamura, T; Matsunaga, T; Urushihara, H | 1 |
| Chen, W; Kang, HJ; Lim, CE; Liu, J | 1 |
| Horiguchi, H; Matsuda, S; Takeuchi, M; Yasunaga, H | 1 |
| Bartsch, A; Dhar, D; Krueger, H; Mohite, PN; Moza, A; Popov, AF; Simon, AR; Zych, B | 1 |
| Chotpitayasunondh, T; Cox, NJ; Daniels, R; Fry, AM; Gubareva, LV; Hayden, FG; Hui, DS; Hungnes, O; Hurt, AC; Lackenby, A; Lim, W; Meijer, A; Penn, C; Tashiro, M; Uyeki, TM; Zambon, M | 1 |
| Doniwa, K; Egashira, K; Hirotsu, N; Ikematsu, H; Iwaki, N; Iwakuni, O; Kashiwagi, S; Kawai, N; Kawashima, T; Kondou, K; Maeda, T; Tanaka, O; Yamaji, K | 1 |
| Breda, I; Coelho, LR; De Souza, BA; Figueiró-Filho, EA; Oliveira, ML; Pompilio, MA; Uehara, SN | 1 |
| Abed, Y; Beaulieu, E; Boivin, G; Bouhy, X; Mallett, C; Pizzorno, A; Russell, R | 1 |
| Deng, YM; Gehrig, N; Hardie, K; Hurt, AC; Kelso, A; Osbourn, M; Wilson, NJ | 1 |
| Boura, P; Mouloudi, E; Sarantopoulos, A; Tselios, K; Tsioka, R | 1 |
| Azendour, H; Balkhi, H; Bensghir, M; Chkoura, K; Chouaib, N; Chouikh, C; Drissi Kamili, N; Haimeur, C | 1 |
| Baldanti, F; Daleno, C; Esposito, S; Galeone, C; Picciolli, I; Principi, N; Scala, A; Tagliabue, C; Taroni, F | 1 |
| Dotsikas, Y; Drakoulis, N; Karalis, V; Loukas, YL; Maltezou, HC; Siahanidou, T; Theodoridou, M; Zervaki, E | 1 |
| Azik, F; Culha, V; Kara, A; Tavil, B; Tezer, H; Tunç, B; Yaral, N | 1 |
| Beasley, R; Berry, N; Blackmore, TK; Jefferies, S; Norton, K; Perrin, K; Raymond, NJ | 1 |
| Buti, M; Esteban, R; Simón-Talero, M | 1 |
| Boxrud, D; DeVries, A; Lees, C; Lynfield, R; Uyeki, T; Wotton, J | 1 |
| Li, P; Wang, CZ; Yuan, CS | 1 |
| Doshi, P; Jefferson, T; Jones, M | 1 |
| Ahmed, BN; Ahmed, M; Al Mamun, A; Alamgir, AS; Azim, T; Azziz-Baumgartner, E; Bresee, J; Brooks, A; Chakraborty, A; Fry, A; Goswami, DR; Haider, MS; Homaira, N; Hossain, MJ; Husain, MM; Jamil, KM; Karmakar, PC; Khatun, S; Klimov, A; Luby, SP; Muneer, SM; Nasreen, S; Rahman, M; Widdowson, MA; Zaman, RU | 1 |
| Gill, P; Harnden, A; Perera, R; Shun-Shin, M; Wang, K | 2 |
| Del Mar, CB; Doshi, P; Hama, R; Heneghan, CJ; Jefferson, T; Jones, MA; Thompson, MJ | 1 |
| Barr, IG; Hurt, AC; Leang, SK; Maurer-Stroh, S; Speers, DJ | 1 |
| Blanchon, T; Bouscambert, M; Carrat, F; Charlois-Ou, C; Dornic, Q; Duval, X; Enouf, V; Leport, C; Mentré, F; Mosnier, A | 1 |
| Aoki, S; Ban, T; Chikahira, M; Endo, R; Furuya, Y; Hanami, T; Hayashi, E; Hayashizaki, Y; Hirai, A; Ishidao, T; Ishikawa, T; Ishizu, Y; Izumi, S; Kanamori, H; Kawai, Y; Kawakami, C; Kawaoka, Y; Kimura, Y; Kogo, Y; Kudo, K; Kurata, H; Lezhava, A; Mitani, Y; Morlighem, JÉ; Oguchi-Katayama, A; Okazaki, N; Saga, S; Saito, T; Saito, Y; Sakai-Tagawa, Y; Soma, T; Toguchi, T; Tsuruoka, S; Uryu, H; Usui, K | 1 |
| Gose, RB; Miller, HB; Nagata, MT; Sciulli, RH; Whelen, AC | 1 |
| Carratalá, J; Fariñas, MC; García-Gasalla, M; Leyes, M; López-Medrano, F; Martínez-Sánchez, N; Ortega, L; Oteo, JA; Pachón, J; Paño-Pardo, JR; Pumarola, T; Rodríguez-Baño, J; Segura, F; Torre-Cisneros, J; Viasus, D | 1 |
| Fry, AM; Gubareva, LV; Klimov, A; Leader, B; Myers, R; Okomo-Adhiambo, M; Pan, CY; Reisdorf, E; Robinson, S; Shannon, M; St George, K; Storms, AD; Su, S; Thompson, M; Wheeling, JT; Wotton, JT | 1 |
| Bause, L; Illgner, U; Krenn, V | 1 |
| Alhan, E; Badur, S; Celik, M; Celik, US; Ceyhan, M; Ciblak, MA; Karadag Oncel, E; Kurugol, Z; Ozsurekci, Y; Parlakay, AO; Saz, EU | 1 |
| Bouscambert, M; Caro, V; Casalegno, JS; Escuret, V; Ferraris, O; Jacquot, F; Lina, B; Ottmann, M; Raoul, H; Valette, M | 1 |
| Ades, EW; Fry, AM; Gubareva, LV; Klimov, AI; Levine, M; Mishin, VP; Nguyen, HT; Shaw, M; Sheu, TG; Trujillo, AA | 1 |
| Lenzi, L; Pontarolo, R | 1 |
| Hussain Basha, S; Prasad, RN | 1 |
| Bonastre, J; Guerrero, JE; Martín-Loeches, I; Pozo, JC; Rodríguez, A; Suberviola, B; Torres, A | 1 |
| Amr, AA; Kherallah, M; Mady, A; Mandourah, Y; Ramadan, OS; Yousef, A | 1 |
| Ajisaka, K; Ikematsu, H; Kashiwagi, K; Kashiwagi, S; Masui, S; Nabeshima, S; Takeoka, H | 1 |
| Antignac, M; Combes, A; Corvol, E; Farinotti, R; Fernandez, C; Lemaitre, F; Luyt, CE; Nieszkowska, A; Roullet-Renoleau, F; Zahr, N | 1 |
| Baumeister, E; Campos, AM; Pontoriero, A; Savy, VL | 1 |
| Chang, LY; Huang, LM; Kao, CL; Lee, CY; Lee, PI; Lu, CY; Shao, PL; Tsou, TP; Yang, PC | 1 |
| Ikematsu, H; Kashiwagi, S; Kawai, N | 1 |
| Bouvy, ML; Fietjé, EH; Philbert, D; van Geffen, EC; Winters, NA | 1 |
| Alves, C; Basílio, C; Castelo-Branco, S; Dias, C; Figueiredo, P; Honrado, T; Mergulhão, P; Mota, AM; Oliveira, T; Paiva, JA; Paiva, L; Roncon-Albuquerque, R; Santos, L; Sarmento, A; Silva, S; Veiga, R | 1 |
| Dzhibladze, KM; Nakashidze, IM; Potskhishvili, ShN; Tsintsadze, NG | 1 |
| Hak, E; Koopmans, M; Niesters, HG; Rahamat-Langendoen, JC; Riezebos-Brilman, A; Schölvinck, EH; Tutuhatunewa, ED | 1 |
| Dix, D; Ethier, MC; Gassas, A; Johnston, DL; Portwine, C; Science, M; Sung, L; Tran, D; Yanofsky, R; Zelcer, S | 1 |
| Adisasmito, W; Bamgboye, E; Chan, PK; Coker, R; Dogan, N; Dreyer, NA; Gasimov, V; Hanshaoworakul, W; Lee, N; Oner, AF; Swenson, A; Toovey, S; Tsang, O; Zaman, M | 1 |
| Marshall, C; Stewardson, AJ; Upjohn, LM | 1 |
| Barquilla, E; Iribarren, JA; Knobel, H; López-Aldeguer, J; Lozano, F; Santos, J; Valencia, E | 1 |
| Bruinse, HW; Kromdijk, W; Meijer, WJ; van den Broek, MP; Wensing, AM | 1 |
| Harahousou, E; Kapetanakis, I; Kyriakou, D; Maltezou, H; Nika, A; Stripeli, F; Tsagris, V; Tsolia, M | 1 |
| Contrini, MM; Fallo, AA; López, EL; Neyro, S | 1 |
| Cho, MH; Kim, S; Kwon, S; Seo, H | 1 |
| Eun, BW; Hong, JY; Kang, JH; Kim, JH; Kim, KH; Ko, JH; Oh, SH | 1 |
| Chan, ES; Ip, M; Lee, NL; Leung, MY; You, JH | 1 |
| Aggarwal, M; Jain, S; Khosla, P | 1 |
| Hou, GQ; Huang, CS; Kuo, TC; Li, YT; Lin, CH; Tasi, SJ | 1 |
| Carrascosa, M; Fariñas, MC; Fariñas-Álvarez, C; González-Fernández, JL; Gutiérrez-Cuadra, M; Parra, JA; Rodríguez-Cundin, P; San Juan, MV | 1 |
| Eom, JS; Ju, YS; Kim, JS; Lee, JS; Park, SY; You, JY | 1 |
| Hosoya, M; Ihara, T; Kumagai, T; Morioka, I; Morishima, T; Nonoyama, S; Okabe, N; Okada, K; Sugaya, N; Tanaka-Taya, K; Ueta, I | 1 |
| Cupelli, L; Dutkowski, R; Marcadis, I; Reisinger, K; Shu, D | 1 |
| Haji, A; Iwajima, Y; Kimura, S; Kurono, Y; Maeda, Y; Nagano, Y; Niwa, Y; Ohi, Y; Ono, H; Yamamoto, S | 1 |
| Gubareva, LV; Hurt, AC; Okomo-Adhiambo, M | 2 |
| Bouvier, NM; Pica, N; Rahmat, S | 1 |
| Bastien, N; Beniprashad, M; Chong-King, E; Gubbay, JB; Higgins, RR; Li, Y; Low, DE | 1 |
| Karthick, V; Rajasekaran, R; Ramanathan, K; Shanthi, V | 1 |
| Yong, E | 1 |
| Rapose, A | 1 |
| Barr, IG; Booy, R; Caldwell, N; Dalton, C; Deng, YM; Dixit, R; Durrheim, D; Dwyer, DE; Gehrig, N; Givney, RC; Hardie, K; Hurt, AC; Iannello, P; Kelso, A; Leang, SK; Lee, RT; Levy, A; Maurer-Stroh, S; Merritt, T; Osbourn, M; Shaw, R; Smith, DW; Wang, B; Wark, P; Wilson, NJ; Xue, L | 1 |
| Fry, AM; Gubareva, LV | 1 |
| Kafetzis, DA; Kapetanakis, I; Maltezou, HC; Nika, A; Standing, JF; Tsagris, V; Tsolia, MN | 1 |
| Hannongbua, S; Malaisree, M; Mulholland, AJ; Pattarapongdilok, N; Sompornpisut, P; Woods, CJ | 1 |
| Duwe, S; Karsch, K; Louis, F; Muehlhans, S; Rath, B; Schweiger, B; Skopnik, H; Tief, F; Tuerk, E; von Kleist, M | 1 |
| Alborzi, A; Bagheri-Lankarani, K; Jamalidoust, M; Moeini, M; Moghadami, M; Mokhtari-Azad, T; Namayandeh, M; Pouladfar, GR; Pourabbas, B; Ziyaeyan, M | 1 |
| Backman, JT; Neuvonen, M; Neuvonen, PJ; Niemi, M; Schwab, M; Tarkiainen, EK | 1 |
| Kourti, A; Politi, L; Spanakis, N; Spanakos, G; Stavropoulou, A; Tsakris, A | 1 |
| Hasegawa, N; Iwata, S; Shinjoh, M; Sugaya, N; Takahashi, T; Takano, Y | 1 |
| Dapat, C; Dapat, IC; Kawashima, T; Kondo, H; Saito, K; Saito, R; Sato, I; Shobugawa, Y; Suzuki, H; Suzuki, Y | 1 |
| Arvia, R; Azzi, A; Corcioli, F; De Santis, R; Donatelli, I; Facchini, M; Orlando, C; Simi, L | 1 |
| Chijiwa, K; Hamada, N; Hara, K; Imamura, Y; Kashiwagi, T; Nakazono, Y; Watanabe, H | 1 |
| Carr, M; Cosgrave, M; Crowley, B; Duffy, M; Igoe, D; O'Herlihy, B; Sayers, G | 1 |
| Borders-Hemphill, V; Mosholder, A | 1 |
| Sakata, H | 1 |
| Chan, MC; Chan, PK; Choi, KW; Lee, N; Lui, GC; Ngai, KK; Wong, RY | 1 |
| Bright-Thomas, R; Flight, WG; Jones, A; Mutton, K; Webb, K | 1 |
| Gandhi, S; Parikh, P; Rana, H; Shah, AN | 1 |
| Bestebroer, TM; Burke, DF; Chutinimitkul, S; de Wit, E; Fouchier, RA; Herfst, S; Linster, M; Munster, VJ; Osterhaus, AD; Rimmelzwaan, GF; Schrauwen, EJ; Smith, DJ; Sorrell, EM | 1 |
| Dutkowski, R; Ison, MG; Kriván, G; Nist, A; Shapira, MY; Szakaly, P | 1 |
| Abramson, J; Gubareva, LV; Guirand, DM; Lin, JJ; Pranikoff, T; Ross, GA; Sechrist, C; Shetty, AK | 1 |
| Booy, R; Dixit, R; Dwyer, DE; Hurt, A; Kesson, A; McPhie, K; Ratnamohan, M; Saksena, N; Taylor, J; Wang, B | 1 |
| Feng, E; Hilgenfeld, R; Jiang, H; Li, J; Liu, H; Wang, J; Ye, D; Zhang, D; Zhao, F; Zheng, M | 1 |
| Brydak, LB; Donevski, S; Gawryluk, D; Romanowska, M; Stefanska, I | 1 |
| Barry, J; Chase, A; Vijayan, S | 1 |
| Jiang, M; Li, XW; Lv, AP; Wang, RB; Wang, YG; Wang, YY; Zha, QL; Zhang, SJ; Zhou, GQ | 1 |
| Eriksson, CO; Graham, DA; Randolph, AG; Uyeki, TM | 1 |
| Hirotsu, N; Ikematsu, H; Iwaki, N; Kashiwagi, S; Kawai, N; Kawashima, T; Maeda, T; Ukai, H | 1 |
| Blanchon, T; Bouscambert-Duchamp, M; Boutitie, F; Cornu, C; Duval, X; Enouf, V; Escuret, V; Gaillard, S; Gueyffier, F; Leport, C; Lina, B; Mosnier, A; Van Der Werf, S | 1 |
| Blanchon, T; Carrat, F; Duval, X; Flahault, A; Leport, C; Mentré, F; Mosnier, A; Tibi, A; Tubach, F; Van der Werf, S | 1 |
| Adisasmito, W; Bamgboye, E; Chan, PK; Coker, R; Dogan, N; Dreyer, NA; Gasimov, V; Hanshaoworakul, W; Lee, N; Oner, AF; Phommasack, B; Swenson, A; Toovey, S; Touch, S; Tsang, O; Zaman, M | 1 |
| Jing, J; Vijayan, V; Zangwill, KM | 1 |
| Chang, LY; Chen, WH; Chung, MY; Huang, LM; Kao, CL; Lee, PI; Lu, CY; Shao, PL | 1 |
| Koay, ES; Loh, TP; Tambyah, PA; Tang, JW | 1 |
| Frampton, C; Gauld, NJ; Huang, QS; Jennings, LC | 1 |
| Al Fraihi, KJ; Latif, S | 1 |
| Kamei, T; Mazda, O; Murata, K; Suzuki, N; Takahashi, I; Toriumi, Y | 1 |
| Cantez, MS; Durmaz, Ö; Gerenlı, N; Hançerlı Törün, S; Salman, N; Somer, A | 1 |
| Boivin, G; DePasse, JV; Fitch, A; Ghedin, E; Hamelin, ME; Holmes, EC; Papenburg, J; Pinilla, LT | 1 |
| Cho, HJ; Cho, YK; Choi, YD; Han, DK; Kim, S; Ma, JS; Yang, ES | 1 |
| Daniels, RS; Hurt, AC; Jonges, M; Koopmans, MP; Meijer, A; Osterhaus, AD; Swaan, CM; van Beek, P | 1 |
| Call, M; Ebell, MH; Shinholser, J | 1 |
| Fujiyama, T; Hirakawa, S; Ito, T; Shimauchi, T; Tokura, Y; Umayahara, T | 1 |
| Adams, O; Babor, F; Bienemann, K; Borkhardt, A; Grund, S; Janßen, G; Kuhlen, M; Laws, HJ; Meisel, R; Oommen, PT; Schuster, FR; Siepermann, M; Wessalowski, R | 1 |
| Alsanosi, AA | 1 |
| Ali, NA; Haas, DM; Mangino, JE; Pan, X; Sopirala, MM; Turner, AN | 1 |
| Boucher, CA; Collins, PJ; Gamblin, SJ; Haire, LF; Hay, AJ; Liu, J; Martin, SR; Osterhaus, AD; Schutten, M; Skehel, JJ; Vachieri, SG; van der Vries, E; Walker, PA; Xiong, X | 1 |
| Gillissen, A | 1 |
| Hurt, AC; Kelso, A | 1 |
| Igarashi, M; Ito, K; Kawaoka, Y; Kiso, M; Le, QM; Sekijima, M; Takada, A; Takano, R | 1 |
| Bansod, S; Britschgi, M; Chu, T; Donner, B; Dutkowski, R; Koerner, A; Prinssen, EP; Rayner, CR; Sirzen-Zelenskaya, A; Thakrar, BT; Toovey, S | 1 |
| Asgeirsson, H; Baldursson, O; Bjarnason, A; Gottfredsson, M; Gudnason, JF; Hallgrimsson, KL; Haraldsson, G; Kristinsson, KG; Kristjansdottir, BS; Löve, A; Thorleifsdottir, G | 1 |
| Booy, R; Chiu, CK; Dean, AS; Dobbins, T; Dwyer, DE; Gao, Z; Heron, LG; Lindley, RI; MacIntyre, CR; Moffatt, CR; Philp, DJ; Rosewell, AE; Yin, JK | 1 |
| Brand, GJ; Harwood, JL; LaVan, JT | 1 |
| Briz, V; Correa-Basurto, J; Ilizaliturri-Flores, I; Muñoz-Fernández, A; Quiliano, M; Reyes-Loyola, P; Rodríguez-Pérez, M; Segura-Cabrera, A; Tolentino-Lopez, L; Zimic, M | 1 |
| Gutiérrez-Mendoza, LM; Méndez de Lira, Jde J; Schwartz, B; Wirtz, VJ | 1 |
| Alexander, WJ; Clezy, K; Collis, PJ; Flynt, A; Hui, DS; Ison, MG; O'Neil, BJ; Simon, TJ | 1 |
| Antón, A; Carratalà, J; Pumarola, T; Viasus, D | 1 |
| Dapat, C; Dapat, IC; Hasegawa, G; Kyaw, Y; Myint, YY; Naito, M; Oo, HN; Oo, KY; Saito, R; Suzuki, H | 1 |
| Jin, XW; Mossad, SB | 1 |
| Acharya, L; Behera, DK; Behera, PM; Dixit, A; Padhi, P | 1 |
| Flechelles, O; Jouvet, P | 1 |
| Baxter, R; Fry, AM; Greene, SK; Irving, SA; Jackson, ML; Jacobsen, SJ; Lee, GM; Li, L; Lieu, TA; Naleway, AL; Narwaney, KJ; Nordin, JD; Shay, DK | 1 |
| Doshi, P; Hama, R; Jefferson, T; Jones, M | 1 |
| Anekthananon, T; Charunwatthana, P; Day, N; Fukuda, C; Jittamala, P; Lawpoolsri, S; Lindegardh, N; Pukritayakamee, S; Pukrittayakamee, S; Puthavathana, P; Ratanasuwan, W; Sapchookul, P; Stepniewska, K; Suwanagool, S; Tarning, J; Taylor, WR; Werarak, P; White, NJ | 1 |
| Holmes, NE; Sood, S; Testro, AG | 1 |
| Ersbøll, AS; Hedegaard, M; Hesselvig, AB; Krebs, L | 1 |
| Eyler, RF; Heung, M; Mueller, BA; Napolitano, LM; Park, PK; Pleva, M; Sowinski, KM | 1 |
| Oldstone, MB; Rosen, H; Teijaro, JR; Walsh, KB | 1 |
| Dumiak, M | 1 |
| Abughali, N; Abzug, MJ; Acosta, EP; Ampofo, K; Ashouri, N; Bradley, JS; Caserta, MT; Cloud, G; Englund, JA; Jester, P; Kimberlin, DW; Lakeman, FD; Lang, D; Lew, J; Michaels, MG; Prichard, MN; Sánchez, PJ; Sood, SK; Spigarelli, MG; Vanchiere, JA; Wan, W; Whitley, RJ | 1 |
| Bishop, A; Finelli, L; Fleischauer, A; Fry, AM; Garg, S; Gubareva, L; Lee, N; McKenna, J; Moore, Z; Nguyen, HT; Sheu, TG; Sleeman, K; Springs, CB | 1 |
| Law, FC; Mak, NK; Wei, XY; Wong, RN; Yang, MS | 1 |
| Chan, YH; Lau, PY; Ng, KH; Quak, ZX; Suhaila, M; Tambyah, PA; Tang, JW; Yap, HK | 1 |
| Choi, JS; Kim, KH; Lee, HJ; Shin, DH | 1 |
| Fujisaki, S; Kageyama, T; Nakauchi, M; Odagiri, T; Takayama, I; Tashiro, M | 1 |
| Boeckh, MJ; de Jong, MD; Englund, JA; Lindegardh, N; Nguyen, JT; Pukrittayakamee, S; Renaud, C; Seo, S; Tambyah, PA; Tarning, J; Went, GT | 1 |
| Cheng, Y; Gubareva, LV; Huang, W; Klimov, AI; Levine, M; Li, X; Nguyen, HT; Shu, Y; Sleeman, K; Tan, M; Wang, D; Xing, X; Xu, X | 1 |
| Cantu, J; Tita, AT | 1 |
| Bae, JY; Cheong, HJ; Heo, J; Hwang, MW; Kim, JI; Kim, WJ; Lee, I; Lee, S; Lim, EJ; Park, MS; Park, S; Seok, WS; Song, JY | 1 |
| Govorkova, EA | 1 |
| Chao, DL | 1 |
| Kim, WY; Lee, JH; Lee, YS; Lim, KS; Oh, BJ; Ryoo, SM; Seo, DW; Sohn, CH | 1 |
| Chang, FY; Hsu, LC; Huang, HY; Huang, YP; Lin, YC; Liu, MT; Pan, YT; Wu, HS; Yang, JR | 1 |
| Alba, A; Álvarez, AM; Catalán, P; Zubleta, M | 1 |
| Boucher, CA; Lina, B; Monto, AS; Nguyen-Van-Tam, JS; Osterhaus, A; Schutten, M; Whitley, RJ | 1 |
| Fell, DB; Liu, N; Smith, GN; Sprague, AE; Walker, MC; Wen, SW; Xie, HY; Xie, RH; Yasseen, AS | 1 |
| Coha, B; Hadžibegović, I; Jandrić Balen, M; Knežević Praveček, M; Mišić, B; Samardžić, P | 1 |
| Chen, D; Chen, J; Chen, L; Dai, W; Gao, Y; Huang, L; Liu, X; Lu, P; Song, J; Xu, H; Yang, H; Yang, Y | 1 |
| Andrianova, EN; Aver'ianov, AV; Babkin, AP; Bart, BIa; Epshteĭn, OI; Kostinov, MP; Kozyrev, OA; Minina, ES; Nechaev, VB; Petrov, DV; Putilovskiĭ, MA; Sel'kova, EP; Volchetskiĭ, AL | 1 |
| Bishop, B; Somekh, E; Stein, M; Tasher, D | 1 |
| Jackevicius, CA; Krumholz, HM; Ross, JS | 1 |
| Harvey, C; Kidy, Z; Mulla, H; Peek, GJ; Ramaiah, R; Westrope, C | 1 |
| Cordonnier, C; de la Camara, R; Engelhard, D; Ljungman, P; Mohty, B | 1 |
| Prober, CG | 1 |
| Englund, JA | 1 |
| Fleming, DM | 1 |
| Clements, DA; Hamilton, JD; Huber, J; Lee, PY; Matchar, DB; Peterson, ED | 1 |
| Davidson, HE; Gravenstein, S | 1 |
| Sugaya, N | 6 |
| Uyeki, T; Winquist, A | 1 |
| Roberts, MS; Smith, KJ | 1 |
| Dumyati, G; Falsey, AR | 1 |
| Barrett, J; Dorr, A; Oo, C; Snell, P | 1 |
| Vogel, GE | 3 |
| Gillissen, A; Höffken, G | 1 |
| Aoki, FY; Carewicz, O; El Sawy, A; Griffiths, M; Macleod, MD; Paggiaro, P; Waalberg, E; Ward, P; Wat, C | 1 |
| Mitamura, K; Nirasawa, M; Shinjoh, M; Sugaya, N; Takeuchi, Y | 1 |
| Noyola, DE | 1 |
| Wutzler, P | 1 |
| Da Silva, PR; Hayward, AC; Nguyen, VT | 1 |
| Lange, W; Vogel, GE | 1 |
| Cai, B; Li, L; Wang, M; Zhu, Y | 2 |
| Eriksson, M; Lindberg, A; Linde, A; Norrby, R; Pauksens, K; Uhnoo, I | 1 |
| Balasingam, S; Bossuyt, S; Lambkin, R; Mann, A; Novelli, P; Oxford, JS | 1 |
| Boas, LS; da Rocha, IF; Dulley, FL; Machado, CM; Mendes, AV; Pannuti, CS; Santos, MF; Sturaro, D | 1 |
| Barrett, J; Dorr, A; Liu, B; Oo, C; Snell, P; Wilding, I | 1 |
| Abrams, KR; Cooper, NJ; Nicholson, KG; Sutton, AJ; Turner, D; Wailoo, A | 1 |
| Hansen, L | 3 |
| Hirotsu, N; Iwaki, N; Kashiwagi, S; Kawai, N; Kawashima, T; Kondoh, K; Kunishima, O; Maeda, T; Satoh, I; Shigematsu, T; Tsuchimoto, T | 1 |
| Hayden, F; Kaiser, L; Mahoney, P; Mills, T; Ward, P; Wat, C | 1 |
| Kirkbride, HA; Watson, J | 1 |
| Boivin, G; Coulombe, Z; Wat, C | 1 |
| Dutkowski, R; Froehlich, E; Oo, C; Suter, P; Thakrar, B; Ward, P | 1 |
| Boellner, S; Dorr, A; Hill, G; Liu, B; Oo, C; Ward, P | 1 |
| Harnden, A; Matheson, NJ; Sheikh, A; Shepperd, S; Symmonds-Abrahams, M | 1 |
| Ijichi, N; Ijichi, S | 1 |
| Bellantonio, S; Rose, DN; Rothberg, MB | 1 |
| Myers, JW | 1 |
| Phillips, TG | 1 |
| Yamaura, K; Yoshihara, M | 1 |
| Owen Hendley, J; Pappas, DE | 1 |
| Kashiwagi, S | 3 |
| Kaji, M | 2 |
| Hosoya, M; Imamura, T; Katayose, M; Kawasaki, Y; Oonishi, N; Sato, K; Suzuki, H | 1 |
| Liedholm, H | 1 |
| Pegram, PS; Williamson, JC | 1 |
| Belshe, R; Carr, J; Dutkowski, R; Hayden, FG; Hughes, C; Lanno, R; Small, I; Villanueva, C; Ward, P | 1 |
| Beyer, WE; de Jong, JC; Fouchier, RA; Osterhaus, AD; Rimmelzwaan, GF | 1 |
| Wooltorton, E | 1 |
| Abbott, A; Pearson, H | 1 |
| Ikeda, S; Ikegami, N; Sakamaki, H | 1 |
| Chan, PK; Chik, KW; Lee, V; Li, CK; Shing, MM; Tam, JS; Yuen, PM | 1 |
| Boas, LS; da Rocha, IF; Dulley, FL; Machado, CM; Mendes, AV; Pannuti, CS; Sturaro, D | 1 |
| Leshel-Hauzeneder, M | 1 |
| Kosaki, K; Mitamura, K; Sato, S; Shinjoh, M; Sugaya, N; Takahashi, T; Takeuchi, Y | 1 |
| L'Italien, GJ; Nordstrom, BL; Oh, K; Sacks, ST | 1 |
| Barr, IG; Hampson, AW; Hurt, AC; Komadina, N | 1 |
| Klimov, A; Mungall, BA; Xu, X | 1 |
| Di Natale, R; Guy, RJ; Hampson, AW; Kelly, HA; Lambert, SB; Robinson, PM; Tallis, G; Tobin, S | 1 |
| Enger, C; Nordstrom, BL; Rothman, KJ; Sacks, S; Thakrar, B | 1 |
| Chen, XY; Cui, DJ; Gao, H; Hu, SL; Huo, ZL; Lin, JT; Wang, AX; Wang, YZ; Wu, XD; Yu, XZ; Zhu, JH; Zhu, SH | 1 |
| Harling, R; Hayward, A; Watson, JM | 1 |
| Elias, S; Herlocher, ML; Monto, AS; Ohmit, SE; Rotthoff, J; Teich, E; Truscon, R; Yen, HL | 1 |
| Kossow, KD; Lode, H; Ruf, BR; Scholz, H; Vogel, GE; Wutzler, P | 1 |
| Laver, WG | 1 |
| Kaiser, J | 1 |
| Barr, IG; Durrant, CJ; Hampson, AW; Hurt, AC; Shaw, RP; Sjogren, HM | 1 |
| Fagan, HB; Moeller, AH | 1 |
| Faughnan, ME; Langley, JM | 1 |
| Chen, XY; Cui, DJ; Gao, H; Hu, SL; Lin, JT; Wang, AX; Wang, YZ; Wu, XD; Yu, XZ; Zhu, JH | 1 |
| Boomer, M; Bush, KA; Clarkson, LM; Dwyer, DE; McAnulty, J; McPhie, K; Quaine, J; Reynolds, R | 1 |
| Crouch, E; Hartshorn, KL; Hartshorn, M; Holmskov, U; Pemberton, L; Tornoe, I; van Eijk, M; White, MR | 1 |
| Suzuki, H | 1 |
| Matkovics, A | 1 |
| Normile, D | 4 |
| Adachi, K; Annaka, M; Chimura, Y; Higuchi, H; Inamatsu, T; Ishikawa, T; Kosugi, Y; Masuda, Y; Sadamasu, K; Shibazaki, S; Shinkai, T | 1 |
| Gyldmark, M; Holme Hansen, E; Vindt Holm, M | 1 |
| Cools, HJ; van Essen, GA | 1 |
| Dutkowski, R; Small, I; Smith, J; Suter, P; Ward, P | 1 |
| Asano, T; Fujino, O; Hamada, H; Hatori, T; Imai, T; Kuwabara, K; Sasaki, N; Yashiro, K | 1 |
| Deng, WW; Li, QY; Zhong, NS | 1 |
| Bowles, SK; McGeer, A; Oh, PI; Risebrough, NA; Simor, AE | 1 |
| Dutkowski, R; Ferrero, F; Garcia, ML; Johnston, SL | 1 |
| McKimm-Breschkin, JL | 2 |
| Hirotsu, N; Ikematsu, H; Iwaki, N; Kashiwagi, S; Kawai, N; Kawashima, T; Maeda, T; Miyachi, K; Satoh, I; Shigematsu, T | 1 |
| Laver, G | 1 |
| Bergemann, R; Gyldmark, M; Hayden, FG; Morris, J; Mueller, E; Sander, B | 1 |
| Abbott, A | 1 |
| Fukui, T; Kamiya, I; Kishida, K; Morimoto, T; Okamoto, S; Shimakawa, T | 1 |
| Nordstrom, BL; Sung, I; Suter, P; Szneke, P | 1 |
| Andrawiss, M | 1 |
| de Jong, JC; Osterhaus, AD | 1 |
| Kikuchi, Y; Miura, T; Tamura, D | 1 |
| Balicer, RD; Davidovitch, N; Grotto, I; Huerta, M | 1 |
| Ferraris, O; Kessler, N; Lina, B | 1 |
| Murray, S | 1 |
| Hasle, G | 1 |
| Hosoya, M; Kato, K; Sato, M; Suzuki, H | 1 |
| Goto, H; Horimoto, T; Kawaoka, Y; Kiso, M; Le, QM; Muramoto, Y; Nguyen, KH; Nguyen, TH; Ngyen, HH; Pham, ND; Sakai, YT; Someya, K; Suzuki, T; Suzuki, Y; Takada, A; Yamada, S | 1 |
| Groeneveld, K; van der Noordaa, J | 1 |
| Schlegel, A | 1 |
| Tanne, JH | 1 |
| Oxford, J | 1 |
| Chung, PH | 1 |
| Dutkowski, R; Smith, JR | 1 |
| Rouse, A | 1 |
| Bricaire, F; Derenne, JP | 1 |
| May, RM | 1 |
| Chenoweth, C; Cinti, S; Monto, AS | 1 |
| Kay, M | 1 |
| Buchholz, U | 1 |
| Taéron, C | 1 |
| Chatterjee, P | 1 |
| Bradley, D | 1 |
| Brett, AS; Zuger, A | 1 |
| Bach, VC; de Jong, MD; Do, QH; Farrar, J; Guan, Y; Nguyen, VC; Peiris, JS; Phan, TQ; Smith, GJ; Tran, TH; Tran, TT; Truong, HK; Vo, MH | 1 |
| Chen, XY; Cui, DJ; Lin, JT; Wang, YZ; Wu, XD; Yu, XZ; Zhu, JH | 1 |
| Parry, J | 1 |
| Amyard, M; Hampson, A; Hay, A; Hayden, F; Klimov, A; Macken, C; McKimm-Breschkin, J; Monto, A; Tashiro, M; Webster, RG; Zambon, M | 1 |
| Barie, PS | 1 |
| Mayor, S | 1 |
| Carroll, KC; Dunn, JJ; Elstad, MR; Gundlapalli, AV; Gwaltney, JM; Hayden, FG; Lahey, T; Lopansri, B; McGuire, HL; Rubin, MA; Samore, MH; Sande, MA; Vosters, RL; Waeckerle, JE; Willick, SE; Winthrop, KL | 1 |
| Howton, JC | 1 |
| Hiebert, M; Linebaugh, K; Prystay, C | 1 |
| Vogel, VG | 1 |
| Linder, JA | 1 |
| Gupta, RK; Nguyen-Van-Tam, JS | 1 |
| Hayashi, Y; Ijuin, K; Matsuda, R | 1 |
| Garrison, LP; Gyldmark, M; Hayden, FG; Sander, B | 1 |
| Bonmarin, I; Desenclos, JC; Doyle, A; Le Strat, Y; Lévy-Bruhl, D | 1 |
| Pickles, HG | 1 |
| Bonhoeffer, S; Regoes, RR | 1 |
| Chen, KT | 1 |
| Barr, IG; Hampson, AW; Hurt, AC; Iannello, P; Jachno, K; Komadina, N; McKimm-Breschkin, JL | 1 |
| Corey, EJ; Hong, S; Yeung, YY | 1 |
| Graves, BJ; Klumpp, K | 1 |
| Kato, T; Kubota, T; Morishima, T; Okumura, A | 1 |
| Davies, T | 1 |
| Suzuki, T; Suzuki, Y; Takahashi, T | 1 |
| Brydak, LB; Gawryluk, D; Lietzau, G; Machała, M; Wiatr, E | 1 |
| Fukunaga, Y; Hajikano, M; Kawabata, K; Madenokouji, N; Matsuoka, K; Ninomiya, K | 1 |
| Brewster, M; Dutkowski, R; Robson, R; Smith, JR | 1 |
| Cools, HJ; Meijer, A; Ruijs, WL; van der Plas, SM; van der Sande, MA | 1 |
| Brewster, M; Buttimore, A; Lynn, K; Robson, R; Ward, P | 1 |
| Deray, G; Izzedine, H; Janus, N; Karie, S; Launay-Vacher, V | 1 |
| Hirotsu, N; Ikematsu, H; Iwaki, N; Kashiwagi, S; Kawai, N; Maeda, T; Satoh, I | 1 |
| Demicheli, V; Di Pietrantonj, C; Jefferson, TO; Jones, M; Rivetti, D | 1 |
| Monto, AS; Ohmit, SE | 1 |
| Arisaka, O; Kano, K; Shimura, N; Sunagawa, S | 1 |
| Del Mar, C; Jones, M | 1 |
| Eng, P; Lam, WK; Liam, CK; Seto, WH; Shim, YS; Tsang, KW; Wong, TK | 1 |
| Le, MQ; Li, D; Masaki, H; Nguyen, HL; Nguyen, HT; Nguyen, TT; Phan, TV; Saito, R; Sato, M; Shimomura, C; Suzuki, H; Suzuki, Y | 1 |
| Barr, IG; Deed, N; Hurt, AC; Iannello, P; Komadina, N; Tomasov, C | 1 |
| Andrieu, AG; Belmin, J; Glomot, L; Jarlier, V; Paute, J | 1 |
| Mitamura, K; Sugaya, N | 1 |
| Brown, JD; Farina, V | 1 |
| Andoh, M; Fukui, H; Kobayashi, Y; Matsumori, A; Nishimura, K; Nunoi, T; Takeda, K; Tsujinoue, H; Yoneda, S | 1 |
| Halloran, ME; Hayden, FG; Longini, IM; Monto, AS; Yang, Y | 1 |
| Barr, IG; Brown, L; Hurt, AC; Komadina, N; Selleck, P; Shaw, R | 1 |
| Dwyer, DE; Emery, S; Harrod, ME | 1 |
| Akdeniz, H; Arslan, S; Bay, A; Cesur, Y; Ceyhan, M; Deger, I; Epcacan, S; Karsen, H; Kizilyildiz, B; Oner, AF; Sahin, HA; Yilmaz, N | 1 |
| Blair, PJ; Chan, KH; Cox, N; Donis, R; Giriputra, S; Guan, Y; Hadisoedarsuno, W; Harun, S; Heriyanto, B; Jeremijenko, A; Kandun, IN; Katz, J; Klimov, A; Kosasih, H; Lim, W; Lindstrom, S; Peiris, M; Poon, LL; Purba, W; Putnam, SD; Samaan, G; Santoso, H; Sedyaningsih, ER; Septiawati, C; Silitonga, M; Soeroso, S; Tresnaningsih, E; Uyeki, TM; Wibisono, H; Yuwono, D | 1 |
| Pearson, H | 1 |
| Mossad, SB | 2 |
| Kubo, T; Nishimura, H | 1 |
| DeCoster, B | 1 |
| Aultman, R; Bettis, R; Fuchs, R; Gyldmark, M; Iacuzio, D; Jung, T | 1 |
| Hayden, FG; Pavia, AT | 1 |
| Fauci, AS | 1 |
| Wright, PF | 1 |
| Hatakeyama, S; Ichikawa, M; Ito, M; Kawakami, C; Kawaoka, Y; Kimura, K; Kiso, M; Mitamura, K; Sugaya, N; Tamura, D; Yamazaki, M | 1 |
| Beigel, J; Bellamy, R; Chotpitayasunondh, T; Croisier, A; Del Mar, C; Farrar, J; Fukuda, K; Hayden, FG; Hill, SR; Kakad, M; Nagjdaliyev, A; Oxman, AD; Ozbay, B; Roth, C; Schünemann, HJ; Shindo, N; Stockman, L; Sugaya, N; Thomson, G; Tran, TH; Uyeki, TM; Vist, GE; Yazdanpanah, Y; Zucker, H | 1 |
| Nothdurft, HD | 1 |
| Bastien, N; Brunham, RC; David, ST; Krajden, M; Lee, SW; Li, Y; Marra, F; Petric, M; Skowronski, DM; Tam, TW; Tweed, SA | 1 |
| Harnden, AR; Matheson, NJ; Perera, R; Sheikh, A; Symmonds-Abrahams, M | 1 |
| Cohen, T; Levin, BR; Lipsitch, M; Murray, M | 1 |
| Enserink, M; Normile, D | 1 |
| Brydak, LB; Gawryluk, D; Machała, M; Wiatr, E | 1 |
| Gras-Masse, H; Willand, N | 1 |
| Amonsin, A; Chieochansin, T; Chutinimitkul, S; Damrongwatanapokin, S; Hanh, NH; Mai, le Q; Payungporn, S; Poovorawan, Y; Suwannakarn, K; Theamboonlers, A | 1 |
| Barr, CE; Bradley, JS; Iacuzio, D; Schulman, K | 1 |
| Gould, EA; Johnson, AC; Nunn, MA; Singer, AC | 1 |
| Gyrd-Hansen, D; Halvorsen, PA; Kristiansen, IS | 2 |
| Hatakeyama, S; Ichikawa, M; Ito, M; Kawakami, C; Kawaoka, Y; Kimura, K; Kiso, M; Koike, K; Mitamura, K; Shimizu, H; Sugaya, N; Yamazaki, M | 1 |
| Ahmed, QA; Arabi, Y; Boynton, BR; Gomersall, CD; Memish, ZA | 1 |
| Lynch, JP; Walsh, EE | 1 |
| Gyldmark, M; Novak, A; Postma, MJ; Scheijbeler, HW; van Genugten, ML; Wilschut, JC | 1 |
| Drinka, PJ; Haupt, T | 1 |
| Chen, MI; Lee, VJ | 1 |
| Amonsin, A; Chaisingh, A; Chieochansin, T; Chutinimitkul, S; Damrongwatanapokin, S; Nuansrichay, B; Payungporn, S; Poovorawan, Y; Songserm, T; Suwannakarn, K; Theamboonlers, A | 1 |
| Collins, C; Cormican, M; Drew, R | 1 |
| Maxwell, SR | 1 |
| Hayden, FG; Ong, AK | 1 |
| Boeckh, M; Corey, L; Englund, JA; Nichols, WG; Peck, AJ; Varley, C; Vu, D | 1 |
| Akiba, T; Fukuyama, T; Satoh, N; Yokoshima, S | 1 |
| Hirotsu, N; Ikematsu, H; Iwaki, N; Kashiwagi, S; Kawai, N; Kawashima, T; Kondou, K; Maeda, T; Mitsuoka, S; Miyachi, K; Satoh, I; Shigematsu, T; Yamaga, S | 1 |
| Bonhoeffer, S; Débarre, F; Regoes, RR | 1 |
| Chan, PK; Choi, KW; Cockram, CS; Hui, DS; Lai, R; Lee, N; Lui, G; Sung, JJ; Tang, JW; Wong, B | 1 |
| Chou, KC; Du, QS; Wang, SQ | 1 |
| Kobayashi, Y; Matsushita, M; Nishihara, H; Nishiyama, R | 1 |
| Kohen, I | 1 |
| Carrat, F; El Sawi, A; Gaillat, J; Grandmottet, G; Schlemmer, C | 1 |
| Govorkova, EA; Hoffmann, E; Ilyushina, NA; Salomon, R; Webster, RG; Yen, HL | 1 |
| Whitley, RJ | 1 |
| Chida, K; Gemma, H; Koshimizu, N; Satoh, M; Suda, T; Suzuki, Y | 1 |
| Hirotsu, N; Horii, S; Ikematsu, H; Iwaki, N; Kanazawa, H; Kashiwagi, S; Kawai, N; Kawamura, K; Kawashima, T; Maeda, T; Nagai, T; Tanaka, O; Yamauchi, S | 1 |
| Blumentals, WA; Schulman, KL | 1 |
| Crusat, M; de Jong, MD | 1 |
| Aoki, FY; Boivin, G; Roberts, N | 1 |
| Chang, YM; Chen, CH; Cheng, YH; Chiang, SL; Huang, CG; Huang, CT; Huang, YC; Li, WC; Tsao, KC; Yang, SY | 1 |
| Ikematsu, H; Iwaki, N; Kashiwagi, S; Kawai, N; Kawamura, K; Kawashima, T | 1 |
| Leach, L; Raymond, LW | 1 |
| Campbell, JD | 1 |
| Blumentals, WA; Orzeck, EA; Shi, N | 1 |
| Wesseling, G | 1 |
| von Itzstein, M | 1 |
| Bouscambert-Duchamp, M; Escuret, V; Ferraris, O; Frobert, E; Grog, I; Lina, B; Morfin, F; Sabatier, M; Valette, M | 1 |
| Moriuchi, H; Moriuchi, M | 1 |
| Renner, R | 1 |
| Akazawa, Y; Amano, Y; Minami, I; Nakamura, S; Uchida, N; Yasui, K | 1 |
| Hozumi, I; Inuzuka, T; Kimura, A; Ogura, S; Sakurai, T; Tanaka, Y | 1 |
| Kawai, Y; Monju, A; Ouchi, K; Terada, K; Wakabayashi, T | 1 |
| Hanafusa, T; Imagawa, A; Sano, H; Terasaki, J; Tsutsumi, C | 1 |
| Abdel-Ghafar, AN; Chotpitayasunondh, T; de Jong, MD; Gao, Z; Hayden, FG; Naghdaliyev, A; Nguyen, DH; Peiris, JS; Shindo, N; Soeroso, S; Uyeki, TM | 1 |
| Blumentals, WA; Gums, JG; Pelletier, EM | 1 |
| Doy, M; Kawada, Y; Ogata, T; Yamato, S; Yamazaki, Y | 1 |
| Jarvinen, KA; McCall, BJ; Mohr, CM | 1 |
| Gejyo, F; Li, D; Oguma, T; Saito, R; Sakai, T; Sasaki, A; Sato, I; Sato, M; Shobugawa, Y; Suzuki, H; Suzuki, Y; Tanabe, N; Tsukada, H | 1 |
| Blumentals, WA; Song, X | 1 |
| Worrall, G | 1 |
| Ginns, LC; Ison, MG; Sharma, A; Shepard, JA; Wain, JC | 1 |
| Panknin, HT; Trautmann, M | 1 |
| Bovin, NV; Govorkova, EA; Gray, TE; Ilyushina, NA; Webster, RG | 1 |
| Aziz, S; Garner, M; Huston, P; King, A; Li, Y; Macey, JF; Reyes, F; Winchester, B | 1 |
| Ichihara, K; Suzuki, E | 1 |
| Brown, G; Keeble, B; Munasinghe, S; Nair, P; Pereira, A; Sundkvist, T | 1 |
| Ciancio, B; Kramarz, P; Nicoll, A | 1 |
| Cheng, YS; Fang, JM; Jeng, KS; Shie, JJ; Su, CY; Temperton, NJ; Wang, SY; Wong, CH | 1 |
| Collins, PJ; Gamblin, SJ; Haire, LF; Hay, AJ; Lin, YP; Liu, J; Martin, SR; Russell, RJ; Skehel, JJ; Walker, PA | 1 |
| Moyad, MA; Robinson, LE | 1 |
| Service, RF | 1 |
| Wade, RC | 1 |
| Bailey, KW; Barnard, DL; Huffman, JH; Kim, CU; Morrison, A; Sidwell, RW; Syndergaard, T; Wong, MH | 1 |
| Hughes, J; Ostroff, S | 1 |
| Calfee, DP; Hayden, FG | 1 |
| Stephenson, J | 1 |
| Betts, RF; Fritz, RS; Hayden, FG; Kinnersley, N; Lobo, M; Miller, M; Mills, RG; Straus, SE; Treanor, JJ; Ward, P | 1 |
| Atmar, RL; Hayden, FG; Huson, L; Johnson, C; Mills, RG; Paar, D; Poretz, D; Schilling, M; Ward, P | 1 |
| Cox, NJ; Hughes, JM | 1 |
| Hayden, FG | 3 |
| Bardsley-Elliot, A; Noble, S | 1 |
| Kelly, GD; Laver, WG | 1 |
| Couch, RB | 1 |
| Barza, M | 1 |
| Koopmans, PP; Simonian, S; van Loon, FP; Voordouw, AC | 1 |
| Goldman, MP; Long, JK; Mossad, SB | 1 |
| Vallée, JP | 1 |
| Barbarash, R; Bettis, R; Hayden, FG; Kinnersley, N; Mills, RG; Riff, D; Singh, S; Treanor, JJ; Vrooman, PS; Ward, P | 1 |
| Wenzel, RP | 1 |
| Gubareva, LV; Hayden, FG; Kaiser, L | 1 |
| Force, RW; Johnson, JM | 1 |
| Lemon, M; Meade, F | 1 |
| Aoki, FY; Carewicz, O; Kinnersley, N; Mercier, CH; Nicholson, KG; Osterhaus, AD; Rode, A; Trottier, S; Ward, P | 1 |
| Citron, A; Clarke, T; Gray, D; Herron, W; Serpe, C; Wiltshire, B; Wiltshire, H | 1 |
| Vogel, G; Wutzler, P | 1 |
| Hayden, FG; Ipe, D; Jackson, H; Jennings, L; McClelland, G; Rana, B; Roberts, N; Robson, R; Schiff, G; Ward, P | 1 |
| Caserta, MT; Hall, CB | 1 |
| Goloubeva, OG; Govorkova, EA; Leneva, IA; Roberts, N; Webster, RG | 1 |
| Ashley, JV; Gum, KD; Montalto, NJ | 1 |
| Rosen, DS | 1 |
| Gubareva, LV; Hayden, FG; Kaiser, L; Matrosovich, MN; Soo-Hoo, Y | 1 |
| Carewicz, O; Hassman, M; Hedrick, J; Huson, L; Jackson, HC; Monto, AS; Oxford, JS; Schatteman, E; Ward, P; Welliver, R | 1 |
| Snell, J | 1 |
| Kashiwagi, S; Kudoh, S; Watanabe, A; Yoshimura, I | 2 |
| Briganti, E; Calza, L; Chiodo, F; Manfredi, R | 1 |
| McNicholl, IR; McNicholl, JJ | 1 |
| Dutkowski, R; Hayden, FG; Ipe, D; Mills, RG; Reisinger, KS; Ward, P; Whitley, RJ; Young, N | 1 |
| Matsumoto, K | 1 |
| Montalto, NJ | 1 |
| Loewen, N; Parker, R; Skowronski, D | 1 |
| McClellan, K; Perry, CM | 1 |
| Barrett, J; Dorr, A; Dutkowski, R; Hill, G; Mann, J; Oo, C; Ward, P | 1 |
| Brocavich, J; Dreitlein, WB; Maratos, J | 1 |
| Das, P | 1 |
| Hayden, FG; Zambon, M | 1 |
| Cross, J; Wedekind, CA | 1 |
| Tooley, P | 1 |
| De Bock, V; Gibbens, M; Gravenstein, S; Norwood, P; Peters, PH; Van Couter, A; von Planta, TA; Ward, P | 1 |
| Preboth, M | 1 |
| Holdiness, MR | 1 |
| Khan, K; Muennig, PA | 1 |
| Barrett, J; Cihlar, T; Hill, G; Ho, ES; Liu, B; Oo, C; Prior, K; Ward, P; Wiltshire, H | 1 |
| Roberts, NA | 1 |
| Aoki, FY; Doucette, KE | 1 |
| Boivin, G; Gaudreau, A; Groen, J; Jackson, HC; Osterhaus, AD; Ward, P | 1 |
| King, JC; Straumanis, JP; Tapia, MD | 1 |
| Gubareva, LV; Hayden, FG; Nedyalkova, MS; Webster, RG | 1 |
| Senior, K | 1 |
| Seaton, TL; Sturpe, D | 1 |
| Farr, BM; Hall, KK; Hayden, FG; Salgado, CD | 1 |
| Pitts, SR | 1 |
| Cox, NJ; Fukuda, K; Uyeki, TM | 1 |
| Bowles, SK; Fearon, M; Lee, W; Li, Y; Loeb, M; McGeer, A; Simor, AE; Tamblyn, S; Vearncombe, M | 1 |
| Bridges, CB; Cox, NJ; Fukuda, K; Singleton, JA; Uyeki, TM | 1 |
| Abe, S; Shijubo, N; Suzuki, T; Takahashi, M; Tokunoh, T; Yamada, G | 1 |
| Boivin, G; Goyette, N | 1 |
| Carr, J; Ives, J; Kelly, L; Lambkin, R; Mendel, D; Oxford, J; Roberts, N; Tai, L | 1 |
| Carr, JA; Hayden, FG; Ives, JA; Kelly, L; Lambkin, R; Mendel, DB; Oxford, JS; Roberts, NA; Tai, CY | 1 |
289 review(s) available for oseltamivir and Grippe
| Article | Year |
|---|---|
Comparative effectiveness of neuraminidase inhibitors in patients with influenza: A systematic review and network meta-analysis.
Topics: Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Network Meta-Analysis; Neuraminidase; Oseltamivir; Zanamivir | 2022 |
Antiviral Treatments for Influenza.
Topics: Antiviral Agents; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2021 |
Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018-2020.
Topics: Amino Acid Substitution; Antiviral Agents; Dibenzothiepins; Drug Resistance, Viral; Endonucleases; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza B virus; Influenza, Human; Morpholines; Neuraminidase; Oseltamivir; Pyridones; Triazines | 2022 |
Influenza antivirals and animal models.
Topics: Animals; Antiviral Agents; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Models, Animal; Oseltamivir | 2022 |
Clinical Efficacy and Safety of Chinese Patent Medicine Combined with Oseltamivir for the Treatment of Adult Influenza: A Systematic Review and Meta-Analysis.
Topics: Adult; China; Drugs, Chinese Herbal; Humans; Influenza, Human; Nonprescription Drugs; Oseltamivir; Randomized Controlled Trials as Topic; Treatment Outcome | 2022 |
Oseltamivir and acute hepatitis, reality association or coincidence?
Topics: Acute Disease; Antiviral Agents; Hepatitis; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir | 2021 |
Preclinical and clinical developments for combination treatment of influenza.
Topics: Animals; Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyridones | 2022 |
[Overview of Meta-analysis of Lianhua Qingwen preparations in treatment of viral diseases].
Topics: Cough; COVID-19 Drug Treatment; Drugs, Chinese Herbal; Fatigue; Fever; Humans; Influenza, Human; Meta-Analysis as Topic; Nonprescription Drugs; Nucleic Acids; Oseltamivir; Ribavirin | 2022 |
[Systematic review and Meta-analysis of Lianhua Qingwen preparations combined with Oseltamivir in treatment of influenza].
Topics: Cough; Drugs, Chinese Herbal; Humans; Influenza, Human; Myalgia; Nucleic Acids; Oseltamivir; Pharyngitis; Rhinorrhea | 2022 |
The current strategies of optimization of oseltamivir against mutant neuraminidases of influenza A：A review.
Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Glycoside Hydrolases; Guanidines; Humans; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Zanamivir | 2022 |
Preparing for pandemics: a systematic review of pandemic influenza clinical management guidelines.
Topics: Aged; Antiviral Agents; Child; Child, Preschool; COVID-19; Female; Humans; Influenza, Human; Oseltamivir; Pandemics; Pregnancy | 2022 |
Essential Oils and Their Compounds as Potential Anti-Influenza Agents.
Topics: Antiviral Agents; Humans; Influenza, Human; Oils, Volatile; Orthomyxoviridae; Oseltamivir | 2022 |
Systematic review and meta-analysis of the efficacy and safety of oseltamivir (Tamiflu) in the treatment of Coronavirus Disease 2019 (COVID-19).
Topics: Antiviral Agents; COVID-19 Drug Treatment; Humans; Influenza, Human; Oseltamivir | 2022 |
Influenza antivirals and their role in pandemic preparedness.
Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pandemics | 2023 |
Antiviral therapies for influenza.
Topics: Antiviral Agents; COVID-19; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2023 |
Conformationally locked sugar derivatives and analogues as potential neuraminidase inhibitors.
Topics: Antiviral Agents; Cyclohexenes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Orthomyxoviridae; Oseltamivir; Zanamivir | 2023 |
Fulminant myocarditis due to the influenza B virus in adults: Report of two cases and literature review
Topics: Acute Kidney Injury; Advanced Cardiac Life Support; Antiviral Agents; Combined Modality Therapy; Emergencies; Extracorporeal Membrane Oxygenation; Fatal Outcome; Female; Hemofiltration; Humans; Influenza B virus; Influenza, Human; Intra-Aortic Balloon Pumping; Middle Aged; Myocarditis; Oseltamivir; Pericardial Effusion; Shock, Cardiogenic; Vasoconstrictor Agents; Young Adult | 2019 |
Influenza in solid organ transplant recipients: epidemiology, management, and outcomes.
Topics: Antiviral Agents; Hospitalization; Humans; Influenza Vaccines; Influenza, Human; Organ Transplantation; Oseltamivir; Transplant Recipients; Vaccination | 2020 |
A Meta-Analysis Comparing the Efficacy and Safety of Peramivir with Other Neuraminidase Inhibitors for Influenza Treatment.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Observational Studies as Topic; Oseltamivir; Randomized Controlled Trials as Topic | 2020 |
Critical care management of adults with community-acquired severe respiratory viral infection.
Topics: Adult; Antiviral Agents; Community-Acquired Infections; Coronavirus Infections; COVID-19; Critical Care; Critical Illness; Evidence-Based Medicine; Humans; Influenza, Human; Intensive Care Units; Macrolides; Noninvasive Ventilation; Oseltamivir; Pneumonia; Pneumonia, Viral; Respiration, Artificial; Severe Acute Respiratory Syndrome; Severity of Illness Index | 2020 |
Influenza management with new therapies.
Topics: Adrenal Cortex Hormones; Amides; Antiviral Agents; Critical Care; Critical Illness; Dibenzothiepins; Enzyme Inhibitors; Humans; Influenza, Human; Morpholines; Neuraminidase; Oseltamivir; Pyrazines; Pyridines; Pyridones; Pyrimidines; Pyrroles; Respiration, Artificial; Triazines; Zanamivir | 2020 |
Antivirals Targeting the Neuraminidase.
Topics: Antibodies, Monoclonal; Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2022 |
Comparison of double-dose vs standard-dose oseltamivir in the treatment of influenza: A systematic review and meta-analysis.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Humans; Influenza, Human; Oseltamivir; Randomized Controlled Trials as Topic; Treatment Outcome | 2020 |
Oseltamivir-Current Dosing Recommendations Reduce the Therapeutic Benefit in Patients With Mild to Moderate Renal Function and/or Large Body Mass: A Review of the Literature With Recommendations to Optimize Dosing, Including the Use of Therapeutic Drug Mo
Topics: Antiviral Agents; Body Mass Index; Drug Monitoring; Humans; Influenza, Human; Kidney; Oseltamivir | 2021 |
Herbal Medicine Treatment for Influenza: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Antiviral Agents; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Humans; Influenza, Human; Male; Oseltamivir; Phytotherapy; Randomized Controlled Trials as Topic; Treatment Outcome | 2020 |
Neuraminidase inhibitors are effective and safe in reducing influenza complications: meta-analysis of randomized controlled trials.
Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Randomized Controlled Trials as Topic; Zanamivir | 2021 |
Comparing intravenous peramivir with oral oseltamivir for patients with influenza: a meta-analysis of randomized controlled trials.
Topics: Acids, Carbocyclic; Administration, Intravenous; Administration, Oral; Antiviral Agents; Guanidines; Humans; Influenza, Human; Oseltamivir; Pneumonia; Randomized Controlled Trials as Topic | 2021 |
Antiviral use in healthcare workers-A systematic review.
Topics: Antiviral Agents; Enzyme Inhibitors; Health Personnel; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2022 |
Antivirals Targeting the Surface Glycoproteins of Influenza Virus: Mechanisms of Action and Resistance.
Topics: Animals; Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Enzyme Inhibitors; Hemagglutinins, Viral; Humans; Influenza, Human; Mice; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Viral Envelope Proteins | 2021 |
Clinical efficacy and safety of baloxavir marboxil in the treatment of influenza: A systematic review and meta-analysis of randomized controlled trials.
Topics: Adolescent; Adult; Antiviral Agents; Child; Dibenzothiepins; Female; Humans; Influenza, Human; Male; Middle Aged; Morpholines; Oseltamivir; Pyridones; Randomized Controlled Trials as Topic; Treatment Outcome; Triazines; Viral Load; Young Adult | 2021 |
Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group.
Topics: Animals; Antiviral Agents; Dibenzothiepins; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza, Human; Knowledge; Morpholines; Neuraminidase; Oseltamivir; Pyridones; SARS-CoV-2; Triazines; Virus Replication; Zanamivir | 2021 |
Influenza in children.
Topics: Antiviral Agents; Child; Cost of Illness; Global Health; Humans; Influenza Vaccines; Influenza, Human; Oseltamivir; Risk Factors | 2017 |
Review of potential drug interaction between Oseltamivir and Warfarin and why it is important for emergency medicine physicians.
Topics: Aged, 80 and over; Anticoagulants; Antiviral Agents; Dose-Response Relationship, Drug; Drug Interactions; Emergency Medicine; Female; Humans; Influenza, Human; International Normalized Ratio; Oseltamivir; Physicians; Pulmonary Embolism; Treatment Outcome; Warfarin | 2017 |
Comparison of Efficacy of Intravenous Peramivir and Oral Oseltamivir for the Treatment of Influenza: Systematic Review and Meta-Analysis.
Topics: Acids, Carbocyclic; Administration, Intravenous; Administration, Oral; Antiviral Agents; Cyclopentanes; Guanidines; Humans; Influenza, Human; Odds Ratio; Oseltamivir; Publication Bias; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome | 2017 |
Safety and effectiveness of neuraminidase inhibitors for influenza treatment, prophylaxis, and outbreak control: a systematic review of systematic reviews and/or meta-analyses.
Topics: Antiviral Agents; Disease Outbreaks; Enzyme Inhibitors; Hospitalization; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pneumonia; Zanamivir | 2017 |
Efficacy and Safety of Oseltamivir in Children: Systematic Review and Individual Patient Data Meta-analysis of Randomized Controlled Trials.
Topics: Adolescent; Antiviral Agents; Child; Humans; Influenza, Human; Oseltamivir; Randomized Controlled Trials as Topic | 2018 |
Prevalence of human influenza virus in Iran: Evidence from a systematic review and meta-analysis.
Topics: Amantadine; Antiviral Agents; Drug Resistance, Viral; Female; Humans; Incidence; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Iran; Male; Oseltamivir; Prevalence; Zanamivir | 2018 |
H3N2 influenza viruses in humans: Viral mechanisms, evolution, and evaluation.
Topics: Antigens, Viral; Evolution, Molecular; Hemagglutination Inhibition Tests; Hemagglutinin Glycoproteins, Influenza Virus; Host Microbial Interactions; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; Seasons | 2018 |
EMERGING PATHOGENS: INFLUENZA - H7N9.
Topics: Animals; Antiviral Agents; Birds; Communicable Diseases, Emerging; Cough; Fever; Humans; Influenza A Virus, H7N9 Subtype; Influenza in Birds; Influenza Vaccines; Influenza, Human; Oseltamivir; Poultry; Radiography, Thoracic; Respiratory Distress Syndrome; Respiratory Tract Infections; Reverse Transcriptase Polymerase Chain Reaction | 2017 |
Peramivir: A Review in Uncomplicated Influenza.
Topics: Acids, Carbocyclic; Administration, Intravenous; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Treatment Outcome | 2018 |
Treatment of influenza with neuraminidase inhibitors.
Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Viral Proteins; Zanamivir | 2018 |
Influenza B virus infection complicated by life-threatening pericarditis: a unique case-report and literature review.
Topics: Antiviral Agents; Female; Humans; Ibuprofen; Influenza B virus; Influenza, Human; Methylprednisolone; Middle Aged; Oseltamivir; Pericardial Effusion; Pericarditis | 2019 |
BET 1: Oseltamivir use for quicker alleviation of symptoms, fewer hospital admissions and lower mortality in adult patients with influenza B.
Topics: Antiviral Agents; Cough; Emergency Service, Hospital; Evidence-Based Emergency Medicine; Fatigue; Humans; Influenza B virus; Influenza, Human; Male; Middle Aged; Oseltamivir | 2019 |
[Oseltamivir for the treatment of influenza in children and adolescents].
Topics: Adolescent; Age Factors; Antiviral Agents; Child; Critical Illness; Humans; Influenza, Human; Oseltamivir; Risk Factors; Time Factors | 2019 |
Neuraminidase inhibitors as a strategy for influenza treatment: pros, cons and future perspectives.
Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Half-Life; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2019 |
Influenza virus resistance to neuraminidase inhibitors.
Topics: Animals; Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Viral Proteins; Zanamivir | 2013 |
Executive summary. Management of influenza infection in solid-organ transplant recipients: consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiolo
Topics: Adult; Anti-Bacterial Agents; Antiviral Agents; Child; Cross Infection; Disease Management; Drug Resistance, Viral; Humans; Influenza Vaccines; Influenza, Human; Organ Transplantation; Oseltamivir; Postoperative Complications; Superinfection; Zanamivir | 2013 |
Management of influenza infection in solid-organ transplant recipients: consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the
Topics: Adult; Anti-Bacterial Agents; Antiviral Agents; Child; Cross Infection; Diagnosis, Differential; Disease Management; Drug Resistance, Viral; HN Protein; Humans; Influenza A virus; Influenza B virus; Influenza Vaccines; Influenza, Human; Inpatients; Kidney Diseases; Organ Transplantation; Oseltamivir; Outpatients; Pneumonia; Postoperative Complications; Superinfection; Zanamivir | 2013 |
Expanding horizons of shikimic acid. Recent progresses in production and its endless frontiers in application and market trends.
Topics: Antiviral Agents; Chemistry, Pharmaceutical; Humans; Influenza, Human; Oseltamivir; Shikimic Acid | 2013 |
The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews.
Topics: Antibiotic Prophylaxis; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Treatment Outcome; Zanamivir | 2013 |
Pharmacokinetics and pharmacodynamics of oseltamivir in neonates, infants and children.
Topics: Antiviral Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Infant; Infant, Newborn; Influenza, Human; Models, Biological; Neuraminidase; Oseltamivir; Viral Proteins | 2013 |
Oseltamivir in neonates, infants and young children: a focus on clinical pharmacology.
Topics: Adolescent; Antibiotic Prophylaxis; Antiviral Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Infant; Infant, Newborn; Influenza A virus; Influenza, Human; Neuraminidase; Oseltamivir; Viral Proteins | 2013 |
Emergence of oseltamivir resistance: control and management of influenza before, during and after the pandemic.
Topics: Adult; Antibiotic Prophylaxis; Antiviral Agents; Child; Dose-Response Relationship, Drug; Drug Resistance, Viral; Enzyme Inhibitors; Global Health; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation, Missense; Neuraminidase; Oseltamivir; Pandemics; Viral Proteins; Zanamivir | 2013 |
Oseltamivir for control of influenza at mass gatherings.
Topics: Adult; Aged, 80 and over; Antibiotic Prophylaxis; Antiviral Agents; Child; Disease Outbreaks; Drug Resistance, Viral; Enzyme Inhibitors; Homes for the Aged; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Prisons; Schools; Viral Proteins | 2013 |
Oseltamivir use in adolescents and adults: clinical and economic considerations.
Topics: Adolescent; Adult; Aged; Antibiotic Prophylaxis; Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Health Care Costs; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Viral Proteins | 2013 |
Oseltamivir effect on antibiotic-treated lower respiratory tract complications in virologically positive randomized trial participants.
Topics: Anti-Bacterial Agents; Antiviral Agents; Bronchopneumonia; Humans; Incidence; Influenza, Human; Oseltamivir; Pneumonia, Bacterial; Randomized Controlled Trials as Topic | 2013 |
Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Viral Proteins; Zanamivir | 2013 |
Antivirals for influenza: a summary of a systematic review and meta-analysis of observational studies.
Topics: Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Humans; Influenza, Human; Oseltamivir; Survival Analysis; Treatment Outcome; Zanamivir | 2013 |
Supply of neuraminidase inhibitors related to reduced influenza A (H1N1) mortality during the 2009-2010 H1N1 pandemic: summary of an ecological study.
Topics: Antiviral Agents; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Pandemics; Survival Analysis; Treatment Outcome; Viral Proteins; Zanamivir | 2013 |
Review of the clinical effectiveness of the neuraminidase inhibitors against influenza B viruses.
Topics: Antiviral Agents; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2013 |
Antiviral drugs for influenza 2013-2014.
Topics: Animals; Antiviral Agents; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Zanamivir | 2014 |
Neuraminidase inhibitors for preventing and treating influenza in adults and children.
Topics: Adult; Antiviral Agents; Child; Drug Evaluation; Enzyme Inhibitors; Europe; Health Status; Humans; Influenza, Human; Japan; Legislation, Drug; Neuraminidase; Oseltamivir; Pneumonia; Publication Bias; Randomized Controlled Trials as Topic; United Kingdom; United States; Zanamivir | 2014 |
Managing seasonal influenza: oseltamivir treatment policy in indonesia?
Topics: Antiviral Agents; Drug Resistance, Viral; Health Policy; Humans; Indonesia; Influenza, Human; Oseltamivir; Risk Assessment; Vaccination | 2014 |
It doesn't have to be EviDense.
Topics: Adult; Anticoagulants; Antiviral Agents; Child; Evidence-Based Medicine; Humans; Influenza, Human; Integrative Medicine; International Normalized Ratio; Obesity; Oseltamivir; Pain Management; Warfarin | 2014 |
[Peculiarities and clinical significance of drug pharmacokinetics and pharmacodynamics during pregnancy].
Topics: Antiviral Agents; Biological Availability; Biotransformation; Blood Proteins; Carrier Proteins; Drug Administration Schedule; Drug Dosage Calculations; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Models, Statistical; Oseltamivir; Pregnancy; Protein Binding | 2014 |
Oseltamivir: the real world data.
Topics: Antiviral Agents; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Treatment Outcome | 2014 |
Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments.
Topics: Adult; Age Factors; Antiviral Agents; Child; Headache; Humans; Influenza, Human; Kidney Diseases; Nausea; Oseltamivir; Randomized Controlled Trials as Topic; Treatment Outcome; Vomiting | 2014 |
Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data.
Topics: Adolescent; Adult; Antiviral Agents; Child; Enzyme Inhibitors; Female; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Pandemics; Proportional Hazards Models; Treatment Outcome; Young Adult; Zanamivir | 2014 |
The epidemiology and spread of drug resistant human influenza viruses.
Topics: Adamantane; Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Mutation, Missense; Neuraminidase; Oseltamivir; Viral Proteins; Virulence | 2014 |
[Multisystem failure: the story of antinfluenza drugs].
Topics: Antiviral Agents; Clinical Trials as Topic; Evidence-Based Medicine; Global Health; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Italy; Neuraminidase; Oseltamivir; Pandemics; Publication Bias; Randomized Controlled Trials as Topic; Risk Factors; Zanamivir | 2014 |
Infection in severe asthma exacerbations and critical asthma syndrome.
Topics: Animals; Asthma; Azithromycin; Bacterial Infections; Ceftriaxone; Coinfection; Critical Illness; Disease Progression; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Seasons; Syndrome | 2015 |
The safety of oseltamivir in pregnancy: an updated review of post-marketing data.
Topics: Antiviral Agents; Databases, Factual; Embryonic Development; Female; Fetal Development; Humans; Influenza, Human; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Product Surveillance, Postmarketing | 2014 |
Antivirals--current trends in fighting influenza.
Topics: Amantadine; Antiviral Agents; Disease Outbreaks; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Influenza A virus; Influenza, Human; Neuraminidase; Oseltamivir; Rimantadine; Viral Matrix Proteins; Zanamivir | 2014 |
Influenza viruses resistant to neuraminidase inhibitors.
Topics: Adult; Aged; Antiviral Agents; Child; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2014 |
Oseltamivir for influenza in pregnancy.
Topics: Antiviral Agents; Female; Humans; Influenza, Human; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious | 2014 |
Developments in the treatment of severe influenza: lessons from the pandemic of 2009 and new prospects for therapy.
Topics: Animals; Antiviral Agents; Birds; Enzyme Inhibitors; Humans; Immunologic Factors; Influenza in Birds; Influenza, Human; Neuraminidase; Oseltamivir; Pandemics; Population Surveillance; Public Health; Randomized Controlled Trials as Topic; Zanamivir | 2014 |
Oseltamivir slightly decreases influenza symptom duration but not hospitalizations.
Topics: Adult; Antiviral Agents; Child; Child, Preschool; Hospitalization; Humans; Influenza, Human; Oseltamivir; Treatment Outcome | 2014 |
Antiviral drugs for seasonal influenza 2014-2015.
Topics: Administration, Inhalation; Administration, Oral; Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Seasons; Zanamivir | 2014 |
In brief: concerns about oseltamivir (Tamiflu).
Topics: Administration, Inhalation; Animals; Antiviral Agents; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Randomized Controlled Trials as Topic | 2015 |
Influenza treatment with oseltamivir outside of labeled recommendations.
Topics: Animals; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Off-Label Use; Oseltamivir; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials.
Topics: Adult; Aged; Antiviral Agents; Double-Blind Method; Humans; Influenza, Human; Middle Aged; Oseltamivir; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2015 |
Clinical experience with intravenous zanamivir under an Emergency IND program in the United States (2011-2014).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Female; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Investigational New Drug Application; Male; Middle Aged; Oseltamivir; Pregnancy; Retrospective Studies; United States; Young Adult; Zanamivir | 2015 |
Optimizing antiviral therapy for influenza: understanding the evidence.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; RNA-Dependent RNA Polymerase; Sialic Acids; Viral Matrix Proteins; Viral Proteins; Zanamivir | 2015 |
Roche perspectives on Tamiflu.
Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza A virus; Influenza, Human; Information Dissemination; Neuraminidase; Oseltamivir; Treatment Outcome | 2015 |
Antiviral medications for influenza.
Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Treatment Outcome; Zanamivir | 2015 |
Oseltamivir-warfarin interaction in hypoplastic left heart syndrome: case report and review.
Topics: Anticoagulants; Antiviral Agents; Child; Drug Interactions; Humans; Hypoplastic Left Heart Syndrome; Influenza, Human; International Normalized Ratio; Male; Oseltamivir; Thrombosis; Warfarin | 2015 |
Oseltamivir for the treatment of H1N1 influenza during pregnancy.
Topics: Animals; Antiviral Agents; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Risk Assessment; Risk Factors; Treatment Outcome | 2015 |
Effectiveness and safety of oseltamivir for treating influenza: an updated meta-analysis of clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Clinical Trials as Topic; Female; Humans; Infant; Influenza, Human; Male; Middle Aged; Oseltamivir; Treatment Outcome; Young Adult | 2015 |
Antiviral therapy in seasonal influenza and 2009 H1N1 pandemic influenza: Korean experiences and perspectives.
Topics: Acids, Carbocyclic; Amides; Antiviral Agents; Clinical Trials as Topic; Cyclopentanes; Drug Resistance, Viral; Guanidines; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pyrans; Pyrazines; Republic of Korea; Sialic Acids; Zanamivir | 2015 |
Influenza A virus infection is associated with systemic capillary leak syndrome: case report and systematic review of the literature.
Topics: Adult; Antiviral Agents; Capillary Leak Syndrome; Female; Humans; Influenza A virus; Influenza, Human; Oseltamivir | 2016 |
Treatment and prophylaxis of influenza and the problem of resistance to neuraminidase inhibitors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Enzyme Inhibitors; Female; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Young Adult; Zanamivir | 2015 |
Oseltamivir for influenza infection in children: risks and benefits.
Topics: Antiviral Agents; Child; Dose-Response Relationship, Drug; Drug Resistance, Viral; Humans; Influenza, Human; Oseltamivir; Treatment Outcome | 2016 |
Influenza and its treatment during pregnancy: A review.
Topics: Animals; Antiviral Agents; Female; Humans; Influenza Vaccines; Influenza, Human; Membrane Transport Proteins; Oseltamivir; Post-Exposure Prophylaxis; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Vaccination; Zanamivir | 2015 |
Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data.
Topics: Adult; Antiviral Agents; Asthma; Child; Dose-Response Relationship, Drug; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Randomized Controlled Trials as Topic; Zanamivir | 2016 |
Community acquired respiratory virus infections in cancer patients-Guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for haematology and Medical Oncology.
Topics: Adenovirus Infections, Human; Antiviral Agents; Cidofovir; Community-Acquired Infections; Cytosine; Germany; Hand Hygiene; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Influenza, Human; Lung; Masks; Medical Oncology; Metapneumovirus; Neoplasms; Neuraminidase; Nucleic Acid Amplification Techniques; Organophosphonates; Oseltamivir; Paramyxoviridae Infections; Patient Isolation; Pneumonia, Viral; Respiratory Syncytial Virus Infections; Respiratory Tract Infections; Ribavirin; Tomography, X-Ray Computed; Virus Diseases | 2016 |
The pharmacological management of severe influenza infection - 'existing and emerging therapies'.
Topics: Animals; Antiviral Agents; Disease Outbreaks; Drug Design; Drug Resistance, Viral; Drugs, Investigational; Global Health; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Severity of Illness Index | 2017 |
Antiviral therapy for respiratory viral infections in immunocompromised patients.
Topics: Acids, Carbocyclic; Amantadine; Antiviral Agents; Coronavirus Infections; Cyclopentanes; Guanidines; Humans; Immunocompromised Host; Influenza, Human; Oseltamivir; Palivizumab; Paramyxoviridae Infections; Picornaviridae Infections; Respiratory Syncytial Virus Infections; Respiratory Tract Infections; Ribavirin; Zanamivir | 2017 |
Safety and effectiveness of neuraminidase inhibitors in situations of pandemic and/or novel/variant influenza: a systematic review of the literature, 2009-15.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Clinical Trials as Topic; Disease Outbreaks; Enzyme Inhibitors; Female; Humans; Infant; Infant, Newborn; Influenza, Human; Male; Middle Aged; Neuraminidase; Observational Studies as Topic; Oseltamivir; Pandemics; Pneumonia; Young Adult; Zanamivir | 2017 |
Clinical Mimics: An Emergency Medicine-Focused Review of Influenza Mimics.
Topics: Acids, Carbocyclic; Aged; Aged, 80 and over; Antiviral Agents; Child, Preschool; Cyclopentanes; Emergency Medicine; Guanidines; Humans; Infant; Influenza, Human; Middle Aged; Oseltamivir; Risk Factors; United States; Zanamivir | 2017 |
[Influenza].
Topics: Adolescent; Adult; Age Factors; Aged; Amantadine; Anti-Bacterial Agents; Antiviral Agents; Child; Child, Preschool; Diagnosis, Differential; Female; Follow-Up Studies; France; Humans; Infant; Influenza Vaccines; Influenza, Human; Male; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Risk Factors; Seasons; Time Factors; Treatment Outcome; Zanamivir | 2008 |
[Significance of the neuraminidase inhibitor oseltamivir for the management of seasonal influenza].
Topics: Age Factors; Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Risk Factors; Seasons; Time Factors; Treatment Outcome; Virus Shedding | 2008 |
[Antiviral treatment of influenza in humans].
Topics: Amantadine; Animals; Antiviral Agents; Clinical Trials as Topic; Disease Outbreaks; Drug Resistance, Viral; Humans; Influenza A virus; Influenza, Human; Neuraminidase; Oseltamivir; Rimantadine; Virus Replication; Virus Shedding; Zanamivir | 2007 |
Nosocomial influenza: new concepts and practice.
Topics: Antiviral Agents; Cross Infection; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Molecular Diagnostic Techniques; Oseltamivir | 2008 |
Antiviral drugs for the control of pandemic influenza virus.
Topics: Amantadine; Animals; Antiviral Agents; Birds; Disease Outbreaks; Global Health; Humans; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Oseltamivir; RNA, Small Interfering | 2008 |
Modifying clinical practices to manage influenza in children effectively.
Topics: Adolescent; Animals; Antiviral Agents; Chemoprevention; Child; Child, Preschool; Hospitalization; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H2N2 Subtype; Influenza A Virus, H5N1 Subtype; Influenza B virus; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2008 |
[Neuraminidase inhibitors in prophylaxis and treatment of influenza].
Topics: Antiviral Agents; Disease Outbreaks; Drug Administration Schedule; Enzyme Inhibitors; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2008 |
Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review.
Topics: Accidents; Age Factors; Antiviral Agents; Behavioral Symptoms; Clinical Trials as Topic; Delirium; Dose-Response Relationship, Drug; Drug Interactions; Humans; Influenza, Human; Oseltamivir; Product Surveillance, Postmarketing; Suicide; Wounds and Injuries | 2008 |
Different synthetic strategies of oseltamivir phosphate: a potent influenza neuraminidase inhibitor.
Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Molecular Conformation; Neuraminidase; Oseltamivir; Stereoisomerism; Structure-Activity Relationship | 2008 |
More resistance to oseltamivir (Tamiflu).
Topics: Age Factors; Anti-HIV Agents; Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Time Factors | 2009 |
Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation.
Topics: Amantadine; Antiviral Agents; Cost-Benefit Analysis; Humans; Influenza, Human; Models, Economic; Oseltamivir; Practice Guidelines as Topic; Premedication; Randomized Controlled Trials as Topic; Seasons; Treatment Outcome; Zanamivir | 2009 |
[Encephalitis and encephalopathy associated with pandemic flu].
Topics: Animals; Antiviral Agents; Birds; Disease Outbreaks; Encephalitis, Viral; Humans; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Oseltamivir; Zoonoses | 2009 |
Oseltamivir for treatment and prophylaxis of influenza infection.
Topics: Animals; Antiviral Agents; Humans; Influenza, Human; Orthomyxoviridae Infections; Oseltamivir | 2009 |
Influenza.
Topics: Acute Disease; Administration, Inhalation; Humans; Incidence; Influenza Vaccines; Influenza, Human; Oseltamivir; Rimantadine; Zanamivir | 2009 |
Cost effectiveness of oseltamivir treatment of influenza: a critique of published methods and outcomes.
Topics: Antiviral Agents; Cost-Benefit Analysis; Humans; Influenza, Human; Oseltamivir; Outcome Assessment, Health Care | 2008 |
Antivirals for the treatment and prevention of epidemic and pandemic influenza.
Topics: Amantadine; Antiviral Agents; Chemoprevention; Disease Outbreaks; Drug Resistance, Viral; Humans; Influenza, Human; Oseltamivir; Rimantadine; Zanamivir | 2007 |
Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women.
Topics: Breast Feeding; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Lactation; Neuraminidase; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Treatment Outcome; Viral Vaccines; Zanamivir | 2009 |
Synthetic approaches to the neuraminidase inhibitors zanamivir (Relenza) and oseltamivir phosphate (Tamiflu) for the treatment of influenza.
Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2009 |
Influenza genome analysis using pyrosequencing method: current applications for a moving target.
Topics: Antiviral Agents; Diphosphates; Drug Resistance, Viral; Expressed Sequence Tags; Genome, Viral; Genotype; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza, Human; Molecular Diagnostic Techniques; Orthomyxoviridae; Oseltamivir; Sequence Analysis, DNA | 2009 |
Human swine influenza A [H1N1]: practical advice for clinicians early in the pandemic.
Topics: Antiviral Agents; Caregivers; Child; Disease Outbreaks; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Internet; Oseltamivir; Public Health; Viral Vaccines | 2009 |
Systematic review: safety and efficacy of extended-duration antiviral chemoprophylaxis against pandemic and seasonal influenza.
Topics: Antiviral Agents; Disease Outbreaks; Drug Administration Schedule; Humans; Influenza A virus; Influenza, Human; Nausea; Neuraminidase; Oseltamivir; Risk Factors; Vomiting; Zanamivir | 2009 |
Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis.
Topics: Adult; Antiviral Agents; Humans; Influenza, Human; Oseltamivir; Treatment Outcome; United Kingdom; Zanamivir | 2009 |
Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomised controlled trials.
Topics: Anti-Bacterial Agents; Antiviral Agents; Asthma; Bias; Child; Child, Preschool; Enzyme Inhibitors; Humans; Infant; Influenza, Human; Neuraminidase; Oseltamivir; Otitis Media; Randomized Controlled Trials as Topic; Risk Factors; Zanamivir | 2009 |
Update on 2009 pandemic influenza A (H1N1) virus.
Topics: Aged; Antiviral Agents; Cross Infection; Disease Outbreaks; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Oseltamivir | 2009 |
[Pandemic influenza A H1N1 2009 flu during pregnancy: Epidemiology, diagnosis and management].
Topics: Antiviral Agents; Disease Outbreaks; Female; France; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Nasopharynx; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Zanamivir | 2009 |
The use of antiviral agents for the management of severe influenza.
Topics: Age Factors; Antiviral Agents; Drug Therapy, Combination; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Interferons; Length of Stay; Neuraminidase; Oseltamivir; Practice Guidelines as Topic; Ribavirin; Risk Factors; Viral Load; Zanamivir | 2010 |
Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis.
Topics: Adult; Antiviral Agents; Decision Making; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Public Health; Randomized Controlled Trials as Topic | 2009 |
What can we learn from observational studies of oseltamivir to treat influenza in healthy adults?
Topics: Adult; Data Interpretation, Statistical; Drug Industry; Epidemiologic Methods; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; Review Literature as Topic | 2009 |
Antiviral treatment and prophylaxis of influenza virus in children.
Topics: Amantadine; Antiviral Agents; Chemoprevention; Child; Child, Preschool; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Post-Exposure Prophylaxis; Zanamivir | 2009 |
Use of oseltamivir in children.
Topics: Antiviral Agents; Canada; Child; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Practice Guidelines as Topic | 2009 |
Novel swine-origin (S-OIV) H1N1 influenza A pneumonia in a lung transplant patient: a case report and review of the literature on performance characteristics of rapid screening tests for the S-OIV.
Topics: Adult; Antiviral Agents; Bronchoalveolar Lavage Fluid; Female; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Lung Transplantation; Opportunistic Infections; Oseltamivir; Pneumonia, Viral; Virology | 2009 |
Antiviral strategies: the present and beyond.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Influenza, Human; Interferon-alpha; Oseltamivir; Ribavirin; Structure-Activity Relationship | 2009 |
[Research progress of neuraminidase inhibitors for anti-influenza].
Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2009 |
Is oseltamivir (Tamiflu) safe? Re-examining the Tamiflu 'ado' from Japan.
Topics: Adolescent; Animals; Antiviral Agents; Death, Sudden; Disease Outbreaks; Humans; Influenza, Human; Japan; Oseltamivir | 2010 |
Neuraminidase inhibitors for preventing and treating influenza in healthy adults.
Topics: Adult; Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Post-Exposure Prophylaxis; Randomized Controlled Trials as Topic; Zanamivir | 2010 |
Treatment options for 2009 H1N1 influenza: evaluation of the published evidence.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antiviral Agents; Child; Child, Preschool; Female; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Time Factors; Young Adult | 2010 |
Oseltamivir in seasonal influenza: cumulative experience in low- and high-risk patients.
Topics: Amino Acid Substitution; Antiviral Agents; Chemoprevention; Clinical Trials as Topic; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Mutation, Missense; Oseltamivir; Seasons; Treatment Outcome | 2010 |
Oseltamivir in human avian influenza infection.
Topics: Administration, Oral; Animals; Antiviral Agents; Chemoprevention; Disease Outbreaks; Humans; Influenza A virus; Influenza in Birds; Influenza, Human; Oseltamivir; Poultry; Treatment Outcome; Zoonoses | 2010 |
Responding to pandemic (H1N1) 2009 influenza: the role of oseltamivir.
Topics: Antiviral Agents; Chemoprevention; Developing Countries; Disease Outbreaks; Drug Resistance, Viral; Guidelines as Topic; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; World Health Organization | 2010 |
Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations.
Topics: Administration, Oral; Antiviral Agents; Biological Availability; Drug Interactions; Humans; Influenza, Human; Oseltamivir; Prodrugs | 2010 |
[Role of neuraminidase inhibitors for the treatment of influenza A virus infections].
Topics: Adult; Antiviral Agents; Child; Clinical Trials as Topic; Disease Outbreaks; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; Humans; Immunocompromised Host; Influenza A virus; Influenza, Human; Male; Models, Molecular; Molecular Structure; Mutation, Missense; Neuraminidase; Oseltamivir; Point Mutation; Pregnancy; Pregnancy Complications, Infectious; Protein Conformation; Viral Proteins; Zanamivir | 2010 |
Targeting pandemic influenza: a primer on influenza antivirals and drug resistance.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Disease Outbreaks; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Models, Biological; Oseltamivir; Recombinant Fusion Proteins; Zanamivir | 2010 |
[Influenza A, pregnancy and neuraminidase inhibitors].
Topics: Animals; Antiviral Agents; Australia; Centers for Disease Control and Prevention, U.S.; Drug Evaluation, Preclinical; Drug Utilization; Europe; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; New Zealand; Oseltamivir; Pandemics; Practice Guidelines as Topic; Pregnancy; Pregnancy Outcome; Risk Assessment; United States; Viral Proteins; World Health Organization; Zanamivir | 2011 |
Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection.
Topics: Antigens, Viral; Antiviral Agents; Disease Outbreaks; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Lung; Oseltamivir; Risk Factors; RNA, Viral; Severity of Illness Index | 2010 |
A sigh of relief about treating influenza in individuals with alcohol-use disorders?
Topics: Alcohol-Related Disorders; Animals; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir | 2010 |
Peramivir and its use in H1N1 influenza.
Topics: Acids, Carbocyclic; Antiviral Agents; Clinical Trials as Topic; Cyclopentanes; Emergencies; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza, Human; Oseltamivir; United States; United States Food and Drug Administration | 2010 |
Safety of oseltamivir in pregnancy: a review of preclinical and clinical data.
Topics: Animals; Antiviral Agents; Drug Evaluation, Preclinical; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Prenatal Exposure Delayed Effects | 2010 |
Influenza in the tropics.
Topics: Animals; Antiviral Agents; Disease Outbreaks; Drug Resistance, Viral; Genetic Variation; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N1 Subtype; Influenza B virus; Influenza, Human; Oseltamivir; Prevalence; Tropical Climate; Zanamivir | 2010 |
Swine flu.
Topics: Antiviral Agents; Contact Tracing; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; Travel; Zanamivir | 2009 |
Oseltamivir: a first line defense against swine flu.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Humans; Influenza Vaccines; Influenza, Human; Oseltamivir | 2010 |
[Change of strategies for novel and seasonal flu during pregnancy].
Topics: Antiviral Agents; Disease Outbreaks; Female; Humans; Influenza Vaccines; Influenza, Human; Oseltamivir; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Infectious; Zanamivir | 2010 |
[Clinical features of, treatments and preventions for newborns with pandemic influenza A (H1N1) 2009].
Topics: Antiviral Agents; Disease Outbreaks; Humans; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pneumonia, Pneumococcal; Respiration, Artificial; Severity of Illness Index; Time Factors | 2010 |
[Drug-resistant influenza viruses: an overview].
Topics: Amantadine; Animals; Antiviral Agents; Disease Outbreaks; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation; Neuraminidase; Oseltamivir | 2010 |
[Present and future in development of new anti-influenza drugs].
Topics: Amantadine; Antiviral Agents; DNA-Directed RNA Polymerases; Drug Design; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2010 |
[Current anti-influenza virus chemotherapy].
Topics: Acids, Carbocyclic; Amantadine; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Drug Utilization; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Infusions, Intravenous; Japan; Oseltamivir; Pandemics; Zanamivir | 2010 |
[Influenza A/H1N1v 2009 during pregnancy and breastfeeding: which antiviral to choose?].
Topics: Adult; Antiviral Agents; Breast Feeding; Female; Fetus; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; Pregnancy; Zanamivir | 2010 |
Treatment options for H5N1: lessons learned from the H1N1 pandemic.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Disease Outbreaks; Drug Resistance, Viral; Guanidines; Humans; Immunocompromised Host; Influenza A Virus, H5N1 Subtype; Influenza, Human; Oseltamivir; Pneumonia, Viral; Pyrans; Severity of Illness Index; Sialic Acids; Zanamivir | 2010 |
Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.
Topics: Antiviral Agents; Area Under Curve; Disease Outbreaks; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; Pandemics; Prodrugs; United States | 2010 |
Oseltamivir, zanamivir and amantadine in the prevention of influenza: a systematic review.
Topics: Amantadine; Antiviral Agents; Disease Outbreaks; Humans; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; Post-Exposure Prophylaxis; Treatment Outcome; Viral Matrix Proteins; Zanamivir | 2011 |
Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza.
Topics: Animals; Antiviral Agents; Disease Models, Animal; Drug Administration Routes; Drug Administration Schedule; Guanidines; Humans; Influenza, Human; Mice; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pandemics; Prodrugs; Pyrans; Rats; Sialic Acids; Zanamivir | 2010 |
Pharmacologic considerations for oseltamivir disposition: focus on the neonate and young infant.
Topics: Adult; Age Factors; Animals; Antiviral Agents; Biological Availability; Dose-Response Relationship, Drug; Female; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pregnancy; Prodrugs | 2011 |
Oseltamivir-resistant pandemic H1N1 influenza.
Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir | 2011 |
[Research progress of anti-influenza virus agents].
Topics: Acids, Carbocyclic; Amantadine; Antiviral Agents; Cyclopentanes; Guanidines; Humans; Indoles; Influenza, Human; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pyrrolidines; Rimantadine; Structure-Activity Relationship; Viral Matrix Proteins; Zanamivir | 2010 |
Early versus late oseltamivir treatment in severely ill patients with 2009 pandemic influenza A (H1N1): speed is life.
Topics: Antiviral Agents; Critical Illness; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Survival Analysis; Time Factors; Treatment Outcome | 2011 |
Preventing and treating secondary bacterial infections with antiviral agents.
Topics: Animals; Antiviral Agents; Bacterial Infections; Child, Preschool; Disease Models, Animal; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mice; Oseltamivir; Pneumonia, Bacterial; Randomized Controlled Trials as Topic; Treatment Outcome | 2011 |
Study of specific oligosaccharide structures related with swine flu (H1N1) and avian flu, and tamiflu as their remedy.
Topics: Animals; Birds; Humans; Influenza A Virus, H1N1 Subtype; Influenza in Birds; Influenza, Human; Oligosaccharides; Orthomyxoviridae Infections; Oseltamivir | 2011 |
[How safe was oseltamivir care in the flu pandemic?].
Topics: Antiviral Agents; Drug Industry; Enzyme Inhibitors; Humans; Indicators and Reagents; Influenza, Human; Neuraminidase; Oseltamivir; Pandemics | 2011 |
Pandemic influenza vaccines and neuraminidase inhibitors: efficacy and side effects.
Topics: Adjuvants, Immunologic; Antiviral Agents; Communicable Disease Control; Excipients; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; Pandemics; Treatment Outcome | 2011 |
Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Humans; Influenza, Human; Male; Middle Aged; Oseltamivir; Pneumonia, Bacterial; Randomized Controlled Trials as Topic; Risk Assessment; Young Adult | 2011 |
Emerging oseltamivir resistance in seasonal and pandemic influenza A/H1N1.
Topics: Antiviral Agents; Drug Resistance, Viral; Genetic Fitness; Genotype; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Pandemics; Phenotype; Seasons | 2011 |
Influenza vaccination, diagnosis, and treatment in children.
Topics: Antiviral Agents; Child; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; Real-Time Polymerase Chain Reaction; Vaccination; Zanamivir | 2011 |
Antiviral drugs for viruses other than human immunodeficiency virus.
Topics: Acyclovir; Adenine; Amantadine; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Foscarnet; Ganciclovir; Guanine; Hepatitis; Hepatitis B, Chronic; Hepatitis C; Herpesviridae Infections; HIV Infections; Humans; Influenza, Human; Interferons; Lamivudine; Nucleosides; Oligopeptides; Organophosphonates; Oseltamivir; Proline; Protease Inhibitors; Pyrimidinones; Ribavirin; Telbivudine; Thymidine; Valacyclovir; Valganciclovir; Valine; Virus Replication; Zanamivir | 2011 |
Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
Topics: Administration, Inhalation; Adult; Animals; Antiviral Agents; Birds; Caprylates; Child; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N1 Subtype; Influenza B virus; Influenza in Birds; Influenza, Human; Japan; Neuraminidase; Oseltamivir; Prodrugs; Pyrans; Sialic Acids; Viral Proteins; Virus Replication; Zanamivir | 2011 |
[Pathogenesis of and therapeutic targets for severe respiratory failure mediated by emerging respiratory virus infection].
Topics: Animals; Antiviral Agents; Communicable Diseases, Emerging; Disease Models, Animal; Drug Design; Humans; Influenza A virus; Influenza, Human; Mice; Molecular Targeted Therapy; Oseltamivir; Respiration, Artificial; Respiratory Distress Syndrome; RNA Interference; Severity of Illness Index | 2011 |
Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience.
Topics: Adult; Aged; Antiviral Agents; Child; Drug Monitoring; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza B virus; Influenza, Human; Oseltamivir; Pandemics; Pharmacovigilance; Practice Guidelines as Topic; Product Surveillance, Postmarketing; Vaccination; World Health Organization | 2011 |
Chinese herbal medicines for the treatment of type A H1N1 influenza: a systematic review of randomized controlled trials.
Topics: China; Drugs, Chinese Herbal; Herbal Medicine; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Phytotherapy; Randomized Controlled Trials as Topic; Research Design; Risk; Treatment Outcome; Virus Shedding | 2011 |
Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives.
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pandemics; Public Health; Time Factors | 2012 |
Antiviral drugs for influenza.
Topics: Adult; Amantadine; Antiviral Agents; Child; Female; Humans; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; Pregnancy; Rimantadine; Zanamivir | 2012 |
Neuraminidase inhibitors for preventing and treating influenza in children.
Topics: Acetamides; Antiviral Agents; Child; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Randomized Controlled Trials as Topic; Sialic Acids; Zanamivir | 2012 |
Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children.
Topics: Adult; Antiviral Agents; Child; Drug Evaluation; Enzyme Inhibitors; Europe; Health Status; Humans; Influenza, Human; Japan; Legislation, Drug; Neuraminidase; Oseltamivir; Publication Bias; Randomized Controlled Trials as Topic; United Kingdom; United States; Zanamivir | 2012 |
Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies.
Topics: Administration, Inhalation; Administration, Oral; Amantadine; Antiviral Agents; Confounding Factors, Epidemiologic; Hospitalization; Humans; Influenza, Human; Oseltamivir; Rimantadine; Treatment Outcome; Zanamivir | 2012 |
Neuraminidase inhibitors for preventing and treating influenza in children (published trials only).
Topics: Antiviral Agents; Child; Child, Preschool; Enzyme Inhibitors; Guanidines; Humans; Infant; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Randomized Controlled Trials as Topic; Sialic Acids; Zanamivir | 2012 |
Recent advances in neuraminidase inhibitor development as anti-influenza drugs.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Benzoic Acid; Cyclopentanes; Drug Design; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza, Human; Models, Molecular; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Zanamivir | 2012 |
Pandemism of swine flu and its prospective drug therapy.
Topics: Antiviral Agents; Biotechnology; Chemoprevention; Fermentation; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pandemics; Shikimic Acid; Technology, Pharmaceutical | 2012 |
Influenza outbreaks in Singapore: epidemiology, diagnosis, treatment and prevention.
Topics: Antiviral Agents; Disease Outbreaks; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; Singapore | 2012 |
Effectiveness of oseltamivir in adults: a meta-analysis of published and unpublished clinical trials.
Topics: Adult; Antiviral Agents; Hospitalization; Humans; Influenza, Human; Intention to Treat Analysis; Models, Statistical; Oseltamivir; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2013 |
Influenza A (H1N1): a rare cause of deafness in two children.
Topics: Antiviral Agents; Bronchopneumonia; Child; Female; Hearing Loss, Sudden; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir | 2012 |
Post-marketing assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: an updated review.
Topics: Adult; Antiviral Agents; Child; Humans; Influenza, Human; Mental Disorders; Oseltamivir | 2012 |
Dissecting influenza virus pathogenesis uncovers a novel chemical approach to combat the infection.
Topics: Animals; Cytokines; Drug Synergism; Drug Therapy, Combination; Endothelial Cells; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Lung; Mice; Mycotoxins; Orthomyxoviridae Infections; Oseltamivir; Receptors, Lysosphingolipid; Survival Rate | 2013 |
Antiviral drugs for influenza 2012-2013.
Topics: Animals; Antiviral Agents; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2012 |
Management of influenza in pregnancy.
Topics: Antiviral Agents; Female; Humans; Influenza Vaccines; Influenza, Human; Oseltamivir; Patient Isolation; Pregnancy; Pregnancy Complications, Infectious; Zanamivir | 2013 |
Consequences of resistance: in vitro fitness, in vivo infectivity, and transmissibility of oseltamivir-resistant influenza A viruses.
Topics: Animals; Disease Models, Animal; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Pandemics; Seasons | 2013 |
[Prophylaxis against respiratory viral disease in pediatric and adult patients undergoing solid organ and hematopoietic stem cells transplantation].
Topics: Adenoviridae Infections; Adult; Antiviral Agents; Child; Drug Administration Schedule; Humans; Incidence; Influenza, Human; Organ Transplantation; Oseltamivir; Paramyxoviridae Infections; Postoperative Complications; Practice Guidelines as Topic; Respiratory Syncytial Virus Infections; Risk Factors; Stem Cell Transplantation | 2012 |
European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS, and ELN.
Topics: Acetamides; Antiviral Agents; Hematopoietic Stem Cell Transplantation; Humans; Influenza, Human; Leukemia; Oseltamivir; Practice Guidelines as Topic; Zanamivir | 2013 |
Antiviral therapy for influenza virus infections.
Topics: Acetamides; Age Factors; Amantadine; Antiviral Agents; Child; Clinical Trials as Topic; Global Health; Guanidines; Humans; Influenza, Human; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Zanamivir | 2002 |
Antiviral therapy of influenza.
Topics: Acetamides; Administration, Inhalation; Administration, Oral; Adult; Amantadine; Antiviral Agents; Child; Drug Resistance, Viral; Guanidines; Humans; Infant; Influenza, Human; Orthomyxoviridae; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Zanamivir | 2002 |
The management of influenza in people of working age.
Topics: Acetamides; Adolescent; Adult; Amantadine; Antiviral Agents; Cost-Benefit Analysis; Guanidines; Humans; Influenza, Human; Middle Aged; Occupational Health; Oseltamivir; Pyrans; Sialic Acids; United Kingdom; Workplace; Zanamivir | 2002 |
[A revolutionary change in the diagnosis and treatment of influenza].
Topics: Acetamides; Antiviral Agents; Encephalitis, Viral; Enzyme Inhibitors; Guanidines; Herpesvirus 6, Human; Herpesvirus 7, Human; Humans; Immunologic Tests; Influenza Vaccines; Influenza, Human; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pyrans; Sialic Acids; Vaccines, Attenuated; Zanamivir | 2002 |
Influenza.
Topics: Acetamides; Administration, Inhalation; Administration, Oral; Adult; Amantadine; Antiviral Agents; Child; Guanidines; Humans; Influenza, Human; Oseltamivir; Pyrans; Randomized Controlled Trials as Topic; Rimantadine; Sialic Acids; Treatment Outcome; Zanamivir | 2002 |
Antivirals for influenza: what is their role in the older patient?
Topics: Acetamides; Aged; Amantadine; Antiviral Agents; Drug Resistance, Viral; Guanidines; Humans; Influenza, Human; Oseltamivir; Practice Guidelines as Topic; Pyrans; Rimantadine; Sialic Acids; Zanamivir | 2002 |
Early therapy with the neuraminidase inhibitor oseltamivir maximizes its efficacy in influenza treatment.
Topics: Acetamides; Adult; Antiviral Agents; Child; Drug Resistance; Drug Tolerance; Enzyme Inhibitors; Humans; Infant; Influenza, Human; Models, Biological; Neuraminidase; Oseltamivir; Time Factors; Treatment Outcome | 2002 |
Neuraminidase inhibitors in pediatric patients: potential place in influenza therapy.
Topics: Acetamides; Child; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Otitis Media; Pyrans; Randomized Controlled Trials as Topic; Sialic Acids; Zanamivir | 2003 |
Influenza diagnosis and treatment in children: a review of studies on clinically useful tests and antiviral treatment for influenza.
Topics: Acetamides; Adolescent; Age Distribution; Amantadine; Antiviral Agents; Centers for Disease Control and Prevention, U.S.; Child; Child, Preschool; DNA, Viral; Female; Fluorescent Antibody Technique, Direct; Follow-Up Studies; Guanidines; Humans; Incidence; Infant; Influenza, Human; Male; Orthomyxoviridae; Oseltamivir; Pyrans; Risk Assessment; Severity of Illness Index; Sex Distribution; Sialic Acids; Treatment Outcome; United States; Zanamivir | 2003 |
Oseltamivir for influenza.
Topics: Acetamides; Adult; Antiviral Agents; Child; Drug Costs; Drug Resistance, Viral; Humans; Influenza, Human; Licensure, Pharmacy; Oseltamivir; Randomized Controlled Trials as Topic | 2002 |
Treatment and prevention of influenza: Swedish recommendations.
Topics: Acetamides; Adult; Age Distribution; Aged; Aged, 80 and over; Antiviral Agents; Female; Health Planning Guidelines; Humans; Immunization Schedule; Incidence; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Oseltamivir; Primary Prevention; Risk Assessment; Sex Distribution; Survival Rate; Sweden | 2003 |
Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors.
Topics: Acetamides; Amantadine; Antiviral Agents; Clinical Trials as Topic; Disease Outbreaks; Endemic Diseases; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Viral Matrix Proteins; Zanamivir | 2003 |
[Influenza].
Topics: Acetamides; Amantadine; Antiviral Agents; Diagnosis, Differential; Enzyme Inhibitors; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Reagent Kits, Diagnostic; Sialic Acids; Vaccines, Attenuated; Zanamivir | 2003 |
[Antiviral agents for influenza].
Topics: Acetamides; Age Factors; Amantadine; Antiviral Agents; Drug Resistance, Viral; Guanidines; Humans; Influenza A virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Viral Matrix Proteins; Zanamivir | 2003 |
Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials.
Topics: Acetamides; Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Enzyme Inhibitors; Guanidines; Humans; Infant; Infant, Newborn; Influenza A virus; Influenza B virus; Influenza, Human; Middle Aged; Neuraminidase; Oseltamivir; Pyrans; Randomized Controlled Trials as Topic; Sialic Acids; Zanamivir | 2003 |
Review of the use of neuraminidase inhibitors for prophylaxis of influenza.
Topics: Acetamides; Amantadine; Antiviral Agents; Enzyme Inhibitors; Guanidines; Health Planning; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Practice Guidelines as Topic; Pyrans; Rimantadine; Sialic Acids; Zanamivir | 2003 |
Safety and pharmacology of oseltamivir in clinical use.
Topics: Acetamides; Adult; Antiviral Agents; Child; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Interactions; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Product Surveillance, Postmarketing; Treatment Outcome | 2003 |
Neuraminidase inhibitors for preventing and treating influenza in children.
Topics: Acetamides; Antiviral Agents; Child; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Randomized Controlled Trials as Topic; Sialic Acids; Zanamivir | 2003 |
Influenza therapy.
Topics: Acetamides; Adult; Age Factors; Amantadine; Antiviral Agents; Child; Cost-Benefit Analysis; Creatine; Disease Outbreaks; Drug Resistance, Viral; Guanidines; Humans; Influenza A virus; Influenza, Human; Kidney Failure, Chronic; Metabolic Clearance Rate; Oseltamivir; Patient Selection; Primary Prevention; Pyrans; Sialic Acids; Treatment Outcome; Zanamivir | 2003 |
Otitis media. A scholarly review of the evidence.
Topics: Acetamides; Acute Disease; Age Factors; Amoxicillin; Anti-Bacterial Agents; Antiviral Agents; Child; Child, Preschool; Humans; Infant; Influenza Vaccines; Influenza, Human; Meta-Analysis as Topic; Oseltamivir; Otitis Media; Otitis Media with Effusion; Placebos; Pneumococcal Infections; Pneumococcal Vaccines; Randomized Controlled Trials as Topic; Recurrence; Streptococcus pneumoniae; Time Factors | 2003 |
[Influenza virus infection in children].
Topics: Acetamides; Age Factors; Child; Child, Preschool; Enzyme Inhibitors; Guanidines; Humans; Infant; Influenza Vaccines; Influenza, Human; Japan; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2003 |
[Criteria for the use of anti-influenza agents].
Topics: Acetamides; Amantadine; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza, Human; Neuraminidase; Oseltamivir; Practice Guidelines as Topic; Prodrugs; Pyrans; Sialic Acids; Time Factors; Virus Latency; Zanamivir | 2003 |
[Neuraminidase inhibitor, anti-influenzal agent--mechanism of action, and how to use clinically].
Topics: Acetamides; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Time Factors; Zanamivir | 2003 |
Neuraminidase inhibitors in patients with underlying airways disease.
Topics: Acetamides; Amantadine; Antiviral Agents; Asthma; Bronchial Spasm; Comorbidity; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Product Surveillance, Postmarketing; Pulmonary Disease, Chronic Obstructive; Pyrans; Rimantadine; Risk Factors; Sialic Acids; Zanamivir | 2002 |
[Neuraminidase inhibitors oseltamivir and zanamivir: new means of defence against influenza].
Topics: Acetamides; Antiviral Agents; Cost-Benefit Analysis; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Risk Factors; Seasons; Sialic Acids; Zanamivir | 2004 |
Neuraminidase inhibitors for treatment of influenza.
Topics: Acetamides; Antiviral Agents; Child; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2004 |
What is the best antiviral agent for influenza infection?
Topics: Acetamides; Administration, Oral; Adult; Amantadine; Antiviral Agents; Child; Contraindications; Evidence-Based Medicine; Family Practice; Guanidines; Humans; Influenza A virus; Influenza, Human; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Zanamivir | 2004 |
Influenza.
Topics: Acetamides; Adult; Amantadine; Antiviral Agents; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Zanamivir | 2003 |
[Super pathogenic avian influenza].
Topics: Acetamides; Amantadine; Animals; Antiviral Agents; Chickens; Disease Outbreaks; Guanidines; Humans; Influenza A virus; Influenza in Birds; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; Poultry Diseases; Pyrans; Sialic Acids; Zanamivir; Zoonoses | 2004 |
[Zanamivir, oseltamivir].
Topics: Acetamides; Antiviral Agents; Biological Availability; Clinical Trials as Topic; Drug Monitoring; Enzyme Inhibitors; Guanidines; Half-Life; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2004 |
[Practice guideline 'Influenza prevention in nursing homes and care homes', issued by the Dutch Society of Nursing Home Specialists; division of tasks between nursing home specialist, general practitioner and company doctor].
Topics: Acetamides; Aged; Aged, 80 and over; Antiviral Agents; Disease Outbreaks; Female; Health Planning Guidelines; Homes for the Aged; Humans; Immunization Schedule; Influenza Vaccines; Influenza, Human; Male; Netherlands; Nursing Homes; Oseltamivir; Practice Guidelines as Topic; Practice Patterns, Physicians'; Primary Prevention; Societies, Medical | 2005 |
Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic.
Topics: Acetamides; Antiviral Agents; Chemistry, Pharmaceutical; Disease Outbreaks; Humans; Influenza, Human; Orthomyxoviridae; Oseltamivir; Risk Assessment | 2005 |
Management of influenza virus infections with neuraminidase inhibitors: detection, incidence, and implications of drug resistance.
Topics: Acetamides; Animals; Drug Resistance; Enzyme Inhibitors; Guanidines; Hemagglutinins; Humans; Influenza Vaccines; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Product Surveillance, Postmarketing; Pyrans; Sialic Acids; Zanamivir | 2005 |
Influenza.
Topics: Acetamides; Adult; Amantadine; Antiviral Agents; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Zanamivir | 2004 |
Neuraminidase inhibitors for influenza.
Topics: Acetamides; Adamantane; Adult; Aged; Antiviral Agents; Child; Disease Outbreaks; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2005 |
Oseltamivir in the management of influenza.
Topics: Acetamides; Adolescent; Adult; Antiviral Agents; Clinical Trials as Topic; Disease Outbreaks; Drug Administration Schedule; Drug Resistance, Viral; Drug Utilization; Enzyme Inhibitors; Humans; Infant; Influenza A Virus, H5N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; World Health Organization | 2005 |
Infectious disease: can we avert a lethal flu pandemic?
Topics: Acetamides; Animals; Antiviral Agents; Bird Diseases; Birds; Chemoprevention; Computer Simulation; Disease Outbreaks; Humans; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Models, Theoretical; Oseltamivir; Zoonoses | 2005 |
[Anti-virals for influenza virus infection].
Topics: Acetamides; Amantadine; Animals; Antiviral Agents; Drug Utilization; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Japan; National Health Programs; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2005 |
Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses.
Topics: Acetamides; Computer Communication Networks; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Viral Matrix Proteins; Zanamivir | 2005 |
[The issue in Japanese pandemic preparedness plan stockpiling of oseltamivir to treat 25% of Japanese population].
Topics: Acetamides; Antiviral Agents; Disease Outbreaks; Humans; Influenza, Human; Japan; Oseltamivir | 2006 |
Optimization of small molecule drugs binding to highly polar target sites: lessons from the discovery and development of neuraminidase inhibitors.
Topics: Acetamides; Animals; Binding Sites; Crystallography, X-Ray; Drug Design; Enzyme Inhibitors; Humans; Influenza, Human; Models, Molecular; Molecular Conformation; Molecular Weight; Neuraminidase; Oseltamivir; Structure-Activity Relationship | 2006 |
[Role of influenza virus sialidase].
Topics: Acetamides; Antiviral Agents; Apoptosis; Caspase 3; Caspases; Disease Outbreaks; Guanidines; Humans; Hydrogen-Ion Concentration; Influenza, Human; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pyrans; Sialic Acids; Viral Envelope Proteins; Zanamivir | 2006 |
Neuraminidase inhibitors for preventing and treating influenza in healthy adults.
Topics: Acetamides; Amines; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2006 |
Safety of neuraminidase inhibitors for influenza.
Topics: Acetamides; Adult; Aged; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Infant; Influenza, Human; Nausea; Neuraminidase; Oseltamivir; Pyrans; Safety; Sialic Acids; Zanamivir | 2006 |
[Diagnosis and Treatment of influenza--clinical investigation on viral shedding in children with influenza].
Topics: Amantadine; Antiviral Agents; Child; Drug Resistance, Viral; Humans; Influenza A virus; Influenza, Human; Oseltamivir; Point-of-Care Systems; Reagent Kits, Diagnostic; Time Factors; Viral Load; Virology; Virus Shedding | 2006 |
Antiviral drugs prophylaxis and treatment of influenza.
Topics: Acetamides; Animals; Antiviral Agents; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2006 |
Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials.
Topics: Antiviral Agents; Disease Transmission, Infectious; Family Characteristics; Humans; Influenza, Human; Multicenter Studies as Topic; Oseltamivir; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome; Zanamivir | 2007 |
Antivirals in the management of an influenza pandemic.
Topics: Amantadine; Antiviral Agents; Australia; Community-Acquired Infections; Disease Outbreaks; Drug Resistance, Viral; Government Programs; Humans; Infection Control; Influenza A Virus, H5N1 Subtype; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; World Health Organization; Zanamivir | 2006 |
Which agents should we use to treat and prevent influenza in 2006-2007?
Topics: Amantadine; Antiviral Agents; Drug Resistance, Viral; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Rimantadine; Zanamivir | 2006 |
Impact of influenza treatment with oseltamivir on health, sleep and daily activities of otherwise healthy adults and adolescents.
Topics: Activities of Daily Living; Adolescent; Adult; Antiviral Agents; Double-Blind Method; Employment; Health Status; Humans; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Middle Aged; Multicenter Studies as Topic; Oseltamivir; Randomized Controlled Trials as Topic; Sex Factors; Sleep; Treatment Outcome | 2006 |
WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus.
Topics: Animals; Antiviral Agents; Birds; Humans; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Neuraminidase; Oseltamivir; Poultry; World Health Organization | 2007 |
[Peramivir. A new and potent neuraminidase inhibitor for the treatment of influenza].
Topics: Acids, Carbocyclic; Amino Acid Substitution; Animals; Antiviral Agents; Binding Sites; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopentanes; Drug Evaluation, Preclinical; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Mice; Molecular Structure; Neuraminidase; Orthomyxoviridae; Oseltamivir; Point Mutation; Viral Proteins | 2006 |
Neuraminidase inhibitors for preventing and treating influenza in children.
Topics: Acetamides; Antiviral Agents; Child; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Randomized Controlled Trials as Topic; Sialic Acids; Zanamivir | 2007 |
[Neuraminidase inhibitors and risk of H5N1 influenza].
Topics: Animals; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2007 |
Antiviral therapy and prophylaxis for influenza in children.
Topics: Adamantane; Amantadine; Antiviral Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infant; Influenza, Human; Male; Oseltamivir; Primary Prevention; Prospective Studies; Randomized Controlled Trials as Topic; Rimantadine; Risk Assessment; Severity of Illness Index; Treatment Outcome; Zanamivir | 2007 |
The critically ill avian influenza A (H5N1) patient.
Topics: Antiviral Agents; Critical Illness; Humans; Infection Control; Influenza A Virus, H5N1 Subtype; Influenza, Human; Multiple Organ Failure; Oseltamivir; Prognosis; Respiratory Distress Syndrome; Reverse Transcriptase Polymerase Chain Reaction | 2007 |
[Antiviral agents for influenza].
Topics: Amantadine; Antiviral Agents; Drug Resistance, Viral; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Viral Matrix Proteins; Zanamivir | 2007 |
Influenza: evolving strategies in treatment and prevention.
Topics: Aged; Amantadine; Antiviral Agents; Centers for Disease Control and Prevention, U.S.; Child, Preschool; Humans; Infant; Influenza A virus; Influenza B virus; Influenza Vaccines; Influenza, Human; Oseltamivir; Practice Guidelines as Topic; Ribavirin; Rimantadine; United States; Zanamivir | 2007 |
[Threat from newly emerging influenza].
Topics: Animals; Antiviral Agents; Birds; Communicable Diseases, Emerging; Disease Outbreaks; Humans; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Oseltamivir; Zanamivir | 2007 |
Current research on drugs and vaccines for fighting bird flu.
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H5N1 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; Zanamivir | 2007 |
Neuraminidase inhibitor resistance in influenza viruses.
Topics: Acids, Carbocyclic; Adult; Animals; Antiviral Agents; Catalytic Domain; Child; Clinical Trials as Topic; Cyclopentanes; Drug Administration Schedule; Enzyme Inhibitors; Guanidines; Humans; Immunocompromised Host; Influenza A Virus, H5N1 Subtype; Influenza, Human; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Seasons; Sentinel Surveillance; Viral Proteins; Virulence; Zanamivir | 2007 |
The role of oseltamivir in the treatment and prevention of influenza in children.
Topics: Antiviral Agents; Child; Disease Outbreaks; Drug and Narcotic Control; Drug Resistance, Viral; Humans; Influenza, Human; Oseltamivir; Quality-Adjusted Life Years | 2007 |
Neuraminidase inhibitors and their role in avian and pandemic influenza.
Topics: Animals; Antiviral Agents; Birds; Disease Outbreaks; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H5N1 Subtype; Influenza A Virus, H9N2 Subtype; Influenza in Birds; Influenza, Human; Mice; Neuraminidase; Oseltamivir; Zanamivir | 2007 |
Influenza virus susceptibility and resistance to oseltamivir.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Infant; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H2N2 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Microbial Sensitivity Tests; Middle Aged; Mutation; Neuraminidase; Oseltamivir | 2007 |
Occasional review: influenza in COPD: pathogenesis, prevention, and treatment.
Topics: Amantadine; Antiviral Agents; Humans; Influenza Vaccines; Influenza, Human; Oseltamivir; Pulmonary Disease, Chronic Obstructive; Rimantadine; Zanamivir | 2007 |
The war against influenza: discovery and development of sialidase inhibitors.
Topics: Animals; Antiviral Agents; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2007 |
[Countermeasures for newly-emerging influenza].
Topics: Antiviral Agents; Communicable Diseases, Emerging; Disease Outbreaks; Enzyme Inhibitors; Humans; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2007 |
[Adverse effects of antiviral agents].
Topics: Acyclovir; Amantadine; Anti-HIV Agents; Antiviral Agents; Cytomegalovirus Infections; Herpes Simplex; Herpes Zoster; HIV Infections; Humans; Influenza, Human; Oseltamivir; Protease Inhibitors; Reverse Transcriptase Inhibitors | 2007 |
Update on avian influenza A (H5N1) virus infection in humans.
Topics: Adult; Age Factors; Animals; Antiviral Agents; Hemagglutinins; Humans; Incidence; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Middle Aged; Oseltamivir; Pneumonia, Viral; Poultry; Virus Replication | 2008 |
Lessons learned from the 2007-2008 cold and flu season: what worked and what was worthless.
Topics: Antiviral Agents; Causality; Common Cold; Diagnosis, Differential; Dietary Supplements; Hand Disinfection; Hospitalization; Humans; Infection Control; Influenza Vaccines; Influenza, Human; Morbidity; Nonprescription Drugs; Oseltamivir; Seasons; United States; Vaccination; Zanamivir | 2008 |
'Flu' and structure-based drug design.
Topics: Amines; Antiviral Agents; Binding Sites; Crystallography, X-Ray; Drug Design; Enzyme Inhibitors; Guanidines; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A virus; Influenza, Human; Models, Molecular; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 1997 |
New approaches to influenza chemotherapy. Neuraminidase inhibitors.
Topics: Acetamides; Animals; Antiviral Agents; Drug Resistance, Microbial; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 1998 |
Update on influenza and rhinovirus infections.
Topics: Acetamides; Amines; Antiviral Agents; Common Cold; Guanidines; Humans; Influenza, Human; Intercellular Adhesion Molecule-1; Neuraminidase; Oseltamivir; Oxadiazoles; Oxazoles; Picornaviridae Infections; Pyrans; Recombinant Proteins; Rhinovirus; Sialic Acids; Zanamivir | 1999 |
Oseltamivir.
Topics: Acetamides; Animals; Antiviral Agents; Enzyme Inhibitors; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Prodrugs; Randomized Controlled Trials as Topic | 1999 |
Measures for control of influenza.
Topics: Amantadine; Amines; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza Vaccines; Influenza, Human; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Zanamivir | 1999 |
[Critical review of anti-influenza drugs].
Topics: Acetamides; Adult; Antiviral Agents; Drug Resistance, Microbial; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Netherlands; Neuraminidase; Oseltamivir; Public Health; Pyrans; Sialic Acids; Zanamivir | 2000 |
Antiviral agents for treating influenza.
Topics: Acetamides; Amantadine; Antiviral Agents; Drug Administration Schedule; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza Vaccines; Influenza, Human; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Zanamivir | 2000 |
Influenza virus neuraminidase inhibitors.
Topics: Acetamides; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pyrans; Sialic Acids; Treatment Outcome; Virus Replication; Zanamivir | 2000 |
Neuraminidase inhibitors in the treatment of influenza A and B--overview and case reports.
Topics: Acetamides; Administration, Inhalation; Adult; Aged; Aged, 80 and over; Antiviral Agents; Bronchitis; Clinical Trials as Topic; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Pericarditis; Pyrans; Sialic Acids; Zanamivir | 2000 |
Updated treatment for influenza A and B.
Topics: Acetamides; Amantadine; Antiviral Agents; Clinical Trials as Topic; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Treatment Outcome; Zanamivir | 2000 |
Influenza virus and rhinovirus-related otitis media: potential for antiviral intervention.
Topics: Acetamides; Adult; Anti-Bacterial Agents; Antiviral Agents; Child; Child, Preschool; Clinical Trials as Topic; Eustachian Tube; Guanidines; Humans; Infant; Influenza A virus; Influenza B virus; Influenza, Human; Interferon-beta; Oseltamivir; Otitis Media; Otitis Media with Effusion; Picornaviridae Infections; Piperidines; Pressure; Pyrans; Pyridazines; Respiratory Tract Infections; Rhinovirus; Rimantadine; Sialic Acids; Superinfection; Virus Replication; Zanamivir | 2000 |
[Influenza].
Topics: Acetamides; Amantadine; Antiviral Agents; Disease Outbreaks; Guanidines; History, 18th Century; History, 19th Century; History, 20th Century; Humans; Influenza, Human; Italy; Orthomyxoviridae; Oseltamivir; Pyrans; Sialic Acids; United States; Zanamivir | 2000 |
Neuraminidase inhibitors: zanamivir and oseltamivir.
Topics: Acetamides; Antiviral Agents; Clinical Trials as Topic; Diarrhea; Enzyme Inhibitors; Guanidines; Headache; Humans; Influenza, Human; Nausea; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2001 |
Prophylactic and symptomatic treatment of influenza. Current and developing options.
Topics: Acetamides; Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Guanidines; Humans; Infant; Influenza Vaccines; Influenza, Human; Middle Aged; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Time Factors; Zanamivir | 2001 |
[Antiinfluenza-drugs and the standard of the use].
Topics: Acetamides; Amantadine; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2000 |
[Neuraminidase inhibitor].
Topics: Acetamides; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2000 |
Oseltamivir: a review of its use in influenza.
Topics: Acetamides; Adolescent; Adult; Aged; Antiviral Agents; Child; Drug Resistance, Microbial; Enzyme Inhibitors; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Middle Aged; Neuraminidase; Oseltamivir | 2001 |
Zanamivir and oseltamivir: two new options for the treatment and prevention of influenza.
Topics: Acetamides; Animals; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2001 |
Position statement: global neuraminidase inhibitor susceptibility network.
Topics: Acetamides; Animals; Antiviral Agents; Drug Resistance; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Mutation; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2001 |
Adverse cutaneous reactions to influenza vaccinations and chemotherapy.
Topics: Acetamides; Amantadine; Antiviral Agents; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Orthomyxoviridae; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Skin; Zanamivir | 2001 |
Perspectives on antiviral use during pandemic influenza.
Topics: Acetamides; Amantadine; Antiviral Agents; Chemoprevention; Disease Outbreaks; Drug Resistance, Multiple, Viral; Drug Tolerance; Guanidines; Humans; Influenza A virus; Influenza, Human; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Zanamivir | 2001 |
Treatment of influenza with neuraminidase inhibitors: virological implications.
Topics: Acetamides; Animals; Antiviral Agents; Drug Resistance, Multiple, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2001 |
Oseltamivir: a clinical and pharmacological perspective.
Topics: Acetamides; Animals; Antiviral Agents; Humans; Influenza, Human; Oseltamivir; Randomized Controlled Trials as Topic | 2001 |
Neuraminidase inhibitors for the treatment and prevention of influenza.
Topics: Acetamides; Drug Resistance, Viral; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Randomized Controlled Trials as Topic; Sialic Acids; Treatment Outcome; Zanamivir | 2002 |
Influenza in the acute hospital setting.
Topics: Acetamides; Amantadine; Antiviral Agents; Cross Infection; Disease Outbreaks; Guanidines; Hospitals; Humans; Influenza Vaccines; Influenza, Human; Nursing Staff, Hospital; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Vaccination; Virginia; Zanamivir | 2002 |
Influenza vaccination for healthy children.
Topics: Acetamides; Antiviral Agents; Child; Health; Humans; Influenza Vaccines; Influenza, Human; Orthomyxoviridae; Oseltamivir; United States | 2002 |
137 trial(s) available for oseltamivir and Grippe
| Article | Year |
|---|---|
Three-day regimen of oseltamivir for post-exposure prophylaxis of influenza in hospital wards: a study protocol for a prospective, multi-center, single-arm trial.
Topics: Adult; Antiviral Agents; Child; Hospitals; Humans; Influenza, Human; Oseltamivir; Post-Exposure Prophylaxis; Prospective Studies | 2021 |
Effectiveness of oseltamivir treatment on clinical failure in hospitalized patients with lower respiratory tract infection.
Topics: Adult; Antiviral Agents; Humans; Influenza, Human; Oseltamivir; Respiratory Tract Infections; Treatment Outcome | 2021 |
Impact of Adding Oseltamivir to Usual Care on Quality-Adjusted Life-Years During Influenza-Like Illness.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Cost-Benefit Analysis; Decision Making; Europe; Health Care Costs; Humans; Influenza, Human; Middle Aged; Oseltamivir; Quality-Adjusted Life Years; Visual Analog Scale; Young Adult | 2022 |
The Hospital Recovery Scale: A clinically useful endpoint in patients hospitalized with influenza.
Topics: Antiviral Agents; COVID-19; Hospitalization; Hospitals; Humans; Influenza, Human; Oseltamivir; Treatment Outcome | 2022 |
A pragmatic randomized controlled trial of rapid on-site influenza and respiratory syncytial virus PCR testing in paediatric and adult populations.
Topics: Adult; Anti-Bacterial Agents; Child; Humans; Influenza, Human; Oseltamivir; Polymerase Chain Reaction; Respiratory Syncytial Virus, Human; Respiratory Tract Infections; Viruses | 2022 |
Results from a test-and-treat study for influenza among residents of homeless shelters in King County, WA: A stepped-wedge cluster-randomized trial.
Topics: Antiviral Agents; Humans; Ill-Housed Persons; Influenza A Virus, H1N1 Subtype; Influenza, Human; Orthomyxoviridae Infections; Oseltamivir | 2023 |
Lessons from resistance analysis in clinical trials of IV zanamivir.
Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2023 |
Rapid Detection of Influenza Outbreaks in Long Term Care Facilities Reduces Emergency Room Visits and Hospitalization.
Topics: Antiviral Agents; Disease Outbreaks; Emergency Service, Hospital; Hospitalization; Humans; Influenza, Human; Long-Term Care; Oseltamivir | 2023 |
Genotypic and phenotypic characterization of influenza A viral variants in study participants treated with pimodivir in the phase 2b TOPAZ study.
Topics: Adult; Antiviral Agents; Genotype; Humans; Influenza A virus; Influenza, Human; Oseltamivir | 2023 |
Rapid Detection of Influenza Outbreaks in Long-Term Care Facilities Reduces Emergency Room Visits and Hospitalization: A Randomized Trial.
Topics: Antiviral Agents; Disease Outbreaks; Emergency Service, Hospital; Hospitalization; Humans; Influenza, Human; Long-Term Care; Oseltamivir | 2023 |
RDN for the treatment of influenza in children: a randomized, double-blinded, parallel-controlled clinical trial.
Topics: Antiviral Agents; Child; Double-Blind Method; Humans; Influenza, Human; Oseltamivir; Phosphates | 2023 |
Multicenter, randomized controlled, open label evaluation of the efficacy and safety of arbidol hydrochloride tablets in the treatment of influenza-like cases.
Topics: Capsules; Fever; Humans; Influenza, Human; Nausea; Oseltamivir; Phosphates; Tablets | 2023 |
[Cost-effectiveness analysis of Chaiyin Granules in treatment of influenza].
Topics: Antipyretics; Antiviral Agents; Cost-Effectiveness Analysis; Double-Blind Method; Humans; Influenza, Human; Nucleic Acids; Oseltamivir; Phosphates; Treatment Outcome | 2023 |
Effect of Oral Oseltamivir on Virological Outcomes in Low-risk Adults With Influenza: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Antiviral Agents; Argentina; Double-Blind Method; Humans; Influenza, Human; Middle Aged; Oseltamivir; Pilot Projects; Thailand; Treatment Outcome; Young Adult | 2020 |
Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial.
Topics: Adult; Antiviral Agents; Betainfluenzavirus; Double-Blind Method; Drug Therapy, Combination; Female; Hospitalization; Humans; Immunoglobulins, Intravenous; Influenza A virus; Influenza, Human; Male; Middle Aged; Oseltamivir; Pilot Projects; Treatment Outcome | 2019 |
Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Combined Modality Therapy; Europe; Female; Humans; Infant; Influenza, Human; Male; Middle Aged; Oseltamivir; Primary Health Care; Severity of Illness Index; Time Factors; Treatment Outcome; Young Adult | 2020 |
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, a Monoclonal Antibody, plus Oseltamivir in Patients Hospitalized with Severe Influenza A Virus Infection.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antiviral Agents; Double-Blind Method; Humans; Influenza A virus; Influenza, Human; Oseltamivir | 2020 |
Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Dibenzothiepins; Double-Blind Method; Female; Humans; Influenza, Human; Male; Middle Aged; Morpholines; Oseltamivir; Oxazines; Pyridines; Pyridones; Thiepins; Triazines; Young Adult | 2020 |
Oseltamivir for coronavirus illness: post-hoc exploratory analysis of an open-label, pragmatic, randomised controlled trial in European primary care from 2016 to 2018.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Coronavirus Infections; COVID-19; Drug Therapy, Combination; Europe; Female; Fever; Headache; Humans; Influenza, Human; Male; Middle Aged; Oseltamivir; Pandemics; Pneumonia, Viral; Time Factors; Treatment Outcome; Young Adult | 2020 |
A Phase 2 Study of Pimodivir (JNJ-63623872) in Combination With Oseltamivir in Elderly and Nonelderly Adults Hospitalized With Influenza A Infection: OPAL Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Humans; Influenza, Human; Middle Aged; Oseltamivir; Pyridines; Pyrroles; Treatment Outcome; Young Adult | 2022 |
Pharmacokinetics of the Monoclonal Antibody MHAA4549A Administered in Combination With Oseltamivir in Patients Hospitalized With Severe Influenza A Infection.
Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antiviral Agents; Drug Therapy, Combination; Half-Life; Humans; Influenza A virus; Influenza, Human; Infusions, Intravenous; Inpatients; Middle Aged; Nasopharynx; Oseltamivir; Trachea | 2020 |
Effect of peramivir on respiratory symptom improvement in patients with influenza virus infection and pre-existing chronic respiratory disease: Findings of a randomized, open-label study.
Topics: Acids, Carbocyclic; Antiviral Agents; Comorbidity; Cyclopentanes; Female; Guanidines; Humans; Influenza, Human; Male; Neuraminidase; Oseltamivir; Respiratory Tract Diseases; Treatment Outcome | 2021 |
Intravenous peramivir vs oral oseltamivir in high-risk emergency department patients with influenza: Results from a pilot randomized controlled study.
Topics: Acids, Carbocyclic; Adult; Antiviral Agents; Cyclopentanes; Emergency Service, Hospital; Guanidines; Humans; Influenza, Human; Oseltamivir; Pilot Projects; Treatment Outcome | 2021 |
Efficacy of oseltamivir compared with zanamivir in COPD patients with seasonal influenza virus infection: a randomized controlled trial.
Topics: Antiviral Agents; Enzyme Inhibitors; Female; Humans; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Pulmonary Disease, Chronic Obstructive; Zanamivir | 2020 |
[Efficacy and safety of Kangbingdu granules in the treatment of influenza: a randomized, double-blind, double-dummy, positive-drug parallel control multicenter clinical trial].
Topics: Adult; Antiviral Agents; China; Double-Blind Method; Humans; Influenza, Human; Male; Middle Aged; Oseltamivir; Pharmaceutical Preparations; Treatment Outcome; Young Adult | 2021 |
Improvement of respiratory symptoms and health-related quality of life with peramivir in influenza patients with chronic respiratory disease: Additional outcomes of a randomized, open-label study.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Guanidines; Humans; Influenza, Human; Oseltamivir; Quality of Life; Treatment Outcome | 2021 |
Direct and Indirect Costs of Influenza-Like Illness Treated with and Without Oseltamivir in 15 European Countries: A Descriptive Analysis Alongside the Randomised Controlled ALIC
Topics: Antiviral Agents; Cost-Benefit Analysis; Europe; Humans; Influenza, Human; Oseltamivir | 2021 |
Clinical and virological outcomes with baloxavir compared with oseltamivir in pediatric patients aged 6 to < 12 years with influenza: an open-label, randomized, active-controlled trial protocol.
Topics: Adolescent; Adult; Antiviral Agents; Child; Dibenzothiepins; Humans; Influenza, Human; Morpholines; Multicenter Studies as Topic; Oseltamivir; Pyridones; Randomized Controlled Trials as Topic; Triazines | 2021 |
Anti-inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: A randomized controlled trial.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antiviral Agents; Azithromycin; Cytokines; Female; Hospitalization; Humans; Influenza, Human; Longitudinal Studies; Macrolides; Male; Middle Aged; Oseltamivir; Plasma; Severity of Illness Index; Treatment Outcome; Viral Load | 2017 |
[Efficacy and safety of oseltamivir in children with suspected influenza: a multicenter randomized open-label trial].
Topics: Abdominal Pain; Antiviral Agents; Child; Diarrhea; Drug Administration Schedule; Female; Fever; Hospitals, Pediatric; Humans; Influenza, Human; Male; Oseltamivir; Treatment Outcome; Vomiting | 2017 |
Factors associated with non-persistence to oral and inhaled antiviral therapies for seasonal influenza: a secondary analysis of a double-blind, multicentre, randomised clinical trial.
Topics: Administration, Inhalation; Administration, Oral; Antiviral Agents; Double-Blind Method; Female; France; Humans; Influenza, Human; Kaplan-Meier Estimate; Lost to Follow-Up; Male; Medication Adherence; Multivariate Analysis; Oseltamivir; Proportional Hazards Models; Treatment Outcome; Zanamivir | 2017 |
Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial.
Topics: Amantadine; Antiviral Agents; Argentina; Australia; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Influenza, Human; Male; Mexico; Oseltamivir; Ribavirin; Thailand; United States | 2017 |
Clinical and virologic effects of four neuraminidase inhibitors in influenza A virus-infected children (aged 4-12 years): an open-label, randomized study in Japan.
Topics: Acids, Carbocyclic; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Female; Guanidines; Humans; Influenza A virus; Influenza, Human; Japan; Male; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Time Factors; Treatment Outcome; Zanamivir | 2018 |
A Randomized Study Evaluating the Effectiveness of Oseltamivir Initiated at the Time of Hospital Admission in Adults Hospitalized With Influenza-Associated Lower Respiratory Tract Infections.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Hospitalization; Humans; Influenza, Human; Length of Stay; Male; Middle Aged; Oseltamivir; Prospective Studies; Respiratory Tract Infections; Time-to-Treatment; Treatment Failure; Treatment Outcome | 2018 |
Antivirals for influenza-Like Illness? A randomised Controlled trial of Clinical and Cost effectiveness in primary CarE (ALIC
Topics: Activities of Daily Living; Antiviral Agents; Cost-Benefit Analysis; Female; Fever; Headache; Hospitalization; Humans; Influenza, Human; Male; Multicenter Studies as Topic; Myalgia; Nonprescription Drugs; Oseltamivir; Pneumonia; Pragmatic Clinical Trials as Topic; Prescription Drugs; Self Care; Symptom Assessment; Time Factors | 2018 |
Evaluation of MEDI8852, an Anti-Influenza A Monoclonal Antibody, in Treating Acute Uncomplicated Influenza.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antiviral Agents; Double-Blind Method; Female; Hemagglutinins; Humans; Influenza A virus; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Virus Shedding; Young Adult | 2018 |
Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.
Topics: Adolescent; Adult; Antiviral Agents; Child; Dibenzothiepins; Double-Blind Method; Endonucleases; Female; Humans; Influenza, Human; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Morpholines; Oseltamivir; Oxazines; Pyridines; Pyridones; Thiepins; Triazines; Viral Load; Virus Replication; Young Adult | 2018 |
Effect of traditional Chinese medicine Bupleurum in the treatment of influenza A (H1N1).
Topics: Adolescent; Adult; Aged; Antiviral Agents; Bupleurum; Drugs, Chinese Herbal; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Tea; Young Adult | 2018 |
Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial.
Topics: Acute Disease; Adult; Antiviral Agents; Diarrhea; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Early Termination of Clinical Trials; Female; Humans; Influenza A virus; Influenza, Human; Male; Middle Aged; Oseltamivir; Pyridines; Pyrimidines; Pyrroles; Time Factors; Viral Load; Viral Proteins; Virus Shedding | 2019 |
Efficacy and safety of Chou-Ling-Dan granules in the treatment of seasonal influenza via combining Western and traditional Chinese medicine: protocol for a multicentre, randomised controlled clinical trial.
Topics: Adolescent; Adult; Antiviral Agents; China; Double-Blind Method; Drugs, Chinese Herbal; Evidence-Based Medicine; Female; Humans; Influenza, Human; Male; Medicine, Chinese Traditional; Middle Aged; Multicenter Studies as Topic; Oseltamivir; Phytotherapy; Randomized Controlled Trials as Topic; Seasons; Sesquiterpenes; Treatment Outcome; Young Adult | 2019 |
Assessment of antiviral and antibiotic combination treatment in influenza-A H1N1 induced acute kidney injury among hospitalized patients.
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antiviral Agents; Drug Therapy, Combination; Female; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Retrospective Studies; Treatment Outcome; Young Adult | 2019 |
Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza.
Topics: Adolescent; Adult; Amino Acid Substitution; Antiviral Agents; Child; Dibenzothiepins; Double-Blind Method; Drug Resistance, Viral; Female; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Male; Middle Aged; Morpholines; Oseltamivir; Oxazines; Pyridines; Pyridones; Risk Factors; Thiepins; Treatment Outcome; Triazines; Viral Load; Young Adult | 2020 |
[A randomized controlled study of peramivir, oseltamivir and placebo in patients with mild influenza].
Topics: Acids, Carbocyclic; Adolescent; Adult; Aged; Antiviral Agents; Cyclopentanes; Double-Blind Method; Guanidines; Humans; Influenza, Human; Middle Aged; Oseltamivir; Treatment Outcome; Young Adult | 2019 |
Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies.
Topics: Adult; Antiviral Agents; Area Under Curve; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza B virus; Influenza, Human; Male; Multivariate Analysis; Neuraminidase; Oseltamivir; Time Factors; Treatment Outcome; Viral Load; Virus Shedding; Young Adult | 2013 |
Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial.
Topics: Administration, Oral; Adult; Antiviral Agents; Child; Clinical Protocols; Dose-Response Relationship, Drug; Double-Blind Method; Hemagglutination Inhibition Tests; Hospitalization; Humans; Indonesia; Infant; Influenza A virus; Influenza B virus; Influenza, Human; Middle Aged; Oseltamivir; Practice Guidelines as Topic; Reverse Transcriptase Polymerase Chain Reaction; Severity of Illness Index; Singapore; Thailand; Treatment Outcome; Vietnam | 2013 |
A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza a and B infections.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Female; Hong Kong; Hospitalization; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Male; Middle Aged; Nasopharynx; Oseltamivir; Prospective Studies; Treatment Outcome; Viral Load | 2013 |
Oseltamivir effectiveness in seasonal influenza patients taking symptomatic therapy: retrospective analysis of RCT data.
Topics: Adolescent; Adult; Antiviral Agents; Female; Humans; Influenza, Human; Male; Middle Aged; Nonprescription Drugs; Oseltamivir; Randomized Controlled Trials as Topic; Retrospective Studies | 2013 |
Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.
Topics: Adolescent; Antiviral Agents; Bangladesh; Child; Child, Preschool; Double-Blind Method; Drug Administration Schedule; Female; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Intention to Treat Analysis; Logistic Models; Male; Multivariate Analysis; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Treatment Outcome; Urban Health; Virus Shedding | 2014 |
Efficacy of combination therapy with oseltamivir phosphate and azithromycin for influenza: a multicenter, open-label, randomized study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Azithromycin; Cytokines; Drug Therapy, Combination; Female; Humans; Inflammation Mediators; Influenza, Human; Male; Middle Aged; Oseltamivir; Treatment Outcome; Young Adult | 2014 |
Clinical effects of oseltamivir, zanamivir, laninamivir and peramivir on seasonal influenza infection in outpatients in Japan during the winter of 2012-2013.
Topics: Acids, Carbocyclic; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Enzyme Inhibitors; Female; Guanidines; Humans; Infant; Influenza, Human; Japan; Male; Middle Aged; Neuraminidase; Oseltamivir; Outpatients; Pyrans; Sialic Acids; Time Factors; Treatment Outcome; Young Adult; Zanamivir | 2013 |
A randomized study of standard versus double dose oseltamivir for treating influenza in the community.
Topics: Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Community-Acquired Infections; Drug Administration Schedule; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Patient Compliance; Treatment Outcome; Viral Load; Young Adult | 2015 |
Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Cytokines; Double-Blind Method; Female; Humans; Immunologic Factors; Influenza A Virus, H3N2 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Retrospective Studies; Treatment Outcome; Viral Load; Virus Shedding; Young Adult | 2015 |
A part-randomized study of intravenous oseltamivir in adolescents and adults.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Blood Chemical Analysis; Critical Illness; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Influenza, Human; Infusions, Intravenous; Male; Middle Aged; Nasal Mucosa; Oseltamivir; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Virus Cultivation; Virus Shedding; Young Adult | 2015 |
Effects of oseltamivir treatment of index patients with influenza on secondary household illness in an urban setting in Bangladesh: secondary analysis of a randomised, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Bangladesh; Child; Child, Preschool; Double-Blind Method; Family Characteristics; Family Health; Female; Humans; Infant; Influenza, Human; Male; Middle Aged; Oseltamivir; Placebos; Treatment Outcome; Urban Population; Young Adult | 2015 |
Viral shedding and susceptibility to oseltamivir in hospitalized immunocompromised patients with influenza in the Influenza Resistance Information Study (IRIS).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hospitalization; Humans; Immunocompromised Host; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Mutation; Oseltamivir; Prospective Studies; Sequence Analysis, DNA; Severity of Illness Index; Survival Analysis; Virus Shedding | 2015 |
Efficacy and safety of Ban-Lan-Gen granules in the treatment of seasonal influenza: study protocol for a randomized controlled trial.
Topics: Adult; Antiviral Agents; Clinical Protocols; Double-Blind Method; Humans; Influenza, Human; Medicine, Chinese Traditional; Middle Aged; Oseltamivir; Phytotherapy | 2015 |
Safety, virology and pharmacokinetics of oseltamivir in infants with laboratory-confirmed influenza: a Phase I/II, prospective, open-label, multicentre clinical trial.
Topics: Antiviral Agents; Cohort Studies; Female; Humans; Infant; Infant, Newborn; Influenza A virus; Influenza B virus; Influenza, Human; Inhibitory Concentration 50; Male; Microbial Sensitivity Tests; Oseltamivir; Treatment Outcome; Virus Shedding | 2015 |
Pharmacokinetics and safety of intravenous oseltamivir in infants and children in open-label studies.
Topics: Age Factors; Antiviral Agents; Child; Child, Preschool; Drug Administration Schedule; Drug Resistance, Viral; Female; Hospitalization; Humans; Infant; Infant, Newborn; Influenza, Human; Infusions, Intravenous; Male; Orthomyxoviridae; Oseltamivir; Patient Safety; Prospective Studies; Risk Assessment; Risk Factors; Treatment Outcome; United States; Viral Load; Virus Shedding | 2015 |
A randomized, double-blind, placebo-controlled trial evaluating the safety of early oseltamivir treatment among children 0-9 years of age hospitalized with influenza in El Salvador and Panama.
Topics: Antiviral Agents; Child; Child, Preschool; Comorbidity; El Salvador; Female; Hospitalization; Humans; Infant; Infant, Newborn; Influenza, Human; Length of Stay; Male; Oseltamivir; Panama; Severity of Illness Index; Treatment Outcome | 2016 |
Efficacy and safety of Ergoferon versus oseltamivir in adult outpatients with seasonal influenza virus infection: a multicenter, open-label, randomized trial.
Topics: Adolescent; Adult; Aged; Antibodies; Antiviral Agents; CD4 Antigens; Female; Fever; Histamine; Humans; Influenza, Human; Interferon-gamma; Male; Middle Aged; Oseltamivir; Outpatients; Quality of Life; Time Factors; Treatment Outcome; Young Adult | 2016 |
Clinical efficacy of laninamivir and peramivir in patients with seasonal influenza: a randomized clinical trial.
Topics: Acids, Carbocyclic; Adult; Antiviral Agents; Cyclopentanes; Female; Guanidines; Humans; Influenza, Human; Japan; Male; Middle Aged; Oseltamivir; Pyrans; Sialic Acids; Treatment Outcome; Zanamivir | 2017 |
Efficacy of Clarithromycin-Naproxen-Oseltamivir Combination in the Treatment of Patients Hospitalized for Influenza A(H3N2) Infection: An Open-label Randomized, Controlled, Phase IIb/III Trial.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Clarithromycin; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hospitalization; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Length of Stay; Male; Mortality; Naproxen; Nasopharynx; Oseltamivir; Severity of Illness Index; Treatment Outcome; Viral Load | 2017 |
Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Double-Blind Method; Female; Hospitalization; Humans; Influenza, Human; Male; Middle Aged; Oseltamivir; Treatment Outcome; Young Adult; Zanamivir | 2017 |
Pharmacokinetics and tolerability of oseltamivir combined with probenecid.
Topics: Adult; Aged; Antiviral Agents; Chemoprevention; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Influenza, Human; Male; Middle Aged; Oseltamivir; Probenecid; Treatment Outcome | 2008 |
Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza.
Topics: Adult; Aged; Antiviral Agents; Area Under Curve; Female; Hemofiltration; Humans; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N1 Subtype; Influenza, Human; Intubation, Gastrointestinal; Male; Oseltamivir; Pregnancy; Respiration, Artificial; Treatment Outcome; Viral Load | 2008 |
Targeted antiviral prophylaxis with oseltamivir in a summer camp setting.
Topics: Adolescent; Alabama; Antiviral Agents; Camping; Child; Disease Outbreaks; Disinfectants; Hand Disinfection; Health Resorts; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir | 2010 |
Impact of oseltamivir treatment on the incidence and course of acute otitis media in children with influenza.
Topics: Acoustic Impedance Tests; Acute Disease; Antiviral Agents; Child; Child, Preschool; Cost of Illness; Female; Humans; Incidence; Infant; Influenza, Human; Male; Oseltamivir; Otitis Media | 2010 |
Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection.
Topics: Administration, Inhalation; Administration, Oral; Antiviral Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Male; Neuraminidase; Oseltamivir; Treatment Outcome; Virus Shedding; Zanamivir | 2010 |
Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial.
Topics: Administration, Oral; Antiviral Agents; Child, Preschool; Double-Blind Method; Female; Humans; Infant; Influenza, Human; Male; Oseltamivir; Placebos; Time Factors; Treatment Outcome | 2010 |
Evaluation of a direct test for seasonal influenza in outpatients.
Topics: Adult; Anti-Bacterial Agents; Antiviral Agents; Diagnosis, Differential; Female; Greece; House Calls; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Male; Middle Aged; Oseltamivir; Outpatients; Reagent Kits, Diagnostic; Seasons | 2010 |
Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial.
Topics: Administration, Inhalation; Administration, Oral; Adult; Aged; Antiviral Agents; Drug Administration Schedule; Female; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Male; Middle Aged; Oseltamivir; Pyrans; Sialic Acids; Viral Load; Zanamivir | 2010 |
Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial.
Topics: Adult; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Influenza, Human; Male; Middle Aged; Oseltamivir; Treatment Outcome; Zanamivir | 2010 |
Respiratory illnesses in Canadian health care workers: a pilot study of influenza vaccine and oseltamivir prophylaxis during the 2007/2008 influenza season.
Topics: Adult; Antiviral Agents; Canada; Female; Health Personnel; Humans; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Oseltamivir; Pilot Projects; Seasons; Young Adult | 2011 |
Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection.
Topics: Acids, Carbocyclic; Administration, Oral; Adult; Aged; Aged, 80 and over; Antiviral Agents; Cyclopentanes; Double-Blind Method; Drug Administration Schedule; Female; Guanidines; Humans; Influenza, Human; Injections, Intravenous; Male; Middle Aged; Oseltamivir; Young Adult | 2011 |
Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Combinations; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Fever; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Nausea; Oseltamivir; Prospective Studies; Virus Shedding; Vomiting; Young Adult | 2011 |
Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state pharmacokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients.
Topics: Adult; Aged; Antiviral Agents; Biotransformation; Cohort Studies; Cross-Over Studies; Cyclosporine; Drug Interactions; Enzyme Inhibitors; Female; Half-Life; Humans; Immunosuppressive Agents; Influenza, Human; Kidney Transplantation; Male; Middle Aged; Mycophenolic Acid; Neuraminidase; Oseltamivir; Tacrolimus; Young Adult | 2011 |
Clinical and virologic outcomes in patients with oseltamivir-resistant seasonal influenza A (H1N1) infections: results from a clinical trial.
Topics: Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Seasons; Young Adult | 2012 |
[Pandemic influenza in Russia: specific features of clinical course and the absence of early etiotropic therapy as a risk factor of severe forms of the disease].
Topics: Adolescent; Adult; Amides; Antiviral Agents; Caproates; Dicarboxylic Acids; Drug Administration Schedule; Female; Humans; Imidazoles; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Pandemics; Risk Factors; Russia; Severity of Illness Index; Time Factors; Treatment Outcome; Young Adult | 2011 |
Effectiveness of a new bioequivalent formulation of oseltamivir (Enfluvir®) on 2010-2011 seasonal influenza viruses: an open phase IV study.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Female; Humans; Infant; Influenza, Human; Male; Oseltamivir; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome | 2012 |
A randomized, controlled trial comparing traditional herbal medicine and neuraminidase inhibitors in the treatment of seasonal influenza.
Topics: Adult; Antiviral Agents; Cytokines; Drugs, Chinese Herbal; Enzyme Inhibitors; Female; Fever; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Statistics, Nonparametric; Treatment Outcome; Zanamivir | 2012 |
Viral load and clinical features in children infected with seasonal influenza B in 2006/2007.
Topics: Abdominal Pain; Adolescent; Age Factors; Antiviral Agents; Child; Child, Preschool; Chills; Female; Fever; Humans; Infant; Influenza B virus; Influenza, Human; Male; Musculoskeletal Pain; Oseltamivir; Prospective Studies; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Sensitivity and Specificity; Viral Load | 2012 |
Safety and tolerability of a 6-week course of oseltamivir prophylaxis for seasonal influenza in children.
Topics: Antiviral Agents; Chemoprevention; Child; Child, Preschool; Female; Humans; Infant; Influenza, Human; Male; Oseltamivir; Seasons; Treatment Outcome | 2013 |
Oseltamivir pharmacokinetics and clinical experience in neonates and infants during an outbreak of H1N1 influenza A virus infection in a neonatal intensive care unit.
Topics: Antiviral Agents; Disease Outbreaks; Female; Humans; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care Units; Male; Oseltamivir | 2012 |
Clinical effectiveness of neuraminidase inhibitors--oseltamivir, zanamivir, laninamivir, and peramivir--for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan.
Topics: Acids, Carbocyclic; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Disease Outbreaks; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Japan; Male; Neuraminidase; Oseltamivir; Treatment Outcome; Zanamivir | 2012 |
Efficacy and safety of oral oseltamivir for influenza prophylaxis in transplant recipients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Kidney Transplantation; Liver Transplantation; Male; Middle Aged; Oseltamivir; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Young Adult | 2012 |
A randomized double-blind controlled study of laninamivir compared with oseltamivir for the treatment of influenza in patients with chronic respiratory diseases.
Topics: Adult; Aged; Antiviral Agents; Asthma; Chronic Disease; Double-Blind Method; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Treatment Outcome; Zanamivir | 2013 |
Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections.
Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; France; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Nasal Mucosa; Oseltamivir; Treatment Outcome; Virus Shedding; Young Adult; Zanamivir | 2012 |
Effect of oseltamivir, zanamivir or oseltamivir-zanamivir combination treatments on transmission of influenza in households.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Cough; Drug Therapy, Combination; Enzyme Inhibitors; Family Characteristics; Female; Fever; Follow-Up Studies; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Male; Middle Aged; Multivariate Analysis; Neuraminidase; Oseltamivir; Time Factors; Young Adult; Zanamivir | 2012 |
Utility of Maoto in an influenza season where reduced effectiveness of oseltamivir was observed - a clinical, non-randomized study in children.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Age Factors; Alphainfluenzavirus; Antiviral Agents; Betainfluenzavirus; Child; Child, Preschool; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Humans; Infant; Influenza, Human; Male; Oseltamivir; Seasons; Treatment Outcome; Zanamivir | 2012 |
Treating and preventing influenza in aged care facilities: a cluster randomised controlled trial.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Australia; Disease Outbreaks; Drug Administration Schedule; Female; Health Services for the Aged; Humans; Incidence; Influenza, Human; Male; Models, Biological; Oseltamivir; Residence Characteristics | 2012 |
A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults.
Topics: Acids, Carbocyclic; Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antiviral Agents; Cyclopentanes; Female; Guanidines; Hospitalization; Humans; Influenza A virus; Influenza, Human; Inhibitory Concentration 50; Male; Microbial Sensitivity Tests; Middle Aged; Oseltamivir; Risk Factors; Seasons; Treatment Outcome; Viral Load | 2013 |
Oseltamivir and inhaled zanamivir as influenza prophylaxis in Thai health workers: a randomized, double-blind, placebo-controlled safety trial over 16 weeks.
Topics: Administration, Inhalation; Adult; Antiviral Agents; Chemoprevention; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Health Personnel; Humans; Influenza, Human; Male; Middle Aged; Oseltamivir; Placebos; Thailand; Young Adult; Zanamivir | 2013 |
Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics.
Topics: Adult; Amantadine; Drug Resistance, Viral; Drug Therapy, Combination; Female; Humans; Immunocompromised Host; Influenza A virus; Influenza, Human; Male; Mutation; Oseltamivir; Pilot Projects; Ribavirin; Viral Load; Young Adult | 2013 |
[Ergoferon and oseltamivir in treatment of influenza: results of multicentre randomized comparative clinical trial].
Topics: Adolescent; Adult; Antipyretics; Antiviral Agents; Body Temperature; CD4 Antigens; Female; Fever; Histamine; Humans; Influenza, Human; Interferon-gamma; Male; Middle Aged; Oseltamivir; Russia; Time Factors; Treatment Outcome; Young Adult | 2012 |
Oseltamivir pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation support.
Topics: Adult; Antiviral Agents; Area Under Curve; Creatinine; Critical Illness; Extracorporeal Membrane Oxygenation; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Nonlinear Dynamics; Oseltamivir; Tissue Distribution | 2013 |
Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids.
Topics: Acetamides; Administration, Oral; Adult; Aluminum Hydroxide; Analysis of Variance; Antacids; Antiviral Agents; Calcium Carbonate; Cross-Over Studies; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Female; Humans; Influenza, Human; Magnesium Hydroxide; Male; Middle Aged; Oseltamivir; Prodrugs; Tablets; Therapeutic Equivalency | 2002 |
Neuraminidase inhibitors in the management of influenza--experience of an outpatient practice.
Topics: Acetamides; Aged; Ambulatory Care; Antiviral Agents; Child; Enzyme Inhibitors; Fibrinogen; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2002 |
A double-blind, randomized, placebo-controlled multicenter study of oseltamivir phosphate for treatment of influenza infection in China.
Topics: Acetamides; Adult; Aged; Antiviral Agents; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir | 2003 |
Pharmacokinetics and delivery of the anti-influenza prodrug oseltamivir to the small intestine and colon using site-specific delivery capsules.
Topics: Acetamides; Adult; Antiviral Agents; Capsules; Colon; Cross-Over Studies; Drug Delivery Systems; Humans; Influenza, Human; Intestine, Small; Male; Middle Aged; Oseltamivir; Prodrugs | 2003 |
Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations.
Topics: Acetamides; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antiviral Agents; Double-Blind Method; Hospitalization; Humans; Incidence; Influenza A virus; Influenza B virus; Influenza, Human; Middle Aged; Oseltamivir; Prospective Studies; Respiratory Tract Diseases; Risk Factors; Treatment Outcome; United States | 2003 |
Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years.
Topics: Acetamides; Administration, Oral; Age Factors; Antiviral Agents; Area Under Curve; Child, Preschool; Female; Half-Life; Humans; Infant; Influenza, Human; Male; Neuraminidase; Oseltamivir; Prodrugs | 2003 |
[Investigation of the reconsultation rate and pharmacoeconomic evaluation of period of influenza treatment by oseltamivir].
Topics: Acetamides; Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Dosage Forms; Drug Prescriptions; Female; Humans; Influenza, Human; Japan; Male; Middle Aged; Oseltamivir; Referral and Consultation; Time Factors; Treatment Outcome | 2003 |
[The study on efficacy of oseltamivir for influenza A in children].
Topics: Acetamides; Amantadine; Analgesics, Non-Narcotic; Antiviral Agents; Child, Preschool; Female; Humans; Influenza A virus; Influenza, Human; Male; Oseltamivir | 2003 |
Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis.
Topics: Acetamides; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Family Characteristics; Female; Humans; Infant; Influenza, Human; Male; Middle Aged; Oseltamivir; Prospective Studies; Time Factors | 2004 |
Oseltamivir prophylaxis during the influenza season in a paediatric cancer centre: prospective observational study.
Topics: Acetamides; Administration, Oral; Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hong Kong; Hospitals, Pediatric; Humans; Immunocompromised Host; Incidence; Influenza, Human; Male; Neoplasms; Oncology Service, Hospital; Oseltamivir; Prospective Studies; Risk Assessment; Treatment Outcome | 2004 |
Use of Oseltamivir to control influenza complications after bone marrow transplantation.
Topics: Acetamides; Alphainfluenzavirus; Antiviral Agents; Betainfluenzavirus; Bone Marrow Transplantation; Follow-Up Studies; Hematologic Neoplasms; Humans; Influenza, Human; Nasal Lavage Fluid; Oseltamivir; Premedication; Seasons; Treatment Outcome | 2004 |
[A multicenter randomized controlled study of the efficacy and safety of oseltamivir in the treatment of influenza in a high risk population].
Topics: Acetamides; Adult; Antiviral Agents; Double-Blind Method; Drug Administration Schedule; Female; Fever; Heart Diseases; Humans; Influenza, Human; Male; Middle Aged; Oseltamivir; Respiratory Tract Diseases; Treatment Outcome | 2004 |
[Cost effectiveness analysis of oseltamivir phosphorus in the treatment of influenza].
Topics: Acetamides; Antiviral Agents; Cost-Benefit Analysis; Female; Humans; Influenza, Human; Male; Oseltamivir; Prospective Studies | 2004 |
[A multicenter study of efficacy and safety of oseltamivir in the treatment of suspected influenza patients].
Topics: Acetamides; Adult; Antiviral Agents; Drug Administration Schedule; Female; Humans; Influenza, Human; Male; Middle Aged; Oseltamivir | 2004 |
Oral oseltamivir improves pulmonary function and reduces exacerbation frequency for influenza-infected children with asthma.
Topics: Acetamides; Administration, Oral; Antiviral Agents; Asthma; Child; Child, Preschool; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Influenza, Human; Male; Oseltamivir; Probability; Reference Values; Respiratory Function Tests; Severity of Illness Index; Treatment Outcome | 2005 |
[A multicenter study of efficacy and safety of oseltamivir in treatment of naturally acquired influenza].
Topics: Acetamides; Adolescent; Adult; Aged; Antiviral Agents; Double-Blind Method; Female; Humans; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir | 2001 |
Viral shedding in children with influenza virus infections treated with neuraminidase inhibitors.
Topics: Acetamides; Animals; Antiviral Agents; Cell Line; Child; Child, Preschool; Chlorocebus aethiops; Guanidines; Humans; Infant; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Treatment Outcome; Vero Cells; Virus Shedding; Zanamivir | 2005 |
A multicentre, randomized, controlled trial of oseltamivir in the treatment of influenza in a high-risk Chinese population.
Topics: Acetamides; Antiviral Agents; Asian People; China; Female; Humans; Influenza, Human; Male; Middle Aged; Oseltamivir; Population; Risk; Treatment Outcome | 2006 |
Active metabolite from Tamiflu solution is bioequivalent to that from capsule delivery in healthy volunteers: a cross-over, randomised, open-label study.
Topics: Administration, Oral; Adult; Antiviral Agents; Area Under Curve; Capsules; Chemistry, Pharmaceutical; Cross-Over Studies; Female; Humans; Influenza, Human; Male; Oseltamivir; Therapeutic Equivalency | 2006 |
The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis.
Topics: Acetamides; Administration, Oral; Antiviral Agents; Dose-Response Relationship, Drug; Drug Resistance, Viral; Female; Follow-Up Studies; Humans; Influenza, Human; Kidney Failure, Chronic; Male; Middle Aged; Neuraminidase; Oseltamivir; Peritoneal Dialysis, Continuous Ambulatory; Renal Dialysis; Treatment Outcome | 2006 |
A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons.
Topics: Acetamides; Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Female; Humans; Infant; Infant, Newborn; Influenza A virus; Influenza B virus; Influenza, Human; Japan; Male; Middle Aged; Oseltamivir; Prospective Studies; Treatment Outcome | 2006 |
Antipyretic effect of Mao-to, a Japanese herbal medicine, for treatment of type A influenza infection in children.
Topics: Administration, Oral; Adolescent; Analgesics, Non-Narcotic; Antiviral Agents; Child; Child, Preschool; DNA Primers; DNA, Viral; Drugs, Chinese Herbal; Female; Fever; Humans; Infant; Influenza A virus; Influenza, Human; Japan; Male; Medicine, Chinese Traditional; Oseltamivir; Phytotherapy; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome | 2007 |
A comparison of the effectiveness of zanamivir and oseltamivir for the treatment of influenza A and B.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Female; Fever; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Japan; Male; Oseltamivir; Treatment Outcome; Zanamivir | 2008 |
Recent changes in the trends of seasonal influenza outbreaks in the Nagano Prefectural area of Japan: an oseltamivir effect?
Topics: Alphainfluenzavirus; Antiviral Agents; Betainfluenzavirus; Disease Outbreaks; Humans; Influenza, Human; Japan; Oseltamivir; Patient Isolation; Seasons | 2007 |
Effectiveness of oseltamivir treatment among children with influenza A or B virus infections during four successive winters in Niigata City, Japan.
Topics: Alphainfluenzavirus; Body Temperature; Child; Cities; Demography; Female; Fever; Humans; Influenza B virus; Influenza, Human; Japan; Male; Multivariate Analysis; Oseltamivir; Seasons; Time Factors; Treatment Outcome | 2008 |
The course of fever following influenza virus infection in children treated with oseltamivir.
Topics: Age Factors; Antiviral Agents; Body Temperature; Child; Child, Preschool; Female; Fever; Humans; Infant; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Japan; Male; Oseltamivir; Regression Analysis; Time Factors; Treatment Outcome | 2008 |
Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment.
Topics: Administration, Oral; Adolescent; Adult; Amines; Area Under Curve; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Influenza A virus; Influenza, Human; Male; Nausea; Neuraminidase; Nose; Oseltamivir | 1999 |
Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza.
Topics: Administration, Oral; Adolescent; Adult; Aged; Amines; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir | 1999 |
Oseltamivir.
Topics: Acetamides; Animals; Antiviral Agents; Enzyme Inhibitors; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Prodrugs; Randomized Controlled Trials as Topic | 1999 |
[Flu and antiviral agents....].
Topics: Acetamides; Administration, Intranasal; Administration, Oral; Adolescent; Adult; Aged; Antiviral Agents; Double-Blind Method; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Placebos; Pyrans; Risk Factors; Sialic Acids; Zanamivir | 2000 |
Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group.
Topics: Acetamides; Acute Disease; Adult; Antiviral Agents; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Severity of Illness Index; Statistics, Nonparametric | 2000 |
Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.
Topics: Acetamides; Administration, Oral; Adult; Antiviral Agents; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Influenza, Human; Male; Neuraminidase; Oseltamivir; Prodrugs; Severity of Illness Index; Surveys and Questionnaires | 2000 |
Oral oseltamivir in human experimental influenza B infection.
Topics: Acetamides; Adolescent; Adult; Antiviral Agents; Double-Blind Method; Humans; Influenza B virus; Influenza, Human; Middle Aged; Oseltamivir | 2000 |
Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir.
Topics: Acetamides; Adolescent; Adult; Amino Acid Substitution; Animals; Antiviral Agents; Base Sequence; Cell Line; Dogs; Drug Resistance, Microbial; Genetic Variation; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A virus; Influenza, Human; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Neuraminidase; Oseltamivir; Receptors, Virus; Viral Plaque Assay | 2001 |
Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial.
Topics: Acetamides; Adolescent; Adult; Aged; Antiviral Agents; Double-Blind Method; Enzyme Inhibitors; Family Characteristics; Female; Humans; Influenza, Human; Male; Middle Aged; Neuraminidase; Nose; Orthomyxoviridae; Oseltamivir; Pharynx; Virus Shedding | 2001 |
[Clinical efficacy and safety of the selective oral neuraminidase inhibitor oseltamivir in treating acute influenza--placebo-controlled double-blind multicenter phase III trial].
Topics: Acetamides; Acute Disease; Administration, Oral; Antiviral Agents; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir | 2000 |
[Efficacy and safety of the selective oral neuraminidase inhibitor oseltamivir for prophylaxis against influenza--placebo-controlled double-blind multicenter phase III trial].
Topics: Acetamides; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir | 2000 |
Oral oseltamivir treatment of influenza in children.
Topics: Acetamides; Administration, Oral; Antiviral Agents; Child; Child, Preschool; Cough; Double-Blind Method; Female; Humans; Infant; Influenza, Human; Male; Oseltamivir; Safety; Time Factors; Treatment Outcome | 2001 |
Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children.
Topics: Acetamides; Administration, Oral; Adolescent; Antiviral Agents; Area Under Curve; Child; Child, Preschool; Double-Blind Method; Enzyme Inhibitors; Female; Half-Life; Humans; Infant; Influenza A virus; Influenza B virus; Influenza, Human; Male; Neuraminidase; Oseltamivir | 2001 |
Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population.
Topics: Acetamides; Aged; Aged, 80 and over; Antiviral Agents; Double-Blind Method; Europe; Female; Frail Elderly; Homes for the Aged; Humans; Influenza, Human; Male; Neuraminidase; Oseltamivir; United States | 2001 |
The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies.
Topics: Acetamides; Adolescent; Adult; Amoxicillin; Animals; Antiviral Agents; Biological Transport; CHO Cells; Cimetidine; Cricetinae; Cross-Over Studies; Drug Interactions; Female; Humans; Influenza, Human; Kidney; Male; Middle Aged; Neuraminidase; Organic Anion Transport Protein 1; Oseltamivir; p-Aminohippuric Acid; Probenecid; Prodrugs | 2002 |
Role of picornaviruses in flu-like illnesses of adults enrolled in an oseltamivir treatment study who had no evidence of influenza virus infection.
Topics: Acetamides; Adolescent; Adult; Aged; Antiviral Agents; Double-Blind Method; Enterovirus; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Middle Aged; Nasopharynx; Oseltamivir; Picornaviridae Infections; Rhinovirus; RNA, Viral | 2002 |
1795 other study(ies) available for oseltamivir and Grippe
| Article | Year |
|---|---|
Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
Topics: Amides; Animals; Antiviral Agents; Cells, Cultured; Cytopathogenic Effect, Viral; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Lung; Mice; Mice, Inbred BALB C; Oseltamivir; Oxygen; Pyrazines; Survival Analysis; Virus Replication | 2007 |
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
Topics: Animals; Antiviral Agents; Cell Line; Dogs; HeLa Cells; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Mice; Neuraminidase; Prodrugs; Zanamivir | 2009 |
Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance.
Topics: Antiviral Agents; Cells, Cultured; Child, Preschool; Drug Resistance, Viral; Genetic Testing; Humans; Immunocompromised Host; Influenza A Virus, H3N2 Subtype; Influenza, Human; Male; Molecular Sequence Data; Neuraminidase; Oseltamivir; Point Mutation; Sequence Analysis, DNA | 2010 |
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
Topics: Acids, Carbocyclic; Animals; Cell Line; Cyclopentanes; Dogs; Enzyme Assays; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Inhibitory Concentration 50; Neuraminidase; Oseltamivir; Zanamivir | 2010 |
C-Methylated Flavonoids from Cleistocalyx operculatus and Their Inhibitory Effects on Novel Influenza A (H1N1) Neuraminidase.
Topics: Antiviral Agents; Flavonoids; HEK293 Cells; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H9N2 Subtype; Influenza, Human; Inhibitory Concentration 50; Kinetics; Molecular Structure; Myrtaceae; Neuraminidase; Oseltamivir | 2010 |
Intramolecular ion-pair prodrugs of zanamivir and guanidino-oseltamivir.
Topics: Administration, Oral; Antiviral Agents; Carbon Dioxide; Cell Line; Drug Evaluation, Preclinical; Enzyme Inhibitors; Esters; Guanidine; Humans; Hydrophobic and Hydrophilic Interactions; Influenza A virus; Influenza, Human; Ions; Molecular Structure; Naphthols; Neuraminidase; Oseltamivir; Prodrugs; Zanamivir | 2011 |
Computer-guided approach to access the anti-influenza activity of licorice constituents.
Topics: Animals; Antiviral Agents; Austria; Computer-Aided Design; Dogs; Enzyme Inhibitors; Flavonoids; Glycyrrhiza; Humans; Influenza A virus; Influenza, Human; Madin Darby Canine Kidney Cells; Molecular Structure; Neuraminidase; Plant Roots; Virus Replication | 2014 |
1,2,3-Triazolyl-4-oxoquinolines: A feasible beginning for promising chemical structures to inhibit oseltamivir-resistant influenza A and B viruses.
Topics: Antiviral Agents; Drug Design; Drug Resistance, Viral; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Molecular Docking Simulation; Neuraminidase; Oseltamivir; Quinolones; Triazoles | 2015 |
4,6-Diphenylpyridines as Promising Novel Anti-Influenza Agents Targeting the PA-PB1 Protein-Protein Interaction: Structure-Activity Relationships Exploration with the Aid of Molecular Modeling.
Topics: Animals; Antiviral Agents; Crystallography, X-Ray; DNA-Directed RNA Polymerases; Dogs; Drug Design; HEK293 Cells; Humans; Influenza A virus; Influenza, Human; Madin Darby Canine Kidney Cells; Models, Molecular; Molecular Docking Simulation; Pyridines; Structure-Activity Relationship; Viral Plaque Assay; Viral Proteins; Virus Replication | 2016 |
Kinetic, thermodynamic and structural analysis of tamiphosphor binding to neuraminidase of H1N1 (2009) pandemic influenza.
Topics: Antiviral Agents; Catalytic Domain; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Kinetics; Neuraminidase; Oseltamivir; Pandemics; Phosphorous Acids; Protein Binding; Thermodynamics | 2016 |
Design, synthesis and biological evaluation of gentiopicroside derivatives as potential antiviral inhibitors.
Topics: Animals; Antiviral Agents; Cell Line; Drug Design; Humans; Influenza, Human; Iridoid Glucosides; Orthomyxoviridae; Structure-Activity Relationship | 2017 |
Boronic Acid Modifications Enhance the Anti-Influenza A Virus Activities of Novel Quindoline Derivatives.
Topics: Alkaloids; Animals; Antiviral Agents; Boronic Acids; Cell Line; Female; Humans; Indoles; Influenza A virus; Influenza, Human; Mice; NF-kappa B; Orthomyxoviridae Infections; Quinolines; Signal Transduction | 2017 |
From Naproxen Repurposing to Naproxen Analogues and Their Antiviral Activity against Influenza A Virus.
Topics: A549 Cells; Animals; Antiviral Agents; Binding Sites; Cyclooxygenase 2 Inhibitors; Dogs; Drug Design; Drug Repositioning; Drug Resistance, Viral; Female; Humans; Influenza A virus; Influenza, Human; Madin Darby Canine Kidney Cells; Mice, Inbred C57BL; Molecular Docking Simulation; Naproxen; Nucleocapsid Proteins; Oseltamivir; RNA-Binding Proteins; Surface Plasmon Resonance; Viral Core Proteins | 2018 |
De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery.
Topics: Alphainfluenzavirus; Amino Acid Sequence; Antiviral Agents; Coronavirus Infections; Drug Discovery; HEK293 Cells; Humans; Influenza, Human; Lipopeptides; Middle East Respiratory Syndrome Coronavirus; Protein Conformation, alpha-Helical; Viral Fusion Proteins; Virus Internalization | 2018 |
Novel amides modified rupestonic acid derivatives as anti-influenza virus reagents.
Topics: Amides; Antiviral Agents; Azulenes; Crystallography, X-Ray; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Sesquiterpenes | 2019 |
Targeting Endoplasmic Reticulum α-Glucosidase I with a Single-Dose Iminosugar Treatment Protects against Lethal Influenza and Dengue Virus Infections.
Topics: alpha-Glucosidases; Animals; Dengue; Dengue Virus; Dose-Response Relationship, Drug; Endoplasmic Reticulum; Glycoside Hydrolase Inhibitors; Humans; Influenza, Human; Mice, 129 Strain; Mice, Inbred BALB C; Protein Structure, Secondary | 2020 |
Synthesis, Optimization, and Structure-Activity Relationships of Imidazo[1,2-
Topics: Antiviral Agents; Hemagglutinin Glycoproteins, Influenza Virus; Hemagglutinins; Humans; Influenza A virus; Influenza, Human; Oseltamivir; Pyrimidines; Structure-Activity Relationship | 2022 |
Clinically Relevant Influenza Virus Evolution Reconstituted in a Human Lung Airway-on-a-Chip.
Topics: Amantadine; Antiviral Agents; Benzamidines; Drug Resistance, Viral; Evolution, Molecular; Guanidines; Humans; Influenza A virus; Influenza, Human; Lab-On-A-Chip Devices; Lung; Microfluidics; Oseltamivir; SARS-CoV-2 | 2021 |
Bleomycin-Fe(II) agent with potentiality for treating drug-resistant H1N1 influenza virus: A study using electrochemical RNA beacons.
Topics: Bleomycin; Drug Resistance, Viral; Ferrous Compounds; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Pharmaceutical Preparations; RNA, Viral | 2021 |
Early oseltamivir reduces risk for influenza-associated aspergillosis in a double-hit murine model.
Topics: Animals; Aspergillosis; Aspergillus; Aspergillus fumigatus; Coinfection; Disease Models, Animal; Humans; Influenza, Human; Invasive Pulmonary Aspergillosis; Mice; Oseltamivir; Pulmonary Aspergillosis; X-Ray Microtomography | 2021 |
Reverse transcription recombinase-aided amplification assay for rapid detection of the influenza A(H1N1)pdm09 H275Y mutation that confers oseltamivir resistance.
Topics: Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation; Mutation, Missense; Neuraminidase; Oseltamivir; Recombinases; Reverse Transcription | 2021 |
Is it possible to hospitalize patients in multiple-bed room without increasing the risk of hospital-acquired influenza? Description of a pragmatic preventive strategy in a French university hospital.
Topics: Antiviral Agents; Beds; Health Personnel; Hospitals, University; Humans; Influenza, Human; Oseltamivir | 2022 |
Influenza-associated Neurologic Complications in Hospitalized Pediatric Patients: A Multicenter Retrospective Study in Republic of Korea.
Topics: Adolescent; Antiviral Agents; Brain Diseases; Child; Child, Preschool; Female; Hospitalization; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Republic of Korea; Retrospective Studies; Risk Factors; Seizures, Febrile | 2021 |
Impact of empirical oseltamivir discontinuation in hospitalized patients with community-acquired pneumonia after confirmed negative for influenza.
Topics: Community-Acquired Infections; Humans; Influenza, Human; Oseltamivir; Pneumonia; Retrospective Studies | 2021 |
Management of hospitalized influenza A patients during the season 2018/19 : Comparison of three medical departments and the effect on outcome and antibiotic usage.
Topics: Adult; Aged; Anti-Bacterial Agents; Female; Hospitalization; Humans; Influenza, Human; Male; Oseltamivir; Seasons | 2021 |
Influenza clinical testing and oseltamivir treatment in hospitalized children with acute respiratory illness, 2015-2016.
Topics: Antiviral Agents; Child; Child, Hospitalized; Hospitalization; Humans; Influenza, Human; Lung Diseases; Oseltamivir | 2022 |
Association of bleeding symptoms during influenza infection and administered drugs.
Topics: Antiviral Agents; Humans; Influenza, Human; Oseltamivir; Pharmaceutical Preparations; Seasons | 2021 |
Association between Maoto Use and Hospitalization for Seasonal Influenza in a Nonelderly Cohort in Japan.
Topics: Antiviral Agents; Hospitalization; Humans; Influenza, Human; Japan; Medicine, Kampo; Middle Aged; Neuraminidase; Oseltamivir; Seasons | 2021 |
Susceptibility of epidemic viruses to neuraminidase inhibitors and treatment-emergent resistance in the Japanese 2019-20 influenza season.
Topics: Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Japan; Neuraminidase; Oseltamivir; Prospective Studies; Seasons | 2022 |
Comparison of the incidence of bleeding between baloxavir marboxil and other anti-influenza drugs among outpatients with influenza virus infection: A retrospective cohort study using an employment-based health insurance claims database in Japan.
Topics: Antiviral Agents; Communicable Diseases; Dibenzothiepins; Employment; Humans; Incidence; Influenza, Human; Insurance, Health; Japan; Morpholines; Oseltamivir; Outpatients; Pyridones; Retrospective Studies; Triazines; Zanamivir | 2022 |
Outcomes of early oseltamivir treatment for hospitalized adult patients with community-acquired influenza pneumonia.
Topics: Adult; Aged; Cohort Studies; Community-Acquired Infections; Female; Hospitalization; Humans; Influenza, Human; Length of Stay; Male; Middle Aged; Oseltamivir; Pneumonia, Viral; Retrospective Studies; Thailand; Treatment Outcome | 2021 |
Risk factors and disease severity in Australian infants aged under 6 months hospitalised with influenza 2011-2019.
Topics: Australia; Cross Infection; Female; Hospitalization; Humans; Infant; Infant, Newborn; Infant, Premature, Diseases; Influenza Vaccines; Influenza, Human; Male; Oseltamivir; Prospective Studies; Risk Factors; Severity of Illness Index | 2022 |
Zanamivir aqueous solution in severe influenza: A global Compassionate Use Program, 2009-2019.
Topics: Antiviral Agents; Compassionate Use Trials; Enzyme Inhibitors; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2022 |
Antiviral Susceptibilities of Avian Influenza A(H5), A(H7), and A(H9) Viruses Isolated in Japan.
Topics: Animals; Antiviral Agents; DNA-Directed RNA Polymerases; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H5N1 Subtype; Influenza A Virus, H5N2 Subtype; Influenza A Virus, H7N7 Subtype; Influenza A Virus, H7N9 Subtype; Influenza A Virus, H9N2 Subtype; Influenza in Birds; Influenza, Human; Japan; Neuraminidase; Oseltamivir; Poultry | 2022 |
Optimization of application schedule of camphecene, a novel anti-influenza compound, based on its pharmacokinetic characteristics.
Topics: Animals; Antiviral Agents; Camphor; Ethanolamines; Hepatitis C, Chronic; Humans; Influenza, Human; Mice; Oseltamivir; Rabbits | 2022 |
Identification of a Permissive Secondary Mutation That Restores the Enzymatic Activity of Oseltamivir Resistance Mutation H275Y.
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Viral Proteins | 2022 |
Genetic and biological properties of H10N3 avian influenza viruses: A potential pandemic candidate?
Topics: Animals; Chick Embryo; Chickens; Humans; Influenza A Virus, H5N1 Subtype; Influenza A Virus, H7N9 Subtype; Influenza in Birds; Influenza, Human; Mammals; Mice; Neuraminidase; Oseltamivir; Pandemics; Phylogeny; Poultry; Rodent Diseases; Zanamivir | 2022 |
Monitoring influenza virus oseltamivir resistance - our experience to date.
Topics: Animals; Antiviral Agents; Dogs; Drug Resistance, Viral; Humans; Influenza, Human; Neuraminidase; Orthomyxoviridae; Oseltamivir | 2021 |
Comparison of Intra-Familial Transmission of Influenza Virus From Index Patients Treated With Baloxavir Marboxil or Oseltamivir Using an Influenza Transmission Model and a Health Insurance Claims Database.
Topics: Antiviral Agents; Dibenzothiepins; Endonucleases; Humans; Influenza, Human; Insurance, Health; Morpholines; Orthomyxoviridae; Oseltamivir; Oxazines; Pyridines; Pyridones; Thiepins; Triazines | 2022 |
Reducing Unnecessary Respiratory Viral Testing to Promote High-Value Care.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Female; Hospitals, Pediatric; Humans; Infant; Infant, Newborn; Influenza, Human; Male; Microbial Sensitivity Tests; Ontario; Oseltamivir; Quality Improvement; Respiratory Tract Infections; Viral Load | 2022 |
Evaluating Confounding Control in Estimations of Influenza Antiviral Effectiveness in Electronic Health Plan Data.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antiviral Agents; Electronics; Hospitalization; Humans; Influenza, Human; Oseltamivir; Pneumonia; Retrospective Studies | 2022 |
Benign acute childhood myositis associated with influenza A/B in the paediatric emergency department and the efficacy of early-onset oseltamivir.
Topics: Acute Disease; Antiviral Agents; Child; Emergency Service, Hospital; Female; Humans; Influenza, Human; Male; Myositis; Oseltamivir; Retrospective Studies; Rhabdomyolysis | 2022 |
Influenza Testing and Treatment Among Patients Hospitalized With Community-Acquired Pneumonia.
Topics: Adult; Anti-Bacterial Agents; Antiviral Agents; Community-Acquired Infections; Hospitalization; Humans; Influenza, Human; Oseltamivir; Pneumonia; Retrospective Studies | 2022 |
Oseltamivir induced oral-only erythema multiforme.
Topics: Adolescent; Erythema Multiforme; Humans; Influenza, Human; Male; Oseltamivir; Skin; Stevens-Johnson Syndrome | 2022 |
Inhaled Zanamivir vs Oral Oseltamivir to Prevent Influenza-related Hospitalization or Death: A Nationwide Population-based Quasi-experimental Study.
Topics: Antiviral Agents; Cohort Studies; Hospitalization; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2022 |
Characterization of influenza B viruses with reduced susceptibility to influenza neuraminidase inhibitors.
Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2022 |
Duration of fever and symptoms in influenza-infected children treated with baloxavir marboxil during the 2019-2020 season in Japan and detection of influenza virus with the PA E23K substitution.
Topics: Adolescent; Antiviral Agents; Child; Dibenzothiepins; Fever; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Morpholines; Nucleotidyltransferases; Oseltamivir; Pyridones; Seasons; Triazines | 2022 |
Baloxavir vs oseltamivir: reduced utilization and costs in influenza.
Topics: Antiviral Agents; Dibenzothiepins; Humans; Influenza, Human; Morpholines; Oseltamivir; Pyridones; Retrospective Studies; Triazines | 2022 |
Is combination antiviral therapy for influenza the optimal approach?
Topics: Antiviral Agents; Combined Modality Therapy; Drug Therapy, Combination; Humans; Influenza, Human; Oseltamivir | 2022 |
Is Inhaled Zanamivir Non-inferior to Oral Oseltamivir in the Treatment of Outpatients With Influenza?
Topics: Antiviral Agents; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Outpatients; Zanamivir | 2022 |
Covid-19: Stockpiling antivirals risks repeating Tamiflu mistakes, experts warn.
Topics: Antiviral Agents; COVID-19; Dermatologic Agents; Humans; Influenza, Human; Oseltamivir | 2022 |
Discovery and development of oseltamivir at Gilead Sciences.
Topics: COVID-19 Drug Treatment; Humans; Influenza, Human; Oseltamivir; SARS-CoV-2 | 2022 |
Frequency and distribution of H1N1 influenza A viruses with oseltamivir-resistant mutations worldwide before and after the 2009 pandemic.
Topics: Animals; Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Swine; Viral Proteins | 2022 |
A Therapeutically Active Minibody Exhibits an Antiviral Activity in Oseltamivir-Resistant Influenza-Infected Mice via Direct Hydrolysis of Viral RNAs.
Topics: Animals; Antiviral Agents; Humans; Hydrolysis; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mice; Oseltamivir; RNA, Viral; Single-Chain Antibodies | 2022 |
Rosmarinic acid interferes with influenza virus A entry and replication by decreasing GSK3β and phosphorylated AKT expression levels.
Topics: Animals; Antiviral Agents; Cinnamates; Depsides; Glycogen Synthase Kinase 3 beta; Humans; Influenza A virus; Influenza, Human; Mice; Oseltamivir; Proto-Oncogene Proteins c-akt; Rosmarinic Acid; Virus Replication | 2022 |
Effects of baloxavir and oseltamivir antiviral therapy on the transmission of seasonal influenza in China: A mathematical modeling analysis.
Topics: Antiviral Agents; Dibenzothiepins; Humans; Influenza, Human; Morpholines; Oseltamivir; Oxazines; Pyridines; Pyridones; Seasons; Thiepins; Triazines | 2022 |
Clinical effectiveness of baloxavir marboxil against influenza in three seasons.
Topics: Antiviral Agents; Dibenzothiepins; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Morpholines; Oseltamivir; Pyridones; Seasons; Treatment Outcome; Triazines | 2022 |
Response to "Inhaled Zanamivir versus Oral Oseltamivir to Prevent Influenza-related Hospitalization or Death: A Nationwide Population-based Quasi-experimental Study".
Topics: Antiviral Agents; Hospitalization; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2022 |
Oseltamivir modified bovine serum albumin inhibits neuraminidase activity and accumulates virion particles to disturb influenza virus replication.
Topics: Antiviral Agents; Enzyme Inhibitors; Esters; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Serum Albumin, Bovine; Virion; Virus Replication | 2022 |
Predicting Permissive Mutations That Improve the Fitness of A(H1N1)pdm09 Viruses Bearing the H275Y Neuraminidase Substitution.
Topics: Amino Acid Substitution; Animals; Antiviral Agents; Computer Simulation; Disease Models, Animal; Drug Resistance, Viral; Ferrets; Genetic Fitness; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Viral Proteins | 2022 |
Structural Investigations and Binding Mechanisms of Oseltamivir Drug Resistance Conferred by the E119V Mutation in Influenza H7N9 Virus.
Topics: Animals; Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H7N9 Subtype; Influenza in Birds; Influenza, Human; Mutation; Neuraminidase; Oseltamivir | 2022 |
Binding mechanism of oseltamivir and influenza neuraminidase suggests perspectives for the design of new anti-influenza drugs.
Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir | 2022 |
PEtOxylated Interferon-α2a Bioconjugates Addressing H1N1 Influenza A Virus Infection.
Topics: Animals; Antiviral Agents; Ferrets; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza, Human; Mice; Oseltamivir | 2022 |
Online searches of children's oseltamivir in public primary and specialized care: Detecting influenza outbreaks in Finland using dedicated databases for health care professionals.
Topics: Antiviral Agents; Child; Child, Preschool; Disease Outbreaks; Finland; Health Personnel; Humans; Influenza, Human; Oseltamivir | 2022 |
The induction of virus-neutralizing antibodies in influenza A-infected mice treated with Oseltamivir phosphate: effect of dosage and scheduling.
Topics: Animals; Antibodies, Neutralizing; Antiviral Agents; Humans; Influenza A virus; Influenza, Human; Lung; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir; Phosphates | 2022 |
Insights into binding molecular mechanism of hemagglutinin H3N2 of influenza virus complexed with arbidol and its derivative: A molecular dynamics simulation perspective.
Topics: Antiviral Agents; Hemagglutinins; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Molecular Dynamics Simulation; Oseltamivir | 2022 |
Exploring the anti-influenza virus activity of novel triptolide derivatives targeting nucleoproteins.
Topics: Antiviral Agents; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza, Human; Nucleoproteins; Oseltamivir | 2022 |
Association of Early Oseltamivir With Improved Outcomes in Hospitalized Children With Influenza, 2007-2020.
Topics: Antiviral Agents; Child; Child, Hospitalized; Child, Preschool; Female; Hospital Mortality; Hospitalization; Humans; Influenza, Human; Length of Stay; Male; Oseltamivir; Retrospective Studies | 2022 |
Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC
Topics: Adolescent; Adult; Child; Cost-Benefit Analysis; Europe; Humans; Influenza, Human; Oseltamivir; Primary Health Care; Quality of Life; Quality-Adjusted Life Years; Virus Diseases | 2023 |
In Silico Studies Reveal Peramivir and Zanamivir as an Optimal Drug Treatment Even If H7N9 Avian Type Influenza Virus Acquires Further Resistance.
Topics: Acids, Carbocyclic; Antiviral Agents; Arginine; Benserazide; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Molecular Docking Simulation; Mutation; Neuraminidase; Oseltamivir; Zanamivir | 2022 |
Assessment of Temporal Patterns and Patient Factors Associated With Oseltamivir Administration in Children Hospitalized With Influenza, 2007-2020.
Topics: Anti-Bacterial Agents; Antiviral Agents; Child; Cross-Sectional Studies; Female; Hospitalization; Humans; Influenza, Human; Male; Oseltamivir; Oxygen; Retrospective Studies; Treatment Outcome | 2022 |
Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza during 2020-2021.
Topics: Antiviral Agents; Australia; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; World Health Organization; Zanamivir | 2022 |
Low prevalence of influenza A strains with resistance markers in Brazil during 2017-2019 seasons.
Topics: Antiviral Agents; Brazil; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Prevalence; Seasons | 2022 |
Influenza vaccine for 2022-2023.
Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza A virus; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir | 2022 |
Benign acute childhood myositis: Factors associated with muscle symptoms and resolution.
Topics: Acute Disease; Adolescent; Antiviral Agents; Child; Child, Preschool; Creatine Kinase; Female; Humans; Infant; Infant, Newborn; Influenza, Human; Male; Muscles; Myositis; Oseltamivir; Retrospective Studies | 2022 |
An optimized cell-based assay to assess influenza virus replication by measuring neuraminidase activity and its applications for virological surveillance.
Topics: Animals; Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Ferrets; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Reproducibility of Results; Virus Replication | 2022 |
Design of new chemical entities targeting both native and H275Y mutant influenza a virus by deep reinforcement learning.
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir | 2023 |
Novel modelling approaches to predict the role of antivirals in reducing influenza transmission.
Topics: Antiviral Agents; Humans; Influenza, Human; Oseltamivir; Oxazines; Pyridines; Thiepins; Triazines | 2023 |
Comparative effectiveness of oseltamivir versus peramivir for hospitalized children (aged 0-5 years) with influenza infection.
Topics: Antiviral Agents; Child; Child, Hospitalized; Child, Preschool; Coinfection; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Oseltamivir; Treatment Outcome | 2023 |
Oseltamivir is protective for in-patient mortality in PCR confirmed influenza B and influenza A(H3N2) infections in an historic cohort of 1,048 patients hospitalised during the 2016-17 and 2017-18 influenza seasons.
Topics: Antiviral Agents; Hospital Mortality; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Oseltamivir; Polymerase Chain Reaction; Retrospective Studies; Seasons | 2023 |
Oseltamivir-resistant h1n1 influenza virus: Case report.
Topics: Animals; Antiviral Agents; Drug Resistance, Viral; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Swine | 2022 |
Death in children with influenza A (H3N2) virus infection-associated encephalopathy: two case reports.
Topics: Brain Diseases; Child; Encephalitis; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Orthomyxoviridae Infections; Oseltamivir | 2023 |
Effect of neuraminidase inhibitor (oseltamivir) treatment on outcome of hospitalised influenza patients, surveillance data from 11 EU countries, 2010 to 2020.
Topics: Aged; Antiviral Agents; Enzyme Inhibitors; Guanidines; Hospital Mortality; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Treatment Outcome; Zanamivir | 2023 |
Determination of the synergistic anti-influenza effect of Huangqin Su tablet and Oseltamivir and investigation of mechanism of the tablet based on gut microbiota and network pharmacology.
Topics: Animals; DNA, Ribosomal; Female; Gastrointestinal Microbiome; Influenza, Human; Male; Mice; Mice, Inbred ICR; Network Pharmacology; Oseltamivir; Pneumonia; Scutellaria baicalensis | 2023 |
Therapeutic Targeting of Inflammation and Virus Simultaneously Ameliorates Influenza Pneumonia and Protects from Morbidity and Mortality.
Topics: Animals; Antiviral Agents; COVID-19; Cytokines; Etanercept; Humans; Inflammation; Influenza A virus; Influenza, Human; Mice; Morbidity; Oseltamivir; Pneumonia; SARS-CoV-2 | 2023 |
Factors associated with viral RNA shedding and evaluation of potential viral infectivity at returning to school in influenza outpatients after treatment with baloxavir marboxil and neuraminidase inhibitors during 2013/2014-2019/2020 seasons in Japan: an o
Topics: Adult; Antiviral Agents; Child; Enzyme Inhibitors; Humans; Influenza, Human; Japan; Neuraminidase; Oseltamivir; Outpatients; RNA, Viral; Seasons; Zanamivir | 2023 |
An oseltamivir-resistant avian H1N1 influenza A virus can transmit from mallards to chickens similarly to a wild-type strain: implications for the risk of resistance transmission to humans.
Topics: Animals; Antiviral Agents; Chickens; Drug Resistance, Viral; Ducks; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza in Birds; Influenza, Human; Neuraminidase; Oseltamivir | 2023 |
Clinical and Virologic Impacts of Respiratory Viral Co-infections in Children With Influenza.
Topics: Antiviral Agents; Child; Coinfection; Humans; Influenza, Human; Oseltamivir; Virus Diseases; Viruses | 2023 |
Detecting the Neuraminidase R294K Mutation in Avian Influenza A (H7N9) Virus Using Reverse Transcription Droplet Digital PCR Method.
Topics: Animals; Antiviral Agents; Birds; Humans; Influenza A Virus, H7N9 Subtype; Influenza in Birds; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Polymerase Chain Reaction; Reverse Transcription | 2023 |
Efficacy of favipiravir against influenza virus resistant to both baloxavir and neuraminidase inhibitors.
Topics: Animals; Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mice; Neuraminidase; Oseltamivir; Pyridones; Triazines | 2023 |
Detection of H275Y oseltamivir resistance gene mutation among Influenza A(H1N1)pdm09 patients by allelic discrimination real-time RT-PCR.
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation; Mutation, Missense; Neuraminidase; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction | 2023 |
In Vivo Antiviral Activity of Baloxavir against PA/I38T-Substituted Influenza A Viruses at Clinically Relevant Doses.
Topics: Animals; Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Mice; Nucleotidyltransferases; Oseltamivir; Oxazines; Phosphates; Pyridines; Thiepins | 2023 |
Trends in Influenza and Related Health Resource Use During 2005-2021 Among Children in Japan.
Topics: Antiviral Agents; Child; COVID-19; Health Resources; Humans; Influenza, Human; Japan; Oseltamivir; Pandemics; Retrospective Studies | 2023 |
Efficacy of oseltamivir treatment in influenza virus-infected obese mice.
Topics: Animals; Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mice; Mice, Obese; Neuraminidase; Oseltamivir | 2023 |
An armed anti-immunoglobulin light chain nanobody protects mice against influenza A and B infections.
Topics: Animals; Humans; Immunoglobulin Light Chains; Influenza, Human; Mice; Mice, Inbred BALB C; Neuraminidase; Oseltamivir; Zanamivir | 2023 |
The combined effect of oseltamivir and favipiravir on influenza A virus evolution in patients hospitalized with severe influenza.
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir | 2023 |
In Silico Design of an Oseltamivir Derivative with Increased Affinity against Wild-Type and Mutant Variants of Neuraminidase and Hemagglutinin of Influenza A H1N1 Virus.
Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Hemagglutinins; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir | 2023 |
Severe forms of influenza infections admitted in intensive care units: Analysis of mortality factors.
Topics: Adult; Coinfection; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care Units; Oseltamivir; Pneumonia; Respiratory Distress Syndrome; Retrospective Studies | 2023 |
Effectiveness of prolonged versus standard-course of oseltamivir in critically ill patients with severe influenza infection: A multicentre cohort study.
Topics: Adult; Antiviral Agents; Critical Illness; Humans; Influenza, Human; Oseltamivir; Retrospective Studies | 2023 |
Resistance profiles for the investigational neuraminidase inhibitor AV5080 in influenza A and B viruses.
Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Guanidine; Guanidines; Herpesvirus 1, Cercopithecine; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N1 Subtype; Influenza A Virus, H7N9 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2023 |
Early Fever Resolution in Early Childhood Influenza Treated with Baloxavir Marboxil: A Retrospective Study Compared to Those with Oseltamivir.
Topics: Child; Child, Preschool; Dibenzothiepins; Fever; Humans; Influenza, Human; Oseltamivir; Retrospective Studies | 2023 |
Development of chalcone-like derivatives and their biological and mechanistic investigations as novel influenza nuclear export inhibitors.
Topics: Active Transport, Cell Nucleus; Antiviral Agents; Chalcones; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir | 2023 |
Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza during 2022.
Topics: Animals; Antiviral Agents; Australia; Chickens; Drug Resistance, Viral; Female; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; World Health Organization; Zanamivir | 2023 |
Influenza vaccine for 2023-2024.
Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir | 2023 |
Antiviral drugs for influenza for 2023-2024.
Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2023 |
Comparison chart: Antiviral drugs for influenza for 2023-2024.
Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2023 |
Trends in Outpatient Influenza Antiviral Use Among Children and Adolescents in the United States.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Cross-Sectional Studies; Humans; Influenza, Human; Oseltamivir; Outpatients; United States | 2023 |
Prophylactic Treatment with Baloxavir Protects Mice from Lethal Infection with Influenza A and B Viruses.
Topics: Animals; Antiviral Agents; Herpesvirus 1, Cercopithecine; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mice; Mice, Inbred BALB C; Oseltamivir; Oxazines; Phosphates; Pyridines; Thiepins | 2023 |
Oseltamivir use in pregnancy: Risk of birth defects, preterm delivery, and small for gestational age infants.
Topics: Adult; Antiviral Agents; Case-Control Studies; Congenital Abnormalities; Female; Gestational Age; Humans; Infant, Newborn; Infant, Small for Gestational Age; Influenza A Virus, H1N1 Subtype; Influenza, Human; Odds Ratio; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Premature Birth; Prenatal Exposure Delayed Effects; Prospective Studies; Risk; Young Adult | 2019 |
Oseltamivir exposure in pregnancy and the risk of specific birth defects.
Topics: Adult; Case-Control Studies; Congenital Abnormalities; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Odds Ratio; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Young Adult | 2019 |
The evolution and characterization of influenza A(H7N9) virus under the selective pressure of peramivir.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Animals; Antiviral Agents; Cyclopentanes; Dogs; Drug Resistance, Viral; Evolution, Molecular; Gene Expression; Guanidines; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Madin Darby Canine Kidney Cells; Neuraminidase; Oseltamivir; Viral Load; Viral Proteins; Virus Replication | 2019 |
Oseltamivir prophylaxis for the prevention of influenza in healthy healthcare workers: Tolerability and compliance challenges.
Topics: Antiviral Agents; Health Personnel; Humans; Influenza Vaccines; Influenza, Human; Oseltamivir | 2019 |
The respiratory microbiota: associations with influenza symptomatology and viral shedding.
Topics: Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Family Characteristics; Female; Humans; Infant; Influenza, Human; Male; Microbiota; Nicaragua; Nose; Oseltamivir; Pharynx; Real-Time Polymerase Chain Reaction; Smoking; Virus Shedding; Young Adult | 2019 |
Effect of aloin on viral neuraminidase and hemagglutinin-specific T cell immunity in acute influenza.
Topics: Aloe; Animals; Antiviral Agents; Cell Line; Drug Resistance, Viral; Emodin; Hemagglutinins; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neuraminidase; Oseltamivir; Plant Leaves; T-Lymphocytes; Viral Proteins | 2019 |
Molecular characterization of influenza A(H1N1)pdm09 viruses circulating at various geographical locations in India, 2017.
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; India; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Mutation, Missense; Oseltamivir; Phylogeny; RNA, Viral; Sequence Analysis, DNA | 2019 |
Pediatric heart transplant from an incompletely treated influenza A-positive donor.
Topics: Antiviral Agents; Donor Selection; Heart Transplantation; Humans; Infant; Influenza A virus; Influenza, Human; Male; Oseltamivir | 2019 |
Resistance of Influenza Virus to Antiviral Medications.
Topics: Antiviral Agents; Cohort Studies; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pneumonia; Respiratory Distress Syndrome | 2020 |
Oseltamivir Resistance in Severe Influenza A(H1N1)pdm09 Pneumonia and Acute Respiratory Distress Syndrome: A French Multicenter Observational Cohort Study.
Topics: Antiviral Agents; Cohort Studies; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Pneumonia; Respiratory Distress Syndrome | 2020 |
Herpes zoster duplex in a patient with influenza A and bacterial superinfection.
Topics: Adult; Ampicillin; Anti-Bacterial Agents; Antiviral Agents; Coinfection; Herpes Zoster; Humans; Influenza A virus; Influenza, Human; Male; Oseltamivir; Streptococcal Infections; Superinfection; Tonsillitis; Torso; Valacyclovir | 2020 |
Characteristics of hospitalised patients with influenza in 2015-2016 in northern Israel: three circulating strains and continued fear of 2009 A/H1N1.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Female; Hospitalization; Humans; Infant; Infant, Newborn; Influenza, Human; Israel; Male; Middle Aged; Orthomyxoviridae; Oseltamivir; Retrospective Studies; Treatment Outcome; Young Adult | 2019 |
Multi-Dimensional Screening Strategy for Drug Repurposing with Statistical Framework-A New Road to Influenza Drug discovery.
Topics: Algorithms; Alprostadil; Antiviral Agents; Binding Sites; Drug Discovery; Drug Repositioning; Humans; Influenza, Human; Ligands; Molecular Docking Simulation; Molecular Dynamics Simulation; Neuraminidase; Oseltamivir; Protein Binding | 2019 |
Viral Kinetics and Resistance Development in Children Treated with Neuraminidase Inhibitors: The Influenza Resistance Information Study (IRIS).
Topics: Adolescent; Aged; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Humans; Infant; Influenza A Virus, H3N2 Subtype; Influenza, Human; Kinetics; Neuraminidase; Oseltamivir; Prospective Studies | 2020 |
Flu Flying in August
Topics: Antiviral Agents; Humans; Immunocompromised Host; Influenza B virus; Influenza, Human; Lupus Erythematosus, Systemic; Male; Oseltamivir; Seasons; Travel; Treatment Outcome; Young Adult | 2019 |
Influenza-associated mortality in hospital care: a retrospective cohort study of risk factors and impact of oseltamivir in an English teaching hospital, 2016 to 2017.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Female; Guideline Adherence; Hospital Mortality; Hospitals, Teaching; Humans; Infant; Infant, Newborn; Influenza A Virus, H3N2 Subtype; Influenza, Human; Inpatients; Male; Middle Aged; Oseltamivir; Polymerase Chain Reaction; Retrospective Studies; Young Adult | 2019 |
Perfil clínico-epidemiológico de las defunciones por influenza con antecedente de vacunación oportuna, México 2010-2018.
Topics: Antiviral Agents; Comorbidity; Cross-Sectional Studies; Diabetes Mellitus; Female; Humans; Hypertension; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Mexico; Middle Aged; Oseltamivir; Sex Distribution; Vaccination | 2019 |
Effectiveness of four types of neuraminidase inhibitors approved in Japan for the treatment of influenza.
Topics: Adolescent; Child; Child, Preschool; Drug Approval; Enzyme Inhibitors; Fever; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Multivariate Analysis; Mutation; Neuraminidase; Oseltamivir; Proportional Hazards Models; Seasons; Temperature; Treatment Outcome; Young Adult | 2019 |
Transmitted and acquired oseltamivir resistance during the 2018-2019 influenza season.
Topics: Adult; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Female; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Mutation, Missense; Neuraminidase; Oseltamivir; Viral Proteins; Whole Genome Sequencing | 2019 |
Unique synergistic antiviral effects of Shufeng Jiedu Capsule and oseltamivir in influenza A viral-induced acute exacerbation of chronic obstructive pulmonary disease.
Topics: Acute Lung Injury; Animals; Antiviral Agents; Bronchi; Bronchoalveolar Lavage Fluid; Cell Line; Coculture Techniques; Drugs, Chinese Herbal; Epithelial Cells; Humans; Inflammasomes; Inflammation; Influenza A virus; Influenza, Human; Interleukin-18; Interleukin-1beta; Lung; Male; Orthomyxoviridae Infections; Oseltamivir; Pulmonary Disease, Chronic Obstructive; Rats; Rats, Sprague-Dawley; RNA, Messenger; Signal Transduction; Viral Load | 2020 |
Route of Oseltamivir Administration Affects Metabolite Concentrations in Critically Ill Children.
Topics: Administration, Oral; Adolescent; Antiviral Agents; Area Under Curve; Child; Child, Preschool; Critical Illness; Female; Humans; Infant; Influenza, Human; Intubation, Gastrointestinal; Male; Oseltamivir; Prospective Studies; Young Adult | 2019 |
Author's response: influenza-associated mortality oseltamivir: beware of misstepping into stepwise procedures.
Topics: Antiviral Agents; Hospitals, Teaching; Humans; Influenza, Human; Oseltamivir; Retrospective Studies; Risk Factors | 2019 |
Letter to the editor: influenza-associated mortality and oseltamivir: beware of misstepping into stepwise procedures.
Topics: Hospitals, Teaching; Humans; Influenza, Human; Oseltamivir; Retrospective Studies; Risk Factors | 2019 |
Source of oseltamivir resistance due to single E119D and double E119D/H274Y mutations in pdm09H1N1 influenza neuraminidase.
Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Molecular Docking Simulation; Mutation; Neuraminidase; Oseltamivir; Point Mutation; Viral Proteins | 2020 |
Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients With Influenza Virus Infection.
Topics: Aged; Amides; Antiviral Agents; Critical Illness; Drug Therapy, Combination; Female; Humans; Influenza, Human; Male; Middle Aged; Oseltamivir; Pyrazines; Retrospective Studies | 2020 |
[Influenza: Protect effectively with simple measures].
Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir | 2019 |
Neuraminidase inhibitors for influenza-like illness in primary care.
Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Primary Health Care | 2020 |
Massive air leak secondary to influenza B in a 7-year-old: A case report.
Topics: Antiviral Agents; Child; Critical Illness; Extracorporeal Membrane Oxygenation; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Radiography, Thoracic; Respiration, Artificial; Respiratory Distress Syndrome | 2020 |
Optimizing Use of Antibiotics and Antivirals in Ambulatory Patients With Influenza.
Topics: Anti-Bacterial Agents; Antiviral Agents; Hospitalization; Humans; Influenza, Human; Laboratories; Oseltamivir | 2021 |
Influenza A-associated severe pneumonia in hospitalized patients: Risk factors and NAI treatments.
Topics: Acids, Carbocyclic; Antiviral Agents; China; Cyclopentanes; Epidemics; Female; Guanidines; Humans; Influenza A virus; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Pneumonia, Viral; Proportional Hazards Models; Retrospective Studies; Risk Factors | 2020 |
Oseltamivir and the Risk of Neuropsychiatric Events: A National, Population-based Study.
Topics: Aged; Antiviral Agents; Cohort Studies; Humans; Influenza, Human; Oseltamivir; Retrospective Studies | 2020 |
Middle East respiratory syndrome coronavirus (MERS-CoV) - Surveillance and testing in North England from 2012 to 2019.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Coronavirus Infections; England; Epidemiological Monitoring; Female; Humans; Infant; Influenza, Human; Male; Middle Aged; Middle East; Middle East Respiratory Syndrome Coronavirus; Oseltamivir; Polymerase Chain Reaction; Retrospective Studies; Travel-Related Illness; Young Adult | 2020 |
Association study of genetic polymorphisms in proteins involved in oseltamivir transport, metabolism, and interactions with adverse reactions in Mexican patients with acute respiratory diseases.
Topics: Acute Disease; Adolescent; Adult; Antiviral Agents; Biological Transport; Child; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Female; Genetic Association Studies; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Mexico; Middle Aged; Oseltamivir; Polymorphism, Single Nucleotide; Protein Transport; Respiration Disorders; Retrospective Studies; Young Adult | 2020 |
Molecular pathway of influenza pan-neuraminidase inhibitor resistance in an immunocompromised patient.
Topics: Aged; Antiviral Agents; Drug Resistance, Multiple, Viral; Enzyme Inhibitors; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Transplant Recipients; Zanamivir | 2019 |
Oseltamivir for All: Should It Become an Over-the-Counter Medication for Influenza Treatment?
Topics: Antiviral Agents; Drug Approval; Humans; Influenza, Human; Nonprescription Drugs; Oseltamivir; United States; United States Food and Drug Administration | 2020 |
Assessment of efficacy of Oseltamivir-Azithromycin combination therapy in prevention of Influenza-A (H1N1)pdm09 infection complications and rapidity of symptoms relief.
Topics: Antiviral Agents; Azithromycin; Cohort Studies; Drug Therapy, Combination; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Length of Stay; Male; Middle Aged; Oseltamivir; Retrospective Studies; Treatment Outcome | 2020 |
Assessment of adverse events related to anti-influenza neuraminidase inhibitors using the FDA adverse event reporting system and online patient reviews.
Topics: Acids, Carbocyclic; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Female; Guanidines; Humans; Infant; Infant, Newborn; Influenza, Human; Internet; Male; Middle Aged; Neuraminidase; Odds Ratio; Oseltamivir; Patient Participation; Pyrans; Risk Factors; Sialic Acids; United States; United States Food and Drug Administration; Young Adult; Zanamivir | 2020 |
Association of moderately abnormal behavior and administered neuraminidase inhibitors.
Topics: Acids, Carbocyclic; Adolescent; Antiviral Agents; Child; Cyclopentanes; Enzyme Inhibitors; Guanidines; Humans; Illness Behavior; Influenza, Human; Japan; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Young Adult; Zanamivir | 2020 |
Epidemic of influenza A(H1N1)pdm09 analyzed by full genome sequences and the first case of oseltamivir-resistant strain in Myanmar 2017.
Topics: Adolescent; Adult; Amino Acid Substitution; Antigens, Viral; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Epidemics; Female; Genome, Viral; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Mutation, Missense; Myanmar; Oseltamivir; Phylogeny; Young Adult | 2020 |
Molecular characterization of Influenza A pandemic H1N1 viruses circulating in eastern India during 2017-19: Antigenic diversity in comparison to the vaccine strains.
Topics: Adolescent; Adult; Amino Acid Substitution; Antigenic Variation; Child; Child, Preschool; Drug Resistance, Viral; Female; Humans; India; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Phylogeny; Viral Proteins; Young Adult | 2020 |
Weakness, Anemia, and Neutropenia in a 9-Year-Old Girl With Influenza.
Topics: Anemia; Antiviral Agents; Child; Diagnosis, Differential; Fatigue; Female; Fever; Gait Disorders, Neurologic; Humans; Influenza, Human; Muscle Weakness; Neutropenia; Oseltamivir; Spinal Cord Diseases; Vitamin B 12 Deficiency; Vomiting | 2020 |
Management of seasonal influenza by family physicians.
Topics: Adult; Attitude of Health Personnel; Family Practice; Female; France; Guideline Adherence; Health Knowledge, Attitudes, Practice; Humans; Influenza, Human; Male; Middle Aged; Oseltamivir; Physicians, Family; Practice Patterns, Physicians'; Seasons; Surveys and Questionnaires; Vaccination | 2020 |
Effectiveness of favipiravir (T-705) against wild-type and oseltamivir-resistant influenza B virus in mice.
Topics: Amides; Animals; Antiviral Agents; Drug Resistance, Viral; Female; Humans; Influenza B virus; Influenza, Human; Mice; Mice, Inbred C57BL; Oseltamivir; Pyrazines | 2020 |
Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza in 2018.
Topics: Animals; Antigens, Viral; Antiviral Agents; Australia; Chickens; Drug Resistance, Viral; Humans; Influenza A virus; Influenza B virus; Influenza Vaccines; Influenza, Human; Oseltamivir; Phylogeny; World Health Organization; Zanamivir | 2020 |
Influenza A (H1N1): outbreak management in a dialysis unit and clinical outcomes of infection in chronic hemodialysis patients.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Brazil; Comorbidity; Disease Outbreaks; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Oseltamivir; Real-Time Polymerase Chain Reaction; Renal Dialysis; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Vaccination | 2020 |
Effect of antiviral treatment in older patients hospitalized with confirmed influenza.
Topics: Adrenal Cortex Hormones; Aged; Antiviral Agents; Female; Hospitalization; Humans; Influenza, Human; Intensive Care Units; Male; Oseltamivir; Retrospective Studies; Time-to-Treatment; Treatment Outcome | 2020 |
Hemorrhagic colitis can be a life-threatening side effect of oseltamivir.
Topics: Adolescent; Anemia; Antiviral Agents; Blood Transfusion; Colitis; Colonoscopy; Gastrointestinal Hemorrhage; Humans; Influenza A virus; Influenza, Human; Male; Oseltamivir; Treatment Outcome | 2020 |
Adding oseltamivir to usual primary care reduced recovery time in influenza-like illness.
Topics: Antiviral Agents; Humans; Influenza, Human; Oseltamivir; Primary Health Care; Virus Diseases | 2020 |
Development of Novel Anti-influenza Thiazolides with Relatively Broad-Spectrum Antiviral Potentials.
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza, Human; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Zanamivir | 2020 |
Oseltamivir and S-Adenosyl-L-Methionine Combination as Effective Therapeutic Strategy for Suppression of Oxidative Damage in Lung Caused by Influenza Virus Infection in Mice.
Topics: Animals; Antioxidants; Antiviral Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Lung; Male; Mice; Mice, Inbred BALB C; Oseltamivir; Oxidative Stress; S-Adenosylmethionine; Virus Replication | 2020 |
Oseltamivir provides up to 3 days earlier time to recovery over usual care.
Topics: Antiviral Agents; Humans; Influenza, Human; Oseltamivir; Primary Health Care; Virus Diseases | 2020 |
Prophylactic oseltamivir during major seasonal influenza H1N1 outbreak might reduce both H1N1 and associated pulmonary aspergillosis in children undergoing haploidentical transplantation.
Topics: Antiviral Agents; Child; Disease Outbreaks; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pulmonary Aspergillosis; Seasons; Transplantation, Haploidentical | 2020 |
Novel oseltamivir-resistant mutations distant from the active site of influenza B neuraminidase.
Topics: Amino Acid Substitution; Antiviral Agents; Catalytic Domain; Child; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza, Human; Mutation, Missense; Neuraminidase; Oseltamivir; Viral Proteins | 2021 |
Baloxavir for the treatment of Influenza in allogeneic hematopoietic stem cell transplant recipients previously treated with oseltamivir.
Topics: Aged; Antiviral Agents; Dibenzothiepins; Drug Resistance, Viral; Enzyme Inhibitors; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Influenza, Human; Male; Middle Aged; Morpholines; Oseltamivir; Pyridones; Transplant Recipients; Treatment Outcome; Triazines; Virus Shedding | 2020 |
Development of Sustained Release Oseltamivir Phosphate Dry Powder Inhaler:
Topics: Administration, Inhalation; Animals; Antiviral Agents; Delayed-Action Preparations; Drug Carriers; Drug Compounding; Drug Liberation; Drug Stability; Dry Powder Inhalers; Humans; Hypromellose Derivatives; Influenza, Human; Oseltamivir; Particle Size; Powders; Prodrugs; Rats; Spray Drying; Toxicity Tests, Acute | 2020 |
Modeling mitigation of influenza epidemics by baloxavir.
Topics: Antiviral Agents; Betacoronavirus; Cell Proliferation; Coronavirus Infections; COVID-19; Dibenzothiepins; Epidemics; Humans; Influenza, Human; Morpholines; Orthomyxoviridae; Oseltamivir; Oxazines; Pandemics; Pneumonia, Viral; Public Health; Pyridines; Pyridones; RNA, Messenger; SARS-CoV-2; Seasons; Thiepins; Triazines; Viral Load; Virus Replication | 2020 |
Oseltamivir and influenza-related complications in children: a retrospective cohort in primary care.
Topics: Adolescent; Antiviral Agents; Child; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Primary Health Care; Retrospective Studies | 2020 |
The antiviral effects of baloxavir marboxil against influenza A virus infection in ferrets.
Topics: Animals; Antiviral Agents; Body Temperature; Dibenzothiepins; Ferrets; Humans; Influenza A virus; Influenza, Human; Microsomes; Morpholines; Orthomyxoviridae Infections; Oseltamivir; Pyridones; Triazines; Viral Load | 2020 |
Effectiveness of Oseltamivir Prophylaxis in Influenza Outbreaks in Residential Aged Care.
Topics: Aged; Antiviral Agents; Cohort Studies; Disease Outbreaks; Homes for the Aged; Humans; Influenza, Human; New South Wales; Oseltamivir; Post-Exposure Prophylaxis; Treatment Outcome | 2020 |
Risks in clinical applications of oseltamivir phosphate in the real world.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Dose-Response Relationship, Drug; Female; Humans; Influenza, Human; Male; Middle Aged; Oseltamivir; Respiratory Tract Infections; Retrospective Studies; Risk Factors; Young Adult | 2020 |
[Review of current and future directions of antiviral therapy of influenza and acute respiratory viral infections in Russia].
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza, Human; Oseltamivir; Russia; Zanamivir | 2019 |
A retrospective observational study of the treatment of a nosocomial infection caused by oseltamivir-resistant influenza virus A with baloxavir marboxil.
Topics: Cross Infection; Dibenzothiepins; Disease Outbreaks; Drug Resistance, Viral; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Male; Morpholines; Oseltamivir; Oxazines; Pre-Exposure Prophylaxis; Pyridines; Pyridones; Retrospective Studies; Thiepins; Treatment Outcome; Triazines | 2020 |
Combinatory Treatment with Oseltamivir and Itraconazole Targeting Both Virus and Host Factors in Influenza A Virus Infection.
Topics: Antiviral Agents; Cell Line; Drug Synergism; Drug Therapy, Combination; Host-Pathogen Interactions; Humans; Influenza A virus; Influenza, Human; Itraconazole; Oseltamivir | 2020 |
Successful treatment with baloxavir marboxil of a patient with peramivir-resistant influenza A/H3N2 with a dual E119D/R292K substitution after allogeneic hematopoietic cell transplantation: a case report.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Dibenzothiepins; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Influenza A Virus, H3N2 Subtype; Influenza, Human; Male; Middle Aged; Morpholines; Mutation; Neuraminidase; Oseltamivir; Oxazines; Pyridines; Pyridones; Thiepins; Transplantation, Homologous; Treatment Outcome; Triazines; Viral Proteins | 2020 |
Characterization of neuraminidase inhibitor-resistant influenza virus isolates from immunocompromised patients in the Republic of Korea.
Topics: Acids, Carbocyclic; Adult; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Female; Guanidines; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation; Neuraminidase; Oropharynx; Oseltamivir; Phylogeny; Republic of Korea; Sequence Analysis, DNA; Zanamivir | 2020 |
Clinical outcomes of baloxavir versus oseltamivir in patients hospitalized with influenza A.
Topics: Adult; Antiviral Agents; Dibenzothiepins; Humans; Influenza, Human; Morpholines; Oseltamivir; Pyridones; Retrospective Studies; Triazines | 2020 |
Successful treatment of influenza B associated acute necrotizing encephalopathy in an adult using combination of high dose oseltamivir-IVIG-pulse metylprednisolone.
Topics: Antiviral Agents; Brain; Drug Therapy, Combination; Female; Humans; Immunoglobulins, Intravenous; Influenza B virus; Influenza, Human; Leukoencephalitis, Acute Hemorrhagic; Methylprednisolone; Middle Aged; Oseltamivir | 2021 |
Pharmacologic effects of oseltamivir in immunocompromised adult patients as assessed by population PK/PD analysis and drug-disease modelling for dosing regimen optimization.
Topics: Adult; Antiviral Agents; Humans; Influenza, Human; Oseltamivir; Pharmaceutical Preparations; Virus Shedding | 2021 |
Influenza-induced hemolytic crisis in glucose-6-phosphate dehydrogenase deficiency.
Topics: Anemia, Hemolytic; Antiviral Agents; Child; Glucosephosphate Dehydrogenase Deficiency; Hemoglobins; Hemoglobinuria; Humans; Influenza A virus; Influenza, Human; Japan; Male; Oseltamivir; Reactive Oxygen Species | 2020 |
Profile and generation of reduced neuraminidase inhibitor susceptibility in highly pathogenic avian influenza H7N9 virus from human cases in Mainland of China, 2016-2019.
Topics: Amino Acid Substitution; Animals; Antiviral Agents; Birds; Drug Resistance, Viral; Enzyme Inhibitors; Gene Expression; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A Virus, H7N9 Subtype; Influenza in Birds; Influenza, Human; Microbial Sensitivity Tests; Models, Molecular; Mutation; Neuraminidase; Oseltamivir; Protein Conformation; Reassortant Viruses; Viral Proteins; Zanamivir | 2020 |
Efficacy comparison of oseltamivir alone and oseltamivir-antibiotic combination for early resolution of symptoms of severe influenza-A and influenza-B hospitalized patients.
Topics: Adult; Aged; Anti-Bacterial Agents; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hospitalization; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Inpatients; Male; Middle Aged; Multicenter Studies as Topic; Oseltamivir; Retrospective Studies; Severity of Illness Index; Time Factors; Treatment Outcome | 2020 |
Effectiveness of oseltamivir in reduction of complications and 30-day mortality in severe seasonal influenza infection.
Topics: Aged; Antiviral Agents; Comorbidity; Female; Hospital Mortality; Humans; Influenza, Human; Length of Stay; Male; Middle Aged; Netherlands; Neuraminidase; Oseltamivir; Propensity Score; Retrospective Studies; Treatment Outcome | 2020 |
The Certainty Framework for Assessing Real-World Data in Studies of Medical Product Safety and Effectiveness.
Topics: Algorithms; Antiviral Agents; Data Analysis; Humans; Influenza, Human; Information Storage and Retrieval; Oseltamivir; Research Design; Rivaroxaban | 2021 |
Teaching NeuroImages: Cytotoxic Lesion of the Corpus Callosum Secondary to Influenza A.
Topics: Adult; Antiviral Agents; Corpus Callosum; Humans; Influenza A virus; Influenza, Human; Male; Oseltamivir | 2021 |
Use of point-of-care molecular tests reduces hospitalization and oseltamivir administration in children presenting with influenza-like illness.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Emergency Service, Hospital; Female; Health Care Costs; Hospitalization; Humans; Immunoassay; Infant; Infant, Newborn; Influenza, Human; Male; Molecular Diagnostic Techniques; Oseltamivir; Point-of-Care Testing; Prospective Studies; Virus Diseases | 2021 |
Efficacy of clarithromycin-naproxen-oseltamivir combination therapy versus oseltamivir alone in hospitalized pediatric influenza patients.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Child; Child, Preschool; Clarithromycin; Drug Therapy, Combination; Female; Hospitalization; Hospitals, Pediatric; Humans; Infant; Influenza, Human; Male; Naproxen; Oseltamivir; Prospective Studies; Single-Blind Method; Treatment Outcome; Viral Load | 2021 |
Evaluation of the Effectiveness of Metabolites of Bacterial Strains Bacillus thuringiensis against Human Influenza Virus A/Aichi/2/68 (H3N2) In Vitro and In Vivo.
Topics: Antiviral Agents; Bacillus thuringiensis; Humans; Influenza A virus; Influenza A Virus, H3N2 Subtype; Influenza, Human; Kobuvirus; Oseltamivir | 2020 |
Duration of fever and symptoms in children after treatment with baloxavir marboxil and oseltamivir during the 2018-2019 season and detection of variant influenza a viruses with polymerase acidic subunit substitutions.
Topics: Adolescent; Amino Acid Substitution; Antiviral Agents; Child; Child, Preschool; Dibenzothiepins; Female; Fever; Genetic Variation; Humans; Influenza A virus; Influenza, Human; Male; Morpholines; Oseltamivir; Prospective Studies; Pyridones; RNA-Dependent RNA Polymerase; Seasons; Triazines; Viral Proteins | 2020 |
Intravenous Zanamivir: A Viable Option for Critically Ill Patients With Influenza.
Topics: Antiviral Agents; Critical Illness; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2021 |
Neuraminidase characterisation reveals very low levels of antiviral resistance and the presence of mutations associated with reduced antibody effectiveness in the Irish influenza 2018/2019 season.
Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Ireland; Mutation; Neuraminidase; Oseltamivir; Seasons | 2020 |
Aphasia and confusion - influenza encephalopathy: atypical presentation of influenza.
Topics: Adult; Aphasia; Confusion; Diagnosis, Differential; Encephalitis, Viral; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Treatment Outcome | 2020 |
Influenza B-associated encephalitis with rapid improvement with oseltamivir.
Topics: Adult; Brain Diseases; Encephalitis; Encephalitis, Viral; Female; Humans; Influenza, Human; Oseltamivir | 2021 |
Point-of-Care Influenza Testing in the Pediatric Emergency Department.
Topics: Adolescent; Anti-Bacterial Agents; Antiviral Agents; Blood Cell Count; Child; Child, Preschool; Diagnostic Imaging; Emergency Service, Hospital; Female; Hospitals, Pediatric; Humans; Infant; Influenza, Human; Male; Oseltamivir; Point-of-Care Testing; Polymerase Chain Reaction; Retrospective Studies; Urinalysis | 2020 |
Comparison of Household Transmission of Influenza Virus From Index Patients Treated With Baloxavir Marboxil or Neuraminidase Inhibitors: A Health Insurance Claims Database Study.
Topics: Antiviral Agents; Dibenzothiepins; Enzyme Inhibitors; Humans; Influenza, Human; Insurance, Health; Morpholines; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pyridones; Triazines | 2021 |
Diagnostic difficulties of AH1N1 influenza infection in children with acute lymphoblastic leukemia: Two case reports.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Child, Preschool; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Risk Factors | 2020 |
Why we should be more careful using hydroxychloroquine in influenza season during COVID-19 pandemic?
Topics: Adult; Aged; Aged, 80 and over; Azithromycin; COVID-19 Drug Treatment; Electrocardiography; Female; Humans; Hydroxychloroquine; Influenza, Human; Long QT Syndrome; Male; Middle Aged; Oseltamivir; SARS-CoV-2 | 2021 |
Association between oseltamivir use and neuropsychiatric adverse events in influenza patients: a nationwide population-based cohort study.
Topics: Adolescent; Adult; Age Factors; Aged; Antiviral Agents; Child; Child, Preschool; Cohort Studies; Databases, Factual; Female; Humans; Incidence; Infant; Infant, Newborn; Influenza, Human; Male; Mental Disorders; Middle Aged; Neurotoxicity Syndromes; Oseltamivir; Republic of Korea; Retrospective Studies; Young Adult | 2021 |
Hyperacute relapse of Lewis-Sumner syndrome during influenza A (H1N1) virus infection.
Topics: Antiviral Agents; Chronic Disease; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Magnetic Resonance Imaging; Male; Middle Aged; Oseltamivir; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Recurrence; Syndrome | 2020 |
Baloxavir treatment of oseltamivir-resistant influenza A/H1pdm09 in two immunocompromised patients.
Topics: Alphainfluenzavirus; Antiviral Agents; Dibenzothiepins; Drug Resistance, Viral; Humans; Immunocompromised Host; Influenza, Human; Morpholines; Neuraminidase; Oseltamivir; Pyridones; Triazines; Zanamivir | 2021 |
Effect of early oseltamivir on outpatients without hypoxia with suspected COVID-19.
Topics: Adult; Antiviral Agents; China; COVID-19; Female; Humans; Hypoxia; Influenza, Human; Male; Middle Aged; Oseltamivir; Outpatients; SARS-CoV-2 | 2021 |
Comparison of Hospitalization Incidence in Influenza Outpatients Treated With Baloxavir Marboxil or Neuraminidase Inhibitors: A Health Insurance Claims Database Study.
Topics: Antiviral Agents; Cohort Studies; Dibenzothiepins; Enzyme Inhibitors; Hospitalization; Humans; Incidence; Influenza, Human; Insurance, Health; Morpholines; Neuraminidase; Oseltamivir; Outpatients; Pyridones; Retrospective Studies; Triazines | 2021 |
Low rate of oseltamivir prescription among adults and children with confirmed influenza illness in France during the 2018-19 influenza season.
Topics: Adult; Antiviral Agents; Child; Enzyme Inhibitors; Female; France; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pregnancy; Prescriptions; Prospective Studies; Seasons; Zanamivir | 2021 |
Reconstitution of Oseltamivir Capsules for Pediatric Use on a Long-Term Cruise: A Treatment Option.
Topics: Administration, Oral; Antiviral Agents; Capsules; Child, Preschool; Drug Compounding; Female; Humans; Infant; Influenza, Human; Male; Oseltamivir; Ships; Travel | 2021 |
Effectiveness of Oseltamivir in reducing 30-day readmissions and mortality among patients with severe seasonal influenza in Australian hospitalized patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Australia; Female; Hospital Mortality; Hospitalization; Humans; Influenza, Human; Length of Stay; Male; Middle Aged; Oseltamivir; Patient Readmission; Retrospective Studies; Seasons; Severity of Illness Index; Treatment Outcome; Young Adult | 2021 |
Administration of a CXC Chemokine Receptor 2 (CXCR2) Antagonist, SCH527123, Together with Oseltamivir Suppresses NETosis and Protects Mice from Lethal Influenza and Piglets from Swine-Influenza Infection.
Topics: Animals; Benzamides; Cyclobutanes; Extracellular Traps; Humans; Influenza, Human; Leukocyte Elastase; Lung; Mice; Neutrophil Activation; Neutrophils; Orthomyxoviridae Infections; Oseltamivir; Receptors, Interleukin-8B; Swine | 2021 |
Comparative efficacy assessment of antiviral alone and antiviral-antibiotic combination in prevention of influenza-B infection associated complications.
Topics: Adult; Aged; Anti-Bacterial Agents; Antiviral Agents; Bacterial Infections; Drug Therapy, Combination; Female; Hospitalization; Humans; Influenza B virus; Influenza, Human; Length of Stay; Male; Middle Aged; Oseltamivir; Retrospective Studies; Treatment Outcome | 2021 |
Assessment of Antiviral combination therapy with Cephalosporin antibiotic for prevention of severe Influenza-A (H1N1)pdm09 infection associated secondary bacterial infection and other complications.
Topics: Antiviral Agents; Bacterial Infections; Cephalosporins; Cohort Studies; Coinfection; Drug Therapy, Combination; Female; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir | 2020 |
Oseltamivir-Associated Bradycardia in Critically Ill Patients.
Topics: Adult; Antiviral Agents; Bradycardia; Critical Illness; Humans; Influenza, Human; Oseltamivir; Retrospective Studies | 2021 |
[Scientific research in times of pandemics.]
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; COVID-19; COVID-19 Vaccines; Disease Outbreaks; Drug Approval; European Union; Humans; Influenza, Human; Information Dissemination; Informed Consent; Oseltamivir; Pandemics; Peer Review, Research; Periodicals as Topic; Politics; Publishing; Research; Risk; SARS-CoV-2; Time Factors; United States | 2021 |
Deciphering molecular mechanics in the taste masking ability of Maltodextrin: Developing pediatric formulation of Oseltamivir for viral pandemia.
Topics: Aversive Agents; Drug Compounding; Female; Humans; Influenza, Human; Male; Molecular Dynamics Simulation; Oseltamivir; Polysaccharides; Solubility; Taste Perception; Young Adult | 2021 |
Secondary substitutions in the hemagglutinin and neuraminidase genes associated with neuraminidase inhibitor resistance are rare in the Influenza Resistance Information Study (IRIS).
Topics: Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Genetic Fitness; Hemagglutinins; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Mutation, Missense; Neuraminidase; Orthomyxoviridae; Oseltamivir; Prospective Studies; RNA, Viral; Viral Proteins | 2021 |
Differences in antibiotic and antiviral use in people with confirmed influenza: a retrospective comparison of rapid influenza PCR and multiplex respiratory virus PCR tests.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antimicrobial Stewardship; Antiviral Agents; Emergency Service, Hospital; Female; Humans; Influenza, Human; Inpatients; Length of Stay; Male; Middle Aged; Multiplex Polymerase Chain Reaction; Oseltamivir; Retrospective Studies | 2021 |
Detection of Variants With Reduced Baloxavir Marboxil and Oseltamivir Susceptibility in Children With Influenza A During the 2019-2020 Influenza Season.
Topics: Antiviral Agents; Child; Dibenzothiepins; Drug Resistance, Viral; Humans; Influenza, Human; Morpholines; Neuraminidase; Oseltamivir; Oxazines; Protein Subunits; Pyridines; Pyridones; RNA, Viral; Seasons; Thiepins; Triazines | 2021 |
[Influenza A-associated acute necrotizing encephalopathy].
Topics: Antiviral Agents; Child; Follow-Up Studies; Glucocorticoids; Humans; Influenza A virus; Influenza, Human; Leukoencephalitis, Acute Hemorrhagic; Magnetic Resonance Imaging; Male; Methylprednisolone; Oseltamivir | 2020 |
Oseltamivir treatment of influenza A and B infections in infants.
Topics: Antiviral Agents; Child; Humans; Infant; Infant, Newborn; Influenza Vaccines; Influenza, Human; Oseltamivir; Prospective Studies; Treatment Outcome | 2021 |
Virological and clinical outcomes in outpatients treated with baloxavir or oseltamivir: A Japanese multicenter study in the 2019-2020 influenza season.
Topics: Antiviral Agents; Dibenzothiepins; Drug Resistance, Viral; Genetic Variation; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Morpholines; Neuraminidase; Oseltamivir; Outpatients; Prospective Studies; Pyridones; RNA-Dependent RNA Polymerase; Seasons; Treatment Outcome; Triazines; Viral Proteins | 2021 |
Assessment of Adherence to Post-exposure Prophylaxis with Oseltamivir in Healthcare Workers: A Retrospective Questionnaire-Based Study.
Topics: Antiviral Agents; Health Personnel; Humans; Influenza, Human; Medication Adherence; Oseltamivir; Post-Exposure Prophylaxis; Retrospective Studies | 2021 |
Cluster of Oseltamivir-Resistant and Hemagglutinin Antigenically Drifted Influenza A(H1N1)pdm09 Viruses, Texas, USA, January 2020.
Topics: Antiviral Agents; Drug Resistance, Viral; Hemagglutinins; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Texas; Viral Proteins | 2021 |
Reducing Influenza Virus Transmission: The Potential Value of Antiviral Treatment.
Topics: Animals; Antiviral Agents; Drug Resistance, Viral; Humans; Influenza, Human; Neuraminidase; Orthomyxoviridae; Oseltamivir; Virus Replication | 2022 |
Substitution of I222L-E119V in neuraminidase from highly pathogenic avian influenza H7N9 virus exhibited synergistic resistance effect to oseltamivir in mice.
Topics: Amino Acid Substitution; Animals; Antiviral Agents; Birds; Cell Line; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Female; HEK293 Cells; Humans; Influenza A Virus, H7N9 Subtype; Influenza in Birds; Influenza, Human; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred C57BL; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Viral Proteins; Virus Replication | 2021 |
Dosing regimen optimisation for oseltamivir in immunocompromised paediatric patients with influenza: Extrapolation of efficacy.
Topics: Adult; Antiviral Agents; Child; Clinical Protocols; Humans; Influenza, Human; Oseltamivir | 2022 |
Rapid Influenza Diagnostic Tests Improve Suitability of Antiviral Treatment in Hospitalized Children.
Topics: Antiviral Agents; Child, Hospitalized; Child, Preschool; Female; Humans; Infant; Influenza A virus; Influenza, Human; Male; Oseltamivir | 2017 |
Influenza A(H1N1)pdm09 outbreak detected in inter-seasonal months during the surveillance of influenza-like illness in Pune, India, 2012-2015.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Climate; Disease Outbreaks; Female; Hemagglutinins, Viral; Humans; India; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Phylogeny; RNA, Viral; Seasons; Sequence Analysis, RNA; Young Adult | 2017 |
Evolution of the neuraminidase gene of seasonal influenza A and B viruses in Thailand between 2010 and 2015.
Topics: Drug Resistance, Viral; Epitopes, B-Lymphocyte; Evolution, Molecular; Genotype; Glycosylation; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Phylogeny; RNA, Viral; Seasons; Thailand | 2017 |
The novel carboxylesterase 1 variant c.662A>G may decrease the bioactivation of oseltamivir in humans.
Topics: Adult; Alleles; Antiviral Agents; Carboxylic Ester Hydrolases; Genotype; Humans; Influenza, Human; Male; Oseltamivir; Pharmacogenetics; Polymorphism, Single Nucleotide; Tandem Mass Spectrometry; Young Adult | 2017 |
Epidemiological & clinical profile of influenza A (H1N1) 2009 virus infections during 2015 epidemic in Rajasthan.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Disease Outbreaks; Female; Humans; India; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Middle Aged; Oseltamivir; Pregnancy; Risk Factors; Young Adult | 2016 |
Antiviral activity of formyl peptide receptor 2 antagonists against influenza viruses.
Topics: A549 Cells; Animals; Antiviral Agents; Cell Survival; Dogs; Drug Combinations; Female; Gelsolin; Haplorhini; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Madin Darby Canine Kidney Cells; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Oligopeptides; Oseltamivir; Peptide Fragments; Receptors, Formyl Peptide; Receptors, Lipoxin; Sequence Alignment; Virus Replication | 2017 |
Combined interventions for mitigation of an influenza A (H1N1) 2009 outbreak in a physical training camp in Beijing, China.
Topics: Adolescent; Adult; Antiviral Agents; Beijing; Disease Outbreaks; Female; Humans; Incidence; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Public Health; Young Adult | 2017 |
Monitoring influenza virus susceptibility to oseltamivir using a new rapid assay, iART.
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir | 2017 |
Findings of an Observational Study of Neuraminidase Inhibitors Highly Sensitive to Decision to Exclude 1652 Treated Patients.
Topics: Antiviral Agents; Enzyme Inhibitors; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Outpatients | 2017 |
Linear polysialoside outperforms dendritic analogs for inhibition of influenza virus infection in vitro and in vivo.
Topics: Analysis of Variance; Animals; Antiviral Agents; Cell Line; Disease Models, Animal; Dogs; Drug Synergism; Enzyme Inhibitors; Glycerol; Humans; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H7N1 Subtype; Influenza in Birds; Influenza, Human; Inhibitory Concentration 50; Madin Darby Canine Kidney Cells; Mice; Models, Statistical; Nanoparticles; Oseltamivir; Polymers; Poultry; Sialic Acids | 2017 |
Pneumomediastinum and subcutaneous emphysema associated with influenza A H1N1 virus.
Topics: Antiviral Agents; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Mediastinal Emphysema; Middle Aged; Oseltamivir; Oxygen; Subcutaneous Emphysema; Tomography, X-Ray Computed | 2017 |
Effect of target-enriched multiplex polymerase chain reaction on patient outcomes and costs during the 2013-14 influenza season.
Topics: Antiviral Agents; Health Care Costs; Humans; Influenza, Human; Molecular Diagnostic Techniques; Multiplex Polymerase Chain Reaction; Nasopharynx; Oseltamivir; Patient Isolation; Retrospective Studies; Treatment Outcome; United States | 2017 |
Preliminary Epidemiology of Human Infections with Highly Pathogenic Avian Influenza A(H7N9) Virus, China, 2017.
Topics: Animals; Antiviral Agents; China; Humans; Influenza A Virus, H7N9 Subtype; Influenza in Birds; Influenza, Human; Oseltamivir; Population Surveillance; Poultry; Poultry Diseases | 2017 |
WHO downgrades oseltamivir on drugs list after reviewing evidence.
Topics: Antiviral Agents; Cost-Benefit Analysis; Evidence-Based Medicine; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; United Kingdom; World Health Organization | 2017 |
Multipathogenic necrotising supraglottitis in an immunocompetent patient.
Topics: Adult; Anti-Bacterial Agents; Critical Illness; Debridement; Enterococcus faecalis; Haemophilus Infections; Haemophilus influenzae type b; Humans; Immunocompetence; Influenza A virus; Influenza, Human; Male; Necrosis; Oseltamivir; Penicillin G; Supraglottitis; Tracheostomy; Treatment Outcome | 2017 |
Dampness Can Promote the Influenza A Virus and Worsen Its Prognosis by Upregulating the TLR7 Signaling Pathway.
Topics: Animals; Antiviral Agents; Environmental Exposure; Humans; Influenza A virus; Influenza, Human; Mice; Mice, Inbred C57BL; Oseltamivir; Prognosis; Signal Transduction; Toll-Like Receptor 7 | 2017 |
[Clinical efficacy observation of atomization inhalation combined with oral administration of oseltamivir in 4 cases with H7N9 avian influenza].
Topics: Administration, Inhalation; Administration, Oral; Antiviral Agents; China; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Oseltamivir; Treatment Outcome | 2017 |
Antiviral activity of a synthesized shikonin ester against influenza A (H1N1) virus and insights into its mechanism.
Topics: A549 Cells; Animals; Antiviral Agents; Apoptosis; Cell Line; Cell Line, Tumor; Dogs; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Madin Darby Canine Kidney Cells; Naphthoquinones; Orthomyxoviridae Infections; Oseltamivir; Structure-Activity Relationship; Viral Proteins | 2017 |
WHO downgrades status of oseltamivir.
Topics: Antiviral Agents; Humans; Influenza, Human; Observational Studies as Topic; Oseltamivir; Strategic Stockpile; World Health Organization | 2017 |
Characterization of oseltamivir-resistant influenza virus populations in immunosuppressed patients using digital-droplet PCR: Comparison with qPCR and next generation sequencing analysis.
Topics: Antiviral Agents; Drug Resistance, Viral; High-Throughput Nucleotide Sequencing; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Molecular Diagnostic Techniques; Mutation, Missense; Neuraminidase; Oseltamivir; Real-Time Polymerase Chain Reaction; Viral Proteins | 2017 |
The anti-influenza drug oseltamivir reduces atrial fibrillation in an experimental whole-heart model.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Antiviral Agents; Atrial Fibrillation; Heart; Humans; In Vitro Techniques; Influenza, Human; Oseltamivir; Rabbits | 2017 |
Adverse events of prophylactic anti-influenza agents in medical staffs.
Topics: Adult; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Humans; Influenza, Human; Medical Staff; Middle Aged; Oseltamivir; Post-Exposure Prophylaxis; Retrospective Studies; Zanamivir | 2017 |
The combination of oseltamivir with azithromycin does not show additional benefits over oseltamivir monotherapy in mice infected with influenza A(H1N1)pdm2009 virus.
Topics: Animals; Antiviral Agents; Azithromycin; Drug Therapy, Combination; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Injections, Intraperitoneal; Lung; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir; Viral Load | 2017 |
Human infection with a novel H7N9 avian influenza virus in Yunnan, China.
Topics: Anti-Bacterial Agents; Antiviral Agents; Cefotaxime; China; Drug Therapy, Combination; Female; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Oseltamivir; Tomography, X-Ray Computed; Vancomycin; Young Adult | 2018 |
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Epidemiological Monitoring; Global Health; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza B virus; Influenza, Human; Inhibitory Concentration 50; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Pyrans; Seasons; Sialic Acids; World Health Organization; Zanamivir | 2017 |
Susceptibility of influenza A(H1N1)/pdm2009, seasonal A(H3N2) and B viruses to Oseltamivir in Guangdong, China between 2009 and 2014.
Topics: Amino Acid Sequence; Animals; Antiviral Agents; Base Sequence; China; Dogs; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Madin Darby Canine Kidney Cells; Mutation; Neuraminidase; Oseltamivir; RNA, Viral; Seasons | 2017 |
Oseltamivir use and severe abnormal behavior in Japanese children and adolescents with influenza: Is a self-controlled case series study applicable?
Topics: Adolescent; Antiviral Agents; Child; Female; Humans; Influenza, Human; Male; Oseltamivir; Prospective Studies; Research Design; Social Behavior Disorders; Treatment Outcome; Young Adult | 2017 |
Clinical Profile and Outcome of Influenza A/H1N1 in Pediatric Oncology Patients During the 2015 Outbreak: A Single Center Experience from Northern India.
Topics: Antineoplastic Agents; Antiviral Agents; Child; Disease Outbreaks; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neoplasms; Oseltamivir; Retrospective Studies; Treatment Outcome | 2017 |
Clinical course of asthma patients with H1N1 influenza infection and oseltamivir.
Topics: Adult; Antiviral Agents; Asthma; Cross-Sectional Studies; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Retrospective Studies; Risk Factors | 2018 |
Influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza annual report, 2015.
Topics: Africa; Annual Reports as Topic; Antigens, Viral; Antiviral Agents; Asia; Australia; Drug Resistance, Viral; Genotype; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza Vaccines; Influenza, Human; Oseltamivir; Phylogeny; World Health Organization; Zanamivir | 2017 |
Drug Susceptibility Evaluation of an Influenza A(H7N9) Virus by Analyzing Recombinant Neuraminidase Proteins.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Databases, Genetic; Drug Resistance, Multiple, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Inhibitory Concentration 50; Neuraminidase; Oseltamivir; Protein Conformation; Pyrans; Recombinant Proteins; Sialic Acids; Viral Proteins; Zanamivir | 2017 |
Finding the right combination antiviral therapy for influenza.
Topics: Antiviral Agents; Drug Therapy, Combination; Humans; Influenza, Human; Oseltamivir | 2017 |
Pharmaceutical lobbying and pandemic stockpiling of Tamiflu: a qualitative study of arguments and tactics.
Topics: Antiviral Agents; Denmark; Drug Industry; Humans; Influenza, Human; Lobbying; Oseltamivir; Pandemics; Strategic Stockpile | 2018 |
Case Report: Severe Imported Influenza Infections Developed during Travel in Reunion Island.
Topics: Aged; Antiviral Agents; Bronchoalveolar Lavage Fluid; Female; France; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Oseltamivir; Reunion; Travel; Vaccination | 2017 |
Early oseltamivir therapy improves the outcome in critically ill patients with influenza: a propensity analysis.
Topics: Aged; Antiviral Agents; Critical Illness; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Treatment Outcome | 2018 |
Screening for Neuraminidase Inhibitor Resistance Markers among Avian Influenza Viruses of the N4, N5, N6, and N8 Neuraminidase Subtypes.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Animals; Antiviral Agents; Birds; Cyclopentanes; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza in Birds; Influenza, Human; Madin Darby Canine Kidney Cells; Mutagenesis; Neuraminidase; Orthomyxoviridae; Oseltamivir; Reverse Genetics; Zanamivir | 2018 |
Triple therapy reduced mortality more than oseltamivir alone in patients admitted for severe influenza infection.
Topics: Antiviral Agents; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir | 2017 |
Molecular and epidemiological analysis of pandemic and post-pandemic influenza A(H1N1)pdm09 virus from central India.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Female; Hemagglutinin Glycoproteins, Influenza Virus; Humans; India; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Mutation; Oseltamivir; Pandemics; Phylogeny; Real-Time Polymerase Chain Reaction; RNA, Viral; Sequence Analysis, DNA; Young Adult | 2018 |
Characterization of the neuraminidase genes from human influenza A viruses circulating in Iran from 2010 to 2015.
Topics: Antiviral Agents; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Iran; Mutation, Missense; Neuraminidase; Oseltamivir; Phylogeny; Viral Proteins | 2018 |
A case of influenza type a myocarditis that presents with ST elevation MI, cardiogenic shock, acute renal failure, and rhabdomyolysis and with rapid recovery after treatment with oseltamivir and intra-aortic balloon pump support.
Topics: Acute Kidney Injury; Antiviral Agents; Coronary Angiography; Echocardiography; Electrocardiography; Humans; Influenza A virus; Influenza, Human; Intra-Aortic Balloon Pumping; Male; Middle Aged; Myocarditis; Oseltamivir; Recovery of Function; Rhabdomyolysis; Shock, Cardiogenic; ST Elevation Myocardial Infarction; Time Factors; Treatment Outcome | 2018 |
Epidemiological and clinical characteristics of humans with avian influenza A (H7N9) infection in Guangdong, China, 2013-2017.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; China; Demography; Female; Hospitalization; Humans; Infant; Influenza A Virus, H7N9 Subtype; Influenza, Human; Intensive Care Units; Male; Middle Aged; Oseltamivir; Retrospective Studies; Risk Factors; Young Adult | 2017 |
Duration of viral shedding and factors associated with prolonged shedding among inpatients with influenza treated with oseltamivir: a prospective cohort study.
Topics: Aged; Antiviral Agents; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Polymerase Chain Reaction; Prospective Studies; Risk Factors; Time Factors; Virus Shedding | 2018 |
The additive effect of clarithromycin on influenza A infection in the elderly patients and patients with comorbid diseases.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antiviral Agents; Clarithromycin; Cohort Studies; Comorbidity; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Influenza A virus; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Phosphorous Acids; Pneumonia; Prospective Studies; Treatment Outcome; Zanamivir | 2017 |
Highlights from IDWeek 2017.
Topics: Anti-Bacterial Agents; Antiviral Agents; Bacteremia; beta-Lactamases; Clostridioides difficile; Cystitis; Drinking; Drug Administration Schedule; Dysbiosis; Humans; Influenza Vaccines; Influenza, Human; Oseltamivir; Respiratory Tract Infections; Staphylococcal Infections | 2017 |
Pharmacokinetics of favipiravir during continuous venovenous haemofiltration in a critically ill patient with influenza.
Topics: Amides; Antiviral Agents; Critical Illness; Fatal Outcome; Hemofiltration; Humans; Influenza, Human; Intensive Care Units; Male; Middle Aged; Netherlands; Oseltamivir; Pyrazines; Tertiary Care Centers | 2018 |
The inhibitory performance of flavonoid cyanidin-3-sambubiocide against H274Y mutation in H1N1 influenza virus.
Topics: Anthocyanins; Antiviral Agents; Disaccharides; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Mutant Proteins; Mutation, Missense; Neuraminidase; Oseltamivir; Protein Binding; Protein Domains | 2018 |
Comparison of anti-influenza virus activity and pharmacokinetics of oseltamivir free base and oseltamivir phosphate.
Topics: Animals; Antiviral Agents; Female; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Lung; Mice; Mice, Inbred BALB C; Oseltamivir; Therapeutic Equivalency | 2017 |
Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the Influenza Resistance Information Study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Female; Humans; Incidence; Infant; Influenza, Human; Male; Microbial Sensitivity Tests; Middle Aged; Mutation, Missense; Nasal Cavity; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pharynx; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Selection, Genetic; Viral Proteins; Young Adult | 2018 |
Oseltamivir-resistant influenza A(H1N1)pdm09 virus associated with high case fatality, India 2015.
Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; Disease Outbreaks; Drug Resistance, Viral; Female; Genotype; Humans; India; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Mortality; Mutation, Missense; Neuraminidase; Oseltamivir; Polymorphism, Restriction Fragment Length; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Sequence Analysis, DNA; Viral Proteins; Young Adult | 2018 |
Oseltamivir Treatment of Influenza in Children.
Topics: Child; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Randomized Controlled Trials as Topic; Zanamivir | 2018 |
Surveillance for antiviral resistance among influenza viruses circulating in Algeria during five consecutive influenza seasons (2009-2014).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algeria; Amino Acid Substitution; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Epidemiological Monitoring; Female; Humans; Infant; Infant, Newborn; Influenza, Human; Inhibitory Concentration 50; Male; Microbial Sensitivity Tests; Middle Aged; Mutation, Missense; Neuraminidase; Orthomyxoviridae; Oseltamivir; Prevalence; Real-Time Polymerase Chain Reaction; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Viral Proteins; Young Adult | 2018 |
Containment of Highly Pathogenic Avian Influenza A(H5N1) Virus, Lebanon, 20161.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antiviral Agents; Chickens; Child; Child, Preschool; Disease Outbreaks; Female; Humans; Infant; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Lebanon; Male; Middle Aged; Oseltamivir; Young Adult | 2018 |
Outbreak of influenza and rhinovirus co-circulation among unvaccinated recruits, U.S. Coast Guard Training Center Cape May, NJ, 24 July-21 August 2016.
Topics: Adenovirus Infections, Human; Adenoviruses, Human; Adult; Antiviral Agents; Coinfection; Cross-Sectional Studies; Disease Outbreaks; Female; Humans; Influenza A Virus, H3N2 Subtype; Influenza Vaccines; Influenza, Human; Male; Military Personnel; New Jersey; Oseltamivir; Picornaviridae Infections; Respiratory Tract Infections; Rhinovirus; Young Adult | 2018 |
Focal Encephalitis, Meningitis, and Acute Respiratory Distress Syndrome Associated with Influenza A Infection.
Topics: Adult; Antiviral Agents; Encephalitis; Female; Humans; Influenza A virus; Influenza, Human; Meningitis; Oseltamivir; Respiratory Distress Syndrome; Treatment Outcome | 2018 |
Subtype-specific Clinical Presentation, Medical Treatment and Family Impact of Influenza in Children 1-5 Years of Age Treated in Outpatient Practices in Germany During Three Postpandemic Years, 2013-2015.
Topics: Antiviral Agents; Bronchitis; Child, Preschool; Epidemiological Monitoring; Female; Fever; Germany; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Male; Multiplex Polymerase Chain Reaction; Oseltamivir; Outpatients; Pandemics; Pharyngitis; Prospective Studies; Respiratory Tract Infections; Seasons | 2018 |
Statin Use and Risks of Influenza-Related Outcomes Among Older Adults Receiving Standard-Dose or High-Dose Influenza Vaccines Through Medicare During 2010-2015.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Female; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Influenza Vaccines; Influenza, Human; Male; Medicare; Oseltamivir; Retrospective Studies; Risk Factors; Seasons; United States | 2018 |
The Prophylactic Effect of Anti-influenza Agents for an Influenza Outbreak in a University Hospital.
Topics: Antiviral Agents; Disease Outbreaks; Female; Hospitals, University; Humans; Influenza, Human; Male; Oseltamivir | 2018 |
Cost-utility analysis of antiviral use under pandemic influenza using a novel approach - linking pharmacology, epidemiology and heath economics.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Cost-Benefit Analysis; Drug Costs; Female; Humans; Infant; Influenza, Human; Male; Middle Aged; Models, Economic; Models, Theoretical; Oseltamivir; Pandemics; Quality-Adjusted Life Years | 2018 |
Antiviral resistance due to deletion in the neuraminidase gene and defective interfering-like viral polymerase basic 2 RNA of influenza A virus subtype H3N2.
Topics: Animals; Antiviral Agents; Defective Viruses; Denmark; Dogs; Drug Resistance, Viral; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Madin Darby Canine Kidney Cells; Neuraminidase; Oseltamivir; Respiratory System; RNA-Dependent RNA Polymerase; RNA, Viral; Sequence Deletion; Treatment Outcome; Viral Proteins; Zanamivir | 2018 |
The effect of P38 MAP kinase inhibition in a mouse model of influenza.
Topics: Animals; Antiviral Agents; Bronchi; Cell Line; Cytokines; Dexamethasone; Disease Models, Animal; Enzyme Inhibitors; Epithelial Cells; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir; p38 Mitogen-Activated Protein Kinases; Treatment Outcome; Virus Replication | 2018 |
Implementation of a rapid influenza A/B and RSV direct molecular assay improves emergency department oseltamivir use in paediatric patients.
Topics: Antiviral Agents; Child; Child Health; Child, Preschool; Emergency Service, Hospital; Female; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Male; Molecular Diagnostic Techniques; Nasopharynx; Oseltamivir; Reagent Kits, Diagnostic; Real-Time Polymerase Chain Reaction; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Sensitivity and Specificity; Treatment Outcome; Virus Diseases | 2018 |
Clinical effectiveness of four neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, and peramivir) for children with influenza A and B in the 2014-2015 to 2016-2017 influenza seasons in Japan.
Topics: Acids, Carbocyclic; Adolescent; Betainfluenzavirus; Child; Child, Preschool; Cyclopentanes; Enzyme Inhibitors; Female; Guanidines; Humans; Infant; Infant, Newborn; Influenza A virus; Influenza, Human; Japan; Male; Neuraminidase; Oseltamivir; Pyrans; Seasons; Sialic Acids; Treatment Outcome; Zanamivir | 2018 |
A novel mutation in the neuraminidase gene of the 2009 pandemic H1N1 influenza A virus confers multidrug resistance.
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Viral Proteins | 2018 |
Evaluating oseltamivir prescriptions in Centers for Medicare and Medicaid Services medical claims records as an indicator of seasonal influenza in the United States.
Topics: Aged; Antiviral Agents; Centers for Medicare and Medicaid Services, U.S.; Humans; Influenza, Human; Medical Records; Oseltamivir; Retrospective Studies; Seasons; Time Factors; United States | 2018 |
The Relationship Between Oseltamivir and Suicide in Pediatric Patients.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Cross-Over Studies; Databases, Factual; Female; Humans; Infant; Influenza, Human; Logistic Models; Male; Odds Ratio; Oseltamivir; Suicide; United States | 2018 |
Clinical characteristics from co-infection with avian influenza A H7N9 and Mycoplasma pneumoniae: a case report.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Coinfection; Female; Fluoroquinolones; Humans; Immunoglobulins; Influenza A Virus, H7N9 Subtype; Influenza, Human; Methylprednisolone; Moxifloxacin; Mycoplasma pneumoniae; Oseltamivir; Pneumonia, Mycoplasma | 2018 |
The inhibitory effect of sodium baicalin on oseltamivir-resistant influenza A virus via reduction of neuraminidase activity.
Topics: Administration, Intravenous; Animals; Antiviral Agents; CHO Cells; Cricetulus; Disease Models, Animal; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Flavonoids; Humans; Influenza A virus; Influenza, Human; Inhibitory Concentration 50; Madin Darby Canine Kidney Cells; Male; Mice; Mice, Inbred ICR; Neuraminidase; Oseltamivir; Scutellaria; Viral Proteins; Virus Replication | 2018 |
Factors Associated With Prolonged Viral Shedding in Patients With Avian Influenza A(H7N9) Virus Infection.
Topics: Aged; Animals; Antiviral Agents; Birds; China; Female; Humans; Influenza A Virus, H7N9 Subtype; Influenza in Birds; Influenza, Human; Male; Middle Aged; Oseltamivir; Retrospective Studies; Virus Shedding | 2018 |
[Clinical guidelines using the GRADE system (Grading of Recommendations Assessment, Development and Evaluation)].
Topics: Adult; Antiviral Agents; Decision Making; Evidence-Based Medicine; Health Personnel; Humans; Influenza, Human; Oseltamivir; Practice Guidelines as Topic | 2017 |
A case of H3N2 complicated by acute kidney injury secondary to rhabdomyolysis.
Topics: Acute Kidney Injury; Aged, 80 and over; Antiviral Agents; Bronchodilator Agents; Cough; Fever; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Male; Methylprednisolone; Myalgia; Oseltamivir; Respiratory Distress Syndrome; Rhabdomyolysis; Treatment Outcome | 2018 |
Trends of neuraminidase inhibitors use in children with influenza related respiratory infections.
Topics: Acids, Carbocyclic; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Drug Utilization; Enzyme Inhibitors; Female; Guanidines; Hospitalization; Humans; Infant; Influenza, Human; Japan; Male; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2018 |
Hyphenated 3D-QSAR statistical model-drug repurposing analysis for the identification of potent neuraminidase inhibitor.
Topics: Antiviral Agents; Binding Sites; Drug Repositioning; Enzyme Inhibitors; Humans; Hydrogen Bonding; Influenza, Human; Ligands; Lisinopril; Molecular Conformation; Neuraminidase; Oseltamivir; Quantitative Structure-Activity Relationship | 2018 |
Dynamic Variation and Reversion in the Signature Amino Acids of H7N9 Virus During Human Infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Resistance, Viral; Female; Genotype; High-Throughput Nucleotide Sequencing; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Male; Middle Aged; Mutation, Missense; Oseltamivir; Point Mutation; Polymorphism, Genetic; Respiratory System; RNA, Viral; Viral Proteins | 2018 |
Clinicians' attitude towards a placebo-controlled randomised clinical trial investigating the effect of neuraminidase inhibitors in adults hospitalised with influenza.
Topics: Adult; Antiviral Agents; Attitude of Health Personnel; Glycoside Hydrolase Inhibitors; Hospitalization; Humans; Influenza, Human; Medical Staff, Hospital; Neuraminidase; Oseltamivir; Randomized Controlled Trials as Topic; Research Personnel; Surveys and Questionnaires; United Kingdom; Zanamivir | 2018 |
Uncommon presentation of a common disease: influenza A presenting as adult croup .
Topics: Administration, Inhalation; Aged, 80 and over; Antiviral Agents; Bronchodilator Agents; Croup; Dexamethasone; Female; Glucocorticoids; Humans; Influenza, Human; Nebulizers and Vaporizers; Oseltamivir; Oxygen Inhalation Therapy; Racepinephrine; Radiography, Thoracic | 2018 |
Humoral immunity to influenza in an at-risk population and severe influenza cases in Russia in 2016-2017.
Topics: Animals; Antibodies, Viral; Antiviral Agents; Birds; Epidemics; Humans; Immunity, Herd; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N1 Subtype; Influenza A Virus, H5N8 Subtype; Influenza B virus; Influenza in Birds; Influenza, Human; Oseltamivir; Poultry; Poultry Diseases; Russia; Zanamivir | 2018 |
Oseltamivir-Associated Increased Libido in an Influenza B-Infected Adolescent.
Topics: Adolescent; Adolescent Behavior; Antiviral Agents; Depersonalization; Disruptive, Impulse Control, and Conduct Disorders; Humans; Influenza, Human; Libido; Male; Oseltamivir | 2018 |
Rhabdomyolysis Following Initiation of Antiviral Therapy with Oseltamivir.
Topics: Antiviral Agents; Humans; Influenza, Human; Male; Middle Aged; Oseltamivir; Rhabdomyolysis | 2018 |
The effect of timing of oseltamivir chemoprophylaxis in controlling influenza A H3N2 outbreaks in long-term care facilities in Manitoba, Canada, 2014-2015: a retrospective cohort study.
Topics: Antiviral Agents; Chemoprevention; Cross Infection; Disease Outbreaks; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Logistic Models; Long-Term Care; Manitoba; Oseltamivir; Retrospective Studies; Time Factors | 2018 |
First human infection by a novel avian influenza A(H7N4) virus.
Topics: Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antiviral Agents; China; Female; Genome, Viral; Humans; Influenza A virus; Influenza, Human; Methylprednisolone; Moxifloxacin; Oseltamivir; Radiography, Thoracic; Sequence Analysis, DNA; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
[Similarity of Clinically Significant Neuropsychiatric Adverse Reactions Listed in Package Inserts between the Anti-influenza Drugs Oseltamivir and Amantadine (Possibility Attributable to Common Pharmacological Effects)].
Topics: Amantadine; Antiviral Agents; Dopamine Agonists; Drug Labeling; Enzyme Inhibitors; Humans; Influenza, Human; Mental Disorders; Molecular Conformation; Nervous System Diseases; Neuraminidase; Nicotinic Antagonists; Oseltamivir | 2018 |
Kinetic, Thermodynamic, and Structural Analysis of Drug Resistance Mutations in Neuraminidase from the 2009 Pandemic Influenza Virus.
Topics: Amino Acid Substitution; Antiviral Agents; Calorimetry; Crystallization; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Kinetics; Mutation, Missense; Neuraminidase; Oseltamivir; Thermodynamics; Viral Proteins; Virus Replication | 2018 |
The effect of neuraminidase inhibitors on household transmission in Japanese patients with influenza A and B infection: A prospective, observational study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Coinfection; Enzyme Inhibitors; Family Characteristics; Female; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza B virus; Influenza, Human; Japan; Male; Middle Aged; Neuraminidase; Oseltamivir; Prospective Studies; Young Adult | 2019 |
Outbreaks of influenza-like illness in care homes in the East of England: impact of variations in neuraminidase inhibitor provision.
Topics: Disease Outbreaks; England; Enzyme Inhibitors; Hospitalization; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Residential Facilities; Retrospective Studies; Treatment Outcome | 2018 |
An easy, rapid, and sensitive method for detection of drug-resistant influenza virus by using a sialidase fluorescent imaging probe, BTP3-Neu5Ac.
Topics: Animals; Antiviral Agents; Biological Assay; Cell Line; Chlorocebus aethiops; Chromatography, Affinity; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Fluorescence; Fluorescent Dyes; Humans; Influenza, Human; Madin Darby Canine Kidney Cells; N-Acetylneuraminic Acid; Neuraminidase; Optical Imaging; Orthomyxoviridae; Oseltamivir; Ultraviolet Rays; Vero Cells | 2018 |
PK/PD-based adaptive tailoring of oseltamivir doses to treat within-host influenza viral infections.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Humans; Influenza, Human; Monte Carlo Method; Oseltamivir | 2018 |
Antigenic and genetic characterization of influenza viruses isolated in Mozambique during the 2015 season.
Topics: Animals; Antiviral Agents; Child; Child, Preschool; Dogs; Female; Hemagglutination Inhibition Tests; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Infant; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Madin Darby Canine Kidney Cells; Male; Mozambique; Neuraminidase; Oseltamivir; Phylogeny; Viral Proteins; Zanamivir | 2018 |
Outpatient influenza antivirals in a distributed data network for influenza surveillance.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Drug Utilization; Epidemiological Monitoring; Female; Humans; Infant; Infant, Newborn; Influenza, Human; Male; Middle Aged; Oseltamivir; Outpatients; Prescriptions; Young Adult; Zanamivir | 2018 |
Development of a quadruple qRT-PCR assay for simultaneous identification of highly and low pathogenic H7N9 avian influenza viruses and characterization against oseltamivir resistance.
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Real-Time Polymerase Chain Reaction; RNA, Viral; Sputum | 2018 |
A study on mother-to-fetus/infant transmission of influenza A(H7N9) virus: Two case reports and a review of literature.
Topics: Acids, Carbocyclic; Adult; Cyclopentanes; Enzyme Inhibitors; Fatal Outcome; Female; Fetal Death; Fetus; Guanidines; Humans; Infant; Influenza A Virus, H7N9 Subtype; Influenza, Human; Maternal-Fetal Exchange; Mothers; Neuraminidase; Oseltamivir; Pregnancy; Secondary Prevention; Treatment Outcome | 2018 |
Neuraminidase Inhibitors in Influenza Treatment and Prevention⁻Is It Time to Call It a Day?
Topics: Algorithms; Antiviral Agents; Enzyme Inhibitors; Epidemics; Humans; Influenza A virus; Influenza, Human; Models, Theoretical; Neuraminidase; Oseltamivir; Software | 2018 |
Rapid and simple detection of Tamiflu-resistant influenza virus: Development of oseltamivir derivative-based lateral flow biosensor for point-of-care (POC) diagnostics.
Topics: Antiviral Agents; Biosensing Techniques; Calorimetry; Diagnostic Tests, Routine; Drug Resistance, Viral; Humans; Influenza, Human; Microbial Sensitivity Tests; Orthomyxoviridae; Oseltamivir; Point-of-Care Systems; Sensitivity and Specificity | 2018 |
Psychiatric adverse events in oseltamivir prophylaxis trials: Novel comparative analysis using data obtained from clinical study reports.
Topics: Adolescent; Adult; Aged; Antibiotic Prophylaxis; Antiviral Agents; Data Interpretation, Statistical; Humans; Influenza, Human; Mental Disorders; Oseltamivir; Pharmacoepidemiology; Randomized Controlled Trials as Topic; Young Adult | 2018 |
Acute Unilateral Isolated Oculomotor Nerve Palsy in an Adult Patient with Influenza A.
Topics: Adult; Antiviral Agents; Female; Humans; Influenza, Human; Magnetic Resonance Imaging; Oculomotor Nerve; Oculomotor Nerve Diseases; Oseltamivir | 2019 |
Comparison of early and recent influenza A(H1N1)pdm09 isolates harboring or not the H275Y neuraminidase mutation, in vitro and in animal models.
Topics: Animals; Antiviral Agents; Disease Models, Animal; Drug Resistance, Multiple, Viral; Female; Ferrets; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mice; Mice, Inbred BALB C; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Viral Proteins | 2018 |
Patterns of seasonal influenza activity in U.S. core-based statistical areas, described using prescriptions of oseltamivir in Medicare claims data.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Data Collection; Female; Geriatric Assessment; Humans; Influenza, Human; Male; Medicare; Oseltamivir; Seasons; Severity of Illness Index; Spatial Analysis; United States | 2019 |
Outcome Switching in Triple Therapy in Influenza A(H3N2) Infection: An Open-label Randomized, Controlled, Phase IIb/III Trial.
Topics: Clarithromycin; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Naproxen; Oseltamivir | 2018 |
Response.
Topics: Clarithromycin; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Naproxen; Oseltamivir | 2018 |
Ancestral and Compensatory Mutations that Promote Antiviral Resistance in Influenza N1 Neuraminidase Revealed by a Phylonumerics Approach.
Topics: Antiviral Agents; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation; Mutation, Missense; Neuraminidase; Oseltamivir; Phylogeny | 2018 |
Facilitating Early Treatment of Influenza in Hospitals: Empiric Antivirals or Empiric Diagnostics?
Topics: Antiviral Agents; Hospitalization; Hospitals; Humans; Influenza, Human; Oseltamivir | 2019 |
Early Oseltamivir After Hospital Admission Is Associated With Shortened Hospitalization: A 5-Year Analysis of Oseltamivir Timing and Clinical Outcomes.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Early Medical Intervention; Female; Hospital Mortality; Humans; Influenza, Human; Length of Stay; Logistic Models; Male; Middle Aged; Oseltamivir; Retrospective Studies; Seasons; Tertiary Care Centers; Time Factors; Treatment Outcome | 2019 |
Clinical management and viral genomic diversity analysis of a child's influenza A(H1N1)pdm09 infection in the context of a severe combined immunodeficiency.
Topics: Antiviral Agents; Child; Cord Blood Stem Cell Transplantation; Drug Resistance, Viral; Genetic Variation; Humans; Immunoglobulins, Intravenous; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation, Missense; Neuraminidase; Oseltamivir; Real-Time Polymerase Chain Reaction; Severe Combined Immunodeficiency; Viral Load; Viral Proteins; Zanamivir | 2018 |
Oseltamivir in pregnancy and birth outcomes.
Topics: Adult; Congenital Abnormalities; Denmark; Female; Humans; Infant, Newborn; Infant, Newborn, Diseases; Influenza, Human; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Premature Birth; Prenatal Exposure Delayed Effects; Registries; Young Adult | 2018 |
Oseltamivir removed from the WHO Essential Medicines List. A convenient decision?
Topics: Antiviral Agents; Humans; Influenza, Human; Oseltamivir; Practice Guidelines as Topic; World Health Organization | 2018 |
An international perspective on hospitalized patients with viral community-acquired pneumonia.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Community-Acquired Infections; Cross-Sectional Studies; Databases, Factual; Female; Hospitalization; Humans; Influenza, Human; Internationality; Logistic Models; Male; Medication Adherence; Middle Aged; Oseltamivir; Pneumonia, Viral; Prospective Studies | 2019 |
DNA-linked inhibitor antibody assay (DIANA) as a new method for screening influenza neuraminidase inhibitors.
Topics: Antiviral Agents; DNA; Drug Evaluation, Preclinical; Enzyme Inhibitors; Humans; Influenza A virus; Influenza, Human; Neuraminidase; Oseltamivir; Phosphorous Acids; Reproducibility of Results; Viral Proteins | 2018 |
Risk of neuropsychiatric adverse events associated with the use of oseltamivir: a nationwide population-based case-crossover study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Cohort Studies; Cross-Over Studies; Female; Humans; Incidence; Infant; Infant, Newborn; Influenza, Human; Male; Mental Disorders; Middle Aged; Oseltamivir; Population Health; Republic of Korea; Risk Factors; Young Adult | 2019 |
Inhibiting Viral Polymerase and Neuraminidase in Treating Influenza.
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Seasons | 2019 |
Evaluation of Influenza A H1N1 infection and antiviral utilization in a tertiary care hospital.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Brazil; Case-Control Studies; Drug Utilization Review; Female; Hospital Mortality; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Pregnancy; Risk Factors; Tertiary Care Centers | 2018 |
Analysis of delays in the prescription of oseltamivir in hospitals and potential for improvement.
Topics: Aged; Aged, 80 and over; Delayed Diagnosis; Early Diagnosis; Emergency Medical Services; Epidemics; Female; France; Hospitalization; Hospitals; Humans; Influenza, Human; Male; Middle Aged; Molecular Diagnostic Techniques; Oseltamivir; Prescriptions; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Time-to-Treatment | 2019 |
Diagnosis and Management of Pediatric Influenza in the Era of Rapid Diagnostics.
Topics: Algorithms; Anti-Bacterial Agents; Antimicrobial Stewardship; Antiviral Agents; Child; Child, Hospitalized; Health Care Surveys; Hospitalization; Humans; Influenza, Human; Molecular Diagnostic Techniques; Oseltamivir; Pediatrics; Practice Patterns, Physicians'; United States | 2020 |
Impact of multiplex molecular assay turn-around-time on antibiotic utilization and clinical management of hospitalized children with acute respiratory tract infections.
Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; Child, Preschool; Critical Pathways; Disease Management; Drug Utilization; Hospitalization; Humans; Infant; Influenza, Human; Inpatients; Molecular Diagnostic Techniques; Multiplex Polymerase Chain Reaction; Oseltamivir; Respiratory Tract Infections; Retrospective Studies; Time Factors | 2019 |
Intravenous zanamivir for influenza myocarditis and enteral malabsorption.
Topics: Administration, Intravenous; Adult; Antiviral Agents; Catecholamines; Female; Humans; Influenza, Human; Malabsorption Syndromes; Middle Aged; Myocarditis; Oseltamivir; Zanamivir | 2018 |
Molecular Point-of-care Testing for Influenza to Improve Early Neuraminidase Inhibitor Treatment and Outcomes in Hospitalized Adults.
Topics: Adult; Antiviral Agents; Enzyme Inhibitors; Hospitalization; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Point-of-Care Testing; Treatment Outcome | 2019 |
Comparison of the Clinical Courses of Patients with Influenza after Neuraminidase Inhibitors Treatment: A Postcard Survey of the 2013-2014 Influenza Season in Osaka.
Topics: Acids, Carbocyclic; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Disease Outbreaks; Enzyme Inhibitors; Female; Guanidines; Humans; Infant; Influenza, Human; Japan; Male; Middle Aged; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Surveys and Questionnaires; Treatment Outcome; Zanamivir | 2016 |
Population Pharmacokinetic and Exposure-Response Analyses of Baloxavir Marboxil in Adults and Adolescents Including Patients With Influenza.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Dibenzothiepins; Female; Humans; Influenza, Human; Male; Middle Aged; Morpholines; Oseltamivir; Oxazines; Prodrugs; Pyridines; Pyridones; Thiepins; Triazines; Virus Replication; Young Adult | 2019 |
Possible association of influenza A infection and reverse takotsubo syndrome.
Topics: Acute Coronary Syndrome; Aged; Antiviral Agents; Aspirin; Atorvastatin; Chest Pain; Coronary Angiography; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Influenza A virus; Influenza, Human; Oseltamivir; Platelet Aggregation Inhibitors; Takotsubo Cardiomyopathy; Treatment Outcome | 2018 |
Boronate, trifluoroborate, sulfone, sulfinate and sulfonate congeners of oseltamivir carboxylic acid: Synthesis and anti-influenza activity.
Topics: Antiviral Agents; Boronic Acids; Carboxylic Acids; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Structure-Activity Relationship; Sulfones; Sulfonic Acids; Sulfur Compounds | 2019 |
Virucidal nano-perforator of viral membrane trapping viral RNAs in the endosome.
Topics: A549 Cells; Animals; Antiviral Agents; Bioengineering; Cell Membrane; Cell Membrane Permeability; Disease Models, Animal; Dogs; Endosomes; Female; Humans; Influenza A virus; Influenza, Human; Lipid Bilayers; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred BALB C; Nanostructures; Oseltamivir; Receptors, Cell Surface; RNA, Viral; Viral Proteins; Virion; Virus Internalization | 2019 |
Effect of Oseltamivir on the Hemagglutination Test and Hemagglutination Inhibition Test of the Influenza A(H3N2) Virus in China.
Topics: Amino Acid Substitution; Antigenic Variation; China; Hemagglutination Inhibition Tests; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Mutation; Oseltamivir | 2017 |
Association of severe abnormal behavior and acetaminophen with/without neuraminidase inhibitors.
Topics: Acetaminophen; Adolescent; Age Factors; Antiviral Agents; Behavioral Symptoms; Child; Drug Therapy, Combination; Enzyme Inhibitors; Female; Guanidines; Humans; Incidence; Influenza, Human; Japan; Male; Neuraminidase; Oseltamivir; Pyrans; Risk Factors; Sialic Acids; Zanamivir | 2019 |
Effect of Early Oseltamivir Treatment on Mortality in Critically Ill Patients With Different Types of Influenza: A Multiseason Cohort Study.
Topics: Adult; Aged; Antiviral Agents; Critical Illness; Female; Humans; Influenza, Human; Intensive Care Units; Male; Middle Aged; Oseltamivir; Survival Analysis; Young Adult | 2019 |
Oseltamivir for prophylaxis of influenza in vaccinated hemodialysis patients.
Topics: Antiviral Agents; Belgium; Humans; Influenza, Human; Oseltamivir; Pre-Exposure Prophylaxis; Program Evaluation; Renal Dialysis; Viral Vaccines | 2019 |
Neuropsychiatric events in an adult patient with influenza a (H3N2) treated with oseltamivir (Tamiflu): a case report.
Topics: Antiviral Agents; Female; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Mental Disorders; Middle Aged; Oseltamivir; RNA, Viral; Treatment Outcome | 2019 |
Oseltamivir phosphate-Lifting the restriction on its use to treat teenagers with influenza in Japan.
Topics: Accidental Falls; Adolescent; Age Factors; Antiviral Agents; Behavioral Symptoms; Child; Child, Preschool; Drug Labeling; Female; Humans; Influenza, Human; Japan; Male; Oseltamivir; Severity of Illness Index; Young Adult | 2019 |
Community spread and late season increased incidence of oseltamivir-resistant influenza A(H1N1) viruses in Norway 2016.
Topics: Adult; Aged; Antiviral Agents; Child, Preschool; Drug Resistance, Viral; Female; Humans; Incidence; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Norway; Oseltamivir; Point Mutation; Sequence Analysis, DNA; Viral Proteins | 2019 |
Influenza A (H3) Outbreak at a Hurricane Harvey Megashelter in Harris County, Texas: Successes and Challenges in Disease Identification and Control Measure Implementation.
Topics: Antiviral Agents; Cyclonic Storms; Disease Outbreaks; Emergency Shelter; Humans; Influenza, Human; Oseltamivir; Population Surveillance; Reverse Transcriptase Polymerase Chain Reaction; Texas | 2019 |
Healthcare professionals' queries on oseltamivir and influenza in Finland 2011-2016-Can we detect influenza epidemics with specific online searches?
Topics: Antiviral Agents; Databases, Factual; Epidemics; Finland; Health Personnel; Humans; Influenza, Human; Online Systems; Oseltamivir | 2019 |
Novel influenza A(H1N2) seasonal reassortant identified in a patient sample, Sweden, January 2019.
Topics: Aged; Antiviral Agents; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H1N2 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Nasopharynx; Neuraminidase; Oseltamivir; Polymerase Chain Reaction; Reassortant Viruses; Seasons; Treatment Outcome | 2019 |
Comment on: Risk of neuropsychiatric adverse events associated with the use of oseltamivir: a nationwide population-based case-crossover study.
Topics: Antiviral Agents; Cross-Over Studies; Humans; Influenza, Human; Oseltamivir | 2019 |
Risk of neuropsychiatric adverse events associated with the use of oseltamivir: a nationwide population-based case-crossover study-authors' response.
Topics: Antiviral Agents; Cross-Over Studies; Humans; Influenza, Human; Oseltamivir | 2019 |
More targeted use of oseltamivir and in-hospital isolation facilities after implementation of a multifaceted strategy including a rapid molecular diagnostic panel for respiratory viruses in immunocompromised adult patients.
Topics: Aged; Antiviral Agents; Emergency Service, Hospital; Female; Humans; Immunocompromised Host; Influenza, Human; Male; Middle Aged; Molecular Diagnostic Techniques; Oseltamivir; Patient Isolation; Reagent Kits, Diagnostic; Respiratory Tract Infections; Viruses | 2019 |
Structures and functions linked to genome-wide adaptation of human influenza A viruses.
Topics: Drug Resistance, Viral; Evolution, Molecular; Genome, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Oseltamivir; Respiratory Tract Infections; Viral Nonstructural Proteins; Virus Replication | 2019 |
Antiviral treatment and virological monitoring of oseltamivir-resistant influenza virus A(H1N1)pdm09 in a patient with chronic B lymphocytic leukemia.
Topics: Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Leukemia, Lymphocytic, Chronic, B-Cell; Oseltamivir; Pneumonia, Viral; Treatment Outcome; Virus Shedding; Zanamivir | 2019 |
Detection of influenza A(H1N1)pdm09 virus in a patient travelling from Shanghai to Italy in July 2018: an uncommon clinical presentation in a non-seasonal period.
Topics: Adult; Antiviral Agents; China; Communicable Diseases, Imported; Fever; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Italy; Leukopenia; Male; Oseltamivir; Phylogeny; Seasons | 2019 |
A dual-functional molecular strategy for in situ suppressing and visualizing of neuraminidase in aqueous solution using iridium(iii) complexes.
Topics: Antiviral Agents; Coordination Complexes; Enzyme Inhibitors; Humans; Influenza, Human; Iridium; Luminescent Agents; Microbial Sensitivity Tests; Neuraminidase; Orthomyxoviridae; Oseltamivir; Solutions; Water | 2019 |
In vitro neuraminidase inhibitory concentration (IC
Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Inhibitory Concentration 50; Japan; Neuraminidase; Oseltamivir; Seasons | 2019 |
Excess mortality is associated with influenza A (H1N1) in patients with severe acute respiratory illness.
Topics: Adult; Aged; Antiviral Agents; Female; Hospital Mortality; Humans; Inflammation; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Oseltamivir; Respiratory Distress Syndrome; Respiratory Tract Infections; Risk Factors; Time-to-Treatment | 2019 |
Effectiveness of the Neuraminidase Inhibitors: The Supporting Evidence Increases.
Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Length of Stay; Neuraminidase; Oseltamivir; Treatment Outcome | 2020 |
Baloxavir marboxil, a novel cap-dependent endonuclease inhibitor potently suppresses influenza virus replication and represents therapeutic effects in both immunocompetent and immunocompromised mouse models.
Topics: Administration, Oral; Animals; Antiviral Agents; Dibenzothiepins; Disease Models, Animal; Drug Administration Schedule; Enzyme Inhibitors; Female; Host Microbial Interactions; Humans; Immunocompetence; Immunocompromised Host; Influenza A virus; Influenza B virus; Influenza, Human; Mice; Mice, Inbred BALB C; Morpholines; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Oxazines; Pyridines; Pyridones; Thiepins; Triazines; Virus Replication | 2019 |
Use of oseltamivir in lung transplant recipients with suspected or proven influenza infection: a 1-year observational study of outcomes and safety.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Humans; Influenza, Human; Lung Transplantation; Male; Middle Aged; Oseltamivir; Retrospective Studies; Transplant Recipients; Treatment Outcome; Young Adult | 2019 |
Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza in 2017
Topics: Animals; Antigens, Viral; Antiviral Agents; Australia; Chickens; Dogs; Drug Resistance, Viral; Eggs; Female; Humans; Influenza A virus; Influenza B virus; Influenza Vaccines; Influenza, Human; Madin Darby Canine Kidney Cells; Neuraminidase; Oseltamivir; Phylogeny; World Health Organization; Zanamivir | 2019 |
A prospective study on the epidemiology and clinical significance of viral respiratory infections among pediatric oncology patients.
Topics: Child; Child, Preschool; Female; Follow-Up Studies; Hospitalization; Humans; Influenza, Human; Male; Neoplasms; Oseltamivir; Prevalence; Prospective Studies | 2019 |
Simply influenza A (H3N2)-associated encephalitis with seizure.
Topics: Acute Disease; Adult; Anticonvulsants; Antiviral Agents; Brain; Diagnosis, Differential; Encephalitis, Viral; Female; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Levetiracetam; Magnetic Resonance Imaging; Oseltamivir; Seizures | 2019 |
Highly pathogenic avian influenza H7N9 viruses with reduced susceptibility to neuraminidase inhibitors showed comparable replication capacity to their sensitive counterparts.
Topics: Amino Acid Substitution; Animals; Antiviral Agents; Chickens; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H7N9 Subtype; Influenza in Birds; Influenza, Human; Madin Darby Canine Kidney Cells; Neuraminidase; Oseltamivir; Virus Replication; Zanamivir | 2019 |
[Clinical analysis of seven cases of H1N1 influenza-associated encephalopathy in children].
Topics: Brain; Brain Diseases; Child; Child, Preschool; Electroencephalography; Encephalitis, Viral; Female; Humans; Immunoglobulins, Intravenous; Influenza A Virus, H1N1 Subtype; Influenza, Human; Magnetic Resonance Imaging; Male; Methylprednisolone; Oseltamivir; Retrospective Studies; Treatment Outcome | 2019 |
Characterization of viral genomic mutations in novel influenza A (H7N9)-infected patients: the association between oseltamivir-resistant variants and viral shedding duration.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; China; Drug Resistance, Viral; Female; Genome, Viral; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Male; Middle Aged; Mutation, Missense; Oseltamivir; RNA, Viral; Sequence Analysis, DNA; Virus Shedding | 2019 |
A Concurrent Comparison of the Epidemiology and Clinical Presentation of Patients Hospitalized with Pandemic 2009 (H1N1) Influenza and Seasonal Influenza-A in Sub-himalayan Region of Himachal Pradesh.
Topics: Humans; India; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Seasons | 2019 |
Viral Factors Associated With the High Mortality Related to Human Infections With Clade 2.1 Influenza A/H5N1 Virus in Indonesia.
Topics: Animals; Antiviral Agents; Humans; Indonesia; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Neuraminidase; Oseltamivir | 2020 |
Impact of a PCR point of care test for influenza A/B on an acute medical unit in a large UK teaching hospital: results of an observational, pre and post intervention study.
Topics: Drug Prescriptions; Hospitalization; Hospitals, Teaching; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Length of Stay; Oseltamivir; Point-of-Care Testing; Polymerase Chain Reaction; Quarantine; Respiratory Tract Infections; Time-to-Treatment; United Kingdom | 2019 |
Clinical characteristics and outcomes during a severe influenza season in China during 2017-2018.
Topics: Adolescent; Adult; Antiviral Agents; China; Epidemics; Female; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Male; Middle Aged; Oseltamivir; Retrospective Studies; Young Adult | 2019 |
Molecular characterization of the influenza A(H1N1)pdm09 isolates collected in the 2015-2016 season and comparison of HA mutations detected in Turkey since 2009.
Topics: Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Genetic Variation; Genotype; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation; Oseltamivir; Phylogeny; Turkey | 2019 |
Heparin-binding protein (HBP) in critically ill patients with influenza A(H1N1) infection.
Topics: Adult; Antimicrobial Cationic Peptides; Antiviral Agents; Blood Proteins; Carrier Proteins; Critical Illness; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care Units; Male; Middle Aged; Oseltamivir; Polymerase Chain Reaction; Prospective Studies; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Shock, Septic | 2013 |
Cardiohemodynamic and electrophysiological effects of anti-influenza drug oseltamivir in vivo and in vitro.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Antiviral Agents; Arterial Pressure; Cardiac Pacing, Artificial; Coronary Circulation; Dogs; Electrocardiography; Female; Guinea Pigs; Heart Atria; Hemodynamics; Humans; In Vitro Techniques; Influenza, Human; Lidocaine; Male; Myocardial Contraction; Oseltamivir; Refractory Period, Electrophysiological | 2013 |
Atrial septostomy in cardiogenic shock related to H1N1 infection.
Topics: Antiviral Agents; Atrial Septum; Electrocardiography; Extracorporeal Membrane Oxygenation; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Middle Aged; Oseltamivir; Pulmonary Edema; Shock, Cardiogenic; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Spread of Influenza A(H1N1) oseltamivir-resistant viruses in Africa in 2008 confirmed by multiple introductions in Senegal.
Topics: Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Middle Aged; Oseltamivir; Phylogeny; Reverse Transcriptase Polymerase Chain Reaction; Senegal | 2013 |
Pharmacokinetics of oseltamivir carboxylate in critically ill patients: each patient is unique.
Topics: Adult; Aged; Antiviral Agents; Area Under Curve; Critical Illness; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Pandemics | 2013 |
Research ethics committees have the power to enforce publication of drug trial results.
Topics: Antiviral Agents; Humans; Influenza, Human; Oseltamivir | 2013 |
Simultaneous detection of oseltamivir- and amantadine-resistant influenza by oligonucleotide microarray visualization.
Topics: Amantadine; Antiviral Agents; Base Sequence; Cost-Benefit Analysis; DNA Primers; Drug Resistance, Viral; Humans; Influenza A virus; Influenza, Human; Oligonucleotide Array Sequence Analysis; Oseltamivir; Polymerase Chain Reaction | 2013 |
Epidemiology, clinical features, and prognosis of elderly adults with severe forms of influenza A (H1N1.
Topics: Age Distribution; Aged; Antiviral Agents; Case-Control Studies; Chronic Disease; Comorbidity; Female; Humans; Incidence; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care Units; Logistic Models; Male; Multivariate Analysis; Oseltamivir; Prognosis; Prospective Studies; Spain; Survival Analysis | 2013 |
Nosocomial outbreak of the pandemic Influenza A (H1N1) 2009 in critical hematologic patients during seasonal influenza 2010-2011: detection of oseltamivir resistant variant viruses.
Topics: Adult; Aged; Antiviral Agents; Cross Infection; Disease Outbreaks; Drug Resistance, Viral; Female; Hematologic Neoplasms; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Retrospective Studies | 2013 |
Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after influenza A virus infection in vitro.
Topics: Antiviral Agents; Drug Synergism; Drug Therapy, Combination; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; MAP Kinase Kinase 1; Oseltamivir; Protein Kinase Inhibitors | 2013 |
Mutations at the monomer-monomer interface away from the active site of influenza B virus neuraminidase reduces susceptibility to neuraminidase inhibitor drugs.
Topics: Animals; Antiviral Agents; Catalytic Domain; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza B virus; Influenza, Human; Japan; Madin Darby Canine Kidney Cells; Models, Molecular; Mutation; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Viral Proteins; Zanamivir | 2013 |
Progressive emergence of an oseltamivir-resistant A(H3N2) virus over two courses of oseltamivir treatment in an immunocompromised paediatric patient.
Topics: Antiviral Agents; Child, Preschool; Drug Resistance, Viral; Humans; Immunocompromised Host; Influenza A Virus, H3N2 Subtype; Influenza, Human; Male; Mutation, Missense; Oseltamivir; Selection, Genetic | 2013 |
Roche offers researchers access to all Tamiflu trials.
Topics: Access to Information; Antiviral Agents; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Confidentiality; Drug Industry; Humans; Influenza, Human; Oseltamivir; Research Personnel; Switzerland | 2013 |
Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season.
Topics: Acids, Carbocyclic; Africa; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Global Health; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Neuraminidase; Oceania; Oseltamivir; Pyrans; Seasons; Sentinel Surveillance; Sialic Acids; South America; Zanamivir | 2013 |
Outcomes of infants exposed to oseltamivir or zanamivir in utero during pandemic (H1N1) 2009.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Antiviral Agents; Female; Humans; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pandemics; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Prospective Studies; Time Factors; Zanamivir | 2013 |
Genetic diversity among pandemic 2009 influenza viruses isolated from a transmission chain.
Topics: Antiviral Agents; Drug Resistance, Viral; Genetic Variation; High-Throughput Nucleotide Sequencing; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; RNA, Viral; Selection, Genetic; Viral Proteins | 2013 |
Case report: oseltamivir-induced resistant pandemic influenza A (H1N1) virus infection in a patient with AIDS and Pneumocystis jirovecii pneumonia.
Topics: Adult; Antiviral Agents; Coinfection; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Pneumocystis carinii; Pneumonia, Pneumocystis | 2013 |
Multiple clusters of A(H1N1)pdm09 virus circulating in severe cases of influenza during the 2010-2011 season: a phylogenetic and molecular analysis of the neuraminidase gene.
Topics: Amino Acid Sequence; Antiviral Agents; Genes, Viral; Glycosylation; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Molecular Sequence Data; Multigene Family; Mutation; Neuraminidase; Oseltamivir; Phylogeny; Seasons; Severity of Illness Index | 2013 |
Pseudovirus-based neuraminidase inhibition assays reveal potential H5N1 drug-resistant mutations.
Topics: Animals; Birds; Drug Resistance, Viral; Enzyme Inhibitors; HEK293 Cells; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Mutagenesis, Site-Directed; Neuraminidase; Oseltamivir | 2013 |
Influenza-related postinfectious encephalomyelitis complicated by a perforated peptic ulcer.
Topics: Adolescent; Combined Modality Therapy; Encephalomyelitis, Acute Disseminated; Female; Follow-Up Studies; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Magnetic Resonance Imaging; Oseltamivir; Peptic Ulcer Perforation; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2013 |
Molecular assays for quantitative and qualitative detection of influenza virus and oseltamivir resistance mutations.
Topics: Drug Resistance, Viral; Evaluation Studies as Topic; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Real-Time Polymerase Chain Reaction; RNA, Viral; Sensitivity and Specificity | 2013 |
[Detection of an influenza a (H1N1) pdm09 strain resistant to Oseltamivir in Peru].
Topics: Adolescent; Antiviral Agents; Drug Resistance, Viral; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Peru | 2013 |
Compliance to oseltamivir among two populations in Oxfordshire, United Kingdom affected by influenza A(H1N1)pdm09, November 2009--a waste water epidemiology study.
Topics: Antiviral Agents; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Medication Adherence; Oseltamivir; Pandemics; Statistics as Topic; United Kingdom; Wastewater | 2013 |
Mass oseltamivir prophylaxis halts pandemic influenza A H1N1 2009 outbreak in a secondary school in Ashanti Region, Ghana.
Topics: Adolescent; Adult; Antiviral Agents; Female; Ghana; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Pandemics; Patient Education as Topic; Patient Isolation; Pharynx; Post-Exposure Prophylaxis; Schools; Young Adult | 2012 |
'Oseltamivir hot topic issue': a one-stop shop for oseltamivir.
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza, Human; Oseltamivir; Pandemics | 2013 |
Oseltamivir pharmacology in young children: a commentary.
Topics: Antiviral Agents; Child, Preschool; Enzyme Inhibitors; Humans; Infant; Infant, Newborn; Influenza, Human; Neuraminidase; Oseltamivir; Viral Proteins | 2013 |
Towards a personalised approach to managing influenza infections in infants and children - food for thought and a note on oseltamivir.
Topics: Antiviral Agents; Child; Child, Preschool; Coinfection; Drug Resistance, Viral; Early Diagnosis; Enzyme Inhibitors; Evidence-Based Medicine; Humans; Infant; Infant, Newborn; Influenza A virus; Influenza, Human; Neuraminidase; Oseltamivir; Patient Isolation; Precision Medicine; Respiratory Tract Infections; Viral Proteins | 2013 |
Acute hemorrhagic colitis after oral administration of oseltamivir for influenza.
Topics: Administration, Oral; Adult; Antiviral Agents; Colitis; Colonic Diseases; Female; Gastrointestinal Hemorrhage; Humans; Influenza, Human; Oseltamivir | 2013 |
Oseltamivir-resistant influenza viruses isolated in South Korea from 2005 to 2010.
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Mutation; Neuraminidase; Orthomyxoviridae; Oseltamivir; Phylogeny; Republic of Korea; Viral Proteins | 2013 |
Value of pharmacy-based influenza surveillance - Ontario, Canada, 2009.
Topics: Adolescent; Adult; Antiviral Agents; Drug Prescriptions; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Ontario; Oseltamivir; Population Surveillance; Reproducibility of Results; Retrospective Studies; Time Factors; Young Adult; Zanamivir | 2013 |
Choice of oseltamivir in 2009 flu pandemic was "worrying," says MP.
Topics: Antiviral Agents; Decision Making; Drug Industry; Drug Prescriptions; Drug Utilization; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Liability, Legal; Male; Oseltamivir; Pandemics; Patient Safety; United Kingdom | 2013 |
Prolonged influenza virus shedding and emergence of antiviral resistance in immunocompromised patients and ferrets.
Topics: Animals; Antiviral Agents; Disease Models, Animal; Drug Resistance, Viral; Female; Ferrets; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Pandemics; Retrospective Studies; Virus Shedding | 2013 |
Oseltamivir treatment for influenza in hospitalized children without underlying diseases.
Topics: Analysis of Variance; Antiviral Agents; Chi-Square Distribution; Child, Preschool; Female; Fever; Hospitalization; Humans; Infant; Influenza, Human; Length of Stay; Male; Oseltamivir; Retrospective Studies | 2013 |
Double dose oseltamivir for severe influenza--does it help?
Topics: Humans; Influenza A virus; Influenza B virus; Influenza, Human; Oseltamivir | 2013 |
Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance.
Topics: Acids, Carbocyclic; Aged; Aged, 80 and over; Antiviral Agents; Base Sequence; China; Cyclopentanes; Drug Resistance, Viral; Female; Guanidines; Humans; Influenza A virus; Influenza, Human; Male; Middle Aged; Molecular Sequence Data; Oseltamivir; RNA, Viral; Virus Shedding | 2013 |
Characterization of neuraminidase inhibitor-resistant influenza A(H1N1)pdm09 viruses isolated in four seasons during pandemic and post-pandemic periods in Japan.
Topics: Acids, Carbocyclic; Alleles; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Genotype; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Neuraminidase; Oseltamivir; Pandemics; RNA, Viral; Sequence Analysis, DNA; Viral Proteins | 2013 |
Early therapy with neuraminidase inhibitors for influenza A (H1N1) pdm 2009 infection.
Topics: Child; Early Medical Intervention; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Zanamivir | 2013 |
Virological self-sampling to monitor influenza antiviral susceptibility in a community cohort.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Cohort Studies; Drug Resistance, Viral; England; Female; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Male; Microbial Sensitivity Tests; Middle Aged; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Self Administration; Specimen Handling; Young Adult | 2013 |
Skin rash and subconjunctival haemorrhage in an adult with pandemic H1N1 influenza.
Topics: Adult; Antiviral Agents; Conjunctiva; Exanthema; Eye Hemorrhage; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Treatment Outcome | 2013 |
Avian influenza A(H7N9) virus infections, Shanghai, China.
Topics: Aged; Antiviral Agents; Child, Preschool; China; Fatal Outcome; Female; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Pneumonia, Viral; Radiography; Respiratory Distress Syndrome | 2013 |
Risk Factors for Complicated Influenza A (H1N1) 2009 Disease in Children.
Topics: Adolescent; Age Factors; Antiviral Agents; Asthma; Bronchitis; Case-Control Studies; Child; Child, Preschool; Cohort Studies; Female; Fluid Therapy; Gastritis; Gastroenteritis; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Obesity; Oseltamivir; Pneumonia, Bacterial; Retrospective Studies; Risk Factors; Seizures; Singapore | 2013 |
Pandemic H1N1 illness prognosis: evidence from clinical and epidemiological data from the first pandemic wave in São Paulo, Brazil.
Topics: Adolescent; Adult; Age Distribution; Antiviral Agents; Brazil; Child; Child, Preschool; Female; Hospitalization; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Pandemics; Prognosis; Sex Distribution; Time Factors; Young Adult | 2013 |
Treatment with oseltamivir and prone positioning for a 9-year-old boy with ARDS caused by pandemic H1N1 2009 influenza.
Topics: Antiviral Agents; Child; Combined Modality Therapy; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Oxygen; Pandemics; Prone Position; Respiratory Distress Syndrome; Tomography, X-Ray Computed | 2013 |
New expert group agrees plan to analyse full data on oseltamivir.
Topics: Antiviral Agents; Humans; Influenza, Human; Oseltamivir; Outcome Assessment, Health Care; Product Surveillance, Postmarketing | 2013 |
The clinical course of late diagnosed fatal cases of A (H1N1) influenza in Poland.
Topics: Adult; Age of Onset; Aged; Antiviral Agents; Arthritis; Cause of Death; Coinfection; Comorbidity; Cross Infection; Delayed Diagnosis; Disease Progression; Fatty Liver; Female; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Pandemics; Pneumonia; Poland; Pregnancy; Pregnancy Complications, Infectious; Respiratory Distress Syndrome; Retrospective Studies; Risk Factors; Survival Rate; Young Adult | 2013 |
Different drug-resistant influenza A(H3N2) variants in two immunocompromised patients treated with oseltamivir during the 2011-2012 influenza season in Italy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Female; Humans; Immunocompromised Host; Infant; Influenza A Virus, H3N2 Subtype; Influenza, Human; Italy; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Neuraminidase; Oseltamivir; Prospective Studies; RNA, Viral; Sequence Analysis, DNA; Viral Proteins; Young Adult | 2013 |
Influenza. Dueling reviews for controversial flu drug.
Topics: Antiviral Agents; Evidence-Based Medicine; Humans; Influenza, Human; Oseltamivir; Pandemics; Randomized Controlled Trials as Topic | 2013 |
Sharing insights and H7N9 patient clinical data.
Topics: Adult; Antiviral Agents; Body Temperature; China; Fatal Outcome; Female; Hemofiltration; Humans; Influenza A virus; Influenza, Human; Lung; Male; Middle Aged; Oseltamivir; Respiration, Artificial; Tomography, X-Ray Computed; Urban Population | 2013 |
Inhibitory and combinatorial effect of diphyllin, a v-ATPase blocker, on influenza viruses.
Topics: Amantadine; Animals; Antiviral Agents; Benzodioxoles; Drug Therapy, Combination; Drugs, Chinese Herbal; Endosomes; Enzyme Inhibitors; Humans; Influenza, Human; Lignans; Magnoliopsida; Membrane Fusion; Orthomyxoviridae; Oseltamivir; Vacuolar Proton-Translocating ATPases; Virus Replication | 2013 |
Complications and factors associated with severity of influenza in hospitalized children and adults during the pandemic wave of A(H1N1)pdm2009 infections--the Fluco French cohort.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Female; France; Hospitalization; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Prospective Studies; Risk Factors; Severity of Illness Index; Young Adult | 2013 |
Impact of the 2009 influenza A (H1N1) pandemic on healthcare workers at a tertiary care center in New York City.
Topics: Adult; Aged; Algorithms; Antiviral Agents; Community-Acquired Infections; Cross Infection; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; New York City; Occupational Diseases; Occupational Exposure; Oseltamivir; Pandemics; Personnel, Hospital; Retrospective Studies; Sick Leave; Tertiary Care Centers; Young Adult | 2013 |
Using high-throughput sequencing to leverage surveillance of genetic diversity and oseltamivir resistance: a pilot study during the 2009 influenza A(H1N1) pandemic.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Epidemiological Monitoring; Female; Genetic Variation; High-Throughput Nucleotide Sequencing; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Mexico; Middle Aged; Mutation; Neuraminidase; Oseltamivir; Pandemics; Pilot Projects; Viral Proteins | 2013 |
Oseltamivir use and outcomes during the 2009 influenza A H1N1 pandemic in Taiwan.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Cohort Studies; Databases, Factual; Drug Prescriptions; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; National Health Programs; Oseltamivir; Taiwan; Treatment Outcome; Young Adult | 2013 |
Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; China; Coinfection; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Oseltamivir; Viral Plaque Assay; Viral Proteins; Zanamivir | 2013 |
Mass balance of anti-influenza drugs discharged into the Yodo River system, Japan, under an influenza outbreak.
Topics: Amantadine; Antiviral Agents; Disease Outbreaks; Environmental Monitoring; Humans; Influenza, Human; Japan; Oseltamivir; Rivers; Water Pollutants, Chemical | 2013 |
Estimated impact of aggressive empirical antiviral treatment in containing an outbreak of pandemic influenza H1N1 in an isolated First Nations community.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Communicable Disease Control; Computer Simulation; Disease Outbreaks; Female; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Models, Theoretical; Ontario; Oseltamivir; Treatment Outcome; Young Adult | 2013 |
What does oseltamivir do, and how will we know?
Topics: Antiviral Agents; Humans; Influenza, Human; Meta-Analysis as Topic; Oseltamivir; Randomized Controlled Trials as Topic; Review Literature as Topic | 2013 |
Compiling of comprehensive data of human infections with novel influenza A (H7N9) virus.
Topics: Animals; Antiviral Agents; China; Disease Outbreaks; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Oseltamivir; Poultry; Prevalence; Survival Rate; Treatment Outcome | 2013 |
A multicenter evaluation of pandemic influenza A/H1N1 in hematopoietic stem cell transplant recipients.
Topics: Adult; Aged; Antiviral Agents; Cross Infection; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hospitalization; Humans; Infection Control; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Pandemics; Risk Factors; Treatment Outcome; Young Adult | 2013 |
Risk factors for prolonged H1N1 influenza among hospitalized patients.
Topics: Adolescent; Adult; Age Factors; Aged; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Nasopharynx; Oseltamivir; Retrospective Studies; Risk Factors; Time Factors; Young Adult | 2013 |
Bioluminescence-based neuraminidase inhibition assay for monitoring influenza virus drug susceptibility in clinical specimens.
Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Assays; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Kinetics; Luminescent Measurements; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Protein Binding; Viral Proteins; Zanamivir | 2013 |
Increased virulence of neuraminidase inhibitor-resistant pandemic H1N1 virus in mice: potential emergence of drug-resistant and virulent variants.
Topics: Animals; Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mice; Mice, Inbred BALB C; Mutation, Missense; Neuraminidase; Oseltamivir; Pandemics; Viral Proteins; Virulence | 2013 |
Should neuraminidase inhibitors be prescribed for patients with influenza?
Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2014 |
[Clinical characteristics and molecular epidemiology of the novel influenza A (H1N1) infection in children in Shanghai].
Topics: Adolescent; Amino Acid Sequence; Antiviral Agents; Child; Child, Preschool; China; Drug Resistance, Viral; Female; Hemagglutinins, Viral; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Molecular Epidemiology; Molecular Sequence Data; Neuraminidase; Oseltamivir; Pandemics; Viral Vaccines | 2013 |
Acute cerebellitis associated with dual influenza A (H1N1) and B infection.
Topics: Acute Disease; Antiviral Agents; Ataxia; Cerebellar Diseases; Child; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza B virus; Influenza, Human; Magnetic Resonance Imaging; Nasopharynx; Oseltamivir; Seasons; Speech Disorders; Treatment Outcome | 2013 |
Pandemic influenza (H1N1) 2009 of pediatric patients at Thammasat University Hospital.
Topics: Age Factors; Antiviral Agents; Child; Child, Preschool; Female; Hospitals, University; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Pandemics; Sensitivity and Specificity; Thailand | 2012 |
Aronia melanocarpa and its components demonstrate antiviral activity against influenza viruses.
Topics: Animals; Antiviral Agents; Cell Line; Drug Resistance, Viral; Ellagic Acid; Female; Flavonoids; Fruit; Humans; Influenza A virus; Influenza A Virus, H5N1 Subtype; Influenza, Human; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir; Photinia; Plant Extracts; Polyphenols; Virus Replication | 2013 |
Virological clearance rate of high-dose oseltamivir or triple-combination antiviral therapy in complicated 2009 pandemic influenza A (H1N1) infection.
Topics: Adolescent; Adult; Aged; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Respiratory Distress Syndrome; Ribavirin; Survival Analysis; Treatment Outcome | 2013 |
Human infection with Eurasian avian-like influenza A(H1N1) virus, China.
Topics: Adolescent; Adult; Animals; Antiviral Agents; Child, Preschool; China; Disease Susceptibility; Female; Humans; Immune Sera; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Molecular Diagnostic Techniques; Multilocus Sequence Typing; Oseltamivir; Sheep; Vaccination; Vaccine Potency; Young Adult | 2013 |
Virological, serological, and antiviral studies in an imported human case of avian influenza A(H7N9) virus in Taiwan.
Topics: Antibodies, Viral; Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Molecular Sequence Data; Mutation, Missense; Oseltamivir; Respiratory System; RNA, Viral; Sequence Analysis, DNA; Taiwan; Viral Load | 2014 |
Antigenicity and transmissibility of a novel clade 2.3.2.1 avian influenza H5N1 virus.
Topics: Animals; Antiviral Agents; Birds; Cell Line; Ferrets; Humans; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Molecular Sequence Data; Orthomyxoviridae Infections; Oseltamivir; Phylogeny; Sequence Analysis, DNA | 2013 |
Electrophysiological effects of an anti-influenza drug oseltamivir on the guinea-pig atrium: comparison with those of pilsicainide.
Topics: Animals; Anti-Arrhythmia Agents; Antiviral Agents; Atrial Fibrillation; Atrial Function; Atrial Function, Left; Atrial Function, Right; Electrophysiological Phenomena; Guinea Pigs; Heart Atria; Humans; Influenza, Human; Lidocaine; Oseltamivir; Potassium Channel Blockers; Refractory Period, Electrophysiological; Sodium Channel Blockers | 2013 |
Emergence of an oseltamivir-resistant influenza A/H3N2 virus in an elderly patient receiving a suboptimal dose of antiviral prophylaxis.
Topics: Aged, 80 and over; Antiviral Agents; Chemoprevention; Drug Resistance, Viral; Female; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Inhibitory Concentration 50; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation, Missense; Neuraminidase; Oseltamivir; RNA, Viral; Sequence Analysis, DNA; Viral Load; Viral Proteins | 2013 |
Laboratory-confirmed influenza B infection in immunized long-term care facility residents receiving oseltamivir prophylaxis in Ontario.
Topics: Antiviral Agents; Disease Outbreaks; Humans; Influenza B virus; Influenza Vaccines; Influenza, Human; Inhibitory Concentration 50; Long-Term Care; Microbial Sensitivity Tests; Middle Aged; Ontario; Oseltamivir; Phylogeny; Post-Exposure Prophylaxis | 2013 |
Surveillance of the first case of human avian influenza A (H7N9) virus in Beijing, China.
Topics: Animals; Antibodies, Neutralizing; Antibodies, Viral; Antiviral Agents; Child; China; Epidemiological Monitoring; Family Health; Feces; Female; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Male; Neutralization Tests; Occupational Exposure; Oseltamivir; Pharynx; Real-Time Polymerase Chain Reaction; Sputum; Zoonoses | 2014 |
Influenza A/H1N1 in pediatric oncology patients.
Topics: Anti-Bacterial Agents; Antiviral Agents; Child; Female; Follow-Up Studies; Hematologic Neoplasms; Hospitalization; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care Units, Pediatric; Male; Nasal Lavage Fluid; Oseltamivir; Pandemics; Polymerase Chain Reaction; Prognosis; Prospective Studies | 2014 |
Exploring the molecular mechanism of action between drug and RNA polymerase based on partially-resolved spatial structures.
Topics: Antiviral Agents; Binding Sites; Computer-Aided Design; DNA-Directed RNA Polymerases; Drug Design; Drug Resistance, Viral; Drug Therapy, Combination; Humans; Influenza A virus; Influenza, Human; Molecular Targeted Therapy; Oseltamivir; Vancomycin; Virus Replication | 2013 |
Prescription of antiviral drugs during the 2009 influenza pandemic: an observational study using electronic medical files of general practitioners in the Netherlands.
Topics: Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Drug Prescriptions; Drug Utilization Review; Electronic Health Records; Female; General Practitioners; Humans; Infant; Influenza, Human; Male; Middle Aged; Netherlands; Oseltamivir; Pandemics; Practice Guidelines as Topic; Young Adult | 2013 |
Therapy of H7N9 pneumonia: current perspectives.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Pulmonary Ventilation; Zanamivir | 2013 |
A novel pyrosequencing assay for the detection of neuraminidase inhibitor resistance-conferring mutations among clinical isolates of avian H7N9 influenza virus.
Topics: Adult; Antiviral Agents; Base Sequence; China; Drug Resistance, Viral; Enzyme Inhibitors; Female; High-Throughput Nucleotide Sequencing; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Male; Molecular Sequence Data; Mutation; Neuraminidase; Oseltamivir; Viral Proteins | 2014 |
Comparative dynamics and distribution of influenza drug resistance acquisition to protein m2 and neuraminidase inhibitors.
Topics: Adamantane; Antiviral Agents; Drug Resistance, Viral; Genome, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Phylogeny; United States; United States Food and Drug Administration; Viral Matrix Proteins | 2014 |
Mutation effects of neuraminidases and their docking with ligands: a molecular dynamics and free energy calculation study.
Topics: Antiviral Agents; Catalytic Domain; Drug Design; Drug Resistance, Viral; Humans; Influenza A virus; Influenza, Human; Ligands; Molecular Docking Simulation; Molecular Dynamics Simulation; Neuraminidase; Oseltamivir; Point Mutation; Thermodynamics | 2013 |
Adverse event analysis in fatal cases of influenza A (H1N1) - a lesson from Poland.
Topics: Adult; Antiviral Agents; Arthritis; Delayed Diagnosis; Diagnostic Errors; Female; Hospitalization; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Office Visits; Oseltamivir; Pandemics; Poland; Practice Patterns, Physicians'; Pregnancy; Pregnancy Complications, Infectious; Respiratory Distress Syndrome; Retrospective Studies; Risk Factors; Time-to-Treatment; Young Adult | 2013 |
Detection of oseltamivir-resistant pandemic influenza A(H1N1)pdm2009 in Brazil: can community transmission be ruled out?
Topics: Adolescent; Adult; Aged; Animals; Antiviral Agents; Brazil; Child; Child, Preschool; Dogs; Drug Resistance, Viral; Epidemiological Monitoring; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Madin Darby Canine Kidney Cells; Middle Aged; Mutation; Neuraminidase; Oseltamivir; Viral Proteins | 2013 |
Impact of potential permissive neuraminidase mutations on viral fitness of the H275Y oseltamivir-resistant influenza A(H1N1)pdm09 virus in vitro, in mice and in ferrets.
Topics: Amino Acid Motifs; Animals; Antiviral Agents; Drug Resistance, Viral; Female; Ferrets; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Mice; Mice, Inbred C57BL; Mutation, Missense; Neuraminidase; Oseltamivir; Viral Proteins; Virulence; Virus Replication | 2014 |
Optimum timing of oseltamivir: lessons from Bangladesh.
Topics: Antiviral Agents; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Male; Oseltamivir | 2014 |
Neuraminidase inhibitors for critically ill children with influenza.
Topics: Acids, Carbocyclic; Adolescent; Betainfluenzavirus; California; Child; Child, Preschool; Critical Care; Critical Illness; Cyclopentanes; Drug Administration Schedule; Enzyme Inhibitors; Guanidines; Hospitalization; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Logistic Models; Multivariate Analysis; Neuraminidase; Odds Ratio; Oseltamivir; Pandemics; Population Surveillance; Treatment Outcome; Zanamivir | 2013 |
Bleeding events following concurrent use of warfarin and oseltamivir by Medicare beneficiaries.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antiviral Agents; Cohort Studies; Drug Interactions; Female; Hemorrhage; Humans; Influenza, Human; International Classification of Diseases; Logistic Models; Male; Medicare; Middle Aged; Multivariate Analysis; Oseltamivir; Pandemics; Retrospective Studies; United States; Warfarin | 2013 |
A patient with acute COPD exacerbation and shock.
Topics: Acute Disease; Aged, 80 and over; Antiviral Agents; Central Venous Catheters; Critical Care; Echocardiography; Embolism, Air; Hemodynamics; Humans; Influenza A virus; Influenza, Human; Male; Oseltamivir; Point-of-Care Systems; Positive-Pressure Respiration; Pulmonary Disease, Chronic Obstructive; Respiration, Artificial; Shock; Treatment Outcome; Ventricular Dysfunction, Right | 2013 |
Methodological concerns about studies on oseltamivir for flu.
Topics: Antiviral Agents; Bias; Humans; Influenza, Human; Oseltamivir; Research Design; Risk Assessment | 2013 |
In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus.
Topics: Amides; Animals; Antiviral Agents; Cell Line; Dogs; Drug Resistance, Viral; Drug Synergism; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Oseltamivir; Pyrazines | 2014 |
Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility.
Topics: Amino Acid Substitution; Animals; Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Mice; Mice, Inbred BALB C; Neuraminidase; Oseltamivir; Viral Proteins; Virulence; Virus Replication | 2013 |
[The first confirmed pediatric case with H7N9 avian influenza virus infection in China].
Topics: Animals; Child, Preschool; China; Communicable Diseases, Emerging; Humans; Influenza A Virus, H7N9 Subtype; Influenza in Birds; Influenza, Human; Male; Oseltamivir; Poultry; Real-Time Polymerase Chain Reaction; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction | 2013 |
Kinetics of serological responses in influenza A(H7N9)-infected patients correlate with clinical outcome in China, 2013.
Topics: Aged; Aged, 80 and over; Antibodies, Viral; Antiviral Agents; China; Female; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Logistic Models; Male; Middle Aged; Neutralization Tests; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction; Survival Rate; Time Factors; Treatment Outcome; Viral Load | 2013 |
Effectiveness of neuraminidase inhibitors in preventing hospitalization during the H1N1 influenza pandemic in British Columbia, Canada.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; British Columbia; Child; Child, Preschool; Cohort Studies; Female; Hospitalization; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Retrospective Studies; Treatment Outcome; Young Adult; Zanamivir | 2014 |
Emergence of a novel drug resistant H7N9 influenza virus: evidence based clinical potential of a natural IFN-α for infection control and treatment.
Topics: Animals; Antiviral Agents; Cell Line; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Immunologic Factors; Influenza A Virus, H7N9 Subtype; Influenza, Human; Interferon-alpha; Madin Darby Canine Kidney Cells; Membrane Transport Modulators; Mutation; Neuraminidase; Oseltamivir; Viral Matrix Proteins; Virus Replication | 2014 |
Host immunological response and factors associated with clinical outcome in patients with the novel influenza A H7N9 infection.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Blood; C-Reactive Protein; China; Cytokines; Drug Resistance, Viral; Female; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Lymphocyte Count; Male; Middle Aged; Mutation, Missense; Neuraminidase; Oseltamivir; Pharynx; Survival Analysis; Viral Load; Viral Proteins | 2014 |
Computational assay of H7N9 influenza neuraminidase reveals R292K mutation reduces drug binding affinity.
Topics: Acids, Carbocyclic; Antiviral Agents; Computational Biology; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Molecular Dynamics Simulation; Mutation; Neuraminidase; Oseltamivir; Protein Binding; Zanamivir | 2013 |
Oseltamivir treatment for influenza does not increase digestive intolerance in preterm infants.
Topics: Antiviral Agents; Digestion; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Retrospective Studies | 2014 |
Discovery process, clinical characteristics, and treatment of patients infected with avian influenza virus (H7N9) in Shanghai.
Topics: Animals; Antiviral Agents; Birds; China; Humans; Influenza A Virus, H7N9 Subtype; Influenza in Birds; Influenza, Human; Oseltamivir | 2014 |
Pyrosequencing reveals an oseltamivir-resistant marker in the quasispecies of avian influenza A (H7N9) virus.
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Molecular Sequence Data; Mutation, Missense; Neuraminidase; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Sequence Analysis, DNA; Taiwan; Viral Proteins | 2015 |
Diagnosis and treatment of children with severe influenza A from the 2009/2010 pandemic in Tianjin, China.
Topics: Administration, Intravenous; Adolescent; Antiviral Agents; Child; Child, Preschool; China; Female; Fever; Glucocorticoids; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Methylprednisolone; Oseltamivir; Pandemics; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Severity of Illness Index; Treatment Outcome | 2014 |
A community cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November to December 2013.
Topics: Acids, Carbocyclic; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; DNA, Viral; Drug Resistance, Viral; Female; Guanidines; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Male; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Neuraminidase; Oseltamivir; Phylogeny; Sequence Analysis, DNA; Treatment Outcome | 2014 |
Sequential influenza B viral load and susceptibility in children treated with oseltamivir and zanamivir.
Topics: Antiviral Agents; Child; Child, Preschool; Female; Humans; Infant; Influenza B virus; Influenza, Human; Microbial Sensitivity Tests; Nasal Cavity; Oseltamivir; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Viral Load; Zanamivir | 2014 |
Avian influenza A(H7N9) virus infection in pregnant woman, China, 2013.
Topics: Antiviral Agents; China; Female; Fetus; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Molecular Typing; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Reassortant Viruses; Viral Proteins | 2014 |
Influenza A/H1/N1/09 infection in patients with cirrhosis has a poor outcome: a case series.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Disease Progression; Fatal Outcome; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Liver Cirrhosis; Male; Middle Aged; Oseltamivir; Young Adult | 2014 |
Safety of oseltamivir during pregnancy: a comparative study using the EFEMERIS database.
Topics: Adult; Antiviral Agents; Cohort Studies; Databases, Factual; Female; Humans; Influenza, Human; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome | 2014 |
Recognizing true H5N1 infections in humans during confirmed outbreaks.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antiviral Agents; Azerbaijan; Child; Child, Preschool; Disease Outbreaks; Female; Humans; Indonesia; Infant; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Male; Middle Aged; Oseltamivir; Pakistan; Poultry; Risk Factors; Turkey; Young Adult | 2014 |
Prospective surveillance and molecular characterization of seasonal influenza in a university cohort in Singapore.
Topics: Adolescent; Adult; Amino Acid Sequence; Animals; Cohort Studies; Drug Resistance, Viral; Enzyme Inhibitors; Female; Genetic Variation; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A virus; Influenza, Human; Male; Middle Aged; Molecular Sequence Data; Neuraminidase; Oseltamivir; Phylogeny; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Seasons; Sentinel Surveillance; Singapore; Universities; Young Adult | 2014 |
Prevalence, genetic drift of haemagglutinin, and antiviral resistance of influenza A/H3N2 viruses circulating in Shanghai in children during 2009-2012.
Topics: Adolescent; Amantadine; Antiviral Agents; Child; Child, Preschool; China; Cluster Analysis; Drug Resistance, Viral; Female; Genetic Drift; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Infant; Infant, Newborn; Influenza A Virus, H3N2 Subtype; Influenza, Human; Mutation, Missense; Nasopharynx; Oseltamivir; Phylogeny; Prevalence; RNA, Viral; Sequence Analysis, DNA; Sequence Homology | 2014 |
Critics attack chief medical officer's advice to use antivirals for flu.
Topics: Antiviral Agents; Evidence-Based Medicine; Humans; Influenza, Human; Oseltamivir; Practice Guidelines as Topic; State Medicine; United Kingdom; Zanamivir | 2014 |
Department of Health's misguided alert recommending neuraminidase inhibitors for flu.
Topics: England; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Practice Guidelines as Topic; Zanamivir | 2014 |
Influenza virus drug resistance: a time-sampled population genetics perspective.
Topics: Bayes Theorem; Drug Resistance, Viral; Genetic Drift; Genetics, Population; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation; Oseltamivir; Selection, Genetic | 2014 |
Emergence of G186D mutation in the presence of R292K mutation in an immunocompromised child infected with influenza A/H3N2 virus, treated with oseltamivir.
Topics: Child; Female; Genes, Viral; Humans; Immunocompromised Host; Influenza A Virus, H3N2 Subtype; Influenza, Human; Mutation; Oseltamivir; Viral Load | 2014 |
Pregnancy outcome following maternal use of zanamivir or oseltamivir during the 2009 influenza A/H1N1 pandemic: a national prospective surveillance study.
Topics: Adolescent; Adult; Antiviral Agents; Epidemiological Monitoring; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Middle Aged; Oseltamivir; Pandemics; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Prospective Studies; United Kingdom; Young Adult; Zanamivir | 2014 |
Neuropsychiatric problems due to oseltamivir treatment in H7N9 bird flu.
Topics: Antiviral Agents; China; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Mental Disorders; Oseltamivir | 2014 |
Contribution of systematic RT-PCR screening for influenza during the epidemic season.
Topics: Adult; Aged; Anti-Bacterial Agents; Antiviral Agents; Cross Infection; Delayed Diagnosis; Diagnosis, Differential; Disease Outbreaks; Emergency Service, Hospital; Female; Fever; France; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Lung Diseases; Male; Middle Aged; Oseltamivir; Patients' Rooms; Reagent Kits, Diagnostic; Real-Time Polymerase Chain Reaction; Seasons; Sensitivity and Specificity | 2014 |
Clinical efficacy of peramivir in adult patients with seasonal influenza during the winter of 2012 in Japan.
Topics: Acids, Carbocyclic; Adult; Aged; Aged, 80 and over; Antiviral Agents; Cyclopentanes; Female; Guanidines; Hospitalization; Humans; Influenza A virus; Influenza, Human; Japan; Male; Middle Aged; Oseltamivir; Retrospective Studies; Seasons; Treatment Outcome | 2015 |
Study claiming Tamiflu saved lives was based on "flawed" analysis.
Topics: Antiviral Agents; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pandemics; Zanamivir | 2014 |
Oseltamivir analogues bearing N-substituted guanidines as potent neuraminidase inhibitors.
Topics: Antiviral Agents; Drug Resistance, Viral; Guanidines; Humans; Influenza A virus; Influenza, Human; Models, Molecular; Molecular Structure; Mutation; Neuraminidase; Oseltamivir; Structure-Activity Relationship | 2014 |
Mammalian pathogenesis of oseltamivir-resistant pandemic (H1N1) 2009 influenza virus isolated in South Korea.
Topics: Animals; Antiviral Agents; Drug Resistance, Viral; Female; Ferrets; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mice; Mice, Inbred BALB C; Oseltamivir; Republic of Korea; Virulence | 2014 |
H7N9 bird flu: emerging of psychological problem.
Topics: Antiviral Agents; China; Fear; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Oseltamivir | 2014 |
[Oseltamivir resistance among pandemic A(H1N1)2009 viruses between 2009 and 2011 in Guangzhou].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Genes, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Mutation; Neuraminidase; Oseltamivir; Pandemics; Polymerase Chain Reaction; Sequence Analysis, DNA; Viral Proteins; Young Adult | 2014 |
Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza viruses.
Topics: Amino Acid Substitution; Animals; Antiviral Agents; Dogs; Drug Resistance, Viral; Ferrets; Genetic Fitness; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Madin Darby Canine Kidney Cells; Mutation, Missense; Neuraminidase; Oseltamivir; Viral Proteins | 2014 |
Association of radiologic findings with mortality in patients with avian influenza H7N9 pneumonia.
Topics: Anti-Bacterial Agents; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Oseltamivir; Pneumonia, Viral; Predictive Value of Tests; Prognosis; Respiration, Artificial; Respiratory Distress Syndrome; Reverse Transcriptase Polymerase Chain Reaction; Statistics, Nonparametric; Tomography, X-Ray Computed | 2014 |
Cochrane review questions effectiveness of neuraminidase inhibitors.
Topics: Antiviral Agents; Humans; Influenza, Human; Oseltamivir; Zanamivir | 2014 |
Multisystem failure: the story of anti-influenza drugs.
Topics: Antiviral Agents; Drug and Narcotic Control; Evidence-Based Medicine; History, 20th Century; History, 21st Century; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pandemics; Policy Making; Zanamivir | 2014 |
Tamiflu purchase worth £49m will go ahead, government says.
Topics: Antiviral Agents; Federal Government; Humans; Influenza, Human; Oseltamivir; Pandemics; Treatment Outcome; United Kingdom | 2014 |
Impact of different oseltamivir regimens on treating influenza A virus infection and resistance emergence: insights from a modelling study.
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A virus; Influenza, Human; Models, Theoretical; Oseltamivir | 2014 |
Comparing clinical characteristics between hospitalized adults with laboratory-confirmed influenza A and B virus infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Length of Stay; Male; Middle Aged; Oseltamivir; Survival Analysis; Young Adult | 2014 |
PCR for detection of oseltamivir resistance mutation in influenza A(H7N9) virus.
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Polymerase Chain Reaction; Viral Proteins | 2014 |
The association between influenza treatment and hospitalization-associated outcomes among Korean children with laboratory-confirmed influenza.
Topics: Adolescent; Anti-Bacterial Agents; Antigens, Viral; Antiviral Agents; Child; Child, Preschool; Cohort Studies; Demography; Drug Therapy, Combination; Female; Hospitalization; Humans; Infant; Infant, Newborn; Influenza A virus; Influenza B virus; Influenza, Human; Male; Oseltamivir; Republic of Korea; Retrospective Studies | 2014 |
Tamiflu report comes under fire.
Topics: Antiviral Agents; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Neuraminidase; Observational Studies as Topic; Oseltamivir; Randomized Controlled Trials as Topic; Strategic Stockpile; Zanamivir | 2014 |
Editor in chief's reply to Nguyen-Van-Tam.
Topics: Antiviral Agents; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pandemics; Zanamivir | 2014 |
Principal author of PRIDE study responds to news story in The BMJ claiming that the study was based on "flawed" analysis.
Topics: Antiviral Agents; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pandemics; Zanamivir | 2014 |
Current evidence shows no place for antiviral drug distribution in a flu pandemic.
Topics: Antiviral Agents; England; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pandemics | 2014 |
Authors' reply to Mark Jones's second critique of the study by Muthuri and colleagues reported in The BMJ.
Topics: Antiviral Agents; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pandemics; Zanamivir | 2014 |
Authors' reply to Mark Jones's critique of the study by Muthuri and colleagues reported in The BMJ.
Topics: Antiviral Agents; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pandemics; Zanamivir | 2014 |
Mark Jones's reply to Myles and Leonardi-Bee's response to his critique of their paper reported in The BMJ.
Topics: Antiviral Agents; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pandemics; Zanamivir | 2014 |
Clinical features and outcomes of influenza infections in lung transplant recipients: a single-season cohort study.
Topics: Adult; Antiviral Agents; Cohort Studies; Female; Humans; Influenza A virus; Influenza, Human; Lung Transplantation; Male; Middle Aged; Oseltamivir; Retrospective Studies; Seasons; Treatment Outcome; Viral Load; Virus Shedding | 2014 |
Tug of war for antiviral drugs data.
Topics: Antiviral Agents; Clinical Trials as Topic; Dissent and Disputes; Drug Industry; Humans; Influenza, Human; Information Dissemination; Oseltamivir; Research Design; Zanamivir | 2014 |
Tamiflu: "a nice little earner".
Topics: Antiviral Agents; Drug Industry; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pandemics | 2014 |
Neuraminidase inhibitors for influenza.
Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Risk Assessment; Zanamivir | 2014 |
The Tamiflu trials.
Topics: Antiviral Agents; Bias; Clinical Trials as Topic; Drug Industry; Humans; Influenza, Human; Oseltamivir; Research Design; Review Literature as Topic | 2014 |
Effectiveness of neuraminidase inhibitors for severe influenza.
Topics: Antiviral Agents; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pandemics; Zanamivir | 2014 |
Equity in the receipt of oseltamivir in the United States during the H1N1 pandemic.
Topics: Adolescent; Adult; Age Factors; Aged; Antiviral Agents; Child; Child, Preschool; Female; Healthcare Disparities; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Logistic Models; Male; Middle Aged; Oseltamivir; Pandemics; Sex Factors; United States; Young Adult | 2014 |
Clinical trials: Tamiflu reviewers respond to critics.
Topics: Antiviral Agents; Humans; Influenza, Human; Oseltamivir; Strategic Stockpile | 2014 |
Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor.
Topics: Acids, Carbocyclic; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Enzyme Inhibitors; Female; Fever; Guanidines; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pyrans; Severity of Illness Index; Sialic Acids; Time Factors; Treatment Outcome; Viral Proteins; Virus Shedding; Zanamivir | 2015 |
Antivirals for influenza: where now for clinical practice and pandemic preparedness?
Topics: Antiviral Agents; Child; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pandemics; Zanamivir | 2014 |
Evaluation of oseltamivir prophylaxis regimens for reducing influenza virus infection, transmission and disease severity in a ferret model of household contact.
Topics: Animals; Antiviral Agents; Disease Models, Animal; Disease Transmission, Infectious; Female; Ferrets; Humans; Influenza, Human; Male; Oseltamivir; Pre-Exposure Prophylaxis; Severity of Illness Index; Viral Load; Virus Shedding | 2014 |
Research transparency: a moral obligation.
Topics: Access to Information; Antiviral Agents; Clinical Trials as Topic; Humans; Influenza, Human; Moral Obligations; Oseltamivir; Pandemics; Publishing; Research | 2014 |
The posology of oseltamivir in infants with influenza infection using a population pharmacokinetic approach.
Topics: Administration, Oral; Age Factors; Antiviral Agents; Biological Availability; Biotransformation; Body Weight; Carboxylic Acids; Computer Simulation; Drug Dosage Calculations; Drug Resistance, Viral; Female; Humans; Infant; Infant, Newborn; Influenza, Human; Linear Models; Male; Models, Biological; Oseltamivir | 2014 |
Combination therapy with hepatocyte growth factor and oseltamivir confers enhanced protection against influenza viral pneumonia.
Topics: Animals; Antiviral Agents; Drug Therapy, Combination; Female; Hepatocyte Growth Factor; Humans; Influenza, Human; Mice; Mice, Inbred BALB C; Oseltamivir; Pneumonia, Viral | 2014 |
Anti-viral drugs in flu: not that good?
Topics: Adult; Antiviral Agents; Child, Preschool; Humans; Influenza, Human; Oseltamivir; Treatment Outcome; Zanamivir | 2014 |
Predictors of fatality in pandemic influenza A (H1N1) virus infection among adults.
Topics: Adult; Antiviral Agents; Cross Infection; Disease Outbreaks; Female; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Multivariate Analysis; Neuraminidase; Odds Ratio; Oseltamivir; Pregnancy; Turkey; Zanamivir | 2014 |
[2009 pandemic influenza A (H1N1) virus infection treated with oseltamivir and possible association with acute pancreatitis in a 12 years old patient].
Topics: Acute Disease; Antiviral Agents; Child; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pancreatitis | 2015 |
Primarily oseltamivir-resistant influenza A (H1N1pdm09) virus evolving into a multidrug-resistant virus carrying H275Y and I223R neuraminidase substitutions.
Topics: Amino Acid Substitution; Antiviral Agents; Drug Resistance, Multiple, Viral; Evolution, Molecular; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Middle Aged; Mutation; Myelodysplastic Syndromes; Neuraminidase; Oseltamivir; Viral Proteins; Zanamivir | 2015 |
Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
Topics: Antiviral Agents; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pandemics; Zanamivir | 2014 |
Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
Topics: Antiviral Agents; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pandemics; Zanamivir | 2014 |
Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
Topics: Antiviral Agents; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pandemics; Zanamivir | 2014 |
Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
Topics: Antiviral Agents; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pandemics; Zanamivir | 2014 |
Risk factors for hospitalization among children with influenza B infection.
Topics: Anti-Bacterial Agents; Antiviral Agents; Child; Child, Hospitalized; Child, Preschool; Female; Humans; Influenza B virus; Influenza, Human; Male; Oseltamivir; Retrospective Studies; Risk Factors | 2014 |
Oseltamivir and zanamivir have limited effect on symptoms and do not reduce hospitalisation or serious complications of influenza.
Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2014 |
Oseltamivir use amongst hospitalized patients infected with influenza.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Canada; Child; Child, Preschool; Drug Prescriptions; Female; Hospitalization; Humans; Influenza, Human; Length of Stay; Male; Middle Aged; Oseltamivir; Young Adult | 2014 |
Glycan based detection and drug susceptibility of influenza virus.
Topics: Antiviral Agents; Biosensing Techniques; Drug Resistance, Viral; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Limit of Detection; Microarray Analysis; Microbial Sensitivity Tests; Oseltamivir; Polysaccharides; Zanamivir | 2014 |
[Phylogenetic and molecular analysis of A/H1N1pdm influenza viruses isolated in the epidemic season 2012/2013 from hospitalised patients with -symptoms of influenza-like illness].
Topics: Czech Republic; Drug Resistance, Viral; Epidemics; Female; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Phylogeny; Time Factors | 2014 |
Y155H amino acid substitution in influenza A(H1N1)pdm09 viruses does not confer a phenotype of reduced susceptibility to neuraminidase inhibitors.
Topics: Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Female; Humans; Immunoenzyme Techniques; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Pandemics; Phenotype; RNA, Viral; Seasons; Sequence Analysis, DNA; Spain; Viral Proteins; Zanamivir | 2014 |
Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to oseltamivir and zanamivir antiviral drugs.
Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Female; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Inhibitory Concentration 50; Male; Middle Aged; Mutation, Missense; Neuraminidase; Oseltamivir; Portugal; Viral Proteins; Zanamivir | 2015 |
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2014 |
Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children.
Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2014 |
Degree of adherence to recommended antiviral treatment during the pandemic and post-pandemic periods of influenza A(H1N1)pdm09 in 148 intensive care units in Spain.
Topics: Adult; Aged; Antiviral Agents; APACHE; Cohort Studies; Comorbidity; Critical Care; Drug Utilization; Female; Hematologic Neoplasms; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care Units; Length of Stay; Male; Medication Adherence; Middle Aged; Oseltamivir; Pandemics; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Infectious; Proportional Hazards Models; Registries; Spain; Survival Rate | 2015 |
Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan.
Topics: Animals; Antiviral Agents; Disease Models, Animal; Drug Resistance, Viral; Ferrets; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mutant Proteins; Mutation, Missense; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Viral Proteins; Virus Cultivation; Virus Replication | 2015 |
Development of 3D-QSAR combination approach for discovering and analysing neuraminidase inhibitors in silico.
Topics: Algorithms; Binding Sites; Computational Biology; Drug Design; Humans; Influenza, Human; Inhibitory Concentration 50; Least-Squares Analysis; Models, Molecular; N-Acetylneuraminic Acid; Neuraminidase; Oseltamivir; Quantitative Structure-Activity Relationship; Software; Technology, Pharmaceutical; Zanamivir | 2014 |
Antiviral activity of novel oseltamivir derivatives against some influenza virus strains.
Topics: Animals; Antiviral Agents; Dogs; Ethylamines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Madin Darby Canine Kidney Cells; Oseltamivir; Virus Replication | 2014 |
Dextran sulfate-resistant A/Puerto Rico/8/34 influenza virus is associated with the emergence of specific mutations in the neuraminidase glycoprotein.
Topics: Amino Acid Sequence; Antiviral Agents; Dextran Sulfate; Drug Resistance, Viral; Humans; Influenza A virus; Influenza, Human; Molecular Sequence Data; Mutation, Missense; Neuraminidase; Oseltamivir; Sequence Alignment; Viral Proteins; Virus Replication | 2014 |
Oseltamivir-resistant seasonal A(H1N1) and A(H1N1)pdm09 influenza viruses from the 2007/2008 to 2012/2013 season in Nara Prefecture, Japan.
Topics: Antiviral Agents; Cluster Analysis; Drug Resistance, Viral; Humans; Incidence; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Mutation, Missense; Neuraminidase; Oseltamivir; Phylogeny; Sequence Analysis, DNA; Sequence Homology; Viral Proteins | 2014 |
Avian Influenza A(H5N1) Virus Outbreak Investigation: Application of the FAO-OIE-WHO Four-way Linking Framework in Indonesia.
Topics: Animals; Antiviral Agents; Birds; Child, Preschool; Cross-Sectional Studies; Disease Outbreaks; Fatal Outcome; Humans; Indonesia; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Male; Oseltamivir; Phylogeny; Risk Assessment; Zoonoses | 2015 |
In vitro anti-influenza A activity of interferon (IFN)-λ1 combined with IFN-β or oseltamivir carboxylate.
Topics: Antiviral Agents; Drug Therapy, Combination; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Interferon-beta; Interferons; Interleukins; Oseltamivir | 2014 |
Multiple influenza A (H3N2) mutations conferring resistance to neuraminidase inhibitors in a bone marrow transplant recipient.
Topics: Acids, Carbocyclic; Adult; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Fatal Outcome; Female; Guanidines; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunosuppressive Agents; Influenza A Virus, H3N2 Subtype; Influenza, Human; Leukemia, B-Cell; Models, Molecular; Mutation; Neuraminidase; Oseltamivir; Transplantation, Homologous; Viral Proteins; Zanamivir | 2014 |
Clinical characteristics of human infection with a novel avian-origin influenza A(H10N8) virus.
Topics: Aged; Antiviral Agents; Female; Fluoroquinolones; Humans; Imipenem; Influenza A Virus, H10N8 Subtype; Influenza, Human; Male; Middle Aged; Moxifloxacin; Oseltamivir | 2014 |
[Drug susceptibility of wild-type and mutant H7N9 neuraminidase to zanamivir and oseltamivir].
Topics: Antiviral Agents; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation; Neuraminidase; Oseltamivir; Viral Proteins; Zanamivir | 2014 |
In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of influenza virus in the Japanese 2012-2013 season.
Topics: Acids, Carbocyclic; Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Inhibitory Concentration 50; Japan; Madin Darby Canine Kidney Cells; Middle Aged; Neuraminidase; Oseltamivir; Young Adult; Zanamivir | 2015 |
Advancing treatment options for influenza: challenges with the human influenza challenge.
Topics: Antibodies, Monoclonal; Female; Humans; Immunologic Factors; Influenza A Virus, H3N2 Subtype; Influenza, Human; Male; Oseltamivir | 2015 |
Abnormal behavior during influenza in Japan during the last seven seasons: 2006-2007 to 2012-2013.
Topics: Antiviral Agents; Behavioral Symptoms; Child; Fever; Humans; Influenza, Human; Japan; Oseltamivir; Retrospective Studies | 2014 |
Characterization of human Influenza Viruses in Lebanon during 2010-2011 and 2011-2012 post-pandemic seasons.
Topics: Acids, Carbocyclic; Amantadine; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Lebanon; Microbial Sensitivity Tests; Mutation; Neuraminidase; Oseltamivir; Pandemics; Phylogeny; Pyrans; Sialic Acids; Zanamivir | 2014 |
Review: Neuraminidase inhibitors reduce symptomatic influenza; oseltamivir does not reduce hospitalizations.
Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2014 |
Impact of time to treatment of oseltamivir on influenza hospitalization cost among Korean children.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Female; Follow-Up Studies; Hospital Costs; Hospitalization; Humans; Incidence; Influenza, Human; Male; Oseltamivir; Republic of Korea; Retrospective Studies; Time Factors; Time-to-Treatment | 2015 |
A prospective observational study of oseltamivir safety and tolerability in infants and young children ≤24 months.
Topics: Antiviral Agents; Cough; Female; Follow-Up Studies; Humans; Infant; Infant, Newborn; Influenza, Human; Male; Oseltamivir; Prospective Studies; Vomiting | 2015 |
Government says it would stockpile Tamiflu again.
Topics: Antiviral Agents; Drug Storage; Government; Health Policy; Humans; Influenza, Human; Oseltamivir; Pandemics; United Kingdom | 2014 |
A severe neurological complication of influenza in a previously well child.
Topics: Australia; Brain; Child, Preschool; Diagnosis, Differential; Female; Glucocorticoids; Humans; Influenza A virus; Influenza, Human; Leukoencephalitis, Acute Hemorrhagic; Magnetic Resonance Imaging; Oseltamivir; Paresis; Prednisolone; Treatment Outcome | 2014 |
The Tamiflu saga continues: will our conduct change after the publication of the latest systematic review on benefits and harms of oseltamivir?
Topics: Antiviral Agents; Drug Industry; Humans; Influenza, Human; Oseltamivir; Practice Patterns, Physicians'; Review Literature as Topic | 2014 |
Oseltamivir prophylaxis in controlling influenza outbreak in nursing homes: a comparison between three different approaches.
Topics: Aged; Aged, 80 and over; Antibiotic Prophylaxis; Antiviral Agents; Disease Outbreaks; Female; Humans; Influenza, Human; Male; Nursing Homes; Oseltamivir; Prospective Studies | 2015 |
The pathological effects of CCR2+ inflammatory monocytes are amplified by an IFNAR1-triggered chemokine feedback loop in highly pathogenic influenza infection.
Topics: Animals; Antiviral Agents; Chemokines; Disease Models, Animal; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mice; Mice, Inbred C57BL; Monocytes; Orthomyxoviridae Infections; Oseltamivir; Receptor, Interferon alpha-beta; Receptors, CCR2; Severity of Illness Index; Specific Pathogen-Free Organisms; Virus Replication | 2014 |
Molecular findings from influenza A(H1N1)pdm09 detected in patients from a Brazilian equatorial region during the pandemic period.
Topics: Antiviral Agents; Biomarkers; Brazil; Drug Resistance, Viral; Female; Gene Frequency; Hemagglutinins; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Pandemics; Phylogeny; Pregnancy; RNA, Viral; Sequence Analysis, DNA; Virulence; Virulence Factors | 2014 |
Prognostic factors for mortality in patients hospitalized with influenza complications, in Taiwan.
Topics: Adult; Age Factors; Aged; Antiviral Agents; Comorbidity; Female; Hospital Mortality; Humans; Influenza, Human; Logistic Models; Male; Middle Aged; Oseltamivir; Prognosis; Retrospective Studies; Sex Factors; Taiwan; Time Factors; Young Adult | 2015 |
Will Tamiflu recommendations change this winter?
Topics: Antiviral Agents; Cost-Benefit Analysis; Humans; Influenza, Human; Oseltamivir; Practice Guidelines as Topic; Seasons; World Health Organization | 2014 |
Drug susceptibility of influenza A/H3N2 strains co-circulating during 2009 influenza pandemic: first report from Mumbai.
Topics: Amantadine; Animals; Antiviral Agents; Dogs; Drug Resistance, Viral; Humans; India; Influenza A Virus, H3N2 Subtype; Influenza, Human; Madin Darby Canine Kidney Cells; Mutation; Nasopharynx; Neuraminidase; Oseltamivir; Pandemics; Phylogeny; Viral Matrix Proteins | 2015 |
Viral genome and antiviral drug sensitivity analysis of two patients from a family cluster caused by the influenza A(H7N9) virus in Zhejiang, China, 2013.
Topics: Amino Acid Substitution; Antiviral Agents; China; Drug Resistance, Viral; Female; Genome, Viral; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Phylogeny | 2014 |
Discovery of potential drugs for human-infecting H7N9 virus containing R294K mutation.
Topics: Antiviral Agents; Arginine; Drug Discovery; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Lysine; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Mutation; Oseltamivir | 2014 |
Early signs show that 2014-15 flu season may be severe, CDC warns.
Topics: Antiviral Agents; Humans; Influenza A Virus, H3N2 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir | 2014 |
Permissive changes in the neuraminidase play a dominant role in improving the viral fitness of oseltamivir-resistant seasonal influenza A(H1N1) strains.
Topics: Antiviral Agents; Drug Resistance, Viral; Genetic Fitness; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation, Missense; Neuraminidase; Oseltamivir; Seasons; Viral Load; Viral Proteins; Virus Replication | 2015 |
Do we need a replacement medication for influenza with good efficacy?
Topics: Antiviral Agents; Drug Combinations; Drug Synergism; Humans; Indoles; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Plant Extracts; Treatment Outcome; Zanamivir | 2014 |
Oseltamivir-resistant influenza A(H1N1)pdm09 viruses, United States, 2013-14.
Topics: Adolescent; Adult; Antiviral Agents; Drug Resistance, Viral; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Phylogeny; Prevalence; United States; Viral Proteins; Young Adult | 2015 |
Neuraminidase inhibitors, superinfection and corticosteroids affect survival of influenza patients.
Topics: Acids, Carbocyclic; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Beijing; Cohort Studies; Cyclopentanes; Enzyme Inhibitors; Female; Guanidines; Hong Kong; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Influenza, Human; Male; Middle Aged; Multivariate Analysis; Neuraminidase; Oseltamivir; Pneumonia, Bacterial; Proportional Hazards Models; Prospective Studies; Protective Factors; Respiratory Insufficiency; Retrospective Studies; Risk Factors; Singapore; Superinfection; Young Adult; Zanamivir | 2015 |
Detection of a transient R292K mutation in influenza A/H3N2 viruses shed for several weeks by an immunocompromised patient.
Topics: Antiviral Agents; Gene Expression Regulation, Viral; Humans; Immunocompromised Host; Influenza A Virus, H3N2 Subtype; Influenza, Human; Male; Middle Aged; Mutation; Neuraminidase; Oseltamivir; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Virus Shedding | 2015 |
GPs are told to treat with scepticism advice on anti-flu drugs from Public Health England.
Topics: Antiviral Agents; England; General Practice; Humans; Influenza, Human; Nursing Homes; Oseltamivir; Practice Patterns, Physicians' | 2015 |
Margaret McCartney: Don't be bullied into prescribing Tamiflu.
Topics: Antiviral Agents; England; Humans; Influenza, Human; Oseltamivir; Practice Guidelines as Topic; State Medicine | 2015 |
Sialidase inhibition to increase platelet counts: A new treatment option for thrombocytopenia.
Topics: Blood Platelets; Enzyme Inhibitors; Female; Humans; Influenza, Human; Male; Middle Aged; N-Acetylneuraminic Acid; Neuraminidase; Oseltamivir; Platelet Count; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2015 |
Departing from guidelines in patients' best interest is defensible, says negligence expert.
Topics: Aged; Antiviral Agents; Guideline Adherence; Homes for the Aged; Humans; Influenza, Human; Malpractice; Nursing Homes; Oseltamivir; Practice Guidelines as Topic | 2015 |
Infection control preparedness for human infection with influenza A H7N9 in Hong Kong.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Air Microbiology; Antibodies, Viral; Antiviral Agents; Child; Child, Preschool; Contact Tracing; Cross Infection; Female; Health Personnel; Hong Kong; Hospitals, Teaching; Humans; Infant; Infection Control; Infectious Disease Transmission, Patient-to-Professional; Influenza A Virus, H7N9 Subtype; Influenza, Human; Male; Middle Aged; Occupational Exposure; Oseltamivir; Polymerase Chain Reaction; Population Surveillance; Post-Exposure Prophylaxis; Respiratory Protective Devices; Young Adult | 2015 |
Tamiflu reduces complications of flu, new review finds.
Topics: Antiviral Agents; Humans; Influenza, Human; Oseltamivir | 2015 |
Plastic bronchitis associated with influenza virus infection in children: a report on 14 cases.
Topics: Antiviral Agents; Bronchitis; Bronchoscopy; Child; Child, Preschool; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Infant; Influenza A virus; Influenza B virus; Influenza, Human; Male; Mediastinal Emphysema; Oseltamivir; Pneumothorax; Pulmonary Atelectasis; Radiography; Subcutaneous Emphysema | 2015 |
Influenza: the rational use of oseltamivir.
Topics: Antiviral Agents; Humans; Influenza, Human; Oseltamivir; Randomized Controlled Trials as Topic | 2015 |
Association of Oseltamivir Treatment With Virus Shedding, Illness, and Household Transmission of Influenza Viruses.
Topics: Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Female; Humans; Infant; Infant, Newborn; Influenza, Human; Male; Orthomyxoviridae; Oseltamivir; Randomized Controlled Trials as Topic; Virus Shedding; Young Adult | 2015 |
BMA tells GPs to follow own judgment in prescribing antiflu drugs.
Topics: Antiviral Agents; Decision Making; England; Family Practice; Humans; Influenza, Human; Judgment; Oseltamivir; Public Health; Societies, Medical; State Medicine | 2015 |
Outbreak of swine flu in India is no worse than seasonal flu, say specialists.
Topics: Antiviral Agents; Disease Outbreaks; Humans; India; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir | 2015 |
A surface plasmon resonance assay for measurement of neuraminidase inhibition, sensitivity of wild-type influenza neuraminidase and its H274Y mutant to the antiviral drugs zanamivir and oseltamivir.
Topics: Animals; Antiviral Agents; Cell Line; Enzyme Inhibitors; Humans; Influenza, Human; Inhibitory Concentration 50; Insecta; Mutation; Neuraminidase; Oseltamivir; Surface Plasmon Resonance; Zanamivir | 2015 |
Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses.
Topics: Animals; Antiviral Agents; Disease Models, Animal; Drug Resistance, Viral; Enzyme Inhibitors; Ferrets; Genes, Viral; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Male; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Respiratory Tract Infections; Virus Replication | 2015 |
Oseltamivir-resistant influenza A(H1N1)pdm2009 strains found in Brazil are endowed with permissive mutations, which compensate the loss of fitness imposed by antiviral resistance.
Topics: Adult; Antiviral Agents; Brazil; Drug Resistance, Viral; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation; Mutation Rate; Nasal Lavage Fluid; Neuraminidase; Oseltamivir; Phylogeny; Phylogeography; RNA, Viral | 2015 |
Fatal cases of human infection with avian influenza A (H7N9) virus in Shanghai, China in 2013.
Topics: Antiviral Agents; China; Cities; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Medical Records; Oseltamivir; Retrospective Studies | 2015 |
Oseltamivir reduces clinical illness in households in Bangladesh.
Topics: Antiviral Agents; Family Characteristics; Family Health; Female; Humans; Influenza, Human; Male; Oseltamivir | 2015 |
Oseltamivir for influenza in adults and children.
Topics: Antiviral Agents; Humans; Influenza, Human; Oseltamivir | 2014 |
Acute exacerbation of psychiatric symptoms during influenza treatment with oseltamivir in chronic schizophrenia.
Topics: Adult; Aged; Antiviral Agents; Chronic Disease; Humans; Influenza, Human; Male; Oseltamivir; Schizophrenia | 2015 |
Influenza A Virus Shedding and Infectivity in Households.
Topics: Adolescent; Adult; Family Characteristics; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Linear Models; Male; Middle Aged; Nose; Oseltamivir; Pharynx; Prospective Studies; Specimen Handling; Viral Load; Virus Shedding; Young Adult | 2015 |
Published sequences do not support transfer of oseltamivir resistance mutations from avian to human influenza A virus strains.
Topics: Animals; Antiviral Agents; Birds; Drug Resistance, Viral; Humans; Influenza A virus; Influenza in Birds; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Phylogeny; Water Pollutants, Chemical | 2015 |
[Flu, its vaccination, and Tamiflu. The Flahault-Goudeau exchange].
Topics: Antiviral Agents; Humans; Influenza Vaccines; Influenza, Human; Oseltamivir | 2015 |
Effect of influenza-induced fever on human bioimpedance values.
Topics: Adolescent; Adult; Antiviral Agents; Body Composition; Child; Child, Preschool; Disease Outbreaks; Electric Impedance; Female; Fever; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Venezuela; Young Adult | 2015 |
[What efficacy/side effects of oseltamivir in the treatment of influenza in adults?].
Topics: Adult; Antiviral Agents; Humans; Influenza, Human; Oseltamivir | 2015 |
Emergence of Multidrug-Resistant Influenza A(H1N1)pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Immunocompromised Host; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Mutation, Missense; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Viral Proteins; Zanamivir | 2015 |
Peramivir is as effective as oral oseltamivir in the treatment of severe seasonal influenza.
Topics: Acids, Carbocyclic; Administration, Oral; Adult; Aged; Aged, 80 and over; Antiviral Agents; Critical Illness; Cyclopentanes; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care Units; Length of Stay; Middle Aged; Organ Dysfunction Scores; Oseltamivir; Retrospective Studies; Seasons; Time Factors; Treatment Outcome; Young Adult | 2015 |
High-dose versus standard dose oseltamivir for treatment of severe influenza in adult intensive care unit patients.
Topics: Aged; Antiviral Agents; Critical Care; Dose-Response Relationship, Drug; Humans; Influenza A virus; Influenza, Human; Intensive Care Units; Middle Aged; Oseltamivir; Oxygen Inhalation Therapy; Retrospective Studies; Severity of Illness Index | 2015 |
[Conflicts of interest in public institutions. It will be the network to exercise control?].
Topics: Antiviral Agents; Centers for Disease Control and Prevention, U.S.; Conflict of Interest; Drug Industry; Humans; Influenza, Human; Oseltamivir; United States; United States Food and Drug Administration | 2015 |
Impact of the H275Y and I223V Mutations in the Neuraminidase of the 2009 Pandemic Influenza Virus In Vitro and Evaluating Experimental Reproducibility.
Topics: Amino Acid Substitution; Antiviral Agents; Computer Simulation; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Models, Statistical; Mutation; Neuraminidase; Oseltamivir; Reproducibility of Results; Viral Proteins; Virion; Virus Replication | 2015 |
Impact of rapid influenza PCR testing on hospitalization and antiviral use: A retrospective cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Hospitalization; Humans; Influenza, Human; Male; Middle Aged; Molecular Diagnostic Techniques; Oseltamivir; Polymerase Chain Reaction; Pregnancy; Retrospective Studies; Time Factors; Young Adult | 2015 |
Mild encephalopathy with reversible splenial lesion in a patient with influenza A infection--first report in an adult patient in the USA.
Topics: Antiviral Agents; Brain Diseases; Corpus Callosum; Diagnosis, Differential; Humans; Influenza, Human; Male; Middle Aged; Oseltamivir; Prognosis | 2015 |
Prevention of nosocomial transmission of influenza A (H7N9) in Hong Kong.
Topics: Antiviral Agents; China; Cross Infection; Disease Outbreaks; Hong Kong; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Personal Protective Equipment; Post-Exposure Prophylaxis; Practice Guidelines as Topic; Public Health Practice; Surveys and Questionnaires; Travel | 2015 |
Control of an H1N1 outbreak in a correctional facility in central Taiwan.
Topics: Adult; Antiviral Agents; Disease Outbreaks; Health Facilities; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Taiwan | 2017 |
Emergence of H7N9 Influenza A Virus Resistant to Neuraminidase Inhibitors in Nonhuman Primates.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza A Virus, H5N1 Subtype; Influenza A Virus, H7N9 Subtype; Influenza Vaccines; Influenza, Human; Macaca; Mice; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Primates; Vaccination; Viral Proteins; Virus Replication | 2015 |
Oseltamivir in influenza outbreaks in care homes: challenges and benefits of use in the real world.
Topics: Antiviral Agents; Cost-Benefit Analysis; Databases, Factual; Disease Outbreaks; England; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Nasal Mucosa; Oseltamivir; Paramyxoviridae Infections; Picornaviridae Infections; Polymerase Chain Reaction; Post-Exposure Prophylaxis; Residential Facilities; Respiratory Syncytial Virus Infections; Retrospective Studies; Rhinovirus | 2015 |
Quantitative analysis of influenza A (H3N2) E119V and R292K variants in clinical specimens by real-time reverse transcription polymerase chain reaction.
Topics: Amino Acid Substitution; Antiviral Agents; Bodily Secretions; Child; Child, Preschool; Drug Resistance, Viral; Female; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Male; Microbial Sensitivity Tests; Molecular Sequence Data; Mutant Proteins; Mutation, Missense; Nasal Cavity; Oseltamivir; Real-Time Polymerase Chain Reaction; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA; Zanamivir | 2015 |
Oseltamivir Prophylaxis Reduces Inflammation and Facilitates Establishment of Cross-Strain Protective T Cell Memory to Influenza Viruses.
Topics: Adolescent; Adult; Animals; Antiviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Child; Child, Preschool; Female; Ferrets; Humans; Infant; Inflammation; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Mice; Mice, Inbred C57BL; Orthomyxoviridae Infections; Oseltamivir; Viral Load; Young Adult | 2015 |
In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of the influenza virus circulating in the Japanese 2013-2014 season.
Topics: Acids, Carbocyclic; Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Cyclopentanes; Enzyme Inhibitors; Female; Guanidines; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Inhibitory Concentration 50; Japan; Male; Middle Aged; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Time Factors; Young Adult; Zanamivir | 2015 |
A case report of avian influenza H7N9 killing a young doctor in Shanghai, China.
Topics: Adult; Anti-Bacterial Agents; China; Glucocorticoids; Humans; Immunoglobulins; Influenza A Virus, H7N9 Subtype; Influenza, Human; Lung; Male; Oseltamivir; Phylogeny; Physicians; Pneumonia; Radiography; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral | 2015 |
Characteristics of oseltamivir-resistant influenza A (H1N1) pdm09 virus during the 2013-2014 influenza season in Mainland China.
Topics: Adolescent; Adult; Aged; Amino Acid Substitution; Antiviral Agents; Child; Child, Preschool; China; Drug Resistance, Viral; Female; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Microbial Sensitivity Tests; Middle Aged; Molecular Sequence Data; Mutation, Missense; Neuraminidase; Oseltamivir; Sequence Analysis, DNA; Viral Proteins; Young Adult | 2015 |
Experience of influenza A H1N1 in a paediatric emergency unit.
Topics: Antiviral Agents; Child; Child, Preschool; Diarrhea; Emergency Service, Hospital; Female; Fever; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Lymphopenia; Male; Myalgia; Oseltamivir; Retrospective Studies; Risk Factors; Treatment Outcome; Turkey | 2015 |
A retrospective evaluation of critically ill patients infected with H1N1 influenza A virus in Bursa, Turkey, during the 2009-2010 pandemic.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antiviral Agents; APACHE; Critical Illness; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care Units; Male; Middle Aged; Oseltamivir; Pandemics; Pneumonia, Viral; Retrospective Studies; Turkey; Young Adult | 2015 |
Psychiatric symptoms during oseltamivir treatment.
Topics: Antiviral Agents; Humans; Influenza, Human; Mental Disorders; Oseltamivir; Treatment Outcome | 2015 |
H5N1 virus resistant to antiviral drug.
Topics: Amantadine; Antiviral Agents; Asia; Drug Resistance, Viral; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Mutation; Oseltamivir | 2015 |
Outcomes and Susceptibility to Neuraminidase Inhibitors in Individuals Infected With Different Influenza B Lineages: The Influenza Resistance Information Study.
Topics: Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Humans; Infant; Influenza B virus; Influenza, Human; Middle Aged; Neuraminidase; Oseltamivir; Young Adult; Zanamivir | 2016 |
Prompt Oseltamivir Therapy Reduces Medical Care and Mortality for Patients With Influenza Infection: An Asian Population Cohort Study.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Antiviral Agents; Asian People; Emergency Service, Hospital; Female; Hospitalization; Humans; Influenza, Human; Inpatients; Insurance Claim Review; Male; Middle Aged; Oseltamivir; Outpatients; Retrospective Studies; Sex Distribution; Time Factors | 2015 |
Proceedings Fifth ESWI Influenza Conference.
Topics: Antiviral Agents; Communicable Disease Control; Congresses as Topic; Health Policy; Humans; Influenza Vaccines; Influenza, Human; Oseltamivir; Pandemics | 2015 |
The virologist and the flu.
Topics: Antiviral Agents; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; RNA, Viral; Viral Load; Virus Shedding | 2015 |
Epidemiology of human influenza A(H7N9) infection in Hong Kong.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antiviral Agents; Child; Child, Preschool; Disease Outbreaks; Female; Hong Kong; Humans; Infant; Influenza A Virus, H7N9 Subtype; Influenza in Birds; Influenza, Human; Male; Middle Aged; Oseltamivir; Poultry; Reverse Transcriptase Polymerase Chain Reaction; Seasons; Virus Shedding; Young Adult; Zoonoses | 2017 |
Demographic and clinical characteristics of deaths associated with influenza A(H1N1) pdm09 in Central America and Dominican Republic 2009-2010.
Topics: Adolescent; Adult; Antiviral Agents; Asthma; Central America; Comorbidity; Costa Rica; Disease Outbreaks; Dominican Republic; El Salvador; Female; Fever; Guatemala; Honduras; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Nicaragua; Oseltamivir; Pregnancy; Pulmonary Disease, Chronic Obstructive; Young Adult | 2015 |
Analysis of a child who developed abnormal neuropsychiatric symptoms after administration of oseltamivir: a case report.
Topics: Adolescent; Antiviral Agents; Female; Hallucinations; Humans; Influenza, Human; Memory Disorders; Mental Disorders; Oseltamivir; Sleep Initiation and Maintenance Disorders | 2015 |
WHO Global Influenza Surveillance and Response System working group on surveillance of influenza antiviral susceptibility.
Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Global Health; Humans; Influenza A Virus, H10N7 Subtype; Influenza, Human; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Polymorphism, Single Nucleotide; Population Surveillance; Practice Guidelines as Topic; World Health Organization; Zanamivir | 2015 |
The validity of clinical practice guidelines for empirical use of oseltamivir for influenza in Thai children.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Decision Support Techniques; Female; Humans; Infant; Infant, Newborn; Influenza, Human; Male; Oseltamivir; Practice Guidelines as Topic; Prospective Studies; Thailand | 2016 |
[Susceptibility of human influenza A (H3N2) viruses to neuraminidase inhibitors isolated during 2011-2012 in China].
Topics: Antiviral Agents; China; Drug Resistance, Viral; Enzyme Inhibitors; Epidemiological Monitoring; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2015 |
Optimization of Droplet Digital PCR from RNA and DNA extracts with direct comparison to RT-qPCR: Clinical implications for quantification of Oseltamivir-resistant subpopulations.
Topics: Antiviral Agents; Child, Preschool; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Polymerase Chain Reaction; Reproducibility of Results; Sensitivity and Specificity; Viral Load; Viral Proteins | 2015 |
Analysis of Neuropsychiatric Adverse Events in Patients Treated with Oseltamivir in Spontaneous Adverse Event Reports.
Topics: Adolescent; Adult; Antiviral Agents; Asia; Behavior; Behavioral Symptoms; Child; Female; Humans; Influenza, Human; Male; Mental Disorders; Odds Ratio; Oseltamivir; Young Adult | 2015 |
Knowledge gaps about Tamiflu and Relenza for pandemic flu are blamed on research failure.
Topics: Antiviral Agents; Biomedical Research; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pandemics; Zanamivir | 2015 |
Oseltamivir for influenza.
Topics: Antiviral Agents; Humans; Influenza, Human; Oseltamivir; Randomized Controlled Trials as Topic | 2015 |
Oseltamivir for influenza.
Topics: Antiviral Agents; Humans; Influenza, Human; Oseltamivir; Randomized Controlled Trials as Topic | 2015 |
Oseltamivir for influenza.
Topics: Antiviral Agents; Humans; Influenza, Human; Oseltamivir; Randomized Controlled Trials as Topic | 2015 |
Oseltamivir for influenza.
Topics: Antiviral Agents; Humans; Influenza, Human; Oseltamivir; Randomized Controlled Trials as Topic | 2015 |
Oseltamivir for influenza - Authors' reply.
Topics: Antiviral Agents; Humans; Influenza, Human; Oseltamivir; Randomized Controlled Trials as Topic | 2015 |
Successful treatment of avian-origin influenza A (H7N9) infection using convalescent plasma.
Topics: Antiviral Agents; Blood Component Transfusion; China; Disease Outbreaks; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Plasma | 2015 |
[Haut Conseil de la Santé Publique (HCSP). Guidance on the prioritization of antiviral drugs in case of seasonal influenza epidemics (March 3, 2015)].
Topics: Adult; Age Factors; Aged; Antiviral Agents; Child; Comorbidity; Disease Management; Disease Susceptibility; Drug Utilization; Epidemics; Female; France; Humans; Influenza Vaccines; Influenza, Human; Male; Meta-Analysis as Topic; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Seasons; Vulnerable Populations; Zanamivir | 2015 |
Editorial Commentary: Symptoms and Viral Shedding in Naturally Acquired Influenza Infections.
Topics: Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Virus Shedding | 2016 |
Neuraminidase inhibitors for influenza: a call for better research.
Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pandemics; Randomized Controlled Trials as Topic; United Kingdom | 2015 |
Effects of corticosteroid and neuraminidase inhibitors on survival in patients with respiratory distress induced by influenza virus.
Topics: Acids, Carbocyclic; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Antiviral Agents; Cyclopentanes; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Metabolic Syndrome; Middle Aged; Neuraminidase; Orthomyxoviridae; Oseltamivir; Respiratory Distress Syndrome; Retrospective Studies; Taiwan; Treatment Outcome | 2017 |
Profiling the Mortality due to Influenza A (H1N1) pdm09 at a Tertiary Care Hospital in Jaipur during the Current Season--January & February 2015.
Topics: Adolescent; Adult; Age Factors; Aged; Antiviral Agents; Disease Progression; Female; Hospital Mortality; Hospitalization; Humans; India; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Pneumonia, Viral; Risk Factors; Sepsis; Sex Factors; Tertiary Care Centers; Time Factors; Young Adult | 2015 |
The accuracy and timeliness of neuraminidase inhibitor dispensing data for predicting laboratory-confirmed influenza.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Drug Utilization; Epidemiological Monitoring; Female; Humans; Infant; Infant, Newborn; Influenza, Human; Male; Middle Aged; Oseltamivir; Quebec; Young Adult; Zanamivir | 2016 |
A Balance between Inhibitor Binding and Substrate Processing Confers Influenza Drug Resistance.
Topics: Animals; Antiviral Agents; Cell Line; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A virus; Influenza, Human; Models, Molecular; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Point Mutation; Viral Proteins | 2016 |
Detection of Rare Drug Resistance Mutations by Digital PCR in a Human Influenza A Virus Model System and Clinical Samples.
Topics: Antiviral Agents; Drug Resistance, Viral; Genes, Viral; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza, Human; Molecular Typing; Mutation; Oseltamivir; Polymorphism, Single Nucleotide; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity | 2016 |
NAIplot: An opensource web tool to visualize neuraminidase inhibitor (NAI) phenotypic susceptibility results using kernel density plots.
Topics: Antiviral Agents; Computer Graphics; Enzyme Assays; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza B virus; Influenza, Human; Inhibitory Concentration 50; Internet; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Zanamivir | 2016 |
The Path of Least Resistance: Mechanisms to Reduce Influenza's Sensitivity to Oseltamivir.
Topics: Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A virus; Influenza, Human; Models, Molecular; Neuraminidase; Oseltamivir; Point Mutation | 2016 |
Acute necrotising encephalopathy in a child with H1N1 influenza infection: a clinicoradiological diagnosis and follow-up.
Topics: Antiviral Agents; Brain; Child, Preschool; Diffusion Magnetic Resonance Imaging; Female; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Influenza A Virus, H1N1 Subtype; Influenza, Human; Leukoencephalitis, Acute Hemorrhagic; Oseltamivir; Thalamus; Tomography, X-Ray Computed | 2016 |
[Evidence under scrutiny. Neuraminidase inhibitors in severe influenza: yes or no?].
Topics: Ambulatory Care; Antiviral Agents; Cause of Death; Evidence-Based Medicine; Germany; Hospitalization; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Survival Analysis; Zanamivir | 2015 |
Virus susceptibility and clinical effectiveness of anti-influenza drugs during the 2010-2011 influenza season in Russia.
Topics: Adult; Animals; Antiviral Agents; Cell Line; Dogs; Enzyme Inhibitors; Female; Humans; Indoles; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Mice; Mice, Inbred BALB C; Middle Aged; Neuraminidase; Oseltamivir; Retrospective Studies; Russia; Treatment Outcome; Young Adult | 2016 |
Influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza annual report, 2014.
Topics: Animals; Antigens, Viral; Antiviral Agents; Australia; Chickens; Drug Resistance, Viral; Epidemiological Monitoring; Hemagglutinins, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza Vaccines; Influenza, Human; International Cooperation; Oseltamivir; Phylogeny; Retrospective Studies; Zanamivir; Zygote | 2015 |
Antiviral activity of SA-2 against influenza A virus in vitro/vivo and its inhibition of RNA polymerase.
Topics: A549 Cells; Acute Lung Injury; Animals; Antiviral Agents; Benzoates; DNA-Directed RNA Polymerases; Dogs; Drug Evaluation, Preclinical; Drug Resistance, Viral; HEK293 Cells; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Madin Darby Canine Kidney Cells; Male; Mice; Mice, Inbred ICR; Orthomyxoviridae Infections; Oseltamivir; Ribavirin; Virus Replication | 2016 |
A study of an influenza A (H1N1)pdm09 outbreak in pregnant women in Rajasthan, India.
Topics: Adult; Antiviral Agents; Disease Outbreaks; Female; Hospitalization; Humans; India; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Retrospective Studies; Tertiary Care Centers; Time-to-Treatment; Vaccination | 2016 |
Lessons from a French collaborative case-control study in cystic fibrosis patients during the 2009 A/H1N1 influenza pandemy.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antiviral Agents; Case-Control Studies; Child; Child, Preschool; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Mutation; Oseltamivir; Pandemics; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Young Adult | 2016 |
Oseltamivir for influenza.
Topics: Antiviral Agents; Humans; Influenza, Human; Oseltamivir; Randomized Controlled Trials as Topic | 2016 |
Oseltamivir for influenza - Authors' reply.
Topics: Antiviral Agents; Humans; Influenza, Human; Oseltamivir; Randomized Controlled Trials as Topic | 2016 |
Efficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for Influenza A (H7N9) infection: a retrospective study.
Topics: Acids, Carbocyclic; Adolescent; Adult; Aged; Antiviral Agents; China; Cyclopentanes; Drug Therapy, Combination; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Respiratory Distress Syndrome; Retrospective Studies; Viral Load; Young Adult | 2016 |
Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses.
Topics: Amantadine; Antibody-Dependent Enhancement; Antiviral Agents; Coronavirus Infections; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Orthomyxoviridae; Oseltamivir; Picornaviridae Infections; Respiratory Tract Infections; Rimantadine; Severe Acute Respiratory Syndrome; Texas; Virus Replication | 2016 |
Emergence of influenza A (H1N1)pdm09 genogroup 6B and drug resistant virus, India, January to May 2015.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Disease Outbreaks; Genotype; Hemagglutinin Glycoproteins, Influenza Virus; Humans; India; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Middle Aged; Molecular Sequence Data; Mutation; Nasopharynx; Neuraminidase; Oseltamivir; Phylogeny; Population Surveillance; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA; Young Adult | 2016 |
Influenza Vaccination and Antiviral Therapy in Pregnant Women.
Topics: Antiviral Agents; Female; Humans; Influenza Vaccines; Influenza, Human; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Pregnant Women; Vaccination | 2016 |
Rising Oseltamivir Use Among Hospitalized Children in a Postpandemic Era.
Topics: Antiviral Agents; Child; Child, Preschool; Colorado; Drug Utilization; Hospitalization; Hospitals, Pediatric; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pandemics; Retrospective Studies | 2016 |
Neuraminidase Activity and Resistance of 2009 Pandemic H1N1 Influenza Virus to Antiviral Activity in Bronchoalveolar Fluid.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antiviral Agents; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Disease Resistance; Drug Resistance, Viral; Female; Ferrets; Host-Pathogen Interactions; Humans; Immunity, Innate; Immunoglobulin A; Immunoglobulin G; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Viral Load; Viral Proteins | 2016 |
Within-Host Models of High and Low Pathogenic Influenza Virus Infections: The Role of Macrophages.
Topics: Animals; Anti-Inflammatory Agents; Antibodies, Viral; Antiviral Agents; B-Lymphocytes; Cell Death; Epithelial Cells; Host-Pathogen Interactions; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza, Human; Macrophage Activation; Macrophages; Mice; Mice, Inbred BALB C; Models, Immunological; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Viral Load; Virulence; Zanamivir | 2016 |
High-flow nasal cannula oxygen supply as treatment in hypercapnic respiratory failure.
Topics: Aged; Antiviral Agents; Cannula; Humans; Hypercapnia; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Noninvasive Ventilation; Oseltamivir; Oxygen Inhalation Therapy; Pneumonia, Viral; Positive-Pressure Respiration; Pulmonary Disease, Chronic Obstructive; Respiratory Insufficiency; Treatment Failure | 2016 |
Considerations on antiviral treatment of suspected influenza infections in hospitalised children.
Topics: Antiviral Agents; Child; Child, Hospitalized; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir | 2016 |
Comparison of High-Dose Versus Standard Dose Oseltamivir in Critically Ill Patients With Influenza.
Topics: Adult; Aged; Antiviral Agents; APACHE; Critical Illness; Dose-Response Relationship, Drug; Extracorporeal Membrane Oxygenation; Female; Humans; Influenza, Human; Intensive Care Units; Length of Stay; Male; Middle Aged; Oseltamivir; Respiration, Artificial; Retrospective Studies; Time Factors; Treatment Outcome | 2017 |
Pharmacokinetics of Oral and Intravenous Oseltamivir Treatment of Severe Influenza B Virus Infection Requiring Organ Replacement Therapy.
Topics: Administration, Intravenous; Administration, Oral; Adult; Antiviral Agents; Child; Female; Humans; Influenza B virus; Influenza, Human; Multiple Organ Failure; Organ Transplantation; Oseltamivir | 2017 |
[Comparison of the clinical effectiveness of three neuraminidase inhibitors for Japanese pediatric patients with influenza in the 2013/2014 season].
Topics: Antiviral Agents; Child; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Japan; Medication Adherence; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Time Factors; Zanamivir | 2015 |
Oseltamivir and influenza: still no robust data.
Topics: Antiviral Agents; Clinical Trials as Topic; Humans; Influenza, Human; Oseltamivir | 2016 |
Oseltamivir: over 15 years of data retention and systematic stonewalling.
Topics: Antiviral Agents; Humans; Influenza, Human; Oseltamivir | 2016 |
Effects of antiviral treatment on influenza-related complications over four influenza seasons: 2006-2010.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Female; Humans; Infant; Infant, Newborn; Influenza, Human; Logistic Models; Male; Middle Aged; Oseltamivir; Retrospective Studies; Time Factors | 2016 |
Oseltamivir for influenza, from birth: no more useful than in adults.
Topics: Adult; Antiviral Agents; Humans; Infant, Newborn; Influenza, Human; Oseltamivir | 2016 |
Oseltamivir Treatment for Children with Influenza-Like Illness in China: A Cost-Effectiveness Analysis.
Topics: Adolescent; Algorithms; Antiviral Agents; Child; Child, Preschool; China; Cost-Benefit Analysis; Decision Making; Health Care Costs; Humans; Infant; Infant, Newborn; Influenza, Human; Models, Economic; Oseltamivir; Probability; Quality-Adjusted Life Years; Sensitivity and Specificity | 2016 |
systemsDock: a web server for network pharmacology-based prediction and analysis.
Topics: Acids, Carbocyclic; Cyclopentanes; Guanidines; Humans; Influenza, Human; Internet; Ligands; Molecular Docking Simulation; Orthomyxoviridae; Oseltamivir; Pharmacology; Software; User-Computer Interface | 2016 |
Identification of new oral dosing regimens for the neuraminidase inhibitor oseltamivir in patients with moderate and severe renal impairment.
Topics: Administration, Oral; Adolescent; Adult; Aged; Area Under Curve; Computer Simulation; Drug Administration Schedule; Female; Glycoside Hydrolase Inhibitors; Humans; Influenza, Human; Kidney; Kidney Diseases; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Neuraminidase; Nonlinear Dynamics; Oseltamivir; Randomized Controlled Trials as Topic; Severity of Illness Index; Young Adult | 2015 |
First Documented Case of Influenza A (H3N2 Subtype) Infection in a Patient With Complete Interferon Gamma Receptor 1 Deficiency: A Call for Systemic Vaccination Strategies.
Topics: Adoptive Transfer; Antiviral Agents; Child, Preschool; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Interferon gamma Receptor; Male; Oseltamivir; Receptors, Interferon; Treatment Outcome | 2016 |
Intravenous anti-influenza drug oseltamivir will not induce torsade de pointes: Evidences from proarrhythmia model and action-potential assay.
Topics: Action Potentials; Animals; Antiviral Agents; Atrioventricular Block; Biological Assay; Dogs; Female; Guinea Pigs; Heart; Humans; In Vitro Techniques; Influenza, Human; Male; Oseltamivir; Torsades de Pointes | 2016 |
Respiratory viruses and children.
Topics: Antiviral Agents; Bacterial Infections; Child; Child, Preschool; Cost of Illness; Humans; Influenza, Human; Oseltamivir; Otitis Media; Respiratory Syncytial Virus Infections; Respiratory Tract Infections; Viral Vaccines; Virus Diseases | 2016 |
Debate Regarding Oseltamivir Use for Seasonal and Pandemic Influenza.
Topics: Antiviral Agents; Clinical Trials as Topic; Disease Management; Humans; Influenza A virus; Influenza, Human; Oseltamivir; Practice Guidelines as Topic; Seasons; Severity of Illness Index; Treatment Outcome | 2016 |
Debate on whether Tamiflu prevents flu deaths reignites after new analysis.
Topics: Antiviral Agents; Bias; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Product Surveillance, Postmarketing; Survival Analysis | 2016 |
Sixty seconds on . . . Tamiflu.
Topics: Antiviral Agents; Humans; Influenza A virus; Influenza Vaccines; Influenza, Human; Oseltamivir; United Kingdom | 2016 |
Understanding the within-host dynamics of influenza A virus: from theory to clinical implications.
Topics: Antiviral Agents; Humans; Influenza A virus; Influenza, Human; Models, Immunological; Oseltamivir; Viral Load | 2016 |
Influenza A(H1N1)pdm09 virus exhibiting enhanced cross-resistance to oseltamivir and peramivir due to a dual H275Y/G147R substitution, Japan, March 2016.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Middle Aged; Mutation; Neuraminidase; Oseltamivir; Treatment Outcome | 2016 |
Unexpected platelets elevation in a patient with idiopathic thrombocytopenia treated with oseltamivir for influenza infection.
Topics: Antiviral Agents; Blood Platelets; Female; Humans; Influenza, Human; Middle Aged; Neuraminidase; Oseltamivir; Platelet Count; Thrombocytopenia | 2016 |
Three-day regimen of oseltamivir for postexposure prophylaxis of influenza in wards.
Topics: Adult; Aged; Antiviral Agents; Chemoprevention; Female; Humans; Influenza, Human; Male; Middle Aged; Oseltamivir; Post-Exposure Prophylaxis; Treatment Outcome | 2016 |
ECDC public consultation on the use of neuraminidase inhibitors.
Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2016 |
Impact of oseltamivir use on the reduction of complications in patients with influenza: a prospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Female; Greece; Humans; Influenza, Human; Male; Middle Aged; Oseltamivir; Young Adult | 2016 |
Chemical constituents from Melicope pteleifolia leaves.
Topics: Acetophenones; Animals; Antiviral Agents; Benzopyrans; Dogs; Flavonoids; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Madin Darby Canine Kidney Cells; Neuraminidase; Oseltamivir; Plant Leaves; Rutaceae | 2016 |
Persistent Infection of Drug-resistant Influenza A Virus during Chemotherapy for Malignant Lymphoma.
Topics: Acids, Carbocyclic; Aged, 80 and over; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Lymphoma; Male; Mutation; Neuraminidase; Oseltamivir | 2016 |
Oseltamivir PK/PD Modeling and Simulation to Evaluate Treatment Strategies against Influenza-Pneumococcus Coinfection.
Topics: Anti-Bacterial Agents; Antiviral Agents; Coinfection; Computer Simulation; Humans; Influenza A virus; Influenza, Human; Models, Theoretical; Neuraminidase; Oseltamivir; Pneumococcal Infections; Streptococcus pneumoniae | 2016 |
Evaluation of the use of oseltamivir prophylaxis in the control of influenza outbreaks in long-term care facilities in Alberta, Canada: a retrospective provincial database analysis.
Topics: Adult; Alberta; Antiviral Agents; Disease Outbreaks; Female; Humans; Influenza Vaccines; Influenza, Human; Long-Term Care; Male; Oseltamivir; Policy Making; Program Evaluation; Retrospective Studies; Skilled Nursing Facilities; Treatment Outcome | 2016 |
Epidemiological, Clinical and Virological Characteristics of Influenza B Virus from Patients at the Hospital Tertiary Care Units in Bangkok during 2011-2014.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cluster Analysis; DNA Mutational Analysis; Female; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Infant; Infant, Newborn; Influenza B virus; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Phenotype; Phylogeny; Real-Time Polymerase Chain Reaction; Tertiary Care Centers; Thailand; Young Adult | 2016 |
Clinical and epidemiological characteristics of a patient infected with H5N6 avian influenza A virus.
Topics: Animals; Antiviral Agents; Chickens; China; Hospitalization; Humans; Influenza A virus; Influenza in Birds; Influenza, Human; Length of Stay; Male; Middle Aged; Oseltamivir; Treatment Outcome; Zoonoses | 2016 |
Transplacental transfer of oseltamivir phosphate and its metabolite oseltamivir carboxylate using the ex vivo human placenta perfusion model in Chinese Hans population.
Topics: Antiviral Agents; Case-Control Studies; China; Female; Fetus; Humans; Influenza, Human; Maternal-Fetal Exchange; Oseltamivir; Perfusion; Placenta; Pregnancy | 2017 |
Contact transmission of influenza virus between ferrets imposes a looser bottleneck than respiratory droplet transmission allowing propagation of antiviral resistance.
Topics: Animals; Antiviral Agents; Disease Transmission, Infectious; Dogs; Drug Resistance, Viral; Female; Ferrets; Genome, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Madin Darby Canine Kidney Cells; Mutation; Orthomyxoviridae Infections; Oseltamivir; Respiratory System | 2016 |
Oseltamivir resistance in an influenza A (H3N2) virus isolated from an immunocompromised patient during the 2014-2015 influenza season in Alberta, Canada.
Topics: Alberta; Antiviral Agents; Drug Resistance, Viral; Humans; Immunocompromised Host; Influenza A Virus, H3N2 Subtype; Influenza, Human; Male; Middle Aged; Mutation; Nasopharynx; Neuraminidase; Oseltamivir; Seasons; Viral Load; Zanamivir | 2016 |
Haze and influenza A virus: Coincidence or causation?
Topics: Adult; Air Pollution; Antiviral Agents; Child; Child, Preschool; China; Disease Outbreaks; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Smog | 2016 |
Patient Perceptions of Oseltamivir for the Treatment of Influenza.
Topics: Adolescent; Adult; Antiviral Agents; Cross-Sectional Studies; Drug Costs; Educational Status; Female; Health Knowledge, Attitudes, Practice; Humans; Influenza, Human; Male; Oseltamivir; Treatment Outcome; Young Adult | 2016 |
Immortal time bias in observational studies of time-to-event outcomes.
Topics: Antiviral Agents; Bias; Computer Simulation; Critical Illness; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Logistic Models; Observational Studies as Topic; Oseltamivir; Proportional Hazards Models; Survival Analysis; Time Factors | 2016 |
Recommendations for Prevention and Control of Influenza in Children, 2016-2017.
Topics: Antiviral Agents; Child; Drug Storage; Egg Hypersensitivity; Health Personnel; Hospitalization; Humans; Immunization Schedule; Infectious Disease Transmission, Patient-to-Professional; Infectious Disease Transmission, Professional-to-Patient; Influenza Vaccines; Influenza, Human; Oseltamivir; United States; Zanamivir | 2016 |
Droplet digital PCR to investigate quasi-species at codons 119 and 275 of the A(H1N1)pdm09 neuraminidase during zanamivir and oseltamivir therapies.
Topics: Antiviral Agents; Codon; Drug Resistance, Viral; Genetic Variation; Genotyping Techniques; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Microbial Sensitivity Tests; Middle Aged; Mutation, Missense; Neuraminidase; Oseltamivir; Polymerase Chain Reaction; Sensitivity and Specificity; Zanamivir | 2017 |
Clinical Utility of On-Demand Multiplex Respiratory Pathogen Testing among Adult Outpatients.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care Facilities; Anti-Bacterial Agents; Asthma; Emergency Service, Hospital; Female; Humans; Influenza, Human; Male; Middle Aged; Orthomyxoviridae; Oseltamivir; Practice Patterns, Physicians'; Pulmonary Disease, Chronic Obstructive; Respiratory Tract Infections; Retrospective Studies | 2016 |
Does oseltamivir shorten flu symptom duration?
Topics: Adult; Antiviral Agents; Child; Humans; Influenza, Human; Oseltamivir; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2016 |
[Encephalopathy and influenza virus].
Topics: Anti-Bacterial Agents; Anticonvulsants; Antiviral Agents; Combined Modality Therapy; Encephalitis, Viral; Humans; Immunoglobulins, Intravenous; Influenza A virus; Influenza, Human; Male; Methylprednisolone; Middle Aged; Oseltamivir; Pneumonia, Mycoplasma; Psychomotor Agitation; Respiration, Artificial; Respiratory Distress Syndrome | 2016 |
Role of R292K mutation in influenza H7N9 neuraminidase toward oseltamivir susceptibility: MD and MM/PB(GB)SA study.
Topics: Antiviral Agents; Binding Sites; Drug Discovery; Drug Resistance, Viral; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Molecular Dynamics Simulation; Molecular Structure; Mutation; Neuraminidase; Oseltamivir; Protein Binding; Static Electricity; Structure-Activity Relationship | 2016 |
Community- and hospital-acquired infections with oseltamivir- and peramivir-resistant influenza A(H1N1)pdm09 viruses during the 2015-2016 season in Japan.
Topics: Acids, Carbocyclic; Adolescent; Adult; Aged; Child; Child, Preschool; Community-Acquired Infections; Cross Infection; Cyclopentanes; Drug Resistance, Viral; Female; Genes, Viral; Guanidines; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Male; Middle Aged; Mutation; Oseltamivir; Phylogeny; Seasons; Young Adult | 2017 |
Factors associated with clinical outcome in 25 patients with avian influenza A (H7N9) infection in Guangzhou, China.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; China; Female; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Respiratory Distress Syndrome; Retrospective Studies; Severe Acute Respiratory Syndrome; Young Adult | 2016 |
Postinfluenza A(H3N2) refractory invasive pulmonary aspergillosis.
Topics: Aged; Antiviral Agents; Bronchoalveolar Lavage Fluid; Disease Management; Disease Progression; Fatal Outcome; Hemopneumothorax; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Invasive Pulmonary Aspergillosis; Lung; Male; Nasopharynx; Oseltamivir; Radiography; Shock, Septic; Thoracentesis | 2017 |
Successful use of oseltamivir prophylaxis in managing a nosocomial outbreak of influenza A in a hematology and allogeneic stem cell transplant unit.
Topics: Adolescent; Adult; Antiviral Agents; Cross Infection; Disease Outbreaks; Female; Humans; Immunocompromised Host; Infection Control; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Retrospective Studies; Stem Cell Transplantation | 2017 |
Oseltamivir for pandemic influenza preparation: Maximizing the use of an existing stockpile.
Topics: Antiviral Agents; Civil Defense; Drug Stability; Humans; Influenza, Human; Oseltamivir; Pandemics; Strategic Stockpile; United States | 2017 |
Seasonal Influenza A H1N1pdm09 Virus and Severe Outcomes: A Reason for Broader Vaccination in Non-Elderly, At-Risk People.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza Vaccines; Influenza, Human; Middle Aged; Oseltamivir; Pneumonia; Respiratory Distress Syndrome; Retrospective Studies; Risk Factors; Seasons; Shock, Septic; Treatment Outcome; Young Adult | 2016 |
Influenza virus infections in patients with malignancies -- characteristics and outcome of the season 2014/15. A survey conducted by the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Medical Oncology (DGHO).
Topics: Aged; Antiviral Agents; Critical Care; Female; Germany; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Male; Middle Aged; Neoplasms; Oseltamivir; Risk Factors; Societies; Superinfection; Survival Analysis; Treatment Outcome | 2017 |
Antiviral susceptibility profile of influenza A viruses; keep an eye on immunocompromised patients under prolonged treatment.
Topics: Aged; Antiviral Agents; Drug Resistance, Viral; Female; Genotype; Greece; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Inhibitory Concentration 50; Male; Microbial Sensitivity Tests; Middle Aged; Mutation, Missense; Neuraminidase; Oseltamivir; Viral Proteins; Zanamivir | 2017 |
Surveillance of antiviral resistance markers in Argentina: detection of E119V neuraminidase mutation in a post-treatment immunocompromised patient.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Argentina; Child; Child, Preschool; Female; Humans; Immunocompromised Host; Infant; Influenza A Virus, H3N2 Subtype; Influenza, Human; Male; Middle Aged; Mutation; Neuraminidase; Oseltamivir; Real-Time Polymerase Chain Reaction; Viral Proteins; Young Adult | 2016 |
Clinical characteristics of critically ill patients with suspected influenza during the 2009-10 and 2013-14 outbreaks.
Topics: Antiviral Agents; APACHE; Cohort Studies; Critical Care; Critical Illness; Disease Outbreaks; Female; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care Units; Male; Maryland; Middle Aged; Oseltamivir; Retrospective Studies | 2017 |
Influenza A (H1N1) Infection Associated Acute Necrotizing Encephalopathy in a Child With Periodic Lateralized Epileptiform Discharges.
Topics: Child, Preschool; Electroencephalography; Female; Humans; Immunoglobulins, Intravenous; Influenza A Virus, H1N1 Subtype; Influenza, Human; Leukoencephalitis, Acute Hemorrhagic; Magnetic Resonance Imaging; Oseltamivir; Phenytoin; Seizures; Treatment Outcome | 2016 |
Monitoring the fitness of antiviral-resistant influenza strains during an epidemic: a mathematical modelling study.
Topics: Antiviral Agents; Drug Resistance, Viral; Epidemics; Global Health; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Models, Theoretical; Oseltamivir; Retrospective Studies; Viral Proteins | 2017 |
Quantifying the fitness of antiviral-resistant influenza strains.
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza, Human; Oseltamivir | 2017 |
Severe acute respiratory infection caused by swine influenza virus in a child necessitating extracorporeal membrane oxygenation (ECMO), the Netherlands, October 2016.
Topics: Animals; Antiviral Agents; Extracorporeal Membrane Oxygenation; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care Units, Pediatric; Netherlands; Orthomyxoviridae Infections; Oseltamivir; Real-Time Polymerase Chain Reaction; Respiratory Tract Infections; Severe Acute Respiratory Syndrome; Swine; Swine Diseases; Treatment Outcome | 2016 |
Contribution of a rapid influenza diagnostic test to manage hospitalized patients with suspected influenza.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Diagnostic Tests, Routine; Disease Management; Female; Hospitalization; Humans; Infant; Infant, Newborn; Influenza A virus; Influenza B virus; Influenza, Human; Male; Middle Aged; Molecular Diagnostic Techniques; Nucleic Acid Amplification Techniques; Oseltamivir; Point-of-Care Systems; Reagent Kits, Diagnostic; Sensitivity and Specificity; Young Adult | 2017 |
Influenza Prophylaxis in Children: Could a Single Dose of One Drug Be an Option?
Topics: Antiviral Agents; Child; Humans; Influenza Vaccines; Influenza, Human; Oseltamivir | 2016 |
Molecular Basis for Differential Patterns of Drug Resistance in Influenza N1 and N2 Neuraminidase.
Topics: Antiviral Agents; Binding Sites; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Hydrogen Bonding; Influenza A virus; Influenza, Human; Molecular Dynamics Simulation; Mutagenesis, Site-Directed; Neuraminidase; Oseltamivir; Protein Binding; Protein Structure, Quaternary; Static Electricity; Substrate Specificity; Thermodynamics; Zanamivir | 2016 |
Combinations of 1,8-cineol and oseltamivir for the treatment of influenza virus A (H3N2) infection in mice.
Topics: Animals; Antiviral Agents; Cyclohexanols; Cytokines; Drug Synergism; Drug Therapy, Combination; Eucalyptol; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Interleukin-10; Lung; Mice; Monoterpenes; Orthomyxoviridae Infections; Oseltamivir; Tumor Necrosis Factor-alpha | 2017 |
Generation and characterization of new monoclonal antibodies against swine origin 2009 influenza A (H1N1) virus and evaluation of their prophylactic and therapeutic efficacy in a mouse model.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Viral; Combined Modality Therapy; Dogs; Drug Synergism; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Immunodominant Epitopes; Immunotherapy; Influenza A Virus, H1N1 Subtype; Influenza, Human; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir; Protein Multimerization; Swine; Viral Vaccines | 2017 |
Genetic Characterization of Circulating 2015 A(H1N1)pdm09 Influenza Viruses from Eastern India.
Topics: Amino Acid Substitution; Drug Resistance, Viral; Genome, Viral; Hemagglutinin Glycoproteins, Influenza Virus; Humans; India; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation, Missense; Neuraminidase; Oseltamivir | 2016 |
Use of Neuraminidase Inhibitors for Treatment of Severe Influenza: Times Are Changing.
Topics: Adult; Antiviral Agents; Child; Child, Hospitalized; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir | 2017 |
Increased Antiviral Treatment Among Hospitalized Children and Adults With Laboratory-Confirmed Influenza, 2010-2015.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Cohort Studies; Female; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Length of Stay; Longitudinal Studies; Male; Middle Aged; Oseltamivir; Pandemics; Prospective Studies; Retrospective Studies; Seasons; United States; Young Adult | 2017 |
The in vivo efficacy of neuraminidase inhibitors cannot be determined from the decay rates of influenza viral titers observed in treated patients.
Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Models, Biological; Models, Theoretical; Neuraminidase; Oseltamivir; Treatment Outcome; Viral Load | 2017 |
Development of oseltamivir and zanamivir resistance in influenza A(H1N1)pdm09 virus, Denmark, 2014.
Topics: Antiviral Agents; Denmark; Drug Resistance, Viral; Genotype; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Mutation; Neuraminidase; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Zanamivir | 2017 |
Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemics.
Topics: Antiviral Agents; Cost-Benefit Analysis; Humans; Influenza, Human; Interdisciplinary Communication; Methods; Models, Theoretical; Oseltamivir; Pandemics | 2017 |
Design, in silico studies, synthesis and in vitro evaluation of oseltamivir derivatives as inhibitors of neuraminidase from influenza A virus H1N1.
Topics: Animals; Antiviral Agents; Chlorocebus aethiops; Computer Simulation; Dogs; Drug Design; Drug Resistance, Viral; Enzyme Inhibitors; HeLa Cells; Humans; In Vitro Techniques; Influenza A Virus, H1N1 Subtype; Influenza, Human; Madin Darby Canine Kidney Cells; Microscopy, Atomic Force; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Vero Cells; Viral Proteins | 2017 |
Survival biases lead to flawed conclusions in observational treatment studies of influenza patients.
Topics: Antiviral Agents; Bias; Hospital Mortality; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Length of Stay; Observational Studies as Topic; Oseltamivir; Proportional Hazards Models; Reproducibility of Results; Survival Analysis; United Kingdom | 2017 |
Prospective surveillance of antiviral resistance in hospitalized infants less than 12 months of age with A(H3N2) influenza infection and treated with oseltamivir.
Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Female; Hospitalization; Humans; Infant; Infant, Newborn; Influenza A Virus, H3N2 Subtype; Influenza, Human; Male; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Public Health Surveillance; RNA, Viral; Viral Load | 2017 |
Stockpile, use during outbreaks, restock, repeat.
Topics: Antiviral Agents; Humans; Influenza Vaccines; Influenza, Human; Oseltamivir; Post-Exposure Prophylaxis; Strategic Stockpile; Zanamivir | 2017 |
Molecular characterization of neuraminidase genes of influenza A(H3N2) viruses circulating in Southwest India from 2009 to 2013.
Topics: Antigens, Viral; Antiviral Agents; Binding Sites; Evolution, Molecular; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Viral; Genetic Variation; Humans; India; Influenza A Virus, H3N2 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Protein Binding | 2017 |
In silico prediction of drug resistance due to S247R mutation of Influenza H1N1 neuraminidase protein.
Topics: Catalytic Domain; Computer Simulation; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Ligands; Mutation; Neuraminidase; Oseltamivir; Protein Binding; Viral Proteins; Zanamivir | 2018 |
Impact of introduction of xpert flu assay for influenza PCR testing on obstetric patients: a quality improvement project.
Topics: Adult; Antiviral Agents; Female; Hospitals, Maternity; Humans; Influenza, Human; Oseltamivir; Patient Admission; Point-of-Care Systems; Polymerase Chain Reaction; Pregnancy; Pregnancy Complications, Infectious; Quality Improvement | 2018 |
[Managing your physician's office during an influenza pandemic--should you or can you prepare yourself?].
Topics: Aged; Antiviral Agents; Communicable Disease Control; Disease Outbreaks; Disinfection; Humans; Infectious Disease Transmission, Patient-to-Professional; Influenza, Human; Masks; Oseltamivir; Practice Guidelines as Topic; Primary Health Care; Switzerland | 2007 |
Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Fever; Humans; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Oseltamivir; Retrospective Studies; Treatment Outcome; Zanamivir | 2008 |
Editorial commentary: viral susceptibility and the choice of influenza antivirals.
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Practice Patterns, Physicians'; Zanamivir | 2008 |
[Impact of rapid influenza test during influenza epidemic in all febrile children less than 6 years old in a pediatric emergency department].
Topics: Age Factors; Alphainfluenzavirus; Antiviral Agents; Betainfluenzavirus; Child; Child, Preschool; Chromatography; Data Interpretation, Statistical; Emergency Service, Hospital; Female; France; Humans; Infant; Infant, Newborn; Influenza, Human; Male; Oseltamivir; Prospective Studies; Sex Factors; Time Factors | 2008 |
[Detection of oseltamivir resistance among human influenza A (H1N1) strains isolated in 2007-2008 flu season].
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir | 2008 |
A concise and flexible synthesis of the potent anti-influenza agents tamiflu and tamiphosphor.
Topics: Acetamides; Antiviral Agents; Cyclohexenes; Humans; Influenza, Human; Oseltamivir; Phosphorous Acids | 2008 |
Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008.
Topics: Animals; Antiviral Agents; Cell Line; Drug Resistance, Viral; Global Health; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Population Surveillance; Seasons | 2008 |
Reassessing the risks of Tamiflu use during a pandemic to the Lower Colorado River.
Topics: Antiviral Agents; Disease Outbreaks; Humans; Influenza, Human; Mexico; Oseltamivir; Rivers; United States; Water Pollutants, Chemical; Water Supply | 2008 |
Improving therapeutic strategies for secondary bacterial pneumonia following influenza.
Topics: Anti-Bacterial Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pneumonia, Bacterial | 2008 |
Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers.
Topics: Administration, Oral; Adult; Antiviral Agents; Asian People; Central Nervous System; Enzyme Inhibitors; Humans; Influenza, Human; Male; Neuraminidase; Orthomyxoviridae; Oseltamivir; White People | 2008 |
Study of the impact of oseltamivir on the risk for pneumonia and other outcomes of influenza, 2000-2005.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Cohort Studies; Female; Humans; Infant; Influenza, Human; Male; Middle Aged; Oseltamivir; Pneumonia; Retrospective Studies; Risk Factors; Treatment Outcome; Young Adult | 2008 |
Mixed treatment comparison with multiple outcomes reported inconsistently across trials: evaluation of antivirals for treatment of influenza A and B.
Topics: Amantadine; Antiviral Agents; Bayes Theorem; Clinical Trials as Topic; Decision Support Techniques; Follow-Up Studies; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Markov Chains; Meta-Analysis as Topic; Monte Carlo Method; Oseltamivir; Statistics as Topic; Time Factors; Treatment Outcome | 2008 |
Oseltamivir prescribing in pharmacy-benefits database, United States, 2004-2005.
Topics: Antiviral Agents; Disease Outbreaks; Drug Prescriptions; Drug Utilization Review; Humans; Influenza, Human; Oseltamivir; Time Factors; United States | 2008 |
Oseltamivir-resistant influenza A viruses are transmitted efficiently among guinea pigs by direct contact but not by aerosol.
Topics: Aerosols; Animals; Antiviral Agents; Cell Line; Disease Transmission, Infectious; Drug Resistance, Viral; Enzyme Inhibitors; Guinea Pigs; Humans; Influenza A virus; Influenza, Human; Mutation; Neuraminidase; Oseltamivir | 2008 |
Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Female; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Oseltamivir; Pregnancy; Seasons; United States; Zanamivir | 2008 |
Fulminating influenza pneumonia in the elderly: a case demonstration.
Topics: Age Factors; Aged, 80 and over; Anti-Bacterial Agents; Antiviral Agents; Clarithromycin; Humans; Influenza A virus; Influenza, Human; Male; Oseltamivir; Pneumonia, Viral | 2008 |
Minimum dataset needed for confirmed human H5N1 cases.
Topics: Antiviral Agents; Humans; Indonesia; Influenza A Virus, H5N1 Subtype; Influenza, Human; Oseltamivir; Population Surveillance; Sample Size | 2008 |
Influenza virus reactivation after remission with oseltamivir treatment in a patient undergoing nonmyeloablative bone marrow transplantation.
Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Hematopoietic Stem Cell Transplantation; Humans; Influenza A virus; Influenza, Human; Male; Oseltamivir; Recurrence; Transplantation Conditioning | 2008 |
Rapid molecular detection of the H275Y oseltamivir resistance gene mutation in circulating influenza A (H1N1) viruses.
Topics: Alleles; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation; Neuraminidase; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Time Factors | 2008 |
The influence of oseltamivir carboxylate and oseltamivir on hemagglutinin inhibition and microneutralization test.
Topics: Animals; Cells, Cultured; Chickens; Erythrocytes; Female; Hemagglutination Inhibition Tests; Hemagglutinin Glycoproteins, Influenza Virus; Horses; Humans; Influenza A virus; Influenza, Human; Male; N-Acetylneuraminic Acid; Neutralization Tests; Oseltamivir | 2008 |
Fatal oseltamivir-resistant influenza virus infection.
Topics: Aged; Antiviral Agents; Drug Resistance, Viral; Fatal Outcome; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mutation; Opportunistic Infections; Oseltamivir | 2008 |
Acute ophthalmoparesis accompanied with Influenza A infection.
Topics: Adult; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Ophthalmoplegia; Oseltamivir | 2008 |
Summer influenza outbreak in a home for the elderly: application of preventive measures.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Cross Infection; Disease Outbreaks; Female; France; Homes for the Aged; Humans; Infection Control; Influenza A virus; Influenza, Human; Male; Nursing Homes; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction; Seasons | 2008 |
Statement on influenza vaccination for the 2008-2009 season. An Advisory Committee Statement (ACS).
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Canada; Female; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza Vaccines; Influenza, Human; Oseltamivir; Pregnancy; Zanamivir | 2008 |
Antivirals and influenza: frequency of resistance.
Topics: Amantadine; Antiviral Agents; Disease Outbreaks; Drug Resistance, Viral; Humans; Influenza A virus; Influenza A Virus, H5N1 Subtype; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Rimantadine; Zanamivir | 2008 |
H5N1 transmission and disease: observations from the frontlines.
Topics: Animals; Antiviral Agents; Cytokines; Female; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Male; Oseltamivir; Pregnancy; Receptors, Cell Surface; Receptors, Virus; Viral Load; Virus Replication | 2008 |
Influenza A H5N1 clade 2.3.4 virus with a different antiviral susceptibility profile replaced clade 1 virus in humans in northern Vietnam.
Topics: Adolescent; Adult; Amantadine; Antiviral Agents; Child; Child, Preschool; Disease Outbreaks; Drug Resistance, Viral; Female; Geography; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Male; Oseltamivir; Phylogeny; Retrospective Studies; Vietnam | 2008 |
[Influenza season 2007/'08 in the Netherlands: antigenic variation, oseltamivir resistance and vaccine composition for the 2008/'09 season].
Topics: Drug Resistance, Viral; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza B virus; Influenza Vaccines; Influenza, Human; Netherlands; Oseltamivir | 2008 |
Adherence with oseltamivir chemoprophylaxis among workers exposed to poultry during avian influenza outbreaks in southern Israel.
Topics: Adolescent; Adult; Aged; Animals; Antiviral Agents; Chemoprevention; Disease Outbreaks; Female; Humans; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Israel; Male; Middle Aged; Occupational Diseases; Occupational Exposure; Oseltamivir; Patient Compliance; Poultry; Young Adult; Zoonoses | 2009 |
Influenza outbreak management on a locked behavioral health unit.
Topics: Antiviral Agents; Chemoprevention; Cross Infection; Disease Outbreaks; Humans; Infection Control; Influenza Vaccines; Influenza, Human; Oseltamivir; Patient Isolation | 2009 |
Widespread oseltamivir resistance in influenza A viruses (H1N1), South Africa.
Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Seasons; South Africa | 2008 |
A successful treatment of avian influenza infection in Turkey.
Topics: Animals; Antiviral Agents; Child, Preschool; Humans; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Male; Oseltamivir; Poultry; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Turkey | 2009 |
The influence of oseltamivir treatment on the risk of stroke after influenza infection.
Topics: Adult; Aged; Antiviral Agents; Comorbidity; Databases, Factual; Female; Humans; Influenza, Human; Male; Middle Aged; Oseltamivir; Retrospective Studies; Risk Factors; Risk Reduction Behavior; Stroke | 2009 |
Evolution of drug resistance in multiple distinct lineages of H5N1 avian influenza.
Topics: Adamantane; Antiviral Agents; Drug Resistance, Viral; Evolution, Molecular; Genome, Viral; Genotype; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Phylogeny; Reassortant Viruses; Selection, Genetic; Viral Matrix Proteins | 2009 |
A novel neuraminidase deletion mutation conferring resistance to oseltamivir in clinical influenza A/H3N2 virus.
Topics: Antiviral Agents; Child, Preschool; Drug Resistance, Viral; Gene Deletion; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Neuraminidase; Oseltamivir | 2009 |
Antiinfluenza medication kits need work, FDA advisers conclude.
Topics: Antiviral Agents; Disease Outbreaks; First Aid; Humans; Influenza, Human; Oseltamivir; United States; United States Food and Drug Administration; Zanamivir | 2008 |
Meeting report: risk assessment of tamiflu use under pandemic conditions.
Topics: Humans; Influenza, Human; Oseltamivir; Risk Assessment | 2008 |
[The smaller number of influenza patients with neuropsychiatric events had taken oseltamivir beforehand].
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Cross-Sectional Studies; Enzyme Inhibitors; Female; Humans; Influenza, Human; Male; Mental Disorders; Neuraminidase; Oseltamivir | 2008 |
A paucity of co-infecting respiratory viral pathogens in nasopharyngeal specimens from patients infected with H274Y-positive influenza A (H1N1) strains.
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation; Nasopharynx; Neuraminidase; Ontario; Oseltamivir; Respiratory Tract Infections; Reverse Transcriptase Polymerase Chain Reaction; Viral Proteins; Virus Diseases; Viruses | 2009 |
Pharmacokinetics of high-dose oseltamivir in healthy volunteers.
Topics: Administration, Oral; Adult; Antiviral Agents; Area Under Curve; Asian People; Biological Availability; Dose-Response Relationship, Drug; Drug Interactions; Female; Half-Life; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Male; Metabolic Clearance Rate; Models, Biological; Nausea; Oseltamivir; Probenecid; Saliva; Thailand; Urinalysis; Vomiting | 2009 |
Human infection with highly pathogenic avian influenza virus (H5N1) in northern Vietnam, 2004-2005.
Topics: Adolescent; Adult; Animals; Antiviral Agents; Female; Glucocorticoids; Humans; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Male; Methylprednisolone; Middle Aged; Oseltamivir; Poultry; Survival Rate; Treatment Outcome; Vietnam; Young Adult | 2009 |
Personal protective equipment and risk for avian influenza (H7N3).
Topics: Animals; Antibodies, Viral; Antiviral Agents; Communicable Disease Control; Conjunctivitis, Viral; Disease Outbreaks; Humans; Influenza A virus; Influenza in Birds; Influenza, Human; Oseltamivir; Poultry; Protective Devices; Surveys and Questionnaires | 2009 |
High-yielding synthesis of the anti-influenza neuramidase inhibitor (-)-oseltamivir by three "one-pot" operations.
Topics: Animals; Antiviral Agents; Catalysis; Ethers; Humans; Influenza, Human; Oseltamivir; Proline; Stereoisomerism | 2009 |
Detection of molecular markers of antiviral resistance in influenza A (H5N1) viruses using a pyrosequencing method.
Topics: Amantadine; Animals; Antiviral Agents; Birds; Drug Resistance, Viral; Genetic Markers; Humans; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Neuraminidase; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction; Rimantadine; RNA, Viral; Sensitivity and Specificity; Sequence Analysis, RNA; Zanamivir | 2009 |
Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children.
Topics: Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Female; Humans; Infant; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Male; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Sequence Analysis, DNA; Viral Load; Viral Proteins | 2009 |
Jeremy Farrar: When disaster strikes. Interview by Amy Maxmen.
Topics: Antibody Formation; Antiviral Agents; Asia, Southeastern; Disease Outbreaks; Humans; Immunity, Cellular; Influenza A Virus, H5N1 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; Vietnam | 2009 |
Neuropsychiatric concerns related to influenza treatment.
Topics: Antiviral Agents; Humans; Influenza Vaccines; Influenza, Human; Mental Disorders; Nervous System Diseases; Oseltamivir; Zanamivir | 2009 |
Emergence of oseltamivir-resistant influenza A/H3N2 virus with altered hemagglutination pattern in a hematopoietic stem cell transplant recipient.
Topics: Amino Acid Substitution; Antiviral Agents; Bronchoalveolar Lavage Fluid; Child, Preschool; Drug Resistance, Viral; Female; Genotype; Hemagglutination Inhibition Tests; Hematopoietic Stem Cell Transplantation; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Inhibitory Concentration 50; Mutation, Missense; Oseltamivir; RNA, Viral | 2009 |
Isolation of oseltamivir-resistant influenza A/H1N1 virus of different origins in Yokohama City, Japan, during the 2007-2008 influenza season.
Topics: Adult; Antiviral Agents; Child; Child, Preschool; Disease Outbreaks; Drug Resistance, Viral; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Male; Middle Aged; Oseltamivir; Seasons | 2009 |
Successful treatment of influenza A virus by oseltamivir in bone marrow transplant recipients.
Topics: Antiviral Agents; Bone Marrow Transplantation; Child, Preschool; Female; Humans; Infant; Influenza A virus; Influenza, Human; Male; Oseltamivir | 2010 |
Outcome of influenza infections in outpatients after allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Antiviral Agents; Bronchoalveolar Lavage Fluid; Female; Hematopoietic Stem Cell Transplantation; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Male; Middle Aged; Nasal Mucosa; Oseltamivir; Polymerase Chain Reaction; Postoperative Complications; Retrospective Studies; RNA, Viral; Switzerland; Time Factors; Treatment Outcome | 2009 |
[In the afternoon the boy was still in top condition. In the evening high fever and severe headache].
Topics: Antiviral Agents; Child; Fever of Unknown Origin; Headache; Humans; Influenza, Human; Male; Oseltamivir | 2008 |
Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Middle Aged; Norway; Oseltamivir; Population Surveillance; Seasons; Young Adult | 2009 |
Oseltamivir treatment for children showing abnormal behavior during influenza virus infection.
Topics: Adolescent; Antiviral Agents; Child; Child Behavior Disorders; Child, Preschool; Disease Progression; Female; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Male; Mental Disorders; Oseltamivir; Time Factors; Treatment Outcome | 2010 |
A Bayesian model for evaluating influenza antiviral efficacy in household studies with asymptomatic infections.
Topics: Antiviral Agents; Bayes Theorem; Family Characteristics; Humans; Influenza, Human; Markov Chains; Models, Biological; Monte Carlo Method; Oseltamivir; Randomized Controlled Trials as Topic; RNA, Viral | 2009 |
Use of oseltamivir in 12 European countries between 2002 and 2007--lack of association with the appearance of oseltamivir-resistant influenza A(H1N1) viruses.
Topics: Antiviral Agents; Disease Outbreaks; Drug Resistance, Viral; Europe; Humans; Incidence; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Prescriptions; Risk Assessment; Risk Factors; Statistics as Topic | 2009 |
Influenza virus resistance to oseltamivir: what are the implications?
Topics: Animals; Antiviral Agents; Disaster Planning; Disease Outbreaks; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir | 2009 |
Molecular characterization and phylogenetic analysis of H3N2 human influenza A viruses in Cheongju, South Korea.
Topics: Adolescent; Amino Acid Sequence; Amino Acid Substitution; Animals; Antigenic Variation; Cell Line; Child; Child, Preschool; DNA, Viral; Dogs; Enzyme Inhibitors; Evolution, Molecular; Humans; Infant; Influenza A Virus, H3N2 Subtype; Influenza, Human; Korea; Lectins; Molecular Sequence Data; Nasopharynx; Neuraminidase; Oseltamivir; Phylogeny | 2009 |
Cost-effectiveness of treating influenzalike illness with oseltamivir in the United States.
Topics: Adult; Aged; Antiviral Agents; Child; Clinical Trials as Topic; Cost of Illness; Cost-Benefit Analysis; Decision Trees; Humans; Influenza, Human; Models, Economic; Oseltamivir; Quality-Adjusted Life Years; Risk Factors; Time Factors; United States | 2009 |
Stockpiling drugs for an avian influenza outbreak: examining the surge in oseltamivir prescriptions during heightened media coverage of the potential for a worldwide pandemic.
Topics: Adult; Aged; Animals; Antiviral Agents; Birds; Case-Control Studies; Communications Media; Disaster Planning; Disease Outbreaks; Health Knowledge, Attitudes, Practice; Humans; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Middle Aged; Oseltamivir; Prescription Drugs; Surveys and Questionnaires | 2009 |
Drug resistance. A 'wimpy' flu strain mysteriously turns scary.
Topics: Amino Acid Substitution; Animals; Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Evolution, Molecular; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation; Neuraminidase; Oseltamivir | 2009 |
Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States.
Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Risk Factors; Seasons; Severity of Illness Index; United States | 2009 |
Morbidity and mortality associated with nosocomial transmission of oseltamivir-resistant influenza A(H1N1) virus.
Topics: Aged; Aged, 80 and over; Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Cross Infection; Disease Transmission, Infectious; Drug Resistance, Viral; Enzyme Inhibitors; Female; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Molecular Sequence Data; Morbidity; Neuraminidase; Oseltamivir | 2009 |
Global transmission of oseltamivir-resistant influenza.
Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Mutation; Neuraminidase; Oseltamivir | 2009 |
Comparison of the effectiveness of Zanamivir and Oseltamivir against influenza A/H1N1, A/H3N2, and B.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Middle Aged; Oseltamivir; Treatment Outcome; Young Adult; Zanamivir | 2009 |
Oseltamivir-resistant influenza a viruses circulating in Japan.
Topics: Amino Acid Substitution; Antiviral Agents; Cluster Analysis; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Inhibitory Concentration 50; Japan; Mutation, Missense; Neuraminidase; Oseltamivir; Phylogeny; Sequence Homology; Viral Proteins | 2009 |
Pandemic influenza: an inconvenient mutation.
Topics: Antiviral Agents; Disaster Planning; Disease Outbreaks; Drug Resistance, Viral; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation; Oseltamivir; Reassortant Viruses | 2009 |
Treatment with oseltamivir in children hospitalized with community-acquired, laboratory-confirmed influenza: review of five seasons and evaluation of an electronic reminder.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Cohort Studies; Community-Acquired Infections; Hospitals, Pediatric; Humans; Infant; Influenza, Human; Oseltamivir; Practice Patterns, Physicians'; Reminder Systems; Retrospective Studies | 2009 |
Computational studies of H5N1 influenza virus resistance to oseltamivir.
Topics: Antiviral Agents; Binding Sites; Computer Simulation; Crystallography, X-Ray; Drug Resistance, Viral; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Models, Molecular; Mutation; Neuraminidase; Oseltamivir; Protein Binding; Thermodynamics; Viral Proteins | 2009 |
Influenza virus resistance to antiviral agents: a plea for rational use.
Topics: Adamantane; Animals; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N1 Subtype; Influenza B virus; Influenza, Human; Oseltamivir | 2009 |
Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season.
Topics: Antiviral Agents; Communicable Diseases, Emerging; Drug Resistance, Viral; Enzyme Inhibitors; Europe; Genes, Viral; Hemagglutinins, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Phylogeny; Population Surveillance; Seasons | 2009 |
Incidence of neuropsychiatric adverse events in influenza patients treated with oseltamivir or no antiviral treatment.
Topics: Adolescent; Adult; Age Factors; Antiviral Agents; Epidemiologic Methods; Female; Humans; Incidence; Influenza, Human; Male; Mental Disorders; Oseltamivir; United States; Young Adult | 2009 |
[Validity in estimating influenza patient numbers from National Epidemiological Survey of Infectious Diseases (NESID) data using Oseltamivir consumption in Hyogo Prefecture].
Topics: Antiviral Agents; Epidemiologic Methods; Humans; Influenza, Human; Japan; Oseltamivir; Prescriptions | 2009 |
Oseltamivir and abnormal behaviors: true or not?
Topics: Adolescent; Antiviral Agents; Child; Cohort Studies; Contraindications; Humans; Influenza, Human; Japan; Mental Disorders; Oseltamivir; Reproducibility of Results | 2009 |
Cranial nerve palsies associated with influenza B.
Topics: Adult; Antiviral Agents; Blepharoptosis; Humans; Influenza B virus; Influenza, Human; Male; Oculomotor Nerve Diseases; Oseltamivir; Trochlear Nerve Diseases | 2009 |
Dynamic versus static models in cost-effectiveness analyses of anti-viral drug therapy to mitigate an influenza pandemic.
Topics: Antiviral Agents; Cost-Benefit Analysis; Decision Trees; Disease Outbreaks; Disease Transmission, Infectious; Humans; Influenza, Human; Models, Econometric; Netherlands; Oseltamivir | 2010 |
Prolonged influenza virus infection during lymphocytopenia and frequent detection of drug-resistant viruses.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; DNA, Viral; Gene Amplification; Humans; Immunocompromised Host; Infant; Influenza A virus; Influenza A Virus, H3N2 Subtype; Influenza, Human; Lymphopenia; Microbial Sensitivity Tests; Middle Aged; Netherlands; Oseltamivir; Respiratory Tract Infections; Retrospective Studies; RNA, Viral; Virus Shedding | 2009 |
Extending the environmental risk assessment for oseltamivir (Tamiflu) under pandemic use conditions to the coastal marine compartment.
Topics: Animals; Antiviral Agents; Diatoms; Disease Outbreaks; Humans; Influenza, Human; Mytilus edulis; No-Observed-Adverse-Effect Level; Oceans and Seas; Oseltamivir; Paracentrotus; Polychaeta; Risk Assessment; Toxicity Tests; Water Pollutants | 2009 |
[Medical ethics in outbreaks of human influenza].
Topics: Antiviral Agents; Civil Rights; Developed Countries; Developing Countries; Disease Outbreaks; Ethics, Medical; France; Global Health; Humans; Influenza, Human; International Cooperation; Oseltamivir; Practice Guidelines as Topic; World Health Organization | 2009 |
Update: infections with a swine-origin influenza A (H1N1) virus--United States and other countries, April 28, 2009.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Disease Outbreaks; Female; Humans; Infection Control; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Mexico; Middle Aged; Oseltamivir; Travel; United States; Zanamivir | 2009 |
A/H1N1 influenza: questions and answers.
Topics: Antiviral Agents; Diagnosis, Differential; Disease Outbreaks; Health Promotion; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Masks; Medical Staff, Hospital; Occupational Diseases; Oseltamivir; Physician-Patient Relations; Professional Practice; Protective Clothing; Treatment Outcome | 2009 |
Swine flu outbreak. What role for antiviral drugs?
Topics: Antiviral Agents; Disease Outbreaks; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Zanamivir | 2009 |
How severe will the flu outbreak be?
Topics: Animals; Antiviral Agents; Disease Outbreaks; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; Time Factors; Zanamivir | 2009 |
Influenza begs many questions.
Topics: Antiviral Agents; Disease Outbreaks; Global Health; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; United Kingdom | 2009 |
Different neuraminidase inhibitor susceptibilities of human H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany from 2001 to 2005/2006.
Topics: Animals; Cell Line; Dogs; Enzyme Inhibitors; Germany; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation; Neuraminidase; Oseltamivir; Phylogeny; Viral Proteins; Zanamivir | 2009 |
Rapid identification of oseltamivir-resistant influenza A(H1N1) viruses with H274Y mutation by RT-PCR/restriction fragment length polymorphism assay.
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation, Missense; Neuraminidase; Oseltamivir; Polymorphism, Restriction Fragment Length; Reverse Transcriptase Polymerase Chain Reaction; Viral Proteins | 2009 |
Clinical features of human influenza A (H5N1) infection in Vietnam: 2004-2006.
Topics: Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Diarrhea; Female; Hemorrhage; Humans; Infant; Influenza A Virus, H5N1 Subtype; Influenza, Human; Lung; Lymphopenia; Male; Middle Aged; Oseltamivir; Radiography; Retrospective Studies; Risk Factors; Transaminases; Treatment Outcome; Vietnam; Young Adult | 2009 |
Sales of oseltamivir in Norway prior to the emergence of oseltamivir resistant influenza A(H1N1) viruses in 2007-08.
Topics: Antiviral Agents; Commerce; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Norway; Oseltamivir | 2009 |
Novel influenza A (H1N1) virus infections in three pregnant women - United States, April-May 2009.
Topics: Adult; Antiviral Agents; Fatal Outcome; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Respiratory Distress Syndrome; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
Genetic microheterogeneity of emerging H275Y influenza virus A (H1N1) in Toronto, Ontario, Canada from the 2007-2008 respiratory season.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Female; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Neuraminidase; Ontario; Oseltamivir; Polymorphism, Genetic; Sequence Analysis, DNA; Viral Proteins; Young Adult | 2009 |
The use of oseltamivir during an influenza B outbreak in a chronic care hospital.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Australia; Chemoprevention; Cross Infection; Disease Outbreaks; Female; Hospitals; Humans; Influenza B virus; Influenza, Human; Long-Term Care; Male; Middle Aged; Oseltamivir; Treatment Outcome | 2009 |
Rapid spread of drug-resistant influenza A viruses in the Basque Country, northern Spain, 2000-1 to 2008-9.
Topics: Adamantane; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation; Oseltamivir; Spain | 2009 |
Susceptibility of antiviral drugs against 2009 influenza A (H1N1) virus.
Topics: Adamantane; Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Viral Matrix Proteins | 2009 |
Pigs might fly.
Topics: Aircraft; Animals; Antiviral Agents; Birds; Drug Resistance, Viral; Global Health; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Patient Isolation; Risk Factors; Triage; World Health Organization | 2009 |
Influenza-associated central nervous system dysfunction in Taiwanese children: clinical characteristics and outcomes with and without administration of oseltamivir.
Topics: Adolescent; Antiviral Agents; Central Nervous System Diseases; Child; Child, Preschool; Female; Humans; Infant; Influenza, Human; Male; Oseltamivir; Taiwan; Treatment Outcome | 2009 |
Antiviral resistance in influenza viruses circulating in Central and South America based on the detection of established genetic markers.
Topics: Adamantane; Amino Acid Sequence; Animals; Antiviral Agents; Cell Line; Central America; Dogs; Drug Resistance, Viral; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Male; Molecular Sequence Data; Neuraminidase; Orthomyxoviridae; Oseltamivir; Sequence Alignment; South America; Viral Matrix Proteins | 2009 |
Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; Asia, Southeastern; Cluster Analysis; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Oceania; Oseltamivir; Phylogeny; RNA, Viral; Sequence Analysis, DNA; Sequence Homology; South Africa; Viral Proteins; Zanamivir | 2009 |
Basic rules of influenza: how to combat the H1N1 influenza (swine flu) virus.
Topics: Antiviral Agents; Disease Outbreaks; Health Planning; Humans; Infectious Disease Incubation Period; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation; Oseltamivir; United States; Vaccination; Zanamivir | 2009 |
Telephone triage of patients with influenza.
Topics: Antiviral Agents; Clinical Protocols; Disease Outbreaks; Family Practice; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mass Screening; Nursing Care; Oseltamivir; Telephone; Triage; Zanamivir | 2009 |
Oseltamivir- and amantadine-resistant influenza viruses A (H1N1).
Topics: Amantadine; Antiviral Agents; Cell Line; Drug Resistance, Viral; Hemagglutinin Glycoproteins, Influenza Virus; Hong Kong; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Phylogeny; Polymerase Chain Reaction; Population Surveillance; Sequence Analysis, DNA | 2009 |
Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus.
Topics: Amino Acid Sequence; Antiviral Agents; Crystallography, X-Ray; Drug Design; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Molecular Sequence Data; Neuraminidase; Oseltamivir; Protein Conformation | 2009 |
Detection limit used for early warning in public health surveillance.
Topics: Chemistry Techniques, Analytical; Clinical Pharmacy Information Systems; Humans; Influenza, Human; Japan; Oseltamivir; Population Surveillance; Public Health; Sensitivity and Specificity | 2009 |
Oseltamivir: gastrointestinal bleeding. Unfavorable risk-benefit balance.
Topics: Europe; Gastrointestinal Hemorrhage; Humans; Influenza, Human; Oseltamivir | 2008 |
Patient-oriented pandemic influenza research.
Topics: Antiviral Agents; Biomedical Research; Disease Outbreaks; Drug Resistance, Viral; Health Services Accessibility; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; World Health Organization | 2009 |
FDA notifications. EUA issued for treating novel 2009 H1N1 flu.
Topics: Antiviral Agents; Child; Child, Preschool; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; United States; United States Food and Drug Administration; Zanamivir | 2009 |
UK swine flu cases near 3000, as GP leader says use of Tamiflu may need to be rethought.
Topics: Antiviral Agents; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; United Kingdom | 2009 |
What is the optimal therapy for patients with H5N1 influenza?
Topics: Animals; Antiviral Agents; Communicable Diseases, Emerging; Disease Outbreaks; Dose-Response Relationship, Drug; Drug Resistance, Viral; Drug Therapy, Combination; Humans; Immunotherapy; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza, Human; Oseltamivir; Practice Guidelines as Topic | 2009 |
Severe human influenza infections in Thailand: oseltamivir treatment and risk factors for fatal outcome.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Female; Geography; Humans; Infant; Infant, Newborn; Influenza, Human; Male; Middle Aged; Oseltamivir; Registries; Risk Factors; Thailand; Treatment Outcome | 2009 |
Detection of the antiviral drug oseltamivir in aquatic environments.
Topics: Antiviral Agents; Chromatography, Liquid; Disease Outbreaks; Drug Resistance, Viral; Humans; Influenza, Human; Inhibitory Concentration 50; Japan; Mass Spectrometry; Oseltamivir; Sewage; Water; Water Pollutants, Chemical; Water Purification | 2009 |
An environmental risk assessment for oseltamivir (Tamiflu) for sewage works and surface waters under seasonal-influenza- and pandemic-use conditions.
Topics: Animals; Antiviral Agents; Daphnia; Disease Outbreaks; Drainage, Sanitary; Environmental Exposure; Environmental Monitoring; Epidemiological Monitoring; Eukaryota; Fishes; Fresh Water; Geologic Sediments; Humans; Influenza, Human; Kinetics; Oseltamivir; Risk Assessment; Seasons; Sewage; Toxicity Tests; Waste Disposal, Fluid; Water Pollutants, Chemical | 2009 |
Apropos "vaccines in a hurry".
Topics: Antiviral Agents; Disease Outbreaks; Drug Industry; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Microbial Sensitivity Tests; Oseltamivir; Zanamivir | 2009 |
Effects of oseltamivir on influenza-related complications in children with chronic medical conditions.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Chronic Disease; Female; Hospitalization; Humans; Infant; Influenza, Human; Lung Diseases; Male; Oseltamivir; Otitis Media; Proportional Hazards Models; Retrospective Studies | 2009 |
Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico.
Topics: Adolescent; Adult; Age Distribution; Antiviral Agents; APACHE; Child; Child, Preschool; Female; Hospitalization; Humans; Infant; Infectious Disease Transmission, Patient-to-Professional; Influenza A Virus, H1N1 Subtype; Influenza, Human; Lung; Male; Mexico; Middle Aged; Oseltamivir; Pneumonia, Viral; Radiography; Respiratory Distress Syndrome; Respiratory Insufficiency; Retrospective Studies; Young Adult | 2009 |
Who should receive Tamiflu for swine flu?
Topics: Antiviral Agents; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Patient Selection; Risk Factors | 2009 |
Pomegranate (Punica granatum) purified polyphenol extract inhibits influenza virus and has a synergistic effect with oseltamivir.
Topics: Animals; Antiviral Agents; Cell Line; Chickens; Dogs; Drug Synergism; Erythrocytes; Hemagglutination; Humans; Hydrolyzable Tannins; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Lythraceae; Oseltamivir; Phytotherapy; Plant Extracts; Reverse Transcriptase Polymerase Chain Reaction; Virus Replication | 2009 |
Forever unprepared--the predictable unpredictability of pathogens.
Topics: Animals; Anti-Bacterial Agents; Birds; Disease Outbreaks; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza in Birds; Influenza, Human; Methicillin-Resistant Staphylococcus aureus; Oseltamivir; Staphylococcal Infections; Unnecessary Procedures | 2009 |
Outbreak of influenza A(H1N1)v without travel history in a school in the Toulouse district, France, June 2009.
Topics: Antiviral Agents; Child; Contact Tracing; Disease Outbreaks; Female; France; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Polymerase Chain Reaction; Population Surveillance; Predictive Value of Tests; Retrospective Studies; Surveys and Questionnaires | 2009 |
An outbreak of influenza A(H1N1)v in a boarding school in South East England, May-June 2009.
Topics: Antiviral Agents; Disease Outbreaks; England; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Polymerase Chain Reaction; Residential Facilities; Schools; Serotyping | 2009 |
Epidemiology and control of influenza A(H1N1)v in the Netherlands: the first 115 cases.
Topics: Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Disease Outbreaks; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Netherlands; Oseltamivir; Population Surveillance; Reverse Transcriptase Polymerase Chain Reaction; Serotyping; Young Adult | 2009 |
Viral loads and duration of viral shedding in adult patients hospitalized with influenza.
Topics: Aged; Aging; Antiviral Agents; Hospitalization; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Prospective Studies; Time Factors; Viral Load; Virus Shedding | 2009 |
Swine influenza: nephrologist's perspective.
Topics: Antiviral Agents; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Nephrology; Oseltamivir; Renal Insufficiency, Chronic; Zanamivir | 2009 |
Clinical effectiveness of oseltamivir for influenza A(H1N1) virus with H274Y neuraminidase mutation.
Topics: Adolescent; Adult; Amino Acid Substitution; Antiviral Agents; Body Temperature; Child; Child, Preschool; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Middle Aged; Mutation; Neuraminidase; Oseltamivir; Treatment Outcome; Young Adult | 2009 |
Surveillance and oseltamivir resistance of human influenza a virus in Turkey during the 2007-2008 season.
Topics: Amino Acid Sequence; Amino Acid Substitution; Animals; Antiviral Agents; Cities; Cluster Analysis; Drug Resistance, Viral; Enzyme-Linked Immunosorbent Assay; Humans; Influenza A Virus, H1N1 Subtype; Influenza B virus; Influenza, Human; Molecular Sequence Data; Mutation, Missense; Nasal Mucosa; Neuraminidase; Oseltamivir; Phylogeny; RNA, Viral; Sequence Analysis, DNA; Sequence Homology; Turkey; Viral Proteins | 2009 |
A/H1N1 influenza update.
Topics: Antiviral Agents; Disease Outbreaks; Family Practice; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; United Kingdom | 2009 |
Pandemic (H1N1) 2009 briefing note 1 Viruses resistant to oseltamivir (Tamiflu) identified.
Topics: Antiviral Agents; Disease Outbreaks; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir | 2009 |
A/H1N1 flu. Time for case-control studies of NSAIDs and oseltamivir.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir | 2009 |
Zanamivir-resistant influenza viruses with a novel neuraminidase mutation.
Topics: Animals; Antiviral Agents; Asia, Southeastern; Australasia; Cell Line; Drug Resistance, Viral; Female; Ferrets; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Zanamivir | 2009 |
Clinical features of cases of influenza A (H1N1)v in Osaka prefecture, Japan, May 2009.
Topics: Adolescent; Adult; Antigens, Viral; Antiviral Agents; Child; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Male; Middle Aged; Oseltamivir; Reagent Kits, Diagnostic; Reverse Transcriptase Polymerase Chain Reaction; Schools; Sensitivity and Specificity; Treatment Outcome; Young Adult; Zanamivir | 2009 |
Compliance and side effects of prophylactic oseltamivir treatment in a school in South West England.
Topics: Antiviral Agents; Child; England; Female; Humans; Incidence; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Patient Compliance; Schools; Surveys and Questionnaires; Treatment Outcome | 2009 |
Pandemic influenza A(H1N1)v viruses currently circulating in New Zealand are sensitive to oseltamivir.
Topics: Antiviral Agents; Disease Outbreaks; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; New Zealand; Oseltamivir; Population Surveillance | 2009 |
Oseltamivir adherence and side effects among children in three London schools affected by influenza A(H1N1)v, May 2009 - an internet-based cross-sectional survey.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Cross-Sectional Studies; Disease Outbreaks; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Internet; London; Male; Medication Adherence; Oseltamivir; Schools; Surveys and Questionnaires | 2009 |
Summary of the Australasian Society for Infectious Diseases and the Thoracic Society of Australia and New Zealand guidelines: treatment and prevention of H1N1 influenza 09 (human swine influenza) with antiviral agents.
Topics: Adult; Antiviral Agents; Child; Child, Preschool; Enzyme Inhibitors; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2009 |
Community transmission of influenza A (H1N1)v virus at a rock festival in Belgium, 2-5 July 2009.
Topics: Adult; Anniversaries and Special Events; Antibiotic Prophylaxis; Antiviral Agents; Belgium; Community-Acquired Infections; Contact Tracing; Disease Outbreaks; Female; Humans; Infection Control; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Population Surveillance; Travel; Young Adult | 2009 |
Emergence of oseltamivir-resistant influenza A H1N1 virus during the 2007-2008 winter season in Luxembourg: clinical characteristics and epidemiology.
Topics: Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Luxembourg; Male; Molecular Sequence Data; Oseltamivir; Phylogeny; Seasons; Young Adult | 2009 |
A/H1N1 pandemic. Too soon for congratulations.
Topics: Antiviral Agents; England; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir | 2009 |
A/H1N1 pandemic. Oseltamivir's adverse events.
Topics: Antiviral Agents; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir | 2009 |
Kinetics of nasopharyngeal shedding of novel H1N1 (swine-like) influenza A virus in an immunocompetent adult under oseltamivir therapy.
Topics: Adult; Animals; Antiviral Agents; Humans; Immunocompetence; Influenza A Virus, H1N1 Subtype; Influenza, Human; Kinetics; Male; Nasopharynx; Oseltamivir; Swine; Virus Shedding | 2009 |
Investment decisions in influenza pandemic contingency planning: cost-effectiveness of stockpiling antiviral drugs.
Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Outbreaks; Humans; Influenza, Human; Models, Theoretical; Netherlands; Oseltamivir; Risk Assessment | 2009 |
[Use of Tamiflu under pandemic conditions].
Topics: Antiviral Agents; Disease Outbreaks; Drug Resistance, Viral; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Oseltamivir | 2009 |
Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009.
Topics: Adolescent; Adult; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Female; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; RNA, Viral; Treatment Outcome; Washington | 2009 |
Person-to-person transmission of oseltamivir-resistant influenza A/H1N1 viruses in two households; Germany 2007/08.
Topics: Adult; Antiviral Agents; Child; Drug Resistance, Viral; Family; Female; Germany; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Nasal Cavity; Neuraminidase; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral | 2009 |
[Black triangle down] Tamiflu--the wrong message?
Topics: Antiviral Agents; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir | 2009 |
Detection of an oseltamivir-resistant pandemic influenza A/H1N1 virus in Hong Kong.
Topics: Adolescent; Animals; Cell Line; Disease Outbreaks; Dogs; Drug Resistance, Viral; Female; Genes, Viral; Hong Kong; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Phylogeny; Population Surveillance; Reverse Transcriptase Polymerase Chain Reaction; Virus Cultivation | 2009 |
Oseltamivir: cardiac and visual disorders: add-on toxicity.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Europe; Humans; Influenza, Human; Oseltamivir; Vision Disorders | 2009 |
Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis--North Carolina, 2009.
Topics: Adolescent; Antiviral Agents; DNA Mutational Analysis; Drug Resistance, Viral; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; North Carolina; Oseltamivir | 2009 |
Intensive care adult patients with severe respiratory failure caused by Influenza A (H1N1)v in Spain.
Topics: Adult; Antiviral Agents; Critical Care; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Medical Audit; Middle Aged; Mutation; Oseltamivir; Pregnancy; Respiratory Insufficiency; Reverse Transcriptase Polymerase Chain Reaction; Severity of Illness Index; Spain | 2009 |
A/H1N1 flu pandemic. Roche responds.
Topics: Antiviral Agents; Child; Drug Industry; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir | 2009 |
Optimization of antiviral prescribing for influenza.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Community-Acquired Infections; Hospitals, Pediatric; Humans; Infant; Influenza, Human; Oseltamivir; Practice Patterns, Physicians'; Reminder Systems | 2009 |
No evidence of transmission of H5N1 highly pathogenic avian influenza to humans after unprotected contact with infected wild swans.
Topics: Animals; Animals, Wild; Anseriformes; Antiviral Agents; England; Humans; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Oseltamivir | 2010 |
Flu's unexpected bonus.
Topics: Antiviral Agents; Disease Outbreaks; Drug Industry; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir | 2009 |
Q&A: What have we found out about the influenza A (H1N1) 2009 pandemic virus?
Topics: Animals; Antiviral Agents; Disease Outbreaks; Drug Resistance, Viral; Humans; Immunity, Active; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; Time Factors; Virulence; Zanamivir | 2009 |
Dispensing antivirals in underserved communities.
Topics: Antiviral Agents; Disease Outbreaks; Female; Health Services Accessibility; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Manitoba; Medically Underserved Area; Needs Assessment; Oseltamivir | 2009 |
Why are oseltamivir and zanamivir effective against the newly emerged influenza A virus (A/H1N1)?
Topics: Antiviral Agents; Base Sequence; Binding Sites; Computer Simulation; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza, Human; Molecular Sequence Data; Oseltamivir; Zanamivir | 2009 |
Keeping alert to changes during the pandemic.
Topics: Antiviral Agents; Disease Outbreaks; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; New Zealand; Oseltamivir; Professional Practice | 2009 |
Genomic diversity of oseltamivir-resistant influenza virus A (H1N1), Luxembourg, 2007-08.
Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Genetic Variation; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Luxembourg; Molecular Sequence Data; Neuraminidase; Oseltamivir; Phylogeny; Prevalence; RNA-Dependent RNA Polymerase; Sequence Analysis, DNA; Viral Proteins | 2009 |
[Clinical experience of successful management of a human case with A/H5N1 infection in Hunan Province].
Topics: Adult; Antiviral Agents; China; Female; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Multiple Organ Failure; Oseltamivir; Treatment Outcome | 2009 |
Detection of influenza A H1N1 and H3N2 mutations conferring resistance to oseltamivir using rolling circle amplification.
Topics: Antifungal Agents; Base Sequence; DNA Mutational Analysis; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Molecular Sequence Data; Mutation; Oseltamivir | 2009 |
A/H1N1 flu pandemic. Managing neutropenic sepsis.
Topics: Antineoplastic Agents; Antiviral Agents; Diagnosis, Differential; Fever; Humans; Infection Control; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neoplasms; Neutropenia; Oseltamivir | 2009 |
Oseltamivir susceptibility in south-western France during the 2007-8 and 2008-9 influenza epidemics and the ongoing influenza pandemic 2009.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Disease Outbreaks; Drug Resistance, Viral; Female; France; Humans; Incidence; Infant; Infant, Newborn; Influenza, Human; Male; Middle Aged; Oseltamivir; Population Surveillance; Risk Assessment; Risk Factors; Young Adult | 2009 |
Atypical clinical presentation of H1N1 influenza in a dialysis patient.
Topics: Adult; Antiviral Agents; Critical Care; Diagnosis, Differential; Dyspnea; Emergency Treatment; Glomerulosclerosis, Focal Segmental; Hemoptysis; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Kidney Failure, Chronic; Male; Oseltamivir; Renal Dialysis | 2009 |
[New influenza A (H1N1) pandemia and cancer patients: what do we do?].
Topics: Antiviral Agents; Disease Outbreaks; Hospitalization; Humans; Immunization Schedule; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Neoplasms; Neutropenia; Oseltamivir; Streptococcal Vaccines | 2009 |
[Inquired of the President of the.Robert Koch Institute. How dangerous is Mexican influenza?].
Topics: Animals; Antiviral Agents; Disease Outbreaks; Enzyme Inhibitors; Germany; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mexico; Orthomyxoviridae Infections; Oseltamivir; Swine; World Health Organization; Zanamivir | 2009 |
Oseltamivir for influenza postexposure prophylaxis: economic evaluation for children aged 1-12 years in the U.S.
Topics: Antiviral Agents; Child; Child, Preschool; Cost-Benefit Analysis; Databases, Factual; Decision Trees; Drug Costs; Humans; Infant; Influenza, Human; Oseltamivir; Quality-Adjusted Life Years; United States | 2009 |
Amantadine- and oseltamivir-resistant variants of influenza A viruses in Thailand.
Topics: Amantadine; Antiviral Agents; Drug Resistance, Multiple, Viral; Genes, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Mutation; Oseltamivir; Phylogeny; Thailand | 2009 |
Pregnancy and H1N1 infection.
Topics: Antibodies, Monoclonal; Antiviral Agents; Drug Resistance, Viral; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Patient Selection; Pregnancy; Pregnancy Complications, Infectious; United States | 2009 |
Pregnancy and H1N1 infection.
Topics: Antiviral Agents; Early Diagnosis; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Singapore; Time Factors; Treatment Outcome | 2009 |
[Pneumonia and the acute respiratory distress syndrome due to influenza A (H1N1) virus].
Topics: Acute Kidney Injury; Acute Lung Injury; Aged; Antiviral Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disseminated Intravascular Coagulation; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Lung Neoplasms; Male; Oseltamivir; Pneumonia, Viral; Pulmonary Edema; Respiratory Distress Syndrome; Thrombocytopenia | 2009 |
[New influenza A (H1N1): advised indication and prescription of antiviral drugs].
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Utilization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Netherlands; Oseltamivir; Zanamivir | 2009 |
[No evidence of fewer influenza complications with oseltamivir].
Topics: Antiviral Agents; Evidence-Based Medicine; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Premedication | 2009 |
Evaluation of a rapid molecular algorithm for detection of pandemic influenza A (H1N1) 2009 virus and screening for a key oseltamivir resistance (H275Y) substitution in neuraminidase.
Topics: Algorithms; Antiviral Agents; Disease Outbreaks; Drug Resistance, Viral; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Linear Models; Neuraminidase; Oseltamivir; Point Mutation; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Viral Proteins | 2010 |
Swine H1N1 influenza in a post liver transplant patient.
Topics: Adult; Antiviral Agents; Critical Care; Diagnosis, Differential; Disease Outbreaks; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care Units; Kidney Failure, Chronic; Liver Cirrhosis; Liver Transplantation; Opportunistic Infections; Oseltamivir; Postoperative Complications; Prednisone; Respiratory Insufficiency; Tacrolimus | 2009 |
Highlights from the 49th ICAAC.
Topics: Antiviral Agents; Biomedical Research; Disease Outbreaks; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Occupational Diseases; Oseltamivir; Respiratory Protective Devices | 2009 |
A model-based assessment of oseltamivir prophylaxis strategies to prevent influenza in nursing homes.
Topics: Aged; Antiviral Agents; Disease Outbreaks; Humans; Influenza Vaccines; Influenza, Human; Models, Biological; Nursing Homes; Oseltamivir | 2009 |
Maximizing the value of drug stockpiles for pandemic influenza.
Topics: Antiviral Agents; Disease Outbreaks; Drug Storage; Global Health; Humans; Influenza, Human; Oseltamivir | 2009 |
[Frequently asked questions concerning the A/H1N1 virus].
Topics: Antiviral Agents; Disease Progression; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir | 2009 |
Oseltamivir boosts 2009 H1N1 virus infectivity in vitro.
Topics: Animals; Antiviral Agents; Cell Line; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mice; Neuraminidase; Oseltamivir; Virus Internalization | 2009 |
H1N1 influenza in pregnancy: cause for concern.
Topics: Adult; Antiviral Agents; Fatal Outcome; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Reagent Kits, Diagnostic | 2009 |
Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein.
Topics: Animals; Antiviral Agents; Bronchi; Dogs; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Kidney; Mice; Mice, Inbred BALB C; Microscopy, Fluorescence; Neuraminidase; Oseltamivir; Recombinant Fusion Proteins | 2009 |
Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein.
Topics: Animals; Antiviral Agents; Binding Sites; Caco-2 Cells; Cell Proliferation; Dogs; Humans; Influenza, Human; Mutation; N-Acetylneuraminic Acid; Neuraminidase; Orthomyxoviridae; Oseltamivir; Recombinant Fusion Proteins; Zanamivir | 2009 |
Oseltamivir-resistant pandemic (H1N1) 2009 influenza virus, October 2009.
Topics: Antiviral Agents; Disease Outbreaks; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir | 2009 |
Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis.
Topics: Adolescent; Antiviral Agents; Asthma; Chemoprevention; Disease Outbreaks; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Microbial Sensitivity Tests; Mutation; Neuraminidase; Oseltamivir; Pulmonary Disease, Chronic Obstructive | 2009 |
Boost of mucosal secretory immunoglobulin A response by clarithromycin in paediatric influenza.
Topics: Adolescent; Anti-Bacterial Agents; Antiviral Agents; Child; Child, Preschool; Clarithromycin; Cough; Drug Therapy, Combination; Humans; Immunoglobulin A; Infant; Influenza A virus; Influenza, Human; Nasal Mucosa; Oseltamivir; Prevalence; Retrospective Studies; RNA, Viral; Treatment Outcome | 2009 |
Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons.
Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Female; Fever; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Mutation; Neuraminidase; Oseltamivir; Time Factors; Zanamivir | 2009 |
Oseltamivir resistance: what does it mean clinically?
Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation; Neuraminidase; Oseltamivir | 2009 |
Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Animals; Antiviral Agents; Cell Line; Cyclopentanes; Dogs; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Inhibitory Concentration 50; Molecular Sequence Data; Mutation, Missense; Neuraminidase; Oseltamivir; RNA, Viral; Sequence Analysis, DNA; Viral Proteins; Zanamivir | 2010 |
First wave of the influenza A/H1N1v pandemic in Switzerland.
Topics: Adult; Comorbidity; Disease Outbreaks; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Polymerase Chain Reaction; Population Surveillance; Prospective Studies; Retrospective Studies; Switzerland; Young Adult | 2009 |
Favourable outcome of pneumonia due to novel influenza A/H1N1 2009 virus in a splenectomised adult patient undergoing therapy for non-Hodgkin lymphoma.
Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Oseltamivir; Pneumonia; Reverse Transcriptase Polymerase Chain Reaction; Splenectomy | 2010 |
H1N1 influenza A virus-associated acute lung injury: response to combination oseltamivir and prolonged corticosteroid treatment.
Topics: Adult; Anti-Inflammatory Agents; Antiviral Agents; Argentina; Catchment Area, Health; Disease Outbreaks; Drug Therapy, Combination; Female; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Length of Stay; Lung; Male; Multiple Organ Failure; Oseltamivir; Prospective Studies; Respiration, Artificial; Respiratory Distress Syndrome; Severity of Illness Index | 2010 |
Pandemic (H1N1) 2009 virus outbreak in a school in London, April-May 2009: an observational study.
Topics: Adolescent; Antiviral Agents; Child; Disease Outbreaks; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; London; Male; Oseltamivir; Schools; Young Adult | 2010 |
The first case of severe novel H1N1 influenza successfully rescued by extracorporeal membrane oxygenation in Taiwan.
Topics: Adult; Extracorporeal Membrane Oxygenation; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir | 2009 |
First cases of spread of oseltamivir resistant swine flu between patients are reported in Wales.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir | 2009 |
Oseltamivir-resistant influenza A(H1N1) viruses detected in Europe during season 2007-8 had epidemiologic and clinical characteristics similar to co-circulating susceptible A(H1N1) viruses.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Case-Control Studies; Child; Child, Preschool; Cohort Studies; Disease Outbreaks; Drug Resistance, Viral; Europe; Female; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Odds Ratio; Oseltamivir; Practice Guidelines as Topic; Retrospective Studies; Risk; Risk Factors; Seasons; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2009 |
Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses.
Topics: Cross Infection; Drug Resistance, Viral; Global Health; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza B virus; Influenza Vaccines; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Population Surveillance; Rimantadine; Zanamivir | 2009 |
Rash associated with pandemic (H1N1) influenza.
Topics: Adult; Antipruritics; Antiviral Agents; Disease Outbreaks; Drug Therapy, Combination; Exanthema; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Ondansetron; Oseltamivir | 2010 |
Safety of oseltamivir compared with the adamantanes in children less than 12 months of age.
Topics: Adamantane; Antiviral Agents; Central Nervous System; Female; Humans; Infant; Infant, Newborn; Influenza, Human; Male; Nervous System Diseases; Oseltamivir; Retrospective Studies; Rimantadine | 2010 |
Novel influenza A (H1N1) outbreak on board a US navy vessel.
Topics: Antiviral Agents; Disease Outbreaks; Humans; Infection Control; Influenza A Virus, H1N1 Subtype; Influenza, Human; Military Personnel; New York City; Oseltamivir; Ships; United States | 2009 |
[Report of the first case of influenza A (H1N1) in mainland China].
Topics: Adult; Antiviral Agents; China; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Prognosis | 2009 |
Post-exposure prophylaxis during pandemic outbreaks.
Topics: Antiviral Agents; Disease Outbreaks; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Models, Theoretical; Oseltamivir; Post-Exposure Prophylaxis | 2009 |
Outbreak of antiviral drug-resistant influenza a in long-term care facility, Illinois, USA, 2008.
Topics: Adolescent; Adult; Antiviral Agents; Disease Outbreaks; Drug Resistance, Viral; Humans; Illinois; Influenza A Virus, H1N1 Subtype; Influenza, Human; Long-Term Care; Middle Aged; Oseltamivir; Time Factors | 2009 |
Emergence of H274Y oseltamivir-resistant A(H1N1) influenza viruses in Japan during the 2008-2009 season.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Female; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Male; Middle Aged; Neuraminidase; Oseltamivir; Phylogeny; Point Mutation; Sentinel Surveillance; Viral Proteins | 2010 |
Neuraminidase inhibitors--the story behind the Cochrane review.
Topics: Adult; Antiviral Agents; Data Interpretation, Statistical; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Randomized Controlled Trials as Topic; Review Literature as Topic | 2009 |
Why don't we have all the evidence on oseltamivir?
Topics: Antiviral Agents; Drug Industry; Epidemiologic Methods; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Randomized Controlled Trials as Topic; Review Literature as Topic | 2009 |
Complications: tracking down the data on oseltamivir.
Topics: Antiviral Agents; Data Interpretation, Statistical; Humans; Influenza, Human; Oseltamivir; Randomized Controlled Trials as Topic; Respiratory Tract Diseases; Review Literature as Topic | 2009 |
Postexposure prophylaxis of H1N1 with oseltamivir in a newly transplanted kidney recipient receiving intense immunosuppressive therapy.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antilymphocyte Serum; Antiviral Agents; Cesarean Section; Female; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Influenza A Virus, H1N1 Subtype; Influenza, Human; Kidney Failure, Chronic; Kidney Transplantation; Living Donors; Medical History Taking; Oseltamivir; Pregnancy; Renal Dialysis; Risk Factors; Rituximab; Siblings; Treatment Outcome | 2009 |
A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza.
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Vietnam | 2010 |
Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antiviral Agents; Azithromycin; Child; Child, Preschool; China; Disease Outbreaks; Drug Therapy, Combination; Female; Humans; Incidence; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Logistic Models; Lymphopenia; Male; Middle Aged; Ofloxacin; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; Time Factors; Virus Shedding; Young Adult | 2009 |
Influenza A/pandemic 2009/H1N1 in the setting of allogeneic hematopoietic cell transplantation: a potentially catastrophic problem in a vulnerable population.
Topics: Adult; Antiviral Agents; Fatal Outcome; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Oseltamivir; Transplantation, Homologous | 2010 |
Pattern of oseltamivir ingestions reported to Texas poison centers.
Topics: Accidents; Aging; Antiviral Agents; Disease Outbreaks; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Medication Errors; Neuraminidase; Oseltamivir; Poison Control Centers; Retrospective Studies; Seasons; Suicide, Attempted; Texas | 2010 |
H1N1 influenza in pregnancy: cause for concern.
Topics: Antiviral Agents; Compassionate Use Trials; Extracorporeal Membrane Oxygenation; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Zanamivir | 2010 |
Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing.
Topics: Amino Acid Sequence; Antiviral Agents; Drug Resistance, Viral; Genetic Markers; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Molecular Sequence Data; Neuraminidase; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Sequence Analysis, DNA; Viral Matrix Proteins; Viral Proteins | 2010 |
Oseltamivir- and amantadine-resistant influenza virus A (H1N1).
Topics: Amantadine; Antiviral Agents; Drug Resistance, Multiple, Viral; Hong Kong; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir | 2010 |
Use of oseltamivir after influenza infection is associated with reduced incidence of recurrent adverse cardiovascular outcomes among military health system beneficiaries with prior cardiovascular diseases.
Topics: Adult; Aged; Antiviral Agents; Cardiovascular Diseases; Female; Follow-Up Studies; Humans; Incidence; Influenza, Human; Logistic Models; Male; Middle Aged; Military Personnel; Multivariate Analysis; Oseltamivir; Risk Factors; Secondary Prevention; United States; United States Government Agencies | 2009 |
Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza.
Topics: Antiviral Agents; Child; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Infusions, Intravenous; Investigational New Drug Application; Oseltamivir; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Zanamivir | 2010 |
Oseltamivir for treatment of influenza in infants less than one year: a retrospective analysis.
Topics: Antiviral Agents; Female; Hospitals, Teaching; Humans; Infant; Influenza, Human; Male; Oseltamivir; Retrospective Studies; Treatment Outcome | 2010 |
Novel 2009 H1N1 influenza virus infection requiring extracorporeal membrane oxygenation in a pediatric heart transplant recipient.
Topics: Antiviral Agents; Child; Combined Modality Therapy; Extracorporeal Membrane Oxygenation; Heart Transplantation; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care Units, Pediatric; Male; Opportunistic Infections; Oseltamivir; Postoperative Complications; Respiratory Distress Syndrome | 2010 |
Homology modeling, docking, and molecular dynamics reveal HR1039 as a potent inhibitor of 2009 A(H1N1) influenza neuraminidase.
Topics: Amino Acid Sequence; Binding Sites; Disaccharides; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Molecular Dynamics Simulation; Molecular Sequence Data; Neuraminidase; Oseltamivir; Plant Extracts; Sequence Alignment; Triterpenes; Zanamivir | 2010 |
Tamiflu still prudent for pandemic influenza, PHAC maintains.
Topics: Antiviral Agents; Canada; Disease Outbreaks; Government Agencies; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Review Literature as Topic | 2010 |
A caution about giving Tamiflu to children.
Topics: Antiviral Agents; Child; Drug Labeling; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir | 2009 |
[Neuraminidase inhibitors and high risk of influenza complications: considered and widely-supported recommendations].
Topics: Age Factors; Antiviral Agents; Centers for Disease Control and Prevention, U.S.; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Practice Guidelines as Topic; Risk Factors; United States; World Health Organization | 2009 |
Oseltamivir carboxylate, the active metabolite of oseltamivir phosphate (Tamiflu), detected in sewage discharge and river water in Japan.
Topics: Antiviral Agents; Chromatography, Liquid; Drug Residues; Drug Resistance, Viral; Environmental Health; Environmental Monitoring; Fresh Water; Humans; Influenza, Human; Japan; Orthomyxoviridae; Oseltamivir; Rivers; Seasons; Sewage; Tandem Mass Spectrometry; Water Pollutants, Chemical; Water Purification | 2010 |
Patients hospitalized with 2009 pandemic influenza A (H1N1) - New York City, May 2009.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Asthma; Child; Child, Preschool; Disease Outbreaks; Female; Hospitalization; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; New York City; Oseltamivir; Retrospective Studies; Risk Factors; Severity of Illness Index; Young Adult | 2010 |
[Pandemic influenza A in the ICU: experience in Spain and Latin America. GETGAG/SEMICYUC/(Spanish Working Group on Severe Pandemic Influenza A/SEMICYUC)].
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Comorbidity; Disease Outbreaks; Female; Hospital Mortality; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care Units; Latin America; Male; Middle Aged; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Registries; Respiration, Artificial; Respiratory Insufficiency; Severity of Illness Index; Shock; Spain; Young Adult | 2010 |
The natural viral load profile of patients with pandemic 2009 influenza A(H1N1) and the effect of oseltamivir treatment.
Topics: Administration, Oral; Adolescent; Adult; Antiviral Agents; Child; Cohort Studies; Disease Outbreaks; Female; Hong Kong; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Nasopharynx; Oseltamivir; Retrospective Studies; Treatment Outcome; Viral Load; Young Adult | 2010 |
Clinical presentation and response to treatment of novel influenza A H1N1 in a university-based summer camp population.
Topics: Adolescent; Antiviral Agents; Disease Outbreaks; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Time Factors; Treatment Outcome; United States; Zanamivir | 2010 |
The truth about Tamiflu? Neuraminidase inhibitors in pandemic A/H1N1 flu.
Topics: Antiviral Agents; Disease Outbreaks; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir | 2010 |
The truth about Tamiflu? Zanamivir should be inhaled, not nebulised.
Topics: Administration, Inhalation; Antiviral Agents; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Nebulizers and Vaporizers; Off-Label Use; Oseltamivir; Zanamivir | 2010 |
The truth about Tamiflu? Data access is matter of trust.
Topics: Access to Information; Antiviral Agents; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir | 2010 |
Administration of neuraminidase inhibitors for the treatment of Japanese patients infected with the novel influenza A (H1N1).
Topics: Adolescent; Adult; Antiviral Agents; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Male; Neuraminidase; Oseltamivir; Treatment Outcome; Young Adult; Zanamivir | 2010 |
T-705 (favipiravir) activity against lethal H5N1 influenza A viruses.
Topics: Aged; Amides; Animals; Antiviral Agents; Cell Line; Child; DNA Replication; DNA-Directed DNA Polymerase; Dogs; Drug Resistance, Viral; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Kidney; Kinetics; Lung; Oseltamivir; Pyrazines; Ribavirin | 2010 |
Antiviral drug profile of seasonal influenza viruses circulating in Portugal from 2004/2005 to 2008/2009 winter seasons.
Topics: Adolescent; Adult; Aged; Amantadine; Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A virus; Influenza, Human; Inhibitory Concentration 50; Male; Middle Aged; Oseltamivir; Portugal; RNA, Viral; Sequence Analysis; Young Adult | 2010 |
The dermatologic manifestation of novel influenza A(H1N1).
Topics: Adult; Antiviral Agents; Biopsy; Diagnosis, Differential; DNA, Viral; Follow-Up Studies; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction; Skin; Skin Diseases, Viral | 2010 |
H1N1 influenza in pregnancy: risks, vaccines, and antivirals.
Topics: Antiviral Agents; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Risk Factors; Zanamivir | 2009 |
Influenza A/H1N1 virus in very low-birth-weight premature infant: case report.
Topics: Antiviral Agents; Apnea; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Infant, Very Low Birth Weight; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intermittent Positive-Pressure Ventilation; Male; Oseltamivir | 2010 |
Sudden death of a patient with pandemic influenza (A/H1N1pdm) virus infection by acute respiratory distress syndrome.
Topics: Adult; Antigens, Viral; Antiviral Agents; Death, Sudden; Female; Humans; Immunohistochemistry; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Lung; Nasopharynx; Oseltamivir; Respiratory Distress Syndrome; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral | 2010 |
Severe influenza A virus (H1N1) infection in pregnancy.
Topics: Adult; Antiviral Agents; Cesarean Section; Female; Humans; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Third; Respiration, Artificial; Respiratory Distress Syndrome | 2010 |
Antiviral treatment of patients with oseltamivir-resistant and oseltamivir-susceptible seasonal Influenza A (H1N1) infection during the 2007-2008 influenza season in the United States.
Topics: Antiviral Agents; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Treatment Outcome; United States | 2010 |
[Infra-usage of oseltamivir in Spain].
Topics: Antiviral Agents; Disease Outbreaks; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Spain | 2010 |
Influenza A/H1N1 2009 pneumonia in kidney transplant recipients: characteristics and outcomes following high-dose oseltamivir exposure.
Topics: Antiviral Agents; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Kidney Transplantation; Male; Middle Aged; Oseltamivir; Pneumonia, Viral; Postoperative Complications; Transplantation; Treatment Outcome | 2010 |
Clinical analysis of 150 cases with the novel influenza A (H1N1) virus infection in Shanghai, China.
Topics: Adolescent; Adult; Aged; CD4-Positive T-Lymphocytes; Child; Child, Preschool; China; Disease Outbreaks; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Lung; Male; Middle Aged; Oseltamivir; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Outbreaks of 2009 pandemic influenza A (H1N1) among long-term-care facility residents - three states, 2009.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Colorado; Disease Outbreaks; Female; Humans; Infection Control; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Long-Term Care; Maine; Male; New York; Oseltamivir; Population Surveillance | 2010 |
Perinatal pandemic (H1N1) 2009 infection, Thailand.
Topics: Antiviral Agents; Disease Outbreaks; Female; Humans; Infant, Newborn; Infant, Premature; Infectious Disease Transmission, Vertical; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Thailand | 2010 |
Detection of pandemic (H1N1) 2009 virus in patients treated with oseltamivir.
Topics: Adult; Antiviral Agents; Disease Outbreaks; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Mexico; Oseltamivir; Reagent Kits, Diagnostic; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity | 2010 |
Tamiflu: what dermatologists need to know.
Topics: Antiviral Agents; Biotransformation; Disease Outbreaks; Drug Eruptions; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir | 2010 |
Does treatment with oseltamivir prevent transmission of influenza to household contacts?
Topics: Antiviral Agents; Family Characteristics; Family Health; Humans; Influenza, Human; Orthomyxoviridae; Oseltamivir; Treatment Outcome; Virus Shedding | 2010 |
Effects of oseltamivir treatment on duration of clinical illness and viral shedding and household transmission of influenza virus.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Family Characteristics; Family Health; Humans; Infant; Influenza, Human; Male; Middle Aged; Nose; Orthomyxoviridae; Oseltamivir; Pharynx; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Treatment Outcome; Virus Shedding; Young Adult | 2010 |
Oseltamivir-resistant pandemic (H1N1) 2009 influenza in a severely ill patient: the first Australian case.
Topics: Adult; Antiviral Agents; Australia; Disease Outbreaks; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Kidney Transplantation; Male; Oseltamivir | 2010 |
[The pandemic--an afterthought].
Topics: Antiviral Agents; Disease Outbreaks; Evidence-Based Medicine; History, 21st Century; Humans; Influenza A Virus, H5N1 Subtype; Influenza Vaccines; Influenza, Human; Mass Vaccination; Norway; Oseltamivir | 2010 |
Genetic makeup of amantadine-resistant and oseltamivir-resistant human influenza A/H1N1 viruses.
Topics: Amantadine; Amino Acid Substitution; Antiviral Agents; Cluster Analysis; Genome, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Molecular Sequence Data; Mutation, Missense; Oseltamivir; Phylogeny; RNA, Viral; Sequence Analysis, DNA; Sequence Homology; Viral Proteins | 2010 |
H1N1 guidelines.
Topics: Antiviral Agents; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Practice Guidelines as Topic | 2010 |
Influenza A/H1N1 (2009) infection in pregnancy--an Asian perspective.
Topics: Administration, Oral; Adolescent; Adult; Antiviral Agents; Cohort Studies; Female; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Prenatal Care; Prospective Studies; Singapore; Time Factors; Young Adult; Zanamivir | 2010 |
Prison outbreak: pandemic (H1N1) 2009 in an Australian prison.
Topics: Antiviral Agents; Australia; Disease Outbreaks; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Prisons | 2010 |
Update on oseltamivir-resistant pandemic A (H1N1) 2009 influenza virus: January 2010.
Topics: Antiviral Agents; Cluster Analysis; Disease Outbreaks; Drug Resistance, Viral; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation; Oseltamivir | 2009 |
Pathologic findings in novel influenza A (H1N1) virus ("Swine Flu") infection: contrasting clinical manifestations and lung pathology in two fatal cases.
Topics: Adult; Antiviral Agents; Fatal Outcome; Female; Humans; Hyperplasia; Influenza A Virus, H1N1 Subtype; Influenza, Human; Lung; Male; Middle Aged; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction | 2010 |
Household transmissibility and other characteristics of seasonal oseltamivir-resistant influenza A(H1N1) viruses, Germany, 2007-8.
Topics: Antiviral Agents; Cohort Studies; Disease Outbreaks; Drug Resistance, Viral; Female; Germany; Housing; Humans; Incidence; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Risk Assessment; Risk Factors; Seasons | 2010 |
Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza.
Topics: Adolescent; Adult; Antiviral Agents; Critical Illness; Disease Outbreaks; Drug Administration Schedule; Female; Gastrointestinal Tract; Half-Life; Humans; Influenza, Human; Intensive Care Units; Kidney; Male; Oseltamivir; Tandem Mass Spectrometry; Young Adult | 2010 |
[Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus].
Topics: Antiviral Agents; Disease Outbreaks; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir | 2010 |
Acute chest syndrome in sickle cell disease due to the new influenza A (H1N1) virus infection.
Topics: Acute Chest Syndrome; Adult; Anemia, Sickle Cell; Antiviral Agents; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Treatment Outcome | 2010 |
Adolescent with neuropsychiatric symptoms associated with novel influenza A (H1N1) virus infection.
Topics: Adolescent; Aggression; Antiviral Agents; Brain Diseases; Confusion; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Nasal Cavity; Oseltamivir; Polymerase Chain Reaction; Spinal Puncture; Tomography, X-Ray Computed | 2010 |
Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection.
Topics: Adult; Antiviral Agents; Cohort Studies; Disease Outbreaks; Female; Fever; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Singapore; Statistics, Nonparametric; Virus Shedding; Young Adult | 2010 |
Selection for resistance to oseltamivir in seasonal and pandemic H1N1 influenza and widespread co-circulation of the lineages.
Topics: Antiviral Agents; Cluster Analysis; Communicable Diseases, Emerging; Disease Outbreaks; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Phylogeny | 2010 |
Antiviral pandemic risk assessment for urban receiving waters.
Topics: Cities; Disease Outbreaks; Environmental Monitoring; Humans; Hydrolysis; Influenza, Human; London; Oseltamivir; Risk; Risk Assessment; Rivers; Sewage; Solubility; Water Pollutants, Chemical; Water Purification | 2010 |
Acute lung injury with alveolar hemorrhage due to a novel swine-origin influenza A (H1N1) virus.
Topics: Acute Lung Injury; Adult; Antiviral Agents; Female; Glycine; Hemorrhage; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Lung Diseases; Oseltamivir; Sulfonamides; Treatment Outcome | 2010 |
Possible neuropsychiatric reaction to high-dose oseltamivir during acute 2009 H1N1 influenza A infection.
Topics: Adult; Antiviral Agents; Confusion; Hallucinations; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Leukemia, Promyelocytic, Acute; Male; Neurotoxicity Syndromes; Oseltamivir; Transplantation, Autologous | 2010 |
Hospitalized patients with novel influenza A (H1N1) virus infection: Shanghai, June - July 2009.
Topics: Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; China; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Retrospective Studies; Young Adult | 2010 |
Oseltamivir-induced mania in a patient with H1N1.
Topics: Adolescent; Antiviral Agents; Bipolar Disorder; Female; Genetic Predisposition to Disease; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir | 2010 |
Swine-origin influenza A (H1N1) in Indian children.
Topics: Animals; Child; Child, Preschool; Female; Gastritis; Humans; India; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Leukocyte Count; Lymphopenia; Male; Nose; Oseltamivir; Pharynx; Radiography, Thoracic; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral | 2010 |
A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir.
Topics: Adolescent; Amino Acid Substitution; Animals; Antiviral Agents; Cell Line; Child, Preschool; Dogs; Drug Resistance, Viral; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Molecular Epidemiology; Molecular Sequence Data; Mutation, Missense; Neuraminidase; Oseltamivir; Phylogeny; Sequence Analysis, DNA; Treatment Outcome; Viral Proteins; Virulence; Zanamivir | 2010 |
Acute encephalopathy/encephalitis in childhood: a relatively common and potentially devastating clinical syndrome.
Topics: Acute Disease; Antiviral Agents; Brain Diseases; Child; Child Behavior Disorders; Encephalitis; Humans; Influenza, Human; Oseltamivir; Seizures; Syndrome | 2010 |
Influenza H1N1 infection in a patient with psoriatic arthritis in treatment with Adalimumab: a case report.
Topics: Adalimumab; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antiviral Agents; Arthritis, Psoriatic; Female; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Treatment Outcome; Young Adult | 2013 |
Severe novel H1N1 influenza A infection in the immediate postoperative period of a liver transplant patient.
Topics: Antiviral Agents; DNA Primers; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Liver Transplantation; Male; Middle Aged; Oseltamivir; Polymerase Chain Reaction; Postoperative Period; Time Factors; Treatment Outcome | 2010 |
Circulation of human influenza viruses and emergence of Oseltamivir-resistant A(H1N1) viruses in Cameroon, Central Africa.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Animals; Antiviral Agents; Cameroon; Cell Line; Child; Child, Preschool; Dogs; Drug Resistance, Viral; Female; Hemagglutination Inhibition Tests; Humans; Infant; Influenza, Human; Male; Middle Aged; Nose; Orthomyxoviridae; Oseltamivir; Pharynx; Prevalence; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Young Adult | 2010 |
Foreword: Oseltamivir for seasonal, avian and pandemic influenza: 10 years of clinical experience.
Topics: Antiviral Agents; Disease Outbreaks; History, 20th Century; History, 21st Century; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza, Human; Oseltamivir | 2010 |
Sugar-based synthesis of Tamiflu and its inhibitory effects on cell secretion.
Topics: Animals; Antiviral Agents; Calcium Gluconate; Humans; Influenza, Human; Oseltamivir; PC12 Cells; Rats; Synaptic Transmission | 2010 |
Oseltamivir-resistant 2009-2010 pandemic influenza A (H1N1) in an immunocompromised patient.
Topics: Adult; Animals; Antiviral Agents; Drug Resistance, Viral; Female; Hematologic Neoplasms; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; United States | 2010 |
Rapid detection of influenza A pandemic (H1N1) 2009 virus neuraminidase resistance mutation H275Y by real-time reverse transcriptase PCR.
Topics: Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Molecular Sequence Data; Mutation, Missense; Neuraminidase; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Sequence Analysis, DNA; Time Factors; Viral Proteins; Virology | 2010 |
Rapid genotypic assay for detection of oseltamivir-resistant influenza A (H1N1) viruses.
Topics: Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation, Missense; Neuraminidase; Oseltamivir; RNA, Viral; Sequence Analysis, DNA; Viral Proteins | 2010 |
Pandemic influenza A (H1N1) virus infections in children with sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Child; Child, Preschool; Disease Outbreaks; Female; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; London; Male; Oseltamivir; Oximetry; RNA, Viral | 2010 |
Maternal and neonatal outcomes after antepartum treatment of influenza with antiviral medications.
Topics: Amantadine; Antiviral Agents; Enterocolitis, Necrotizing; Female; Humans; Infant, Newborn; Influenza, Human; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Rimantadine | 2010 |
[Controversies about neuraminidase inhibitor. Is the influenza drug less effective than assumed?].
Topics: Adolescent; Adult; Age Factors; Antiviral Agents; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Infant; Influenza A virus; Influenza, Human; Male; Meta-Analysis as Topic; Middle Aged; Neuraminidase; Oseltamivir; Pregnancy; Risk Factors; Seasons; Zanamivir | 2010 |
Oseltamivir-induced resistant pandemic A/H1N1 influenza virus in a child with cystic fibrosis and Pseudomonas aeruginosa infection.
Topics: Antiviral Agents; Child; Cystic Fibrosis; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Mutation; Oseltamivir; Pseudomonas aeruginosa; Pseudomonas Infections; Zanamivir | 2010 |
Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Female; Guanidines; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Oseltamivir; RNA, Viral; Selection, Genetic; Sequence Analysis, DNA; Young Adult | 2010 |
Pandemic influenza A (2009 H1N1) in children with acute lymphoblastic leukaemia.
Topics: Antiviral Agents; Child; Child, Preschool; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Prospective Studies | 2010 |
Household transmission of pandemic (H1N1) 2009, San Antonio, Texas, USA, April-May 2009.
Topics: Adolescent; Adult; Age Factors; Antiviral Agents; Child; Child, Preschool; Disease Outbreaks; Family Characteristics; Female; Humans; Infectious Disease Incubation Period; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Texas; Young Adult | 2010 |
Rapid emergence of oseltamivir resistance.
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Male; Oseltamivir; Young Adult | 2010 |
Development of oseltamivir resistance during oseltamivir therapy in a child with severe 2009 H1N1 influenza.
Topics: Antiviral Agents; Child; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Israel; Male; Oseltamivir; Pneumonia, Staphylococcal; Severity of Illness Index; Staphylococcus aureus; Treatment Outcome | 2010 |
First isolation of a oseltamivir-resistant influenza A (H1N1) strain in Argentina.
Topics: Antiviral Agents; Argentina; Chemoprevention; Child, Preschool; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Mutation; Neuraminidase; Oseltamivir | 2010 |
Hydrocortisone therapy for patients with H1N1 influenza A infection.
Topics: Anti-Inflammatory Agents; Antiviral Agents; Critical Care; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Hydrocortisone; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir | 2010 |
H1N1 infection: a pediatric nephrologist's perspective.
Topics: Child; Child, Preschool; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Kidney Diseases; Oseltamivir | 2010 |
Tongue swelling complicating management of a ventilated patient with acute respiratory distress syndrome secondary to novel influenza A (H1N1).
Topics: Adult; Antiviral Agents; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Lip Diseases; Oseltamivir; Respiration, Artificial; Respiratory Distress Syndrome; Tongue Diseases | 2010 |
Oseltamivir carboxylate accumulation in a patient treated by haemodiafiltration and extracorporeal membrane oxygenation.
Topics: Antiviral Agents; Biological Availability; Extracorporeal Membrane Oxygenation; Female; Hemofiltration; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Respiratory Distress Syndrome; Young Adult | 2010 |
Detection of the rapid emergence of the H275Y mutation associated with oseltamivir resistance in severe pandemic influenza virus A/H1N1 09 infections.
Topics: Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Female; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Mutation, Missense; Neuraminidase; Nucleic Acid Amplification Techniques; Oseltamivir; Sequence Analysis, DNA; Viral Proteins; Virology | 2010 |
The emergence of oseltamivir-resistant pandemic influenza A (H1N1) 2009 virus amongst hospitalised immunocompromised patients in Scotland, November-December, 2009.
Topics: Drug Resistance, Viral; Follow-Up Studies; Hospitalization; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pandemics; Scotland | 2010 |
Correspondence (letter to the editor): Comparison group would have been useful.
Topics: Antiviral Agents; Cross-Sectional Studies; Disease Outbreaks; Germany; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Polymerase Chain Reaction; Practice Guidelines as Topic; Randomized Controlled Trials as Topic | 2010 |
Correspondence (letter to the editor): Neurological complications.
Topics: Antiviral Agents; Berlin; Child; Child, Preschool; Electroencephalography; Encephalitis, Viral; Female; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Virulence | 2010 |
Oseltamivir dosing in children undergoing hemodialysis.
Topics: Antiviral Agents; Child; Child, Preschool; Chromatography, Liquid; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Plasma; Renal Dialysis; Renal Insufficiency; Tandem Mass Spectrometry | 2010 |
Possible transmission of pandemic (HIN1) 2009 virus with oseltamivir resistance.
Topics: Adolescent; Antiviral Agents; Child; Disease Outbreaks; Drug Resistance, Viral; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Mutation, Missense; Oseltamivir; Retrospective Studies; RNA, Viral; Sequence Analysis, RNA | 2010 |
Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment?
Topics: Amino Acid Substitution; Animals; Antiviral Agents; Aspartic Acid; Catalytic Domain; Cell Line; Dogs; Hemagglutination Inhibition Tests; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Mutation, Missense; Neuraminidase; Neutralization Tests; Oseltamivir; Protein Binding; Receptors, Virus; Viral Proteins; Virus Attachment | 2010 |
[Oseltamivir in pregnancy, lactation and neonatal period--comparison of international recommendations].
Topics: Female; Humans; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Lactation; Oseltamivir; Postnatal Care; Pregnancy; Pregnancy Complications, Infectious | 2010 |
Use of intravenous zanamivir after development of oseltamivir resistance in a critically Ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus.
Topics: Antiviral Agents; Compassionate Use Trials; Critical Illness; Drug Resistance, Viral; Female; Humans; Immunocompromised Host; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Injections, Intravenous; Oseltamivir; Treatment Outcome; Viral Load; Zanamivir | 2010 |
In silico identification of the potential drug resistance sites over 2009 influenza A (H1N1) virus neuraminidase.
Topics: Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Molecular Dynamics Simulation; Neuraminidase; Oseltamivir; Zanamivir | 2010 |
[Clinical feature and treatment of 69 Chinese children patients infected with influenza A (H1N1)].
Topics: Adolescent; Antiviral Agents; Asian People; Child; Child, Preschool; China; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Medicine, Chinese Traditional; Oseltamivir; Treatment Outcome | 2010 |
Prophylactic oseltamivir treatment for prevention of donor-recipient influenza A H1N1 virus transmission does not compromise stem cell mobilization or engraftment.
Topics: Antiviral Agents; Blood Donors; Female; Hematopoietic Stem Cell Mobilization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Middle Aged; Oseltamivir; Peripheral Blood Stem Cell Transplantation | 2011 |
Reduced effectiveness of oseltamivir in children infected with oseltamivir-resistant influenza A (H1N1) viruses with His275Tyr mutation.
Topics: Adolescent; Amino Acid Substitution; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Female; Fever; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Male; Microbial Sensitivity Tests; Mutation, Missense; Nasopharynx; Neuraminidase; Oseltamivir; Treatment Outcome; Viral Proteins; Zanamivir | 2010 |
First case in Italy of acquired resistance to oseltamivir in an immunocompromised patient with influenza A/H1N1v infection.
Topics: Amino Acid Substitution; Antiviral Agents; Bodily Secretions; Child, Preschool; Drug Resistance, Viral; Female; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Italy; Molecular Sequence Data; Mutation, Missense; Neuraminidase; Nose; Oseltamivir; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome; Viral Load; Viral Proteins; Withholding Treatment | 2010 |
Oseltamivir-resistant pandemic (H1N1)2009 in Yemen - case report.
Topics: Amino Acid Substitution; Animals; Antiviral Agents; Child, Preschool; Drug Resistance, Viral; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation, Missense; Nasal Mucosa; Neuraminidase; Oseltamivir; Viral Matrix Proteins; Viral Proteins; Yemen | 2010 |
Obstetric outcomes of influenza A H1N1 (2009) infection in pregnancy--experience of a Singapore tertiary hospital.
Topics: Adolescent; Adult; Antiviral Agents; Apgar Score; Birth Weight; Female; Gestational Age; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Obstetrics and Gynecology Department, Hospital; Oseltamivir; Outcome Assessment, Health Care; Pregnancy; Pregnancy Complications; Singapore; Young Adult | 2010 |
[Fatal pneumonitis due to oseltamivir-resistant new influenza A(H1N1) in the case of an intensive care patient].
Topics: Antiviral Agents; Drug Resistance, Viral; Fatal Outcome; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Pneumonia; Zanamivir | 2010 |
Influenza: a recurrent challenge to transplantation.
Topics: Antiviral Agents; Drug Administration Schedule; Humans; Influenza Vaccines; Influenza, Human; Organ Transplantation; Oseltamivir; Postoperative Complications; Vaccination | 2010 |
Oseltamivir treatment prevents the increased influenza virus disease severity and lethality occurring in chronic ethanol consuming mice.
Topics: Alcohol Drinking; Animals; Ethanol; Humans; Influenza, Human; Mice; Mice, Inbred BALB C; Orthomyxoviridae; Oseltamivir; Severity of Illness Index; Treatment Outcome; Viral Load | 2010 |
Clinical and molecular evidence for transmission of novel influenza A(H1N1/2009) on a commercial airplane.
Topics: Adult; Antiviral Agents; Disease Transmission, Infectious; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir | 2010 |
[Clinical manifestations, diagnosis and treatment of swine flu (A/H1N1) infection among patients hospitalized in the Hospital of Infectious Diseases in Warsaw in 2009].
Topics: Adolescent; Adult; Age Distribution; Aged; Antiviral Agents; Female; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Inpatients; Male; Middle Aged; Oseltamivir; Pneumonia, Viral; Poland; Respiratory Distress Syndrome; Respiratory Insufficiency; Severity of Illness Index; Treatment Outcome; Urban Population; Young Adult | 2010 |
Perinatal and maternal outcomes in critically ill obstetrics patients with pandemic H1N1 Influenza A.
Topics: Abortion, Spontaneous; Adolescent; Adult; Antiviral Agents; Critical Illness; Disease Outbreaks; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care Units; Manitoba; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Premature Birth; Respiration, Artificial | 2010 |
Early pandemic influenza (2009 H1N1) in Ho Chi Minh City, Vietnam: a clinical virological and epidemiological analysis.
Topics: Aircraft; Disease Outbreaks; Disease Transmission, Infectious; Humans; Incidence; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mass Screening; Oseltamivir; Time Factors; Travel; Vietnam | 2010 |
Transatlantic issues: report from Scotland.
Topics: Antiviral Agents; Bioethical Issues; Confidentiality; Criminals; Disease Outbreaks; Empathy; Health Care Reform; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; National Health Programs; Oseltamivir; Primary Prevention; Quality-Adjusted Life Years; Scotland; Suicide, Assisted; Terminally Ill; Terrorism; United Kingdom; United States | 2010 |
Oseltamivir-resistant influenza viruses A (H1N1) during 2007-2009 influenza seasons, Japan.
Topics: Amantadine; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Hemagglutination Inhibition Tests; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Neuraminidase; Oseltamivir; Phylogeny; Seasons; Sequence Analysis, Protein; Time Factors; Viral Matrix Proteins; Zanamivir | 2010 |
Pandemic (H1N1) 2009, Shanghai, China.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; China; Disease Outbreaks; Female; Fever; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Population Surveillance; Pregnancy; Pregnancy Complications, Infectious; Retrospective Studies; RNA, Viral; Time Factors; Travel | 2010 |
Community-acquired oseltamivir-resistant pandemic (H1N1) 2009 in child, Israel.
Topics: Accidents, Traffic; Antiviral Agents; Child, Preschool; Community-Acquired Infections; Contusions; Disease Outbreaks; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Israel; Lung Injury; Male; Oseltamivir; Respiratory Distress Syndrome; Time Factors | 2010 |
Clinical course of avian influenza A(H5N1) in patients at the Persahabatan Hospital, Jakarta, Indonesia, 2005-2008.
Topics: Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Cohort Studies; Humans; Indonesia; Influenza A Virus, H5N1 Subtype; Influenza, Human; Middle Aged; Oseltamivir; Pleural Effusion; Respiration, Artificial; Retrospective Studies; Treatment Outcome; Young Adult | 2010 |
Influence of country of study on student responsiveness to the H1N1 pandemic.
Topics: Animals; Antiviral Agents; Communicable Disease Control; Confidence Intervals; Cross-Sectional Studies; Disease Outbreaks; Factor Analysis, Statistical; Health Behavior; Health Knowledge, Attitudes, Practice; Hong Kong; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Internationality; Logistic Models; Odds Ratio; Oseltamivir; Patient Compliance; Public Health; Public Health Practice; Singapore; Students; Surveys and Questionnaires; United States | 2010 |
Antiviral drug susceptibilities of seasonal human influenza viruses in Lebanon, 2008-09 season.
Topics: Amantadine; Animals; Antiviral Agents; Cell Line; Child, Preschool; Dogs; Drug Resistance, Viral; Environmental Monitoring; Epidemiological Monitoring; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Lebanon; Male; Microbial Sensitivity Tests; Oseltamivir; Phylogeny; Seasons; Zanamivir | 2010 |
Influenza A(H1N1) outbreak in a long-term care facility for severely handicapped residents, Slovenia, March-April 2009.
Topics: Adolescent; Adult; Antiviral Agents; Disabled Persons; Disease Outbreaks; Drug Resistance; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Residential Facilities; Severity of Illness Index; Slovenia; Young Adult; Zanamivir | 2010 |
Unusual nosocomial exposure to H1N1 influenza virus via open-chest cardiac massage.
Topics: Adult; Antiviral Agents; Chemoprevention; Cross Infection; Health Personnel; Heart Arrest; Heart Massage; Humans; Infectious Disease Transmission, Patient-to-Professional; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Occupational Exposure; Oseltamivir | 2010 |
Virology. Helping the resistance.
Topics: Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Evolution, Molecular; Genetic Fitness; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Phylogeny; Selection, Genetic | 2010 |
Permissive secondary mutations enable the evolution of influenza oseltamivir resistance.
Topics: Amino Acid Substitution; Animals; Antiviral Agents; Cell Line; Cell Line, Tumor; Cell Membrane; Drug Resistance, Viral; Evolution, Molecular; Genes, Viral; Genetic Fitness; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Phylogeny; Selection, Genetic | 2010 |
Seroconversion and asymptomatic infections during oseltamivir prophylaxis against Influenza A H1N1 2009.
Topics: Adult; Antibodies, Viral; Antiviral Agents; Chemoprevention; Cohort Studies; Disease Outbreaks; Hemagglutination Inhibition Tests; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Military Personnel; Nasopharynx; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Singapore; Surveys and Questionnaires; Young Adult | 2010 |
Successful bilateral lung transplantation in a patient with end-stage lung disease and positive novel influenza virus (H1N1).
Topics: Antiviral Agents; Bronchoalveolar Lavage; Humans; Incidental Findings; Influenza A Virus, H1N1 Subtype; Influenza, Human; Lung; Lung Transplantation; Male; Middle Aged; Oseltamivir; Pulmonary Disease, Chronic Obstructive; Treatment Outcome | 2010 |
Influenza A H5N1 and HIV co-infection: case report.
Topics: Adult; Anti-Bacterial Agents; Antiviral Agents; CD28 Antigens; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Cytokines; Fatal Outcome; HIV Antibodies; HIV Infections; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Male; Oseltamivir; Tumor Necrosis Factor Receptor Superfamily, Member 7 | 2010 |
[Pandemic influenza one year after the first wave: what did we learn?].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Chile; Disease Outbreaks; Fluorescent Antibody Technique; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Middle Aged; Oseltamivir; Polymerase Chain Reaction; Risk Factors; Sensitivity and Specificity | 2010 |
Influenza A H1N1 and severe asthma exacerbation.
Topics: Adult; Anti-Asthmatic Agents; Antiviral Agents; Asthma; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Respiratory Insufficiency; Reverse Transcriptase Polymerase Chain Reaction; Severity of Illness Index; Treatment Outcome | 2010 |
[Antivirals and pandemic flu].
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza, Human; Oseltamivir; Pandemics | 2011 |
Pandemic influenza (H1N1): impact on lung transplant recipients and candidates.
Topics: Adolescent; Adult; Antiviral Agents; Child; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Israel; Lung Diseases; Lung Transplantation; Male; Middle Aged; Oseltamivir; Pandemics; Patient Selection | 2010 |
Oseltamivir ring prophylaxis for containment of 2009 H1N1 influenza outbreaks.
Topics: Adolescent; Antiviral Agents; Bacterial Typing Techniques; Communicable Disease Control; Disease Outbreaks; Disease Transmission, Infectious; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Military Personnel; Oseltamivir; Phylogeny; Singapore; Young Adult | 2010 |
2009 H1N1 virus transmission and outbreaks.
Topics: Antiviral Agents; Disease Outbreaks; Disease Transmission, Infectious; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza, Human; Military Personnel; Oseltamivir | 2010 |
A novel influenza a (H1N1) virus as a possible cause of pityriasis rosea?
Topics: Antiviral Agents; Biopsy; Child; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pityriasis Rosea; Skin | 2011 |
A school outbreak of pandemic (H1N1) 2009 infection: assessment of secondary household transmission and the protective role of oseltamivir.
Topics: Adolescent; Adult; Antiviral Agents; Child; Family Characteristics; Female; Hong Kong; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Pandemics; Risk Factors; Schools; Young Adult | 2011 |
Managing outbreaks of viral respiratory infection in aged care facilities - challenges and difficulties during the first pandemic wave.
Topics: Aged; Antiviral Agents; Contact Tracing; Disease Outbreaks; Female; Homes for the Aged; Humans; Infection Control; Influenza, Human; Male; New South Wales; Nursing Homes; Oseltamivir; Picornaviridae Infections | 2010 |
Allele-specific conventional reverse-transcription polymerase chain reaction as a screening assay for discriminating influenza a H1N1 (H275Y) oseltamivir-resistant and wild-type viruses.
Topics: Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mass Screening; Molecular Sequence Data; Nasopharynx; Neuraminidase; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Sensitivity and Specificity; Sequence Analysis, DNA; Viral Proteins; Virology | 2010 |
An unusual cause of fever in a neonate: influenza A (H1N1) virus pneumonia.
Topics: Antiviral Agents; Fever; Gentamicins; Humans; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Pneumonia, Viral; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Zanamivir | 2010 |
Hemoptysis in children with pandemic influenza H1N1 2009 infection.
Topics: Adolescent; Antiviral Agents; Child; Disease Outbreaks; Hemoptysis; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction; Thailand | 2009 |
Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia.
Topics: Antiviral Agents; Australia; Disease Outbreaks; Drug Resistance, Viral; Hematopoietic Stem Cell Transplantation; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care Units; Oseltamivir; Transplantation, Homologous | 2010 |
Zoonotic transmission of avian influenza virus (H5N1), Egypt, 2006-2009.
Topics: Adolescent; Adult; Aged; Animals; Chickens; Child; Child, Preschool; Drug Resistance, Viral; Egypt; Female; Humans; Infant; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Male; Middle Aged; Oseltamivir; Time Factors; Zoonoses | 2010 |
Oseltamivir-resistant pandemic (H1N1) 2009 in patient with impaired immune system.
Topics: Antiviral Agents; Disease Outbreaks; Drug Resistance, Viral; Humans; Immune Tolerance; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Time Factors | 2010 |
Do immunosupressive patients really have a severe outcome with H1N1 virus infection?
Topics: Antiviral Agents; Child; Female; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pregnancy; Risk Factors; Treatment Outcome | 2011 |
H1N1 in dialysis units: prevention and management.
Topics: Adult; Anti-Bacterial Agents; Antiviral Agents; Community-Acquired Infections; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Renal Dialysis | 2010 |
Oseltamivir dosing for influenza infection in premature neonates.
Topics: Adult; Antiviral Agents; Cross Infection; Female; Humans; Infant, Newborn; Infant, Premature; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir | 2010 |
Pandemic (H1N1) 2009 influenza in the UK: clinical and epidemiological findings from the first few hundred (FF100) cases.
Topics: Adolescent; Adult; Age Distribution; Aged; Antiviral Agents; Child; Child, Preschool; Disease Outbreaks; Female; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Risk Factors; Sex Characteristics; Time Factors; United Kingdom; Young Adult | 2010 |
Do general practice patients who are prescribed Tamiflu actually take it?
Topics: Antiviral Agents; General Practice; Humans; Influenza, Human; Medication Adherence; Oseltamivir | 2010 |
The detection of oseltamivir-resistant pandemic influenza A/H1N1 2009 viruses using a real-time RT-PCR assay.
Topics: Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Oseltamivir; Point Mutation; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Viral Proteins | 2010 |
Suspected oseltamivir-induced bradycardia.
Topics: Adult; Antiviral Agents; Bradycardia; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Young Adult | 2010 |
Oseltamivir dose adjustment in an H1N1 patient requiring haemodialysis.
Topics: Antiviral Agents; Combined Modality Therapy; Dose-Response Relationship, Drug; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Multiple Organ Failure; Oseltamivir; Renal Dialysis; Respiratory Insufficiency; Treatment Outcome | 2010 |
Transmission of novel influenza A(H1N1) in households with post-exposure antiviral prophylaxis.
Topics: Adolescent; Adult; Age Factors; Aged; Antiviral Agents; Child; Child, Preschool; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Young Adult | 2010 |
[42-year-old obese man with H1N1 influenza A infection necessitating mechanical ventilation].
Topics: Adult; Antiviral Agents; Bronchopneumonia; Critical Care; Diagnosis, Differential; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Obesity; Oseltamivir; Positive-Pressure Respiration; Respiratory Distress Syndrome; Tomography, X-Ray Computed | 2010 |
Influenza A/H1N1v in pregnancy: an investigation of the characteristics and management of affected women and the relationship to pregnancy outcomes for mother and infant.
Topics: Adolescent; Adult; Antiviral Agents; Female; Humans; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Premature Birth; Prospective Studies; Risk Factors; United Kingdom; Young Adult | 2010 |
Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model.
Topics: Animals; Antiviral Agents; Drug Resistance, Viral; Ferrets; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Models, Theoretical; Molecular Sequence Data; Mutation, Missense; Neuraminidase; Oseltamivir; RNA, Viral; Sequence Analysis, DNA; Viral Proteins; Virus Replication | 2010 |
Corticosteroids do not cause harmful increase of viral load in severe H1N1 virus infection.
Topics: Adult; Antiviral Agents; Bronchoalveolar Lavage Fluid; Extracorporeal Membrane Oxygenation; Glucocorticoids; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Methylprednisolone; Oseltamivir; Respiration, Artificial; Severity of Illness Index; Viral Load; World Health Organization | 2010 |
Community transmission of pandemic influenza A (H1N1) in China.
Topics: Adult; Antiviral Agents; Base Sequence; China; Disease Outbreaks; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Molecular Sequence Data; Oseltamivir; Population Surveillance; Time Factors | 2010 |
The Clinical Impact of Infection with Swine Flu (H1N109) Strain of Influenza Virus in Hematopoietic Stem Cell Transplant Recipients.
Topics: Adult; Animals; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Influenza, Human; Male; Middle Aged; Neutropenia; Orthomyxoviridae; Oseltamivir; Respiratory Tract Diseases; Retrospective Studies; Swine | 2011 |
Methylprednisolone infusion for life-threatening H1N1-virus infection.
Topics: Adult; Aged; Antiviral Agents; Bronchoalveolar Lavage; Combined Modality Therapy; Extracorporeal Membrane Oxygenation; Female; Glucocorticoids; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Methylprednisolone; Middle Aged; Oseltamivir; Respiration, Artificial; Severity of Illness Index; Treatment Outcome; Young Adult | 2010 |
Patients with influenza A/H1N1v- associated pneumonia: the perspective of a tertiary care hospital in Switzerland.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Algorithms; Antiviral Agents; Comorbidity; Critical Care; Drug Therapy, Combination; Female; Guideline Adherence; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Pandemics; Patient Admission; Pneumonia, Viral; Risk Factors; Switzerland | 2010 |
Oseltamivir for treatment and prevention of pandemic influenza A/H1N1 virus infection in households, Milwaukee, 2009.
Topics: Adult; Antiviral Agents; Chemoprevention; Child; Child, Preschool; Disease Transmission, Infectious; Family Characteristics; Family Health; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Wisconsin | 2010 |
Severe myopathy caused by the new pandemic influenza A (H1N1) in a child.
Topics: Antiviral Agents; Child; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Muscular Diseases; Oseltamivir; Seizures; Treatment Outcome | 2010 |
H1N1 2009 influenza in kidney transplant patients.
Topics: Antiviral Agents; Disease Outbreaks; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Kidney Transplantation; Oseltamivir; Polymerase Chain Reaction | 2010 |
[The World Health Organization, the BMJ and the truth].
Topics: Antiviral Agents; Conflict of Interest; Disease Outbreaks; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Periodicals as Topic; World Health Organization | 2010 |
Influenza A (H1N1) virus-induced hepatocellular injury in a kidney transplant patient.
Topics: Acute Disease; Aged; Antiviral Agents; Hepatitis; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Kidney Transplantation; Male; Oseltamivir; Treatment Outcome | 2011 |
Clinical features of hospitalised children with 2009 H1N1 influenza virus infection.
Topics: Adolescent; Antiviral Agents; Child; Child, Hospitalized; Child, Preschool; Cough; Female; Fever; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Italy; Lung Diseases; Male; Medical Records; Nervous System Diseases; Oseltamivir; Treatment Outcome | 2010 |
Irreversible marrow aplasia after single course of 2-chlorodeoxyadenosine for hairy cell leukaemia preceding by A pandemic 2009-H1N1-associated pneumonia.
Topics: Amoxicillin; Anemia, Aplastic; Anti-Infective Agents; Antineoplastic Agents; Antiviral Agents; Aspergillosis; Bone Marrow; Ciprofloxacin; Cladribine; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Leukemia, Hairy Cell; Male; Oseltamivir; Pancytopenia; Pandemics; Pneumonia, Viral; Young Adult | 2011 |
Sotalol-induced torsades de pointes precipitated during treatment with oseltamivir for H1N1 influenza.
Topics: Aged; Anti-Arrhythmia Agents; Antiviral Agents; Drug Interactions; Electrocardiography; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Middle Aged; Oseltamivir; Sotalol; Torsades de Pointes | 2010 |
Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Birds; Catalytic Domain; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza in Birds; Influenza, Human; Models, Molecular; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Protein Conformation; Species Specificity; Swine; Swine Diseases; Viral Proteins; Zanamivir | 2010 |
Pericardial effusion complicating novel influenza A (H1N1) infection in an infant.
Topics: Anti-Inflammatory Agents; Antiviral Agents; Drainage; Humans; Ibuprofen; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Pericardial Effusion | 2010 |
Oseltamivir-resistant influenza A(H1N1) viruses in south of France, 2007/2009.
Topics: Amino Acid Substitution; Animals; Antiviral Agents; Cell Line; Dogs; Drug Resistance, Viral; France; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Inhibitory Concentration 50; Kinetics; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Oseltamivir; Protein Binding; Sequence Analysis, DNA; Viral Proteins | 2010 |
Highly sensitive and quantitative detection of the H274Y oseltamivir resistance mutation in seasonal A/H1N1 influenza virus.
Topics: Amino Acid Substitution; Drug Resistance, Viral; Europe; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Viral Proteins | 2010 |
Neuraminidase inhibitors for influenza treatment and prevention in healthy adults.
Topics: Adult; Antiviral Agents; Disease Transmission, Infectious; Enzyme Inhibitors; Family; Female; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Primary Prevention; Zanamivir | 2010 |
Diagnostic accuracy of an allele-specific reverse transcriptase-PCR assay targeting the H275Y oseltamivir resistant mutation in 2009 pandemic influenza A/H1N1 virus.
Topics: Alleles; Antiviral Agents; DNA Primers; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation; Oseltamivir; Pandemics; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity | 2010 |
Antiviral agents: to treat or not to treat? An old dilemma revisited in light of new data from the 2009 influenza A(H1N1) pandemic.
Topics: Antiviral Agents; Drug Utilization; Europe; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pandemics | 2010 |
Pandemic influenza H1N1 2009 in north Queensland--risk factors for admission in a region with a large indigenous population.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Critical Care; Disease Notification; Disease Outbreaks; Female; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Native Hawaiian or Other Pacific Islander; Oseltamivir; Pregnancy; Queensland; Risk Factors; Young Adult | 2010 |
Correlation of pandemic (H1N1) 2009 viral load with disease severity and prolonged viral shedding in children.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Cohort Studies; Epidemics; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Statistics, Nonparametric; Taiwan; Virus Shedding; Young Adult | 2010 |
Possible recurrent pandemic (H1N1) 2009 infection, Israel.
Topics: Adolescent; Antibodies, Viral; Antiviral Agents; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Israel; Male; Neuraminidase; Oseltamivir; Pandemics; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Young Adult | 2010 |
Genetic characterization of circulating seasonal Influenza A viruses (2005-2009) revealed introduction of oseltamivir resistant H1N1 strains during 2009 in eastern India.
Topics: Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Base Sequence; Drug Resistance, Viral; Genetic Variation; Hemagglutinin Glycoproteins, Influenza Virus; Humans; India; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Molecular Sequence Data; Neuraminidase; Oseltamivir; Phylogeny; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Sequence Analysis, RNA; Viral Proteins | 2010 |
Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets.
Topics: Animals; Base Sequence; Cell Line; Disease Outbreaks; Dogs; Drug Resistance, Viral; Ferrets; Genome, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir | 2010 |
Concurrent comparison of epidemiology, clinical presentation and outcome between adult patients suffering from the pandemic influenza A (H1N1) 2009 virus and the seasonal influenza A virus infection.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Disease Outbreaks; Female; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Obesity; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Retrospective Studies; Seasons; Treatment Outcome; Young Adult | 2010 |
[Naturally occurring oseltamivir resistance in influenza A].
Topics: Amantadine; Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Zanamivir | 2010 |
Oseltamivir resistance mutation N294S in human influenza A(H5N1) virus in Egypt.
Topics: Adolescent; Antiviral Agents; Base Sequence; Drug Resistance, Viral; Egypt; Female; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Inhibitory Concentration 50; Male; Microbial Sensitivity Tests; Mutation; Neuraminidase; Oseltamivir; Phenotype; Polymerase Chain Reaction; RNA, Viral; Young Adult | 2009 |
Prescribing in a pandemic: best use of oseltamivir in paediatric intensive care.
Topics: Antiviral Agents; Child; Child, Preschool; Drug Utilization; England; Female; Guideline Adherence; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care Units, Pediatric; Male; Medical Audit; Oseltamivir; Pandemics; Practice Guidelines as Topic; Prescription Drugs | 2011 |
Complex febrile seizures followed by complete recovery in an infant with high-titer 2009 pandemic influenza A (H1N1) virus infection.
Topics: Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Nasopharynx; Oseltamivir; Seizures, Febrile; Viral Load | 2010 |
Foreword: this issue of the Seton Hall Law Review presents contributions to Preparing for Pharmaceutical Response to Pandemic Influenza, a two-day Symposium held at Seton hall University School of Law in the fall of 2008.
Topics: Animals; Antiviral Agents; Birds; Disease Outbreaks; Global Health; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza Vaccines; Influenza, Human; Oseltamivir; United States; Zanamivir | 2009 |
[Influenza A H1N1v treated with extracorporeal membrane oxygenation].
Topics: Adult; Antiviral Agents; Extracorporeal Membrane Oxygenation; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pneumonia, Viral; Zanamivir | 2010 |
Clinical importance and impact on the households of oseltamivir-resistant seasonal A/H1N1 influenza virus in healthy children in Italy.
Topics: Adolescent; Amino Acid Substitution; Child; Child, Preschool; Drug Resistance, Viral; Family Health; Female; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Italy; Male; Mutation, Missense; Neuraminidase; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA; Viral Proteins | 2010 |
Influenza antiviral prescribing practices during the 2007-08 and 2008-09 influenza seasons in the setting of increased resistance to oseltamivir among circulating influenza viruses.
Topics: Adamantane; Antiviral Agents; Disease Outbreaks; Drug Resistance, Viral; Drug Utilization; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Oseltamivir; Practice Guidelines as Topic; Practice Patterns, Physicians'; Retrospective Studies; Rimantadine; Seasons; Surveys and Questionnaires; Zanamivir | 2010 |
Oseltamivir-resistant variants of the 2009 pandemic H1N1 influenza A virus are not attenuated in the guinea pig and ferret transmission models.
Topics: Animals; Disease Models, Animal; Drug Resistance, Viral; Ferrets; Guinea Pigs; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation, Missense; Orthomyxoviridae Infections; Oseltamivir; Zanamivir | 2010 |
Rhabdomyolysis following pandemic influenza A (H1N1) infection.
Topics: Acetaminophen; Adolescent; Alanine Transaminase; Analgesics, Non-Narcotic; Antiviral Agents; Aspartate Aminotransferases; Creatine Kinase; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; L-Lactate Dehydrogenase; Oseltamivir; Pandemics; Rhabdomyolysis | 2010 |
Pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1): an experience from a tertiary care center in north India.
Topics: Adolescent; Child; Child, Preschool; Cohort Studies; Combined Modality Therapy; Female; Fluid Therapy; Hospital Mortality; Hospitalization; Hospitals, Pediatric; Humans; India; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care Units, Pediatric; Male; Oseltamivir; Pandemics; Respiration, Artificial; Respiratory Distress Syndrome; Retrospective Studies; Severity of Illness Index; Survival Analysis | 2010 |
Pandemic (H1N1) 2009 infection in adult solid organ transplant recipients in Singapore.
Topics: Adult; Antiviral Agents; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Organ Transplantation; Oseltamivir; Pandemics; Polymerase Chain Reaction; Singapore | 2010 |
Factors associated with severe disease in hospitalized adults with pandemic (H1N1) 2009 in Spain.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Bacterial Infections; Disease Outbreaks; Female; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care Units; Male; Middle Aged; Obesity; Oseltamivir; Pandemics; Pneumonia; Prospective Studies; Risk Factors; Severity of Illness Index; Spain; Treatment Outcome | 2011 |
Mania in a patient with H1N1: is oseltamivir the culprit or a red herring?
Topics: Adolescent; Antiviral Agents; Bipolar Disorder; Confusion; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir | 2010 |
Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Female; Global Health; Humans; Infant; Influenza A Virus, H5N1 Subtype; Influenza, Human; Kaplan-Meier Estimate; Male; Middle Aged; Oseltamivir; Registries; Risk Factors; Time Factors; Treatment Outcome; Young Adult | 2010 |
Has oseltamivir been shown to be effective for treatment of H5N1 influenza?
Topics: Animals; Antiviral Agents; Disease Notification; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Oseltamivir; Time Factors | 2010 |
Synergistic effects in the designs of neuraminidase ligands: analysis from docking and molecular dynamics studies.
Topics: Acids, Carbocyclic; Benzoates; Catalytic Domain; Cyclohexenes; Cyclopentanes; Drug Design; Guanidines; Humans; Hydrogen Bonding; Influenza, Human; Inhibitory Concentration 50; Ligands; Models, Molecular; Molecular Dynamics Simulation; Molecular Structure; Neuraminidase; Orthomyxoviridae; Oseltamivir; Protein Binding; Static Electricity; Structure-Activity Relationship; Thermodynamics | 2010 |
Simplified screening method for detecting oseltamivir resistant pandemic influenza A (H1N1) 2009 virus by a RT-PCR/restriction fragment length polymorphism assay.
Topics: Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Polymorphism, Restriction Fragment Length; Reverse Transcriptase Polymerase Chain Reaction; Sequence Alignment; Sequence Analysis, DNA | 2010 |
Emergence of intratreatment resistance to oseltamivir in pandemic influenza A H1N1 2009 virus.
Topics: Antiviral Agents; Argentina; Child; Child, Preschool; DNA, Complementary; Drug Resistance, Viral; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Mutation; Neuraminidase; Oseltamivir; Pandemics; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral | 2010 |
[High prevalence of antiviral resistant influenza, and reduced clinical effectiveness of the antivirals against resistant influenza strains].
Topics: Antiviral Agents; Awards and Prizes; Disease Outbreaks; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza, Human; Japan; Neuraminidase; Orthomyxoviridae; Oseltamivir; Prevalence; Time Factors | 2010 |
Oseltamivir-resistant influenza A 2009 H1N1 virus in immunocompromised patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Female; Hematopoietic Stem Cell Transplantation; Hospitalization; Humans; Immunocompromised Host; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Mutation; Neuraminidase; Oseltamivir; Young Adult | 2010 |
Hematemesis in a 2009 H1N1 influenza patient.
Topics: Antiviral Agents; Child; Emergency Treatment; Hematemesis; Histamine Antagonists; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Proton Pump Inhibitors; Rare Diseases; Risk Factors | 2010 |
Detection of oseltamivir resistance during treatment of 2009 H1N1 influenza virus infection in immunocompromised patients: utility of cycle threshold values of qualitative real-time reverse transcriptase PCR.
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Microbial Sensitivity Tests; Middle Aged; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA; Sputum; Time Factors; Viral Load; Virus Shedding | 2010 |
[Pandemic (H1N1) 2009 in children].
Topics: Adolescent; Age Factors; Antiviral Agents; Child; Child, Preschool; Encephalitis, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Pandemics; Respiratory Distress Syndrome; Time Factors | 2010 |
[Case of novel influenza A (H1N1) encephalopathy with transient low TSH level].
Topics: Acute-Phase Reaction; Antiviral Agents; Biomarkers; Child; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Methylprednisolone; Oseltamivir; Pulse Therapy, Drug; Thyrotropin; Thyrotropin-Releasing Hormone | 2010 |
Development of a novel bead-based multiplex PCR assay for combined subtyping and oseltamivir resistance genotyping (H275Y) of seasonal and pandemic H1N1 influenza A viruses.
Topics: Antiviral Agents; DNA Primers; Hemagglutinins, Viral; Humans; Influenza A virus; Influenza, Human; Microspheres; Neuraminidase; Oseltamivir; Polymerase Chain Reaction; Viral Proteins; Virology | 2010 |
Healthcare personnel infected with novel influenza A H1N1 virus in university hospitals in Buenos Aires, Argentina.
Topics: Adult; Antiviral Agents; Argentina; Chemoprevention; Female; Health Personnel; Hospitals, University; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Oseltamivir; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; Vaccination; Virology | 2011 |
Swine influenza A (H1N1) virus infection in infants.
Topics: Antiviral Agents; Female; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Pandemics; Treatment Outcome; Turkey | 2011 |
A simple allele-specific polymerase chain reaction method to detect the Gly143Glu polymorphism in the human carboxylesterase 1 gene: importance of genotyping for pharmacogenetic treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alleles; Amino Acid Substitution; Antiviral Agents; Attention Deficit Disorder with Hyperactivity; Carboxylic Ester Hydrolases; Central Nervous System Stimulants; Female; Gene Frequency; Glutamic Acid; Glycine; Humans; Inactivation, Metabolic; Influenza, Human; Male; Methylphenidate; Middle Aged; Oseltamivir; Polymerase Chain Reaction; Polymorphism, Genetic; Young Adult | 2010 |
Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir.
Topics: Adolescent; Antiviral Agents; Drug Resistance, Multiple, Viral; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation, Missense; Neuraminidase; Oseltamivir; Viral Proteins | 2010 |
Early findings of oseltamivir-resistant pandemic (H1N1) 2009 influenza A viruses in Taiwan.
Topics: Adolescent; Adult; Amino Acid Sequence; Amino Acid Substitution; Animals; Antiviral Agents; Cell Line; Child; Child, Preschool; Dogs; Drug Resistance, Viral; Female; Genes, Viral; Hemagglutinins; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Molecular Sequence Data; Mutation; Neuraminidase; Oseltamivir; Pandemics; Phylogeny; Taiwan; Time Factors; Young Adult | 2010 |
Novel influenza A (H1N1)-associated encephalopathy/encephalitis with severe neurological sequelae and unique image features--a case report.
Topics: Acyclovir; Adult; Anti-Bacterial Agents; Antiviral Agents; Brain; Cerebral Angiography; Electroencephalography; Encephalitis; Hemiplegia; Humans; Hypnotics and Sedatives; Influenza A Virus, H1N1 Subtype; Influenza, Human; Magnetic Resonance Angiography; Magnetic Resonance Imaging; Male; Muscle Rigidity; Nervous System Diseases; Oseltamivir; Propofol; Tomography, X-Ray Computed; Tremor | 2010 |
Effectiveness of personal protective equipment and oseltamivir prophylaxis during avian influenza A (H7N7) epidemic, the Netherlands, 2003.
Topics: Adolescent; Adult; Animal Husbandry; Animals; Antiviral Agents; Chemoprevention; Disease Outbreaks; Eye Protective Devices; Female; Humans; Influenza A Virus, H7N7 Subtype; Influenza in Birds; Influenza, Human; Male; Middle Aged; Netherlands; Occupational Exposure; Oseltamivir; Poultry; Poultry Diseases; Protective Devices; Respiratory Protective Devices; Treatment Outcome; Young Adult | 2010 |
Pandemic (H1N1) 2009 and seasonal influenza A (H1N1) co-infection, New Zealand, 2009.
Topics: Adolescent; Adult; Antiviral Agents; Child; Disease Outbreaks; Drug Resistance, Viral; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Microbial Sensitivity Tests; Middle Aged; New Zealand; Oseltamivir; Pandemics; Seasons; Virus Cultivation; Young Adult | 2010 |
Emergence of oseltamivir-resistant pandemic (H1N1) 2009 virus within 48 hours.
Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Evolution, Molecular; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation; Oseltamivir; Pandemics; Phylogeny; Sequence Analysis, DNA; Time Factors | 2010 |
Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China.
Topics: Adolescent; Adult; Antiviral Agents; Child; China; Disease Outbreaks; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Retrospective Studies; Risk Factors; RNA, Viral; Treatment Outcome; Virus Shedding; Young Adult | 2010 |
Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus.
Topics: Amino Acid Substitution; Antiviral Agents; Child, Preschool; Disease Outbreaks; Drug Resistance, Multiple, Bacterial; Enzyme Inhibitors; Fatal Outcome; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Mutation; Neuraminidase; Oseltamivir; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Viral Load; Zanamivir | 2010 |
Clinical profile of swine flu in children at Puducherry.
Topics: Antiviral Agents; Child; Child, Preschool; Female; Humans; India; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir | 2010 |
Clinical features of 2009 pandemic influenza A (H1N1) virus infection in chronic hemodialysis patients.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; China; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Kidney Failure, Chronic; Male; Middle Aged; Oseltamivir; Pandemics; Renal Dialysis; Respiratory Insufficiency; Reverse Transcriptase Polymerase Chain Reaction; Virus Shedding | 2010 |
High levels and safety of oseltamivir carboxylate plasma concentrations after nasogastric administration in critically ill children in a pediatric intensive care unit.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Critical Illness; Female; Humans; Infant; Influenza, Human; Intensive Care Units; Intubation, Gastrointestinal; Male; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction | 2011 |
A case of asthma-complicated influenza myocarditis.
Topics: Adult; Asthma; Betamethasone; Humans; Influenza, Human; Male; Myocarditis; Oseltamivir | 2011 |
Viral replication rate regulates clinical outcome and CD8 T cell responses during highly pathogenic H5N1 influenza virus infection in mice.
Topics: Animals; CD8 Antigens; CD8-Positive T-Lymphocytes; Cells, Cultured; Dogs; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Lung Diseases; Lymphocyte Activation; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Orthomyxoviridae Infections; Oseltamivir; Prognosis; Virus Replication | 2010 |
The validation of a real-time RT-PCR assay which detects influenza A and types simultaneously for influenza A H1N1 (2009) and oseltamivir-resistant (H275Y) influenza A H1N1 (2009).
Topics: Amino Acid Substitution; Drug Resistance, Viral; Humans; Influenza A virus; Influenza, Human; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Viral Proteins | 2011 |
Selection and viral load kinetics of an oseltamivir-resistant pandemic influenza A (H1N1) virus in an immunocompromised patient during treatment with neuraminidase inhibitors.
Topics: Aged; Antiviral Agents; Drug Resistance, Viral; Genotype; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Nasopharynx; Oseltamivir; RNA, Viral; Selection, Genetic; Viral Load; Virus Shedding | 2010 |
Influenza a (H1N1) virus pneumonia in newborns: experience of a referral level III neonatal intensive care unit in Turkey.
Topics: Antiviral Agents; Breast Feeding; Female; Humans; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Mothers; Oseltamivir; Pandemics; Pneumonia, Viral; Turkey | 2011 |
Serological response to H1N1 influenza virus infections in adults treated with oseltamivir.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Viral; Antiviral Agents; Cohort Studies; Female; Hemagglutination Inhibition Tests; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Viral Load | 2010 |
Neuraminidase inhibitors for treatment of human and avian strain influenza: A comparative modeling study.
Topics: Animals; Antiviral Agents; Birds; Enzyme Inhibitors; Humans; Influenza in Birds; Influenza, Human; Models, Biological; Neuraminidase; Oseltamivir; Viral Load | 2011 |
Clinical profile of H1N1 positive HIV- infected children.
Topics: Antibiotic Prophylaxis; Antiviral Agents; Child; Child, Preschool; Female; HIV Infections; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir | 2011 |
2009 pandemic influenza A (H1N1) virus infection in pediatric oncology and hematopoietic stem cell transplantation patients.
Topics: Adolescent; Child; Child, Preschool; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Neoplasms; Oseltamivir; Pandemics; Retrospective Studies; Treatment Outcome | 2011 |
[The clinical characteristics and treatment of community outbreaks of the new influenza A (H1N1) infection].
Topics: Adolescent; Adult; Antiviral Agents; Community-Acquired Infections; Drugs, Chinese Herbal; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Medicine, Chinese Traditional; Oseltamivir; Phytotherapy; Treatment Outcome; Young Adult | 2010 |
Feasibility of diagnosing influenza within 24 hours of symptom onset in children 1-3 years of age.
Topics: Antigens, Viral; Antiviral Agents; Child, Preschool; Early Diagnosis; Feasibility Studies; Fluoroimmunoassay; Humans; Infant; Influenza A virus; Influenza B virus; Influenza, Human; Oseltamivir; Point-of-Care Systems; Polymerase Chain Reaction; Reagent Kits, Diagnostic; Sensitivity and Specificity; Zanamivir | 2011 |
Pandemic (H1N1) 2009 and oseltamivir resistance in hematology/oncology patients.
Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Neoplasms; Oseltamivir; Pandemics | 2010 |
Oseltamivir-resistant pandemic (H1N1) 2009 treated with nebulized zanamivir.
Topics: Child, Preschool; Dosage Forms; Drug Resistance, Viral; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Mutation; Nebulizers and Vaporizers; Oseltamivir; Pandemics; Zanamivir | 2010 |
Paediatric mortality related to pandemic influenza A H1N1 infection in England: an observational population-based study.
Topics: Adolescent; Age Distribution; Antiviral Agents; Asian People; Bangladesh; Black People; Child; Child Mortality; Child, Preschool; Disease Outbreaks; England; Female; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Oseltamivir; Time Factors | 2010 |
Clinical features of initial cases of 2009 pandemic influenza A (H1N1) in Macau, China.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; China; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Macau; Male; Middle Aged; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction; Young Adult | 2010 |
Pandemic influenza A (H1N1) outbreak among 15 school-aged HIV-1-infected children.
Topics: Adolescent; Antibodies, Viral; Antiviral Agents; CD4 Lymphocyte Count; Child; Disease Outbreaks; Female; Germany; HIV Infections; HIV-1; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Treatment Outcome; Virus Shedding | 2010 |
Prolonged shedding of amantadine- and oseltamivir-resistant influenza A(H3N2) virus with dual mutations in an immunocompromised infant.
Topics: Amantadine; Amino Acid Sequence; Antiviral Agents; Drug Resistance, Multiple, Viral; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Immunocompromised Host; Infant; Influenza A Virus, H3N2 Subtype; Influenza, Human; Male; Molecular Sequence Data; Mutation; Neuraminidase; Oseltamivir; Viral Matrix Proteins | 2010 |
Approach to Pandemic 2009 influenza: first report from a main referral hospital for Pandemic H1N1 influenza care in Iran.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Cross-Sectional Studies; Female; Hospitals; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Iran; Male; Middle Aged; Oseltamivir; Pandemics; Prospective Studies; Young Adult | 2010 |
Genetic and phylogenetic analyses of influenza A H1N1pdm virus in Buenos Aires, Argentina.
Topics: Animals; Antiviral Agents; Argentina; Cell Line; Dogs; Drug Resistance, Viral; Evolution, Molecular; Genome, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Molecular Epidemiology; Molecular Sequence Data; Oseltamivir; Phylogeny; Polymorphism, Genetic; RNA, Viral; Sequence Analysis, DNA; Viral Plaque Assay; Viral Proteins | 2011 |
Transient hyperglycemia in a H1N1 positive child on oseltamivir.
Topics: Antiviral Agents; Child; Female; Humans; Hyperglycemia; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir | 2010 |
Oseltamivir-resistant influenza A and B viruses pre- and postantiviral therapy in children and young adults with cancer.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Humans; Immunocompromised Host; Infant; Influenza A virus; Influenza B virus; Influenza, Human; Microbial Sensitivity Tests; Neoplasms; Neuraminidase; Oseltamivir; Sequence Analysis, DNA; Viral Matrix Proteins; Viral Proteins; Young Adult | 2011 |
Epidemiological and clinical features of 308 hospitalized patients with novel 2009 influenza A (H1N1) virus infection in China during the first pandemic wave.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; China; Female; Hospitalization; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Treatment Outcome; Young Adult | 2011 |
Serious pH1N1 influenza illness and pneumonia despite inactivated vaccine: success of prompt diagnosis and treatment.
Topics: Adult; Antiviral Agents; Comorbidity; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Oseltamivir; Pneumonia, Bacterial; Superinfection; Treatment Failure; Vaccines, Inactivated | 2010 |
Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Fatal Outcome; Guanidines; Hematopoietic Stem Cell Transplantation; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Mutation; Neuraminidase; Oseltamivir | 2010 |
An experience of oseltamivir phosphate (tamiflu™) in a pediatric patient with chronic idiopathic thrombocytopenic purpura: a case report.
Topics: Adolescent; Antiviral Agents; Chronic Disease; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Platelet Count; Purpura, Thrombocytopenic, Idiopathic | 2010 |
Genotypic and phenotypic resistance of pandemic A/H1N1 influenza viruses circulating in Germany.
Topics: Adult; Amino Acid Substitution; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Female; Germany; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Microbial Sensitivity Tests; Middle Aged; Mutation, Missense; Neuraminidase; Oseltamivir; Viral Matrix Proteins; Viral Proteins; Young Adult; Zanamivir | 2011 |
Resistance and virulence mutations in patients with persistent infection by pandemic 2009 A/H1N1 influenza.
Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Molecular Sequence Data; Mutation; Neuraminidase; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Virulence; Zanamivir | 2011 |
Oseltamivir-induced dyskinesia in Parkinson's disease.
Topics: Dyskinesias; Female; Humans; Influenza, Human; Middle Aged; Oseltamivir; Parkinson Disease | 2011 |
Identification of oseltamivir resistance among pandemic and seasonal influenza A (H1N1) viruses by an His275Tyr genotyping assay using the cycling probe method.
Topics: Amino Acid Substitution; Antiviral Agents; Genotype; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Molecular Typing; Neuraminidase; Oseltamivir; Polymorphism, Single Nucleotide; Sensitivity and Specificity; Viral Proteins | 2011 |
Peri-operative novel 2009 H1N1 influenza virus infection successfully treated with oseltamivir and zanamivir in a lung transplant recipient.
Topics: Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Lung Transplantation; Oseltamivir; Perioperative Care; Treatment Outcome; Young Adult; Zanamivir | 2011 |
Investigation of causes of oseltamivir chemoprophylaxis failures during influenza A (H1N1-2009) outbreaks.
Topics: Adult; Antiviral Agents; Disease Outbreaks; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Mutation; Nasal Lavage Fluid; Oseltamivir; Polymerase Chain Reaction; RNA, Viral; Treatment Failure | 2011 |
The I222V neuraminidase mutation has a compensatory role in replication of an oseltamivir-resistant influenza virus A/H3N2 E119V mutant.
Topics: Amino Acid Substitution; Animals; Antiviral Agents; Cell Line; Dogs; Drug Resistance, Viral; Humans; Immunocompromised Host; Influenza A Virus, H3N2 Subtype; Influenza, Human; Mutation, Missense; Neuraminidase; Oseltamivir; Suppression, Genetic; Viral Plaque Assay; Viral Proteins; Virus Replication | 2011 |
["Oseltamivir-induced delirium"].
Topics: Antiviral Agents; Delirium; Homicide; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Pneumonia, Viral; Psychoses, Substance-Induced; Switzerland | 2010 |
Retrospective analysis of pediatric cancer patients diagnosed with the pandemic H1N1 influenza infection.
Topics: Adolescent; Child; Child, Preschool; Fever; Hematologic Neoplasms; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neoplasms; Oseltamivir; Pandemics; Retrospective Studies; Time Factors; Young Adult | 2011 |
[Clinical and laboratory characteristics of a new influenza A (HIN1) epidemic].
Topics: Adolescent; Adult; Disease Outbreaks; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Young Adult | 2010 |
Neuraminidase inhibitors were widely used in the UK during the 2009 influenza A(H1N1) pandemic.
Topics: Antiviral Agents; Drug Utilization; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; United Kingdom | 2011 |
Comparison of the clinical symptoms and the effectiveness of neuraminidase inhibitors for patients with pandemic influenza H1N1 2009 or seasonal H1N1 influenza in the 2007-2008 and 2008-2009 seasons.
Topics: Adolescent; Adult; Antiviral Agents; Enzyme Inhibitors; Female; Fever; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pandemics; Seasons; Young Adult; Zanamivir | 2011 |
Lessons from the swine flu: pandemic, panic and/or pandemonium?
Topics: Antiviral Agents; Australia; Child; Disease Outbreaks; Emergency Medical Services; Female; Global Health; Humans; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Seizures, Febrile; Young Adult | 2010 |
Oseltamivir-resistant pandemic (H1N1) 2009 virus, South Korea.
Topics: Amino Acid Substitution; Antiviral Agents; Child, Preschool; Disease Outbreaks; Drug Resistance, Viral; Female; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Molecular Epidemiology; Molecular Sequence Data; Neuraminidase; Oseltamivir; Republic of Korea; Viral Proteins | 2010 |
Novel H1N1 influenza A virus infection in a patient with acute rejection after liver transplantation.
Topics: Acute Disease; Antiviral Agents; Graft Rejection; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Liver Transplantation; Male; Middle Aged; Oseltamivir | 2010 |
[Prophylactic and therapeutic efficacies of Ingavirin, a novel Russian chemotherapeutic, with respect to influenza pathogen A (H5N1)].
Topics: Amides; Animals; Antiviral Agents; Caproates; Dicarboxylic Acids; Humans; Imidazoles; Indoles; Influenza A Virus, H5N1 Subtype; Influenza, Human; Mice; Mice, Inbred Strains; Orthomyxoviridae Infections; Oseltamivir | 2010 |
Dealing with pandemic influenza A during postpartum and early neonatal period in a busy family-centered neonatal intensive care unit.
Topics: Antiviral Agents; Family Nursing; Female; Hospitalization; Humans; Infant, Newborn; Infant, Newborn, Diseases; Influenza A virus; Influenza, Human; Intensive Care Units, Neonatal; Oseltamivir; Pandemics; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Retrospective Studies | 2011 |
Swine H1N1 infection in a renal transplant recipient.
Topics: Adult; Antiviral Agents; Humans; Immunosuppressive Agents; Influenza A Virus, H1N1 Subtype; Influenza, Human; Kidney Transplantation; Male; Oseltamivir; Treatment Outcome | 2010 |
Emerging influenza antiviral resistance threats.
Topics: Adamantane; Antiviral Agents; Drug Resistance, Multiple, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation, Missense; Oseltamivir; Reassortant Viruses; Virus Replication | 2011 |
Dual resistance to adamantanes and oseltamivir among seasonal influenza A(H1N1) viruses: 2008-2010.
Topics: Adamantane; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Multiple, Viral; Genome, Viral; Genotype; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation, Missense; Neuraminidase; Oseltamivir; RNA, Viral; Viral Matrix Proteins; Viral Proteins | 2011 |
Evidence of person-to-person transmission of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus in a hematology unit.
Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; Cross Infection; Drug Resistance, Viral; Hemagglutinins, Viral; Hospitals; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Lymphopenia; Middle Aged; Mutation, Missense; Neuraminidase; Oseltamivir; RNA, Viral; Sequence Analysis, DNA; United Kingdom; Viral Proteins | 2011 |
Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Oseltamivir; Pyrrolidines; Recombination, Genetic; Viral Plaque Assay; Viral Proteins; Virus Replication; Zanamivir | 2011 |
Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
Topics: Acids, Carbocyclic; Adamantane; Amino Acid Substitution; Animals; Antiviral Agents; Cell Line; Cyclopentanes; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Oseltamivir; Pyrans; Pyrrolidines; Sialic Acids; Viral Plaque Assay; Zanamivir | 2010 |
H1N1pdm influenza infection in hospitalized cancer patients: clinical evolution and viral analysis.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biological Evolution; Brazil; Child; Child, Preschool; Comorbidity; Female; Hospital Mortality; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Neoplasms; Oseltamivir; Pandemics; Prospective Studies; Virus Shedding; Young Adult | 2010 |
Detection of an oseltamivir-resistant pandemic influenza A/H1N1 virus in the United Arab Emirates.
Topics: Antiviral Agents; Databases, Nucleic Acid; DNA Primers; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pandemics; Polymerase Chain Reaction; United Arab Emirates | 2011 |
Bronchoscopic findings in a child with pandemic novel H1N1 influenza A and methicillin-resistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Bronchoscopy; Child; Fatal Outcome; Female; Fibrinolytic Agents; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Lung; Meropenem; Methicillin-Resistant Staphylococcus aureus; Oseltamivir; Respiratory Distress Syndrome; Respiratory Insufficiency; Staphylococcal Infections; Thienamycins; Tissue Plasminogen Activator; Vancomycin | 2011 |
Pandemic H1N1 2009 influenza virus with the H275Y oseltamivir resistance neuraminidase mutation shows a small compromise in enzyme activity and viral fitness.
Topics: Animals; Antiviral Agents; Cells, Cultured; Dogs; Drug Resistance, Viral; Epithelial Cells; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation, Missense; Neuraminidase; Oseltamivir; Sialic Acids; Viral Proteins; Virus Replication | 2011 |
Iota-carrageenan is a potent inhibitor of influenza A virus infection.
Topics: Animals; Antiviral Agents; Carrageenan; Disease Models, Animal; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A virus; Influenza, Human; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred C57BL; Neuraminidase; Oseltamivir; Polymers; Polysaccharides | 2010 |
High mortality in critically ill patients infected with 2009 pandemic influenza A (H1N1) with pneumonia and acute kidney injury.
Topics: Acute Kidney Injury; Adolescent; Adult; Antiviral Agents; APACHE; Critical Illness; Female; Humans; India; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Multiple Organ Failure; Oseltamivir; Pandemics; Pneumonia, Viral; Renal Replacement Therapy; Respiration, Artificial; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Young Adult | 2011 |
Conversion to type 1 diabetes after H1N1 influenza infection: a case report.
Topics: Adult; Diabetes Mellitus, Type 1; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Oseltamivir | 2011 |
2009 Influenza A H1N1 infections: delays in starting treatment with oseltamivir were associated with a more severe disease.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Critical Care; Female; Hospitalization; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Respiratory Insufficiency; Time Factors | 2011 |
Mixtures of oseltamivir-sensitive and -resistant pandemic influenza A/H1N1/2009 viruses in immunocompromised hospitalized children.
Topics: Antiviral Agents; Bacterial Infections; Child; Child, Hospitalized; Child, Preschool; Drug Resistance, Viral; Genetic Variation; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir | 2011 |
Antivirals in treatment of H1N1 infection: are they really effective?
Topics: Antiviral Agents; Child; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Treatment Outcome; Zanamivir | 2011 |
Characterization of neuraminidases from the highly pathogenic avian H5N1 and 2009 pandemic H1N1 influenza A viruses.
Topics: Amino Acid Sequence; Animals; Antiviral Agents; Birds; Dimerization; Gene Deletion; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Microscopy, Electron, Transmission; Molecular Sequence Data; Mutation; Neuraminidase; Oseltamivir; Protein Structure, Tertiary; Sequence Homology, Amino Acid | 2010 |
H1N1 infection in a cohort of hematopoietic stem cell transplant recipients: prompt antiviral therapy might be life saving.
Topics: Adult; Antiviral Agents; Female; Hematopoietic Stem Cell Transplantation; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Retrospective Studies; Young Adult | 2011 |
Fatal cases of 2009 pandemic influenza A (H1N1) in Korea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Bacterial Infections; Child; Child, Preschool; Female; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Pandemics; Republic of Korea | 2011 |
Risk factors for severe illness with 2009 pandemic influenza A (H1N1) virus infection in China.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; China; Chronic Disease; Female; Hospitalization; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Obesity; Oseltamivir; Pregnancy; Risk Factors; Young Adult | 2011 |
Ensuring safe and effective drugs: who can do what it takes?
Topics: Clinical Trials as Topic; Data Collection; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Review Literature as Topic; Selection Bias | 2011 |
[Case of novel influenza A (H1N1) pneumonia with shrinkage of a pulmonary lesion].
Topics: Acute Lung Injury; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Lung; Male; Middle Aged; Oseltamivir; Pneumonia, Viral; Respiratory Distress Syndrome; Tomography, X-Ray Computed | 2010 |
Oseltamivir treatment and prophylaxis in a neonatal intensive care unit during a 2009 H1N1 influenza outbreak.
Topics: Antiviral Agents; Cohort Studies; Disease Outbreaks; Female; Follow-Up Studies; Hospitals, Pediatric; Humans; Infant, Newborn; Infant, Premature; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care Units, Neonatal; Male; Oseltamivir; Retrospective Studies; Risk Assessment; Survival Rate; Treatment Outcome; Urban Population | 2011 |
Infections with the 2009 H1N1 influenza virus among hematopoietic SCT recipients: a single center experience.
Topics: Adolescent; Adult; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunosuppression Therapy; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Retrospective Studies; Transplantation, Homologous | 2011 |
Antiviral treatment of influenza A (H1N1-09) guided by molecular resistance testing in aplasia after allo-SCT.
Topics: Antiviral Agents; Drug Resistance, Viral; Female; Hematopoietic Stem Cell Transplantation; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Middle Aged; Oseltamivir; Zanamivir | 2011 |
Oseltamivir compounding in the hospital pharmacy during the (H1N1) influenza pandemic.
Topics: Antiviral Agents; Brazil; Chromatography, High Pressure Liquid; Drug Compounding; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pandemics; Pharmacy Service, Hospital; Quality Control; Time Factors | 2010 |
Resistance to neuraminidase inhibitors.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Humans; Influenza, Human; Neuraminidase; Orthomyxoviridae; Oseltamivir; Virus Shedding; Zanamivir | 2011 |
Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Female; Humans; Influenza, Human; Male; Microbial Sensitivity Tests; Nasal Mucosa; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pharynx; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome; Virus Shedding; Zanamivir | 2011 |
Neuraminidase-inhibitor resistance testing for pandemic influenza A (H1N1) 2009 in Ontario, Canada.
Topics: Adolescent; Adult; Amino Acid Substitution; Antiviral Agents; Child; Drug Resistance, Viral; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Mutation, Missense; Neuraminidase; Ontario; Oseltamivir; Viral Proteins; Young Adult | 2011 |
Encephalitis-associated pandemic A (H1N1) 2009 in a Kuwaiti girl.
Topics: Antiviral Agents; Child; Disease Outbreaks; Electroencephalography; Encephalitis; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Kuwait; Magnetic Resonance Imaging; Oseltamivir | 2011 |
2009 pandemic influenza A (H1N1) and vaccine failure in pregnancy.
Topics: Adult; Antiviral Agents; Cesarean Section; Female; Humans; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; Pandemics; Pregnancy; Pregnancy Complications, Infectious; Respiration, Artificial; Respiratory Distress Syndrome; Treatment Failure | 2011 |
Journalism as health education: media coverage of a nonbranded pharma web site.
Topics: Advertising; Antiviral Agents; Drug Industry; Feasibility Studies; Health Education; Health Knowledge, Attitudes, Practice; Humans; Influenza, Human; Information Dissemination; Internet; Journalism, Medical; Marketing; Mass Media; Oseltamivir; Patient Education as Topic; Statistics as Topic | 2011 |
2009H1N1 Infection in a 1-day-old neonate.
Topics: Anesthesia, Obstetrical; Antiviral Agents; Cesarean Section; Female; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Influenza A Virus, H1N2 Subtype; Influenza, Human; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Young Adult | 2010 |
Exertional rhabdomyolysis after influenza A (H3N2) infection in a basketball player boy.
Topics: Adolescent; Antiviral Agents; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Male; Oseltamivir; Physical Exertion; Rhabdomyolysis | 2011 |
Oseltamivir-resistant influenza viruses circulating during the first year of the influenza A(H1N1) 2009 pandemic in the Asia-Pacific region, March 2009 to March 2010.
Topics: Antiviral Agents; Asia; Australia; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation; Neuraminidase; Oseltamivir; Pacific Islands; Pandemics; Phylogeny; Population Surveillance; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Sequence Analysis; Time Factors; World Health Organization | 2011 |
Severe 2009 A/H1N1v influenza in pregnant women in Spain.
Topics: Adolescent; Adult; Age Distribution; Antiviral Agents; Communicable Disease Control; Confidence Intervals; Critical Care; Female; Hospitalization; Humans; Incidence; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care Units; Linear Models; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Registries; Retrospective Studies; Risk Assessment; Severity of Illness Index; Spain; Statistics, Nonparametric; Survival Rate; Young Adult | 2011 |
Clinical and epidemiological characteristics of patients with influenza A (H1N1) 2009 attended to at the emergency room of a children's hospital.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Emergency Service, Hospital; Female; Hospitals, Pediatric; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Pandemics; Patient Admission; Risk Factors; Spain; Young Adult | 2011 |
Pandemic influenza A(H1N1) 2009: molecular characterisation and duration of viral shedding in intensive care patients in Bordeaux, south-west France, May 2009 to January 2010.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Comorbidity; Female; France; Hemagglutinin Glycoproteins, Influenza Virus; Hospitals, University; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care Units; Male; Middle Aged; Neuraminidase; Oseltamivir; Pandemics; Polymerase Chain Reaction; Time Factors; Virus Shedding; Young Adult | 2011 |
Mesenteric venous thrombosis in a child with type 2 protein S deficiency.
Topics: Antiviral Agents; Blood Proteins; Child, Preschool; Female; Humans; Influenza A virus; Influenza, Human; Intestines; Ischemia; Mesenteric Vascular Occlusion; Mutation; Oseltamivir; Protein S; Protein S Deficiency; Venous Thrombosis | 2011 |
Hemophagocytic lymphohistiocytosis associated with 2009 pandemic influenza A (H1N1) virus infection.
Topics: Antiviral Agents; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Lymphohistiocytosis, Hemophagocytic; Male; Oseltamivir; Pandemics | 2011 |
Deep sequencing reveals mixed infection with 2009 pandemic influenza A (H1N1) virus strains and the emergence of oseltamivir resistance.
Topics: Adolescent; Antiviral Agents; Biodiversity; Drug Resistance, Viral; Genotype; High-Throughput Nucleotide Sequencing; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Molecular Sequence Data; Oseltamivir; Pandemics; Phylogeny; RNA, Viral; Sequence Homology | 2011 |
Characteristics of patients with oseltamivir-resistant pandemic (H1N1) 2009, United States.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Enzyme Inhibitors; Female; Humans; Immunocompromised Host; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Pandemics; Population Surveillance; United States; Young Adult | 2011 |
Oseltamivir-resistant pandemic (H1N1) 2009 virus, Mexico.
Topics: Adamantane; Antiviral Agents; Drug Resistance, Viral; Female; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mexico; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Pandemics; Point Mutation; Reverse Transcriptase Polymerase Chain Reaction; Zanamivir | 2011 |
Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated critically ill patients with pandemic influenza A (H1N1)v.
Topics: Administration, Inhalation; Administration, Oral; Adult; Aged; Antiviral Agents; Child; Critical Illness; Drug Therapy, Combination; Extracorporeal Membrane Oxygenation; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Respiration, Artificial; Time Factors; Treatment Failure; Virus Shedding; Zanamivir | 2011 |
Continued emergence and changing epidemiology of oseltamivir-resistant influenza A(H1N1)2009 virus, United Kingdom, winter 2010/11.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Female; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Microbial Sensitivity Tests; Middle Aged; Neuraminidase; Oseltamivir; Pandemics; Polymorphism, Single Nucleotide; Population Surveillance; Seasons; United Kingdom; Young Adult | 2011 |
Monitoring of the h275y mutation in pandemic influenza A(H1N1) 2009 strains isolated in Malaysia.
Topics: Amino Acid Substitution; Antiviral Agents; Disease Outbreaks; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Malaysia; Mutation, Missense; Neuraminidase; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA; Viral Proteins | 2011 |
[Transient splenial lesion in influenza A H1N1 2009 infection].
Topics: Acyclovir; Anticonvulsants; Antiviral Agents; Child; Corpus Callosum; Diffusion Magnetic Resonance Imaging; Drug Therapy, Combination; Encephalitis, Viral; Epilepsy, Tonic-Clonic; Follow-Up Studies; Humans; Image Enhancement; Image Processing, Computer-Assisted; Influenza A Virus, H1N1 Subtype; Influenza, Human; Levetiracetam; Magnetic Resonance Imaging; Male; Oseltamivir; Pandemics; Piracetam; Reverse Transcriptase Polymerase Chain Reaction | 2011 |
Safety of influenza immunizations and treatment during pregnancy: the Vaccines and Medications in Pregnancy Surveillance System.
Topics: Adverse Drug Reaction Reporting Systems; Antiviral Agents; Case-Control Studies; Congenital Abnormalities; Female; Humans; Immunization; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Prospective Studies; Risk Assessment; Societies, Medical; United States; Zanamivir | 2011 |
Cluster of oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infections on a hospital ward among immunocompromised patients--North Carolina, 2009.
Topics: Adult; Aged; Antiviral Agents; Case-Control Studies; Cross Infection; Disease Outbreaks; Drug Resistance, Viral; Hospitals; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Interviews as Topic; Middle Aged; North Carolina; Oseltamivir; Pandemics; Phylogeny; Retrospective Studies | 2011 |
Uptake of influenza vaccine in pregnant women during the 2009 H1N1 influenza pandemic.
Topics: Antiviral Agents; Female; Health Knowledge, Attitudes, Practice; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Massachusetts; Oseltamivir; Pandemics; Patient Acceptance of Health Care; Pregnancy; Pregnancy Complications, Infectious; Pregnant Women; Safety; Seasons; Treatment Refusal; Vaccination | 2011 |
Hematopoietic stem cell transplantation from a related donor infected with influenza H1N1 2009.
Topics: Adult; Child; Female; Hematopoietic Stem Cell Transplantation; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Republic of Korea | 2011 |
Development of a real-time RT-PCR assay for detection of resistance to oseltamivir in influenza A pandemic (H1N1) 2009 virus using single nucleotide polymorphism probes.
Topics: Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation, Missense; Oseltamivir; Polymorphism, Single Nucleotide; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity | 2011 |
Extracorporeal membrane oxygenation for severe refractory respiratory failure secondary to 2009 H1N1 influenza A.
Topics: Adolescent; Adult; Antiviral Agents; Child; Critical Illness; Extracorporeal Membrane Oxygenation; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care Units, Pediatric; Male; Oseltamivir; Respiratory Insufficiency; Retrospective Studies; Young Adult; Zanamivir | 2011 |
Substitutions in position 222 of haemagglutinin of pandemic influenza A (H1N1) 2009 viruses in Spain.
Topics: Adolescent; Adult; Amino Acid Substitution; Antiviral Agents; Female; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Mutation; Oseltamivir; Pandemics; Sequence Analysis, DNA; Spain | 2011 |
Clinical features and outcome of children and adolescents hospitalized with influenza A (H1N1) virus infection compared with flu-like symptoms and negative rapid tests for influenza A (H1N1) admitted in the same period of time.
Topics: Anti-Bacterial Agents; Antiviral Agents; Child; Child, Preschool; Critical Care; Female; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Length of Stay; Male; Oseltamivir; Respiration, Artificial; Respiratory Tract Infections; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome | 2011 |
Comparison of the efficacies of amantadine treatment of swine-origin influenza virus A H1N1 and seasonal influenza H1N1 and H3N2 in Japan (2008-2009).
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Amantadine; Amino Acid Sequence; Analysis of Variance; Antiviral Agents; Body Temperature; Child; Child, Preschool; Disease Outbreaks; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Japan; Middle Aged; Molecular Sequence Data; Mutation; Oseltamivir; Seasons; Sequence Alignment; Treatment Outcome; Viral Matrix Proteins; Zanamivir | 2011 |
The impact of the 2009 H1N1 influenza pandemic on pediatric patients with sickle cell disease.
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Antisickling Agents; Antiviral Agents; Blood Transfusion; Child; Female; Humans; Hydroxyurea; Incidence; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Pandemics; Retrospective Studies | 2011 |
Influenza A virus hemagglutinin antibody escape promotes neuraminidase antigenic variation and drug resistance.
Topics: Amino Acid Substitution; Antibodies, Viral; Antigenic Variation; Antiviral Agents; Drug Resistance, Viral; Hemagglutinins; Humans; Immune Evasion; Influenza A virus; Influenza, Human; Models, Molecular; Mutation; Neuraminidase; Oseltamivir; Zanamivir | 2011 |
Development of a concise synthesis of (-)-oseltamivir (Tamiflu).
Topics: Alkylation; Allyl Compounds; Antiviral Agents; Catalysis; Humans; Influenza, Human; Oseltamivir; Palladium; Stereoisomerism | 2011 |
[A suspected case of in utero transmission of influenza A (H1N1) 2009].
Topics: Adult; Antiviral Agents; Female; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Nasopharynx; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious | 2011 |
Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A.
Topics: Adult; Antiviral Agents; Critical Illness; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Prospective Studies; Time Factors; Treatment Outcome | 2011 |
Real-time estimation and prediction for pandemic A/H1N1(2009) in Japan.
Topics: Antiviral Agents; Databases, Factual; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Models, Statistical; Oseltamivir; Pandemics; Population Surveillance; Predictive Value of Tests; Zanamivir | 2011 |
Fatal 2009 pandemic influenza A (H1N1) in a bone marrow transplant recipient.
Topics: Antiviral Agents; Bone Marrow Transplantation; Fatal Outcome; Humans; Immunosuppression Therapy; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction | 2011 |
Monitoring and characterization of oseltamivir-resistant pandemic (H1N1) 2009 virus, Japan, 2009-2010.
Topics: Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Female; Hemagglutination Inhibition Tests; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Neuraminidase; Oseltamivir; Pandemics; Sequence Analysis, DNA; Young Adult | 2011 |
Benefit of early treatment with oseltamivir in hospitalized patients with documented 2009 influenza A (H1N1): retrospective cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Critical Care; Female; Hospitalization; Humans; Hypoxia; Influenza A Virus, H1N1 Subtype; Influenza, Human; Israel; Male; Middle Aged; Oseltamivir; Pneumonia, Bacterial; Respiration, Artificial; Retrospective Studies; Time Factors; Treatment Outcome; Young Adult | 2011 |
Surge in expression of carboxylesterase 1 during the post-neonatal stage enables a rapid gain of the capacity to activate the anti-influenza prodrug oseltamivir.
Topics: Adolescent; Adult; Age Factors; Antiviral Agents; Carboxylic Ester Hydrolases; Gene Expression Regulation, Developmental; Humans; Infant; Infant, Newborn; Influenza, Human; Liver; Oseltamivir; Prodrugs; Young Adult | 2011 |
Management of the 2009 A/H1N1 influenza pandemic in patients with hematologic diseases: a prospective experience at an Italian center.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Female; Hematologic Diseases; Humans; Influenza, Human; Italy; Male; Middle Aged; Oseltamivir; Polymerase Chain Reaction; Prospective Studies; Young Adult | 2011 |
Timing of oseltamivir administration and outcomes in hospitalized adults with pandemic 2009 influenza A(H1N1) virus infection.
Topics: Antiviral Agents; Cohort Studies; Female; Hospital Mortality; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Inpatients; Length of Stay; Logistic Models; Male; Middle Aged; Oseltamivir; Pandemics; Prospective Studies; Respiration, Artificial; Retrospective Studies; Spain; Time Factors; Treatment Outcome | 2011 |
Fulminant myocarditis in an adult with 2009 pandemic influenza A (H1N1 influenza) infection.
Topics: Adult; Extracorporeal Membrane Oxygenation; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Myocarditis; Oseltamivir; Pandemics | 2011 |
Clinical features and outcome of 2009-influenza A (H1N1) after allogeneic hematopoietic SCT.
Topics: Adult; Antiviral Agents; Hematopoietic Stem Cell Transplantation; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Middle Aged; Oseltamivir; Pandemics; Treatment Outcome; Young Adult | 2012 |
Rhabdomyolysis induced by influenza A infection: case report and review of literature.
Topics: Acute Kidney Injury; Adult; Antiviral Agents; Humans; Influenza A virus; Influenza, Human; Male; Oseltamivir; Plasma Exchange; Renal Dialysis; Rhabdomyolysis | 2011 |
A severely immunocompromised child with uncomplicated oseltamivir-resistant 2009 H1N1 pandemic influenza infection.
Topics: Antiviral Agents; Child; Drug Resistance, Viral; Female; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Kidney Transplantation; Oseltamivir; Pneumonia, Viral; Postoperative Complications | 2012 |
Replication inhibition activity of carbocycles related to oseltamivir on influenza A virus in vitro.
Topics: Animals; Antiviral Agents; Cell Line; Enzyme Inhibitors; Humans; Influenza A virus; Influenza, Human; Kinetics; Molecular Structure; Neuraminidase; Oseltamivir; Viral Proteins; Virus Replication | 2011 |
Pandemic influenza A(H1N1) 2009 virus outbreak among boarding school pupils in Madagascar: compliance and adverse effects of prophylactic oseltamivir treatment.
Topics: Adolescent; Antiviral Agents; Chemoprevention; Disease Outbreaks; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Madagascar; Male; Medication Adherence; Oseltamivir; Schools; Students; Surveys and Questionnaires | 2011 |
Safety profile of oseltamivir during the 2009 influenza pandemic.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Antiviral Agents; Child; Child, Preschool; Female; Humans; Infant; Infant, Newborn; Influenza, Human; Japan; Male; Medication Errors; Middle Aged; Oseltamivir; Pandemics; United States; Young Adult | 2011 |
[Outbreak of influenza pandemic virus A(H1N1) 2009 infections in the Emergency Department, Saint-Pierre, Réunion Island, July-September 2009].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Bronchial Spasm; Comorbidity; Emergency Service, Hospital; Epidemics; Female; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Reunion; Risk Factors; Time Factors; Young Adult | 2011 |
Pandemic 2009 H1N1 influenza in patients with hematopoietic stem cell transplantation and hematologic malignancy: single center experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Polymerase Chain Reaction; Retrospective Studies | 2010 |
Early corticosteroid treatment for severe pneumonia caused by 2009 H1N1 influenza virus.
Topics: Antiviral Agents; Child; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Methylprednisolone; Oseltamivir; Pneumonia, Viral; Republic of Korea | 2011 |
[Clinical features and outcome of 2009 H1N1 influenza in the pediatric setting. Multicenter prospective study in the ED].
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Emergency Service, Hospital; Female; Hospitalization; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Prospective Studies; Treatment Outcome | 2011 |
Drug-resistant pandemic (H1N1) 2009, South Korea.
Topics: Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Female; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Mutation; Oseltamivir; Republic of Korea; Treatment Outcome; Viral Proteins; Young Adult | 2011 |
[Pulmonary complications from pandemic AH1N1 influenza: clinical-radiological features].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Combined Modality Therapy; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Pandemics; Pneumonia, Viral; Pregnancy; Pregnancy Complications, Infectious; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2011 |
[Clinical course of influenza A(H1N1)v in children treated in Warsaw in season 2009/2010].
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Communicable Diseases, Emerging; Comorbidity; Cough; Female; Fever; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Pneumonia; Poland; Retrospective Studies; Seasons; Treatment Outcome; Urban Population | 2010 |
Prolonged lymphopenia in a patient with lymphoma and severe Pandemic influenza A H1N1 2009 virus infection.
Topics: Adolescent; Antiviral Agents; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Lymphoma; Lymphopenia; Male; Oseltamivir | 2011 |
Reassortment and mutations associated with emergence and spread of oseltamivir-resistant seasonal influenza A/H1N1 viruses in 2005-2009.
Topics: Animals; Antiviral Agents; Cell Line; Dogs; Drug Resistance, Viral; Epidemics; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Molecular Sequence Data; Mutation; Neuraminidase; Oseltamivir; Reassortant Viruses; Taiwan | 2011 |
2009 H1N1 influenza and experience in three critical care units.
Topics: Adult; Anti-Bacterial Agents; APACHE; C-Reactive Protein; Comorbidity; Creatinine; Enzymes; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care Units; Male; Middle Aged; Oseltamivir; Oxygen; Respiration, Artificial; Retrospective Studies; Turkey | 2011 |
Pharmacokinetics of oseltamivir according to trimester of pregnancy.
Topics: Adolescent; Adult; Antiviral Agents; Area Under Curve; Female; Half-Life; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza B virus; Influenza, Human; Maximum Allowable Concentration; Oseltamivir; Pandemics; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimesters; Time Factors; Young Adult | 2011 |
Pharmacokinetics of oseltamivir among pregnant and nonpregnant women.
Topics: Adolescent; Adult; Antibiotic Prophylaxis; Antiviral Agents; Area Under Curve; Case-Control Studies; Female; Humans; Influenza, Human; Metabolic Clearance Rate; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Young Adult | 2011 |
An Infection Control Program for a 2009 influenza A H1N1 outbreak in a university-based summer camp.
Topics: Adolescent; Antiviral Agents; Camping; Chemoprevention; Disease Outbreaks; Humans; Infection Control; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mass Screening; North Carolina; Oseltamivir; Students; Universities; Young Adult | 2011 |
Clinical characteristics of pregnant women with influenza-like illness during the 2009 H1N1 pandemic and use of a standardized management algorithm.
Topics: Adolescent; Adult; Algorithms; Ambulatory Care; Antiviral Agents; Body Temperature; Female; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pandemics; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Treatment Outcome; United States; Young Adult | 2011 |
Pandemic (H1N1) 2009 influenza in hospitalized children in Manitoba: nosocomial transmission and lessons learned from the first wave.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Community-Acquired Infections; Cross Infection; Female; Humans; Infant; Infant, Newborn; Infection Control; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza B virus; Influenza, Human; Length of Stay; Male; Manitoba; Oseltamivir; Pandemics; Retrospective Studies; Risk Factors; Seasons | 2011 |
Ultrasensitive detection of drug-resistant pandemic 2009 (H1N1) influenza A virus by rare-variant-sensitive high-resolution melting-curve analysis.
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation, Missense; Oseltamivir; RNA, Viral; Sensitivity and Specificity; Transition Temperature | 2011 |
Clinical aspects of 2009 pandemic influenza A (H1N1) virus infection in Austria.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Austria; Child; Child, Preschool; Comorbidity; Cross-Sectional Studies; Female; Hospitalization; Humans; Incidence; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Logistic Models; Male; Middle Aged; Oseltamivir; Pandemics; Prospective Studies; Risk Factors; Young Adult | 2011 |
Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Hematopoietic Stem Cell Transplantation; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Lymphopenia; Middle Aged; Oseltamivir; Pandemics; Pneumonia; Risk Factors; Treatment Outcome; Vaccination; Young Adult | 2011 |
Mixed influenza A and B infections complicate the detection of influenza viruses with altered sensitivities to neuraminidase inhibitors.
Topics: Animals; Antiviral Agents; Cell Line; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H2N2 Subtype; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2011 |
Genetic diversity and antiviral drug resistance of pandemic H1N1 2009 in Lebanon.
Topics: Animals; Antiviral Agents; Drug Resistance, Viral; Genetic Variation; Genotype; Guinea Pigs; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Lebanon; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation, Missense; Nasopharynx; Neuraminidase; Oseltamivir; Pandemics; Phylogeny; RNA, Viral; Sequence Analysis, DNA; Viral Proteins | 2011 |
Rapid discrimination of oseltamivir-resistant 275Y and -susceptible 275H substitutions in the neuraminidase gene of pandemic influenza A/H1N1 2009 virus by duplex one-step RT-PCR assay.
Topics: Amino Acid Substitution; Animals; Antiviral Agents; Cell Line; Dogs; Drug Resistance, Viral; Genetic Testing; Genotype; Hemagglutination Inhibition Tests; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Molecular Typing; Mutation, Missense; Neuraminidase; Oseltamivir; Pandemics; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Sequence Analysis, DNA; Viral Proteins; Zanamivir | 2011 |
[The use of antiviral drugs in treating novel influenza A (H1N1) inpatients in Suzhou city, Jiangsu province, China, 2009 - 2010].
Topics: Antiviral Agents; China; Drug Utilization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Inpatients; Oseltamivir | 2011 |
Mutation analysis of 2009 pandemic influenza A(H1N1) viruses collected in Japan during the peak phase of the pandemic.
Topics: Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Bayes Theorem; Cluster Analysis; DNA Mutational Analysis; Drug Resistance, Viral; Hemagglutinins, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Models, Molecular; Molecular Sequence Data; Mutation; Neuraminidase; Oseltamivir; Pandemics; Phylogeny; Protein Conformation; Protein Multimerization; Seasons; Viral Proteins | 2011 |
Oseltamivir-resistant pandemic influenza a (H1N1) 2009 viruses in Spain.
Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Mutation, Missense; Neuraminidase; Nucleic Acid Hybridization; Oseltamivir; Pandemics; Prevalence; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA; Spain; Viral Proteins | 2011 |
Adamantane- and oseltamivir-resistant seasonal A (H1N1) and pandemic A (H1N1) 2009 influenza viruses in Guangdong, China, during 2008 and 2009.
Topics: Adamantane; China; Cluster Analysis; Drug Resistance, Viral; Genotype; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Molecular Sequence Data; Neuraminidase; Oseltamivir; Sequence Analysis, DNA; Viral Matrix Proteins; Viral Proteins | 2011 |
Emergence of oseltamivir-resistant pandemic H1N1 in an immunocompetent child with severe status asthmaticus.
Topics: Amino Acid Substitution; Child; Drug Resistance, Viral; Humans; Immunocompetence; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Pandemics; Radiography, Thoracic; Respiration, Artificial; Reverse Transcriptase Polymerase Chain Reaction; Status Asthmaticus | 2011 |
How we optimized prevention and control of pandemic 2009 influenza A (H1N1) in a resource-limited nation's pediatric oncology unit.
Topics: Anti-Bacterial Agents; Antiviral Agents; Guatemala; Hospitals, Pediatric; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Oncology Service, Hospital; Oseltamivir; Pandemics | 2011 |
Novel H1N1 influenza in neonates: from mild to fatal disease.
Topics: Antiviral Agents; Diagnosis, Differential; Fatal Outcome; Female; Humans; Infant; Infant, Newborn; Infant, Premature, Diseases; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Pandemics; Prognosis; Respiratory Insufficiency; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors | 2011 |
Simultaneous detection and subtyping of H274Y-positive influenza A (H1N1) using pyrosequencing.
Topics: Adult; Amino Acid Substitution; Antiviral Agents; Disease Outbreaks; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Molecular Diagnostic Techniques; Mutation, Missense; Oseltamivir; Sequence Analysis, DNA; Thailand; Virology | 2011 |
Oseltamivir pharmacokinetics in pregnancy: a commentary.
Topics: Antibiotic Prophylaxis; Antiviral Agents; Biomedical Research; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pandemics; Pregnancy; Pregnancy Complications, Infectious; Research Design | 2011 |
Abnormal liver chemistry in patients with influenza A H1N1.
Topics: Adolescent; Adult; Antiviral Agents; Bile Acids and Salts; Bilirubin; Biomarkers; Child; Child, Preschool; Enzymes; Female; gamma-Globulins; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Liver; Male; Oseltamivir; Prealbumin; Predictive Value of Tests; RNA, Viral; Serum Albumin; Young Adult | 2011 |
Oseltamivir use in low-birth weight infants during the 2009 nH1N1 influenza a outbreak in the Western Cape, South Africa.
Topics: Antiviral Agents; Disease Outbreaks; Enterocolitis, Necrotizing; Humans; Infant, Low Birth Weight; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; South Africa; Treatment Outcome | 2012 |
Online monitoring of flu in Belgium.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Belgium; Child; Child, Preschool; Disease Notification; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Online Systems; Oseltamivir; Pandemics; Population Surveillance; Young Adult; Zanamivir | 2011 |
Oseltamivir treatment of mice before or after mild influenza infection reduced cellular and cytokine inflammation in the lung.
Topics: Animals; Antiviral Agents; Cytokines; Disease Models, Animal; Humans; Influenza A virus; Influenza, Human; Lung; Male; Mice; Mice, Inbred BALB C; Oseltamivir; Treatment Outcome | 2011 |
Compliance to oseltamivir and subsequent occurrence of self-reported adverse drug reactions among nursery and primary school children following exposure to Influenza A(H1N1)v.
Topics: Antiviral Agents; Child; Child, Preschool; Disease Outbreaks; Female; Health Surveys; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Medication Adherence; Oseltamivir; Schools; Scotland; Surveys and Questionnaires | 2011 |
Influenza A (H1N1) and myocarditis.
Topics: Antiviral Agents; Electrocardiography; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Magnetic Resonance Imaging; Middle Aged; Myocarditis; Oseltamivir; Respiration, Artificial | 2011 |
The sponsored pandemic of the Mexican flu?
Topics: Australia; Conflict of Interest; Drug Industry; Enzyme Inhibitors; Ethics, Professional; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Mass Vaccination; Neuraminidase; New Zealand; Oseltamivir; Pandemics; Politics | 2011 |
Comparison of clinical presentation of respiratory tract infections in H1N1/09-positive and H1N1/09-negative patients.
Topics: Adolescent; Antiviral Agents; Asthma; Case-Control Studies; Child; Child, Preschool; Diagnosis, Differential; Hospitalization; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Prospective Studies; Respiratory Sounds; Risk Factors; Seizures, Febrile | 2012 |
Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation.
Topics: Antiviral Agents; Australia; Drug Resistance; Genetic Predisposition to Disease; Genetic Variation; Humans; Incidence; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Polymorphism, Single Nucleotide; Population Surveillance; Risk Assessment; Risk Factors; Singapore; Zanamivir | 2011 |
Neuraminidase of 2007-2008 influenza A(H1N1) viruses shows increased affinity for sialic acids due to the D344N substitution.
Topics: Amino Acid Substitution; Antiviral Agents; Cell Line; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Models, Molecular; Mutagenesis, Site-Directed; Neuraminidase; Oseltamivir; Sialic Acids; Virus Replication | 2011 |
An influenza outbreak among pilgrims sleeping at a school without purpose built overnight accommodation facilities.
Topics: Antiviral Agents; Catholicism; Disease Outbreaks; Housing; Humans; Influenza, Human; New South Wales; Oseltamivir; Population Surveillance; Schools; Travel | 2011 |
Long-term respiratory follow-up of H1N1 infection.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antiviral Agents; Female; Follow-Up Studies; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Lung; Male; Middle Aged; Oseltamivir; Pneumonia, Bacterial; Radiography, Thoracic; Respiratory Function Tests; Time Factors; Young Adult | 2011 |
Risk factors for prolonged shedding of 2009 H1N1 influenza virus.
Topics: Antiviral Agents; Child, Preschool; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Real-Time Polymerase Chain Reaction; Retrospective Studies; Risk Assessment; Virus Shedding | 2011 |
Biotin-, fluorescein- and 'clickable' conjugates of phospha-oseltamivir as probes for the influenza virus which utilize selective binding to the neuraminidase.
Topics: Antiviral Agents; Biotin; Click Chemistry; Enzyme Inhibitors; Fluorescein; Humans; Influenza, Human; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Protein Binding | 2011 |
Very low pandemic influenza A (H1N1) 2009 mortality associated with early neuraminidase inhibitor treatment in Japan: analysis of 1000 hospitalized children.
Topics: Adolescent; Antiviral Agents; Child; Child, Hospitalized; Child, Preschool; Female; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Male; Neuraminidase; Oseltamivir; Retrospective Studies; Time Factors; Viral Proteins; Young Adult | 2011 |
Characterization of the binding affinities of peramivir and oseltamivir carboxylate to the neuraminidase enzyme.
Topics: Acids, Carbocyclic; Antiviral Agents; Buffers; Cyclopentanes; Drug Combinations; Drug Interactions; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Protein Binding; Solutions; Spectrometry, Fluorescence; Viral Proteins | 2011 |
Acute anterior uveitis and optic neuritis as ocular complications of influenza A infection in an 11-year-old boy.
Topics: Acute Disease; Administration, Topical; Antiviral Agents; Child; Drug Therapy, Combination; Fluorescein Angiography; Glucocorticoids; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Infusions, Intravenous; Male; Methylprednisolone; Optic Neuritis; Oseltamivir; Prednisolone; Pulse Therapy, Drug; Respiratory Tract Infections; Tomography, Optical Coherence; Uveitis, Anterior | 2011 |
Severe H1N1-infection during pregnancy.
Topics: Abortion, Spontaneous; Antiviral Agents; Extracorporeal Membrane Oxygenation; Fatal Outcome; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Respiration, Artificial; Severity of Illness Index; Young Adult; Zanamivir | 2011 |
Alice in Wonderland syndrome caused by the 2009 pandemic H1N1 influenza A virus.
Topics: Antibodies, Viral; Child, Preschool; Female; Hemagglutination Inhibition Tests; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Vision Disorders | 2011 |
Post-exposure prophylaxis for H1N1 with oseltamivir in renal allograft recipient--safe and effective without any immunosuppresive drug interaction.
Topics: Adult; Antiviral Agents; Drug Interactions; Fatal Outcome; Female; Humans; Immunosuppressive Agents; Influenza A Virus, H1N1 Subtype; Influenza, Human; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Oseltamivir; Postoperative Complications; Pregnancy; Reverse Transcriptase Polymerase Chain Reaction; Transplantation, Homologous; Treatment Outcome | 2011 |
Pandemic (H1N1) 2009 influenza with neurological complications diagnosed using specific serology with the haemagglutinin inhibition assay.
Topics: Adolescent; Antibodies, Viral; Anticonvulsants; Antiviral Agents; Child; Female; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Immunoenzyme Techniques; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Methylprednisolone; Nervous System Diseases; Oseltamivir; Serologic Tests; Status Epilepticus; Treatment Outcome | 2011 |
Surveillance of illness associated with pandemic (H1N1) 2009 virus infection among adults using a global clinical site network approach: the INSIGHT FLU 002 and FLU 003 studies.
Topics: Adult; Age Distribution; Female; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Pandemics; Population Surveillance; Seasons; Zanamivir | 2011 |
2009 pandemic influenza A (H1N1) in critically ill children in Cincinnati, Ohio.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Critical Care; Critical Illness; Female; Hospitalization; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care Units, Pediatric; Male; Ohio; Oseltamivir; Pandemics; Respiratory Therapy; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2012 |
Reducing occurrence and severity of pneumonia due to pandemic H1N1 2009 by early oseltamivir administration: a retrospective study in Mexico.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Female; Hospitalization; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Mexico; Middle Aged; Multivariate Analysis; Oseltamivir; Pandemics; Patient Admission; Patient Discharge; Pneumonia, Viral; Probability; Retrospective Studies; Severity of Illness Index; Young Adult | 2011 |
Age as risk factor for death from pandemic (H1N1) 2009, Chile.
Topics: Adolescent; Adult; Age Factors; Antiviral Agents; Child; Child, Preschool; Chile; Demography; Female; Hospitalization; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Pandemics; Polymerase Chain Reaction; Risk Factors; Seasons | 2011 |
Characterization of 2009 H1N1 pandemic influenza in a population of Dutch children with influenza-like signs and symptoms.
Topics: Antiviral Agents; Child; Child, Preschool; Female; Hospitals, Teaching; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Netherlands; Oseltamivir; Pandemics; Real-Time Polymerase Chain Reaction | 2012 |
Oseltamivir-resistant pandemic A(H1N1) 2009 influenza viruses detected through enhanced surveillance in the Netherlands, 2009-2010.
Topics: Adolescent; Adult; Aged; Animals; Cell Line; Child; Child, Preschool; Drug Resistance, Viral; Female; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Molecular Sequence Data; Mutation; Netherlands; Neuraminidase; Oseltamivir; Pandemics; Phylogeny; Sentinel Surveillance; Viral Proteins; Young Adult | 2011 |
Prospective evaluation of 2009 H1N1 influenza A in patients admitted with fever to an oncology unit.
Topics: Adult; Antiviral Agents; Child; Fever; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Middle Aged; Neoplasms; Oncology Service, Hospital; Oseltamivir; Prospective Studies; Treatment Outcome | 2011 |
Postpartum pharmacokinetics of peramivir in the treatment of 2009 H1N1 influenza.
Topics: Acids, Carbocyclic; Adult; Antiviral Agents; Cesarean Section; Cyclopentanes; Disease Outbreaks; Female; Guanidines; Humans; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Severity of Illness Index; Treatment Outcome | 2011 |
Birth outcomes among women exposed to neuraminidase inhibitors during pregnancy.
Topics: Adult; Antiviral Agents; Cohort Studies; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Female; Humans; Infant, Low Birth Weight; Infant, Newborn; Influenza, Human; Male; Maternal Age; Maternal-Fetal Exchange; Neuraminidase; Oseltamivir; Parity; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Risk Factors; Young Adult; Zanamivir | 2011 |
Pandemic A/H1N1/2009 influenza in a paediatric haematology and oncology unit: successful management of a sudden outbreak.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Contact Tracing; Cross Infection; Disease Outbreaks; France; Hematology; Hospital Units; Humans; Infection Control; Influenza A Virus, H1N1 Subtype; Influenza, Human; Medical Oncology; Oseltamivir; Pandemics; Patient Isolation; Pediatrics | 2011 |
Antiviral resistance surveillance for influenza A virus in Brazil: investigation on 2009 pandemic influenza A (H1N1) resistance to oseltamivir.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Brazil; Child; Child, Preschool; Drug Resistance, Viral; Female; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Pandemics; Young Adult | 2011 |
[Etiotropic therapy of influenza: lessons from the last pandemic].
Topics: Antiviral Agents; Communicable Diseases, Emerging; Drug Resistance, Viral; Early Diagnosis; Hemagglutination, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; Pandemics; Pneumonia, Viral; Prognosis; Severity of Illness Index; Viral Interference; Viral Tropism; Zanamivir | 2011 |
[Clinical features and contagiousness of influenza A(H1N1) in health care workers and hospitalized patients in a Mexico City hospital].
Topics: Adult; Aged; Antiviral Agents; Comorbidity; Contact Tracing; Cross Infection; Disease Outbreaks; Female; Hospital Mortality; Hospitals, Urban; Humans; Immunocompromised Host; Infectious Disease Transmission, Patient-to-Professional; Infectious Disease Transmission, Professional-to-Patient; Influenza A Virus, H1N1 Subtype; Influenza, Human; Inpatients; Male; Mexico; Middle Aged; Neoplasms; Occupational Diseases; Oseltamivir; Personnel, Hospital; Virulence; Zanamivir | 2011 |
A computational-experimental approach identifies mutations that enhance surface expression of an oseltamivir-resistant influenza neuraminidase.
Topics: Computational Biology; Drug Resistance, Viral; Gene Expression Regulation, Viral; HEK293 Cells; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Models, Molecular; Mutation; Neuraminidase; Oseltamivir; Pandemics; Protein Conformation; Tissue Culture Techniques | 2011 |
Delayed oseltamivir treatment is associated with longer viral shedding of pandemic (H1N1) 2009 virus.
Topics: Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Time Factors; Virus Shedding; Young Adult | 2012 |
Multidrug-resistant pandemic (H1N1) 2009 infection in immunocompetent child.
Topics: Adolescent; Antiviral Agents; Drug Resistance, Multiple, Viral; Enzyme Inhibitors; Female; Humans; Immunocompetence; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Pandemics; Zanamivir | 2011 |
Influenza A H1N1 (2009): clinical spectrum of disease among adult patients admitted to a regional hospital in Singapore.
Topics: Adolescent; Adult; Antiviral Agents; Comorbidity; Emergency Medical Services; Epidemics; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Retrospective Studies; Severity of Illness Index; Singapore | 2011 |
Intravenous zanamivir in critically ill patients due to pandemic 2009 (H1N1) influenza A virus.
Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Infusions, Intravenous; Intensive Care Units; Male; Middle Aged; Oseltamivir; Pneumonia, Viral; Singapore; Survival Analysis; Zanamivir | 2011 |
Detection of oseltamivir sensitive/resistant strains of pandemic influenza A virus (H1N1) from patients admitted to hospitals in Thailand.
Topics: Adolescent; Adult; Base Sequence; Child; Drug Resistance, Viral; Female; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Limit of Detection; Male; Molecular Sequence Data; Mutagenesis, Site-Directed; Oseltamivir; Pandemics; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Thailand; Treatment Outcome | 2011 |
Pandemic H1N1 influenza A viral infection complicated by atypical hemolytic uremic syndrome and diffuse alveolar hemorrhage.
Topics: Adult; Antiviral Agents; Atypical Hemolytic Uremic Syndrome; Hemodiafiltration; Hemolytic-Uremic Syndrome; Hemorrhage; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Lung Diseases; Male; Oseltamivir; Pandemics; Plasma Exchange; Pulse Therapy, Drug; Republic of Korea; Steroids; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Acute hemorrhagic colitis induced by the oral administration of oseltamivir used for influenza A treatment.
Topics: Acute Disease; Adult; Antiviral Agents; Colitis; Colonoscopy; Female; Gastrointestinal Hemorrhage; Humans; Influenza A virus; Influenza, Human; Oseltamivir | 2011 |
Pandemic (H1N1) 2009 virus infection: persistent viral shedding after Oseltamivir treatment.
Topics: Antiviral Agents; Cohort Studies; Follow-Up Studies; Hospitals; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pharynx; Prospective Studies; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Thailand; Treatment Outcome; Virus Shedding | 2011 |
Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A (H1N1) infection.
Topics: Adolescent; Adult; Child, Preschool; Critical Illness; Drug Therapy, Combination; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Infusions, Intravenous; Middle Aged; Netherlands; Oseltamivir; Retrospective Studies; Time Factors; Treatment Outcome; Viral Load; Zanamivir | 2011 |
Adult respiratory distress syndrome caused by 2009 H1N1 influenza during pregnancy: success of ECMO for both the mother and the child.
Topics: Antiviral Agents; Extracorporeal Membrane Oxygenation; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Respiratory Distress Syndrome; Treatment Outcome | 2011 |
Novel antiviral activity of neuraminidase inhibitors against an avian influenza a virus.
Topics: Animals; Antiviral Agents; Cell Line; Chickens; Dogs; Humans; Influenza A virus; Influenza in Birds; Influenza, Human; Microscopy, Electron, Scanning; Neuraminidase; Oseltamivir; Virion; Virus Assembly; Zanamivir | 2011 |
Clinical and prognostic features of patients with pandemic 2009 influenza A (H1N1) virus in the intensive care unit.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Cause of Death; Comorbidity; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care Units; Male; Middle Aged; Nigeria; Oseltamivir; Pandemics; Patient Admission; Pneumonia, Viral; Prognosis; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Severity of Illness Index; Treatment Outcome; Young Adult | 2011 |
The global spread of drug-resistant influenza.
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mathematical Concepts; Models, Biological; Oseltamivir; Seasons; Stochastic Processes | 2012 |
High-resolution melting approach to efficient identification and quantification of H275Y mutant influenza H1N1/2009 virus in mixed-virus-population samples.
Topics: Antiviral Agents; Coinfection; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Molecular Diagnostic Techniques; Mutant Proteins; Mutation, Missense; Neuraminidase; Oseltamivir; Sensitivity and Specificity; Transition Temperature; Viral Load; Viral Proteins | 2011 |
Estimating effect of antiviral drug use during pandemic (H1N1) 2009 outbreak, United States.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Hospitalization; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Middle Aged; Oseltamivir; Pandemics; Prescription Drugs; United States; Young Adult | 2011 |
Pandemic (H1N1) 2009 in neonates, Japan.
Topics: Antiviral Agents; Female; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Male; Oseltamivir; Pandemics; Pregnancy; Pregnancy Complications, Infectious | 2011 |
[H1N1V influenza epidemic of 2009 in Russia].
Topics: Adult; Antiviral Agents; Child; Drug Resistance, Viral; Epidemics; Genes, Viral; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza, Human; Middle Aged; Mutation; Neuraminidase; Oseltamivir; Russia | 2011 |
ABCB1 polymorphisms and neuropsychiatric adverse events in oseltamivir-treated children during influenza H1N1/09 pandemia.
Topics: Adolescent; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Capillary Permeability; Child; Child, Preschool; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mental Disorders; Oseltamivir; Pandemics; Polymorphism, Single Nucleotide | 2011 |
Pandemic A/H1N1(2009) influenza infections in very-low-birth-weight infants--a case series from the German Neonatal Network.
Topics: Antiviral Agents; Cause of Death; Cross Infection; Diagnosis, Differential; Female; Germany; Gestational Age; Humans; Infant, Extremely Low Birth Weight; Infant, Newborn; Infant, Premature, Diseases; Infant, Very Low Birth Weight; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Pneumonia, Viral; Respiratory Distress Syndrome, Newborn; Risk Factors; Sepsis; Survival Rate | 2011 |
[Susceptibility of pandemic influenza virus A 2009 H1N1 and highly pathogenic avian influenza virus A H5N1 to antiinfluenza agents in cell culture].
Topics: Animals; Antiviral Agents; Birds; Cell Line; Drug Resistance, Viral; Humans; Indoles; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Oseltamivir; Ribavirin; Rimantadine; Virus Replication | 2011 |
Cost-effectiveness of oseltamivir treatment for children with uncomplicated seasonal influenza.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Cost-Benefit Analysis; Drug Resistance, Viral; Humans; Infant; Influenza, Human; Oseltamivir; Seasons | 2012 |
Novel influenza (H1N1) infection in pediatric renal transplant recipients: a single center experience.
Topics: Adolescent; Antiviral Agents; Case-Control Studies; Child; Child, Preschool; Female; Humans; Immunocompromised Host; Immunosuppressive Agents; Influenza A Virus, H1N1 Subtype; Influenza, Human; Kidney Transplantation; Male; Ontario; Oseltamivir; Postoperative Complications; Retrospective Studies | 2012 |
[Influenza A H1N1 in neonatal intensive care unit: analysis and lessons].
Topics: Antiviral Agents; Apnea; Cough; Disease Outbreaks; Female; Follow-Up Studies; France; Humans; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care Units, Neonatal; Male; Oseltamivir; Polymerase Chain Reaction; Respiration, Artificial; Treatment Outcome; Twins, Monozygotic | 2011 |
Acute myocarditis mimicking acute myocardial infarction associated with pandemic 2009 (H1N1) influenza A virus.
Topics: Acute Disease; Adult; Antiviral Agents; Coronary Angiography; Diagnosis, Differential; Electrocardiography; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Myocardial Infarction; Myocarditis; Oseltamivir; Predictive Value of Tests; Treatment Outcome | 2011 |
Transplantation of solid organs procured from influenza A H1N1 infected donors.
Topics: Antiviral Agents; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Kidney Transplantation; Liver Transplantation; Male; Middle Aged; Oseltamivir; Tissue and Organ Procurement; Tissue Donors; Young Adult | 2011 |
Recommendations for and compliance with social restrictions during implementation of school closures in the early phase of the influenza A (H1N1) 2009 outbreak in Melbourne, Australia.
Topics: Antiviral Agents; Australia; Chemoprevention; Child; Disease Outbreaks; Guideline Adherence; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Patient Acceptance of Health Care; Quarantine; Schools | 2011 |
[Influenza H1N1 in obstetric population of a general hospital in Oaxaca].
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antiviral Agents; Combined Modality Therapy; Female; Hospitals, General; Humans; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mexico; Oseltamivir; Pandemics; Pneumonia, Viral; Pre-Eclampsia; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Respiration, Artificial; Retrospective Studies; Water-Electrolyte Imbalance; Young Adult | 2011 |
Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiviral Agents; Cohort Studies; Critical Illness; Drug Therapy, Combination; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Korea; Male; Middle Aged; Oseltamivir; Pandemics; Respiration, Artificial; Retrospective Studies; Ribavirin; Treatment Outcome | 2011 |
Pulmonary aspergillosis in non-immunocompromised patient with acute respiratory distress syndrome during A (H1N1) infection.
Topics: Antiviral Agents; Disease Progression; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Pulmonary Aspergillosis; Respiratory Distress Syndrome; Respiratory Function Tests | 2011 |
Multiphasic acute disseminated encephalomyelitis (ADEM) following influenza type A (swine specific H1N1).
Topics: Anti-Inflammatory Agents; Antiviral Agents; Brain; Encephalomyelitis, Acute Disseminated; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Metapneumovirus; Methylprednisolone; Middle Aged; Oseltamivir; Paramyxoviridae Infections | 2012 |
Oseltamivir shortens hospital stays of critically ill children hospitalized with seasonal influenza: a retrospective cohort study.
Topics: Antiviral Agents; Child, Hospitalized; Child, Preschool; Critical Illness; Databases, Factual; Female; Hospital Mortality; Hospitalization; Hospitals, Pediatric; Humans; Infant; Influenza, Human; Intensive Care Units, Pediatric; Length of Stay; Male; Orthomyxoviridae; Oseltamivir; Retrospective Studies; Treatment Outcome; United States | 2011 |
Otolaryngological complications in patients infected with the influenza A (H1N1) virus.
Topics: Adolescent; Age Distribution; Anti-Bacterial Agents; Child; Child, Preschool; Chile; Cohort Studies; Comorbidity; Emergency Service, Hospital; Female; Hospitalization; Humans; Incidence; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Otitis Media; Pandemics; Respiratory Tract Infections; Retrospective Studies; Rhinitis; Severity of Illness Index; Sex Distribution; Sinusitis; Tonsillitis; Treatment Outcome; Young Adult | 2012 |
Reverse-transcription polymerase chain reaction/pyrosequencing to characterize neuraminidase H275 residue of influenza A 2009 H1N1 virus for rapid and specific detection of the viral oseltamivir resistance marker in a clinical laboratory.
Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Sequence Analysis, DNA; Viral Proteins | 2011 |
Oseltamivir-resistant pandemic (H1N1) 2009 virus infection in England and Scotland, 2009-2010.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Case-Control Studies; Child; Child, Preschool; Drug Resistance, Viral; England; Female; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Mutation; Neuraminidase; Oseltamivir; Pandemics; Risk Factors; Scotland; Young Adult | 2011 |
Pandemic (H1N1) 2009 encephalitis in woman, Taiwan.
Topics: Antiviral Agents; Brain; Encephalitis, Viral; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Magnetic Resonance Imaging; Middle Aged; Oseltamivir; Pandemics; Treatment Outcome | 2011 |
Fatal pandemic influenza A/H1N1 infection complicated by probable invasive pulmonary aspergillosis.
Topics: Aged; Antifungal Agents; Antiviral Agents; Fatal Outcome; Humans; Immunocompetence; Influenza A Virus, H1N1 Subtype; Influenza, Human; Invasive Pulmonary Aspergillosis; Male; Oseltamivir; Pyrimidines; Triazoles; Voriconazole | 2012 |
Amino acid changes in hemagglutinin contribute to the replication of oseltamivir-resistant H1N1 influenza viruses.
Topics: Amino Acid Sequence; Amino Acid Substitution; Animals; Antiviral Agents; Cell Line; Drug Resistance, Viral; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Molecular Sequence Data; Mutation, Missense; Neuraminidase; Oseltamivir; Phylogeny; Sequence Alignment; Viral Proteins; Virus Replication | 2012 |
Description of antiviral treatment among adults hospitalized with influenza before and during the 2009 pandemic: United States, 2005-2009.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Guideline Adherence; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Odds Ratio; Oseltamivir; Pandemics; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pregnancy; Pregnancy Complications, Infectious; Rimantadine; United States; Young Adult; Zanamivir | 2011 |
Clinical features, oseltamivir treatment and outcome in infants aged <12 months with laboratory-confirmed influenza A in 2009.
Topics: Antiviral Agents; Female; Humans; Infant; Infant, Newborn; Influenza A virus; Influenza, Human; Male; Oseltamivir; Treatment Outcome | 2011 |
Oseltamivir overuse at a Chicago hospital during the 2009 influenza pandemic and the poor predictive value of influenza-like illness criteria.
Topics: Adolescent; Adult; Antiviral Agents; Chicago; Child; Female; Humans; Inappropriate Prescribing; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Odds Ratio; Oseltamivir; Pandemics; Predictive Value of Tests; Risk Factors; Sensitivity and Specificity; Statistics, Nonparametric | 2012 |
Clinical significance of pleural effusion in the new influenza A (H1N1) viral pneumonia in children and adolescent.
Topics: Adolescent; Antistreptolysin; Antiviral Agents; C-Reactive Protein; Child; Child, Preschool; Female; Fever; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Length of Stay; Lymphopenia; Male; Oseltamivir; Oxygen Inhalation Therapy; Pleural Effusion; Pneumonia, Viral; Retrospective Studies; Severity of Illness Index | 2012 |
Pandemic A/H1N1v influenza 2009 in hospitalized children: a multicenter Belgian survey.
Topics: Adolescent; Age Distribution; Anti-Bacterial Agents; Antiviral Agents; Belgium; Child; Child, Hospitalized; Child, Preschool; Critical Care; Female; Gastrointestinal Diseases; Humans; Infant; Infant, Newborn; Influenza, Human; Male; Nervous System Diseases; Oseltamivir; Pandemics; Respiratory Tract Diseases; Survival Analysis | 2011 |
Does oseltamivir really reduce complications of influenza?
Topics: Antiviral Agents; Female; Humans; Influenza, Human; Male; Oseltamivir; Pneumonia, Bacterial | 2011 |
Corticosteroid therapy in intensive care unit patients with PCR-confirmed influenza A(H1N1) infection in Finland.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Critical Care; Critical Illness; Data Collection; Female; Finland; Hospital Mortality; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care Units; Length of Stay; Male; Middle Aged; Multiple Organ Failure; Oseltamivir; Polymerase Chain Reaction; Prospective Studies; Respiratory Distress Syndrome; Respiratory Mechanics; Young Adult | 2011 |
Thrombotic thrombocytopenic purpura triggered by influenza A virus subtype H1N1 infection.
Topics: Adult; Anti-Inflammatory Agents; Antiviral Agents; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Methylprednisolone; Oseltamivir; Pneumonia, Viral; Purpura, Thrombotic Thrombocytopenic; Remission Induction | 2012 |
Influenza B viruses with mutation in the neuraminidase active site, North Carolina, USA, 2010-11.
Topics: Acids, Carbocyclic; Adolescent; Adult; Antiviral Agents; Catalytic Domain; Child; Child, Preschool; Cyclopentanes; Drug Resistance, Viral; Guanidines; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Infant; Influenza B virus; Influenza, Human; Microbial Sensitivity Tests; Middle Aged; Mutation; Neuraminidase; North Carolina; Oseltamivir; Phylogeny; Polymorphism, Single Nucleotide; Young Adult | 2011 |
Why we need easy access to all data from all clinical trials and how to accomplish it.
Topics: Clinical Trials as Topic; Data Collection; Drug and Narcotic Control; Drug Industry; Humans; Influenza, Human; Information Dissemination; Oseltamivir | 2011 |
Relapse of minimal change disease following infection with the 2009 pandemic influenza (H1N1) virus.
Topics: Antiviral Agents; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Kidney; Male; Nephrosis, Lipoid; Oseltamivir; Pandemics; Recurrence; Young Adult | 2012 |
Pharmacokinetic assessment of peramivir in a hospitalized adult undergoing continuous venovenous hemofiltration.
Topics: Acids, Carbocyclic; Acute Kidney Injury; Adolescent; Cyclopentanes; Guanidines; Hemofiltration; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir | 2011 |
Environmental release of oseltamivir from a Norwegian sewage treatment plant during the 2009 influenza A (H1N1) pandemic.
Topics: Chromatography, Liquid; Environmental Monitoring; Epidemiological Monitoring; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Molecular Structure; Norway; Oseltamivir; Pandemics; Sewage; Waste Disposal, Fluid; Water Pollutants, Chemical | 2012 |
Epidemiology and clinical presentation of pandemic influenza A (H1N1) among hospitalized children in Kuwait.
Topics: Anti-Bacterial Agents; Antiviral Agents; Chi-Square Distribution; Child; Child Welfare; Child, Preschool; Female; Hospitalization; Humans; Infant; Infant Welfare; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Kuwait; Male; Oseltamivir; Public Health; Statistics as Topic | 2012 |
Tamiflu-resistant but HA-mediated cell-to-cell transmission through apical membranes of cell-associated influenza viruses.
Topics: Animals; Antibodies, Neutralizing; Base Sequence; Cell Line; Cell Membrane; Cell Polarity; Dogs; Drug Resistance, Viral; HEK293 Cells; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza, Human; Molecular Sequence Data; Movement; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir | 2011 |
Effect of oseltamivir on bleeding risk associated with warfarin therapy: a retrospective review.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Female; Hemorrhage; Hospitals, University; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; International Normalized Ratio; Male; Middle Aged; Oseltamivir; Prothrombin Time; Retrospective Studies; Time Factors; Warfarin | 2012 |
Oseltamivir inhibits H7 influenza virus replication in mice inoculated by the ocular route.
Topics: Animals; Antiviral Agents; Conjunctivitis; Eye; Humans; Influenza A Virus, H7N3 Subtype; Influenza A Virus, H7N7 Subtype; Influenza, Human; Injections, Intraocular; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Viral Proteins; Virus Replication; Vision, Ocular | 2012 |
Oseltamivir and early deterioration leading to death: a proportional mortality study for 2009A/H1N1 influenza.
Topics: Adolescent; Adult; Age Distribution; Aged; Antiviral Agents; Child; Child, Preschool; Death, Sudden; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Middle Aged; Oseltamivir; Young Adult; Zanamivir | 2011 |
Drugs: Lines of defence.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2011 |
Oseltamivir prescription and regulatory actions vis-à-vis abnormal behavior risk in Japan: drug utilization study using a nationwide pharmacy database.
Topics: Adolescent; Adult; Antiviral Agents; Behavior; Child; Child Behavior Disorders; Clinical Pharmacy Information Systems; Databases, Factual; Drug Utilization; Humans; Influenza, Human; Japan; Oseltamivir; Pharmacies; Retrospective Studies; Risk; Risk-Taking; Time Factors; Treatment Outcome | 2011 |
Clinical features of infants hospitalized for 2009 pandemic influenza A (H1N1) in Japan: analysis using a national hospital discharge database.
Topics: Age Factors; Antiviral Agents; Female; Hospitals, Pediatric; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Male; Oseltamivir; Pandemics; Retrospective Studies; Treatment Outcome | 2012 |
Successful treatment of novel H1N1 influenza related fulminant myocarditis with extracorporeal life support.
Topics: Adolescent; Antiviral Agents; Extracorporeal Circulation; Female; Follow-Up Studies; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Myocarditis; Oseltamivir; Polymerase Chain Reaction; RNA, Viral | 2011 |
Persistence of pandemic influenza H1N1 virus in young patients after oseltamivir therapy in the 2009-2010 season: a comparison with seasonal H1N1 with or without H275Y mutation.
Topics: Adolescent; Adult; Antiviral Agents; Child; Drug Resistance, Viral; Female; Fever; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Inhibitory Concentration 50; Japan; Male; Mutation; Oseltamivir; Pandemics; Seasons; Sequence Analysis, DNA; Treatment Outcome; Virus Shedding; Young Adult | 2012 |
Obstetric, clinical, and perinatal implications of H1N1 viral infection during pregnancy.
Topics: Adolescent; Adult; Antiviral Agents; Brazil; Cross-Sectional Studies; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Maternal Mortality; Oseltamivir; Pandemics; Perinatal Mortality; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Treatment Outcome; Young Adult | 2012 |
Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Animals; Antiviral Agents; Cell Line; Cyclopentanes; Dogs; Drug Resistance, Viral; Ferrets; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Inhibitory Concentration 50; Male; Models, Molecular; Mutagenesis, Site-Directed; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Pandemics; Reverse Genetics; Viral Proteins; Virus Replication; Zanamivir | 2012 |
Community transmission of oseltamivir-resistant A(H1N1)pdm09 influenza.
Topics: Community-Acquired Infections; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; New South Wales; Oseltamivir | 2011 |
Influenza A/H1N1 septic shock in a patient with systemic lupus erythematosus. A case report.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Antiviral Agents; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Lupus Erythematosus, Systemic; Middle Aged; Oseltamivir; Radiography, Thoracic; Shock, Septic; Steroids; Tomography, X-Ray Computed; Vasoconstrictor Agents | 2011 |
[Acute respiratory distress syndrome secondary to influenza A (H1N1) infection: a report of a case].
Topics: Adult; Antiviral Agents; Extracorporeal Membrane Oxygenation; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Respiratory Distress Syndrome | 2012 |
Antibody response of healthy children to pandemic A/H1N1/2009 influenza virus.
Topics: Antibodies, Viral; Antibody Formation; Antiviral Agents; Child; Child, Preschool; Cohort Studies; Female; Hemagglutination Inhibition Tests; Hospitalization; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Italy; Male; Oseltamivir; Pandemics; Pneumonia, Viral; Reverse Transcriptase Polymerase Chain Reaction; Severity of Illness Index; Viral Load | 2011 |
Safety and pharmacokinetics of oseltamivir for prophylaxis of neonates exposed to influenza H1N1.
Topics: Antiviral Agents; Chemoprevention; Female; Humans; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir | 2012 |
Pandemic H1N1 influenza infection in children with acute leukemia: a single-center experience.
Topics: Child; Child, Preschool; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Leukemia, Myeloid, Acute; Male; Oseltamivir; Pandemics; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2012 |
Pandemic influenza A(H1N1)2009 in hospital healthcare workers in New Zealand.
Topics: Antiviral Agents; Humans; Infection Control; Influenza A Virus, H1N1 Subtype; Influenza, Human; Medical Staff, Hospital; New Zealand; Oseltamivir; Pandemics; Retrospective Studies; Surveys and Questionnaires | 2012 |
Severe anaemia related to oseltamivir during treatment of chronic hepatitis C: a new drug interaction?
Topics: Adult; Anemia; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Interferon alpha-2; Interferon-alpha; Oseltamivir; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2012 |
Neuraminidase H275Y and hemagglutinin D222G mutations in a fatal case of 2009 pandemic influenza A (H1N1) virus infection.
Topics: Amino Acid Substitution; Antiviral Agents; Bronchoalveolar Lavage Fluid; Drug Resistance, Viral; Fatal Outcome; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Mutation, Missense; Neuraminidase; Oseltamivir; RNA, Viral; Sequence Analysis, DNA; Viral Proteins | 2012 |
Traditional Chinese herbal therapy as a treatment option for H1N1 influenza.
Topics: Antiviral Agents; Drugs, Chinese Herbal; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir | 2012 |
Rethinking credible evidence synthesis.
Topics: Access to Information; Clinical Trials as Topic; Data Mining; Health Policy; Humans; Influenza, Human; Meta-Analysis as Topic; Oseltamivir; Publication Bias; Publishing; Review Literature as Topic | 2012 |
Questions remain over safety and effectiveness of oseltamivir.
Topics: Access to Information; Antiviral Agents; Drug Industry; Humans; Influenza, Human; Meta-Analysis as Topic; Oseltamivir | 2012 |
Search for evidence goes on.
Topics: Access to Information; Antiviral Agents; Bias; Clinical Trials as Topic; Drug Approval; Drug Industry; Europe; Government Regulation; Humans; Influenza, Human; Meta-Analysis as Topic; Oseltamivir; United States; United States Food and Drug Administration | 2012 |
Early detection of pandemic (H1N1) 2009, Bangladesh.
Topics: Adolescent; Adult; Aged; Antigens, Viral; Antiviral Agents; Bangladesh; Child; Child, Preschool; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Middle Aged; Oseltamivir; Pandemics; Time Factors; Young Adult | 2012 |
Mutations I117V and I117M and oseltamivir sensitivity of pandemic (H1N1) 2009 viruses.
Topics: Antiviral Agents; Drug Resistance, Viral; Global Health; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Models, Molecular; Oseltamivir; Pandemics; Protein Conformation | 2012 |
Factors associated with clinical and virological response in patients treated with oseltamivir or zanamivir for influenza A during the 2008-2009 winter.
Topics: Adolescent; Adult; Age Factors; Aged; Anti-Bacterial Agents; Antiviral Agents; Female; Humans; Influenza, Human; Male; Middle Aged; Oseltamivir; Severity of Illness Index; Treatment Outcome; Viral Load; Young Adult; Zanamivir | 2013 |
One-step detection of the 2009 pandemic influenza A(H1N1) virus by the RT-SmartAmp assay and its clinical validation.
Topics: Aged; Child; DNA Primers; Drug Resistance, Viral; Female; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Nucleic Acid Amplification Techniques; Oseltamivir; Pandemics; RNA-Directed DNA Polymerase; RNA, Viral; Time Factors | 2012 |
Pacific region influenza surveillance for oseltamivir resistance.
Topics: Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Hawaii; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutant Proteins; Mutation, Missense; Neuraminidase; Oseltamivir; Pacific Islands; Prevalence; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Viral Proteins | 2012 |
Prognosis of 2009 A(H1N1) influenza in hospitalized pregnant women in a context of early diagnosis and antiviral therapy.
Topics: Adolescent; Adult; Antiviral Agents; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Middle Aged; Oseltamivir; Pandemics; Pregnancy; Pregnancy Complications, Infectious; Spain; Young Adult | 2012 |
Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010-11.
Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Pandemics; Prevalence; United States | 2012 |
[Purulent gonarthritis resulting from H1N1 viral pneumonia].
Topics: Acinetobacter Infections; Adult; Anti-Bacterial Agents; Antiviral Agents; Arthritis, Infectious; Arthroscopy; Diagnosis, Differential; Drug Therapy, Combination; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Osteoarthritis, Knee; Pneumonia, Viral; Streptococcal Infections; Streptococcus pyogenes; Synovitis | 2012 |
H1N1 influenza A virus neuraminidase modulates infectivity in mice.
Topics: Animals; Antiviral Agents; Drug Resistance, Viral; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mice; Mice, Inbred BALB C; Neuraminidase; Oseltamivir; Viral Proteins; Virulence | 2012 |
Analysis of influenza viruses from patients clinically suspected of infection with an oseltamivir resistant virus during the 2009 pandemic in the United States.
Topics: Animals; Antiviral Agents; Cell Line; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation, Missense; Neuraminidase; Oseltamivir; Pandemics; United States; Viral Proteins | 2012 |
Evaluation of pregnancy as a risk factor in the outcomes of influenza A (H1N1)/2009 in women of childbearing age.
Topics: Adolescent; Adult; Age Factors; Antiviral Agents; Brazil; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pandemics; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Pregnant Women; Risk Factors; Young Adult | 2012 |
In-Silico screening of Pleconaril and its novel substituted derivatives with Neuraminidase of H1N1 Influenza strain.
Topics: Amino Acids; Antiviral Agents; Binding Sites; Biocatalysis; Catalytic Domain; Drug Evaluation, Preclinical; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Hydrogen Bonding; Influenza A Virus, H1N1 Subtype; Influenza, Human; Models, Molecular; Molecular Structure; Neuraminidase; Oseltamivir; Oxadiazoles; Oxazoles; Protein Binding; Protein Structure, Tertiary | 2012 |
[Extracorporeal lung support in patients with severe respiratory failure secondary to the 2010-2011 winter seasonal outbreak of influenza A (H1N1) in Spain].
Topics: Acute Kidney Injury; Adult; Antiviral Agents; Disease Outbreaks; Extracorporeal Membrane Oxygenation; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care Units; Length of Stay; Male; Multiple Organ Failure; Oseltamivir; Pneumonia, Viral; Prospective Studies; Renal Replacement Therapy; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Seasons; Shock, Septic; Spain | 2012 |
Clinical experience with severe 2009 H1N1 influenza in the intensive care unit at King Saud Medical City, Saudi Arabia.
Topics: Adolescent; Adult; Aged; Antiviral Agents; APACHE; Child; Child, Preschool; Female; Hospital Mortality; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care Units; Male; Middle Aged; Oseltamivir; Pregnancy; Retrospective Studies; Risk Factors; Saudi Arabia; Young Adult | 2012 |
Impact of extracorporeal membrane oxygenation and continuous venovenous hemodiafiltration on the pharmacokinetics of oseltamivir carboxylate in critically ill patients with pandemic (H1N1) influenza.
Topics: Acute Kidney Injury; Adult; Antiviral Agents; Area Under Curve; Critical Illness; Dose-Response Relationship, Drug; Extracorporeal Membrane Oxygenation; Female; Hemodiafiltration; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Pandemics; Respiratory Distress Syndrome; Young Adult | 2012 |
Virological surveillance and antiviral resistance of human influenza virus in Argentina, 2005-2008.
Topics: Amantadine; Animals; Antiviral Agents; Argentina; Cell Line; Dogs; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza B virus; Influenza, Human; Morbidity; Mutation, Missense; Neuraminidase; Oseltamivir; Point Mutation; Population Surveillance; Seasons; Virus Cultivation; Zanamivir | 2011 |
In vitro neuraminidase inhibitory activities of four neuraminidase inhibitors against influenza viruses isolated in the 2010-2011 season in Japan.
Topics: Acids, Carbocyclic; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Enzyme Inhibitors; Female; Guanidines; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Inhibitory Concentration 50; Japan; Male; Microbial Sensitivity Tests; Middle Aged; Neuraminidase; Oseltamivir; Zanamivir | 2012 |
Adherence to oseltamivir guidelines during influenza pandemic, the Netherlands.
Topics: Adolescent; Adult; Antiviral Agents; Female; Guideline Adherence; Humans; Influenza, Human; Male; Middle Aged; Netherlands; Oseltamivir; Pandemics; Practice Guidelines as Topic; Surveys and Questionnaires; Young Adult | 2012 |
Portable miniaturized extracorporeal membrane oxygenation systems for H1N1-related severe acute respiratory distress syndrome: a case series.
Topics: Adrenal Cortex Hormones; Adult; Antiviral Agents; Comorbidity; Cross Infection; Extracorporeal Membrane Oxygenation; Female; Hemodynamics; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Length of Stay; Male; Middle Aged; Oseltamivir; Point-of-Care Systems; Respiratory Distress Syndrome | 2012 |
[Clinical trials and intensive therapy of the swine flu (H1N1)].
Topics: Administration, Inhalation; Adult; Aged; Bilirubin; Disease Outbreaks; Female; Georgia (Republic); Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care Units; Male; Middle Aged; Oseltamivir; Zanamivir | 2012 |
Influenza in the immediate post-pandemic era: a comparison with seasonal and pandemic influenza in hospitalized patients.
Topics: Adolescent; Adult; Antiviral Agents; Drug Resistance, Viral; Female; Humans; Influenza, Human; Inpatients; Male; Middle Aged; Orthomyxoviridae; Oseltamivir; Pneumonia; Retrospective Studies; Severity of Illness Index; Young Adult | 2012 |
Lack of oseltamivir-resistance in A/H1N1p-infected patients, Singapore.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Female; Genotype; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Mutation, Missense; Oseltamivir; Prevalence; Retrospective Studies; RNA, Viral; Singapore | 2012 |
Pandemic (H1N1) 2009 influenza in Canadian pediatric cancer and hematopoietic stem cell transplant patients.
Topics: Adolescent; Antiviral Agents; Canada; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Hospitals, Pediatric; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neoplasms; Oseltamivir; Retrospective Studies; Time Factors; Treatment Outcome; Virus Shedding | 2012 |
H5N1 avian influenza in children.
Topics: Adolescent; Antiviral Agents; Asia; Azerbaijan; Chi-Square Distribution; Child; Child, Preschool; Egypt; Humans; Infant; Influenza A Virus, H5N1 Subtype; Influenza, Human; Logistic Models; Nigeria; Odds Ratio; Oseltamivir; Risk Factors; Survival Analysis | 2012 |
Oseltamivir adherence and tolerability in health care workers treated prophylactically after occupational influenza exposure.
Topics: Antiviral Agents; Attitude of Health Personnel; Chemoprevention; Drug-Related Side Effects and Adverse Reactions; Female; Health Knowledge, Attitudes, Practice; Health Personnel; Humans; Influenza, Human; Male; Medication Adherence; Oseltamivir; Retrospective Studies; Treatment Outcome | 2012 |
Outcomes in HIV-infected patients admitted due to pandemic influenza.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; Cohort Studies; Comorbidity; Female; HIV Infections; Hospital Mortality; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Inpatients; Intensive Care Units; Length of Stay; Male; Middle Aged; Obesity; Oseltamivir; Pandemics; Respiratory Tract Diseases; Sepsis; Smoking; Spain; Symptom Assessment; Treatment Outcome; Vaccination | 2012 |
Oseltamivir and its active metabolite cross the placenta at significant levels.
Topics: Adult; Antiviral Agents; Chromatography, Liquid; Female; Fetal Blood; Humans; Influenza, Human; Oseltamivir; Placenta; Plasma; Pregnancy; Pregnancy Complications, Infectious; Tandem Mass Spectrometry | 2012 |
Influenza A/H1N1/2009 outbreak in a neonatal intensive care unit.
Topics: Antiviral Agents; Chemoprevention; Cross Infection; Disease Outbreaks; Female; Humans; Infant, Newborn; Infection Control; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care, Neonatal; Male; Oseltamivir; Prospective Studies; Treatment Outcome | 2012 |
Case characteristics and use of oseltamivir in children and household contacts.
Topics: Adolescent; Child; Child, Preschool; Disease Transmission, Infectious; Family Characteristics; Family Health; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Time Factors; Treatment Outcome | 2012 |
Neurologic complications and outcomes of pandemic (H1N1) 2009 in Korean children.
Topics: Antiviral Agents; Child; Child, Preschool; Electroencephalography; Female; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Magnetic Resonance Imaging; Male; Oseltamivir; Pandemics; Republic of Korea; Retrospective Studies; Seizures | 2012 |
Characteristics of hospitalized children with 2009 pandemic influenza A (H1N1): a multicenter study in Korea.
Topics: Adolescent; Antiviral Agents; Child; Child, Hospitalized; Child, Preschool; Critical Illness; Dyspnea; Female; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Lymphopenia; Male; Oseltamivir; Pandemics; Republic of Korea; Retrospective Studies | 2012 |
A cost-effectiveness analysis of "test" versus "treat" patients hospitalized with suspected influenza in Hong Kong.
Topics: Adult; Aged; Antiviral Agents; Cost-Benefit Analysis; Fluorescent Antibody Technique; Hong Kong; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Models, Economic; Monte Carlo Method; Oseltamivir; Outcome Assessment, Health Care; Polymerase Chain Reaction; Prevalence; Quality-Adjusted Life Years; Respiratory Tract Infections | 2012 |
Swine flu encephalitis--first adult case report from India.
Topics: Antiviral Agents; Electroencephalography; Encephalitis, Viral; Humans; India; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Treatment Outcome | 2011 |
Severe 2009 H1N1 infection in early pregnancy.
Topics: Abortion, Induced; Acyclovir; Adult; Antiviral Agents; Disseminated Intravascular Coagulation; Female; Herpes Genitalis; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, First; Valacyclovir; Valine; Young Adult | 2012 |
Clinical characteristics and outcome of patients with pandemic 2009 Influenza A(H1N1)v virus infection admitted to hospitals with different levels of health-care.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Cohort Studies; Comorbidity; Data Collection; Disease Outbreaks; Female; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Length of Stay; Male; Middle Aged; Oseltamivir; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Respiration, Artificial; Risk Factors; Spain; Treatment Outcome; Young Adult | 2012 |
The clinical effectiveness of oseltamivir in mild cases of pandemic influenza A H1N1 2009 infection.
Topics: Adolescent; Adult; Antiviral Agents; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Pandemics; Retrospective Studies | 2012 |
Survey of Japanese infants younger than 3 months who were treated with oseltamivir for influenza: safety of oseltamivir treatment.
Topics: Antiviral Agents; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Oseltamivir; Treatment Outcome | 2012 |
High doses of oseltamivir phosphate induce acute respiratory arrest in anaesthetized rats.
Topics: Animals; Blood Pressure; Dose-Response Relationship, Drug; Humans; Influenza, Human; Male; Oseltamivir; Rats; Rats, Wistar; Respiration; Respiration, Artificial; Respiratory Insufficiency; Respiratory Rate; Vagotomy | 2012 |
The chemiluminescent neuraminidase inhibition assay: a functional method for detection of influenza virus resistance to the neuraminidase inhibitors.
Topics: Antiviral Agents; Biological Assay; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Kinetics; Luminescence; Luminescent Measurements; Neuraminidase; Oseltamivir; Sequence Analysis, RNA; Software; Viral Proteins; Zanamivir | 2012 |
The fluorescence neuraminidase inhibition assay: a functional method for detection of influenza virus resistance to the neuraminidase inhibitors.
Topics: Antiviral Agents; Biological Assay; Drug Resistance, Viral; Enzyme Inhibitors; Fluorescence; Humans; Influenza, Human; Kinetics; Neuraminidase; Orthomyxoviridae; Oseltamivir; Sequence Analysis, RNA; Software; Spectrometry, Fluorescence; Viral Proteins; Zanamivir | 2012 |
Enhanced mammalian transmissibility of seasonal influenza A/H1N1 viruses encoding an oseltamivir-resistant neuraminidase.
Topics: Amino Acid Substitution; Animals; Antiviral Agents; Disease Models, Animal; Drug Resistance, Viral; Female; Guinea Pigs; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Molecular Sequence Data; Mutation, Missense; Neuraminidase; New York; Orthomyxoviridae Infections; Oseltamivir; Reverse Genetics; RNA, Viral; Sequence Analysis, DNA; Viral Proteins | 2012 |
Recovery of influenza B virus with the H273Y point mutation in the neuraminidase active site from a human patient.
Topics: Acids, Carbocyclic; Adult; Antiviral Agents; Catalytic Domain; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza B virus; Influenza, Human; Male; Molecular Sequence Data; Mutation, Missense; Neuraminidase; Oseltamivir; Point Mutation; RNA, Viral; Sequence Analysis, DNA; Zanamivir | 2012 |
Exploring the cause of oseltamivir resistance against mutant H274Y neuraminidase by molecular simulation approach.
Topics: Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Molecular Dynamics Simulation; Mutation, Missense; Neuraminidase; Oseltamivir; Viral Proteins | 2012 |
Trials at the ready: preparing for the next pandemic.
Topics: Antiviral Agents; Clinical Trials as Topic; Disaster Planning; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; International Cooperation; Oseltamivir; Pandemics; Research; Research Support as Topic; Treatment Outcome; United Kingdom | 2012 |
Pandemic (H1N1) 2009 virus infection: prolonged viral shedding and the role of corticosteroids.
Topics: Antiviral Agents; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Virus Shedding | 2012 |
Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia.
Topics: Adolescent; Adult; Antiviral Agents; Australia; Base Sequence; Child; Child, Preschool; Community-Acquired Infections; Disease Outbreaks; DNA, Viral; Drug Resistance, Viral; Female; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Molecular Sequence Data; Mutation; Neuraminidase; Oseltamivir; Phylogeny; Sequence Alignment; Young Adult | 2012 |
Understanding influenza virus resistance to antiviral agents; early warning signs for wider community circulation.
Topics: Antiviral Agents; Disease Outbreaks; Drug Resistance, Viral; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir | 2012 |
Shining a light on trial data.
Topics: Access to Information; Biotechnology; Clinical Trials as Topic; Drug and Narcotic Control; Drug Approval; Drug Industry; Europe; Humans; Influenza, Human; Oseltamivir; United States; United States Food and Drug Administration | 2012 |
Long time scale GPU dynamics reveal the mechanism of drug resistance of the dual mutant I223R/H275Y neuraminidase from H1N1-2009 influenza virus.
Topics: Amino Acid Substitution; Antiviral Agents; Computer Graphics; Computer Simulation; Crystallography, X-Ray; Drug Resistance, Multiple, Viral; Enzyme Inhibitors; History, 21st Century; Humans; Hydrogen Bonding; Influenza A Virus, H1N1 Subtype; Influenza, Human; Models, Molecular; Molecular Dynamics Simulation; Neuraminidase; Oseltamivir; Pandemics; Point Mutation; Protein Conformation; Protein Structure, Secondary; Static Electricity; Zanamivir | 2012 |
Virus load kinetics and resistance development during oseltamivir treatment in infants and children infected with Influenza A(H1N1) 2009 and Influenza B viruses.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Female; Fever; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza B virus; Influenza, Human; Kaplan-Meier Estimate; Male; Oseltamivir; Prospective Studies; Viral Load | 2012 |
Pandemic 2009 influenza A (H1N1) infection among 2009 Hajj Pilgrims from Southern Iran: a real-time RT-PCR-based study.
Topics: Adult; Aged; Antiviral Agents; Crowding; Drug Resistance, Viral; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Iran; Male; Middle Aged; Oseltamivir; Pharynx; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Saudi Arabia; Travel | 2012 |
Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans.
Topics: Adult; Antiviral Agents; Area Under Curve; Carboxylic Ester Hydrolases; Dose-Response Relationship, Drug; Drug Monitoring; Female; Genotype; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Male; Oseltamivir; Polymorphism, Genetic; Prodrugs | 2012 |
Oseltamivir-resistant influenza A(H1N1) 2009 virus in Greece during the post-pandemic 2010-2011 season.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Resistance, Viral; Female; Greece; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Mutation, Missense; Oseltamivir; Real-Time Polymerase Chain Reaction; RNA, Viral; Young Adult | 2012 |
Postexposure prophylaxis for influenza in pediatric wards oseltamivir or zanamivir after rapid antigen detection.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Antigens, Viral; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Health Personnel; Humans; Infant; Influenza, Human; Inpatients; Orthomyxoviridae; Oseltamivir; Young Adult; Zanamivir | 2012 |
Monitoring the susceptibility to oseltamivir of Influenza A(H1N1) 2009 virus by nested-PCR and pyrosequencing during the pandemic and in the season 2010-2011.
Topics: Adolescent; Adult; Amino Acid Substitution; Antiviral Agents; Child; Child, Preschool; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Italy; Microbial Sensitivity Tests; Mutation, Missense; Oseltamivir; Polymerase Chain Reaction; RNA, Viral; Sequence Analysis, DNA | 2012 |
Intrahost emergent dynamics of oseltamivir-resistant virus of pandemic influenza A (H1N1) 2009 in a fatally immunocompromised patient.
Topics: Aged; Amino Acid Sequence; Antiviral Agents; Child; Drug Resistance, Viral; Fatal Outcome; Female; Host-Pathogen Interactions; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Molecular Sequence Data; Mutation; Oseltamivir; Young Adult | 2012 |
High morbidity and mortality associated with an outbreak of influenza A(H3N2) in a psycho-geriatric facility.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Cross Infection; Disease Outbreaks; Female; Humans; Infection Control; Influenza A Virus, H3N2 Subtype; Influenza Vaccines; Influenza, Human; Ireland; Male; Middle Aged; Nursing Homes; Oseltamivir; Vaccination | 2013 |
U.S. utilization patterns of influenza antiviral medications during the 2009 H1N1 influenza pandemic.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Drug Prescriptions; Drug Utilization; Female; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; United States; Young Adult; Zanamivir | 2012 |
[Clinical efficiency in children treated with intravenous drip infusion of peramivir].
Topics: Acids, Carbocyclic; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Guanidines; Humans; Infant; Infant, Newborn; Influenza A virus; Influenza B virus; Influenza, Human; Infusions, Intravenous; Oseltamivir; Retrospective Studies; Time Factors; Treatment Outcome | 2011 |
Comparisons of oseltamivir-resistant (H275Y) and concurrent oseltamivir-susceptible seasonal influenza A(H1N1) virus infections in hospitalized adults, 2008-2009.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Drug Resistance, Viral; Female; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Mutation, Missense; Oseltamivir; Seasons | 2013 |
Persistent oseltamivir-resistant pandemic influenza A/H1N1 infection in an adult with cystic fibrosis.
Topics: Adult; Antiviral Agents; Bronchiectasis; Cystic Fibrosis; Drug Resistance, Viral; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pandemics | 2011 |
[A genetic analysis of A H1N1 pandemic influenza virus in the course of the epidemic].
Topics: Amantadine; Antiviral Agents; Drug Resistance, Viral; Genetic Testing; Genome, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pandemics; Polymorphism, Genetic; Prognosis; Russia | 2012 |
Epidemiology and clinical outcome of H1N1 in Gujarat from July 2009 to March 2010.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Antiviral Agents; Disease Outbreaks; Female; Hospitalization; Hospitals, Private; Hospitals, Public; Humans; Incidence; India; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Retrospective Studies; Severity of Illness Index; Sex Distribution; Treatment Outcome; Young Adult | 2012 |
Airborne transmission of influenza A/H5N1 virus between ferrets.
Topics: Air Microbiology; Amino Acid Substitution; Animals; Antiviral Agents; Containment of Biohazards; Disease Models, Animal; Female; Ferrets; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Immune Sera; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Molecular Sequence Data; Mutagenesis, Site-Directed; Mutation; Orthomyxoviridae Infections; Oseltamivir; Pandemics; Poultry; Reassortant Viruses; Receptors, Virus; Respiratory System; Reverse Genetics; RNA-Dependent RNA Polymerase; Serial Passage; Sialic Acids; Viral Proteins; Virulence; Virus Replication; Virus Shedding | 2012 |
Oseltamivir-resistant 2009 H1N1 influenza pneumonia during therapy in a renal transplant recipient.
Topics: Antiviral Agents; Child; Drug Resistance, Viral; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Kidney Transplantation; Male; Oseltamivir; Pneumonia, Viral; Postoperative Complications | 2012 |
Frequency of oseltamivir resistance in Sydney, during the Newcastle outbreak of community transmitted oseltamivir-resistant influenza A(H1N1)pdm09 virus, Australia, June to August 2011.
Topics: Adult; Antiviral Agents; Australia; Base Sequence; Community-Acquired Infections; Disease Outbreaks; DNA Viruses; Drug Resistance, Viral; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Mutation; Neuraminidase; Oseltamivir; Polymerase Chain Reaction; Prevalence; RNA, Viral; Sequence Analysis, DNA | 2012 |
Co-infections with influenza and other respiratory viruses.
Topics: Adult; Aged; Alphainfluenzavirus; Antiviral Agents; Child, Preschool; Coinfection; Coronavirus; Coronavirus Infections; Female; Humans; Immunocompromised Host; Influenza, Human; Male; Middle Aged; Oseltamivir; Parainfluenza Virus 3, Human; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Respiratory Tract Infections; Respirovirus Infections | 2013 |
Swine flu myocarditis presenting with life threatening ventricular tachycardia.
Topics: Antiviral Agents; Echocardiography; Electric Countershock; Electrocardiography; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Myocarditis; Oseltamivir; Severity of Illness Index; Tachycardia, Ventricular; Treatment Outcome | 2012 |
Duration of viral shedding of influenza A (H1N1) virus infection treated with oseltamivir and/or traditional Chinese medicine in China: a retrospective analysis.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Female; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Medicine, Chinese Traditional; Middle Aged; Oseltamivir; Retrospective Studies; Time Factors; Virus Shedding | 2012 |
Risk factors for mechanical ventilation in U.S. children hospitalized with seasonal influenza and 2009 pandemic influenza A*.
Topics: Antiviral Agents; Child; Child, Preschool; Confidence Intervals; Female; Hospitalization; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Logistic Models; Male; Multivariate Analysis; Odds Ratio; Oseltamivir; Pandemics; Respiration, Artificial; Retrospective Studies; Risk Factors; United States | 2012 |
Increased symptom severity but unchanged neuraminidase inhibitor effectiveness for A(H1N1)pdm09 in the 2010-2011 season: comparison with the previous season and with seasonal A(H3N2) and B.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Enzyme Inhibitors; Female; Fever; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Inhibitory Concentration 50; Male; Middle Aged; Neuraminidase; Oseltamivir; Seasons; Severity of Illness Index; Treatment Outcome; Young Adult; Zanamivir | 2013 |
Determinants of antiviral effectiveness in influenza virus A subtype H5N1.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Female; Humans; Infant; Influenza A Virus, H5N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Respiratory Insufficiency; Secondary Prevention; Survival Analysis; Treatment Outcome; Young Adult | 2012 |
Evaluation of diagnostic and therapeutic approaches for suspected influenza A(H1N1)pdm09 infection, 2009-2010.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Cohort Studies; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Inpatients; Los Angeles; Middle Aged; Oseltamivir; Outpatients; Pandemics; Patient Compliance; Retrospective Studies; Young Adult | 2012 |
Risk factors of severe novel influenza A (H1N1) infections in hospitalized children.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Critical Care; Female; Hospitalization; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Risk Factors; Severity of Illness Index; Taiwan; Treatment Outcome | 2012 |
Five years of non-prescription oseltamivir: effects on resistance, immunization and stockpiling.
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; New Zealand; Oseltamivir; Vaccination | 2012 |
Novel influenza A (H1N1) outbreak at a training institute in the Eastern Province of Saudi Arabia.
Topics: Antiviral Agents; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Saudi Arabia; Students | 2012 |
Documented 2009 H1N1 Influenza A infection in pediatric liver transplant patients--description and follow-up of 7 patients.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Humans; Immunocompromised Host; Immunosuppressive Agents; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Liver Transplantation; Male; Oseltamivir; Retrospective Studies | 2012 |
Presence of oseltamivir-resistant pandemic A/H1N1 minor variants before drug therapy with subsequent selection and transmission.
Topics: Adolescent; Antiviral Agents; Child, Preschool; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Zanamivir | 2012 |
Recurrent plastic bronchitis in a child with 2009 influenza A (H1N1) and influenza B virus infection.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Antiviral Agents; Bronchitis; Bronchoscopy; Child; DNA, Viral; Dyspnea; Humans; Hypersensitivity; Influenza A Virus, H1N1 Subtype; Influenza B virus; Influenza, Human; Male; Oseltamivir; Pulmonary Atelectasis; Real-Time Polymerase Chain Reaction; Tachypnea; Tomography, X-Ray Computed | 2012 |
Oseltamivir-resistant influenza A(H1N1)pdm09 virus in Dutch travellers returning from Spain, August 2012.
Topics: Adolescent; Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Molecular Sequence Data; Mutation; Netherlands; Neuraminidase; Oseltamivir; Sentinel Surveillance; Spain; Travel; Treatment Outcome; Young Adult | 2012 |
Supply of neuraminidase inhibitors related to reduced influenza A (H1N1) mortality during the 2009-2010 H1N1 pandemic: an ecological study.
Topics: Antiviral Agents; Enzyme Inhibitors; Geography; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Pandemics; Poisson Distribution; Regression Analysis; Socioeconomic Factors; World Health Organization; Zanamivir | 2012 |
Paediatric acute generalized exanthematous pustulosis induced by paracetamol with high serum levels of interleukin-8 and -22: a case report.
Topics: Acetaminophen; Acute Generalized Exanthematous Pustulosis; Antipyretics; Antiviral Agents; Biopsy; Drug Eruptions; Enzyme-Linked Immunosorbent Assay; Glucocorticoids; Humans; Influenza, Human; Interleukin-22; Interleukin-8; Interleukins; Male; Oseltamivir; Prednisolone; Skin; Treatment Outcome; Up-Regulation | 2013 |
Epidemiology and clinical characteristics of pandemic (H1N1) 2009 influenza infection in pediatric hemato-oncology and hematopoietic stem cell transplantation patients.
Topics: Adolescent; Antineoplastic Agents; Antiviral Agents; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neoplasms; Oseltamivir; Pandemics; Young Adult | 2012 |
Effect of fever on hospital presentation, diagnosis, and treatment in patients with H1N1/09 influenza.
Topics: Adult; Antiviral Agents; Comorbidity; Female; Fever; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care Units; Male; Middle Aged; Ohio; Oseltamivir; Outcome Assessment, Health Care; Patient Admission; Retrospective Studies; Tertiary Care Centers; Time Factors; United States | 2013 |
H1N1 2009 pandemic influenza virus: resistance of the I223R neuraminidase mutant explained by kinetic and structural analysis.
Topics: Adamantane; Amino Acid Substitution; Antiviral Agents; Binding Sites; Crystallography, X-Ray; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Hydrophobic and Hydrophilic Interactions; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Pandemics; Protein Conformation; Zanamivir | 2012 |
[Neuraminidase inhibitors: effects still unclear].
Topics: Administration, Inhalation; Antiviral Agents; Bias; Conflict of Interest; Double-Blind Method; Drug Industry; Humans; Influenza, Human; Length of Stay; Neuraminidase; Oseltamivir; Publication Bias; Randomized Controlled Trials as Topic; Research Design; Zanamivir | 2012 |
The ongoing battle against influenza: Drug-resistant influenza viruses: why fitness matters.
Topics: Antiviral Agents; Drug Resistance, Viral; Genetic Fitness; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Zanamivir | 2012 |
Molecular mechanisms underlying oseltamivir resistance mediated by an I117V substitution in the neuraminidase of subtype H5N1 avian influenza A viruses.
Topics: Animals; Antiviral Agents; Birds; Drug Resistance, Viral; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Mice; Mice, Inbred BALB C; Molecular Dynamics Simulation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Point Mutation; Poultry; Viral Proteins; Virus Replication | 2013 |
Are neuraminidase inhibitors effective for preventing and treating influenza in healthy adults and children?
Topics: Adult; Child; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir | 2012 |
Severity of influenza A 2009 (H1N1) pneumonia is underestimated by routine prediction rules. Results from a prospective, population-based study.
Topics: Adult; Aged; Anti-Bacterial Agents; Antiviral Agents; Coinfection; Community-Acquired Infections; Comorbidity; Female; Humans; Iceland; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care Units; Length of Stay; Male; Middle Aged; Mycoplasma pneumoniae; Oseltamivir; Pandemics; Patient Admission; Pneumonia, Bacterial; Prospective Studies; Severity of Illness Index; Streptococcus pneumoniae | 2012 |
Two aircraft carriers’ perspectives: a comparative of control measures in shipboard H1N1 outbreaks.
Topics: Adult; Antiviral Agents; Clinical Protocols; Disease Outbreaks; Female; Humans; Infection Control; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Masks; Middle Aged; Military Personnel; Oseltamivir; Quarantine; Ships; Time Factors | 2013 |
Outside-binding site mutations modify the active site's shapes in neuraminidase from influenza A H1N1.
Topics: Amino Acid Sequence; Binding Sites; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Molecular Dynamics Simulation; Mutation; Neuraminidase; Oseltamivir; Sequence Alignment | 2013 |
Synchronous dynamics of observed and predicted values of anti-influenza drugs in environmental waters during a seasonal influenza outbreak.
Topics: Amantadine; Antiviral Agents; Disease Outbreaks; Environmental Monitoring; Humans; Influenza, Human; Japan; Oseltamivir; Rivers; Sewage; Water Pollutants, Chemical; Zanamivir | 2012 |
Oseltamivir storage, distribution and dispensing following the 2009 H1N1 influenza outbreak in Mexico.
Topics: Antiviral Agents; Dosage Forms; Drug Storage; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mexico; Oseltamivir; Pandemics; Strategic Stockpile | 2012 |
Influenza A(H1N1)pdm09: beyond the pandemic.
Topics: Antiviral Agents; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; Pandemics; Prognosis | 2012 |
Delayed emergence of oseltamivir-resistant seasonal influenza A (H1N1) and pandemic influenza A(H1N1)pdm09 viruses in Myanmar.
Topics: Amantadine; Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Myanmar; Oseltamivir; Pandemics; Phylogeny; Seasons | 2013 |
2012-2013 influenza update: hitting a rapidly moving target.
Topics: Antiviral Agents; Drug Resistance, Multiple, Viral; Humans; Influenza A virus; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; Pandemics; Practice Guidelines as Topic | 2012 |
In silico biology of H1N1: molecular modelling of novel receptors and docking studies of inhibitors to reveal new insight in flu treatment.
Topics: Antiviral Agents; Computational Biology; Enzyme Inhibitors; Humans; Hydrogen Bonding; Influenza A Virus, H1N1 Subtype; Influenza, Human; Molecular Docking Simulation; N-Acetylneuraminic Acid; Neuraminidase; Oseltamivir; Receptors, Virus | 2012 |
2009 H1N1 pandemic: still questions to answer!*.
Topics: Antiviral Agents; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Respiration, Artificial | 2012 |
Risk of adverse events following oseltamivir treatment in influenza outpatients, Vaccine Safety Datalink Project, 2007-2010.
Topics: Antiviral Agents; Humans; Influenza Vaccines; Influenza, Human; Mental Disorders; Oseltamivir; Risk | 2013 |
Neuropsychiatric adverse events and oseltamivir for prophylaxis.
Topics: Antiviral Agents; Humans; Influenza, Human; Mental Disorders; Oseltamivir; Randomized Controlled Trials as Topic | 2012 |
Liver transplantation in a patient acutely infected with pandemic influenza A H1N1.
Topics: Graft Survival; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Liver Failure; Liver Transplantation; Male; Middle Aged; Oseltamivir; Postoperative Period; Risk Factors; Vietnam | 2013 |
[Report: complicated influenza A(H1N1) in a second-trimester pregnancy].
Topics: Adult; Antibiotic Prophylaxis; Antiviral Agents; Cesarean Section; Female; Humans; Infant, Extremely Premature; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Pneumonia; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Second; Radiography; Risk Factors | 2012 |
Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation.
Topics: Academic Medical Centers; Adolescent; Adult; Antiviral Agents; Area Under Curve; Critical Illness; Extracorporeal Membrane Oxygenation; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Prospective Studies; Renal Dialysis; Time Factors | 2012 |
Push needed for pandemic planning.
Topics: Antiviral Agents; Disaster Planning; Global Health; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; Pandemics | 2012 |
Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenza.
Topics: Administration, Oral; Drug Resistance, Viral; Female; Humans; Infant; Infant, Newborn; Influenza, Human; Male; Orthomyxoviridae; Oseltamivir | 2013 |
A cluster of patients infected with I221V influenza b virus variants with reduced oseltamivir susceptibility--North Carolina and South Carolina, 2010-2011.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Chi-Square Distribution; Child; Child, Preschool; Cluster Analysis; Female; Humans; Infant; Influenza B virus; Influenza, Human; Male; Middle Aged; Neuraminidase; North Carolina; Oseltamivir; South Carolina; Statistics, Nonparametric; Time Factors; Young Adult | 2013 |
Interaction between oseltamivir and herbal medicines used for treating avian influenza.
Topics: Animals; Antiviral Agents; Carboxylesterase; Cell Death; Cells, Cultured; Drugs, Chinese Herbal; Enzyme Activation; Glutathione; Herb-Drug Interactions; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Lonicera; Oseltamivir; Perilla frutescens; Phytotherapy; Rats | 2012 |
Benign clinical course in H1N1 2009 influenza infection in young oseltamivir-treated immunocompromised patients with kidney disease in Singapore.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Female; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Kidney Diseases; Male; Oseltamivir; Renal Dialysis; Singapore; Time Factors; Treatment Outcome; Virus Shedding; Young Adult | 2013 |
Leukocytoclastic vasculitis associated with influenza A virus infection.
Topics: Anti-Inflammatory Agents; Antiviral Agents; Child, Preschool; Female; Fever; Humans; Influenza A virus; Influenza, Human; Nasopharynx; Oseltamivir; Prednisolone; Reverse Transcriptase Polymerase Chain Reaction; Skin; Vasculitis, Leukocytoclastic, Cutaneous | 2012 |
Rapid detection of the S247N neuraminidase mutation in influenza A(H1N1)pdm09 virus by one-step duplex RT-PCR assay.
Topics: Antiviral Agents; Asia; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Multiplex Polymerase Chain Reaction; Mutant Proteins; Mutation, Missense; Neuraminidase; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction | 2013 |
Neuraminidase inhibitor susceptibility testing of influenza type B viruses in China during 2010 and 2011 identifies viruses with reduced susceptibility to oseltamivir and zanamivir.
Topics: Antiviral Agents; China; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza B virus; Influenza, Human; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Oseltamivir; Zanamivir | 2013 |
Susceptibility of human H3N2 influenza virus to oseltamivir in South Korea, 2009-2011.
Topics: Antiviral Agents; Drug Resistance, Viral; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation; Neuraminidase; Oseltamivir; Republic of Korea; Viral Plaque Assay | 2012 |
Modeling the global transmission of antiviral-resistant influenza viruses.
Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Global Health; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Models, Biological; Neuraminidase; Oseltamivir | 2013 |
Factors promoting the prolonged shedding of the pandemic (H1N1) 2009 influenza virus in patients treated with oseltamivir for 5 days.
Topics: Adult; Antiviral Agents; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Pandemics; Prospective Studies; Republic of Korea; Virus Shedding; Young Adult | 2013 |
Characterization of oseltamivir-resistant influenza A(H1N1)pdm09 viruses in Taiwan in 2009-2011.
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Molecular Sequence Data; Mutation, Missense; Neuraminidase; Oseltamivir; RNA, Viral; Selection, Genetic; Sequence Analysis, DNA; Taiwan; Viral Proteins | 2013 |
Global assessment of resistance to neuraminidase inhibitors, 2008-2011: the Influenza Resistance Information Study (IRIS).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Female; Humans; Infant; Influenza A virus; Influenza, Human; Male; Microbial Sensitivity Tests; Middle Aged; Neuraminidase; Oseltamivir; Prospective Studies; RNA, Viral; Treatment Outcome; Viral Load; Young Adult | 2013 |
Infant outcomes among pregnant women who used oseltamivir for treatment of influenza during the H1N1 epidemic.
Topics: Adult; Antiviral Agents; Apgar Score; Female; Fetal Growth Retardation; Humans; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Premature Birth; Retrospective Studies; Young Adult | 2013 |
Pericardial effusion complicating swine origin influenzae A (H1N1) infection in a 50-year-old woman.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Drug Therapy, Combination; Female; Humans; Ibuprofen; Influenza A Virus, H1N1 Subtype; Influenza, Human; Middle Aged; Oseltamivir; Pericardial Effusion; Treatment Outcome | 2013 |
Pathway Pattern-based prediction of active drug components and gene targets from H1N1 influenza's treatment with maxingshigan-yinqiaosan formula.
Topics: Antiviral Agents; Carboxylic Ester Hydrolases; Data Mining; Drugs, Chinese Herbal; Gene Frequency; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Medicine, Chinese Traditional; Metabolic Networks and Pathways; Molecular Docking Simulation; Molecular Sequence Annotation; Neuraminidase; Oseltamivir; Phenotype; Protein Binding | 2013 |
[Compliance and safety of oseltamivir treatment in children and infants less than one year of age].
Topics: Adolescent; Age Factors; Antiviral Agents; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Infant; Infant, Newborn; Influenza, Human; Male; Medication Adherence; Oseltamivir | 2012 |
Tamiflu: 14 flu seasons and still questions.
Topics: Antiviral Agents; Disease Outbreaks; Evidence-Based Medicine; Humans; Influenza, Human; Oseltamivir; Treatment Outcome | 2013 |
Economic analysis of influenza vaccination and antiviral treatment for healthy working adults.
Topics: Acetamides; Adolescent; Adult; Antiviral Agents; Computer Simulation; Cost of Illness; Cost-Benefit Analysis; Decision Trees; Drug Costs; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Middle Aged; Oseltamivir; Pyrans; Rimantadine; Sensitivity and Specificity; Sialic Acids; Vaccination; Zanamivir | 2002 |
Summaries for patients. Influenza vaccination or antiviral treatment for healthy working adults: an economic analysis.
Topics: Acetamides; Adolescent; Adult; Antiviral Agents; Computer Simulation; Cost of Illness; Cost-Benefit Analysis; Drug Costs; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Middle Aged; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Vaccination; Zanamivir | 2002 |
Current strategies for management of influenza in the elderly population.
Topics: Acetamides; Aged; Aged, 80 and over; Chemoprevention; Complementary Therapies; Cost-Benefit Analysis; Disease Management; Guanidines; Health Services for the Aged; Humans; Influenza, Human; Institutionalization; Oseltamivir; Patient Compliance; Population Surveillance; Prevalence; Pyrans; Rimantadine; Sialic Acids; Vaccination; Zanamivir | 2002 |
Influenza prevention 2002-2003.
Topics: Acetamides; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Guanidines; Headache; Humans; Infant; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; Pregnancy; Pyrans; Sialic Acids; Zanamivir | 2002 |
Cost-effectiveness of newer treatment strategies for influenza.
Topics: Acetamides; Adult; Age Distribution; Aged; Aged, 80 and over; Amantadine; Antiviral Agents; Cost-Benefit Analysis; Decision Trees; Diagnostic Tests, Routine; Drug Costs; Female; Guanidines; Humans; Influenza, Human; Male; Middle Aged; Monte Carlo Method; Neuraminidase; Oseltamivir; Pennsylvania; Pyrans; Quality-Adjusted Life Years; Sialic Acids; Zanamivir | 2002 |
[Neuraminidase inhibitor permitted. The first pill against influenza].
Topics: Acetamides; Administration, Inhalation; Administration, Oral; Aged; Antiviral Agents; Child; Child, Preschool; Guanidines; Humans; Infant; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Time Factors; Zanamivir | 2002 |
Early administration of oral oseltamivir increases the benefits of influenza treatment.
Topics: Acetamides; Administration, Oral; Adolescent; Adult; Aged; Animals; Antiviral Agents; Cell Line; Child; Confidence Intervals; Dogs; Drug Administration Schedule; Female; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Internationality; Male; Middle Aged; Oseltamivir; Prospective Studies | 2003 |
[Effectiveness of oseltamivir treatment against influenza type A and type B infection in children].
Topics: Acetamides; Alphainfluenzavirus; Antiviral Agents; Betainfluenzavirus; Child; Child, Preschool; Disease Outbreaks; Humans; Influenza, Human; Oseltamivir | 2002 |
[New diagnostic possibilities and medications. Fit for influenza?].
Topics: Acetamides; Administration, Inhalation; Administration, Oral; Aged; Antiviral Agents; Child; Enzyme Inhibitors; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Time Factors; Zanamivir | 2002 |
Logistic issues and potential prescribing costs associated with use of neuraminidase inhibitors for the treatment of influenza in primary care.
Topics: Acetamides; Adolescent; Adult; Aged; Antiviral Agents; Child; Family Practice; Guanidines; Humans; Influenza, Human; Middle Aged; Neuraminidase; Oseltamivir; Patient Acceptance of Health Care; Pyrans; Sialic Acids; State Medicine; United Kingdom; Zanamivir | 2003 |
[Oral neuraminidase inhibitor and an early warning system. New weapons against influenza].
Topics: Acetamides; Adult; Aged; Antiviral Agents; Female; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Pyrans; Sentinel Surveillance; Sialic Acids; Zanamivir | 2003 |
[Influenza or flu-like infection? Diagnosis has consequences for therapy].
Topics: Acetamides; Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Humans; Infant; Influenza, Human; Neuraminidase; Orthomyxoviridae; Oseltamivir; Treatment Outcome | 2003 |
Low mortality rates related to respiratory virus infections after bone marrow transplantation.
Topics: Acetamides; Aerosols; Antigens, Viral; Antiviral Agents; Bone Marrow Transplantation; Fluorescent Antibody Technique, Indirect; Hematologic Neoplasms; Humans; Influenza, Human; Oseltamivir; Paramyxoviridae Infections; Postoperative Complications; Respirovirus Infections; Ribavirin; Transplantation, Autologous; Transplantation, Homologous; Virus Shedding | 2003 |
Infectious diseases. Avian flu outbreak sets off alarm bells.
Topics: Acetamides; Animals; Antiviral Agents; Chickens; Conjunctivitis, Viral; Disease Outbreaks; Humans; Influenza A virus; Influenza in Birds; Influenza Vaccines; Influenza, Human; Netherlands; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Recombination, Genetic; Swine; Vaccination | 2003 |
We need to determine who benefits most from flu treatments.
Topics: Acetamides; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2003 |
[Effectiveness of oseltamivir on influenza and influencing factors: age of patients, type of influenza virus and timing of initial administration].
Topics: Acetamides; Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Enzyme Inhibitors; Female; Humans; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Time Factors | 2003 |
Quantification of the influenza virus load by real-time polymerase chain reaction in nasopharyngeal swabs of patients treated with oseltamivir.
Topics: Acetamides; Adolescent; Adult; Aged; Female; Humans; Influenza A virus; Influenza, Human; Male; Middle Aged; Nasopharynx; Oseltamivir; Polymerase Chain Reaction; Viral Load | 2003 |
Too early cure of influenza: recurrence in oseltamivir-treated children.
Topics: Acetamides; Child, Preschool; Female; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Recurrence | 2003 |
Management of influenza in adults older than 65 years of age: cost-effectiveness of rapid testing and antiviral therapy.
Topics: Acetamides; Aged; Amantadine; Antiviral Agents; Computer Simulation; Cost-Benefit Analysis; Decision Support Techniques; Guanidines; Humans; Influenza, Human; Oseltamivir; Pyrans; Quality-Adjusted Life Years; Rimantadine; Sensitivity and Specificity; Sialic Acids; Zanamivir | 2003 |
Summaries for patients. Cost-effective management of flu in adults older than 65 years of age.
Topics: Acetamides; Aged; Amantadine; Antiviral Agents; Computer Simulation; Cost-Benefit Analysis; Decision Support Techniques; Guanidines; Humans; Influenza, Human; Oseltamivir; Pyrans; Quality-Adjusted Life Years; Rimantadine; Sensitivity and Specificity; Sialic Acids; Zanamivir | 2003 |
Neuraminidase inhibitors slightly beneficial for shortening flu symptoms.
Topics: Acetamides; Adolescent; Adult; Aged; Antiviral Agents; Child; Double-Blind Method; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Middle Aged; Neuraminidase; Oseltamivir; Pyrans; Randomized Controlled Trials as Topic; Sialic Acids; Time Factors; Treatment Outcome; Zanamivir | 2003 |
[Benign common cold or real influenza? Deciding without laboratory tests!].
Topics: Acetamides; Adult; Antiviral Agents; Child; Common Cold; Disease Outbreaks; Humans; Influenza, Human; Neuraminidase; Oseltamivir | 2002 |
[English meta-analysis on zanamivir and oseltamivir. Knowledge of effects of influenza agents still not sufficient].
Topics: Acetamides; Antiviral Agents; Guanidines; Humans; Influenza, Human; Meta-Analysis as Topic; Oseltamivir; Practice Guidelines as Topic; Pyrans; Sialic Acids; Treatment Outcome; Zanamivir | 2003 |
Oseltamivir (Tamiflu) unsafe in infants under 1 year old.
Topics: Acetamides; Animals; Antiviral Agents; Blood-Brain Barrier; Drug-Related Side Effects and Adverse Reactions; Humans; Infant; Infant, Newborn; Influenza, Human; Oseltamivir; Rats; Treatment Outcome | 2004 |
Fear of human pandemic grows as bird flu sweeps through Asia.
Topics: Acetamides; Animals; Antiviral Agents; Chickens; Disease Outbreaks; Global Health; Humans; Influenza Vaccines; Influenza, Human; Internationality; Orthomyxoviridae; Oseltamivir; Public Health; Vietnam; World Health Organization; Zoonoses | 2004 |
Flu antiviral contraindicated in infants.
Topics: Acetamides; Animals; Antiviral Agents; Contraindications; Humans; Infant; Influenza, Human; Oseltamivir; Rats | 2004 |
[Pharmacoeconomic evaluation of oseltamivir as prophylaxis against influenza infection].
Topics: Acetamides; Antiviral Agents; Cost-Benefit Analysis; Enzyme Inhibitors; Humans; Influenza, Human; Models, Statistical; Neuraminidase; Oseltamivir; Premedication | 2004 |
[Highly selective virostatic therapy. Influenza wave could have been stopped].
Topics: Acetamides; Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytokines; Endothelium, Vascular; Enzyme Inhibitors; Fibrinogen; Germany; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Placebos; Time Factors; Treatment Outcome | 2003 |
[Effect of post-exposure prophylaxis with oseltamivir for those in contacts with influenza patients in pediatric wards].
Topics: Acetamides; Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Cross Infection; Disease Outbreaks; Enzyme Inhibitors; Female; Hospital Departments; Humans; Infant; Influenza, Human; Male; Oseltamivir; Pediatrics | 2004 |
Skin reactions in patients with influenza treated with oseltamivir: a retrospective cohort study.
Topics: Acetamides; Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Cohort Studies; Databases, Factual; Female; Health Services; Humans; Incidence; Infant; Influenza, Human; Insurance Claim Review; Male; Middle Aged; Oseltamivir; Retrospective Studies; Skin Diseases | 2004 |
A novel means of identifying the neuraminidase type of currently circulating human A(H1) influenza viruses.
Topics: Acetamides; Antiviral Agents; Fluorescence; Guanidines; Humans; Influenza A virus; Influenza, Human; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Virology; Zanamivir | 2004 |
Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons.
Topics: Acetamides; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Luminescent Measurements; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Population Surveillance; Pyrans; Sialic Acids; Zanamivir | 2004 |
Influenza outbreaks in aged-care facilities: staff vaccination and the emerging use of antiviral therapy.
Topics: Acetamides; Adult; Aged; Aged, 80 and over; Amantadine; Antiviral Agents; Disease Outbreaks; Female; Guanidines; Homes for the Aged; Humans; Infection Control; Infectious Disease Transmission, Patient-to-Professional; Influenza A virus; Influenza, Human; Middle Aged; Oseltamivir; Pyrans; Sialic Acids; Vaccination; Victoria; Zanamivir | 2004 |
Health outcomes among patients receiving oseltamivir.
Topics: Acetamides; Adult; Aged; Antiviral Agents; Cardiovascular Diseases; Female; Humans; Influenza, Human; Male; Mental Disorders; Middle Aged; Oseltamivir; Respiratory Tract Diseases | 2004 |
Implications of the incidence of influenza-like illness in nursing homes for influenza chemoprophylaxis: descriptive study.
Topics: Acetamides; Aged; Antiviral Agents; Cross Infection; Female; Guideline Adherence; Homes for the Aged; Humans; Incidence; Influenza, Human; Male; Nursing Homes; Oseltamivir; Practice Guidelines as Topic | 2004 |
Detection and control of influenza outbreaks in well-vaccinated nursing home populations.
Topics: Acetamides; Aged; Antiviral Agents; Diagnostic Techniques and Procedures; Disease Outbreaks; Homes for the Aged; Humans; Immunization Programs; Influenza A virus; Influenza B virus; Influenza, Human; Michigan; Nursing Homes; Observation; Oseltamivir; Population Surveillance; Seasons; Sensitivity and Specificity | 2004 |
Antiviral treatment and prophylaxis of influenza in primary care: German recommendations.
Topics: Acetamides; Amantadine; Antiviral Agents; Drug Resistance, Viral; Germany; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Oseltamivir; Primary Health Care; Pyrans; Sialic Acids; Zanamivir | 2004 |
Avian influenza should be ruffling our feathers.
Topics: Acetamides; Amantadine; Animals; Antiviral Agents; Asia, Eastern; Asia, Southeastern; Birds; Disease Outbreaks; Guanidines; Humans; Influenza in Birds; Influenza Vaccines; Influenza, Human; International Cooperation; Neuraminidase; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; World Health Organization; Zanamivir | 2004 |
From the Great Barrier Reef to a "cure" for the flu: tall tales, but true.
Topics: Acetamides; Antiviral Agents; Australia; Biomedical Research; History, 20th Century; Humans; Influenza, Human; Oseltamivir | 2004 |
Biocontainment. 1918 flu experiments spark concerns about biosafety.
Topics: Acetamides; Animals; Antiviral Agents; Containment of Biohazards; Genetic Engineering; Guidelines as Topic; Humans; Influenza A virus; Influenza Vaccines; Influenza, Human; Mice; Oseltamivir; United States | 2004 |
Surveillance for neuraminidase inhibitor resistance in human influenza viruses from Australia.
Topics: Acetamides; Antiviral Agents; Australia; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Population Surveillance; Pyrans; Sialic Acids; Zanamivir | 2003 |
Prevention of influenza in the general population: recommendation statement from the Canadian Task Force on Preventive Health Care.
Topics: Acetamides; Aged; Canada; Guanidines; Health Policy; Humans; Infant; Influenza Vaccines; Influenza, Human; Middle Aged; Neuraminidase; Oseltamivir; Preventive Medicine; Public Health; Pyrans; Risk Factors; Sialic Acids; Zanamivir | 2004 |
Antiviral prophylaxis in the management of an influenza outbreak in an aged care facility.
Topics: Acetamides; Adult; Aged; Aged, 80 and over; Antiviral Agents; Disease Outbreaks; Female; Health Personnel; Humans; Infection Control; Influenza A virus; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Nursing Homes; Oseltamivir | 2004 |
Cooperative anti-influenza activities of respiratory innate immune proteins and neuraminidase inhibitor.
Topics: Acetamides; Animals; Antiviral Agents; Chick Embryo; Chickens; CHO Cells; Cricetinae; Hemagglutinins; Humans; Influenza A virus; Influenza, Human; Mucins; N-Acetylneuraminic Acid; Neuraminidase; Oseltamivir; Pulmonary Surfactant-Associated Protein A; Pulmonary Surfactant-Associated Protein D; Receptors, Immunologic | 2005 |
[Current indications for levamisole].
Topics: Acetamides; Adjuvants, Immunologic; Antiviral Agents; Drug Administration Schedule; Humans; Influenza, Human; Levamisole; Oseltamivir; Time Factors | 2004 |
Avian flu. Mild illnesses confound researchers.
Topics: Acetamides; Agricultural Workers' Diseases; Antibodies, Viral; Antiviral Agents; Disease Outbreaks; Humans; Influenza A virus; Influenza, Human; Japan; Oseltamivir; Protective Clothing | 2005 |
The threat of an avian influenza pandemic.
Topics: Acetamides; Animals; Antiviral Agents; Birds; Disease Outbreaks; Disease Transmission, Infectious; Genome, Viral; Humans; Influenza A virus; Influenza in Birds; Influenza, Human; Neuraminidase; Oseltamivir; Virulence; Zoonoses | 2005 |
[Control of hospital infection of influenza: administration of neuraminidase inhibitor and cohort isolation of influenza patients].
Topics: Acetamides; Aged; Antiviral Agents; Cross Infection; Disease Outbreaks; Female; Humans; Influenza, Human; Male; Neuraminidase; Oseltamivir; Patient Isolation | 2004 |
Pharmacoeconomic assessment of oseltamivir in treating influenza--the case of otherwise healthy Danish adolescents and adults.
Topics: Acetamides; Adolescent; Adult; Antiviral Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Denmark; Female; Humans; Influenza, Human; Male; Middle Aged; Models, Economic; Monte Carlo Method; Multivariate Analysis; Oseltamivir; Quality-Adjusted Life Years; Time Factors; Treatment Outcome | 2004 |
Acute pancreatitis with Kawasaki disease: analysis of cases with elevated serum amylase levels.
Topics: Acetamides; Acute Disease; Amylases; Antiviral Agents; Humans; Infant; Influenza A virus; Influenza, Human; Male; Mucocutaneous Lymph Node Syndrome; Oseltamivir; Pancreatitis; Retrospective Studies | 2005 |
Economic evaluation of oseltamivir phosphate for postexposure prophylaxis of influenza in long-term care facilities.
Topics: Acetamides; Aged; Amantadine; Antiviral Agents; Canada; Cost-Benefit Analysis; Decision Support Techniques; Disease Outbreaks; Humans; Influenza, Human; Long-Term Care; Models, Economic; Nursing Homes; Oseltamivir | 2005 |
UK stocks up on antiviral drug to tackle flu outbreak.
Topics: Acetamides; Antiviral Agents; Disease Outbreaks; Drug Storage; Humans; Influenza, Human; Oseltamivir; United Kingdom | 2005 |
Avian influenzavirus: are we prepared?
Topics: Acetamides; Animal Husbandry; Animals; Antiviral Agents; Asia, Southeastern; Birds; Chickens; Disease Outbreaks; Disease Transmission, Infectious; Humans; Influenza A virus; Influenza, Human; Oseltamivir | 2005 |
Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002-2003 influenza season.
Topics: Acetamides; Adolescent; Adult; Aged; Aging; Amantadine; Antiviral Agents; Child; Child, Preschool; Female; Humans; Infant; Influenza A virus; Influenza B virus; Influenza Vaccines; Influenza, Human; Japan; Male; Middle Aged; Oseltamivir; Sex Characteristics | 2005 |
Influenza drug could abort a pandemic.
Topics: Acetamides; Animals; Birds; Diagnostic Tests, Routine; Humans; Influenza Vaccines; Influenza, Human; Nonprescription Drugs; Oseltamivir | 2005 |
Influenza treatment with neuraminidase inhibitors: cost-effectiveness and cost-utility in healthy adults in the United Kingdom.
Topics: Acetamides; Adolescent; Adult; Antiviral Agents; Cost-Benefit Analysis; Decision Support Techniques; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Middle Aged; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; United Kingdom; Zanamivir | 2005 |
[Early prevention of influenza].
Topics: Acetamides; Animals; Birds; Disease Outbreaks; Early Diagnosis; Global Health; Humans; Influenza A virus; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; Risk Factors; Virulence; World Health Organization | 2005 |
Avian flu special: what's in the medicine cabinet?
Topics: Acetamides; Animals; Antiviral Agents; Guanidines; Humans; Influenza, Human; Internationality; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pyrans; Sialic Acids; World Health Organization; Zanamivir | 2005 |
Use of influenza antivirals during 2003-2004 and monitoring of neuraminidase inhibitor resistance.
Topics: Acetamides; Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir | 2005 |
Infectious diseases. Genetic analyses suggest bird flu virus is evolving.
Topics: Acetamides; Animals; Antiviral Agents; Asia; Disease Outbreaks; Drug Resistance, Viral; Evolution, Molecular; Genes, Viral; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Infant; Influenza A virus; Influenza in Birds; Influenza, Human; Oseltamivir; Poultry; Vietnam | 2005 |
Experience with oseltamivir for infants younger than 1 year old in Japan.
Topics: Acetamides; Antiviral Agents; Humans; Infant; Infant, Newborn; Influenza, Human; Neurotoxicity Syndromes; Oseltamivir | 2005 |
Statement on influenza vaccination for the 2005-2006 season. An advisory committee statement.
Topics: Acetamides; Adolescent; Age Factors; Amantadine; Animals; Antiviral Agents; Canada; Child; Child, Preschool; Female; Health Personnel; Humans; Infant; Influenza A virus; Influenza B virus; Influenza in Birds; Influenza Vaccines; Influenza, Human; Male; Oseltamivir; Poultry; Pregnancy; Risk Factors; Time Factors | 2005 |
Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir.
Topics: Acetamides; Adult; Anti-Bacterial Agents; Antiviral Agents; Female; Hospitalization; Humans; Influenza, Human; Insurance Claim Review; Male; Middle Aged; Oseltamivir; Pneumonia; Proportional Hazards Models; Retrospective Studies; Risk Factors | 2005 |
Flu pills for a pandemic threat.
Topics: Acetamides; Animals; Antiviral Agents; Humans; Influenza, Human; Oseltamivir | 2005 |
[The threatening influenza pandemic: a national store of oseltamivir is necessary].
Topics: Acetamides; Antiviral Agents; Disaster Planning; Disease Outbreaks; Humans; Influenza, Human; Netherlands; Oseltamivir; Public Health | 2005 |
[The threatening influenza pandemic: a national store ofoseltamivir is a waste of money].
Topics: Acetamides; Antiviral Agents; Disaster Planning; Disease Outbreaks; Drug Costs; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza, Human; Netherlands; Oseltamivir; Public Health | 2005 |
Epidemiology. Drugs, quarantine might stop a pandemic before it starts.
Topics: Acetamides; Antiviral Agents; Computer Simulation; Disease Outbreaks; Global Health; Humans; Influenza, Human; Models, Biological; Oseltamivir; Thailand | 2005 |
Epidemiology. A drug makes it big-but can it deliver?
Topics: Acetamides; Disease Outbreaks; Global Health; Humans; Influenza, Human; Oseltamivir; Patient Selection | 2005 |
Oseltamivir phosphate in infants under 1 year of age with influenza infection.
Topics: Acetamides; Antiviral Agents; Humans; Infant; Influenza, Human; Oseltamivir | 2005 |
Cost-benefit of stockpiling drugs for influenza pandemic.
Topics: Acetamides; Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Cost-Benefit Analysis; Disease Outbreaks; Humans; Infant; Influenza, Human; Israel; Middle Aged; Models, Biological; Models, Economic; Oseltamivir; World Health Organization | 2005 |
WHO urges regional offices to stockpile flu drug for staff.
Topics: Acetamides; Antiviral Agents; Humans; Influenza, Human; Internationality; Masks; Oseltamivir; World Health Organization | 2005 |
Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice.
Topics: Acetamides; Enzyme Inhibitors; France; Guanidines; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2005 |
"Unrealistic" to share North American antiviral supply.
Topics: Acetamides; Animals; Antiviral Agents; Birds; Canada; Disease Outbreaks; Drug Storage; Humans; Influenza in Birds; Influenza, Human; International Cooperation; Oseltamivir; United States | 2005 |
[Private hoarding of influenza medications].
Topics: Acetamides; Antiviral Agents; Humans; Influenza, Human; Norway; Oseltamivir | 2005 |
[Bird flu, this new menace that glides in our skies].
Topics: Acetamides; Animals; Antiviral Agents; Birds; Disease Outbreaks; Humans; Influenza A virus; Influenza in Birds; Influenza, Human; Oseltamivir | 2005 |
From rhetoric to reality.
Topics: Acetamides; Cooperative Behavior; Drug Industry; Federal Government; Humans; Influenza A virus; Influenza Vaccines; Influenza, Human; Internationality; Oseltamivir; Patents as Topic; United States; World Health Organization | 2005 |
Avian flu: isolation of drug-resistant H5N1 virus.
Topics: Acetamides; Adolescent; Adult; DNA Mutational Analysis; Drug Resistance, Viral; Female; Ferrets; Guanidines; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A virus; Influenza A Virus, H5N1 Subtype; Influenza, Human; Inhibitory Concentration 50; Mutation; Neuraminidase; Oseltamivir; Polymerase Chain Reaction; Pyrans; Sialic Acids; Zanamivir | 2005 |
[Awaiting a pandemic].
Topics: Acetamides; Animals; Antiviral Agents; Communicable Diseases, Emerging; Disease Outbreaks; Humans; Influenza A virus; Influenza, Human; Oseltamivir | 2005 |
Avian influenza. Europe scrambles to control deadly H5N1 Strain.
Topics: Acetamides; Animals; Antiviral Agents; Birds; Disease Outbreaks; Europe; Humans; Influenza A virus; Influenza in Birds; Influenza, Human; International Cooperation; Oseltamivir; Poultry | 2005 |
Use of antiviral agents and other measures in an influenza pandemic.
Topics: Acetamides; Antiviral Agents; Disease Outbreaks; Guanidines; Humans; Influenza A virus; Influenza, Human; Netherlands; Neuraminidase; Oseltamivir; Practice Guidelines as Topic; Pyrans; Risk; Sialic Acids; Zanamivir | 2005 |
[Oseltamivir resistant influenza in children].
Topics: Acetamides; Antiviral Agents; Child; Drug Resistance, Viral; Humans; Influenza A virus; Influenza, Human; Oseltamivir | 2005 |
[Bird flu, this new menace that glides in our skies (4)].
Topics: Acetamides; Antiviral Agents; Communicable Diseases, Emerging; Disease Outbreaks; Humans; Influenza A virus; Influenza, Human; Oseltamivir | 2005 |
Roche considers licensing companies to make oseltamivir.
Topics: Acetamides; Antiviral Agents; Drug Industry; Drugs, Generic; Humans; Influenza, Human; Licensure; Oseltamivir | 2005 |
Wartime tactic doubles power of scarce bird-flu drug.
Topics: Acetamides; Drug Combinations; Drug Industry; Humans; Influenza, Human; Oseltamivir; Probenecid; World Health Organization | 2005 |
Influenza. Meeting seeks global consensus, highlights global disparities.
Topics: Acetamides; Animals; Antiviral Agents; Birds; Disease Outbreaks; Health Planning; Health Services Accessibility; Humans; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; International Cooperation; Oseltamivir; World Health Organization | 2005 |
Preparing for the worst-case scenario.
Topics: Acetamides; Antiviral Agents; Developing Countries; Disease Outbreaks; Health Planning; Humans; Influenza, Human; Models, Biological; Models, Statistical; Oseltamivir; Public Health | 2005 |
Stockpiling oseltamivir: Roche clarifies data for improved mortality with oseltamivir.
Topics: Acetamides; Antiviral Agents; Drug Storage; Humans; Influenza, Human; Oseltamivir | 2005 |
Stockpiling oseltamivir: what is the number needed to treat with oseltamivir to prevent one flu death?
Topics: Acetamides; Antiviral Agents; Drug Storage; Humans; Influenza, Human; Oseltamivir; United Kingdom | 2005 |
[Bird flu: too much ado about it?].
Topics: Acetamides; Animals; Antiviral Agents; Birds; Disease Outbreaks; Humans; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; International Cooperation; Mutation; Oseltamivir | 2005 |
Preparing for pandemic influenza: should hospitals stockpile oseltamivir?
Topics: Acetamides; Antiviral Agents; Disaster Planning; Disease Outbreaks; Hospitals; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Oseltamivir | 2005 |
Influenza pandemic preparedness: can we handle the truth?
Topics: Acetamides; Antiviral Agents; Communicable Disease Control; Disease Outbreaks; Humans; Influenza A virus; Influenza Vaccines; Influenza, Human; Oseltamivir; Primary Prevention; United States | 2005 |
[Tamiflu: 300 million treatments will be produced in the next few months].
Topics: Acetamides; Antiviral Agents; Drug Industry; Humans; Influenza, Human; Oseltamivir; Time Factors | 2005 |
[Influenza prevention in your practice (interview by Waldtraud Paukstadt)].
Topics: Acetamides; Adult; Antiviral Agents; Child; Child, Preschool; Disease Outbreaks; Drug Resistance, Viral; Guanidines; Humans; Infant; Influenza Vaccines; Influenza, Human; Oseltamivir; Pyrans; Sialic Acids; Treatment Outcome; Zanamivir | 2005 |
[Oseltamivir].
Topics: Acetamides; Antiviral Agents; Humans; Influenza, Human; Oseltamivir | 2005 |
Hong Kong battens down the hatches.
Topics: Acetamides; Animals; Antiviral Agents; Asia, Southeastern; Birds; Disaster Planning; Disease Outbreaks; Hong Kong; Humans; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Oseltamivir | 2005 |
Star role for bacteria in controlling flu pandemic?
Topics: Acetamides; Animals; Antiviral Agents; Birds; Chemistry, Pharmaceutical; Disease Outbreaks; Drugs, Generic; Escherichia coli; Genetic Engineering; Global Health; Guanidines; Humans; Illicium; Influenza in Birds; Influenza, Human; Oseltamivir; Pyrans; Shikimic Acid; Sialic Acids; Technology, Pharmaceutical; Zanamivir | 2005 |
Oseltamivir resistance--disabling our influenza defenses.
Topics: Acetamides; Binding Sites; Child; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Pyrans; Self Administration; Sialic Acids; Zanamivir | 2005 |
The run on tamiflu--should physicians prescribe on demand?
Topics: Acetamides; Drug Prescriptions; Drug Resistance, Viral; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Physician's Role; Practice Patterns, Physicians' | 2005 |
Oseltamivir resistance during treatment of influenza A (H5N1) infection.
Topics: Acetamides; Adolescent; Adult; Amino Acid Substitution; Antiviral Agents; Base Sequence; Child; Drug Resistance, Viral; Fatal Outcome; Female; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Lung; Male; Neuraminidase; Oseltamivir; Pneumonia, Viral; Radiography; Sequence Analysis, DNA; Viral Load | 2005 |
[Neuraminidase inhibitors and their potential use in the avian influenza pandemic].
Topics: Acetamides; Antiviral Agents; Disease Outbreaks; Enzyme Inhibitors; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir | 2005 |
Boston hospital drill tests pandemic flu readiness.
Topics: Acetamides; Antiviral Agents; Boston; Disaster Planning; Disease Outbreaks; Ethics, Clinical; Health Care Rationing; Hospitals, University; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Intensive Care Units; Oseltamivir; Problem-Based Learning | 2006 |
[Tam-tam and Tamiflu].
Topics: Acetamides; Antiviral Agents; Disease Outbreaks; Europe; Humans; Influenza, Human; Oseltamivir | 2005 |
Uncertainty still surrounds oseltamivir after 13 year old dies.
Topics: Acetamides; Adolescent; Antiviral Agents; Drug Resistance, Viral; Fatal Outcome; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Oseltamivir; Viral Load | 2006 |
Avian influenza. WHO proposes plan to stop pandemic in its tracks.
Topics: Acetamides; Antiviral Agents; Communicable Disease Control; Developing Countries; Disease Outbreaks; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; International Cooperation; Oseltamivir; Quarantine; World Health Organization | 2006 |
Bird flu redux.
Topics: Acetamides; Animals; Antiviral Agents; Birds; Disease Outbreaks; Health Policy; Humans; Influenza A virus; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza Vaccines; Influenza, Human; Oseltamivir; World Health Organization | 2005 |
Review says oseltamivir and zanamivir should be kept for epidemics of flu.
Topics: Acetamides; Antiviral Agents; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2006 |
[When the Avian virus (H5N1) become resistant to Tamiflu and the resulting consequences].
Topics: Acetamides; Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Oseltamivir | 2006 |
Molecule of the month: oseltamivir phosphate (Tamiflu).
Topics: Acetamides; Animals; Antiviral Agents; Birds; Humans; Influenza, Human; Mutation; Orthomyxoviridae; Oseltamivir | 2005 |
Influenza, Winter Olympiad, 2002.
Topics: Acetamides; Adolescent; Adult; Aged; Antiviral Agents; Disease Outbreaks; Female; Humans; Influenza, Human; Male; Middle Aged; Oseltamivir; Seasons; Sports; Utah | 2006 |
Probenecid with oseltamivir for human influenza A (H5N1) virus infection?
Topics: Acetamides; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Oseltamivir; Probenecid | 2006 |
Companies face ethical issues over Tamiflu.
Topics: Acetamides; Antiviral Agents; Asia; Disaster Planning; Disease Outbreaks; Drug Storage; Humans; Industry; Influenza A Virus, H5N1 Subtype; Influenza, Human; Oseltamivir; Social Responsibility | 2006 |
[Procedure in V.a. influenza].
Topics: Acetamides; Adolescent; Ambulatory Care; Antiviral Agents; Cytokines; Humans; Influenza B virus; Influenza, Human; Male; Neuraminidase; Oseltamivir; Treatment Outcome; Virus Replication | 2006 |
Influenza-associated deaths among children.
Topics: Acetamides; Adamantane; Antiviral Agents; Child; Humans; Influenza, Human; Oseltamivir; United States | 2006 |
Oseltamivir resistance in influenza A (H5N1) infection.
Topics: Acetamides; Administration, Inhalation; Administration, Oral; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanidines; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2006 |
Method for estimating the order of influenza infection between adults and children.
Topics: Acetamides; Adult; Antiviral Agents; Child; Data Interpretation, Statistical; Dosage Forms; Drug Prescriptions; Humans; Influenza, Human; Japan; Oseltamivir; Time Factors | 2006 |
Post-exposure influenza prophylaxis with oseltamivir: cost effectiveness and cost utility in families in the UK.
Topics: Acetamides; Adolescent; Adult; Antiviral Agents; Case-Control Studies; Clinical Trials as Topic; Computer Simulation; Cost-Benefit Analysis; Family; Health Care Costs; Humans; Influenza, Human; Insurance, Health, Reimbursement; Middle Aged; Models, Economic; Oseltamivir; United Kingdom | 2006 |
Influenza pandemic preparedness in France: modelling the impact of interventions.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Chronic Disease; Computer Simulation; Disease Outbreaks; Female; France; Hospitalization; Humans; Infant; Infant, Newborn; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Models, Theoretical; Oseltamivir | 2006 |
More on bird flu.
Topics: Acetamides; Antiviral Agents; Humans; Influenza, Human; Oseltamivir | 2006 |
Oseltamivir becomes plentiful--but still not cheap.
Topics: Acetamides; Animals; Antiviral Agents; Chemistry, Pharmaceutical; Developing Countries; Drug Costs; Drug Industry; Drugs, Generic; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Orthomyxoviridae Infections; Oseltamivir; Patents as Topic; Randomized Controlled Trials as Topic | 2006 |
Emergence of drug-resistant influenza virus: population dynamical considerations.
Topics: Acetamides; Amantadine; Antiviral Agents; Computer Simulation; Disease Outbreaks; Drug Resistance, Viral; Humans; Influenza A virus; Influenza, Human; Mathematics; Models, Biological; Mutation; Neuraminidase; Orthomyxoviridae; Oseltamivir; Population Dynamics | 2006 |
Bird flu prevention.
Topics: Acetamides; Animals; Antiviral Agents; Attitude to Health; Chickens; Female; Hong Kong; Humans; Influenza in Birds; Influenza, Human; Oseltamivir | 2006 |
Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient.
Topics: Acetamides; Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; Baculoviridae; Base Sequence; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Female; Guanidines; Humans; Infant; Influenza B virus; Influenza, Human; Inhibitory Concentration 50; Microbial Sensitivity Tests; Molecular Sequence Data; Neuraminidase; Oseltamivir; Pyrans; Recombinant Proteins; Sialic Acids; Zanamivir | 2006 |
A short enantioselective pathway for the synthesis of the anti-influenza neuramidase inhibitor oseltamivir from 1,3-butadiene and acrylic acid.
Topics: Acrylates; Antiviral Agents; Butadienes; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Stereoisomerism | 2006 |
Update on influenza vaccination for the 2005-2006 season. An Advisory Committee Statement (ACS).
Topics: Acetamides; Amantadine; Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A virus; Influenza A Virus, H3N2 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir | 2006 |
Oseltamivir and delirious behavior in children with influenza.
Topics: Acetamides; Age Distribution; Antiviral Agents; Child; Child, Preschool; Delirium; Female; Humans; Incidence; Influenza, Human; Japan; Male; Oseltamivir; Retrospective Studies; Risk Assessment; Severity of Illness Index; Sex Distribution | 2006 |
Non-voluntary licensing of antivirals under patent: options the Australian Government should consider in light of a potential bird flu pandemic.
Topics: Acetamides; Animals; Antiviral Agents; Australia; Birds; Drugs, Generic; Guanidines; Health Services Needs and Demand; Humans; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Legislation, Drug; Oseltamivir; Patents as Topic; Public Health; Pyrans; Sialic Acids; Zanamivir | 2006 |
[Influenza diagnostics in patient with leukemia suspicion].
Topics: Acetamides; Aged; Antiviral Agents; Diagnosis, Differential; Humans; Influenza, Human; Leukemia, Lymphoid; Male; Oseltamivir | 2006 |
H5N1 virus resistant to oseltamivir isolated from Vietnamese patient.
Topics: Acetamides; Adolescent; Antiviral Agents; Dose-Response Relationship, Drug; Drug Resistance, Viral; Female; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Oseltamivir; Treatment Outcome; Vietnam | 2005 |
Frequency and effects of bacterial infection in children with influenza under oseltamivir treatment.
Topics: Acetamides; Anti-Bacterial Agents; Antiviral Agents; Child; Child, Preschool; Female; Fever; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Japan; Male; Oseltamivir; Pneumococcal Infections; Superinfection; Time Factors | 2006 |
Use of oseltamivir in Dutch nursing homes during the 2004-2005 influenza season.
Topics: Antiviral Agents; Disease Outbreaks; Female; Health Planning Guidelines; Humans; Influenza, Human; Male; Nursing Homes; Oseltamivir; Practice Guidelines as Topic; Practice Patterns, Physicians'; Primary Prevention; Retrospective Studies | 2006 |
Pharmacokinetics and dosage adjustment of oseltamivir and zanamivir in patients with renal failure.
Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Kidney Failure, Chronic; Oseltamivir; Zanamivir | 2006 |
Statement on influenza vaccination for the 2006-2007 season. An Advisory Committee Statement (ACS).
Topics: Acetamides; Adolescent; Adult; Aged; Amantadine; Animals; Antiviral Agents; Canada; Child; Child, Preschool; Contraindications; Disease Outbreaks; Drug Resistance, Viral; Female; Health Personnel; Humans; Immunization Schedule; Infant; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N1 Subtype; Influenza B virus; Influenza in Birds; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Oseltamivir; Poultry; Pregnancy | 2006 |
Oseltamivir and the influenza alphabet.
Topics: Acetamides; Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Disease Outbreaks; Humans; Infant; Infant, Newborn; Influenza Vaccines; Influenza, Human; Middle Aged; Oseltamivir | 2006 |
Symptomatic predictors of influenza virus positivity in children during the influenza season.
Topics: Acetamides; Aging; Antiviral Agents; Child; Child, Preschool; Cough; Fever; Guanidines; Headache; Humans; Infant; Influenza, Human; Logistic Models; Muscular Diseases; Odds Ratio; Oseltamivir; Pyrans; Risk Factors; Seasons; Sialic Acids; Zanamivir | 2006 |
Duration of isolation of children with influenza A treated with oseltamivir.
Topics: Antibodies, Viral; Antiviral Agents; Child; Child, Preschool; Disease Outbreaks; Follow-Up Studies; Humans; Infant; Infection Control; Influenza A virus; Influenza, Human; Oseltamivir; Patient Isolation; Prognosis; Retrospective Studies; Time Factors | 2007 |
Possible case scenarios and logistic issues in H5N1 pandemic.
Topics: Antiviral Agents; Disease Outbreaks; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Oseltamivir; Severe Acute Respiratory Syndrome; Zanamivir | 2006 |
An off-seasonal amantadine-resistant H3N2 influenza outbreak in Japan.
Topics: Acetamides; Adolescent; Adult; Aged; Aged, 80 and over; Amantadine; Amino Acid Substitution; Antiviral Agents; Child; Child, Preschool; Disease Outbreaks; Drug Resistance, Viral; Female; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Infant; Influenza A Virus, H3N2 Subtype; Influenza, Human; Japan; Male; Middle Aged; Molecular Sequence Data; Oseltamivir; Phylogeny; Seasons; Treatment Outcome; Viral Matrix Proteins | 2006 |
Increased adamantane resistance in influenza A(H3) viruses in Australia and neighbouring countries in 2005.
Topics: Adamantane; Antiviral Agents; Australia; Drug Resistance, Viral; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A virus; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Phylogeny; Rimantadine; Zanamivir | 2007 |
[Avian influenza pandemic prevention - current research].
Topics: Acetamides; Animals; Antiviral Agents; Disease Outbreaks; Guanidines; Humans; Influenza A Virus, H5N1 Subtype; Influenza Vaccines; Influenza, Human; Models, Animal; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2006 |
[Nosocomial influenza outbreak in a geriatrics department: Effectiveness of preventive measures].
Topics: Aged, 80 and over; Antiviral Agents; Chemoprevention; Cross Infection; Disease Outbreaks; Female; France; Hospital Units; Humans; Infection Control; Influenza Vaccines; Influenza, Human; Male; Oseltamivir | 2006 |
Tamiflu: the supply problem.
Topics: Antiviral Agents; Humans; Influenza, Human; Molecular Structure; Oseltamivir | 2006 |
[Acute hemorrhagic colitis induced by the neuraminidase inhibitor oseltamivir].
Topics: Adult; Antiviral Agents; Colitis; Female; Gastrointestinal Hemorrhage; Humans; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir | 2006 |
Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes.
Topics: Acids, Carbocyclic; Amantadine; Animals; Antiviral Agents; Base Sequence; Birds; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2007 |
Avian influenza A (H5N1) infection in eastern Turkey in 2006.
Topics: Adolescent; Anti-Bacterial Agents; Antiviral Agents; Child; Child, Preschool; Disease Outbreaks; Female; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Male; Oseltamivir; Polymerase Chain Reaction; Respiration, Artificial; Turkey | 2006 |
Three Indonesian clusters of H5N1 virus infection in 2005.
Topics: Adult; Animals; Antiviral Agents; Child; Child, Preschool; Disease Outbreaks; Female; Humans; Indonesia; Infant; Influenza A Virus, H5N1 Subtype; Influenza, Human; Male; Oseltamivir; Respiration, Artificial | 2006 |
Controlling immune response may cut bird flu death rate.
Topics: Antiviral Agents; Communicable Diseases, Emerging; Cytokines; Disease Outbreaks; Humans; Immune System; Influenza A Virus, H5N1 Subtype; Influenza, Human; Oseltamivir; Vietnam | 2006 |
Oseltamivir: cutaneous and neurological adverse effects in children.
Topics: Adolescent; Adult; Animals; Antiviral Agents; Child; Europe; Humans; Influenza, Human; Nervous System Diseases; Oseltamivir; Rats; Skin Diseases; Suicide; Treatment Outcome; United States | 2006 |
Avian influenza and the failure of public rationing discussions.
Topics: Animals; Antiviral Agents; Attitude to Health; Birds; Disease Outbreaks; Fear; Health Care Rationing; Humans; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza Vaccines; Influenza, Human; Oseltamivir; Public Opinion; Social Responsibility; United States; Value of Life; Zoonoses | 2006 |
Antiviral management of seasonal and pandemic influenza.
Topics: Amantadine; Animals; Antiviral Agents; Clinical Trials as Topic; Disease Outbreaks; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N1 Subtype; Influenza, Human; Mice; Neuraminidase; Oseltamivir; Rimantadine; Seasons; Zanamivir | 2006 |
Prevention and treatment of influenza in high-risk groups: children, pregnant women, immunocompromised hosts, and nursing home residents.
Topics: Adolescent; Adult; Aged; Animals; Child; Child, Preschool; Clinical Trials as Topic; Disease Outbreaks; Enzyme Inhibitors; Female; Homes for the Aged; Humans; Immunocompromised Host; Infant; Influenza Vaccines; Influenza, Human; Leukemia; Middle Aged; Nursing Homes; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Rats; Risk; United States; Vaccination; Zanamivir | 2006 |
Seasonal and pandemic influenza preparedness: science and countermeasures.
Topics: Academies and Institutes; Adult; Animals; Antiviral Agents; Clinical Trials as Topic; Disease Outbreaks; Drug Therapy, Combination; Enzyme Inhibitors; Global Health; Health Planning; Humans; Infant; Influenza A virus; Influenza Vaccines; Influenza, Human; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Seasons; United States; Vaccination | 2006 |
Does oseltamivir work against influenza B?
Topics: Aging; Antiviral Agents; Humans; Influenza B virus; Influenza, Human; Japan; Oseltamivir; United States | 2007 |
Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children.
Topics: Adolescent; Aging; Antiviral Agents; Child; Child, Preschool; Humans; Infant; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Oseltamivir | 2007 |
[Bird flu: increased resistance to oseltamivir. Are our weapons already blunt? (interview by Dr. Elke Oberhofer)].
Topics: Animals; Antiviral Agents; Birds; Disease Outbreaks; Drug Resistance, Viral; Humans; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Oseltamivir; Risk Factors | 2006 |
Protective measures and human antibody response during an avian influenza H7N3 outbreak in poultry in British Columbia, Canada.
Topics: Adolescent; Adult; Aged; Animals; Antibodies, Viral; Antiviral Agents; British Columbia; Child; Child, Preschool; Communicable Disease Control; Disease Outbreaks; Female; Humans; Infant; Influenza A virus; Influenza in Birds; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Oseltamivir; Poultry | 2007 |
[Tamiflu resistance].
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Oseltamivir | 2006 |
Antiviral resistance and the control of pandemic influenza.
Topics: Antiviral Agents; Computer Simulation; Disease Outbreaks; Drug Resistance, Viral; Humans; Influenza, Human; Orthomyxoviridae; Oseltamivir; Planning Techniques | 2007 |
Avian influenza. With change in the seasons, bird flu returns.
Topics: Animals; Antiviral Agents; Asia; Birds; Disease Outbreaks; Drug Resistance, Viral; Humans; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Mutation; Oseltamivir; Poultry; Seasons | 2007 |
[Significance of virological diagnostics for the effective treatment of hospitalized patients infected with influenza virus].
Topics: Adult; Amantadine; Antiviral Agents; Diagnosis, Differential; Fluorescent Antibody Technique; Hospitalization; Humans; Influenza A virus; Influenza, Human; Middle Aged; Oseltamivir; Respiratory Tract Diseases; Reverse Transcriptase Polymerase Chain Reaction; Rimantadine; Treatment Outcome; Zanamivir | 2006 |
Oseltamivir: new indication. Prevention of influenza in at-risk children: vaccination is best.
Topics: Amantadine; Antiviral Agents; Child; Drug Approval; Drug Resistance; Europe; Humans; Influenza Vaccines; Influenza, Human; Oseltamivir; Vaccination; Zanamivir | 2007 |
Assay to detect H5N1 oseltamivir resistance.
Topics: Animals; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Point Mutation; Polymerase Chain Reaction | 2006 |
Effect of oseltamivir on the risk of pneumonia and use of health care services in children with clinically diagnosed influenza.
Topics: Age Distribution; Antiviral Agents; Child; Child, Preschool; Confidence Intervals; Early Diagnosis; Female; Health Services Accessibility; Hospitalization; Humans; Incidence; Infant; Influenza, Human; Male; Oseltamivir; Pneumonia, Viral; Probability; Reference Values; Registries; Retrospective Studies; Sensitivity and Specificity; Severity of Illness Index; Sex Distribution; Treatment Outcome | 2007 |
Potential risks associated with the proposed widespread use of Tamiflu.
Topics: Animals; Antiviral Agents; Birds; Drug Resistance, Viral; Humans; Influenza A virus; Influenza in Birds; Influenza Vaccines; Influenza, Human; Models, Theoretical; Oseltamivir; Risk Assessment; Rivers; United Kingdom; United States; Water Pollutants, Chemical; Water Supply | 2007 |
Willingness-to-pay for a statistical life in the times of a pandemic.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Cross-Sectional Studies; Decision Making; Disease Outbreaks; Economics, Medical; Fear; Female; Health Knowledge, Attitudes, Practice; Humans; Influenza, Human; Male; Middle Aged; Oseltamivir; Risk Assessment; Sex Factors; Socioeconomic Factors | 2008 |
Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors.
Topics: Adolescent; Adult; Amino Acid Substitution; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Enzyme Inhibitors; Female; Hemagglutinins; Humans; Infant; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N1 Subtype; Influenza B virus; Influenza, Human; Japan; Male; Middle Aged; Mutation, Missense; Neuraminidase; Oseltamivir; Prevalence; Seasons | 2007 |
Influenza pandemic: perception of risk and individual precautions in a general population. Cross sectional study.
Topics: Adolescent; Adult; Antiviral Agents; Cross-Sectional Studies; Data Collection; Disease Outbreaks; Employment; Health Knowledge, Attitudes, Practice; Humans; Hygiene; Influenza, Human; Information Services; Mass Media; Middle Aged; Norway; Oseltamivir; Public Opinion; Trust | 2007 |
Monitoring of neuraminidase inhibitor resistance among clinical influenza virus isolates in Japan during the 2003-2006 influenza seasons.
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Japan; Neuraminidase; Orthomyxoviridae; Oseltamivir; Zanamivir | 2007 |
[Tamiflu, suicides and seasonal influenza].
Topics: Animals; Antiviral Agents; Birds; Disease Outbreaks; France; Humans; Influenza A virus; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Japan; Nervous System Diseases; Oseltamivir; Seasons; Suicide | 2007 |
Cost effectiveness of oseltamivir treatment for patients with influenza-like illness who are at increased risk for serious complications of influenza: illustration for the Netherlands.
Topics: Aged; Antiviral Agents; Chronic Disease; Cost of Illness; Cost-Benefit Analysis; Female; Humans; Influenza, Human; Male; Models, Economic; Netherlands; Oseltamivir; Risk | 2007 |
Emergence of rimantadine-resistant virus within 6 days of starting rimantadine prophylaxis with oseltamivir treatment of symptomatic cases.
Topics: Antiviral Agents; Cohort Studies; Drug Administration Schedule; Drug Resistance, Viral; Humans; Infection Control; Influenza A virus; Influenza, Human; Nursing Homes; Oseltamivir; Retrospective Studies; Rimantadine; Treatment Failure | 2007 |
Effectiveness of neuraminidase inhibitors for preventing staff absenteeism during pandemic influenza.
Topics: Absenteeism; Adult; Disease Outbreaks; Disease Transmission, Infectious; Enzyme Inhibitors; Health Personnel; Humans; Influenza, Human; Middle Aged; Models, Theoretical; Oseltamivir; Singapore | 2007 |
New strain of influenza A virus (H5N1), Thailand.
Topics: Amantadine; Animals; Antigens, Viral; Antiviral Agents; Chickens; Disease Outbreaks; Genes, Viral; Genome, Viral; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Male; Microbial Sensitivity Tests; Oseltamivir; Phylogeny; Sequence Analysis; Species Specificity; Thailand | 2007 |
Ethical considerations regarding the administration of oseltamivir for infection control indications.
Topics: Antiviral Agents; Ethics, Medical; Humans; Infection Control; Influenza, Human; Oseltamivir | 2007 |
Tamiflu and neuropsychiatric disturbance in adolescents.
Topics: Adolescent; Antiviral Agents; Child; Humans; Influenza, Human; Nervous System Diseases; Oseltamivir | 2007 |
John F. Enders lecture 2006: antivirals for influenza.
Topics: Antiviral Agents; Drug Design; Drug Resistance, Viral; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2007 |
Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Case-Control Studies; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Influenza, Human; Male; Middle Aged; Oseltamivir; Probability; Reference Values; Retrospective Studies; Risk Assessment; Treatment Outcome | 2007 |
A practical synthesis of (-)-oseltamivir.
Topics: Antiviral Agents; Humans; Influenza, Human; Molecular Structure; Oseltamivir | 2007 |
Longer virus shedding in influenza B than in influenza A among outpatients treated with oseltamivir.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Female; Humans; Infant; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Inhibitory Concentration 50; Male; Middle Aged; Oseltamivir; Virus Shedding | 2007 |
The effect of population structure on the emergence of drug resistance during influenza pandemics.
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Models, Biological; Models, Statistical; Oseltamivir; Population Dynamics; Time Factors | 2007 |
[Avoiding invasion of influenza viruses: early treatment prevents serious sequelae].
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Double-Blind Method; Early Diagnosis; Humans; Influenza, Human; Oseltamivir; Randomized Controlled Trials as Topic | 2007 |
[Influenza is not a "childhood illness: children with influenza need special attention].
Topics: Antiviral Agents; Child; Child, Preschool; Humans; Infant; Influenza, Human; Oseltamivir; Otitis Media; Randomized Controlled Trials as Topic; Superinfection | 2007 |
Statement on influenza vaccination for the 2007-2008 season. An Advisory Committee Statement (ACS).
Topics: Adolescent; Adult; Aged; Animals; Antiviral Agents; Canada; Child; Child, Preschool; Contraindications; Disease Outbreaks; Female; Health Personnel; Humans; Immunization Schedule; Infant; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza in Birds; Influenza Vaccines; Influenza, Human; Middle Aged; Oseltamivir; Poultry; Pregnancy | 2007 |
Factors associated with early hospital discharge of adult influenza patients.
Topics: Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Female; Hong Kong; Hospitalization; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Length of Stay; Male; Middle Aged; Nasopharynx; Oseltamivir; Patient Discharge; Proportional Hazards Models; Time Factors | 2007 |
Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus.
Topics: Animals; Antiviral Agents; Binding Sites; Birds; Computer Simulation; Crystallography, X-Ray; Drug Design; Drug Resistance, Viral; Humans; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Molecular Structure; Neuraminidase; Oseltamivir; Protein Structure, Tertiary; Structure-Activity Relationship | 2007 |
Acute hemorrhagic colitis associated with oral administration of oseltamivir for the treatment of influenza A.
Topics: Antiviral Agents; Colitis; Gastrointestinal Hemorrhage; Humans; Influenza A virus; Influenza, Human; Male; Middle Aged; Oseltamivir | 2007 |
Oseltamivir-induced delirium in a geriatric patient.
Topics: Aged, 80 and over; Antiviral Agents; Delirium; Dementia, Vascular; Humans; Influenza, Human; Male; Oseltamivir | 2007 |
General practitioners' management of influenza with or without neuraminidase inhibitors.
Topics: Adolescent; Adult; Antiviral Agents; Cohort Studies; Enzyme Inhibitors; Female; France; Humans; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Physicians, Family; Practice Patterns, Physicians'; Prospective Studies; Time Factors; Zanamivir | 2007 |
Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo.
Topics: Animals; Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Kinetics; Mice; Mice, Inbred BALB C; Neuraminidase; Oseltamivir; Viral Proteins; Virulence; Virus Replication | 2007 |
Oseltamivir: neuropsychiatric disorders.
Topics: Adolescent; Adult; Child; Child, Preschool; France; Humans; Influenza, Human; Japan; Mental Disorders; Nervous System Diseases; Oseltamivir; Suicide; United States | 2007 |
[Clinical feature of 23 cases of combined influenza virus and bacterial pneumonia].
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antiviral Agents; Female; Humans; Influenza, Human; Male; Middle Aged; Orthomyxoviridae; Oseltamivir; Pneumonia, Bacterial; Pneumonia, Viral | 2007 |
Impact of oseltamivir on the incidence of secondary complications of influenza in adolescent and adult patients: results from a retrospective population-based study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Female; Humans; Incidence; Influenza, Human; Male; Middle Aged; Oseltamivir; Otitis; Population; Respiratory Tract Diseases; Retrospective Studies; Treatment Outcome | 2007 |
Use of oseltamivir during an outbreak of influenza A in a long-term care facility in Taiwan.
Topics: Adult; Aged; Antiviral Agents; Disease Outbreaks; Female; Health Personnel; Homes for the Aged; Humans; Infectious Disease Transmission, Professional-to-Patient; Influenza A virus; Influenza Vaccines; Influenza, Human; Long-Term Care; Male; Middle Aged; Oseltamivir; Taiwan | 2008 |
A change in the effectiveness of amantadine for the treatment of influenza over the 2003-2004, 2004-2005, and 2005-2006 influenza seasons in Japan.
Topics: Adolescent; Adult; Age Factors; Amantadine; Child; Child, Preschool; Disease Outbreaks; Drug Resistance, Viral; Female; Humans; Infant; Influenza A virus; Influenza, Human; Japan; Male; Middle Aged; Oseltamivir; Retrospective Studies; Seasons | 2007 |
Treatment of post-influenza pneumonia in health care workers.
Topics: Anti-Infective Agents; Antiviral Agents; Health Personnel; Humans; Influenza Vaccines; Influenza, Human; Occupational Health; Oseltamivir; Pneumonia | 2007 |
Pandemic flu vaccine: are we doing enough?
Topics: Adamantane; Adjuvants, Immunologic; Animals; Antiviral Agents; Disease Outbreaks; Drug Approval; Drug Design; Drug Resistance, Viral; Enzyme Inhibitors; History, 20th Century; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; Poultry; United States; United States Food and Drug Administration | 2007 |
Oseltamivir and the risk of influenza-related complications and hospitalizations in patients with diabetes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Delivery of Health Care; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Hospitalization; Humans; Influenza, Human; Insurance Claim Review; Male; Managed Care Programs; Middle Aged; Oseltamivir; Otitis Media; Respiratory Tract Diseases; Retrospective Studies; Risk; Treatment Outcome | 2007 |
Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors.
Topics: Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; France; Humans; Influenza A Virus, H1N1 Subtype; Influenza B virus; Influenza, Human; Inhibitory Concentration 50; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Oseltamivir; Sequence Analysis, DNA; Viral Proteins; Zanamivir | 2008 |
Tamiflu survives sewage treatment.
Topics: Biodegradation, Environmental; Chemistry, Pharmaceutical; Drug Resistance, Viral; Environmental Monitoring; Humans; Influenza, Human; Japan; Oseltamivir; Pharmaceutical Preparations; Sewage; Technology, Pharmaceutical | 2007 |
[Case of adult influenza type A virus-associated encephalopathy successfully treated with primary multidisciplinary treatments].
Topics: Adult; Anticoagulants; Antithrombin III; Antiviral Agents; Biomarkers; Brain Edema; Combined Modality Therapy; Disseminated Intravascular Coagulation; Encephalitis, Viral; Female; Humans; Hypothermia, Induced; Immunoglobulins, Intravenous; Influenza A virus; Influenza, Human; Interleukin-6; Magnetic Resonance Imaging; Methylprednisolone; Oseltamivir; Pulse Therapy, Drug; Tomography, X-Ray Computed; Treatment Outcome; Unconsciousness | 2007 |
Adolescent jump case in Japan associated with influenza but not oseltamivir.
Topics: Adolescent; Adult; Antiviral Agents; Child; Female; Humans; Influenza, Human; Japan; Male; Oseltamivir; Suicide | 2008 |
A case of fulminant type 1 diabetes mellitus after influenza B infection.
Topics: Amylases; Antiviral Agents; C-Peptide; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Glycated Hemoglobin; Humans; Hyperglycemia; Influenza B virus; Influenza, Human; Male; Middle Aged; Oseltamivir | 2008 |
Oseltamivir and influenza-related complications, hospitalization and healthcare expenditure in healthy adults and children.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cohort Studies; Female; Health Expenditures; Hospitalization; Humans; Infant; Infant, Newborn; Influenza, Human; Male; Middle Aged; Oseltamivir; Otitis Media; Pneumonia; Retrospective Studies | 2008 |
Effects of oseltamivir phosphate (Tamiflu) in human sera on results of microneutralization and hemagglutinin-inhibition tests for H5N2 avian influenza virus.
Topics: Adult; Animals; Antibodies, Viral; Antiviral Agents; Female; Guinea Pigs; Hemagglutination Inhibition Tests; Horses; Humans; Influenza A Virus, H5N2 Subtype; Influenza, Human; Japan; Male; Middle Aged; Neutralization Tests; Oseltamivir | 2008 |
Observations on managing an outbreak of influenza A infection in an aged care facility.
Topics: Aged; Antiviral Agents; Cross Infection; Disease Outbreaks; Homes for the Aged; Humans; Influenza A virus; Influenza, Human; Oseltamivir; Queensland | 2007 |
The safety of oseltamivir in patients with influenza: analysis of healthcare claims data from six influenza seasons.
Topics: Adolescent; Adult; Age Distribution; Antiviral Agents; Brain; Case-Control Studies; Central Nervous System Diseases; Child; Cohort Studies; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Incidence; Influenza, Human; Insurance, Health; Male; Mental Disorders; Middle Aged; Odds Ratio; Oseltamivir; Probability; Registries; Retrospective Studies; Severity of Illness Index; Sex Distribution | 2007 |
Influenza.
Topics: Amantadine; Antiviral Agents; Humans; Influenza Vaccines; Influenza, Human; Mass Vaccination; Oseltamivir; Rimantadine; Zanamivir | 2008 |
Outcome of influenza infection managed with oseltamivir in lung transplant recipients.
Topics: Adult; Antiviral Agents; Cohort Studies; Female; Humans; Influenza, Human; Lung Transplantation; Male; Middle Aged; Oseltamivir; Pneumonia; Postoperative Complications; Retrospective Studies; Treatment Outcome | 2008 |
[Influenza in children: what should be considered in prevention and treatment?].
Topics: Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Cross-Sectional Studies; Female; Germany; Humans; Infant; Infectious Disease Transmission, Professional-to-Patient; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Seasons; Zanamivir | 2008 |
Human-like receptor specificity does not affect the neuraminidase-inhibitor susceptibility of H5N1 influenza viruses.
Topics: Animals; Antiviral Agents; Cell Line; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation; Neuraminidase; Oseltamivir; Receptors, Virus; Recombination, Genetic; Respiratory Mucosa; Species Specificity; Viral Proteins; Virus Replication; Zanamivir | 2008 |
Influenza in Canada: 2006-2007 season.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amantadine; Antiviral Agents; Canada; Child; Child, Preschool; Drug Resistance, Viral; Hospitalization; Humans; Infant; Influenza A virus; Influenza A Virus, H5N1 Subtype; Influenza B virus; Influenza, Human; Middle Aged; Oseltamivir; Seasons; Sentinel Surveillance | 2008 |
Public health response to an avian influenza A (H5N1) poultry outbreak in Suffolk, United Kingdom, in November 2007.
Topics: Agricultural Workers' Diseases; Animals; Antiviral Agents; Disease Outbreaks; Disease Transmission, Infectious; Humans; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza Vaccines; Influenza, Human; Oseltamivir; Poultry; Poultry Diseases; United Kingdom | 2008 |
Observed oseltamivir resistance in seasonal influenza viruses in Europe interpretation and potential implications.
Topics: Antiviral Agents; Drug Resistance, Viral; Europe; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Seasons; Virulence; World Health Organization | 2008 |
Oseltamivir resistance in human seasonal influenza viruses (A/H1N1) in EU and EFTA countries: an update.
Topics: Antiviral Agents; Disease Outbreaks; Drug Resistance, Viral; Europe; European Union; Humans; Incidence; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Seasons | 2008 |
In vitro evaluation of neuraminidase inhibitors using the neuraminidase-dependent release assay of hemagglutinin-pseudotyped viruses.
Topics: Animals; Antiviral Agents; Cell Line; Chick Embryo; Drug Evaluation, Preclinical; Enzyme Inhibitors; Genes, Reporter; Genetic Engineering; Hemagglutinins, Viral; Humans; Influenza, Human; Leukemia Virus, Murine; Neuraminidase; Orthomyxoviridae; Oseltamivir; Virus Shedding; Zanamivir | 2008 |
Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants.
Topics: Binding Sites; Crystallography, X-Ray; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza, Human; Kinetics; Models, Molecular; Molecular Conformation; Mutation; Neuraminidase; Oseltamivir; Protein Binding; Zanamivir | 2008 |
Researchers seek new weapon against the flu.
Topics: Administration, Oral; Amines; Animals; Antiviral Agents; Binding Sites; Clinical Trials as Topic; Drug Design; Drug Evaluation, Preclinical; Humans; Influenza, Human; Membrane Proteins; Molecular Structure; Neuraminidase; Orthomyxoviridae; Oseltamivir; Plant Proteins; Protein Conformation | 1997 |
Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor.
Topics: Acetamides; Administration, Intranasal; Administration, Oral; Amines; Animals; Antiviral Agents; Cell Line; Disease Models, Animal; Dogs; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Lung Diseases; Mice; Mice, Inbred BALB C; Molecular Structure; Neuraminidase; Oseltamivir; Pyrans; Ribavirin; Sialic Acids; Zanamivir | 1998 |
New ways to tackle influenza highlighted at ICAAC. Interscience Conference on Antimicrobial Agents and Chemotherapy.
Topics: Adolescent; Amines; Child; Child, Preschool; Clinical Trials as Topic; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 1998 |
Progress treating, preventing influenza.
Topics: Amines; Antiviral Agents; Disease Outbreaks; Enzyme Inhibitors; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 1998 |
Two neuraminidase inhibitors for treatment of influenza.
Topics: Acetamides; Administration, Inhalation; Administration, Oral; Amantadine; Amines; Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Microbial; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Prodrugs; Pyrans; Sialic Acids; Zanamivir | 1999 |
New options for the prevention of influenza.
Topics: Amines; Antiviral Agents; Drug Resistance, Microbial; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir | 1999 |
[Neuraminidase inhibitors against influenza].
Topics: Amines; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 1999 |
Influenza--a new problem?
Topics: Amines; Antiviral Agents; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 1999 |
Do the new flu drugs measure up?
Topics: Acetamides; Antiviral Agents; Guanidines; Humans; Influenza, Human; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 1999 |
Neuraminidase inhibitors for treatment of influenza A and B infections.
Topics: Acetamides; Adolescent; Adult; Antiviral Agents; Drug Interactions; Drug Resistance, Microbial; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 1999 |
Oseltamivir. EN 241104, GS 4104, RO 640796, Tamiflu.
Topics: Acetamides; Animals; Antiviral Agents; Drug Interactions; Humans; Influenza, Human; Oseltamivir; Randomized Controlled Trials as Topic | 1999 |
Oseltamivir phosphate.
Topics: Amines; Antiviral Agents; Contraindications; Humans; Influenza, Human; Oseltamivir | 2000 |
Expanding the treatment options for influenza.
Topics: Acetamides; Antiviral Agents; Cost of Illness; Cost-Benefit Analysis; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir | 2000 |
Oseltamivir for flu prevention.
Topics: Acetamides; Adolescent; Adult; Aged; Antiviral Agents; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Influenza, Human; Male; Middle Aged; Multicenter Studies as Topic; Oseltamivir; Randomized Controlled Trials as Topic; Reproducibility of Results; Treatment Outcome | 2000 |
Neuraminidase inhibitors and relief of influenza symptoms.
Topics: Acetamides; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2000 |
[Influenza loses it's fright].
Topics: Acetamides; Antiviral Agents; Clinical Trials as Topic; Humans; Influenza, Human; Neuraminidase; Oseltamivir | 1999 |
[New flu therapy. Progress or burden for the budget?].
Topics: Acetamides; Antiviral Agents; Cost-Benefit Analysis; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2000 |
Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine.
Topics: Acetamides; Animals; Antiviral Agents; Chromatography, High Pressure Liquid; Humans; Influenza, Human; Mass Spectrometry; Oseltamivir; Reference Standards; Reproducibility of Results; Sensitivity and Specificity | 2000 |
Antiviral agents for influenza.
Topics: Acetamides; Adolescent; Adult; Aged; Amantadine; Antiviral Agents; Child; Child, Preschool; Guanidines; Guidelines as Topic; Humans; Infant; Influenza, Human; Middle Aged; Oseltamivir; Pyrans; Randomized Controlled Trials as Topic; Sialic Acids; Treatment Outcome; Zanamivir | 2000 |
The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses.
Topics: Acetamides; Animals; Antiviral Agents; Brain; Cell Line; Dogs; Enzyme Inhibitors; Female; Humans; Influenza A virus; Influenza A Virus, H5N1 Subtype; Influenza A Virus, H9N2 Subtype; Influenza, Human; Kidney; Lung; Mice; Mice, Inbred BALB C; Neuraminidase; Oseltamivir; Rimantadine; Virus Replication | 2000 |
Flu-fighting options: decisions, decisions....
Topics: Acetamides; Amantadine; Antiviral Agents; Guanidines; Humans; Influenza, Human; Oseltamivir; Pneumonia; Pyrans; Rimantadine; Sialic Acids; Zanamivir | 2000 |
Flu drugs. Have I got news for flu.
Topics: Acetamides; Drug Approval; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; United Kingdom; Zanamivir | 2000 |
[Early Tamiflu therapy of influenza can reduce disease time by half].
Topics: Acetamides; Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Child; Child, Preschool; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Infant; Influenza, Human; Male; Neuraminidase; Oseltamivir; Time Factors | 2000 |
Update on treatment of influenza A and B with tamiflu.
Topics: Acetamides; Antiviral Agents; Drug Administration Schedule; Humans; Influenza, Human; Oseltamivir | 2001 |
Experience with oseltamivir in the control of a nursing home influenza B outbreak.
Topics: Acetamides; Antiviral Agents; British Columbia; Cross Infection; Disease Outbreaks; Humans; Influenza B virus; Influenza, Human; Nursing Homes; Oseltamivir | 2001 |
Flu experts fear countries are unprepared for a future pandemic.
Topics: Acetamides; Antiviral Agents; Disease Outbreaks; Humans; Influenza Vaccines; Influenza, Human; Oseltamivir; United Kingdom | 2001 |
Advances in pharmacology. New treatments for influenza: neuraminidase inhibitors.
Topics: Acetamides; Antiviral Agents; Drug Approval; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sensitivity and Specificity; Sialic Acids; United States; Zanamivir | 2001 |
Unprepared for an influenza pandemic.
Topics: Acetamides; Amantadine; Antiviral Agents; Disease Outbreaks; Drug Resistance, Microbial; Guanidines; Humans; Influenza, Human; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2001 |
ACIP releases guidelines on the prevention and control of influenza. Advisory Committee on Immunization Practices.
Topics: Acetamides; Age Factors; Amantadine; Antiviral Agents; Drug Administration Schedule; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Oseltamivir; Patient Selection; Pyrans; Rimantadine; Sialic Acids; Zanamivir | 2001 |
Cost-effectiveness of vaccination versus treatment of influenza in healthy adolescents and adults.
Topics: Acetamides; Adolescent; Adult; Aged; Antiviral Agents; Cost-Benefit Analysis; Enzyme Inhibitors; Humans; Influenza Vaccines; Influenza, Human; Middle Aged; Neuraminidase; Oseltamivir; Vaccines, Inactivated | 2001 |
Influenza B infection associated with encephalitis: treatment with oseltamivir.
Topics: Acetamides; Antiviral Agents; Child; DNA, Viral; Encephalitis, Viral; Humans; Influenza B virus; Influenza, Human; Male; Muscle Weakness; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome | 2002 |
Accumulation of defective neuraminidase (NA) genes by influenza A viruses in the presence of NA inhibitors as a marker of reduced dependence on NA.
Topics: Acetamides; Acids, Carbocyclic; Animals; Cell Line; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza, Human; Microbial Sensitivity Tests; Molecular Sequence Data; Neuraminidase; Oseltamivir; Viral Plaque Assay | 2002 |
Are we ready for the next flu pandemic?
Topics: Acetamides; Adult; Antiviral Agents; Disease Outbreaks; Enzyme Inhibitors; Global Health; Guanidines; Humans; Influenza, Human; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2001 |
[Pneumonia diagnosis in the practice on the test-bench: how much diagnosis is necessary?].
Topics: Acetamides; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Diagnosis, Differential; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pneumonia; Pyrans; Research; Sialic Acids; Time Factors; Zanamivir | 2002 |
Is oral oseltamivir safe and effective for the prevention of influenza and its complications in frail elderly long-term care residents who have received influenza vaccine?
Topics: Acetamides; Aged; Aged, 80 and over; Antiviral Agents; Combined Modality Therapy; Frail Elderly; Humans; Influenza Vaccines; Influenza, Human; Multicenter Studies as Topic; Oseltamivir; Randomized Controlled Trials as Topic | 2002 |
Evidence-based emergency medicine/systematic review abstract. Use of the neuraminidase inhibitor class of antiviral drugs for treatment of healthy adults with an acute influenza-like illness.
Topics: Acetamides; Adolescent; Adult; Age Factors; Antiviral Agents; Confidence Intervals; Emergency Medicine; Enzyme Inhibitors; Evidence-Based Medicine; Guanidines; Humans; Influenza, Human; Middle Aged; Neuraminidase; Oseltamivir; Pyrans; Randomized Controlled Trials as Topic; Sialic Acids; Systematic Reviews as Topic; Time Factors; Treatment Outcome; Zanamivir | 2002 |
Influenza surveillance with rapid diagnostic tests.
Topics: Acetamides; Amantadine; Antiviral Agents; Centers for Disease Control and Prevention, U.S.; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Oseltamivir; Population Surveillance; Rimantadine; United States | 2002 |
Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000.
Topics: Acetamides; Aged; Aged, 80 and over; Amantadine; Antiviral Agents; Disease Outbreaks; Female; Humans; Influenza Vaccines; Influenza, Human; Long-Term Care; Male; Middle Aged; Nursing Homes; Ontario; Oseltamivir; Treatment Outcome | 2002 |
Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Topics: Acetamides; Adolescent; Adult; Aged; Amantadine; Antiviral Agents; Child; Child, Preschool; Cost-Benefit Analysis; Guanidines; Humans; Infant; Influenza A virus; Influenza B virus; Influenza Vaccines; Influenza, Human; Middle Aged; Oseltamivir; Pyrans; Rimantadine; Risk Factors; Sialic Acids; United States; Vaccination; Zanamivir | 2002 |
Experience with oseltamivir in the control of nursing home influenza A outbreak.
Topics: Acetamides; Aged; Aged, 80 and over; Antiviral Agents; Disease Outbreaks; Drug Evaluation; Enzyme-Linked Immunosorbent Assay; Female; Humans; Influenza A virus; Influenza, Human; Male; Middle Aged; Neuraminidase; Nursing Homes; Oseltamivir; Safety; Treatment Outcome | 2002 |
Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors.
Topics: Acetamides; Acids, Carbocyclic; Canada; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Fluorometry; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Inhibitory Concentration 50; Luminescent Measurements; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2002 |
Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo.
Topics: Acetamides; Animals; Antiviral Agents; Disease Models, Animal; DNA, Viral; Drug Resistance, Viral; Female; Ferrets; Humans; Influenza A virus; Influenza, Human; Lung; Mice; Mice, Inbred BALB C; Mutation; Neuraminidase; Oseltamivir; Sequence Analysis, DNA; Specific Pathogen-Free Organisms; Virus Replication | 2002 |
The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo.
Topics: Acetamides; Amino Acid Substitution; Animals; Antiviral Agents; Body Weight; Cell Line; Disease Models, Animal; Drug Resistance, Viral; Ferrets; Fever; Humans; In Vitro Techniques; Inflammation; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mice; Mice, Inbred BALB C; Mutagenesis, Site-Directed; Mutation; Neuraminidase; Oseltamivir; Sequence Analysis, DNA; Virus Replication | 2002 |